1	The	DT	O	the	det	4	SENT_1	[p1l425t81r463b103],
2	NEW	NNP	O	NEW	nn	4	SENT_1	[p1l475t83r555b103],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_1	[p1l569t83r744b103],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_1	[p1l758t83r924b110],
5	ofMEDICINE	NN	O	ofmedicine	dep	4	SENT_1	[p1l938t81r1154b109],

1	1	CD	NUMBER	1	num	3	SENT_2	[p1l90t187r92b312],
2	ORIGINAL	NNP	O	ORIGINAL	nn	3	SENT_2	[p1l561t234r803b261],
3	ARTICLE	NN	O	article	_	0	SENT_2	[p1l819t235r1018b261],
4	1	CD	NUMBER	1	dep	3	SENT_2	[p1l1490t187r1492b312],

1	Cetuximab	NNP	O	Cetuximab	nn	2	SENT_3	[p1l195t387r513b443],
2	Monotherapy	NNP	O	Monotherapy	_	0	SENT_3	[p1l529t387r930b457],
3	and	CC	O	and	_	0	SENT_3	[p1l944t387r1052b442],
4	Cetuximab	NNP	PERSON	Cetuximab	conj_and	2	SENT_3	[p1l1070t387r1387b443],
5	plus	CC	O	plus	_	0	SENT_3	[p1l208t470r331b540],
6	Irinotecan	NNP	MISC	Irinotecan	conj_plus	4	SENT_3	[p1l349t470r652b525],
7	in	IN	O	in	_	0	SENT_3	[p1l668t470r725b524],
8	Irinotecan-Refractory	NNP	O	Irinotecan-Refractory	prep_in	2	SENT_3	[p1l742t469r1378b540],

1	Metastatic	JJ	O	metastatic	amod	3	SENT_4	[p1l366t554r674b609],
2	Colorectal	JJ	O	colorectal	amod	3	SENT_4	[p1l691t554r994b609],
3	Cancer	NN	O	cancer	_	0	SENT_4	[p1l1011t558r1217b609],

1	David	NNP	PERSON	David	nn	2	SENT_5	[p1l131t684r224b715],
2	Cunningham	NNP	PERSON	Cunningham	_	0	SENT_5	[p1l240t684r469b725],
3	,	,	O	,	_	0	SENT_5	[p1l240t684r469b725],
4	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l487t687r577b721],
5	,	,	O	,	_	0	SENT_5	[p1l487t687r577b721],
6	Yves	NNP	PERSON	Yves	nn	7	SENT_5	[p1l590t687r664b715],
7	Humblet	NNP	PERSON	Humblet	appos	2	SENT_5	[p1l681t684r838b721],
8	,	,	O	,	_	0	SENT_5	[p1l681t684r838b721],
9	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l855t687r945b721],
10	,	,	O	,	_	0	SENT_5	[p1l855t687r945b721],
11	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_5	[p1l962t684r1061b721],
12	,	,	O	,	_	0	SENT_5	[p1l962t684r1061b721],
13	Salvatore	NNP	PERSON	Salvatore	nn	14	SENT_5	[p1l1077t684r1232b715],
14	Siena	NNP	PERSON	Siena	appos	2	SENT_5	[p1l1245t686r1345b721],
15	,	,	O	,	_	0	SENT_5	[p1l1245t686r1345b721],
16	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l1362t687r1452b721],
17	,	,	O	,	_	0	SENT_5	[p1l1362t687r1452b721],
18	David	NNP	PERSON	David	nn	19	SENT_5	[p1l103t734r196b765],
19	Khayat	NNP	PERSON	Khayat	appos	2	SENT_5	[p1l213t734r331b775],
20	,	,	O	,	_	0	SENT_5	[p1l213t734r331b775],
21	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l348t737r438b771],
22	,	,	O	,	_	0	SENT_5	[p1l348t737r438b771],
23	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_5	[p1l455t734r554b771],
24	,	,	O	,	_	0	SENT_5	[p1l455t734r554b771],
25	Harry	NNP	PERSON	Harry	nn	26	SENT_5	[p1l571t737r663b775],
26	Bleiberg	NNP	PERSON	Bleiberg	appos	2	SENT_5	[p1l678t734r822b775],
27	,	,	O	,	_	0	SENT_5	[p1l678t734r822b775],
28	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l839t737r929b771],
29	,	,	O	,	_	0	SENT_5	[p1l839t737r929b771],
30	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_5	[p1l946t734r1045b771],
31	,	,	O	,	_	0	SENT_5	[p1l946t734r1045b771],
32	Armando	NNP	PERSON	Armando	nn	35	SENT_5	[p1l1058t734r1217b765],
33	Santoro	NNP	PERSON	Santoro	nn	35	SENT_5	[p1l1231t736r1372b771],
34	,	,	O	,	_	0	SENT_5	[p1l1231t736r1372b771],
35	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l1389t737r1479b771],
36	,	,	O	,	_	0	SENT_5	[p1l1389t737r1479b771],

1	Danny	NNP	PERSON	Danny	nn	2	SENT_6	[p1l204t787r311b825],
2	Bets	NNS	PERSON	bet	_	0	SENT_6	[p1l326t787r404b821],
3	,	,	O	,	_	0	SENT_6	[p1l326t787r404b821],
4	M.	NNP	PERSON	M.	nn	5	SENT_6	[p1l422t786r523b821],
5	Sc.	NNP	PERSON	Sc.	dep	2	SENT_6	[p1l422t786r523b821],
6	,	,	O	,	_	0	SENT_6	[p1l422t786r523b821],
7	Matthias	NNP	PERSON	Matthias	nn	8	SENT_6	[p1l540t784r686b815],
8	Mueser	NNP	PERSON	Mueser	appos	5	SENT_6	[p1l703t787r833b821],
9	,	,	O	,	_	0	SENT_6	[p1l703t787r833b821],
10	M.D.	NNP	O	M.D.	appos	5	SENT_6	[p1l851t787r941b821],
11	,	,	O	,	_	0	SENT_6	[p1l851t787r941b821],
12	Andreas	NNP	PERSON	Andreas	nn	13	SENT_6	[p1l954t784r1093b815],
13	Harstrick	NNP	PERSON	Harstrick	appos	5	SENT_6	[p1l1110t784r1272b821],
14	,	,	O	,	_	0	SENT_6	[p1l1110t784r1272b821],
15	M.D.	NNP	O	M.D.	appos	5	SENT_6	[p1l1289t787r1379b821],
16	,	,	O	,	_	0	SENT_6	[p1l1289t787r1379b821],

1	Chris	NNP	PERSON	Chris	nn	2	SENT_7	[p1l372t834r458b865],
2	Verslype	NNP	PERSON	Verslype	_	0	SENT_7	[p1l471t834r620b875],
3	,	,	O	,	_	0	SENT_7	[p1l471t834r620b875],
4	M.D.	NNP	O	M.D.	nn	13	SENT_7	[p1l638t837r728b871],
5	,	,	O	,	_	0	SENT_7	[p1l638t837r728b871],
6	Ph.D.	NNP	O	Ph.D.	appos	13	SENT_7	[p1l745t834r844b871],
7	,	,	O	,	_	0	SENT_7	[p1l745t834r844b871],
8	Ian	NNP	PERSON	Ian	appos	13	SENT_7	[p1l861t837r909b865],
9	Chau	NNP	PERSON	Chau	nn	13	SENT_7	[p1l924t834r1019b871],
10	,	,	O	,	_	0	SENT_7	[p1l924t834r1019b871],
11	M.B.	NNP	LOCATION	M.B.	appos	13	SENT_7	[p1l1036t837r1121b871],
12	,	,	O	,	_	0	SENT_7	[p1l1036t837r1121b871],
13	B.S.	NNP	O	B.S.	appos	2	SENT_7	[p1l1138t836r1209b871],
14	,	,	O	,	_	0	SENT_7	[p1l1138t836r1209b871],

1	and	CC	O	and	dep	4	SENT_8	[p1l503t884r562b915],
2	Eric	NNP	PERSON	Eric	nn	4	SENT_8	[p1l580t887r640b915],
3	Van	NNP	PERSON	Van	nn	4	SENT_8	[p1l651t887r711b915],
4	Cutsem	NNP	PERSON	Cutsem	_	0	SENT_8	[p1l726t886r865b921],
5	,	,	O	,	_	0	SENT_8	[p1l726t886r865b921],
6	M.D.	NNP	O	M.D.	nn	8	SENT_8	[p1l883t887r973b921],
7	,	,	O	,	_	0	SENT_8	[p1l883t887r973b921],
8	Ph.D.	NNP	O	Ph.D.	appos	4	SENT_8	[p1l990t884r1079b915],
9	.	.	O	.	_	0	SENT_8	[p1l990t884r1079b915],

1	ABSTRACT	NN	O	abstract	_	0	SENT_9	[p1l680t1028r898b1051],

1	BACKGROUND	NN	O	background	_	0	SENT_10	[p1l94t1155r321b1175],
2	The	DT	O	the	dep	1	SENT_10	[p1l91t1188r154b1219],
3	e	SYM	O	e	dep	11	SENT_10	[p1l167t1199r183b1219],
4	idermal	JJ	O	idermal	amod	7	SENT_10	[p1l206t1188r332b1219],
5	rowth	NN	O	rowth	nn	7	SENT_10	[p1l366t1188r463b1220],
6	factor	NN	O	factor	nn	7	SENT_10	[p1l476t1188r571b1219],
7	rece	NN	O	rece	nsubj	11	SENT_10	[p1l584t1199r649b1219],
8	tor	NN	O	tor	nn	11	SENT_10	[p1l673t1195r720b1219],
9	(	CD	NUMBER	(	num	11	SENT_10	[p1l734t1191r864b1226],
10	EGFR	NN	ORGANIZATION	egfr	nn	11	SENT_10	[p1l734t1191r864b1226],
11	)	NN	O	)	dep	1	SENT_10	[p1l734t1191r864b1226],
12	,	,	O	,	_	0	SENT_10	[p1l734t1191r864b1226],
13	which	WDT	O	which	nsubj	14	SENT_10	[p1l877t1188r978b1220],
14	artici	VBP	O	artici	rcmod	11	SENT_10	[p1l1013t1189r1095b1219],
15	ates	NNS	O	ate	dobj	14	SENT_10	[p1l1118t1195r1181b1219],
16	in	IN	O	in	_	0	SENT_10	[p1l1195t1189r1226b1219],
17	si	NN	O	si	nn	19	SENT_10	[p1l1240t1189r1266b1219],
18	nalin	NN	O	nalin	nn	19	SENT_10	[p1l1288t1188r1371b1219],
19	ath	NN	O	ath	prep_in	15	SENT_10	[p1l1426t1188r1490b1219],
20	—	CD	NUMBER	—	dep	11	SENT_10	[p1l1426t1188r1490b1219],
21	From	IN	O	from	dep	20	SENT_10	[p1l1532t1197r1593b1219],
22	the	DT	O	the	det	25	SENT_10	[p1l1604t1195r1642b1219],
23	Royal	NNP	LOCATION	Royal	nn	25	SENT_10	[p1l1654t1195r1717b1226],
24	Marsden	NNP	LOCATION	Marsden	nn	25	SENT_10	[p1l1730t1195r1837b1219],
25	Hospital	NNP	LOCATION	Hospital	pobj	21	SENT_10	[p1l1850t1195r1960b1226],
26	,	,	O	,	_	0	SENT_10	[p1l1850t1195r1960b1226],
27	London	NNP	LOCATION	London	appos	25	SENT_10	[p1l1973t1195r2065b1219],

1	P	NN	O	p	nn	4	SENT_11	[p1l184t1198r204b1228],
2	8	CD	NUMBER	8	num	4	SENT_11	[p1l345t1199r366b1228],
3	P	NN	O	p	nn	4	SENT_11	[p1l651t1198r670b1228],
4	P	NN	O	p	_	0	SENT_11	[p1l991t1198r1011b1228],
5	P	NN	O	p	dep	4	SENT_11	[p1l1096t1198r1116b1228],
6	8	CD	NUMBER	8	number	7	SENT_11	[p1l1267t1199r1288b1228],
7	8	CD	NUMBER	8	num	8	SENT_11	[p1l1373t1199r1393b1228],
8	P	NN	O	p	dep	5	SENT_11	[p1l1405t1198r1424b1228],

1	Ways	NNP	O	Ways	nsubj	10	SENT_12	[p1l91t1249r170b1278],
2	that	WDT	O	that	nsubjpass	4	SENT_12	[p1l188t1239r252b1269],
3	are	VBP	O	be	auxpass	4	SENT_12	[p1l267t1249r316b1269],
4	deregulated	VBN	O	deregulate	rcmod	1	SENT_12	[p1l334t1239r526b1278],
5	in	IN	O	in	_	0	SENT_12	[p1l542t1239r574b1269],
6	cancer	NN	O	cancer	nn	7	SENT_12	[p1l591t1249r698b1269],
7	cells	NNS	O	cell	prep_in	4	SENT_12	[p1l714t1239r795b1276],
8	,	,	O	,	_	0	SENT_12	[p1l714t1239r795b1276],
9	commonly	RB	O	commonly	advmod	4	SENT_12	[p1l814t1239r991b1278],
10	appears	VBZ	O	appear	_	0	SENT_12	[p1l1006t1249r1133b1278],
11	on	IN	O	on	_	0	SENT_12	[p1l1151t1249r1192b1269],
12	colorectal-cancer	NN	O	colorectal-cancer	prep_on	10	SENT_12	[p1l1210t1239r1492b1269],
13	and	CC	O	and	_	0	SENT_12	[p1l1530t1233r1575b1257],
14	Surrey	NNP	ORGANIZATION	Surrey	conj_and	12	SENT_12	[p1l1590t1235r1674b1264],
15	.	.	O	.	_	0	SENT_12	[p1l1590t1235r1674b1264],

1	United	NNP	LOCATION	United	nn	2	SENT_13	[p1l1690t1233r1773b1257],
2	Kingdom	NNP	LOCATION	Kingdom	nsubj	3	SENT_13	[p1l1789t1233r1990b1294],
3	|	VBD	O	|	_	0	SENT_13	[p1l1789t1233r1990b1294],
4	(	CD	NUMBER	(	num	5	SENT_13	[p1l1789t1233r1990b1294],
5	D.c.	NNP	O	D.c.	dobj	3	SENT_13	[p1l1789t1233r1990b1294],
6	,	,	O	,	_	0	SENT_13	[p1l1789t1233r1990b1294],
7	|	CD	NUMBER	|	appos	5	SENT_13	[p1l2006t1235r2064b1264],
8	.	.	O	.	_	0	SENT_13	[p1l2006t1235r2064b1264],

1	C.	NNP	O	C.	nn	2	SENT_14	[p1l2006t1235r2064b1264],
2	)	NNP	O	)	_	0	SENT_14	[p1l2006t1235r2064b1264],
3	;	:	O	;	_	0	SENT_14	[p1l2006t1235r2064b1264],
4	.	.	O	.	_	0	SENT_14	[p1l282t1289r379b1295],

1	. . .	NN	O	. . .	nn	2	SENT_15	[p1l940t1289r945b1295],[p1l282t1289r379b1295],
2	S	NN	O	s	_	0	SENT_15	[p1l1530t1272r2064b1298],
3	‘	SYM	O	‘	dep	2	SENT_15	[p1l1530t1272r2064b1298],
4	-	:	O	-	_	0	SENT_15	[p1l1530t1272r2064b1298],
5	LU	NN	O	lu	dep	2	SENT_15	[p1l1530t1272r2064b1298],
6	"	''	O	"	punct	5	SENT_15	[p1l1530t1272r2064b1298],
7	H	NN	O	h	rcmod	5	SENT_15	[p1l1530t1272r2064b1298],
8	'	''	O	'	_	0	SENT_15	[p1l1530t1272r2064b1298],
9	,	,	O	,	_	0	SENT_15	[p1l1530t1272r2064b1298],
10	U	NNP	O	U	dep	7	SENT_15	[p1l1530t1272r2064b1298],
11	"	``	O	"	punct	12	SENT_15	[p1l1530t1272r2064b1298],
12	’	NN	O	’	nn	13	SENT_15	[p1l1530t1272r2064b1298],
13	cells	NNS	O	cell	dep	10	SENT_15	[p1l93t1289r173b1320],
14	.	.	O	.	_	0	SENT_15	[p1l93t1289r173b1320],

1	Cetuximab	NNP	PERSON	Cetuximab	nsubj	5	SENT_16	[p1l185t1289r362b1320],
2	IS	VBZ	O	be	cop	5	SENT_16	[p1l371t1299r397b1319],
3	a	DT	O	a	det	5	SENT_16	[p1l407t1299r424b1320],
4	monoclonal	JJ	O	monoclonal	amod	5	SENT_16	[p1l433t1289r631b1345],
5	antibody	NN	O	antibody	_	0	SENT_16	[p1l640t1289r784b1345],
6	that	WDT	O	that	nsubj	8	SENT_16	[p1l792t1289r857b1345],
7	speciﬁcally	RB	O	speciﬁcally	advmod	8	SENT_16	[p1l865t1289r1046b1345],
8	blocks	VBZ	O	block	rcmod	5	SENT_16	[p1l1054t1289r1161b1345],
9	the	DT	O	the	det	10	SENT_16	[p1l1170t1289r1220b1320],
10	EGFR	NN	ORGANIZATION	egfr	dobj	8	SENT_16	[p1l1230t1291r1335b1322],
11	.	.	O	.	_	0	SENT_16	[p1l1230t1291r1335b1322],

1	We	PRP	O	we	nsubj	29	SENT_17	[p1l1345t1292r1397b1320],
2	com	NN	O	com	dep	1	SENT_17	[p1l1407t1299r1490b1345],
3	-	:	O	-	_	0	SENT_17	[p1l1407t1299r1490b1345],
4	C	NN	O	c	dep	2	SENT_17	[p1l1530t1275r1661b1339],
5	:	:	O	:	_	0	SENT_17	[p1l1530t1275r1661b1339],
6	l	NN	O	l	dep	4	SENT_17	[p1l1530t1275r1661b1339],
7	:	:	O	:	_	0	SENT_17	[p1l1530t1275r1661b1339],
8	:	:	O	:	_	0	SENT_17	[p1l1530t1275r1661b1339],
9	,	,	O	,	_	0	SENT_17	[p1l1530t1275r1661b1339],
10	“	CD	NUMBER	“	dep	6	SENT_17	[p1l1530t1275r1661b1339],
11	:	:	O	:	_	0	SENT_17	[p1l1530t1275r1661b1339],
12	:	:	O	:	_	0	SENT_17	[p1l1530t1275r1661b1339],
13	e	LS	O	e	dep	2	SENT_17	[p1l1530t1275r1661b1339],
14	d	NN	O	d	dep	13	SENT_17	[p1l1670t1275r1812b1336],
15	:	:	O	:	_	0	SENT_17	[p1l1670t1275r1812b1336],
16	'	''	O	'	_	0	SENT_17	[p1l1670t1275r1812b1336],
17	:	:	O	:	_	0	SENT_17	[p1l1670t1275r1812b1336],
18	:	:	O	:	_	0	SENT_17	[p1l1670t1275r1812b1336],
19	LSJ	NN	O	lsj	dep	1	SENT_17	[p1l1670t1275r1812b1336],
20	:	:	O	:	_	0	SENT_17	[p1l1670t1275r1812b1336],
21	)	CD	NUMBER	)	dep	19	SENT_17	[p1l1670t1275r1812b1336],
22	;	:	O	;	_	0	SENT_17	[p1l1670t1275r1812b1336],
23	n	NN	O	n	dep	1	SENT_17	[p1l1670t1275r1812b1336],
24	,	,	O	,	_	0	SENT_17	[p1l1670t1275r1812b1336],
25	grsupstgls	NNS	O	grsupstgl	appos	23	SENT_17	[p1l1825t1275r1925b1332],
26	i	FW	O	i	dep	25	SENT_17	[p1l1939t1275r2066b1339],
27	P	NN	O	p	dep	1	SENT_17	[p1l1939t1275r2066b1339],
28	+	CC	O	+	cc	29	SENT_17	[p1l1939t1275r2066b1339],
29	pared	VBD	O	pare	_	0	SENT_17	[p1l92t1339r184b1378],
30	the	DT	O	the	det	31	SENT_17	[p1l194t1339r244b1370],
31	efficacy	NN	O	efficacy	dobj	29	SENT_17	[p1l255t1339r378b1378],
32	of	IN	O	of	_	0	SENT_17	[p1l387t1339r426b1370],
33	cetuximab	NN	O	cetuximab	prep_of	31	SENT_17	[p1l429t1339r597b1370],
34	in	IN	O	in	_	0	SENT_17	[p1l607t1349r639b1369],
35	combination	NN	O	combination	nn	38	SENT_17	[p1l649t1339r858b1370],
36	Wlth	NN	O	wlth	nn	38	SENT_17	[p1l866t1339r940b1370],
37	irinotecan	NN	O	irinotecan	nn	38	SENT_17	[p1l949t1346r1115b1370],
38	Wlth	NN	O	wlth	prep_in	29	SENT_17	[p1l1123t1339r1197b1370],
39	that	WDT	O	that	nsubj	45	SENT_17	[p1l1207t1339r1271b1370],
40	of	IN	O	of	_	0	SENT_17	[p1l1280t1339r1319b1370],
41	cetuximab	NN	O	cetuximab	nn	43	SENT_17	[p1l1322t1339r1490b1370],
42	pedale	NN	O	pedale	nn	43	SENT_17	[p1l1531t1346r1612b1377],
43	Niguarda	NNP	O	Niguarda	prep_of	45	SENT_17	[p1l1622t1346r1739b1377],
44	Ca	MD	O	can	aux	45	SENT_17	[p1l1749t1348r1786b1369],
45	’	VB	O	’	rcmod	38	SENT_17	[p1l1749t1348r1786b1369],
46	Granda	NNP	PERSON	Granda	nn	48	SENT_17	[p1l1796t1346r1897b1374],
47	,	,	O	,	_	0	SENT_17	[p1l1796t1346r1897b1374],
48	Milan	NNP	LOCATION	Milan	dobj	45	SENT_17	[p1l1909t1346r1978b1369],
49	(	CD	NUMBER	(	num	51	SENT_17	[p1l1990t1348r2064b1377],
50	s.s.	NN	O	s.s.	nn	51	SENT_17	[p1l1990t1348r2064b1377],
51	)	NN	O	)	dep	48	SENT_17	[p1l1990t1348r2064b1377],
52	;	:	O	;	_	0	SENT_17	[p1l1990t1348r2064b1377],
53	alone	RB	O	alone	advmod	48	SENT_17	[p1l92t1389r181b1419],
54	in	IN	O	in	_	0	SENT_17	[p1l190t1389r222b1419],
55	metastatic	JJ	O	metastatic	amod	57	SENT_17	[p1l231t1389r401b1419],
56	colorectal	JJ	O	colorectal	amod	57	SENT_17	[p1l411t1389r571b1419],
57	cancer	NN	O	cancer	prep_in	53	SENT_17	[p1l581t1399r688b1419],
58	that	WDT	O	that	nsubj	60	SENT_17	[p1l696t1389r761b1419],
59	was	VBD	O	be	cop	60	SENT_17	[p1l767t1399r829b1420],
60	refractory	JJ	O	refractory	rcmod	57	SENT_17	[p1l840t1388r999b1428],
61	to	TO	O	to	_	0	SENT_17	[p1l1007t1395r1038b1419],
62	treatment	NN	O	treatment	prep_to	60	SENT_17	[p1l1048t1395r1209b1419],
63	with	IN	O	with	_	0	SENT_17	[p1l1215t1389r1288b1420],
64	irinotecan	NN	O	irinotecan	prep_with	60	SENT_17	[p1l1298t1389r1473b1419],
65	.	.	O	.	_	0	SENT_17	[p1l1298t1389r1473b1419],

1	H6P	NN	O	h6p	_	0	SENT_18	[p1l1532t1383r1624b1414],
2	"	''	O	"	punct	1	SENT_18	[p1l1532t1383r1624b1414],
3	a	DT	O	a	dep	1	SENT_18	[p1l1532t1383r1624b1414],
4	'	''	O	'	_	0	SENT_18	[p1l1532t1383r1624b1414],
5	5a	NN	O	5a	nn	7	SENT_18	[p1l1640t1383r1782b1414],
6	'	''	O	'	_	0	SENT_18	[p1l1640t1383r1782b1414],
7	Pé	NN	O	pé	dep	23	SENT_18	[p1l1640t1383r1782b1414],
8	“	CD	NUMBER	“	dep	14	SENT_18	[p1l1640t1383r1782b1414],
9	lé	NN	O	lé	dep	8	SENT_18	[p1l1640t1383r1782b1414],
10	'	''	O	'	_	0	SENT_18	[p1l1640t1383r1782b1414],
11	ei	FW	O	ei	dep	9	SENT_18	[p1l1640t1383r1782b1414],
12	Pall	NN	O	pall	dep	14	SENT_18	[p1l1800t1385r1860b1406],
13	‘	CD	NUMBER	‘	num	12	SENT_18	[p1l1800t1385r1860b1406],
14	(	CD	NUMBER	(	dep	7	SENT_18	[p1l1877t1385r1958b1414],
15	D-K-li	NN	O	d-k-li	dep	14	SENT_18	[p1l1877t1385r1958b1414],
16	'	''	O	'	_	0	SENT_18	[p1l1975t1385r2066b1407],
17	“	CD	NUMBER	“	number	18	SENT_18	[p1l1975t1385r2066b1407],
18	5	CD	NUMBER	5	num	22	SENT_18	[p1l1975t1385r2066b1407],
19	“	NN	O	“	nn	22	SENT_18	[p1l1975t1385r2066b1407],
20	t	NN	O	t	nn	22	SENT_18	[p1l1975t1385r2066b1407],
21	”	CD	NUMBER	”	num	22	SENT_18	[p1l1975t1385r2066b1407],
22	t	NN	O	t	dep	15	SENT_18	[p1l1975t1385r2066b1407],
23	Jules	NNP	PERSON	Jules	prep	3	SENT_18	[p1l1525t1420r1588b1451],
24	Bordet	NNP	PERSON	Bordet	dep	23	SENT_18	[p1l1600t1420r1686b1448],
25	,	,	O	,	_	0	SENT_18	[p1l1600t1420r1686b1448],
26	Brussels	NNP	LOCATION	Brussels	nn	29	SENT_18	[p1l1700t1420r1801b1444],
27	(	NNP	O	(	nn	29	SENT_18	[p1l1815t1422r1894b1451],
28	H.B.	NNP	LOCATION	H.B.	nn	29	SENT_18	[p1l1815t1422r1894b1451],
29	)	NNP	O	)	appos	24	SENT_18	[p1l1815t1422r1894b1451],
30	;	:	O	;	_	0	SENT_18	[p1l1815t1422r1894b1451],
31	Istituto	NNP	PERSON	Istituto	nn	33	SENT_18	[p1l1908t1423r1993b1444],
32	Clinico	NNP	PERSON	Clinico	nn	33	SENT_18	[p1l2004t1420r2066b1444, p1l1530t1466r1557b1481],
33	Humanitas	NNP	PERSON	Humanitas	dep	23	SENT_18	[p1l1567t1460r1709b1486],
34	,	,	O	,	_	0	SENT_18	[p1l1567t1460r1709b1486],
35	Rozzano	NNP	PERSON	Rozzano	appos	33	SENT_18	[p1l1720t1458r1925b1486],
36	.	.	O	.	_	0	SENT_18	[p1l1720t1458r1925b1486],

1	—	NN	O	—	_	0	SENT_19	[p1l1720t1458r1925b1486],
2	.	.	O	.	_	0	SENT_19	[p1l1720t1458r1925b1486],

1	Mi	FW	O	mi	_	0	SENT_20	[p1l1720t1458r1925b1486],
2	|	FW	O	|	nn	3	SENT_20	[p1l1720t1458r1925b1486],
3	ano	FW	O	ano	nsubj	23	SENT_20	[p1l1720t1458r1925b1486],
4	,	,	O	,	_	0	SENT_20	[p1l1720t1458r1925b1486],
5	Italy	NNP	LOCATION	Italy	appos	3	SENT_20	[p1l1935t1458r1983b1489],
6	(	CD	NUMBER	(	num	5	SENT_20	[p1l1993t1459r2064b1489],
7	A.S.	NNP	ORGANIZATION	A.S.	dep	5	SENT_20	[p1l1993t1459r2064b1489],
8	)	CD	NUMBER	)	num	7	SENT_20	[p1l1993t1459r2064b1489],
9	;	:	O	;	_	0	SENT_20	[p1l1993t1459r2064b1489],
10	M	NN	O	m	nn	12	SENT_20	[p1l95t1496r115b1515],
11	ETHODS	NN	O	ethod	nn	12	SENT_20	[p1l125t1496r254b1515],
12	Merck	NNP	PERSON	Merck	dep	5	SENT_20	[p1l1532t1492r1615b1520],
13	,	,	O	,	_	0	SENT_20	[p1l1532t1492r1615b1520],
14	Amsterdam	NNP	LOCATION	Amsterdam	nn	17	SENT_20	[p1l1627t1492r1777b1516],
15	(	NNP	O	(	nn	17	SENT_20	[p1l1793t1494r1874b1523],
16	D.B.	NNP	LOCATION	D.B.	nn	17	SENT_20	[p1l1793t1494r1874b1523],
17	)	NNP	O	)	appos	12	SENT_20	[p1l1793t1494r1874b1523],
18	;	:	O	;	_	0	SENT_20	[p1l1793t1494r1874b1523],
19	Merck	NNP	PERSON	Merck	dep	5	SENT_20	[p1l1889t1492r1972b1520],
20	,	,	O	,	_	0	SENT_20	[p1l1889t1492r1972b1520],
21	DarmWe	NNP	O	DarmWe	appos	19	SENT_20	[p1l1987t1494r2065b1516, p1l91t1539r143b1566],
22	randomly	RB	O	randomly	advmod	23	SENT_20	[p1l156t1536r314b1575],
23	assigned	VBD	O	assign	rcmod	1	SENT_20	[p1l326t1536r470b1575],
24	329	CD	NUMBER	329	num	25	SENT_20	[p1l483t1538r542b1567],
25	patients	NNS	O	patient	dobj	23	SENT_20	[p1l555t1536r685b1575],
26	Whose	WP$	O	whose	poss	27	SENT_20	[p1l697t1536r804b1567],
27	disease	NN	O	disease	nsubj	29	SENT_20	[p1l817t1536r935b1566],
28	had	VBD	O	have	aux	29	SENT_20	[p1l948t1536r1008b1566],
29	progressed	VBN	O	progress	rcmod	25	SENT_20	[p1l1021t1536r1203b1575],
30	during	IN	O	during	_	0	SENT_20	[p1l1217t1536r1327b1575],
31	or	CC	O	or	dep	32	SENT_20	[p1l1339t1546r1374b1566],
32	Within	IN	O	within	dep	29	SENT_20	[p1l1384t1536r1491b1567],
33	5_tt3dtI	NN	O	5_tt3dti	pobj	32	SENT_20	[p1l1530t1530r1729b1591],
34	:	:	O	:	_	0	SENT_20	[p1l1530t1530r1729b1591],
35	|	CD	NUMBER	|	num	37	SENT_20	[p1l1530t1530r1729b1591],
36	G	NN	O	g	nn	37	SENT_20	[p1l1530t1530r1729b1591],
37	°	NN	O	°	dep	33	SENT_20	[p1l1530t1530r1729b1591],
38	'	''	O	'	_	0	SENT_20	[p1l1530t1530r1729b1591],
39	f	FW	O	f	nn	40	SENT_20	[p1l1530t1530r1729b1591],
40	‘	FW	O	‘	amod	41	SENT_20	[p1l1530t1530r1729b1591],
41	t	NN	O	t	prep_during	29	SENT_20	[p1l1530t1530r1729b1591],
42	"	''	O	"	punct	41	SENT_20	[p1l1530t1530r1729b1591],
43	j	NN	O	j	nn	45	SENT_20	[p1l1530t1530r1729b1591],
44	"	''	O	"	punct	45	SENT_20	[p1l1530t1530r1729b1591],
45	é	NN	O	é	dep	41	SENT_20	[p1l1530t1530r1729b1591],
46	(	NN	O	(	dobj	29	SENT_20	[p1l1738t1532r1822b1591],
47	'	''	O	'	_	0	SENT_20	[p1l1738t1532r1822b1591],
48	\	CD	NUMBER	\	dep	46	SENT_20	[p1l1738t1532r1822b1591],
49	:	:	O	:	_	0	SENT_20	[p1l1738t1532r1822b1591],
50	EM	NNP	O	EM	dep	46	SENT_20	[p1l1738t1532r1822b1591],
51	_	SYM	O	_	dep	46	SENT_20	[p1l1738t1532r1822b1591],
52	-	:	O	-	_	0	SENT_20	[p1l1738t1532r1822b1591],
53	i	FW	O	i	nn	55	SENT_20	[p1l1738t1532r1822b1591],
54	[	FW	O	[	nn	55	SENT_20	[p1l1828t1530r1962b1591],
55	ft-H	NN	O	ft-h	dep	1	SENT_20	[p1l1828t1530r1962b1591],
56	-	:	O	-	_	0	SENT_20	[p1l1828t1530r1962b1591],
57	)	NN	O	)	dep	55	SENT_20	[p1l1828t1530r1962b1591],
58	:	:	O	:	_	0	SENT_20	[p1l1828t1530r1962b1591],
59	Land	NNP	O	Land	nn	61	SENT_20	[p1l1828t1530r1962b1591],
60	Unliéer	NNP	O	Unliéer	nn	61	SENT_20	[p1l1975t1532r2065b1591],
61	. . . . .	NNP	O	. . . . .	dep	57	SENT_20	[p1l1239t1586r1244b1591],[p1l602t1586r606b1591],
62	.	.	O	.	_	0	SENT_20	[p1l1310t1586r1315b1591],

1	SI	NNP	O	SI	nn	2	SENT_21	[p1l1530t1576r1548b1591],
2	OS	NNP	O	OS	nsubj	12	SENT_21	[p1l1611t1576r1638b1591],
3	I	PRP	O	I	dep	2	SENT_21	[p1l1660t1576r1662b1591],
4	3	CD	NUMBER	3	number	5	SENT_21	[p1l1676t1576r1688b1591],
5	35	CD	NUMBER	35	num	6	SENT_21	[p1l1733t1576r1759b1591],
6	UIS	NN	O	ui	dep	2	SENT_21	[p1l1789t1576r1824b1591],
7	El	NNP	O	El	nn	8	SENT_21	[p1l1843t1576r1867b1591],
8	’	NNP	O	’	dep	6	SENT_21	[p1l1843t1576r1867b1591],
9	,	,	O	,	_	0	SENT_21	[p1l1885t1587r1889b1595],
10	euven	NN	O	euven	appos	8	SENT_21	[p1l1920t1576r2002b1595],
11	,	,	O	,	_	0	SENT_21	[p1l1920t1576r2002b1595],
12	C	NN	O	c	_	0	SENT_21	[p1l2037t1576r2049b1591],
13	three	CD	DURATION	three	num	14	SENT_21	[p1l2059t1582r2065b1585, p1l92t1586r175b1616],
14	months	NNS	NUMBER	month	dep	17	SENT_21	[p1l184t1586r310b1616],
15	after	IN	O	after	dep	17	SENT_21	[p1l320t1585r395b1616],
16	treatment	NN	O	treatment	nsubj	17	SENT_21	[p1l403t1592r564b1616],
17	Wlth	VBD	O	wlth	ccomp	12	SENT_21	[p1l569t1586r643b1617],
18	an	DT	O	a	det	20	SENT_21	[p1l652t1596r691b1616],
19	irinotecan-based	JJ	O	irinotecan-based	amod	20	SENT_21	[p1l700t1586r975b1616],
20	regimen	NN	O	regimen	dobj	17	SENT_21	[p1l984t1596r1120b1625],
21	to	TO	O	to	aux	22	SENT_21	[p1l1129t1592r1160b1616],
22	receive	VB	O	receive	xcomp	17	SENT_21	[p1l1170t1596r1280b1616],
23	either	CC	O	either	dep	24	SENT_21	[p1l1290t1586r1384b1616],
24	cetux	NN	O	cetux	nn	40	SENT_21	[p1l1393t1592r1490b1617],
25	-	:	O	-	_	0	SENT_21	[p1l1393t1592r1490b1617],
26	gizm	NN	O	gizm	nn	28	SENT_21	[p1l1530t1576r1593b1636],
27	(	CD	NUMBER	(	num	28	SENT_21	[p1l1609t1576r1669b1636],
28	C3	NN	O	c3	dep	24	SENT_21	[p1l1609t1576r1669b1636],
29	,	,	O	,	_	0	SENT_21	[p1l1609t1576r1669b1636],
30	E_C	NN	O	e_c	nn	31	SENT_21	[p1l1683t1607r1746b1636],
31	_	NN	O	_	appos	28	SENT_21	[p1l1683t1607r1746b1636],
32	)	CD	NUMBER	)	number	33	SENT_21	[p1l1683t1607r1746b1636],
33	_	CD	NUMBER	_	num	36	SENT_21	[p1l1683t1607r1746b1636],
34	Address	NN	O	address	nn	36	SENT_21	[p1l1757t1605r1857b1629],
35	fepm	NN	O	fepm	nn	36	SENT_21	[p1l1869t1576r1951b1636],
36	mquests	NNS	O	mquest	dep	31	SENT_21	[p1l1963t1609r2065b1636],
37	imab	JJ	O	imab	amod	40	SENT_21	[p1l92t1636r174b1666],
38	and	CC	O	and	_	0	SENT_21	[p1l184t1636r245b1666],
39	irinotecan	JJ	O	irinotecan	amod	40	SENT_21	[p1l255t1636r420b1666],
40	(	NN	O	(	dobj	22	SENT_21	[p1l432t1639r474b1671],
41	at	IN	O	at	_	0	SENT_21	[p1l432t1639r474b1671],
42	the	DT	O	the	det	44	SENT_21	[p1l483t1636r533b1666],
43	same	JJ	O	same	amod	44	SENT_21	[p1l543t1646r628b1666],
44	dose	NN	O	dose	prep_at	22	SENT_21	[p1l638t1636r713b1666],
45	and	CC	O	and	_	0	SENT_21	[p1l723t1636r784b1666],
46	schedule	NN	O	schedule	conj_and	44	SENT_21	[p1l794t1636r937b1667],
47	as	IN	O	as	prep	22	SENT_21	[p1l947t1646r980b1666],
48	in	IN	O	in	pcomp	47	SENT_21	[p1l990t1636r1022b1666],
49	a	DT	O	a	det	52	SENT_21	[p1l1032t1646r1049b1666],
50	prestudy	JJ	O	prestudy	amod	52	SENT_21	[p1l1058t1636r1200b1675],
51	regimen	NN	O	regimen	nn	52	SENT_21	[p1l1209t1636r1345b1675],
52	[	NN	O	[	pobj	48	SENT_21	[p1l1358t1638r1429b1671],
53	218	CD	NUMBER	218	num	54	SENT_21	[p1l1358t1638r1429b1671],
54	pa	NN	O	pa	dep	72	SENT_21	[p1l1439t1646r1490b1675],
55	-	:	O	-	_	0	SENT_21	[p1l1439t1646r1490b1675],
56	to	TO	O	to	dep	54	SENT_21	[p1l1529t1647r1553b1666],
57	Dr.	NNP	O	Dr.	nn	58	SENT_21	[p1l1566t1645r1598b1666],
58	Cunningham	NNP	PERSON	Cunningham	pobj	56	SENT_21	[p1l1611t1642r1775b1674],
59	at	IN	O	at	_	0	SENT_21	[p1l1789t1647r1812b1666],
60	the	DT	O	the	det	61	SENT_21	[p1l1823t1642r1863b1666],
61	Department	NNP	O	Department	prep_at	58	SENT_21	[p1l1877t1645r2030b1673],
62	of	IN	O	of	_	0	SENT_21	[p1l2042t1642r2070b1666],
63	tients	NNS	O	tient	prep_of	61	SENT_21	[p1l92t1756r208b1791],
64	]	CD	NUMBER	]	number	65	SENT_21	[p1l92t1756r208b1791],
65	)	CD	NUMBER	)	dep	63	SENT_21	[p1l92t1756r208b1791],
66	or	CC	O	or	_	0	SENT_21	[p1l220t1766r255b1786],
67	cetuximab	JJ	O	cetuximab	amod	69	SENT_21	[p1l263t1756r432b1787],
68	monotherapy	NN	O	monotherapy	nn	69	SENT_21	[p1l441t1756r663b1795],
69	(	NN	O	(	conj_or	63	SENT_21	[p1l672t1758r743b1791],
70	111	CD	NUMBER	111	num	71	SENT_21	[p1l672t1758r743b1791],
71	patients	NNS	O	patient	dep	69	SENT_21	[p1l753t1756r906b1795],
72	)	CD	NUMBER	)	dep	22	SENT_21	[p1l753t1756r906b1795],
73	.	.	O	.	_	0	SENT_21	[p1l753t1756r906b1795],

1	In	IN	O	in	dep	20	SENT_22	[p1l917t1759r950b1786],
2	cases	NNS	O	case	pobj	1	SENT_22	[p1l960t1766r1044b1786],
3	of	IN	O	of	_	0	SENT_22	[p1l1055t1755r1094b1786],
4	disease	NN	O	disease	nn	5	SENT_22	[p1l1096t1756r1214b1786],
5	progression	NN	O	progression	prep_of	2	SENT_22	[p1l1223t1756r1429b1795],
6	,	,	O	,	_	0	SENT_22	[p1l1223t1756r1429b1795],
7	the	DT	O	the	det	9	SENT_22	[p1l1441t1756r1491b1786],
8	M	NN	O	m	dep	9	SENT_22	[p1l1532t1750r1652b1778],
9	‘	NN	O	‘	appos	5	SENT_22	[p1l1532t1750r1652b1778],
10	~	CD	NUMBER	~	num	9	SENT_22	[p1l1532t1750r1652b1778],
11	"	``	O	"	punct	9	SENT_22	[p1l1532t1750r1652b1778],
12	“	NN	O	“	nn	13	SENT_22	[p1l1532t1750r1652b1778],
13	C	NN	O	c	dep	9	SENT_22	[p1l1532t1750r1652b1778],
14	‘	CD	NUMBER	‘	dep	13	SENT_22	[p1l1532t1750r1652b1778],
15	"	``	O	"	punct	20	SENT_22	[p1l1532t1750r1652b1778],
16	°	CD	NUMBER	°	num	20	SENT_22	[p1l1532t1750r1652b1778],
17	v	LS	O	v	dep	20	SENT_22	[p1l1532t1750r1652b1778],
18	R	NN	O	r	nn	20	SENT_22	[p1l1663t1750r1726b1781],
19	°	CD	NUMBER	°	num	20	SENT_22	[p1l1663t1750r1726b1781],
20	Ya	NN	O	ya	_	0	SENT_22	[p1l1663t1750r1726b1781],
21	'	''	O	'	_	0	SENT_22	[p1l1663t1750r1726b1781],
22	Mmde	JJ	O	mmde	amod	23	SENT_22	[p1l1738t1750r1846b1773],
23	”	NN	O	”	dep	20	SENT_22	[p1l1738t1750r1846b1773],
24	H	NN	O	h	prep	23	SENT_22	[p1l1857t1750r1969b1793],
25	°	CD	NUMBER	°	num	27	SENT_22	[p1l1857t1750r1969b1793],
26	5P	NN	O	5p	nn	27	SENT_22	[p1l1857t1750r1969b1793],
27	”	NN	O	”	dep	24	SENT_22	[p1l1857t1750r1969b1793],
28	?	.	O	?	_	0	SENT_22	[p1l1857t1750r1969b1793],
29	"	''	O	"	punct	23	SENT_22	[p1l1857t1750r1969b1793],

1	v	LS	O	v	prep	15	SENT_23	[p1l1857t1750r1969b1793],
2	D	NN	ORGANIZATION	d	dep	1	SENT_23	[p1l1980t1752r2065b1793],
3	°	CD	NUMBER	°	number	4	SENT_23	[p1l1980t1752r2065b1793],
4	‘	CD	NUMBER	‘	dep	5	SENT_23	[p1l1980t1752r2065b1793],
5	_	NN	O	_	dep	2	SENT_23	[p1l1980t1752r2065b1793],
6	”“	CD	NUMBER	”“	number	7	SENT_23	[p1l1980t1752r2065b1793],
7	5	CD	NUMBER	5	num	8	SENT_23	[p1l1980t1752r2065b1793],
8	addition	NN	O	addition	nsubjpass	15	SENT_23	[p1l92t1806r229b1836],
9	of	IN	O	of	_	0	SENT_23	[p1l243t1805r282b1836],
10	irinotecan	NN	O	irinotecan	prep_of	8	SENT_23	[p1l289t1806r455b1836],
11	to	TO	O	to	_	0	SENT_23	[p1l469t1812r500b1836],
12	cetuximab	JJ	O	cetuximab	amod	13	SENT_23	[p1l515t1806r684b1837],
13	monotherapy	NN	O	monotherapy	prep_to	10	SENT_23	[p1l698t1806r920b1845],
14	was	VBD	O	be	auxpass	15	SENT_23	[p1l931t1816r993b1837],
15	permitted	VBN	O	permit	_	0	SENT_23	[p1l1008t1806r1178b1845],
16	.	.	O	.	_	0	SENT_23	[p1l1008t1806r1178b1845],

1	The	DT	O	the	det	2	SENT_24	[p1l1193t1806r1255b1836],
2	patients	NNS	O	patient	nsubj	4	SENT_24	[p1l1269t1806r1399b1845],
3	were	VBD	O	be	cop	4	SENT_24	[p1l1413t1816r1491b1836],
4	Lnkg	NNP	O	Lnkg	_	0	SENT_24	[p1l1530t1787r2065b1856],
5	:	:	O	:	_	0	SENT_24	[p1l1530t1787r2065b1856],
6	evaluated	VBN	O	evaluate	dep	4	SENT_24	[p1l93t1856r245b1887],
7	radiologically	RB	O	radiologically	advmod	6	SENT_24	[p1l255t1856r478b1895],
8	for	IN	O	for	_	0	SENT_24	[p1l486t1855r534b1886],
9	tumor	NN	O	tumor	nn	10	SENT_24	[p1l543t1862r645b1887],
10	response	NN	O	response	prep_for	6	SENT_24	[p1l654t1866r801b1895],
11	and	CC	O	and	_	0	SENT_24	[p1l811t1856r871b1886],
12	were	VBD	O	be	auxpass	14	SENT_24	[p1l879t1866r957b1887],
13	also	RB	O	also	advmod	14	SENT_24	[p1l967t1856r1032b1886],
14	evaluated	VBN	O	evaluate	conj_and	6	SENT_24	[p1l1043t1856r1195b1887],
15	for	IN	O	for	_	0	SENT_24	[p1l1205t1855r1253b1886],
16	the	DT	O	the	det	17	SENT_24	[p1l1262t1856r1312b1886],
17	time	NN	O	time	prep_for	14	SENT_24	[p1l1322t1856r1395b1886],
18	to	TO	O	to	_	0	SENT_24	[p1l1405t1862r1436b1886],
19	tumor	NN	O	tumor	nn	20	SENT_24	[p1l1446t1862r1490b1887, p1l92t1916r161b1936],
20	progression	NN	O	progression	prep_to	14	SENT_24	[p1l169t1906r375b1945],
21	,	,	O	,	_	0	SENT_24	[p1l169t1906r375b1945],
22	survival	NN	O	survival	prep_to	14	SENT_24	[p1l387t1906r520b1943],
23	,	,	O	,	_	0	SENT_24	[p1l387t1906r520b1943],
24	and	CC	O	and	_	0	SENT_24	[p1l531t1906r592b1936],
25	side	JJ	O	side	amod	26	SENT_24	[p1l602t1906r666b1936],
26	effects	NNS	O	effect	conj_and	20	SENT_24	[p1l676t1905r781b1936],
27	of	IN	O	of	_	0	SENT_24	[p1l792t1905r831b1936],
28	treatment	NN	O	treatment	prep_of	26	SENT_24	[p1l833t1912r1001b1936],
29	.	.	O	.	_	0	SENT_24	[p1l833t1912r1001b1936],

1	zpiggtJ	NN	O	zpiggtj	_	0	SENT_25	[p1l1530t1900r1861b1967],
2	©	CD	NUMBER	©	num	3	SENT_25	[p1l1530t1900r1861b1967],
3	M	NN	O	m	rcmod	1	SENT_25	[p1l1530t1900r1861b1967],
4	;	:	O	;	_	0	SENT_25	[p1l1530t1900r1861b1967],
5	‘	CD	NUMBER	‘	number	6	SENT_25	[p1l1530t1900r1861b1967],
6	:42	CD	NUMBER	:42	dep	3	SENT_25	[p1l1530t1900r1861b1967],
7	ABS	NNS	O	ab	dep	6	SENT_25	[p1l1530t1900r1861b1967],
8	:	:	O	:	_	0	SENT_25	[p1l1530t1900r1861b1967],
9	:	:	O	:	_	0	SENT_25	[p1l1530t1900r1861b1967],
10	:	:	O	:	_	0	SENT_25	[p1l1530t1900r1861b1967],
11	:	:	O	:	_	0	SENT_25	[p1l1530t1900r1861b1967],
12	u	NN	O	u	dep	10	SENT_25	[p1l1530t1900r1861b1967],
13	:	:	O	:	_	0	SENT_25	[p1l1530t1900r1861b1967],
14	:	:	O	:	_	0	SENT_25	[p1l1530t1900r1861b1967],
15	’	CD	NUMBER	’	number	16	SENT_25	[p1l1530t1900r1861b1967],
16	Z	NN	O	z	dep	12	SENT_25	[p1l1866t1902r1943b1961],
17	/	:	O	/	punct	16	SENT_25	[p1l1866t1902r1943b1961],
18	;	:	O	;	_	0	SENT_25	[p1l1866t1902r1943b1961],
19	:	:	O	:	_	0	SENT_25	[p1l1866t1902r1943b1961],
20	'	''	O	'	_	0	SENT_25	[p1l1866t1902r1943b1961],
21	;	:	O	;	_	0	SENT_25	[p1l1866t1902r1943b1961],
22	C	NN	O	c	dep	1	SENT_25	[p1l1866t1902r1943b1961],
23	-	:	O	-	_	0	SENT_25	[p1l1866t1902r1943b1961],
24	“	NN	O	“	dep	1	SENT_25	[p1l1866t1902r1943b1961],
25	I	PRP	O	I	dobj	24	SENT_25	[p1l1866t1902r1943b1961],
26	Society	NNP	O	Society	dep	1	SENT_25	[p1l1950t1943r2018b1967],

1	R	NN	O	r	nn	2	SENT_26	[p1l94t2016r108b2035],
2	E	NN	O	e	nsubj	5	SENT_26	[p1l115t2016r128b2036],
3	s	VBZ	O	s	cop	5	SENT_26	[p1l133t2016r147b2036],
4	u	FW	O	u	nn	5	SENT_26	[p1l154t2016r171b2036],
5	LTS	FW	O	lts	_	0	SENT_26	[p1l179t2016r229b2036],
6	The	DT	O	the	det	7	SENT_26	[p1l91t2055r154b2086],
7	rate	NN	O	rate	nsubj	16	SENT_26	[p1l165t2062r226b2086],
8	of	IN	O	of	_	0	SENT_26	[p1l238t2055r277b2086],
9	response	NN	O	response	prep_of	7	SENT_26	[p1l282t2065r429b2095],
10	in	IN	O	in	_	0	SENT_26	[p1l441t2056r472b2086],
11	the	DT	O	the	det	13	SENT_26	[p1l484t2055r534b2086],
12	combination-therapy	JJ	O	combination-therapy	amod	13	SENT_26	[p1l546t2055r894b2095],
13	group	NN	O	group	prep_in	9	SENT_26	[p1l904t2065r1001b2095],
14	was	VBD	O	be	cop	16	SENT_26	[p1l1011t2066r1074b2086],
15	signiﬁcantly	RB	O	signiﬁcantly	advmod	16	SENT_26	[p1l1087t2055r1289b2095],
16	higher	JJR	O	higher	rcmod	5	SENT_26	[p1l1299t2055r1407b2095],
17	than	IN	O	than	_	0	SENT_26	[p1l1418t2055r1491b2086],
18	that	DT	O	that	det	44	SENT_26	[p1l92t2105r158b2136],
19	in	IN	O	in	_	0	SENT_26	[p1l165t2106r197b2136],
20	the	DT	O	the	det	22	SENT_26	[p1l207t2105r258b2136],
21	monotherapy	NN	O	monotherapy	nn	22	SENT_26	[p1l268t2105r493b2145],
22	group	NN	O	group	prep_in	41	SENT_26	[p1l501t2115r600b2145],
23	(	CD	PERCENT	(	number	24	SENT_26	[p1l612t2108r696b2141],
24	22.9	CD	PERCENT	22.9	num	25	SENT_26	[p1l612t2108r696b2141],
25	percent	NN	PERCENT	percent	dep	22	SENT_26	[p1l706t2112r832b2145],
26	[	CD	PERCENT	[	number	27	SENT_26	[p1l844t2108r893b2141],
27	95	CD	PERCENT	95	dep	22	SENT_26	[p1l844t2108r893b2141],
28	percent	NN	PERCENT	percent	nn	30	SENT_26	[p1l904t2112r1031b2145],
29	conﬁdence	NN	O	conﬁdence	nn	30	SENT_26	[p1l1039t2105r1221b2136],
30	interval	NN	O	interval	dep	27	SENT_26	[p1l1231t2105r1365b2143],
31	,	,	O	,	_	0	SENT_26	[p1l1231t2105r1365b2143],
32	17.5	CD	NUMBER	17.5	number	34	SENT_26	[p1l1378t2108r1448b2136],
33	to	TO	O	to	dep	34	SENT_26	[p1l1459t2112r1490b2136],
34	29.1	CD	PERCENT	29.1	num	35	SENT_26	[p1l92t2158r164b2186],
35	percent	NN	PERCENT	percent	appos	22	SENT_26	[p1l179t2158r313b2194],
36	]	CD	PERCENT	]	num	35	SENT_26	[p1l179t2158r313b2194],
37	vs.	CC	PERCENT	vs.	prep	35	SENT_26	[p1l329t2165r371b2186],
38	10.8	CD	PERCENT	10.8	num	39	SENT_26	[p1l388t2158r457b2186],
39	percent	NN	PERCENT	percent	dep	37	SENT_26	[p1l471t2162r595b2194],
40	[	CD	PERCENT	[	number	41	SENT_26	[p1l611t2158r660b2190],
41	95	CD	PERCENT	95	nn	44	SENT_26	[p1l611t2158r660b2190],
42	percent	NN	PERCENT	percent	nn	44	SENT_26	[p1l674t2162r798b2194],
43	conﬁdence	NN	O	conﬁdence	nn	44	SENT_26	[p1l810t2155r989b2186],
44	interval	NN	O	interval	prep_than	16	SENT_26	[p1l1003t2155r1134b2192],
45	,	,	O	,	_	0	SENT_26	[p1l1003t2155r1134b2192],
46	5.7	CD	NUMBER	5.7	number	48	SENT_26	[p1l1150t2158r1199b2186],
47	to	TO	O	to	dep	48	SENT_26	[p1l1214t2162r1244b2186],
48	18.1	CD	PERCENT	18.1	num	50	SENT_26	[p1l1260t2158r1329b2186],
49	percent	NN	PERCENT	percent	nn	50	SENT_26	[p1l1342t2158r1489b2194],
50	]	NN	O	]	appos	44	SENT_26	[p1l1342t2158r1489b2194],
51	,	,	O	,	_	0	SENT_26	[p1l1342t2158r1489b2194],
52	P	NN	O	p	appos	44	SENT_26	[p1l92t2207r256b2240],
53	=	JJ	O	=	amod	55	SENT_26	[p1l92t2207r256b2240],
54	0.007	CD	NUMBER	0.007	tmod	53	SENT_26	[p1l92t2207r256b2240],
55	)	NN	O	)	dep	52	SENT_26	[p1l92t2207r256b2240],
56	.	.	O	.	_	0	SENT_26	[p1l92t2207r256b2240],

1	The	DT	O	the	det	3	SENT_27	[p1l269t2204r332b2235],
2	median	JJ	O	median	amod	3	SENT_27	[p1l344t2204r466b2235],
3	time	NN	O	time	nsubj	8	SENT_27	[p1l479t2205r551b2235],
4	to	TO	O	to	_	0	SENT_27	[p1l564t2211r594b2235],
5	progression	NN	O	progression	prep_to	3	SENT_27	[p1l606t2205r803b2244],
6	was	VBD	O	be	cop	8	SENT_27	[p1l814t2215r876b2236],
7	signiﬁcantly	RB	O	signiﬁcantly	advmod	8	SENT_27	[p1l890t2204r1092b2244],
8	greater	JJR	O	greater	_	0	SENT_27	[p1l1102t2211r1218b2244],
9	in	IN	O	in	_	0	SENT_27	[p1l1228t2205r1260b2235],
10	the	DT	O	the	det	13	SENT_27	[p1l1272t2204r1322b2235],
11	combination-therapy	JJ	O	combination-therapy	amod	13	SENT_27	[p1l1335t2204r1490b2235, p1l92t2254r295b2293],
12	group	NN	O	group	nn	13	SENT_27	[p1l302t2264r399b2293],
13	(	NN	O	(	prep_in	8	SENT_27	[p1l410t2256r472b2289],
14	4.1	CD	NUMBER	4.1	amod	13	SENT_27	[p1l410t2256r472b2289],
15	vs.	CC	O	vs.	prep	13	SENT_27	[p1l479t2264r522b2285],
16	1.5	CD	DURATION	1.5	num	17	SENT_27	[p1l534t2256r582b2284],
17	months	NNS	NUMBER	month	dep	15	SENT_27	[p1l592t2254r727b2291],
18	,	,	O	,	_	0	SENT_27	[p1l592t2254r727b2291],
19	P	NN	O	p	npadvmod	20	SENT_27	[p1l738t2256r873b2284],
20	<	JJR	O	<	dep	8	SENT_27	[p1l738t2256r873b2284],
21	0.001	CD	NUMBER	0.001	dep	8	SENT_27	[p1l738t2256r873b2284],
22	by	IN	O	by	_	0	SENT_27	[p1l883t2254r920b2293],
23	the	DT	O	the	det	26	SENT_27	[p1l927t2254r977b2284],
24	log-rank	JJ	O	log-rank	amod	26	SENT_27	[p1l986t2254r1128b2293],
25	test	NN	O	test	nn	26	SENT_27	[p1l1135t2256r1215b2289],
26	)	NN	O	)	prep_by	8	SENT_27	[p1l1135t2256r1215b2289],
27	.	.	O	.	_	0	SENT_27	[p1l1135t2256r1215b2289],

1	The	DT	O	the	det	4	SENT_28	[p1l1224t2254r1287b2284],
2	median	JJ	O	median	amod	4	SENT_28	[p1l1296t2254r1418b2284],
3	survival	NN	O	survival	nn	4	SENT_28	[p1l1427t2264r1490b2285, p1l91t2303r164b2334],
4	time	NN	O	time	nsubj	23	SENT_28	[p1l177t2303r249b2333],
5	was	VBD	O	be	cop	23	SENT_28	[p1l261t2313r323b2334],
6	8.6	CD	DURATION	8.6	num	7	SENT_28	[p1l337t2305r387b2333],
7	months	NNS	NUMBER	month	nn	23	SENT_28	[p1l401t2303r527b2333],
8	in	IN	O	in	_	0	SENT_28	[p1l541t2303r572b2333],
9	the	DT	O	the	det	11	SENT_28	[p1l585t2303r636b2333],
10	combination-therapy	JJ	O	combination-therapy	amod	11	SENT_28	[p1l649t2303r997b2342],
11	group	NN	O	group	prep_in	7	SENT_28	[p1l1008t2313r1105b2342],
12	and	CC	O	and	_	0	SENT_28	[p1l1119t2303r1179b2333],
13	6.9	CD	DURATION	6.9	num	14	SENT_28	[p1l1193t2305r1243b2333],
14	months	NNS	NUMBER	month	nn	23	SENT_28	[p1l1256t2303r1382b2333],
15	in	IN	O	in	_	0	SENT_28	[p1l1396t2303r1427b2333],
16	the	DT	O	the	det	20	SENT_28	[p1l1441t2303r1491b2333],
17	monotherapy	NN	O	monotherapy	nn	20	SENT_28	[p1l92t2352r314b2392],
18	group	NN	O	group	nn	20	SENT_28	[p1l324t2362r422b2392],
19	(	CD	NUMBER	(	num	20	SENT_28	[p1l437t2355r592b2388],
20	P	NN	O	p	prep_in	14	SENT_28	[p1l437t2355r592b2388],
21	=	JJ	O	=	amod	23	SENT_28	[p1l437t2355r592b2388],
22	0.48	CD	NUMBER	0.48	tmod	21	SENT_28	[p1l437t2355r592b2388],
23	)	NN	O	)	_	0	SENT_28	[p1l437t2355r592b2388],
24	.	.	O	.	_	0	SENT_28	[p1l437t2355r592b2388],

1	Toxic	JJ	O	toxic	amod	2	SENT_29	[p1l605t2353r693b2383],
2	eﬁects	NNS	O	eﬁects	nsubj	5	SENT_29	[p1l705t2352r810b2383],
3	were	VBD	O	be	cop	5	SENT_29	[p1l822t2362r900b2384],
4	more	RBR	O	more	advmod	5	SENT_29	[p1l913t2362r998b2383],
5	frequent	JJ	O	frequent	_	0	SENT_29	[p1l1011t2352r1151b2392],
6	in	IN	O	in	_	0	SENT_29	[p1l1161t2353r1192b2383],
7	the	DT	O	the	det	9	SENT_29	[p1l1205t2352r1255b2383],
8	combinationtherapy	JJ	O	combinationtherapy	amod	9	SENT_29	[p1l1268t2352r1490b2383, p1l92t2402r215b2441],
9	group	NN	O	group	prep_in	5	SENT_29	[p1l223t2412r330b2441],
10	,	,	O	,	_	0	SENT_29	[p1l223t2412r330b2441],
11	but	CC	O	but	_	0	SENT_29	[p1l341t2402r396b2433],
12	their	PRP$	O	they	poss	13	SENT_29	[p1l403t2402r480b2432],
13	severity	NN	O	severity	nsubj	17	SENT_29	[p1l489t2402r611b2441],
14	and	CC	O	and	_	0	SENT_29	[p1l618t2402r679b2432],
15	incidence	NN	O	incidence	conj_and	13	SENT_29	[p1l688t2402r844b2432],
16	were	VBD	O	be	cop	17	SENT_29	[p1l852t2412r930b2433],
17	similar	JJ	O	similar	conj_but	5	SENT_29	[p1l939t2402r1057b2432],
18	to	TO	O	to	_	0	SENT_29	[p1l1065t2408r1097b2432],
19	those	DT	O	those	prep_to	17	SENT_29	[p1l1107t2402r1197b2432],
20	that	WDT	O	that	nsubjpass	23	SENT_29	[p1l1207t2402r1273b2432],
21	would	MD	O	would	aux	23	SENT_29	[p1l1280t2402r1384b2433],
22	be	VB	O	be	auxpass	23	SENT_29	[p1l1394t2402r1432b2432],
23	expected	VBN	O	expect	rcmod	19	SENT_29	[p1l1442t2412r1490b2432, p1l92t2451r201b2490],
24	with	IN	O	with	_	0	SENT_29	[p1l209t2451r283b2482],
25	irinotecan	NN	O	irinotecan	prep_with	23	SENT_29	[p1l292t2451r458b2482],
26	alone	RB	O	alone	advmod	23	SENT_29	[p1l467t2451r565b2482],
27	.	.	O	.	_	0	SENT_29	[p1l467t2451r565b2482],

1	c	NN	O	c	nn	7	SENT_30	[p1l93t2561r109b2581],
2	o	NN	O	o	nn	7	SENT_30	[p1l114t2561r135b2581],
3	N	NN	O	n	nn	7	SENT_30	[p1l143t2561r159b2581],
4	c	NN	O	c	nn	7	SENT_30	[p1l167t2561r184b2581],
5	L	NN	O	l	nn	7	SENT_30	[p1l190t2561r202b2581],
6	u	NN	O	u	nn	7	SENT_30	[p1l208t2561r225b2581],
7	s	NNS	O	s	dep	8	SENT_30	[p1l231t2561r245b2581],
8	I	PRP	O	I	dep	13	SENT_30	[p1l252t2561r257b2581],
9	o	NN	O	o	nn	10	SENT_30	[p1l264t2561r285b2581],
10	N	NN	O	n	nsubj	11	SENT_30	[p1l293t2561r310b2581],
11	s	VBZ	O	s	parataxis	13	SENT_30	[p1l317t2561r331b2581],
12	Cetuximab	NNP	O	Cetuximab	nsubj	13	SENT_30	[p1l92t2598r269b2630],
13	has	VBZ	O	have	_	0	SENT_30	[p1l281t2598r335b2629],
14	clinically	RB	O	clinically	advmod	15	SENT_30	[p1l348t2598r494b2638],
15	signiﬁcant	JJ	O	signiﬁcant	amod	16	SENT_30	[p1l504t2598r679b2638],
16	activity	NN	O	activity	dobj	13	SENT_30	[p1l688t2599r803b2638],
17	when	WRB	O	when	advmod	18	SENT_30	[p1l810t2598r901b2629],
18	given	VBN	O	give	ccomp	16	SENT_30	[p1l912t2599r999b2638],
19	alone	RB	O	alone	advmod	18	SENT_30	[p1l1010t2598r1099b2629],
20	or	CC	O	or	_	0	SENT_30	[p1l1111t2608r1145b2629],
21	in	IN	O	in	ccomp	16	SENT_30	[p1l1155t2599r1187b2629],
22	combination	NN	O	combination	pobj	21	SENT_30	[p1l1199t2598r1408b2629],
23	with	IN	O	with	_	0	SENT_30	[p1l1417t2598r1491b2629],
24	irinotecan	NN	O	irinotecan	prep_with	21	SENT_30	[p1l92t2647r258b2677],
25	in	IN	O	in	_	0	SENT_30	[p1l267t2647r299b2676],
26	patients	NNS	O	patient	prep_in	21	SENT_30	[p1l308t2647r438b2685],
27	with	IN	O	with	_	0	SENT_30	[p1l446t2646r520b2677],
28	irinotecan-refractory	JJ	O	irinotecan-refractory	amod	30	SENT_30	[p1l529t2646r869b2685],
29	colorectal	JJ	O	colorectal	amod	30	SENT_30	[p1l878t2646r1038b2677],
30	cancer	NN	O	cancer	prep_with	26	SENT_30	[p1l1048t2656r1161b2677],
31	.	.	O	.	_	0	SENT_30	[p1l1048t2656r1161b2677],

1	N	NN	O	n	nn	2	SENT_31	[p1l429t2762r443b2777],
2	ENGLJ	NN	O	englj	nsubj	3	SENT_31	[p1l458t2761r542b2783],
3	MED	VBD	O	med	_	0	SENT_31	[p1l557t2762r609b2777],
4	351,4	CD	NUMBER	351,4	num	6	SENT_31	[p1l622t2761r686b2783],
5	WWW.NEJM.ORG	NNP	O	WWW.NEJM.ORG	nn	6	SENT_31	[p1l720t2761r932b2783],
6	JULY	NNP	DATE	JULY	dobj	3	SENT_31	[p1l965t2762r1025b2783],
7	22	CD	DATE	22	num	6	SENT_31	[p1l1037t2761r1074b2781],
8	,	,	DATE	,	_	0	SENT_31	[p1l1037t2761r1074b2781],
9	2004	CD	DATE	2004	num	10	SENT_31	[p1l1087t2761r1155b2783],
10	337	CD	NUMBER	337	appos	6	SENT_31	[p1l2008t2760r2065b2782],

1	The	DT	O	the	det	4	SENT_32	[p1l750t2858r801b2882],
2	New	NNP	O	New	nn	4	SENT_32	[p1l810t2859r872b2882],
3	England	NNP	O	England	nn	4	SENT_32	[p1l882t2858r992b2889],
4	Joumal	NNP	O	Joumal	_	0	SENT_32	[p1l1001t2858r1098b2882],
5	of	IN	O	of	_	0	SENT_32	[p1l1108t2858r1137b2882],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_32	[p1l1144t2858r1269b2882],

1	Downloaded	VBN	O	download	_	0	SENT_33	[p1l193t2899r362b2922],
2	from	IN	O	from	_	0	SENT_33	[p1l371t2899r436b2922],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_33	[p1l445t2899r563b2929],
4	at	IN	O	at	_	0	SENT_33	[p1l573t2902r596b2922],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_33	[p1l605t2899r787b2922],
6	on	IN	O	on	_	0	SENT_33	[p1l797t2906r829b2922],
7	January	NNP	DATE	January	prep_on	1	SENT_33	[p1l838t2899r940b2929],
8	5	CD	DATE	5	num	7	SENT_33	[p1l950t2899r973b2926],
9	,	,	DATE	,	_	0	SENT_33	[p1l950t2899r973b2926],
10	2014	CD	DATE	2014	num	7	SENT_33	[p1l984t2899r1056b2922],
11	.	.	O	.	_	0	SENT_33	[p1l984t2899r1056b2922],

1	For	IN	O	for	_	0	SENT_34	[p1l1066t2899r1113b2922],
2	personal	JJ	O	personal	amod	3	SENT_34	[p1l1121t2899r1233b2929],
3	use	NN	O	use	pobj	1	SENT_34	[p1l1243t2906r1286b2922],
4	only	RB	O	only	advmod	3	SENT_34	[p1l1296t2899r1360b2929],
5	.	.	O	.	_	0	SENT_34	[p1l1296t2899r1360b2929],

1	No	DT	O	no	det	3	SENT_35	[p1l1371t2899r1411b2922],
2	other	JJ	O	other	amod	3	SENT_35	[p1l1421t2899r1489b2922],
3	uses	NNS	O	use	_	0	SENT_35	[p1l1497t2906r1553b2922],
4	without	IN	O	without	_	0	SENT_35	[p1l1563t2899r1664b2922],
5	permission	NN	O	permission	prep_without	3	SENT_35	[p1l1673t2899r1825b2929],
6	.	.	O	.	_	0	SENT_35	[p1l1673t2899r1825b2929],

1	Copyright	NN	O	copyright	_	0	SENT_36	[p1l543t2940r677b2971],
2	©	CD	NUMBER	©	num	6	SENT_36	[p1l687t2940r710b2964],
3	2004	CD	DATE	2004	num	6	SENT_36	[p1l720t2940r785b2964],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_36	[p1l795t2940r986b2964],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_36	[p1l996t2940r1103b2964],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_36	[p1l1114t2940r1219b2971],
7	.	.	O	.	_	0	SENT_36	[p1l1114t2940r1219b2971],

1	All	DT	O	all	det	2	SENT_37	[p1l1230t2940r1271b2964],
2	rights	NNS	O	rights	nsubj	3	SENT_37	[p1l1280t2940r1355b2971],
3	reserved	VBN	O	reserve	_	0	SENT_37	[p1l1365t2940r1484b2964],
4	.	.	O	.	_	0	SENT_37	[p1l1365t2940r1484b2964],

1	The	DT	O	the	det	4	SENT_38	[p1l715t3046r752b3067],
2	NEW	NNP	O	NEW	nn	4	SENT_38	[p1l764t3048r845b3067],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_38	[p1l859t3048r1034b3067],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_38	[p1l1048t3048r1214b3074],
5	ofMEDICINE	NN	O	ofmedicine	dep	4	SENT_38	[p1l1228t3046r1444b3073],

1	N	NN	O	n	nsubj	18	SENT_39	[p1l222t3279r290b3335],
2	THE	DT	DATE	the	det	4	SENT_39	[p1l322t3279r509b3334],
3	PAST	NN	DATE	past	nn	4	SENT_39	[p1l544t3279r753b3335],
4	DECADE	NN	DATE	decade	dep	1	SENT_39	[p1l785t3279r1173b3352],
5	,	,	O	,	_	0	SENT_39	[p1l785t3279r1173b3352],
6	THE	DT	O	the	det	8	SENT_39	[p1l1206t3279r1394b3334],
7	MEDIAN	NNP	O	MEDIAN	nn	8	SENT_39	[p1l1427t3279r1808b3335],
8	DURAtion	NN	O	duration	nsubj	18	SENT_39	[p1l1845t3279r2134b3335, p1l220t3387r387b3464],
9	of	IN	O	of	_	0	SENT_39	[p1l449t3385r550b3464],
10	survival	NN	O	survival	prep_of	8	SENT_39	[p1l595t3386r920b3465],
11	among	IN	O	among	_	0	SENT_39	[p1l982t3411r1285b3486],
12	patients	NNS	O	patient	prep_among	10	SENT_39	[p1l1343t3387r1685b3486],
13	with	IN	O	with	_	0	SENT_39	[p1l1745t3386r1938b3465],
14	advanced	JJ	O	advanced	amod	16	SENT_39	[p1l2000t3386r2133b3464, p1l215t3514r514b3594],
15	colorectal	JJ	O	colorectal	amod	16	SENT_39	[p1l545t3515r968b3593],
16	cancer	NN	O	cancer	prep_with	12	SENT_39	[p1l999t3540r1280b3593],
17	has	VBZ	O	have	aux	18	SENT_39	[p1l1307t3515r1451b3593],
18	increased	VBN	O	increase	_	0	SENT_39	[p1l1483t3515r1893b3593],
19	from	IN	O	from	prep	18	SENT_39	[p1l1924t3514r2134b3593],

1	12	CD	DURATION	12	num	2	SENT_40	[p1l15t3649r112b3721],
2	months	NNS	DURATION	month	_	0	SENT_40	[p1l136t3644r458b3722],
3	to	TO	O	to	aux	4	SENT_40	[p1l483t3660r562b3722],
4	about	IN	DURATION	about	infmod	2	SENT_40	[p1l586t3644r827b3723],
5	18	CD	DURATION	18	number	7	SENT_40	[p1l848t3649r944b3722],
6	to	TO	DURATION	to	dep	7	SENT_40	[p1l969t3660r1047b3722],
7	21	CD	DURATION	21	num	8	SENT_40	[p1l1072t3649r1172b3721],
8	months	NNS	NUMBER	month	pobj	4	SENT_40	[p1l1195t3644r1542b3739],
9	,	,	O	,	_	0	SENT_40	[p1l1195t3644r1542b3739],
10	mainly	RB	O	mainly	advmod	4	SENT_40	[p1l1570t3644r1857b3744],
11	owing	VBG	O	owe	partmod	2	SENT_40	[p1l1877t3644r2139b3744],
12	to	TO	O	to	_	0	SENT_40	[p2l12t37r90b99],
13	the	DT	O	the	det	14	SENT_40	[p2l123t21r253b99],
14	introduction	NN	O	introduction	prep_to	11	SENT_40	[p2l288t21r829b100],
15	of	IN	O	of	_	0	SENT_40	[p2l865t20r967b99],
16	irinotecan	NN	O	irinotecan	prep_of	14	SENT_40	[p2l982t21r1420b99],
17	and	CC	O	and	_	0	SENT_40	[p2l1454t21r1612b99],
18	oxaliplatin	NN	O	oxaliplatin	conj_and	16	SENT_40	[p2l1647t20r2129b121],
19	.	.	O	.	_	0	SENT_40	[p2l1647t20r2129b121],

1	Irinotecan	NNP	O	Irinotecan	nsubj	2	SENT_41	[p2l10t149r451b227],
2	(	VBD	O	(	_	0	SENT_41	[p2l496t156r569b240],
3	a	DT	O	a	det	5	SENT_41	[p2l496t156r569b240],
4	semisynthetic	JJ	O	semisynthetic	amod	5	SENT_41	[p2l609t149r1190b249],
5	camptothecin	NN	O	camptothecin	dobj	2	SENT_41	[p2l1230t148r1834b249],
6	,	,	O	,	_	0	SENT_41	[p2l1230t148r1834b249],
7	which	WDT	O	which	nsubj	8	SENT_41	[p2l1875t149r2135b228],
8	inhibits	VBZ	O	inhibit	rcmod	5	SENT_41	[p2l11t277r332b355],
9	topoisomerase	NN	O	topoisomerase	dobj	8	SENT_41	[p2l368t277r991b377],
10	I	PRP	O	I	nsubj	13	SENT_41	[p2l1023t284r1082b368],
11	)	VBP	O	)	rcmod	9	SENT_41	[p2l1023t284r1082b368],
12	and	CC	O	and	_	0	SENT_41	[p2l1119t277r1275b355],
13	oxaliplatin	VBP	O	oxaliplatin	conj_and	11	SENT_41	[p2l1308t276r1755b377],
14	(	CD	NUMBER	(	dobj	11	SENT_41	[p2l1792t283r1866b368],
15	a	DT	O	a	det	19	SENT_41	[p2l1792t283r1866b368],
16	thirdgeneration	NN	O	thirdgeneration	nn	19	SENT_41	[p2l1898t276r2134b355, p2l11t405r465b505],
17	platinum	NN	O	platinum	nn	19	SENT_41	[p2l505t405r891b505],
18	compound	NN	O	compound	nn	19	SENT_41	[p2l932t405r1420b505],
19	)	NN	O	)	nsubjpass	22	SENT_41	[p2l932t405r1420b505],
20	are	VBP	O	be	auxpass	22	SENT_41	[p2l1466t431r1591b483],
21	widely	RB	O	widely	advmod	22	SENT_41	[p2l1628t404r1904b505],
22	used	VBN	O	use	rcmod	14	SENT_41	[p2l1940t405r2135b484],
23	in	IN	O	in	_	0	SENT_41	[p2l11t533r92b610],
24	combination	NN	O	combination	prep_in	22	SENT_41	[p2l115t533r655b611],
25	with	IN	O	with	_	0	SENT_41	[p2l674t532r862b612],
26	ﬂuorouracil	NN	O	ﬂuorouracil	prep_with	22	SENT_41	[p2l885t532r1383b612],
27	and	CC	O	and	_	0	SENT_41	[p2l1405t533r1561b611],
28	leucovorin	NN	O	leucovorin	prep_with	22	SENT_41	[p2l1583t533r2027b612],
29	as	IN	O	as	_	0	SENT_41	[p2l2049t559r2133b611],
30	first	JJ	ORDINAL	first	amod	33	SENT_41	[p2l11t660r381b739],
31	—	NN	O	—	nn	33	SENT_41	[p2l11t660r381b739],
32	line	NN	O	line	nn	33	SENT_41	[p2l11t660r381b739],
33	treatment	NN	O	treatment	prep_as	22	SENT_41	[p2l423t677r847b739],
34	for	IN	O	for	_	0	SENT_41	[p2l883t660r1008b739],
35	advanced	JJ	O	advanced	amod	37	SENT_41	[p2l1046t660r1445b740],
36	colorectal	JJ	O	colorectal	amod	37	SENT_41	[p2l1488t660r1911b739],
37	cancer	NN	O	cancer	prep_for	33	SENT_41	[p2l1952t686r2133b739, p2l12t783r270b867],
38	.	.	O	.	_	0	SENT_41	[p2l1952t686r2133b739, p2l12t783r270b867],

1	”	NN	O	”	_	0	SENT_42	[p2l1952t686r2133b739, p2l12t783r270b867],

1	Irinotecan	NN	O	irinotecan	nsubj	5	SENT_43	[p2l308t790r741b867],
2	alone	RB	O	alone	advmod	5	SENT_43	[p2l776t789r1004b867],
3	can	MD	O	can	aux	5	SENT_43	[p2l1041t814r1185b867],
4	also	RB	O	also	advmod	5	SENT_43	[p2l1219t789r1387b867],
5	confer	VB	O	confer	_	0	SENT_43	[p2l1424t788r1695b867],
6	beneﬁt	NN	O	beneﬁt	dobj	5	SENT_43	[p2l1728t788r2024b867],
7	in	IN	O	in	_	0	SENT_43	[p2l2054t790r2135b866],
8	patients	NNS	O	patient	prep_in	6	SENT_43	[p2l10t917r344b1017],
9	with	IN	O	with	_	0	SENT_43	[p2l371t917r560b996],
10	colorectal	JJ	O	colorectal	amod	11	SENT_43	[p2l590t917r1003b995],
11	cancer	NN	O	cancer	prep_with	5	SENT_43	[p2l1032t942r1307b995],
12	that	WDT	O	that	nsubj	14	SENT_43	[p2l1334t917r1500b995],
13	is	VBZ	O	be	cop	14	SENT_43	[p2l1524t917r1588b995],
14	refractory	JJ	O	refractory	rcmod	11	SENT_43	[p2l1619t916r2030b1017],
15	to	TO	O	to	_	0	SENT_43	[p2l2055t933r2134b995],
16	treatment	NN	O	treatment	prep_to	14	SENT_43	[p2l12t1060r426b1122],
17	with	IN	O	with	_	0	SENT_43	[p2l447t1044r636b1123],
18	ﬂuorouracil	NN	O	ﬂuorouracil	nn	20	SENT_43	[p2l667t1037r1296b1139],
19	,6	CD	NUMBER	,6	num	20	SENT_43	[p2l667t1037r1296b1139],
20	’	NN	O	’	prep_with	16	SENT_43	[p2l667t1037r1296b1139],
21	7	CD	NUMBER	7	num	20	SENT_43	[p2l667t1037r1296b1139],
22	and	CC	O	and	_	0	SENT_43	[p2l1326t1044r1482b1122],
23	oxaliplatin	NN	O	oxaliplatin	nsubj	26	SENT_43	[p2l1513t1044r1960b1144],
24	can	MD	O	can	aux	26	SENT_43	[p2l1991t1069r2135b1122],
25	be	VB	O	be	cop	26	SENT_43	[p2l12t1172r108b1251],
26	effective	JJ	O	effective	conj_and	5	SENT_43	[p2l132t1172r477b1252],
27	in	IN	O	in	_	0	SENT_43	[p2l500t1173r581b1250],
28	patients	NNS	O	patient	prep_in	26	SENT_43	[p2l603t1173r937b1273],
29	with	IN	O	with	_	0	SENT_43	[p2l959t1173r1148b1252],
30	disease	NN	O	disease	prep_with	28	SENT_43	[p2l1172t1172r1475b1251],
31	that	WDT	O	that	nsubj	33	SENT_43	[p2l1499t1173r1666b1251],
32	is	VBZ	O	be	cop	33	SENT_43	[p2l1684t1173r1749b1251],
33	refractory	JJ	O	refractory	rcmod	28	SENT_43	[p2l1774t1172r2134b1251, p2l11t1326r91b1399],
34	to	TO	O	to	_	0	SENT_43	[p2l112t1315r190b1377],
35	irinotecan	JJ	O	irinotecan	amod	36	SENT_43	[p2l217t1300r644b1377],
36	treatment	NN	O	treatment	prep_to	33	SENT_43	[p2l670t1295r1147b1377],
37	?	.	O	?	_	0	SENT_43	[p2l670t1295r1147b1377],

1	‘	NN	O	‘	_	0	SENT_44	[p2l670t1295r1147b1377],

1	Epidermal	JJ	O	epidermal	amod	7	SENT_45	[p2l139t1427r585b1528],
2	growth	NN	O	growth	nn	7	SENT_45	[p2l633t1428r941b1528],
3	factor	NN	O	factor	nn	7	SENT_45	[p2l990t1427r1242b1506],
4	receptor	NN	O	receptor	nn	7	SENT_45	[p2l1287t1444r1646b1528],
5	(	CD	NUMBER	(	num	7	SENT_45	[p2l1697t1433r2037b1523],
6	EGFR	NN	ORGANIZATION	egfr	nn	7	SENT_45	[p2l1697t1433r2037b1523],
7	)	NN	O	)	nsubj	19	SENT_45	[p2l1697t1433r2037b1523],
8	,	,	O	,	_	0	SENT_45	[p2l1697t1433r2037b1523],
9	a	DT	O	a	det	10	SENT_45	[p2l2091t1454r2135b1506],
10	member	NN	O	member	appos	7	SENT_45	[p2l11t1556r373b1634],
11	of	IN	O	of	_	0	SENT_45	[p2l395t1555r497b1634],
12	the	DT	O	the	det	14	SENT_45	[p2l502t1556r631b1634],
13	ErbB	NN	O	erbb	nn	14	SENT_45	[p2l653t1556r858b1634],
14	family	NN	O	family	prep_of	10	SENT_45	[p2l883t1555r1149b1656],
15	of	IN	O	of	_	0	SENT_45	[p2l1168t1555r1268b1634],
16	receptors	NNS	O	receptor	prep_of	14	SENT_45	[p2l1272t1572r1688b1656],
17	,	,	O	,	_	0	SENT_45	[p2l1272t1572r1688b1656],
18	is	VBZ	O	be	cop	19	SENT_45	[p2l1715t1556r1779b1634],
19	relevant	JJ	O	relevant	ccomp	52	SENT_45	[p2l1805t1556r2140b1635],
20	in	IN	O	in	_	0	SENT_45	[p2l11t1684r92b1761],
21	colorectal	JJ	O	colorectal	amod	22	SENT_45	[p2l121t1683r535b1762],
22	cancer	NN	O	cancer	prep_in	19	SENT_45	[p2l563t1709r838b1762],
23	because	IN	O	because	mark	35	SENT_45	[p2l865t1684r1196b1763],
24	expression	NN	O	expression	nsubj	35	SENT_45	[p2l1226t1684r1679b1784],
25	or	CC	O	or	_	0	SENT_45	[p2l1708t1709r1797b1762],
26	up	IN	O	up	advmod	30	SENT_45	[p2l1823t1710r2134b1784],
27	—	CD	NUMBER	—	num	28	SENT_45	[p2l1823t1710r2134b1784],
28	reg	NN	O	reg	pobj	26	SENT_45	[p2l1823t1710r2134b1784],
29	—	NN	O	—	nn	30	SENT_45	[p2l1823t1710r2134b1784],
30	ulation	NN	O	ulation	nsubj	35	SENT_45	[p2l11t1812r308b1891],
31	of	IN	O	of	_	0	SENT_45	[p2l334t1811r434b1890],
32	the	DT	O	the	det	34	SENT_45	[p2l443t1811r571b1890],
33	EGFR	NN	ORGANIZATION	egfr	nn	34	SENT_45	[p2l595t1818r808b1891],
34	gene	NN	O	gene	prep_of	30	SENT_45	[p2l827t1837r1026b1912],
35	occurs	VBZ	O	occur	advcl	19	SENT_45	[p2l1053t1837r1325b1891],
36	in	IN	O	in	_	0	SENT_45	[p2l1353t1812r1434b1889],
37	60	CD	NUMBER	60	number	39	SENT_45	[p2l1461t1817r1560b1890],
38	to	TO	O	to	dep	39	SENT_45	[p2l1587t1828r1666b1890],
39	80	CD	PERCENT	80	num	40	SENT_45	[p2l1694t1817r1794b1890],
40	percent	NN	PERCENT	percent	prep_in	35	SENT_45	[p2l1819t1828r2140b1912],
41	of	IN	O	of	_	0	SENT_45	[p2l12t1939r113b2018],
42	cases	NNS	O	case	prep_of	40	SENT_45	[p2l115t1934r513b2018],
43	.9	CD	NUMBER	.9	number	44	SENT_45	[p2l115t1934r513b2018],
44	’11	CD	NUMBER	’11	num	42	SENT_45	[p2l115t1934r513b2018],
45	Moreover	RB	O	moreover	advmod	35	SENT_45	[p2l530t1947r953b2035],
46	,	,	O	,	_	0	SENT_45	[p2l530t1947r953b2035],
47	expression	NN	O	expression	nsubjpass	52	SENT_45	[p2l980t1941r1434b2040],
48	of	IN	O	of	_	0	SENT_45	[p2l1455t1939r1555b2018],
49	the	DT	O	the	det	50	SENT_45	[p2l1558t1940r1687b2018],
50	gene	NN	O	gene	prep_of	47	SENT_45	[p2l1708t1965r1907b2040],
51	is	VBZ	O	be	auxpass	52	SENT_45	[p2l1927t1941r1992b2018],
52	associated	VBN	O	associate	_	0	SENT_45	[p2l2015t1966r2134b2018, p2l13t2068r363b2146],
53	with	IN	O	with	_	0	SENT_45	[p2l404t2068r596b2147],
54	poor	JJ	O	poor	amod	55	SENT_45	[p2l640t2093r844b2168],
55	survival	NN	O	survival	prep_with	52	SENT_45	[p2l888t2062r1430b2147],
56	.12	CD	NUMBER	.12	number	57	SENT_45	[p2l888t2062r1430b2147],
57	’13	CD	NUMBER	’13	dep	55	SENT_45	[p2l888t2062r1430b2147],
58	When	WRB	O	when	advmod	64	SENT_45	[p2l1473t2068r1731b2146],
59	inactive	JJ	O	inactive	ccomp	64	SENT_45	[p2l1775t2068r2128b2163],
60	,	,	O	,	_	0	SENT_45	[p2l1775t2068r2128b2163],
61	EGFR	NN	ORGANIZATION	egfr	nsubj	64	SENT_45	[p2l10t2201r272b2279],
62	is	VBZ	O	be	cop	64	SENT_45	[p2l294t2196r360b2274],
63	a	DT	O	a	det	64	SENT_45	[p2l395t2222r439b2274],
64	monomer	NN	O	monomer	advcl	52	SENT_45	[p2l471t2221r916b2291],
65	,	,	O	,	_	0	SENT_45	[p2l471t2221r916b2291],
66	but	CC	O	but	_	0	SENT_45	[p2l956t2196r1099b2275],
67	when	WRB	O	when	advmod	68	SENT_45	[p2l1123t2196r1359b2275],
68	bound	VBN	O	bind	advcl	83	SENT_45	[p2l1393t2196r1670b2275],
69	by	IN	O	by	_	0	SENT_45	[p2l1703t2195r1801b2296],
70	epidermal	JJ	O	epidermal	amod	72	SENT_45	[p2l1831t2195r2133b2296, p2l11t2323r171b2402],
71	growth	NN	O	growth	nn	72	SENT_45	[p2l195t2324r500b2424],
72	factor	NN	O	factor	prep_by	68	SENT_45	[p2l523t2323r768b2402],
73	or	CC	O	or	_	0	SENT_45	[p2l789t2349r878b2402],
74	transforming	VBG	O	transform	advcl	83	SENT_45	[p2l898t2323r1464b2424],
75	growth	NN	O	growth	nn	76	SENT_45	[p2l1483t2324r1786b2424],
76	factor	NN	O	factor	nsubj	80	SENT_45	[p2l1809t2323r2055b2402],
77	a	DT	O	a	det	80	SENT_45	[p2l2073t2353r2130b2401],
78	(	NN	O	(	nn	80	SENT_45	[p2l16t2456r393b2545],
79	TGF-oz	NN	O	tgf-oz	nn	80	SENT_45	[p2l16t2456r393b2545],
80	)	NN	O	)	xcomp	74	SENT_45	[p2l16t2456r393b2545],
81	,	,	O	,	_	0	SENT_45	[p2l16t2456r393b2545],
82	it	PRP	O	it	nsubj	83	SENT_45	[p2l439t2451r500b2528],
83	forms	VBZ	O	form	advcl	52	SENT_45	[p2l536t2450r789b2529],
84	homodimers	NNS	O	homodimer	dobj	83	SENT_45	[p2l832t2450r1385b2529],
85	or	CC	O	or	_	0	SENT_45	[p2l1429t2476r1519b2529],
86	heterodimers	NNS	O	heterodimer	conj_or	84	SENT_45	[p2l1557t2450r2132b2529],
87	with	IN	O	with	_	0	SENT_45	[p2l7t2579r199b2658],
88	another	DT	O	another	det	89	SENT_45	[p2l229t2579r560b2657],
89	member	NN	O	member	prep_with	83	SENT_45	[p2l585t2579r942b2657],
90	of	IN	O	of	_	0	SENT_45	[p2l968t2578r1069b2657],
91	the	DT	O	the	det	93	SENT_45	[p2l1079t2579r1208b2657],
92	ErbB	NN	O	erbb	nn	93	SENT_45	[p2l1235t2579r1444b2657],
93	family	NN	O	family	prep_of	89	SENT_45	[p2l1475t2578r1741b2679],
94	of	IN	O	of	_	0	SENT_45	[p2l1765t2578r1866b2657],
95	receptors	NNS	O	receptor	prep_of	93	SENT_45	[p2l1876t2605r2134b2679, p2l12t2723r197b2785],
96	.	.	O	.	_	0	SENT_45	[p2l1876t2605r2134b2679, p2l12t2723r197b2785],

1	Dimerization	NN	O	dimerization	nsubj	2	SENT_46	[p2l230t2707r802b2785],
2	activates	VBZ	O	activate	_	0	SENT_46	[p2l830t2707r1194b2786],
3	the	DT	O	the	det	8	SENT_46	[p2l1224t2706r1355b2785],
4	intracellular	JJ	O	intracellular	amod	8	SENT_46	[p2l1383t2706r1910b2786],
5	tyrosine	NN	O	tyrosine	nn	8	SENT_46	[p2l1935t2723r2133b2807, p2l13t2835r182b2913],
6	kinase	NN	O	kinase	nn	8	SENT_46	[p2l210t2835r476b2914],
7	region	NN	O	region	nn	8	SENT_46	[p2l504t2835r772b2935],
8	ofEGFR	NN	O	ofegfr	dobj	2	SENT_46	[p2l801t2834r1177b2930],
9	,	,	O	,	_	0	SENT_46	[p2l801t2834r1177b2930],
10	resulting	VBG	O	result	dep	2	SENT_46	[p2l1210t2835r1582b2935],
11	in	IN	O	in	_	0	SENT_46	[p2l1606t2835r1686b2912],
12	autophos	NNS	O	autopho	prep_in	10	SENT_46	[p2l1713t2835r2134b2935],
13	—	CD	NUMBER	—	num	14	SENT_46	[p2l1713t2835r2134b2935],
14	phorylation	NN	O	phorylation	dep	12	SENT_46	[p2l10t2962r495b3063],
15	and	CC	O	and	_	0	SENT_46	[p2l520t2962r674b3041],
16	initiating	VBG	O	initiate	conj_and	10	SENT_46	[p2l698t2963r1083b3063],
17	a	DT	O	a	det	18	SENT_46	[p2l1104t2989r1149b3041],
18	cascade	NN	O	cascade	dobj	16	SENT_46	[p2l1173t2963r1493b3041],
19	of	IN	O	of	_	0	SENT_46	[p2l1519t2962r1619b3041],
20	intracellular	JJ	O	intracellular	amod	21	SENT_46	[p2l1625t2962r2137b3042],
21	events	NNS	O	event	prep_of	18	SENT_46	[p2l12t3085r393b3170],
22	.	.	O	.	_	0	SENT_46	[p2l12t3085r393b3170],

1	“	NN	O	“	nsubj	6	SENT_47	[p2l12t3085r393b3170],
2	The	DT	O	the	det	5	SENT_47	[p2l425t3091r589b3169],
3	EGFR	NN	ORGANIZATION	egfr	nn	5	SENT_47	[p2l624t3096r886b3174],
4	signaling	NN	O	signaling	nn	5	SENT_47	[p2l914t3091r1316b3191],
5	pathway	NN	O	pathway	dep	1	SENT_47	[p2l1348t3091r1710b3191],
6	regulates	VBZ	O	regulate	_	0	SENT_47	[p2l1742t3091r2132b3191],
7	cell	NN	O	cell	nn	8	SENT_47	[p2l12t3219r153b3297],
8	differentiation	NN	O	differentiation	dobj	6	SENT_47	[p2l176t3218r798b3314],
9	,	,	O	,	_	0	SENT_47	[p2l176t3218r798b3314],
10	proliferation	NN	O	proliferation	appos	8	SENT_47	[p2l825t3218r1375b3319],
11	,	,	O	,	_	0	SENT_47	[p2l825t3218r1375b3319],
12	migration	NN	O	migration	conj_and	10	SENT_47	[p2l1402t3219r1841b3319],
13	,	,	O	,	_	0	SENT_47	[p2l1402t3219r1841b3319],
14	angiogenesis	NN	O	angiogenesis	appos	8	SENT_47	[p2l1867t3219r2134b3319, p2l11t3347r354b3447],
15	,	,	O	,	_	0	SENT_47	[p2l1867t3219r2134b3319, p2l11t3347r354b3447],
16	and	CC	O	and	_	0	SENT_47	[p2l396t3346r554b3425],
17	apoptosis	NN	O	apoptosis	appos	8	SENT_47	[p2l590t3347r1033b3447],
18	,	,	O	,	_	0	SENT_47	[p2l590t3347r1033b3447],
19	all	DT	O	all	dep	20	SENT_47	[p2l1075t3347r1176b3425],
20	of	IN	O	of	nsubj	23	SENT_47	[p2l1213t3346r1314b3425],
21	which	WDT	O	which	pobj	20	SENT_47	[p2l1329t3346r1593b3426],
22	become	VBP	O	become	cop	23	SENT_47	[p2l1631t3346r1964b3425],
23	deregulated	VBN	O	deregulate	rcmod	8	SENT_47	[p2l2002t3346r2133b3425, p2l11t3475r415b3575],
24	in	IN	O	in	_	0	SENT_47	[p2l457t3476r539b3552],
25	cancer	NN	O	cancer	nn	26	SENT_47	[p2l582t3500r862b3553],
26	cells	NNS	O	cell	prep_in	23	SENT_47	[p2l903t3469r1202b3553],
27	.	.	O	.	_	0	SENT_47	[p2l903t3469r1202b3553],

1	“	NN	O	“	nsubj	14	SENT_48	[p2l903t3469r1202b3553],
2	Cetuximab	NN	O	cetuximab	nn	4	SENT_48	[p2l1248t3475r1711b3554],
3	(	CD	NUMBER	(	num	4	SENT_48	[p2l1760t3475r2128b3570],
4	Erbitux	NNP	O	Erbitux	dep	1	SENT_48	[p2l1760t3475r2128b3570],
5	,	,	O	,	_	0	SENT_48	[p2l1760t3475r2128b3570],
6	Merck	NNP	PERSON	Merck	nn	10	SENT_48	[p2l8t3603r284b3682],
7	and	CC	O	and	_	0	SENT_48	[p2l316t3603r474b3681],
8	Imclone	NNP	ORGANIZATION	Imclone	nn	10	SENT_48	[p2l510t3603r864b3681],
9	Systems	NNPS	ORGANIZATION	Systems	nn	10	SENT_48	[p2l903t3608r1279b3703],
10	)	NN	O	)	appos	1	SENT_48	[p2l903t3608r1279b3703],
11	is	VBZ	O	be	cop	14	SENT_48	[p2l1321t3603r1387b3681],
12	a	DT	O	a	det	14	SENT_48	[p2l1426t3629r1470b3681],
13	chimeric	JJ	O	chimeric	amod	14	SENT_48	[p2l1507t3603r1883b3681],
14	IgG1	NN	O	igg1	_	0	SENT_48	[p2l1918t3608r2134b3703],

1	monoclonal	JJ	O	monoclonal	amod	2	SENT_49	[p3l11t21r530b99],
2	antibody	NN	O	antibody	nsubj	28	SENT_49	[p3l553t20r932b121],
3	that	WDT	O	that	nsubj	4	SENT_49	[p3l948t21r1112b99],
4	binds	VBZ	O	bind	rcmod	2	SENT_49	[p3l1128t20r1356b99],
5	to	TO	O	to	_	0	SENT_49	[p3l1379t37r1457b99],
6	EGFRWith	NN	O	egfrwith	nn	8	SENT_49	[p3l1477t21r1926b104],
7	high	JJ	O	high	amod	8	SENT_49	[p3l1947t21r2136b121],
8	speciﬁcity	NN	O	speciﬁcity	prep_to	4	SENT_49	[p3l13t148r431b249],
9	and	CC	O	and	_	0	SENT_49	[p3l449t148r603b227],
10	with	IN	O	with	_	0	SENT_49	[p3l622t148r809b228],
11	a	DT	O	a	det	13	SENT_49	[p3l831t175r876b227],
12	higher	JJR	O	higher	amod	13	SENT_49	[p3l897t149r1173b249],
13	affinity	NN	O	affinity	prep_with	4	SENT_49	[p3l1192t148r1489b249],
14	than	IN	O	than	mark	21	SENT_49	[p3l1508t149r1694b227],
15	either	CC	O	either	preconj	18	SENT_49	[p3l1718t149r1958b227],
16	epidermal	JJ	O	epidermal	amod	18	SENT_49	[p3l1979t149r2134b249, p3l12t277r310b355],
17	growth	NN	O	growth	nn	18	SENT_49	[p3l338t277r642b377],
18	factor	NN	O	factor	nsubj	21	SENT_49	[p3l669t276r914b355],
19	or	CC	O	or	_	0	SENT_49	[p3l938t302r1027b355],
20	TGF	NN	O	tgf	conj_or	18	SENT_49	[p3l1048t282r1358b372],
21	—	VBP	O	—	advcl	4	SENT_49	[p3l1048t282r1358b372],
22	a	DT	O	a	det	27	SENT_49	[p3l1048t282r1358b372],
23	,	,	O	,	_	0	SENT_49	[p3l1048t282r1358b372],
24	thus	RB	O	thus	advmod	25	SENT_49	[p3l1391t277r1570b356],
25	blocking	VBG	O	block	dep	27	SENT_49	[p3l1600t276r1973b377],
26	ligand	NN	O	ligand	dobj	25	SENT_49	[p3l1994t276r2133b377, p3l11t404r535b484],
27	—	NN	O	—	dobj	21	SENT_49	[p3l1994t276r2133b377, p3l11t404r535b484],
28	induced	VBD	O	induce	_	0	SENT_49	[p3l1994t276r2133b377, p3l11t404r535b484],
29	phosphorylation	NN	O	phosphorylation	dobj	28	SENT_49	[p3l554t404r1243b505],
30	of	IN	O	of	_	0	SENT_49	[p3l1264t404r1363b483],
31	EGFR	NN	ORGANIZATION	egfr	prep_of	29	SENT_49	[p3l1364t410r1632b488],
32	.	.	O	.	_	0	SENT_49	[p3l1364t410r1632b488],

1	In	IN	O	in	_	0	SENT_50	[p3l1656t412r1742b482],
2	addition	NN	O	addition	prep_in	5	SENT_50	[p3l1762t405r2130b500],
3	,	,	O	,	_	0	SENT_50	[p3l1762t405r2130b500],
4	cetuximab	NN	O	cetuximab	nsubj	5	SENT_50	[p3l12t532r452b611],
5	enhances	VBZ	O	enhance	_	0	SENT_50	[p3l475t532r867b610],
6	the	DT	O	the	det	7	SENT_50	[p3l891t532r1020b610],
7	effects	NNS	O	effect	dobj	5	SENT_50	[p3l1043t531r1315b610],
8	of	IN	O	of	_	0	SENT_50	[p3l1341t531r1441b610],
9	irinotecan	NN	O	irinotecan	nn	10	SENT_50	[p3l1444t525r1958b610],
10	“	NN	O	“	prep_of	7	SENT_50	[p3l1444t525r1958b610],
11	and	CC	O	and	_	0	SENT_50	[p3l1979t532r2135b610],
12	radiotherapy	NN	O	radiotherapy	prep_of	7	SENT_50	[p3l11t660r550b760],
13	in	IN	O	in	_	0	SENT_50	[p3l570t660r652b737],
14	experimental	JJ	O	experimental	amod	15	SENT_50	[p3l678t660r1231b760],
15	systems	NNS	O	system	prep_in	5	SENT_50	[p3l1258t676r1612b760],
16	.	.	O	.	_	0	SENT_50	[p3l1258t676r1612b760],

1	A	DT	O	a	det	4	SENT_51	[p3l137t795r203b865],
2	phase	NN	O	phase	nn	4	SENT_51	[p3l226t788r473b888],
3	2	CD	NUMBER	2	num	4	SENT_51	[p3l501t793r549b865],
4	study	NN	O	study	nsubj	24	SENT_51	[p3l579t788r805b888],
5	of	IN	O	of	_	0	SENT_51	[p3l830t787r930b866],
6	Weekly	NNP	SET	Weekly	nn	7	SENT_51	[p3l935t787r1229b888],
7	cetuximab	NN	O	cetuximab	prep_of	4	SENT_51	[p3l1253t788r1688b867],
8	and	CC	O	and	_	0	SENT_51	[p3l1717t787r1872b866],
9	irinotecan	NN	O	irinotecan	prep_of	4	SENT_51	[p3l1900t788r2134b866, p3l12t932r237b994],
10	in	IN	O	in	_	0	SENT_51	[p3l275t916r357b993],
11	121	CD	NUMBER	121	num	12	SENT_51	[p3l400t921r553b993],
12	patients	NNS	O	patient	prep_in	7	SENT_51	[p3l591t916r933b1016],
13	who	WP	O	who	nsubj	14	SENT_51	[p3l970t916r1155b995],
14	had	VBD	O	have	rcmod	12	SENT_51	[p3l1196t916r1354b994],
15	colorectal	JJ	O	colorectal	amod	16	SENT_51	[p3l1393t916r1817b994],
16	cancer	NN	O	cancer	dobj	14	SENT_51	[p3l1856t941r2137b994],
17	that	WDT	O	that	nsubj	19	SENT_51	[p3l12t1044r181b1122],
18	was	VBD	O	be	cop	19	SENT_51	[p3l205t1070r368b1123],
19	refractory	JJ	O	refractory	rcmod	16	SENT_51	[p3l403t1043r824b1144],
20	to	TO	O	to	_	0	SENT_51	[p3l852t1060r932b1122],
21	ﬂuorouracil	NN	O	ﬂuorouracil	prep_to	19	SENT_51	[p3l966t1043r1475b1123],
22	and	CC	O	and	_	0	SENT_51	[p3l1507t1043r1665b1122],
23	irinotecan	NN	O	irinotecan	prep_to	19	SENT_51	[p3l1697t1044r2134b1122],
24	found	VBD	O	find	_	0	SENT_51	[p3l11t1171r266b1251],
25	a	DT	O	a	det	29	SENT_51	[p3l299t1198r344b1250],
26	17	CD	PERCENT	17	num	29	SENT_51	[p3l379t1177r477b1250],
27	percent	NN	PERCENT	percent	nn	29	SENT_51	[p3l510t1188r837b1272],
28	response	NN	O	response	nn	29	SENT_51	[p3l866t1197r1252b1272],
29	rate	NN	O	rate	dobj	24	SENT_51	[p3l1286t1166r1559b1250],
30	.	.	O	.	_	0	SENT_51	[p3l1286t1166r1559b1250],

1	“	NN	O	“	dep	30	SENT_52	[p3l1286t1166r1559b1250],
2	In	IN	O	in	_	0	SENT_52	[p3l1592t1179r1680b1249],
3	a	DT	O	a	det	4	SENT_52	[p3l1713t1198r1757b1250],
4	study	NN	O	study	prep_in	23	SENT_52	[p3l1791t1172r2021b1272],
5	of	IN	O	of	_	0	SENT_52	[p3l2051t1171r2152b1250],
6	57	CD	NUMBER	57	num	7	SENT_52	[p3l13t1307r112b1378],
7	patients	NNS	O	patient	prep_of	4	SENT_52	[p3l155t1300r495b1400],
8	With	IN	O	with	_	0	SENT_52	[p3l533t1300r722b1379],
9	EGFR	NN	O	egfr	prep_with	7	SENT_52	[p3l761t1300r1368b1400],
10	—	CD	NUMBER	—	num	13	SENT_52	[p3l761t1300r1368b1400],
11	positiVe	JJ	O	positive	amod	13	SENT_52	[p3l761t1300r1368b1400],
12	colorectal	JJ	O	colorectal	amod	13	SENT_52	[p3l1409t1300r1822b1378],
13	cancer	NN	O	cancer	nsubj	23	SENT_52	[p3l1863t1325r2138b1378],
14	that	WDT	O	that	nsubj	16	SENT_52	[p3l12t1428r179b1506],
15	was	VBD	O	be	cop	16	SENT_52	[p3l191t1454r353b1507],
16	refractory	JJ	O	refractory	rcmod	13	SENT_52	[p3l377t1427r789b1528],
17	to	TO	O	to	_	0	SENT_52	[p3l807t1444r886b1506],
18	both	DT	O	both	det	19	SENT_52	[p3l911t1427r1104b1506],
19	ﬂuorouracil	NN	O	ﬂuorouracil	prep_to	16	SENT_52	[p3l1126t1427r1624b1507],
20	and	CC	O	and	_	0	SENT_52	[p3l1645t1428r1801b1506],
21	irinote	JJ	O	irinote	amod	22	SENT_52	[p3l1823t1428r2134b1506],
22	—	NN	O	—	prep_to	16	SENT_52	[p3l1823t1428r2134b1506],
23	can	MD	O	can	rcmod	1	SENT_52	[p3l12t1581r181b1651],
24	,	,	O	,	_	0	SENT_52	[p3l12t1581r181b1651],
25	8.8	CD	PERCENT	8.8	num	26	SENT_52	[p3l226t1561r355b1634],
26	percent	NN	PERCENT	percent	nsubj	30	SENT_52	[p3l395t1572r722b1656],
27	of	IN	O	of	_	0	SENT_52	[p3l756t1555r857b1634],
28	the	DT	O	the	det	29	SENT_52	[p3l878t1556r1009b1634],
29	patients	NNS	O	patient	prep_of	26	SENT_52	[p3l1046t1556r1388b1656],
30	had	VBD	O	have	_	0	SENT_52	[p3l1429t1555r1586b1634],
31	a	DT	O	a	det	33	SENT_52	[p3l1624t1582r1668b1634],
32	partial	JJ	O	partial	amod	33	SENT_52	[p3l1703t1555r1982b1656],
33	response	NN	O	response	dobj	30	SENT_52	[p3l2019t1582r2133b1634, p3l13t1709r312b1784],
34	to	TO	O	to	_	0	SENT_52	[p3l347t1700r426b1762],
35	cetuximab	JJ	O	cetuximab	amod	36	SENT_52	[p3l463t1684r897b1763],
36	monotherapy	NN	O	monotherapy	prep_to	33	SENT_52	[p3l933t1684r1515b1784],
37	,	,	O	,	_	0	SENT_52	[p3l933t1684r1515b1784],
38	and	CC	O	and	_	0	SENT_52	[p3l1555t1683r1710b1762],
39	36.8	CD	PERCENT	36.8	num	40	SENT_52	[p3l1745t1689r1929b1762],
40	percent	NN	PERCENT	percent	nsubj	41	SENT_52	[p3l1965t1710r2134b1784, p3l12t1828r191b1890],
41	had	VBD	O	have	conj_and	30	SENT_52	[p3l211t1811r366b1890],
42	stable	JJ	O	stable	amod	43	SENT_52	[p3l392t1812r639b1890],
43	disease	NN	O	disease	dobj	41	SENT_52	[p3l665t1806r1078b1890],
44	.	.	O	.	_	0	SENT_52	[p3l665t1806r1078b1890],

1	”	NN	O	”	_	0	SENT_53	[p3l665t1806r1078b1890],

1	In	IN	O	in	_	0	SENT_54	[p3l139t1947r226b2017],
2	the	DT	O	the	det	4	SENT_54	[p3l255t1940r384b2018],
3	present	JJ	DATE	present	amod	4	SENT_54	[p3l412t1956r731b2040],
4	trial	NN	O	trial	prep_in	7	SENT_54	[p3l755t1940r944b2035],
5	,	,	O	,	_	0	SENT_54	[p3l755t1940r944b2035],
6	We	PRP	O	we	nsubj	7	SENT_54	[p3l974t1966r1092b2019],
7	compared	VBD	O	compare	_	0	SENT_54	[p3l1122t1940r1545b2040],
8	the	DT	O	the	det	9	SENT_54	[p3l1574t1940r1702b2018],
9	combination	NN	O	combination	dobj	7	SENT_54	[p3l1732t1940r2134b2018, p3l12t2068r180b2146],
10	of	IN	O	of	_	0	SENT_54	[p3l213t2067r315b2146],
11	cetuximab	NN	O	cetuximab	prep_of	9	SENT_54	[p3l331t2068r773b2147],
12	and	CC	O	and	_	0	SENT_54	[p3l808t2068r965b2146],
13	irinotecan	NN	O	irinotecan	conj_and	11	SENT_54	[p3l997t2068r1435b2146],
14	With	IN	O	with	_	0	SENT_54	[p3l1463t2067r1656b2147],
15	cetuximab	JJ	O	cetuximab	amod	16	SENT_54	[p3l1690t2068r2133b2147],
16	monotherapy	NN	O	monotherapy	nsubj	22	SENT_54	[p3l11t2196r593b2296],
17	in	IN	O	in	_	0	SENT_54	[p3l634t2196r716b2273],
18	patients	NNS	O	patient	prep_in	16	SENT_54	[p3l760t2196r1102b2296],
19	with	IN	O	with	_	0	SENT_54	[p3l1146t2195r1338b2275],
20	EGFR	NN	ORGANIZATION	egfr	prep_with	18	SENT_54	[p3l1383t2196r2138b2296],
21	—	CD	NUMBER	—	num	20	SENT_54	[p3l1383t2196r2138b2296],
22	eXpressing	VBG	O	express	prepc_with	7	SENT_54	[p3l1383t2196r2138b2296],
23	irinotecan	JJ	O	irinotecan	amod	24	SENT_54	[p3l11t2323r895b2424],
24	—	NN	O	—	dobj	22	SENT_54	[p3l11t2323r895b2424],
25	refractory	JJ	O	refractory	amod	27	SENT_54	[p3l11t2323r895b2424],
26	colorectal	JJ	O	colorectal	amod	27	SENT_54	[p3l916t2324r1329b2402],
27	cancer	NN	O	cancer	dep	24	SENT_54	[p3l1355t2349r1646b2402],
28	.	.	O	.	_	0	SENT_54	[p3l1355t2349r1646b2402],

1	METHODS	NNS	O	method	_	0	SENT_55	[p3l791t2682r1341b2741],

1	PATI	NN	O	patus	nn	4	SENT_56	[p3l17t2859r185b2908],
2	E	NN	O	e	nn	4	SENT_56	[p3l207t2859r240b2908],
3	N	NN	O	n	nn	4	SENT_56	[p3l260t2859r304b2908],
4	TS	NN	O	t	_	0	SENT_56	[p3l320t2859r408b2908],

1	We	PRP	O	we	nsubj	2	SENT_57	[p3l8t2967r141b3038],
2	considered	VBD	O	consider	_	0	SENT_57	[p3l176t2960r639b3038],
3	patients	NNS	O	patient	nsubj	11	SENT_57	[p3l672t2960r1007b3060],
4	eligible	JJ	O	eligible	dep	11	SENT_57	[p3l1044t2959r1351b3060],
5	if	IN	O	if	mark	11	SENT_57	[p3l1385t2959r1460b3037],
6	they	PRP	O	they	nsubj	11	SENT_57	[p3l1476t2960r1653b3060],
7	were	VBD	O	be	cop	11	SENT_57	[p3l1678t2986r1880b3039],
8	more	JJR	DURATION	more	mwe	9	SENT_57	[p3l1915t2985r2135b3038],
9	than	IN	DURATION	than	quantmod	10	SENT_57	[p3l12t3088r202b3166],
10	18	CD	DURATION	18	num	11	SENT_57	[p3l241t3093r337b3166],
11	years	NNS	NUMBER	year	xcomp	2	SENT_57	[p3l372t3114r589b3188],
12	of	IN	O	of	_	0	SENT_57	[p3l629t3087r730b3166],
13	age	NN	O	age	prep_of	11	SENT_57	[p3l747t3114r892b3188],
14	and	CC	O	and	_	0	SENT_57	[p3l928t3088r1085b3166],
15	had	VBD	O	have	conj_and	2	SENT_57	[p3l1121t3087r1278b3166],
16	stage	NN	O	stage	dobj	15	SENT_57	[p3l1315t3104r1537b3188],
17	IV	CD	NUMBER	iv	num	16	SENT_57	[p3l1573t3095r1676b3183],
18	,	,	O	,	_	0	SENT_57	[p3l1573t3095r1676b3183],
19	histologically	RB	O	histologically	advmod	20	SENT_57	[p3l1717t3088r2134b3188, p3l12t3215r201b3316],
20	conﬁrmed	VBN	O	conﬁrmed	partmod	16	SENT_57	[p3l225t3215r664b3294],
21	colorectal	JJ	O	colorectal	amod	22	SENT_57	[p3l692t3215r1106b3294],
22	adenocarcinoma	NN	O	adenocarcinoma	dobj	20	SENT_57	[p3l1133t3216r1861b3294],
23	.	.	O	.	_	0	SENT_57	[p3l1133t3216r1861b3294],

1	Other	JJ	O	other	amod	2	SENT_58	[p3l1894t3215r2138b3294],
2	criteria	NNS	O	criterion	nsubj	9	SENT_58	[p3l12t3344r301b3422],
3	for	IN	O	for	_	0	SENT_58	[p3l319t3343r440b3422],
4	eligibility	NN	O	eligibility	prep_for	2	SENT_58	[p3l458t3343r840b3444],
5	were	VBD	O	be	cop	9	SENT_58	[p3l852t3370r1049b3423],
6	a	DT	O	a	det	9	SENT_58	[p3l1069t3370r1114b3422],
7	Karnofsky	NNP	PERSON	Karnofsky	nn	9	SENT_58	[p3l1131t3343r1559b3444],
8	performancestatus	NN	O	performancestatus	nn	9	SENT_58	[p3l1572t3343r2135b3444, p3l13t3488r264b3551],
9	score	NN	NUMBER	score	_	0	SENT_58	[p3l294t3497r518b3550],
10	of	IN	O	of	_	0	SENT_58	[p3l546t3471r647b3550],
11	60	CD	NUMBER	60	prep_of	9	SENT_58	[p3l657t3477r757b3550],
12	or	CC	O	or	_	0	SENT_58	[p3l786t3497r876b3550],
13	more	JJR	O	more	prep_of	9	SENT_58	[p3l900t3497r1148b3567],
14	,	,	O	,	_	0	SENT_58	[p3l900t3497r1148b3567],
15	adequate	JJ	O	adequate	amod	17	SENT_58	[p3l1180t3471r1565b3572],
16	hematologic	JJ	O	hematologic	amod	17	SENT_58	[p3l1592t3471r2134b3572],
17	function	NN	O	function	appos	9	SENT_58	[p3l11t3599r375b3679],
18	(	CD	NUMBER	(	num	19	SENT_58	[p3l425t3600r1008b3700],
19	hemoglobin	NN	O	hemoglobin	dep	17	SENT_58	[p3l425t3600r1008b3700],
20	,	,	O	,	_	0	SENT_58	[p3l425t3600r1008b3700],
21	at	IN	O	at	quantmod	23	SENT_58	[p3l1058t3616r1138b3678],
22	least	JJS	O	least	mwe	21	SENT_58	[p3l1177t3600r1377b3678],
23	9	CD	NUMBER	9	num	24	SENT_58	[p3l1418t3605r1464b3678],
24	g	NN	O	g	appos	9	SENT_58	[p3l1510t3626r1563b3700],
25	per	IN	O	per	_	0	SENT_58	[p3l1603t3626r1744b3700],
26	deciliter	NN	O	deciliter	prep_per	24	SENT_58	[p3l1787t3599r2137b3678],

1	[	RB	O	[	advmod	3	SENT_59	[p4l20t26r177b111],
2	5.6	CD	NUMBER	5.6	num	3	SENT_59	[p4l20t26r177b111],
3	mmol	NN	O	mmol	_	0	SENT_59	[p4l202t21r451b99],
4	per	IN	O	per	_	0	SENT_59	[p4l472t47r609b121],
5	liter	NN	O	liter	nn	6	SENT_59	[p4l628t21r852b116],
6	]	NN	O	]	prep_per	3	SENT_59	[p4l628t21r852b116],
7	;	:	O	;	_	0	SENT_59	[p4l628t21r852b116],
8	neutrophil	NN	O	neutrophil	nn	9	SENT_59	[p4l879t21r1318b121],
9	count	NN	O	count	conj_and	3	SENT_59	[p4l1341t37r1597b116],
10	,	,	O	,	_	0	SENT_59	[p4l1341t37r1597b116],
11	at	IN	O	at	quantmod	13	SENT_59	[p4l1626t37r1703b99],
12	least	JJS	O	least	mwe	11	SENT_59	[p4l1720t21r1914b99],
13	1500	CD	DATE	1500	appos	9	SENT_59	[p4l1935t26r2135b99],
14	per	IN	O	per	_	0	SENT_59	[p4l10t175r150b249],
15	cubic	JJ	O	cubic	amod	16	SENT_59	[p4l191t149r419b228],
16	millimeter	NN	O	millimeter	prep_per	13	SENT_59	[p4l461t148r937b244],
17	;	:	O	;	_	0	SENT_59	[p4l461t148r937b244],
18	and	CC	O	and	_	0	SENT_59	[p4l981t148r1137b227],
19	platelet	NN	O	platelet	nn	20	SENT_59	[p4l1175t148r1489b249],
20	count	NN	O	count	conj_and	3	SENT_59	[p4l1525t165r1786b244],
21	,	,	O	,	_	0	SENT_59	[p4l1525t165r1786b244],
22	at	IN	O	at	quantmod	24	SENT_59	[p4l1831t165r1910b227],
23	least	JJS	O	least	mwe	22	SENT_59	[p4l1943t149r2140b227],
24	100,000	CD	NUMBER	100,000	appos	3	SENT_59	[p4l15t282r353b372],
25	per	IN	O	per	_	0	SENT_59	[p4l385t303r524b377],
26	cubic	JJ	O	cubic	amod	28	SENT_59	[p4l555t277r777b356],
27	millimeter	NN	O	millimeter	nn	28	SENT_59	[p4l810t277r1310b372],
28	)	NN	O	)	prep_per	24	SENT_59	[p4l810t277r1310b372],
29	,	,	O	,	_	0	SENT_59	[p4l810t277r1310b372],
30	renal	JJ	O	renal	amod	34	SENT_59	[p4l1348t277r1559b355],
31	function	NN	O	function	nn	34	SENT_59	[p4l1592t276r1948b356],
32	(	JJ	O	(	amod	34	SENT_59	[p4l1987t284r2134b368, p4l11t431r185b484],
33	serum	NN	O	serum	nn	34	SENT_59	[p4l1987t284r2134b368, p4l11t431r185b484],
34	creatinine	NN	O	creatinine	appos	28	SENT_59	[p4l215t405r656b500],
35	,	,	O	,	_	0	SENT_59	[p4l215t405r656b500],
36	less	JJR	O	less	mwe	37	SENT_59	[p4l688t405r843b483],
37	than	IN	O	than	quantmod	39	SENT_59	[p4l874t404r1062b483],
38	1.5	CD	NUMBER	1.5	number	39	SENT_59	[p4l1093t410r1217b483],
39	times	NNS	O	time	num	42	SENT_59	[p4l1249t405r1476b483],
40	the	DT	O	the	det	42	SENT_59	[p4l1507t405r1636b483],
41	upper	JJ	O	upper	amod	42	SENT_59	[p4l1665t431r1913b505],
42	limit	NN	O	limit	conj_and	28	SENT_59	[p4l1938t405r2140b483],
43	of	IN	O	of	_	0	SENT_59	[p4l12t531r113b609],
44	normal	JJ	O	normal	amod	45	SENT_59	[p4l122t531r486b626],
45	)	NN	O	)	prep_of	42	SENT_59	[p4l122t531r486b626],
46	,	,	O	,	_	0	SENT_59	[p4l122t531r486b626],
47	and	CC	O	and	_	0	SENT_59	[p4l519t531r674b610],
48	liver	NN	O	liver	nn	49	SENT_59	[p4l701t532r882b610],
49	function	NN	O	function	conj_and	28	SENT_59	[p4l907t531r1263b610],
50	(	CD	NUMBER	(	num	51	SENT_59	[p4l1296t532r1716b626],
51	bilirubin	NN	O	bilirubin	dep	49	SENT_59	[p4l1296t532r1716b626],
52	,	,	O	,	_	0	SENT_59	[p4l1296t532r1716b626],
53	not	RB	O	not	advmod	49	SENT_59	[p4l1749t548r1893b610],
54	more	JJR	O	more	mwe	55	SENT_59	[p4l1915t557r2135b610],
55	than	IN	O	than	quantmod	57	SENT_59	[p4l12t660r199b738],
56	1.5	CD	NUMBER	1.5	number	57	SENT_59	[p4l228t665r351b738],
57	times	NNS	O	time	pobj	53	SENT_59	[p4l381t660r608b738],
58	the	DT	O	the	det	60	SENT_59	[p4l636t659r765b738],
59	upper	JJ	O	upper	amod	60	SENT_59	[p4l790t686r1039b760],
60	limit	NN	O	limit	dep	57	SENT_59	[p4l1059t659r1263b738],
61	of	IN	O	of	_	0	SENT_59	[p4l1284t659r1384b738],
62	normal	JJ	O	normal	prep_of	53	SENT_59	[p4l1391t659r1722b755],
63	;	:	O	;	_	0	SENT_59	[p4l1391t659r1722b755],
64	aspartate	NN	O	aspartate	nn	65	SENT_59	[p4l1751t676r2135b760],
65	aminotransferase	NN	O	aminotransferase	dep	3	SENT_59	[p4l11t786r750b865],
66	and	CC	O	and	_	0	SENT_59	[p4l801t786r957b865],
67	alanine	NN	O	alanine	nn	68	SENT_59	[p4l1009t786r1315b864],
68	aminotransferase	NN	O	aminotransferase	conj_and	65	SENT_59	[p4l1367t786r2129b881],
69	,	,	O	,	_	0	SENT_59	[p4l1367t786r2129b881],
70	not	RB	O	not	neg	65	SENT_59	[p4l11t931r154b993],
71	more	JJR	O	more	mwe	72	SENT_59	[p4l175t940r394b993],
72	than	IN	O	than	quantmod	74	SENT_59	[p4l420t915r608b993],
73	5	CD	NUMBER	5	number	74	SENT_59	[p4l635t922r678b993],
74	times	NNS	O	time	num	77	SENT_59	[p4l706t915r935b993],
75	the	DT	O	the	det	77	SENT_59	[p4l963t914r1091b993],
76	upper	JJ	O	upper	amod	77	SENT_59	[p4l1116t941r1365b1015],
77	limit	NN	O	limit	dep	65	SENT_59	[p4l1386t915r1589b993],
78	of	IN	O	of	_	0	SENT_59	[p4l1610t914r1710b993],
79	normal	JJ	O	normal	amod	80	SENT_59	[p4l1717t915r2081b1006],
80	)	NN	O	)	prep_of	3	SENT_59	[p4l1717t915r2081b1006],
81	.	.	O	.	_	0	SENT_59	[p4l1717t915r2081b1006],

1	To	TO	O	to	aux	3	SENT_60	[p4l137t1048r242b1121],
2	be	VB	O	be	cop	3	SENT_60	[p4l274t1042r370b1121],
3	eligible	JJ	O	eligible	purpcl	9	SENT_60	[p4l401t1042r732b1143],
4	,	,	O	,	_	0	SENT_60	[p4l401t1042r732b1143],
5	patients	NNS	O	patient	nsubj	9	SENT_60	[p4l767t1043r1101b1143],
6	must	MD	O	must	aux	9	SENT_60	[p4l1134t1059r1351b1122],
7	also	RB	O	also	advmod	9	SENT_60	[p4l1376t1043r1543b1121],
8	have	VB	O	have	aux	9	SENT_60	[p4l1575t1043r1763b1122],
9	received	VBN	O	receive	_	0	SENT_60	[p4l1794t1043r2135b1122],
10	one	CD	NUMBER	one	dobj	9	SENT_60	[p4l12t1196r164b1249],
11	of	IN	O	of	_	0	SENT_60	[p4l193t1170r293b1249],
12	several	JJ	O	several	prep_of	10	SENT_60	[p4l304t1170r589b1250],
13	qualifying	VBG	O	qualify	partmod	12	SENT_60	[p4l617t1170r1062b1271],
14	,	,	O	,	_	0	SENT_60	[p4l617t1170r1062b1271],
15	prestudy	JJ	O	prestudy	amod	17	SENT_60	[p4l1094t1171r1462b1271],
16	irinotecan	NN	O	irinotecan	nn	17	SENT_60	[p4l1485t1171r1912b1249],
17	regimens	NNS	O	regimen	appos	10	SENT_60	[p4l1940t1171r2134b1271, p4l11t1324r238b1377],
18	for	IN	O	for	_	0	SENT_60	[p4l265t1298r388b1377],
19	at	IN	DURATION	at	quantmod	21	SENT_60	[p4l409t1315r488b1377],
20	least	JJS	DURATION	least	mwe	19	SENT_60	[p4l506t1299r704b1377],
21	six	CD	DURATION	six	num	22	SENT_60	[p4l724t1299r839b1377],
22	weeks	NNS	NUMBER	week	prep_for	17	SENT_60	[p4l857t1299r1116b1378],
23	and	CC	O	and	_	0	SENT_60	[p4l1142t1298r1298b1377],
24	must	MD	O	must	aux	27	SENT_60	[p4l1322t1315r1539b1378],
25	have	VB	O	have	aux	27	SENT_60	[p4l1558t1299r1747b1378],
26	had	VBD	O	have	aux	27	SENT_60	[p4l1771t1298r1926b1377],
27	documented	VBN	O	document	conj_and	9	SENT_60	[p4l1952t1298r2134b1377, p4l11t1427r390b1506],

1	progression	NN	O	progression	conj_or	1	SENT_61	[p4l417t1427r936b1527],
2	of	IN	O	of	_	0	SENT_61	[p4l965t1426r1066b1505],
3	disease	NN	O	disease	prep_of	1	SENT_61	[p4l1077t1426r1386b1505],
4	during	IN	O	during	_	0	SENT_61	[p4l1416t1427r1706b1527],
5	receipt	NN	O	receipt	prep_during	1	SENT_61	[p4l1731t1427r2027b1527],
6	of	IN	O	of	_	0	SENT_61	[p4l2051t1426r2152b1505],
7	this	DT	O	this	det	8	SENT_61	[p4l12t1554r167b1633],
8	regimen	NN	O	regimen	prep_of	5	SENT_61	[p4l212t1555r569b1655],
9	or	CC	O	or	_	0	SENT_61	[p4l612t1580r701b1633],
10	within	IN	O	within	_	0	SENT_61	[p4l736t1555r1016b1634],
11	three	CD	DURATION	three	num	12	SENT_61	[p4l1058t1555r1275b1633],
12	months	NNS	NUMBER	month	npadvmod	13	SENT_61	[p4l1317t1555r1647b1633],
13	thereafter	RB	O	thereafter	prepc_within	1	SENT_61	[p4l1691t1554r2129b1633],
14	.	.	O	.	_	0	SENT_61	[p4l1691t1554r2129b1633],

1	These	DT	O	these	det	2	SENT_62	[p4l8t1683r255b1761],
2	regimens	NNS	O	regimen	nsubj	4	SENT_62	[p4l278t1683r664b1783],
3	were	VBD	O	be	cop	4	SENT_62	[p4l684t1709r884b1762],
4	irinotecan	NN	O	irinotecan	_	0	SENT_62	[p4l906t1683r1325b1761],
5	at	IN	O	at	_	0	SENT_62	[p4l1347t1699r1425b1761],
6	a	DT	O	a	det	7	SENT_62	[p4l1442t1709r1487b1761],
7	dose	NN	O	dose	prep_at	4	SENT_62	[p4l1508t1682r1698b1761],
8	of	IN	O	of	_	0	SENT_62	[p4l1722t1682r1822b1761],
9	125	CD	NUMBER	125	num	10	SENT_62	[p4l1829t1688r1974b1761],
10	mg	NN	O	mg	prep_of	7	SENT_62	[p4l2000t1709r2139b1783],
11	per	IN	O	per	_	0	SENT_62	[p4l10t1837r148b1911],
12	square	NN	O	square	nn	13	SENT_62	[p4l169t1837r447b1911],
13	meter	NN	O	meter	prep_per	10	SENT_62	[p4l470t1827r716b1889],
14	of	IN	O	of	_	0	SENT_62	[p4l737t1810r837b1889],
15	body	NN	O	body	nn	18	SENT_62	[p4l843t1810r1385b1911],
16	—	CD	NUMBER	—	num	18	SENT_62	[p4l843t1810r1385b1911],
17	surface	NN	O	surface	nn	18	SENT_62	[p4l843t1810r1385b1911],
18	area	NN	O	area	prep_of	13	SENT_62	[p4l1408t1837r1583b1889],
19	given	VBN	O	give	partmod	4	SENT_62	[p4l1604t1811r1828b1911],
20	weekly	JJ	SET	weekly	dobj	19	SENT_62	[p4l1846t1811r2139b1911],
21	for	IN	O	for	_	0	SENT_62	[p4l11t1938r134b2017],
22	four	CD	NUMBER	four	num	24	SENT_62	[p4l154t1938r331b2018],
23	consecutive	JJ	O	consecutive	amod	24	SENT_62	[p4l351t1939r839b2018],
24	weeks	NNS	DURATION	week	prep_for	20	SENT_62	[p4l857t1939r1142b2034],
25	,	,	O	,	_	0	SENT_62	[p4l857t1939r1142b2034],
26	followed	VBN	O	follow	conj_or	26	SENT_62	[p4l1170t1938r1537b2018],
27	by	IN	O	by	_	0	SENT_62	[p4l1560t1938r1657b2039],
28	two	CD	DURATION	two	num	29	SENT_62	[p4l1675t1955r1827b2018],
29	weeks	NNS	NUMBER	week	agent	26	SENT_62	[p4l1846t1939r2130b2018],
30	’	CD	NUMBER	’	num	31	SENT_62	[p4l1846t1939r2130b2018],
31	rest	NN	O	rest	tmod	29	SENT_62	[p4l11t2083r188b2162],
32	,	,	O	,	_	0	SENT_62	[p4l11t2083r188b2162],
33	as	IN	O	as	_	0	SENT_62	[p4l219t2093r304b2145],
34	a	DT	O	a	det	36	SENT_62	[p4l332t2093r376b2145],
35	single	JJ	O	single	amod	36	SENT_62	[p4l402t2067r652b2167],
36	agent	NN	O	agent	prep_as	26	SENT_62	[p4l679t2083r915b2167],
37	or	CC	O	or	_	0	SENT_62	[p4l937t2092r1026b2145],
38	in	IN	O	in	_	0	SENT_62	[p4l1049t2067r1131b2144],
39	combination	NN	O	combination	prep_in	26	SENT_62	[p4l1158t2067r1698b2145],
40	with	IN	O	with	_	0	SENT_62	[p4l1720t2066r1909b2146],
41	ﬂuorouracil	NN	O	ﬂuorouracil	prep_with	26	SENT_62	[p4l1935t2066r2134b2146, p4l11t2194r344b2272],
42	and	CC	O	and	_	0	SENT_62	[p4l388t2194r546b2272],
43	leucovorin	NN	O	leucovorin	prep_with	26	SENT_62	[p4l590t2194r1070b2288],
44	;	:	O	;	_	0	SENT_62	[p4l590t2194r1070b2288],
45	irinotecan	NN	O	irinotecan	conj_and	4	SENT_62	[p4l1119t2194r1555b2272],
46	at	IN	O	at	_	0	SENT_62	[p4l1600t2210r1680b2271],
47	a	DT	O	a	det	48	SENT_62	[p4l1720t2220r1764b2271],
48	dose	NN	O	dose	prep_at	45	SENT_62	[p4l1809t2194r2005b2272],
49	of	IN	O	of	_	0	SENT_62	[p4l2051t2193r2152b2272],
50	180	CD	NUMBER	180	num	51	SENT_62	[p4l15t2327r166b2400],
51	mg	NN	O	mg	prep_of	48	SENT_62	[p4l196t2348r337b2422],
52	per	IN	O	per	_	0	SENT_62	[p4l362t2348r502b2422],
53	square	NN	O	square	nn	54	SENT_62	[p4l528t2348r806b2422],
54	meter	NN	O	meter	prep_per	51	SENT_62	[p4l833t2338r1079b2400],
55	given	VBN	O	give	partmod	54	SENT_62	[p4l1102t2322r1326b2422],
56	every	DT	SET	every	det	58	SENT_62	[p4l1354t2348r1568b2422],
57	two	CD	SET	two	num	58	SENT_62	[p4l1591t2338r1742b2401],
58	weeks	NNS	NUMBER	week	tmod	55	SENT_62	[p4l1766t2322r2026b2401],
59	in	IN	O	in	_	0	SENT_62	[p4l2054t2322r2135b2399],
60	combination	NN	O	combination	prep_in	55	SENT_62	[p4l12t2449r552b2527],
61	with	IN	O	with	_	0	SENT_62	[p4l571t2449r760b2528],
62	ﬂuorouracil	NN	O	ﬂuorouracil	prep_with	60	SENT_62	[p4l784t2448r1282b2528],
63	and	CC	O	and	_	0	SENT_62	[p4l1304t2449r1460b2527],
64	leucovorin	NN	O	leucovorin	prep_with	60	SENT_62	[p4l1483t2449r1952b2543],
65	;	:	O	;	_	0	SENT_62	[p4l1483t2449r1952b2543],
66	and	CC	O	and	_	0	SENT_62	[p4l1979t2449r2135b2527],
67	irinotecan	NN	O	irinotecan	conj_and	4	SENT_62	[p4l11t2577r446b2655],
68	at	IN	O	at	_	0	SENT_62	[p4l482t2593r562b2655],
69	a	DT	O	a	det	70	SENT_62	[p4l593t2603r638b2655],
70	dose	NN	O	dose	prep_at	67	SENT_62	[p4l673t2577r869b2655],
71	of	IN	O	of	_	0	SENT_62	[p4l907t2576r1008b2655],
72	350	CD	NUMBER	350	num	73	SENT_62	[p4l1027t2582r1182b2655],
73	mg	NN	O	mg	prep_of	70	SENT_62	[p4l1219t2603r1360b2677],
74	per	IN	O	per	_	0	SENT_62	[p4l1392t2603r1533b2677],
75	square	NN	O	square	nn	76	SENT_62	[p4l1568t2603r1850b2677],
76	meter	NN	O	meter	prep_per	73	SENT_62	[p4l1887t2593r2137b2655],
77	given	VBN	O	give	partmod	76	SENT_62	[p4l11t2705r239b2805],
78	every	DT	SET	every	det	80	SENT_62	[p4l274t2731r488b2805],
79	three	CD	SET	three	num	80	SENT_62	[p4l515t2705r728b2783],
80	weeks	NNS	NUMBER	week	tmod	77	SENT_62	[p4l755t2705r1015b2784],
81	as	IN	O	as	_	0	SENT_62	[p4l1048t2731r1132b2783],
82	a	DT	O	a	det	84	SENT_62	[p4l1165t2731r1209b2783],
83	single	JJ	O	single	amod	84	SENT_62	[p4l1240t2705r1490b2805],
84	agent	NN	O	agent	prep_as	77	SENT_62	[p4l1521t2721r1777b2805],
85	.	.	O	.	_	0	SENT_62	[p4l1521t2721r1777b2805],

1	Disease	NN	O	disease	nn	2	SENT_63	[p4l1812t2705r2134b2783],
2	progression	NN	O	progression	nsubjpass	4	SENT_63	[p4l10t2833r513b2933],
3	was	VBD	O	be	auxpass	4	SENT_63	[p4l533t2859r692b2912],
4	documented	VBN	O	document	_	0	SENT_63	[p4l719t2832r1242b2912],
5	by	IN	O	by	_	0	SENT_63	[p4l1266t2832r1363b2933],
6	computed	JJ	O	computed	amod	7	SENT_63	[p4l1382t2832r1804b2933],
7	tomography	NN	O	tomography	agent	4	SENT_63	[p4l1828t2849r2134b2933, p4l11t2961r251b3060],
8	(	CD	NUMBER	(	num	7	SENT_63	[p4l279t2966r457b3051],
9	CT	NN	O	ct	dep	7	SENT_63	[p4l279t2966r457b3051],
10	)	CD	NUMBER	)	num	9	SENT_63	[p4l279t2966r457b3051],
11	or	CC	O	or	_	0	SENT_63	[p4l491t2985r580b3038],
12	magnetic	JJ	O	magnetic	amod	14	SENT_63	[p4l604t2961r995b3060],
13	resonance	NN	O	resonance	nn	14	SENT_63	[p4l1022t2985r1451b3038],
14	imaging	NN	O	imaging	agent	4	SENT_63	[p4l1478t2961r1833b3060],
15	(	CD	NUMBER	(	num	16	SENT_63	[p4l1862t2967r2132b3055],
16	MRI	NNP	O	MRI	dep	14	SENT_63	[p4l1862t2967r2132b3055],
17	)	CD	NUMBER	)	num	16	SENT_63	[p4l1862t2967r2132b3055],
18	;	:	O	;	_	0	SENT_63	[p4l1862t2967r2132b3055],
19	new	JJ	O	new	amod	21	SENT_63	[p4l11t3114r187b3168],
20	lung	NN	O	lung	nn	21	SENT_63	[p4l205t3089r399b3189],
21	lesions	NNS	O	lesion	nsubjpass	24	SENT_63	[p4l418t3089r712b3167],
22	could	MD	O	could	aux	24	SENT_63	[p4l738t3089r971b3168],
23	be	VB	O	be	auxpass	24	SENT_63	[p4l994t3088r1089b3167],
24	documented	VBN	O	document	parataxis	4	SENT_63	[p4l1114t3088r1641b3168],
25	by	IN	O	by	_	0	SENT_63	[p4l1664t3089r1761b3189],
26	chest	NN	O	chest	nn	27	SENT_63	[p4l1781t3088r2003b3167],
27	radiography	NN	O	radiography	agent	24	SENT_63	[p4l2021t3115r2134b3167, p4l12t3217r461b3317],
28	.	.	O	.	_	0	SENT_63	[p4l2021t3115r2134b3167, p4l12t3217r461b3317],

1	At	IN	O	at	quantmod	3	SENT_64	[p4l487t3224r587b3295],
2	least	JJS	O	least	mwe	1	SENT_64	[p4l605t3216r806b3295],
3	one	CD	NUMBER	one	dep	5	SENT_64	[p4l826t3242r980b3295],
4	unidimensionally	RB	O	unidimensionally	advmod	5	SENT_64	[p4l1004t3216r1763b3317],
5	measurable	JJ	O	measurable	amod	6	SENT_64	[p4l1782t3243r2133b3296, p4l11t3344r185b3423],
6	lesion	NN	O	lesion	nsubjpass	8	SENT_64	[p4l229t3345r487b3423],
7	was	VBD	O	be	auxpass	8	SENT_64	[p4l527t3371r691b3424],
8	required	VBN	O	require	_	0	SENT_64	[p4l737t3345r1124b3445],
9	,	,	O	,	_	0	SENT_64	[p4l737t3345r1124b3445],
10	as	IN	O	as	mark	15	SENT_64	[p4l1173t3371r1258b3423],
11	was	VBD	O	be	cop	15	SENT_64	[p4l1300t3371r1463b3424],
12	immunohisto	JJ	O	immunohisto	amod	15	SENT_64	[p4l1508t3345r2133b3424],
13	—	NN	O	—	nn	15	SENT_64	[p4l1508t3345r2133b3424],
14	chemical	NN	O	chemical	nn	15	SENT_64	[p4l12t3473r384b3551],
15	evidence	NN	O	evidence	advcl	8	SENT_64	[p4l406t3472r760b3552],
16	of	IN	O	of	_	0	SENT_64	[p4l783t3472r883b3551],
17	EGFR	NN	ORGANIZATION	egfr	nn	18	SENT_64	[p4l884t3478r1141b3556],
18	expression	NN	O	expression	prep_of	15	SENT_64	[p4l1153t3473r1621b3573],
19	,	,	O	,	_	0	SENT_64	[p4l1153t3473r1621b3573],
20	either	CC	O	either	preconj	8	SENT_64	[p4l1649t3473r1888b3551],
21	in	IN	O	in	_	0	SENT_64	[p4l1906t3473r1986b3550],
22	the	DT	O	the	det	24	SENT_64	[p4l2009t3472r2136b3551],
23	primary	JJ	O	primary	amod	24	SENT_64	[p4l10t3601r345b3701],
24	tumor	NN	O	tumor	prep_in	8	SENT_64	[p4l366t3617r629b3680],
25	or	CC	O	or	_	0	SENT_64	[p4l651t3626r740b3679],
26	in	IN	O	in	_	0	SENT_64	[p4l761t3601r843b3678],
27	at	IN	O	at	quantmod	29	SENT_64	[p4l869t3617r949b3679],
28	least	JJS	O	least	mwe	27	SENT_64	[p4l969t3600r1171b3679],
29	one	CD	NUMBER	one	num	31	SENT_64	[p4l1193t3626r1347b3679],
30	metastatic	JJ	O	metastatic	amod	31	SENT_64	[p4l1374t3601r1822b3679],
31	lesion	NN	O	lesion	prep_in	8	SENT_64	[p4l1846t3600r2130b3679],
32	.	.	O	.	_	0	SENT_64	[p4l1846t3600r2130b3679],

1	All	PDT	O	all	predet	3	SENT_65	[p5l137t20r255b98],
2	the	DT	O	the	det	3	SENT_65	[p5l275t21r403b99],
3	patients	NNS	O	patient	nsubj	4	SENT_65	[p5l422t21r753b121],
4	signed	VBD	O	sign	_	0	SENT_65	[p5l777t20r1053b121],
5	a	DT	O	a	det	7	SENT_65	[p5l1072t47r1116b99],
6	consent	NN	O	consent	nn	7	SENT_65	[p5l1137t37r1467b99],
7	form	NN	O	form	dobj	4	SENT_65	[p5l1483t20r1711b99],
8	.	.	O	.	_	0	SENT_65	[p5l1483t20r1711b99],

1	The	DT	O	the	det	2	SENT_66	[p5l1734t21r1894b99],
2	study	NN	O	study	nsubjpass	4	SENT_66	[p5l1917t20r2140b121],
3	was	VBD	O	be	auxpass	4	SENT_66	[p5l7t175r168b228],
4	approved	VBN	O	approve	_	0	SENT_66	[p5l202t149r600b249],
5	by	IN	O	by	_	0	SENT_66	[p5l633t149r731b249],
6	the	DT	O	the	det	9	SENT_66	[p5l759t149r890b227],
7	institutional	JJ	O	institutional	amod	9	SENT_66	[p5l921t149r1451b228],
8	ethics	NNS	O	ethic	nn	9	SENT_66	[p5l1483t149r1731b227],
9	committees	NNS	O	committee	agent	4	SENT_66	[p5l1766t149r2133b227, p5l12t293r174b355],
10	of	IN	O	of	_	0	SENT_66	[p5l203t276r305b355],
11	all	PDT	O	all	predet	14	SENT_66	[p5l311t276r411b355],
12	the	DT	O	the	det	14	SENT_66	[p5l435t277r564b355],
13	participating	VBG	O	participate	amod	14	SENT_66	[p5l588t277r1134b377],
14	centers	NNS	O	center	prep_of	9	SENT_66	[p5l1156t293r1480b355],
15	.	.	O	.	_	0	SENT_66	[p5l1156t293r1480b355],

1	sru	NN	O	sru	nn	3	SENT_67	[p5l12t561r157b610],
2	DY	NN	O	dy	nn	3	SENT_67	[p5l178t561r278b610],
3	DESIG	NN	O	desig	nsubj	25	SENT_67	[p5l320t561r564b610],
4	N	NN	O	n	prep	3	SENT_67	[p5l587t561r630b610],
5	AN	DT	O	a	det	8	SENT_67	[p5l675t561r782b610],
6	D	NN	O	d	nn	8	SENT_67	[p5l805t561r852b610],
7	TREATM	NN	O	treatm	nn	8	SENT_67	[p5l889t561r1208b610],
8	ENT	NN	O	ent	dep	4	SENT_67	[p5l1231t561r1386b610],
9	This	DT	O	this	det	12	SENT_67	[p5l8t661r194b740],
10	open	JJ	O	open	amod	12	SENT_67	[p5l227t662r708b762],
11	—	NN	O	—	nn	12	SENT_67	[p5l227t662r708b762],
12	label	NN	O	label	nsubjpass	17	SENT_67	[p5l227t662r708b762],
13	,	,	O	,	_	0	SENT_67	[p5l227t662r708b762],
14	randomized	VBN	O	randomize	partmod	12	SENT_67	[p5l743t662r1265b740],
15	trial	NN	O	trial	dobj	14	SENT_67	[p5l1294t662r1465b740],
16	was	VBD	O	be	auxpass	17	SENT_67	[p5l1490t688r1653b741],
17	conducted	VBN	O	conduct	rcmod	3	SENT_67	[p5l1687t661r2134b741],
18	in	IN	O	in	_	0	SENT_67	[p5l11t790r93b867],
19	56	CD	NUMBER	56	num	20	SENT_67	[p5l118t795r217b868],
20	centers	NNS	O	center	prep_in	17	SENT_67	[p5l242t806r547b868],
21	in	IN	O	in	_	0	SENT_67	[p5l572t790r654b867],
22	11	CD	NUMBER	11	num	24	SENT_67	[p5l680t795r779b867],
23	European	JJ	MISC	european	amod	24	SENT_67	[p5l801t797r1216b890],
24	countries	NNS	O	country	prep_in	20	SENT_67	[p5l1240t790r1638b869],
25	(	VBP	O	(	_	0	SENT_67	[p5l1668t789r1831b881],
26	the	DT	O	the	det	28	SENT_67	[p5l1668t789r1831b881],
27	participating	VBG	O	participate	amod	28	SENT_67	[p5l1853t790r2133b890, p5l11t918r310b1018],
28	investigators	NNS	O	investigator	nsubjpass	30	SENT_67	[p5l325t918r857b1018],
29	are	VBP	O	be	auxpass	30	SENT_67	[p5l879t944r1003b996],
30	listed	VBN	O	list	ccomp	25	SENT_67	[p5l1023t918r1248b996],
31	in	IN	O	in	_	0	SENT_67	[p5l1267t918r1347b995],
32	the	DT	O	the	det	34	SENT_67	[p5l1368t918r1496b996],
33	Appendix	NNP	MISC	Appendix	nn	34	SENT_67	[p5l1513t917r1974b1018],
34	)	NN	O	)	prep_in	30	SENT_67	[p5l1513t917r1974b1018],
35	.	.	O	.	_	0	SENT_67	[p5l1513t917r1974b1018],

1	Before	IN	O	before	_	0	SENT_68	[p5l1999t924r2134b996, p5l11t1044r176b1123],
2	randomization	NN	O	randomization	prep_before	11	SENT_68	[p5l206t1044r856b1139],
3	,	,	O	,	_	0	SENT_68	[p5l206t1044r856b1139],
4	the	DT	O	the	det	6	SENT_68	[p5l891t1045r1020b1122],
5	EGFR	NN	ORGANIZATION	egfr	nn	6	SENT_68	[p5l1048t1050r1307b1128],
6	status	NN	O	status	nsubjpass	11	SENT_68	[p5l1328t1061r1573b1123],
7	of	IN	O	of	_	0	SENT_68	[p5l1605t1044r1705b1123],
8	the	DT	O	the	det	9	SENT_68	[p5l1716t1045r1845b1122],
9	tumor	NN	O	tumor	prep_of	6	SENT_68	[p5l1876t1061r2138b1123],
10	was	VBD	O	be	auxpass	11	SENT_68	[p5l7t1199r167b1252],
11	determined	VBN	O	determine	_	0	SENT_68	[p5l203t1173r697b1251],
12	at	IN	O	at	_	0	SENT_68	[p5l730t1189r810b1251],
13	a	DT	O	a	det	15	SENT_68	[p5l839t1199r883b1251],
14	central	JJ	O	central	amod	15	SENT_68	[p5l915t1173r1208b1251],
15	location	NN	O	location	prep_at	11	SENT_68	[p5l1241t1173r1590b1251],
16	in	IN	O	in	_	0	SENT_68	[p5l1623t1173r1705b1250],
17	Germany	NNP	LOCATION	Germany	prep_in	15	SENT_68	[p5l1739t1178r2138b1273],
18	by	IN	O	by	_	0	SENT_68	[p5l12t1300r110b1401],
19	immunohistochemical	JJ	O	immunohistochemical	amod	20	SENT_68	[p5l145t1300r1128b1380],
20	analysis	NN	O	analysis	agent	11	SENT_68	[p5l1168t1300r1506b1401],
21	of	IN	O	of	_	0	SENT_68	[p5l1550t1300r1652b1379],
22	a	DT	O	a	det	27	SENT_68	[p5l1673t1327r1718b1379],
23	parafﬁn	JJ	O	parafﬁn	amod	27	SENT_68	[p5l1756t1300r2133b1401],
24	—	NN	O	—	nn	27	SENT_68	[p5l1756t1300r2133b1401],
25	embedded	JJ	O	embedded	amod	27	SENT_68	[p5l12t1429r447b1507],
26	tumor	NN	O	tumor	nn	27	SENT_68	[p5l467t1445r727b1508],
27	specimen	NN	O	specimen	prep_of	20	SENT_68	[p5l745t1429r1142b1529],
28	with	IN	O	with	_	0	SENT_68	[p5l1157t1429r1344b1508],
29	the	DT	O	the	det	30	SENT_68	[p5l1365t1429r1492b1507],
30	use	NN	O	use	prep_with	11	SENT_68	[p5l1512t1455r1649b1508],
31	of	IN	O	of	_	0	SENT_68	[p5l1671t1428r1770b1507],
32	an	DT	O	a	det	35	SENT_68	[p5l1772t1454r1871b1507],
33	EGFR	NN	ORGANIZATION	egfr	nn	35	SENT_68	[p5l1890t1434r2147b1512],
34	diagnostic	JJ	O	diagnostic	amod	35	SENT_68	[p5l12t1557r446b1657],
35	kit	NN	O	kit	prep_of	30	SENT_68	[p5l469t1556r581b1636],
36	(	CD	NUMBER	(	num	39	SENT_68	[p5l604t1557r853b1648],
37	Dako	NNP	PERSON	Dako	nn	39	SENT_68	[p5l604t1557r853b1648],
38	Cytomation	NNP	O	Cytomation	nn	39	SENT_68	[p5l878t1557r1423b1657],
39	)	NN	O	)	dep	35	SENT_68	[p5l878t1557r1423b1657],
40	.	.	O	.	_	0	SENT_68	[p5l878t1557r1423b1657],

1	Random	NNP	O	Random	nn	2	SENT_69	[p5l1451t1556r1813b1640],
2	assignment	NN	O	assignment	_	0	SENT_69	[p5l1836t1557r2134b1657, p5l11t1701r233b1763],
3	of	IN	O	of	_	0	SENT_69	[p5l256t1684r356b1763],
4	the	DT	O	the	det	6	SENT_69	[p5l365t1685r494b1763],
5	eligible	JJ	O	eligible	amod	6	SENT_69	[p5l521t1684r828b1785],
6	patients	NNS	O	patient	prep_of	2	SENT_69	[p5l854t1685r1188b1785],
7	to	TO	O	to	dep	2	SENT_69	[p5l1218t1701r1296b1763],
8	either	CC	O	either	dep	2	SENT_69	[p5l1325t1685r1568b1763],
9	cetuximab	NN	O	cetuximab	dep	8	SENT_69	[p5l1593t1685r2027b1764],
10	in	IN	O	in	prep	9	SENT_69	[p5l2054t1685r2135b1762],

1	338	CD	NUMBER	338	num	4	SENT_70	[p5l149t1860r205b1882],
2	N	NN	O	n	nn	4	SENT_70	[p5l917t1862r930b1877],
3	ENGLJ	NN	O	englj	nn	4	SENT_70	[p5l946t1861r1030b1883],
4	MED	NN	O	med	_	0	SENT_70	[p5l1045t1862r1097b1877],
5	351	CD	NUMBER	351	dep	4	SENT_70	[p5l1110t1861r1174b1883],
6	;	:	O	;	_	0	SENT_70	[p5l1110t1861r1174b1883],
7	4	CD	NUMBER	4	dep	4	SENT_70	[p5l1110t1861r1174b1883],
8	WWW	NNP	O	WWW	dep	7	SENT_70	[p5l1208t1862r1320b1877],
9	.	.	O	.	_	0	SENT_70	[p5l1208t1862r1320b1877],

1	NE	NN	O	ne	nn	3	SENT_71	[p5l1208t1862r1320b1877],
2	M.ORG	NN	O	m.org	nn	3	SENT_71	[p5l1336t1861r1420b1877],
3	JULY	NN	DATE	july	_	0	SENT_71	[p5l1453t1862r1513b1883],
4	22	CD	DATE	22	dep	3	SENT_71	[p5l1525t1861r1562b1881],
5	,	,	O	,	_	0	SENT_71	[p5l1525t1861r1562b1881],
6	2oo4	CD	NUMBER	2oo4	appos	4	SENT_71	[p5l1575t1861r1643b1883],

1	The	DT	O	the	det	5	SENT_72	[p5l936t1894r987b1918],
2	New	NNP	O	New	nn	5	SENT_72	[p5l996t1895r1058b1918],
3	England	NNP	O	England	nn	5	SENT_72	[p5l1067t1894r1178b1925],
4	Journal	NNP	O	Journal	nn	5	SENT_72	[p5l1187t1894r1284b1918],
5	o	NN	O	o	_	0	SENT_72	[p5l1294t1902r1309b1918],
6	edicine	NN	O	edicine	dep	5	SENT_72	[p5l1360t1894r1455b1918],

1	Downloaded	VBN	O	download	_	0	SENT_73	[p5l378t1935r548b1958],
2	from	IN	O	from	_	0	SENT_73	[p5l557t1935r621b1958],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_73	[p5l630t1935r748b1965],
4	at	IN	O	at	_	0	SENT_73	[p5l759t1939r782b1958],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_73	[p5l790t1935r973b1958],
6	on	IN	O	on	_	0	SENT_73	[p5l982t1942r1015b1958],
7	Janu	NNP	DATE	Janu	prep_on	1	SENT_73	[p5l1023t1935r1084b1958],
8	5	CD	DATE	5	num	7	SENT_73	[p5l1136t1935r1159b1962],
9	,	,	DATE	,	_	0	SENT_73	[p5l1136t1935r1159b1962],
10	2014	CD	DATE	2014	num	7	SENT_73	[p5l1170t1935r1242b1958],
11	.	.	O	.	_	0	SENT_73	[p5l1170t1935r1242b1958],

1	For	IN	O	for	_	0	SENT_74	[p5l1252t1935r1299b1958],
2	personal	JJ	O	personal	amod	3	SENT_74	[p5l1307t1935r1419b1965],
3	use	NN	O	use	pobj	1	SENT_74	[p5l1428t1942r1472b1958],
4	only	RB	O	only	advmod	3	SENT_74	[p5l1482t1935r1546b1965],
5	.	.	O	.	_	0	SENT_74	[p5l1482t1935r1546b1965],

1	No	DT	O	no	det	3	SENT_75	[p5l1557t1935r1597b1958],
2	other	JJ	O	other	amod	3	SENT_75	[p5l1607t1935r1675b1958],
3	uses	NNS	O	use	_	0	SENT_75	[p5l1683t1942r1739b1958],
4	without	IN	O	without	_	0	SENT_75	[p5l1749t1935r1850b1958],
5	permission	NN	O	permission	prep_without	3	SENT_75	[p5l1859t1935r2011b1965],
6	.	.	O	.	_	0	SENT_75	[p5l1859t1935r2011b1965],

1	Copyright	NN	O	copyright	nsubj	6	SENT_76	[p5l728t1976r863b2007],
2	©	CD	NUMBER	©	num	1	SENT_76	[p5l872t1976r896b2000],
3	2004	CD	DATE	2004	num	5	SENT_76	[p5l906t1976r971b2000],
4	Massa	NNP	PERSON	Massa	nn	5	SENT_76	[p5l980t1977r1065b2000],
5	u	NN	O	u	dep	1	SENT_76	[p5l1097t1984r1113b2000],
6	etts	VBZ	O	ett	_	0	SENT_76	[p5l1127t1980r1171b2000],
7	Medical	NNP	ORGANIZATION	Medical	nn	8	SENT_76	[p5l1181t1976r1289b2000],
8	Society	NNP	ORGANIZATION	Society	dobj	6	SENT_76	[p5l1300t1976r1405b2007],
9	.	.	O	.	_	0	SENT_76	[p5l1300t1976r1405b2007],

1	All	DT	O	all	det	2	SENT_77	[p5l1416t1976r1457b2000],
2	rights	NNS	O	rights	nsubj	3	SENT_77	[p5l1466t1976r1541b2007],
3	reserved	VBN	O	reserve	_	0	SENT_77	[p5l1551t1976r1670b2000],
4	.	.	O	.	_	0	SENT_77	[p5l1551t1976r1670b2000],

1	CETUXIMAB	NNP	O	CETUXIMAB	_	0	SENT_78	[p5l533t2082r727b2101],
2	IN	IN	O	in	dep	1	SENT_78	[p5l742t2082r780b2101],
3	IRINOTECAN-REFRACTORY	NNP	O	IRINOTECAN-REFRACTORY	nn	5	SENT_78	[p5l796t2082r1248b2101],
4	COLORECTAL	NNP	O	COLORECTAL	nn	5	SENT_78	[p5l1260t2082r1477b2101],
5	CANCER	NNP	O	CANCER	pobj	2	SENT_78	[p5l1490t2082r1626b2101],

1	combination	NN	O	combination	nsubjpass	13	SENT_79	[p5l11t2296r551b2374],
2	with	IN	O	with	_	0	SENT_79	[p5l570t2296r760b2375],
3	irinotecan	NN	O	irinotecan	prep_with	1	SENT_79	[p5l782t2296r1210b2374],
4	or	CC	O	or	_	0	SENT_79	[p5l1234t2321r1323b2374],
5	cetuximab	NN	O	cetuximab	conj_or	3	SENT_79	[p5l1344t2296r1779b2375],
6	alone	RB	O	alone	advmod	3	SENT_79	[p5l1803t2296r2031b2374],
7	in	IN	O	in	_	0	SENT_79	[p5l2054t2296r2135b2373],
8	a	DT	O	a	det	9	SENT_79	[p5l10t2450r54b2502],
9	ratio	NN	O	ratio	prep_in	3	SENT_79	[p5l86t2424r277b2502],
10	of	IN	O	of	_	0	SENT_79	[p5l312t2423r412b2502],
11	2:1	CD	NUMBER	2:1	prep_of	9	SENT_79	[p5l426t2429r556b2502],
12	was	VBD	O	be	auxpass	13	SENT_79	[p5l584t2450r745b2503],
13	carried	VBN	O	carry	_	0	SENT_79	[p5l780t2423r1071b2502],
14	out	RP	O	out	prt	13	SENT_79	[p5l1104t2440r1244b2503],
15	centrally	RB	O	centrally	amod	20	SENT_79	[p5l1272t2424r1633b2524],
16	by	IN	O	by	_	0	SENT_79	[p5l1662t2424r1759b2524],
17	an	DT	O	a	det	19	SENT_79	[p5l1786t2449r1886b2502],
18	independent	JJ	O	independent	amod	19	SENT_79	[p5l1918t2424r2134b2502, p5l9t2552r352b2652],
19	randomization	NN	O	randomization	prep_by	15	SENT_79	[p5l367t2552r978b2630],
20	service	NN	O	service	dobj	13	SENT_79	[p5l1000t2552r1295b2631],
21	.	.	O	.	_	0	SENT_79	[p5l1000t2552r1295b2631],

1	Randomization	NN	O	randomization	nsubjpass	3	SENT_80	[p5l1320t2551r1960b2635],
2	Was	VBD	O	be	auxpass	3	SENT_80	[p5l1976t2578r2135b2631],
3	performed	VBN	O	perform	_	0	SENT_80	[p5l9t2679r452b2780],
4	by	IN	O	by	_	0	SENT_80	[p5l477t2679r573b2780],
5	a	DT	O	a	det	7	SENT_80	[p5l593t2706r637b2758],
6	minimization	NN	O	minimization	nn	7	SENT_80	[p5l660t2680r1227b2758],
7	technique	NN	O	technique	agent	3	SENT_80	[p5l1252t2680r1684b2780],
8	,	,	O	,	_	0	SENT_80	[p5l1252t2680r1684b2780],
9	with	IN	O	with	_	0	SENT_80	[p5l1709t2680r1896b2759],
10	stratiﬁcation	NN	O	stratiﬁcation	prep_with	3	SENT_80	[p5l1922t2696r2135b2758, p5l10t2807r351b2886],
11	according	VBG	O	accord	_	0	SENT_80	[p5l387t2808r803b2908],
12	to	TO	O	to	prepc_according_to	10	SENT_80	[p5l837t2824r915b2886],
13	Karnofsky	NNP	PERSON	Karnofsky	nn	14	SENT_80	[p5l953t2807r1383b2908],
14	performance	NN	O	performance	pobj	10	SENT_80	[p5l1413t2807r1948b2908],
15	status	NN	O	status	nn	18	SENT_80	[p5l1986t2824r2135b2886, p5l11t2952r156b3031],
16	,	,	O	,	_	0	SENT_80	[p5l1986t2824r2135b2886, p5l11t2952r156b3031],
17	previous	JJ	O	previous	amod	18	SENT_80	[p5l193t2936r548b3036],
18	treatment	NN	O	treatment	conj_or	18	SENT_80	[p5l585t2952r1000b3014],
19	With	IN	O	with	_	0	SENT_80	[p5l1024t2936r1217b3015],
20	or	CC	O	or	_	0	SENT_80	[p5l1255t2961r1344b3014],
21	Without	IN	O	without	_	0	SENT_80	[p5l1374t2936r1715b3015],
22	prior	JJ	O	prior	amod	23	SENT_80	[p5l1745t2936r1962b3036],
23	use	NN	O	use	prep_without	18	SENT_80	[p5l1996t2962r2135b3015],
24	of	IN	O	of	_	0	SENT_80	[p5l11t3063r112b3142],
25	oxaliplatin	NN	O	oxaliplatin	prep_of	23	SENT_80	[p5l119t3064r589b3164],
26	,	,	O	,	_	0	SENT_80	[p5l119t3064r589b3164],
27	and	CC	O	and	_	0	SENT_80	[p5l619t3063r775b3142],
28	treatment	NN	O	treatment	nn	29	SENT_80	[p5l800t3080r1215b3142],
29	center	NN	O	center	conj_and	14	SENT_80	[p5l1235t3080r1512b3142],
30	.	.	O	.	_	0	SENT_80	[p5l1235t3080r1512b3142],

1	Cetuximab	NNP	MISC	Cetuximab	nsubjpass	3	SENT_81	[p5l140t3192r588b3271],
2	Was	VBD	MISC	be	auxpass	3	SENT_81	[p5l607t3218r766b3271],
3	given	VBN	O	give	_	0	SENT_81	[p5l790t3192r1011b3292],
4	at	IN	O	at	_	0	SENT_81	[p5l1033t3208r1111b3270],
5	an	DT	O	a	det	7	SENT_81	[p5l1127t3217r1227b3270],
6	initial	JJ	O	initial	amod	7	SENT_81	[p5l1248t3192r1486b3270],
7	dose	NN	O	dose	prep_at	3	SENT_81	[p5l1509t3192r1699b3270],
8	of	IN	O	of	_	0	SENT_81	[p5l1723t3191r1823b3270],
9	400	CD	NUMBER	400	num	10	SENT_81	[p5l1824t3197r1978b3270],
10	mg	NN	O	mg	prep_of	7	SENT_81	[p5l2001t3218r2139b3292],
11	per	IN	O	per	_	0	SENT_81	[p5l9t3346r147b3420],
12	square	NN	O	square	nn	13	SENT_81	[p5l177t3346r453b3420],
13	meter	NN	O	meter	prep_per	10	SENT_81	[p5l485t3336r745b3415],
14	,	,	O	,	_	0	SENT_81	[p5l485t3336r745b3415],
15	followed	VBN	O	follow	_	0	SENT_81	[p5l784t3319r1151b3399],
16	by	IN	O	by	prepc_followed_by	3	SENT_81	[p5l1184t3320r1281b3420],
17	Weekly	NNP	SET	Weekly	nn	18	SENT_81	[p5l1304t3320r1597b3420],
18	infusions	NNS	O	infusion	pobj	3	SENT_81	[p5l1624t3319r2018b3399],
19	of	IN	O	of	_	0	SENT_81	[p5l2053t3319r2153b3398],
20	250	CD	NUMBER	250	num	21	SENT_81	[p5l11t3453r164b3525],
21	mg	NN	O	mg	prep_of	18	SENT_81	[p5l186t3473r326b3547],
22	per	IN	O	per	_	0	SENT_81	[p5l343t3473r481b3547],
23	square	NN	O	square	nn	24	SENT_81	[p5l501t3473r778b3547],
24	meter	NN	O	meter	prep_per	21	SENT_81	[p5l799t3464r1062b3525],
25	.	.	O	.	_	0	SENT_81	[p5l799t3464r1062b3525],

1	A	DT	O	a	det	5	SENT_82	[p5l1085t3454r1151b3524],
2	histamine	NN	O	histamine	nn	5	SENT_82	[p5l1169t3448r1983b3547],
3	—	NN	O	—	nn	5	SENT_82	[p5l1169t3448r1983b3547],
4	receptor	NN	O	receptor	nn	5	SENT_82	[p5l1169t3448r1983b3547],
5	antagonistwas	NNS	O	antagonistwa	nsubj	6	SENT_82	[p5l2001t3472r2134b3525, p5l11t3576r535b3676],
6	given	VBN	O	give	_	0	SENT_82	[p5l559t3576r783b3676],
7	as	IN	O	as	_	0	SENT_82	[p5l806t3602r890b3654],
8	premedication	NN	O	premedication	prep_as	6	SENT_82	[p5l913t3576r1529b3676],
9	before	IN	O	before	_	0	SENT_82	[p5l1553t3575r1824b3654],
10	at	IN	O	at	advmod	14	SENT_82	[p5l1847t3592r1927b3654],
11	least	JJS	O	least	pobj	10	SENT_82	[p5l1944t3576r2140b3654],
12	the	DT	O	the	det	14	SENT_82	[p5l11t3704r140b3782],
13	ﬁrst	JJ	O	ﬁrst	amod	14	SENT_82	[p5l174t3703r347b3782],
14	infusion	NN	O	infusion	prep_before	6	SENT_82	[p5l375t3703r751b3783],
15	.	.	O	.	_	0	SENT_82	[p5l375t3703r751b3783],

1	Patients	NNS	O	patient	nsubj	2	SENT_83	[p5l788t3704r1120b3782],
2	assigned	VBN	O	assign	_	0	SENT_83	[p5l1155t3704r1526b3804],
3	to	TO	O	to	_	0	SENT_83	[p5l1559t3720r1638b3782],
4	the	DT	O	the	det	7	SENT_83	[p5l1673t3704r1802b3782],
5	combination	NN	O	combination	nn	7	SENT_83	[p5l1837t3704r2134b3782, p6l11t20r650b121],
6	—	NN	O	—	nn	7	SENT_83	[p5l1837t3704r2134b3782, p6l11t20r650b121],
7	therapy	NN	O	therapy	prep_to	2	SENT_83	[p5l1837t3704r2134b3782, p6l11t20r650b121],

1	group	NN	O	group	nsubj	3	SENT_84	[p6l686t46r941b121],
2	also	RB	O	also	advmod	3	SENT_84	[p6l982t21r1153b99],
3	received	VBD	O	receive	_	0	SENT_84	[p6l1194t20r1543b100],
4	irinotecan	NN	O	irinotecan	dobj	3	SENT_84	[p6l1582t21r2019b99],
5	at	IN	O	at	_	0	SENT_84	[p6l2059t37r2139b99],
6	the	DT	O	the	det	8	SENT_84	[p6l11t149r142b227],
7	same	JJ	O	same	amod	8	SENT_84	[p6l180t175r399b227],
8	dose	NN	O	dose	prep_at	3	SENT_84	[p6l435t149r628b227],
9	as	IN	O	as	_	0	SENT_84	[p6l661t175r746b227],
10	that	DT	O	that	prep_as	3	SENT_84	[p6l781t149r948b227],
11	given	VBN	O	give	prep	10	SENT_84	[p6l976t149r1200b249],
12	during	IN	O	during	pcomp	11	SENT_84	[p6l1234t148r1519b249],
13	their	PRP$	O	they	poss	17	SENT_84	[p6l1549t149r1747b227],
14	most	RBS	O	most	advmod	15	SENT_84	[p6l1777t165r1994b227],
15	recent	JJ	O	recent	amod	17	SENT_84	[p6l2022t175r2134b227, p6l11t293r191b355],
16	prestudy	NN	O	prestudy	nn	17	SENT_84	[p6l221t276r589b377],
17	therapy	NN	O	therapy	pobj	12	SENT_84	[p6l623t276r951b377],
18	.	.	O	.	_	0	SENT_84	[p6l623t276r951b377],

1	All	PDT	O	all	predet	3	SENT_85	[p6l990t277r1109b354],
2	the	DT	O	the	det	3	SENT_85	[p6l1146t277r1276b355],
3	patients	NNS	O	patient	nsubj	4	SENT_85	[p6l1312t277r1646b377],
4	were	VBD	O	be	_	0	SENT_85	[p6l1682t303r1883b356],
5	to	TO	O	to	aux	7	SENT_85	[p6l1922t293r2000b355],
6	be	VB	O	be	auxpass	7	SENT_85	[p6l2039t277r2135b355],
7	treated	VBN	O	treat	xcomp	4	SENT_85	[p6l11t405r300b483],
8	until	IN	O	until	mark	15	SENT_85	[p6l337t405r532b484],
9	disease	NN	O	disease	nn	10	SENT_85	[p6l570t404r872b483],
10	progression	NN	O	progression	nsubj	15	SENT_85	[p6l909t405r1417b505],
11	or	CC	O	or	_	0	SENT_85	[p6l1455t430r1544b483],
12	unacceptable	JJ	O	unacceptable	amod	13	SENT_85	[p6l1579t404r2135b505],
13	toxic	JJ	O	toxic	amod	14	SENT_85	[p6l11t533r208b611],
14	effects	NNS	O	effect	conj_or	10	SENT_85	[p6l229t532r491b611],
15	occurred	VBD	O	occur	advcl	7	SENT_85	[p6l514t532r898b612],
16	.	.	O	.	_	0	SENT_85	[p6l514t532r898b612],

1	In	IN	O	in	_	0	SENT_86	[p6l922t540r1007b610],
2	the	DT	O	the	det	3	SENT_86	[p6l1028t533r1155b611],
3	case	NN	O	case	prep_in	15	SENT_86	[p6l1176t559r1348b611],
4	of	IN	O	of	_	0	SENT_86	[p6l1369t532r1468b611],
5	disease	NN	O	disease	nn	6	SENT_86	[p6l1470t533r1766b611],
6	progression	NN	O	progression	prep_of	3	SENT_86	[p6l1785t558r2135b633, p6l12t661r213b756],
7	,	,	O	,	_	0	SENT_86	[p6l1785t558r2135b633, p6l12t661r213b756],
8	patients	NNS	O	patient	nsubj	15	SENT_86	[p6l241t661r583b761],
9	assigned	VBN	O	assign	partmod	8	SENT_86	[p6l610t661r988b761],
10	to	TO	O	to	_	0	SENT_86	[p6l1013t677r1093b739],
11	the	DT	O	the	det	13	SENT_86	[p6l1119t661r1251b739],
12	monotherapy	JJ	O	monotherapy	amod	13	SENT_86	[p6l1276t661r1858b761],
13	group	NN	O	group	prep_to	9	SENT_86	[p6l1878t686r2133b761],
14	could	MD	O	could	aux	15	SENT_86	[p6l11t788r244b867],
15	continue	VB	O	continue	_	0	SENT_86	[p6l281t788r650b866],
16	to	TO	O	to	aux	17	SENT_86	[p6l688t804r766b866],
17	receive	VB	O	receive	xcomp	15	SENT_86	[p6l806t788r1091b866],
18	cetuximab	NN	O	cetuximab	dobj	17	SENT_86	[p6l1130t788r1588b882],
19	,	,	O	,	_	0	SENT_86	[p6l1130t788r1588b882],
20	and	CC	O	and	_	0	SENT_86	[p6l1631t788r1787b866],
21	irinote	JJ	O	irinote	amod	22	SENT_86	[p6l1823t788r2134b866],
22	—	NN	O	—	nsubjpass	26	SENT_86	[p6l1823t788r2134b866],
23	can	MD	O	can	aux	26	SENT_86	[p6l11t941r156b994],
24	could	MD	O	could	aux	26	SENT_86	[p6l187t916r419b995],
25	be	VB	O	be	auxpass	26	SENT_86	[p6l451t916r546b994],
26	added	VBN	O	add	conj_and	15	SENT_86	[p6l576t915r832b994],
27	at	IN	O	at	_	0	SENT_86	[p6l861t932r940b994],
28	the	DT	O	the	det	30	SENT_86	[p6l967t916r1096b994],
29	same	JJ	O	same	amod	30	SENT_86	[p6l1129t942r1346b994],
30	dose	NN	O	dose	prep_at	26	SENT_86	[p6l1378t915r1571b994],
31	as	IN	O	as	_	0	SENT_86	[p6l1602t942r1686b994],
32	that	DT	O	that	prep_as	26	SENT_86	[p6l1719t916r1886b994],
33	given	VBN	O	give	prep	32	SENT_86	[p6l1912t916r2135b1016],
34	during	IN	O	during	pcomp	33	SENT_86	[p6l11t1044r296b1144],
35	their	PRP$	O	they	poss	39	SENT_86	[p6l318t1044r516b1122],
36	most	RBS	O	most	advmod	37	SENT_86	[p6l538t1060r754b1122],
37	recent	JJ	O	recent	amod	39	SENT_86	[p6l775t1060r1037b1122],
38	prestudy	NN	O	prestudy	nn	39	SENT_86	[p6l1056t1043r1432b1144],
39	therapy	NN	O	therapy	pobj	34	SENT_86	[p6l1454t1043r1782b1144],
40	.	.	O	.	_	0	SENT_86	[p6l1454t1043r1782b1144],

1	Tumor	NN	O	tumor	nn	2	SENT_87	[p6l136t1177r432b1251],
2	response	NN	O	response	nsubjpass	4	SENT_87	[p6l468t1197r854b1272],
3	was	VBD	O	be	auxpass	4	SENT_87	[p6l889t1198r1052b1251],
4	evaluated	VBN	O	evaluate	_	0	SENT_87	[p6l1093t1171r1495b1251],
5	every	DT	SET	every	det	7	SENT_87	[p6l1534t1198r1752b1272],
6	6	CD	SET	6	num	7	SENT_87	[p6l1786t1177r1833b1250],
7	weeks	NNS	NUMBER	week	tmod	4	SENT_87	[p6l1868t1171r2132b1251],
8	for	IN	O	for	_	0	SENT_87	[p6l11t1299r135b1378],
9	the	DT	O	the	det	10	SENT_87	[p6l155t1299r285b1378],
10	ﬁrst	NN	O	ﬁrst	prep_for	4	SENT_87	[p6l307t1299r480b1378],
11	24	CD	DURATION	24	num	12	SENT_87	[p6l496t1305r598b1378],
12	weeks	NNS	NUMBER	week	tmod	10	SENT_87	[p6l615t1300r875b1379],
13	and	CC	O	and	_	0	SENT_87	[p6l899t1299r1054b1378],
14	thereafter	RB	O	thereafter	advmod	25	SENT_87	[p6l1077t1299r1487b1378],
15	every	DT	SET	every	quantmod	16	SENT_87	[p6l1506t1326r1720b1400],
16	3	CD	SET	3	num	17	SENT_87	[p6l1739t1305r1783b1378],
17	months	NNS	NUMBER	month	pobj	14	SENT_87	[p6l1808t1300r2132b1378],
18	with	IN	O	with	_	0	SENT_87	[p6l6t1427r198b1507],
19	the	DT	O	the	det	20	SENT_87	[p6l251t1428r382b1506],
20	use	NN	O	use	prep_with	14	SENT_87	[p6l433t1454r575b1507],
21	of	IN	O	of	_	0	SENT_87	[p6l628t1427r729b1506],
22	consistent	JJ	O	consistent	amod	24	SENT_87	[p6l763t1428r1210b1506],
23	imaging	NN	O	imaging	nn	24	SENT_87	[p6l1255t1428r1617b1528],
24	techniques	NNS	O	technique	prep_of	20	SENT_87	[p6l1665t1428r2132b1528],
25	(	VBP	O	(	conj_and	4	SENT_87	[p6l15t1561r170b1647],
26	CT	NN	O	ct	dobj	25	SENT_87	[p6l15t1561r170b1647],
27	or	CC	O	or	_	0	SENT_87	[p6l207t1581r298b1634],
28	MRI	NNP	MISC	MRI	conj_or	26	SENT_87	[p6l331t1562r577b1647],
29	)	CD	NUMBER	)	num	28	SENT_87	[p6l331t1562r577b1647],
30	.	.	O	.	_	0	SENT_87	[p6l331t1562r577b1647],

1	Assessment	NNP	O	Assessment	nsubjpass	3	SENT_88	[p6l619t1563r1138b1634],
2	was	VBD	O	be	auxpass	3	SENT_88	[p6l1168t1582r1331b1635],
3	performed	VBN	O	perform	_	0	SENT_88	[p6l1371t1555r1829b1656],
4	by	IN	O	by	_	0	SENT_88	[p6l1869t1555r1967b1656],
5	the	DT	O	the	det	6	SENT_88	[p6l2003t1556r2134b1634],
6	investigators	NNS	O	investigator	agent	3	SENT_88	[p6l10t1684r588b1784],
7	,	,	O	,	_	0	SENT_88	[p6l10t1684r588b1784],
8	who	WP	O	who	nsubj	9	SENT_88	[p6l621t1684r806b1763],
9	used	VBD	O	use	rcmod	6	SENT_88	[p6l839t1684r1038b1763],
10	the	DT	O	the	det	13	SENT_88	[p6l1070t1683r1201b1762],
11	Response	NN	O	response	nn	13	SENT_88	[p6l1233t1690r1649b1784],
12	Evaluation	NN	O	evaluation	nn	13	SENT_88	[p6l1680t1683r2134b1763],
13	Criteria	NNS	O	criterion	nsubj	17	SENT_88	[p6l11t1813r334b1890],
14	in	IN	O	in	_	0	SENT_88	[p6l359t1813r441b1889],
15	Solid	JJ	O	solid	amod	16	SENT_88	[p6l469t1812r685b1890],
16	Tumors	NNS	O	tumor	prep_in	13	SENT_88	[p6l708t1818r1042b1891],
17	(	VBP	O	(	ccomp	9	SENT_88	[p6l1077t1806r1558b1903],
18	RECIST	NN	O	recist	dobj	17	SENT_88	[p6l1077t1806r1558b1903],
19	)	CD	NUMBER	)	num	20	SENT_88	[p6l1077t1806r1558b1903],
20	19	CD	NUMBER	19	dep	18	SENT_88	[p6l1077t1806r1558b1903],
21	and	CC	O	and	_	0	SENT_88	[p6l1585t1812r1743b1890],
22	by	IN	O	by	_	0	SENT_88	[p6l1770t1812r1868b1912],
23	an	DT	O	a	det	26	SENT_88	[p6l1889t1837r1991b1890],
24	independent	JJ	O	independent	amod	26	SENT_88	[p6l2016t1813r2133b1889, p6l11t1940r470b2040],
25	review	NN	O	review	nn	26	SENT_88	[p6l503t1940r780b2019],
26	committee	NN	O	committee	conj_and	6	SENT_88	[p6l815t1940r1273b2018],
27	consisting	VBG	O	consist	partmod	26	SENT_88	[p6l1312t1940r1761b2040],
28	of	IN	O	of	_	0	SENT_88	[p6l1797t1939r1898b2018],
29	three	CD	NUMBER	three	num	30	SENT_88	[p6l1917t1940r2134b2018],
30	radiologists	NNS	O	radiologist	prep_of	27	SENT_88	[p6l11t2068r520b2168],
31	and	CC	O	and	_	0	SENT_88	[p6l562t2068r718b2146],
32	one	CD	NUMBER	one	num	33	SENT_88	[p6l757t2093r909b2146],
33	oncologist	NN	O	oncologist	prep_of	27	SENT_88	[p6l948t2068r1398b2168],
34	who	WP	O	who	nsubj	35	SENT_88	[p6l1426t2068r1610b2147],
35	used	VBD	O	use	rcmod	33	SENT_88	[p6l1648t2068r1844b2147],
36	modiﬁed	JJ	O	modiﬁed	amod	40	SENT_88	[p6l1881t2068r2134b2146, p6l11t2196r168b2275],
37	World	NNP	ORGANIZATION	World	nn	40	SENT_88	[p6l189t2197r452b2275],
38	Health	NNP	ORGANIZATION	Health	nn	40	SENT_88	[p6l477t2197r760b2275],
39	Organization	NNP	ORGANIZATION	Organization	nn	40	SENT_88	[p6l784t2197r1343b2297],
40	(	NNP	O	(	dobj	35	SENT_88	[p6l1373t2202r1673b2288],
41	WHO	WP	O	who	dep	43	SENT_88	[p6l1373t2202r1673b2288],
42	)	CD	NUMBER	)	num	43	SENT_88	[p6l1373t2202r1673b2288],
43	criteria	NNS	O	criterion	rcmod	40	SENT_88	[p6l1704t2192r2108b2275],
44	?	.	O	?	_	0	SENT_88	[p6l1704t2192r2108b2275],

1	”	NN	O	”	npadvmod	17	SENT_89	[p6l1704t2192r2108b2275],
2	In	IN	O	in	_	0	SENT_89	[p6l138t2331r224b2400],
3	brief	NN	O	brief	prep_in	17	SENT_89	[p6l247t2323r462b2418],
4	,	,	O	,	_	0	SENT_89	[p6l247t2323r462b2418],
5	on	IN	O	on	_	0	SENT_89	[p6l490t2349r596b2402],
6	the	DT	O	the	det	7	SENT_89	[p6l619t2324r746b2401],
7	basis	NN	O	basis	prep_on	17	SENT_89	[p6l769t2324r976b2402],
8	of	IN	O	of	_	0	SENT_89	[p6l1001t2323r1101b2402],
9	the	DT	O	the	prep_of	7	SENT_89	[p6l1104t2324r1233b2401],
10	WHO	WP	O	who	dep	11	SENT_89	[p6l1251t2329r1494b2402],
11	criteria	NNS	O	criterion	rcmod	7	SENT_89	[p6l1517t2324r1830b2418],
12	,	,	O	,	_	0	SENT_89	[p6l1517t2324r1830b2418],
13	a	DT	O	a	det	15	SENT_89	[p6l1856t2350r1901b2401],
14	complete	JJ	O	complete	amod	15	SENT_89	[p6l1922t2349r2134b2402, p6l9t2452r211b2552],
15	response	NN	O	response	nsubjpass	17	SENT_89	[p6l241t2477r619b2552],
16	was	VBD	O	be	auxpass	17	SENT_89	[p6l644t2478r805b2531],
17	deﬁned	VBN	O	deﬁned	_	0	SENT_89	[p6l838t2451r1153b2530],
18	as	IN	O	as	_	0	SENT_89	[p6l1182t2478r1267b2530],
19	the	DT	O	the	det	21	SENT_89	[p6l1299t2452r1428b2530],
20	complete	JJ	O	complete	amod	21	SENT_89	[p6l1459t2452r1846b2552],
21	disappearance	NN	O	disappearance	prep_as	17	SENT_89	[p6l1877t2451r2134b2552, p6l9t2605r387b2680],
22	of	IN	O	of	_	0	SENT_89	[p6l412t2579r513b2658],
23	all	DT	O	all	det	25	SENT_89	[p6l518t2580r617b2658],
24	measurable	JJ	O	measurable	amod	25	SENT_89	[p6l640t2580r1127b2659],
25	lesions	NNS	O	lesion	prep_of	21	SENT_89	[p6l1150t2579r1471b2675],
26	,	,	O	,	_	0	SENT_89	[p6l1150t2579r1471b2675],
27	without	IN	O	without	_	0	SENT_89	[p6l1495t2580r1830b2659],
28	the	DT	O	the	det	29	SENT_89	[p6l1850t2579r1979b2658],
29	appearance	NN	O	appearance	prep_without	17	SENT_89	[p6l2002t2606r2134b2680, p6l9t2733r384b2808],
30	of	IN	O	of	_	0	SENT_89	[p6l407t2707r507b2786],
31	any	DT	O	any	det	33	SENT_89	[p6l510t2733r656b2808],
32	new	JJ	O	new	amod	33	SENT_89	[p6l674t2733r849b2787],
33	lesions	NNS	O	lesion	prep_of	29	SENT_89	[p6l866t2708r1183b2786],
34	.	.	O	.	_	0	SENT_89	[p6l866t2708r1183b2786],

1	A	DT	O	a	det	3	SENT_90	[p6l1207t2715r1273b2785],
2	partial	JJ	O	partial	amod	3	SENT_90	[p6l1291t2708r1558b2808],
3	response	NN	O	response	nsubjpass	5	SENT_90	[p6l1580t2733r1956b2808],
4	was	VBD	O	be	auxpass	5	SENT_90	[p6l1973t2734r2134b2787],
5	deﬁned	VBN	O	deﬁned	_	0	SENT_90	[p6l11t2835r326b2914],
6	as	IN	O	as	_	0	SENT_90	[p6l350t2862r434b2914],
7	a	DT	O	a	det	8	SENT_90	[p6l460t2862r504b2914],
8	reduction	NN	O	reduction	prep_as	5	SENT_90	[p6l527t2836r931b2915],
9	in	IN	O	in	_	0	SENT_90	[p6l954t2836r1036b2913],
10	bidimensionally	RB	O	bidimensionally	advmod	11	SENT_90	[p6l1061t2835r1761b2936],
11	measurable	JJ	O	measurable	amod	12	SENT_90	[p6l1782t2862r2133b2915, p6l10t2964r182b3042],
12	lesions	NNS	O	lesion	prep_in	8	SENT_90	[p6l207t2964r499b3042],
13	by	IN	O	by	_	0	SENT_90	[p6l529t2964r625b3064],
14	at	IN	O	at	quantmod	16	SENT_90	[p6l647t2980r725b3042],
15	least	JJS	O	least	mwe	14	SENT_90	[p6l746t2964r940b3042],
16	50	CD	PERCENT	50	num	17	SENT_90	[p6l964t2969r1062b3042],
17	percent	NN	PERCENT	percent	agent	5	SENT_90	[p6l1088t2980r1406b3064],
18	of	IN	O	of	_	0	SENT_90	[p6l1428t2963r1528b3042],
19	the	DT	O	the	det	20	SENT_90	[p6l1536t2964r1664b3042],
20	sum	NN	O	sum	prep_of	17	SENT_90	[p6l1693t2990r1872b3043],
21	of	IN	O	of	_	0	SENT_90	[p6l1899t2963r1999b3042],
22	the	DT	O	the	det	23	SENT_90	[p6l2007t2964r2135b3042],
23	products	NNS	O	product	prep_of	20	SENT_90	[p6l9t3092r388b3192],
24	of	IN	O	of	_	0	SENT_90	[p6l420t3091r522b3170],
25	their	PRP$	O	they	poss	28	SENT_90	[p6l533t3092r735b3170],
26	largest	JJS	O	largest	amod	28	SENT_90	[p6l759t3091r1054b3192],
27	perpendicular	JJ	O	perpendicular	amod	28	SENT_90	[p6l1077t3092r1683b3192],
28	diameters	NNS	O	diameter	prep_of	23	SENT_90	[p6l1710t3092r2132b3170],
29	and	CC	O	and	_	0	SENT_90	[p6l10t3220r166b3298],
30	an	DT	O	a	det	31	SENT_90	[p6l211t3245r311b3298],
31	absence	NN	O	absence	agent	5	SENT_90	[p6l355t3220r691b3298],
32	of	IN	O	of	_	0	SENT_90	[p6l738t3219r838b3298],
33	progression	NN	O	progression	prep_of	31	SENT_90	[p6l864t3220r1372b3320],
34	in	IN	O	in	_	0	SENT_90	[p6l1417t3220r1498b3297],
35	other	JJ	O	other	amod	36	SENT_90	[p6l1544t3220r1768b3298],
36	lesions	NNS	O	lesion	prep_in	33	SENT_90	[p6l1810t3220r2130b3315],
37	,	,	O	,	_	0	SENT_90	[p6l1810t3220r2130b3315],
38	without	IN	O	without	_	0	SENT_90	[p6l6t3348r341b3427],
39	the	DT	O	the	det	40	SENT_90	[p6l367t3348r495b3426],
40	appearance	NN	O	appearance	prep_without	5	SENT_90	[p6l526t3373r1006b3448],
41	of	IN	O	of	_	0	SENT_90	[p6l1037t3347r1137b3426],
42	any	DT	O	any	det	44	SENT_90	[p6l1148t3373r1295b3448],
43	new	JJ	O	new	amod	44	SENT_90	[p6l1321t3373r1496b3427],
44	lesions	NNS	O	lesion	prep_of	40	SENT_90	[p6l1522t3348r1842b3426],
45	.	.	O	.	_	0	SENT_90	[p6l1522t3348r1842b3426],

1	Stable	JJ	O	stable	amod	2	SENT_91	[p6l1880t3347r2135b3426],
2	disease	NN	O	disease	nsubjpass	4	SENT_91	[p6l11t3476r312b3554],
3	was	VBD	O	be	auxpass	4	SENT_91	[p6l330t3502r490b3555],
4	deﬁned	VBN	O	deﬁned	_	0	SENT_91	[p6l516t3475r828b3554],
5	as	IN	O	as	_	0	SENT_91	[p6l850t3502r934b3554],
6	a	DT	O	a	det	7	SENT_91	[p6l958t3502r1002b3554],
7	reduction	NN	O	reduction	prep_as	4	SENT_91	[p6l1024t3475r1424b3555],
8	in	IN	O	in	_	0	SENT_91	[p6l1446t3476r1526b3553],
9	tumor	NN	O	tumor	nn	10	SENT_91	[p6l1549t3492r1810b3555],
10	volume	NN	O	volume	prep_in	7	SENT_91	[p6l1825t3476r2135b3555],
11	of	IN	O	of	_	0	SENT_91	[p6l11t3603r113b3682],
12	less	JJR	O	less	mwe	13	SENT_91	[p6l118t3604r276b3682],
13	than	IN	O	than	quantmod	14	SENT_91	[p6l303t3604r491b3682],
14	50	CD	PERCENT	50	num	15	SENT_91	[p6l516t3609r614b3682],
15	percent	NN	PERCENT	percent	prep_of	10	SENT_91	[p6l636t3620r956b3704],
16	or	CC	O	or	_	0	SENT_91	[p6l974t3629r1063b3682],
17	an	DT	O	a	det	18	SENT_91	[p6l1082t3629r1183b3682],
18	increase	NN	O	increase	prep_in	7	SENT_91	[p6l1204t3604r1549b3682],
19	in	IN	O	in	_	0	SENT_91	[p6l1571t3604r1653b3681],
20	the	DT	O	the	det	21	SENT_91	[p6l1675t3603r1805b3682],
21	volume	NN	O	volume	prep_in	18	SENT_91	[p6l1823t3603r2135b3683],
22	of	IN	O	of	_	0	SENT_91	[p6l11t3731r113b3810],
23	one	CD	NUMBER	one	num	27	SENT_91	[p6l122t3757r276b3810],
24	or	CC	O	or	_	0	SENT_91	[p6l303t3757r393b3810],
25	more	JJR	O	more	num	27	SENT_91	[p6l416t3757r640b3810],
26	measurable	JJ	O	measurable	amod	27	SENT_91	[p6l666t3731r1163b3811],
27	lesions	NNS	O	lesion	prep_of	21	SENT_91	[p6l1189t3732r1490b3810],
28	of	IN	O	of	_	0	SENT_91	[p6l1519t3731r1621b3810],
29	less	JJR	O	less	mwe	30	SENT_91	[p6l1628t3732r1786b3810],
30	than	IN	O	than	quantmod	31	SENT_91	[p6l1815t3732r2006b3810],
31	25	CD	NUMBER	25	prep_of	27	SENT_91	[p6l2032t3737r2131b3810],

1	percent	NN	O	percent	_	0	SENT_92	[p7l9t60r344b144],
2	,	,	O	,	_	0	SENT_92	[p7l9t60r344b144],
3	without	IN	O	without	dep	1	SENT_92	[p7l366t44r698b123],
4	the	DT	O	the	det	5	SENT_92	[p7l714t44r842b122],
5	appearance	NN	O	appearance	pobj	3	SENT_92	[p7l862t69r1338b144],
6	of	IN	O	of	_	0	SENT_92	[p7l1359t43r1459b122],
7	any	DT	O	any	det	9	SENT_92	[p7l1461t69r1607b144],
8	new	JJ	O	new	amod	9	SENT_92	[p7l1623t69r1797b123],
9	lesions	NNS	O	lesion	prep_of	5	SENT_92	[p7l1813t44r2130b122],
10	.	.	O	.	_	0	SENT_92	[p7l1813t44r2130b122],

1	Progressive	JJ	O	progressive	amod	2	SENT_93	[p7l9t172r492b272],
2	disease	NN	O	disease	nsubjpass	4	SENT_93	[p7l530t172r832b250],
3	was	VBD	O	be	auxpass	4	SENT_93	[p7l864t198r1025b251],
4	deﬁned	VBN	O	deﬁned	_	0	SENT_93	[p7l1064t171r1380b250],
5	as	IN	O	as	_	0	SENT_93	[p7l1415t198r1499b250],
6	an	DT	O	a	det	7	SENT_93	[p7l1537t197r1637b250],
7	increase	NN	O	increase	prep_as	4	SENT_93	[p7l1673t172r2018b250],
8	in	IN	O	in	_	0	SENT_93	[p7l2054t172r2135b249],
9	the	DT	O	the	det	10	SENT_93	[p7l11t300r140b378],
10	size	NN	O	size	prep_in	7	SENT_93	[p7l165t300r323b378],
11	of	IN	O	of	_	0	SENT_93	[p7l346t299r446b378],
12	at	IN	O	at	quantmod	14	SENT_93	[p7l450t316r529b378],
13	least	JJS	O	least	mwe	12	SENT_93	[p7l545t299r742b378],
14	one	CD	NUMBER	one	dep	16	SENT_93	[p7l761t325r912b378],
15	bidimensionally	RB	O	bidimensionally	advmod	16	SENT_93	[p7l936t299r1620b400],
16	measurable	JJ	O	measurable	amod	17	SENT_93	[p7l1638t300r2134b379],
17	lesion	NN	O	lesion	prep_of	10	SENT_93	[p7l10t428r268b506],
18	by	IN	O	by	_	0	SENT_93	[p7l294t428r392b528],
19	at	IN	O	at	quantmod	21	SENT_93	[p7l411t444r491b506],
20	least	JJS	O	least	mwe	19	SENT_93	[p7l510t428r711b506],
21	25	CD	PERCENT	25	num	22	SENT_93	[p7l731t433r829b506],
22	percent	NN	PERCENT	percent	agent	4	SENT_93	[p7l856t444r1183b528],
23	and	CC	O	and	_	0	SENT_93	[p7l1202t427r1360b506],
24	the	DT	O	the	det	25	SENT_93	[p7l1385t427r1516b506],
25	appearance	NN	O	appearance	agent	4	SENT_93	[p7l1540t453r2029b528],
26	of	IN	O	of	_	0	SENT_93	[p7l2053t427r2153b506],
27	new	JJ	O	new	amod	28	SENT_93	[p7l11t581r187b635],
28	lesions	NNS	O	lesion	prep_of	25	SENT_93	[p7l216t555r536b634],
29	.	.	O	.	_	0	SENT_93	[p7l216t555r536b634],

1	The	DT	O	the	det	2	SENT_94	[p7l574t556r735b634],
2	change	NN	O	change	_	0	SENT_94	[p7l771t556r1072b656],
3	from	IN	O	from	_	0	SENT_94	[p7l1108t555r1315b634],
4	use	NN	O	use	prep_from	2	SENT_94	[p7l1350t582r1489b635],
5	of	IN	O	of	_	0	SENT_94	[p7l1526t555r1626b634],
6	the	DT	O	the	det	8	SENT_94	[p7l1643t556r1772b634],
7	RECIST	NNP	O	RECIST	nn	8	SENT_94	[p7l1806t561r2138b639],
8	criteria	NNS	O	criterion	prep_of	2	SENT_94	[p7l11t684r307b762],
9	to	TO	O	to	dep	2	SENT_94	[p7l344t700r423b762],
10	the	DT	O	the	pobj	9	SENT_94	[p7l464t684r592b762],
11	WHO	WP	O	who	dobj	13	SENT_94	[p7l628t689r871b762],
12	criteria	NNS	O	criterion	nsubj	13	SENT_94	[p7l911t684r1206b762],
13	followed	VBD	O	follow	dep	9	SENT_94	[p7l1243t683r1611b763],
14	a	DT	O	a	det	15	SENT_94	[p7l1648t710r1693b762],
15	Food	NNP	O	Food	dobj	13	SENT_94	[p7l1728t683r1942b762],
16	and	CC	O	and	cc	15	SENT_94	[p7l1980t683r2135b762],

1	Drug	NNP	O	Drug	nn	3	SENT_95	[p7l9t818r228b912],
2	Administration	NNP	O	Administration	nn	3	SENT_95	[p7l259t812r908b890],
3	advisory	NN	O	advisory	_	0	SENT_95	[p7l945t811r1297b912],
4	that	WDT	O	that	nsubj	5	SENT_95	[p7l1331t812r1498b890],
5	indicated	VBD	O	indicate	rcmod	3	SENT_95	[p7l1531t812r1928b890],
6	that	IN	O	that	_	0	SENT_95	[p7l1970t812r2139b890],
7	use	NN	O	use	prep_that	5	SENT_95	[p7l11t966r152b1019],
8	of	IN	O	of	_	0	SENT_95	[p7l189t939r291b1018],
9	the	DT	O	the	prep_of	3	SENT_95	[p7l310t940r441b1018],
10	WHO	WP	MISC	who	dobj	13	SENT_95	[p7l474t945r720b1018],
11	criteria	NNS	O	criterion	nsubj	13	SENT_95	[p7l758t940r1061b1018],
12	would	MD	O	would	aux	13	SENT_95	[p7l1090t940r1356b1019],
13	facilitate	VB	O	facilitate	rcmod	9	SENT_95	[p7l1389t939r1751b1018],
14	an	DT	O	a	det	15	SENT_95	[p7l1785t965r1885b1018],
15	independent	JJ	O	independent	dobj	13	SENT_95	[p7l1918t940r2134b1018, p7l9t1068r360b1168],

1	review	NN	O	review	_	0	SENT_96	[p7l376t1068r648b1147],
2	of	IN	O	of	_	0	SENT_96	[p7l666t1067r766b1146],
3	three	CD	NUMBER	three	num	5	SENT_96	[p7l770t1067r982b1146],
4	major	JJ	O	major	amod	5	SENT_96	[p7l1003t1068r1251b1168],
5	studies	NNS	O	study	prep_of	1	SENT_96	[p7l1270t1067r1564b1147],
6	to	TO	O	to	aux	8	SENT_96	[p7l1588t1084r1667b1146],
7	be	VB	O	be	auxpass	8	SENT_96	[p7l1690t1068r1784b1146],
8	submitted	VBN	O	submit	infmod	1	SENT_96	[p7l1807t1068r2134b1147, p7l11t1195r139b1274],
9	for	IN	O	for	_	0	SENT_96	[p7l170t1195r293b1274],
10	approval	NN	O	approval	prep_for	8	SENT_96	[p7l320t1196r685b1296],
11	of	IN	O	of	_	0	SENT_96	[p7l717t1195r817b1274],
12	cetuximab	NN	O	cetuximab	prep_of	10	SENT_96	[p7l830t1196r1265b1275],
13	in	IN	O	in	_	0	SENT_96	[p7l1297t1196r1378b1273],
14	the	DT	O	the	det	16	SENT_96	[p7l1410t1196r1539b1274],
15	United	NNP	LOCATION	United	nn	16	SENT_96	[p7l1570t1196r1855b1274],
16	States	NNPS	LOCATION	States	prep_in	8	SENT_96	[p7l1888t1201r2133b1274],
17	and	CC	O	and	_	0	SENT_96	[p7l10t1324r166b1402],
18	Europe	NNP	LOCATION	Europe	prep_in	8	SENT_96	[p7l189t1331r516b1424],
19	.	.	O	.	_	0	SENT_96	[p7l189t1331r516b1424],

1	577	CD	NUMBER	577	num	2	SENT_97	[p8l825t156r904b194],
2	Patients	NNS	O	patient	nsubj	3	SENT_97	[p8l926t156r1106b194],
3	screened	VBN	O	screen	_	0	SENT_97	[p8l1126t152r1328b194],

1	474	CD	NUMBER	474	num	2	SENT_98	[p8l694t654r775b692],
2	Patients	NNS	O	patient	nsubj	3	SENT_98	[p8l797t654r977b692],
3	had	VBD	O	have	_	0	SENT_98	[p8l998t650r1077b692],
4	tumors	NNS	O	tumor	dobj	3	SENT_98	[p8l1096t658r1261b692],
5	positive	JJ	O	positive	amod	4	SENT_98	[p8l1283t654r1459b705],
6	for	IN	O	for	_	0	SENT_98	[p8l973t714r1036b756],
7	EGFR	NN	ORGANIZATION	egfr	prep_for	5	SENT_98	[p8l1056t717r1181b756],

1	145	CD	NUMBER	145	num	2	SENT_99	[p8l1391t937r1464b976],
2	Patients	NNS	O	patient	nsubj	5	SENT_99	[p8l1487t937r1663b976],
3	did	VBD	O	do	aux	5	SENT_99	[p8l1681t933r1748b976],
4	not	RB	O	not	neg	5	SENT_99	[p8l1770t942r1841b976],
5	undergo	VB	O	undergo	_	0	SENT_99	[p8l1859t933r2044b989],
6	randomization	NN	O	randomization	dobj	5	SENT_99	[p8l1502t997r1829b1040],

1	Poor	NNP	O	Poor	_	0	SENT_100	[p8l1447t1066r1551b1104],
2	physical	JJ	O	physical	amod	3	SENT_100	[p8l1570t1062r1749b1117],
3	condition	NN	O	condition	dep	1	SENT_100	[p8l1769t1062r1984b1104],
4	or	CC	O	or	_	0	SENT_100	[p8l1500t1141r1546b1168],
5	death	NN	O	death	nn	7	SENT_100	[p8l1563t1126r1687b1168],
6	(	NN	O	(	nn	7	SENT_100	[p8l1713t1129r1863b1182],
7	n	NN	O	n	dep	1	SENT_100	[p8l1713t1129r1863b1182],
8	=	JJ	O	=	amod	10	SENT_100	[p8l1713t1129r1863b1182],
9	31	CD	NUMBER	31	tmod	8	SENT_100	[p8l1713t1129r1863b1182],
10	)	NN	O	)	dep	3	SENT_100	[p8l1713t1129r1863b1182],

1	No	DT	O	no	det	2	SENT_101	[p8l1447t1194r1512b1233],
2	disease	NN	O	disease	_	0	SENT_101	[p8l1530t1190r1700b1233],
3	progression	NN	O	progression	dep	2	SENT_101	[p8l1720t1194r1989b1246],
4	before	IN	O	before	_	0	SENT_101	[p8l1502t1254r1643b1296],
5	trial	NN	O	trial	nn	6	SENT_101	[p8l1659t1254r1745b1296],
6	recruitment	NN	O	recruitment	prep_before	3	SENT_101	[p8l1768t1258r2035b1297],

1	ﬁnished	VBN	O	ﬁnished	_	0	SENT_102	[p8l1499t1318r1679b1361],
2	(	NN	O	(	nn	3	SENT_102	[p8l1705t1322r1855b1374],
3	n	NN	O	n	nsubj	6	SENT_102	[p8l1705t1322r1855b1374],
4	=	JJ	O	=	amod	6	SENT_102	[p8l1705t1322r1855b1374],
5	57	CD	NUMBER	57	num	6	SENT_102	[p8l1705t1322r1855b1374],
6	)	NN	O	)	xcomp	1	SENT_102	[p8l1705t1322r1855b1374],

1	Eligibility	NN	O	eligibility	nn	2	SENT_103	[p8l1447t1383r1652b1439],
2	criteria	NNS	O	criterion	nsubj	4	SENT_103	[p8l1668t1387r1825b1425],
3	not	RB	O	not	neg	4	SENT_103	[p8l1846t1391r1918b1425],
4	met	VBD	O	meet	_	0	SENT_103	[p8l1938t1391r2024b1425],

1	(	NN	O	(	nn	2	SENT_104	[p8l1505t1450r1655b1502],
2	n	NN	O	n	_	0	SENT_104	[p8l1505t1450r1655b1502],
3	=	JJ	O	=	dep	2	SENT_104	[p8l1505t1450r1655b1502],
4	41	CD	NUMBER	41	num	5	SENT_104	[p8l1505t1450r1655b1502],
5	)	NN	O	)	dep	2	SENT_104	[p8l1505t1450r1655b1502],

1	Refusal	NN	O	refusal	_	0	SENT_105	[p8l1447t1511r1608b1554],
2	to	TO	O	to	aux	3	SENT_105	[p8l1627t1519r1671b1554],
3	enter	VB	O	enter	dep	1	SENT_105	[p8l1690t1519r1807b1554],
4	the	DT	O	the	det	5	SENT_105	[p8l1822t1511r1893b1554],
5	study	NN	O	study	dobj	3	SENT_105	[p8l1912t1511r2034b1567],

1	(	NN	O	(	nn	2	SENT_106	[p8l1505t1579r1627b1631],
2	n	NN	O	n	_	0	SENT_106	[p8l1505t1579r1627b1631],
3	=	JJ	O	=	amod	2	SENT_106	[p8l1505t1579r1627b1631],
4	9	CD	NUMBER	9	tmod	3	SENT_106	[p8l1505t1579r1627b1631],
5	>	JJR	O	>	dep	2	SENT_106	[p8l1505t1579r1627b1631],

1	No	DT	O	no	det	4	SENT_107	[p8l1447t1644r1512b1682],
2	information	NN	O	information	nn	4	SENT_107	[p8l1532t1639r1799b1682],
3	(	NN	O	(	nn	4	SENT_107	[p8l1825t1643r1947b1695],
4	n	NN	O	n	_	0	SENT_107	[p8l1825t1643r1947b1695],
5	=	JJ	O	=	dep	4	SENT_107	[p8l1825t1643r1947b1695],
6	7	CD	NUMBER	7	num	7	SENT_107	[p8l1825t1643r1947b1695],
7	)	NN	O	)	dep	4	SENT_107	[p8l1825t1643r1947b1695],

1	329	CD	NUMBER	329	num	2	SENT_108	[p8l805t1873r884b1912],
2	Patients	NNS	O	patient	nsubj	3	SENT_108	[p8l906t1874r1086b1912],
3	underwent	VBD	O	undergo	_	0	SENT_108	[p8l1108t1870r1351b1912],
4	randomization	NN	O	randomization	dobj	3	SENT_108	[p8l910t1934r1244b1976],

1	218	CD	NUMBER	218	num	2	SENT_109	[p8l122t2391r202b2431],
2	Patients	NNS	O	patient	nsubj	15	SENT_109	[p8l224t2393r404b2431],
3	randomly	RB	O	randomly	advmod	4	SENT_109	[p8l426t2389r641b2444],
4	assigned	VBN	O	assign	partmod	2	SENT_109	[p8l658t2389r858b2444],
5	to	TO	O	to	_	0	SENT_109	[p8l877t2397r921b2431],
6	111	CD	NUMBER	111	num	7	SENT_109	[p8l1244t2393r1318b2430],
7	Patients	NNS	O	patient	prep_to	4	SENT_109	[p8l1342t2393r1522b2431],
8	randomly	RB	O	randomly	advmod	9	SENT_109	[p8l1544t2389r1759b2444],
9	assigned	VBN	O	assign	partmod	7	SENT_109	[p8l1776t2389r1976b2444],
10	to	TO	O	to	aux	11	SENT_109	[p8l1995t2397r2039b2431],
11	receive	VB	O	receive	xcomp	9	SENT_109	[p8l144t2457r300b2495],
12	cetuximab	NN	O	cetuximab	dobj	11	SENT_109	[p8l318t2453r553b2495],
13	and	CC	O	and	_	0	SENT_109	[p8l572t2453r653b2495],
14	irinotecan	NN	O	irinotecan	dobj	11	SENT_109	[p8l675t2457r900b2495],
15	receive	VBP	O	receive	_	0	SENT_109	[p8l1274t2457r1430b2495],
16	cetuximab	NN	O	cetuximab	nn	17	SENT_109	[p8l1448t2453r1683b2495],
17	monotherapy	NN	O	monotherapy	dobj	15	SENT_109	[p8l1704t2453r2010b2508],

1	56	CD	NUMBER	56	num	2	SENT_110	[p8l1286t2911r1338b2950],
2	Patients	NNS	O	patient	nsubj	3	SENT_110	[p8l1360t2912r1540b2950],
3	received	VBD	O	receive	_	0	SENT_110	[p8l1561t2908r1745b2950],
4	irinotecan	NN	O	irinotecan	dobj	3	SENT_110	[p8l1767t2912r1992b2950],
5	because	IN	O	because	_	0	SENT_110	[p8l1280t2972r1463b3015],
6	ofdisease	NN	O	ofdisease	nn	7	SENT_110	[p8l1481t2972r1711b3014],
7	progression	NN	O	progression	prep_because	3	SENT_110	[p8l1731t2976r2000b3028],

1	Figure	NNP	O	Figure	_	0	SENT_111	[p8l66t3184r228b3246],
2	1	CD	NUMBER	1	dep	1	SENT_111	[p8l248t3187r289b3231],
3	.	.	O	.	_	0	SENT_111	[p8l248t3187r289b3231],

1	Design	NN	O	design	_	0	SENT_112	[p8l311t3184r491b3246],
2	of	IN	O	of	_	0	SENT_112	[p8l511t3182r571b3231],
3	the	DT	O	the	det	4	SENT_112	[p8l576t3183r660b3231],
4	Study	NN	O	study	prep_of	1	SENT_112	[p8l677t3183r835b3246],
5	.	.	O	.	_	0	SENT_112	[p8l677t3183r835b3246],

1	The	DT	O	the	det	4	SENT_113	[p9l104t80r225b138],
2	independent	JJ	O	independent	amod	4	SENT_113	[p9l246t79r647b154],
3	review	NN	O	review	nn	4	SENT_113	[p9l664t80r867b139],
4	committee	NN	O	committee	nsubj	14	SENT_113	[p9l886t80r1240b151],
5	,	,	O	,	_	0	SENT_113	[p9l886t80r1240b151],
6	which	WDT	O	which	nsubjpass	8	SENT_113	[p9l1262t80r1457b139],
7	was	VBD	O	be	auxpass	8	SENT_113	[p9l1475t99r1595b138],
8	blinded	VBN	O	blind	rcmod	4	SENT_113	[p9l11t174r250b233],
9	to	TO	O	to	_	0	SENT_113	[p9l270t187r329b233],
10	the	DT	O	the	det	12	SENT_113	[p9l350t175r445b233],
11	treatment	NN	O	treatment	nn	12	SENT_113	[p9l466t187r772b233],
12	assignment	NN	O	assignment	prep_to	8	SENT_113	[p9l788t175r1168b249],
13	,	,	O	,	_	0	SENT_113	[p9l788t175r1168b249],
14	assessed	VBN	O	assess	_	0	SENT_113	[p9l1192t175r1461b233],
15	disease	NN	O	disease	nn	16	SENT_113	[p9l1481t175r1595b233, p9l11t289r145b328],
16	progression	NN	O	progression	dobj	14	SENT_113	[p9l176t270r564b344],
17	during	IN	O	during	_	0	SENT_113	[p9l596t270r812b344],
18	the	DT	O	the	det	20	SENT_113	[p9l842t270r940b328],
19	irinotecan	JJ	O	irinotecan	amod	20	SENT_113	[p9l971t270r1297b328],
20	regimen	NN	O	regimen	prep_during	14	SENT_113	[p9l1328t270r1596b344],
21	given	VBN	O	give	prep	20	SENT_113	[p9l10t365r181b439],
22	before	IN	O	before	pcomp	21	SENT_113	[p9l209t364r412b423],
23	enrollment	NN	O	enrollment	pobj	22	SENT_113	[p9l441t365r801b423],
24	in	IN	O	in	_	0	SENT_113	[p9l824t365r886b422],
25	the	DT	O	the	det	26	SENT_113	[p9l914t364r1012b423],
26	study	NN	O	study	prep_in	23	SENT_113	[p9l1042t364r1213b439],
27	and	CC	O	and	_	0	SENT_113	[p9l1237t365r1355b423],
28	the	DT	O	the	det	29	SENT_113	[p9l1384t365r1482b423],
29	response	NN	O	response	conj_and	14	SENT_113	[p9l1510t384r1595b423, p9l12t478r235b534],
30	and	CC	O	and	_	0	SENT_113	[p9l261t459r377b518],
31	time	NN	O	time	conj_and	14	SENT_113	[p9l403t460r542b518],
32	to	TO	O	to	_	0	SENT_113	[p9l568t472r627b518],
33	progression	NN	O	progression	prep_to	29	SENT_113	[p9l651t460r1031b534],
34	during	IN	O	during	_	0	SENT_113	[p9l1057t460r1270b534],
35	the	DT	O	the	det	36	SENT_113	[p9l1293t460r1389b518],
36	study	NN	O	study	prep_during	29	SENT_113	[p9l1416t460r1592b534],
37	.	.	O	.	_	0	SENT_113	[p9l1416t460r1592b534],

1	To	TO	O	to	aux	2	SENT_114	[p9l8t559r86b613],
2	do	VB	O	do	purpcl	7	SENT_114	[p9l104t554r181b613],
3	so	RB	O	so	advmod	2	SENT_114	[p9l200t573r286b625],
4	,	,	O	,	_	0	SENT_114	[p9l200t573r286b625],
5	the	DT	O	the	det	6	SENT_114	[p9l306t555r403b613],
6	committee	NN	O	committee	nsubj	7	SENT_114	[p9l420t555r756b613],
7	used	VBD	O	use	_	0	SENT_114	[p9l773t554r918b613],
8	the	DT	O	the	dobj	7	SENT_114	[p9l935t554r1031b613],
9	WHO	WP	O	who	dep	10	SENT_114	[p9l1045t559r1227b613],
10	criteria	NNS	O	criterion	rcmod	8	SENT_114	[p9l1245t555r1465b613],
11	and	CC	O	and	_	0	SENT_114	[p9l1480t555r1597b613],
12	compared	VBN	O	compare	conj_and	10	SENT_114	[p9l11t650r327b724],
13	CT	NN	O	ct	nn	14	SENT_114	[p9l356t654r448b708],
14	scans	NNS	O	scan	dep	12	SENT_114	[p9l477t668r647b708],
15	or	CC	O	or	_	0	SENT_114	[p9l678t668r745b708],
16	MRI	NNP	O	MRI	nn	17	SENT_114	[p9l770t654r908b712],
17	images	NNS	O	image	conj_or	8	SENT_114	[p9l936t650r1160b724],
18	obtained	VBN	O	obtain	partmod	17	SENT_114	[p9l1192t649r1469b708],
19	before	IN	O	before	_	0	SENT_114	[p9l1500t650r1595b708, p9l11t744r134b803],
20	enrollment	NN	O	enrollment	prep_before	18	SENT_114	[p9l155t745r507b803],
21	and	CC	O	and	_	0	SENT_114	[p9l522t744r639b803],
22	during	IN	O	during	_	0	SENT_114	[p9l659t744r871b819],
23	the	DT	O	the	det	24	SENT_114	[p9l889t744r986b803],
24	study	NN	O	study	prep_during	18	SENT_114	[p9l1006t744r1183b819],
25	.	.	O	.	_	0	SENT_114	[p9l1006t744r1183b819],

1	Toxic	JJ	O	toxic	amod	2	SENT_115	[p9l1204t745r1374b803],
2	effects	NNS	O	effect	nsubjpass	4	SENT_115	[p9l1393t744r1595b803],
3	were	VBD	O	be	auxpass	4	SENT_115	[p9l7t859r158b898],
4	assessed	VBN	O	assess	_	0	SENT_115	[p9l174t840r446b898],
5	according	VBG	O	accord	_	0	SENT_115	[p9l462t839r778b914],
6	to	TO	O	to	prepc_according_to	4	SENT_115	[p9l792t852r851b898],
7	the	DT	O	the	det	13	SENT_115	[p9l870t840r966b898],
8	National	NNP	ORGANIZATION	National	nn	13	SENT_115	[p9l981t840r1255b898],
9	Cancer	NNP	ORGANIZATION	Cancer	nn	13	SENT_115	[p9l1271t844r1492b898],
10	Institute	NNP	ORGANIZATION	Institute	nn	13	SENT_115	[p9l1506t845r1595b897, p9l12t935r205b993],
11	Common	NNP	ORGANIZATION	Common	nn	13	SENT_115	[p9l225t939r524b993],
12	Toxicity	NNP	ORGANIZATION	Toxicity	nn	13	SENT_115	[p9l541t935r790b1009],
13	Criteria	NNP	ORGANIZATION	Criteria	pobj	4	SENT_115	[p9l806t935r1059b1005],
14	,	,	O	,	_	0	SENT_115	[p9l806t935r1059b1005],
15	version	NN	O	version	appos	13	SENT_115	[p9l1079t935r1310b993],
16	2	CD	NUMBER	2	num	15	SENT_115	[p9l1329t939r1383b993],
17	.	.	O	.	_	0	SENT_115	[p9l1329t939r1383b993],

1	Modiﬁcations	NNS	O	modiﬁcations	nsubjpass	8	SENT_116	[p9l1404t934r1596b993, p9l10t1029r280b1088],
2	of	IN	O	of	_	0	SENT_116	[p9l303t1029r378b1088],
3	the	DT	O	the	det	4	SENT_116	[p9l386t1029r483b1088],
4	dose	NN	O	dose	prep_of	1	SENT_116	[p9l505t1030r649b1088],
5	of	IN	O	of	_	0	SENT_116	[p9l671t1029r746b1088],
6	cetuximab	NN	O	cetuximab	prep_of	4	SENT_116	[p9l754t1030r1079b1088],
7	were	VBD	O	be	auxpass	8	SENT_116	[p9l1098t1049r1249b1089],
8	made	VBN	O	make	_	0	SENT_116	[p9l1270t1030r1442b1088],
9	only	RB	O	only	advmod	8	SENT_116	[p9l1464t1030r1600b1104],
10	in	IN	O	in	_	0	SENT_116	[p9l10t1125r71b1182],
11	cases	NNS	O	case	prep_in	8	SENT_116	[p9l95t1144r257b1183],
12	of	IN	O	of	_	0	SENT_116	[p9l283t1124r358b1183],
13	toxic	JJ	O	toxic	amod	14	SENT_116	[p9l369t1125r519b1183],
14	effects	NNS	O	effect	prep_of	11	SENT_116	[p9l543t1124r744b1183],
15	to	TO	O	to	_	0	SENT_116	[p9l770t1137r829b1183],
16	the	DT	O	the	det	17	SENT_116	[p9l854t1125r951b1183],
17	skin	NN	O	skin	prep_to	8	SENT_116	[p9l976t1125r1125b1195],
18	,	,	O	,	_	0	SENT_116	[p9l976t1125r1125b1195],
19	and	CC	O	and	_	0	SENT_116	[p9l1152t1125r1269b1183],
20	modiﬁcations	NNS	O	modiﬁcations	nsubjpass	27	SENT_116	[p9l1293t1124r1596b1183, p9l11t1221r165b1279],
21	in	IN	O	in	_	0	SENT_116	[p9l189t1221r250b1278],
22	the	DT	O	the	det	23	SENT_116	[p9l273t1221r369b1279],
23	dose	NN	O	dose	prep_in	20	SENT_116	[p9l392t1220r537b1279],
24	of	IN	O	of	_	0	SENT_116	[p9l560t1220r635b1279],
25	irinotecan	NN	O	irinotecan	prep_of	23	SENT_116	[p9l643t1221r962b1279],
26	were	VBD	O	be	auxpass	27	SENT_116	[p9l982t1240r1132b1280],
27	made	VBN	O	make	conj_and	8	SENT_116	[p9l1155t1221r1327b1279],
28	in	IN	O	in	_	0	SENT_116	[p9l1349t1221r1410b1278],
29	cases	NNS	O	case	prep_in	27	SENT_116	[p9l1433t1240r1595b1279],
30	of	IN	O	of	_	0	SENT_116	[p9l11t1315r86b1374],
31	hematologic	JJ	O	hematologic	amod	35	SENT_116	[p9l91t1315r494b1390],
32	or	CC	O	or	_	0	SENT_116	[p9l514t1334r581b1374],
33	nonhematologic	JJ	O	nonhematologic	conj_or	31	SENT_116	[p9l599t1315r1131b1390],
34	toxic	JJ	O	toxic	amod	35	SENT_116	[p9l1150t1316r1300b1374],
35	effects	NNS	O	effect	prep_of	29	SENT_116	[p9l1319t1315r1540b1374],
36	.	.	O	.	_	0	SENT_116	[p9l1319t1315r1540b1374],

1	The	DT	O	the	det	2	SENT_117	[p9l104t1410r227b1469],
2	investigators	NNS	O	investigator	nsubj	7	SENT_117	[p9l275t1411r686b1485],
3	and	CC	O	and	_	0	SENT_117	[p9l736t1410r854b1469],
4	representatives	NNS	O	representative	nsubj	7	SENT_117	[p9l903t1411r1388b1485],
5	from	IN	O	from	_	0	SENT_117	[p9l1439t1410r1596b1469],
6	Merck	NNP	PERSON	Merck	prep_from	2	SENT_117	[p9l8t1506r214b1565],
7	designed	VBD	O	design	_	0	SENT_117	[p9l233t1505r519b1580],
8	the	DT	O	the	det	9	SENT_117	[p9l540t1506r636b1564],
9	study	NN	O	study	dobj	7	SENT_117	[p9l657t1505r834b1580],
10	.	.	O	.	_	0	SENT_117	[p9l657t1505r834b1580],

1	The	DT	O	the	det	2	SENT_118	[p9l856t1506r976b1564],
2	data	NNS	O	datum	nsubjpass	4	SENT_118	[p9l997t1505r1131b1564],
3	were	VBD	O	be	auxpass	4	SENT_118	[p9l1146t1525r1297b1565],
4	collected	VBN	O	collect	_	0	SENT_118	[p9l1318t1505r1596b1564],

1	N	NN	O	n	nn	2	SENT_119	[p9l524t1649r537b1664],
2	ENGLJ	NN	O	englj	nsubj	3	SENT_119	[p9l553t1648r637b1670],
3	MED	VBD	O	med	_	0	SENT_119	[p9l652t1649r704b1664],
4	351:4	CD	NUMBER	351:4	num	6	SENT_119	[p9l717t1648r781b1670],
5	WWW.NEjM.ORG	NNP	O	WWW.NEjM.ORG	nn	6	SENT_119	[p9l815t1648r1027b1670],
6	JULY	NNP	DATE	JULY	dobj	3	SENT_119	[p9l1060t1649r1120b1670],
7	22,2004	CD	NUMBER	22,2004	num	6	SENT_119	[p9l1132t1648r1250b1670],
8	The	DT	O	the	det	11	SENT_119	[p9l702t1681r752b1705],
9	New	NNP	O	New	nn	11	SENT_119	[p9l762t1682r824b1705],
10	England	NNP	O	England	nn	11	SENT_119	[p9l833t1681r944b1712],
11	Journal	NNP	O	Journal	dep	6	SENT_119	[p9l952t1681r1050b1705],
12	of	IN	O	of	_	0	SENT_119	[p9l1060t1681r1088b1705],
13	Medicine	NNP	O	Medicine	prep_of	11	SENT_119	[p9l1095t1681r1220b1705],

1	Downloaded	VBN	O	download	_	0	SENT_120	[p9l144t1722r314b1745],
2	from	IN	O	from	_	0	SENT_120	[p9l322t1722r387b1745],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_120	[p9l396t1722r514b1752],
4	at	IN	O	at	_	0	SENT_120	[p9l524t1726r547b1745],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_120	[p9l556t1722r738b1745],
6	on	IN	O	on	_	0	SENT_120	[p9l748t1729r780b1745],
7	January	NNP	DATE	January	prep_on	1	SENT_120	[p9l789t1722r892b1752],
8	5	CD	DATE	5	num	7	SENT_120	[p9l902t1722r924b1749],
9	,	,	DATE	,	_	0	SENT_120	[p9l902t1722r924b1749],
10	2014	CD	DATE	2014	num	7	SENT_120	[p9l935t1722r1007b1745],
11	.	.	O	.	_	0	SENT_120	[p9l935t1722r1007b1745],

1	For	IN	O	for	_	0	SENT_121	[p9l1018t1722r1064b1745],
2	personal	JJ	O	personal	amod	3	SENT_121	[p9l1072t1722r1184b1752],
3	use	NN	O	use	pobj	1	SENT_121	[p9l1194t1729r1237b1745],
4	only	RB	O	only	advmod	3	SENT_121	[p9l1247t1722r1312b1752],
5	.	.	O	.	_	0	SENT_121	[p9l1247t1722r1312b1752],

1	No	DT	O	no	det	3	SENT_122	[p9l1322t1722r1362b1745],
2	other	JJ	O	other	amod	3	SENT_122	[p9l1372t1722r1440b1745],
3	uses	NNS	O	use	_	0	SENT_122	[p9l1448t1729r1504b1745],
4	without	IN	O	without	_	0	SENT_122	[p9l1515t1722r1616b1745],
5	permission	NN	O	permission	prep_without	3	SENT_122	[p9l1624t1722r1777b1752],
6	.	.	O	.	_	0	SENT_122	[p9l1624t1722r1777b1752],

1	Copyright	NN	O	copyright	_	0	SENT_123	[p9l494t1763r628b1794],
2	©	CD	NUMBER	©	num	6	SENT_123	[p9l638t1763r661b1787],
3	2004	CD	DATE	2004	num	6	SENT_123	[p9l671t1763r736b1787],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_123	[p9l746t1763r937b1787],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_123	[p9l947t1763r1055b1787],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_123	[p9l1065t1763r1170b1794],
7	.	.	O	.	_	0	SENT_123	[p9l1065t1763r1170b1794],

1	All	DT	O	all	det	2	SENT_124	[p9l1181t1763r1222b1787],
2	rights	NNS	O	rights	nsubj	3	SENT_124	[p9l1232t1763r1306b1794],
3	reserved	VBN	O	reserve	_	0	SENT_124	[p9l1316t1763r1435b1787],
4	.	.	O	.	_	0	SENT_124	[p9l1316t1763r1435b1787],

1	The	DT	O	the	det	4	SENT_125	[p9l715t1869r752b1890],
2	NEW	NNP	O	NEW	nn	4	SENT_125	[p9l764t1871r845b1890],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_125	[p9l859t1871r1034b1890],
4	IOURNAL	NNP	O	IOURNAL	_	0	SENT_125	[p9l1048t1871r1214b1897],
5	ofMEDICINE	NN	O	ofmedicine	dep	4	SENT_125	[p9l1228t1869r1444b1896],

1	Characteristic	JJ	O	characteristic	_	0	SENT_126	[p10l61t396r425b445],

1	Age	NNP	O	Age	_	0	SENT_127	[p10l60t518r302b578],
2	—	CD	NUMBER	—	num	3	SENT_127	[p10l60t518r302b578],
3	yr	NN	DURATION	yr	dep	1	SENT_127	[p10l60t518r302b578],

1	Median	JJ	MISC	median	amod	2	SENT_128	[p10l163t587r354b635],
2	Range	NNP	MISC	Range	_	0	SENT_128	[p10l163t663r320b723],

1	Sex	NN	O	sex	nn	3	SENT_129	[p10l63t759r150b804],
2	—	CD	NUMBER	—	num	3	SENT_129	[p10l165t785r230b790],
3	no.	NN	O	no.	_	0	SENT_129	[p10l249t772r325b804],
4	(	CD	PERCENT	(	num	5	SENT_129	[p10l353t758r438b819],
5	%	NN	PERCENT	%	dep	3	SENT_129	[p10l353t758r438b819],
6	)	CD	NUMBER	)	dep	3	SENT_129	[p10l353t758r438b819],

1	Male	JJ	O	male	_	0	SENT_130	[p10l163t828r287b876],
2	Female	JJ	O	female	dep	1	SENT_130	[p10l163t900r345b948],

1	Race	NN	O	race	nn	3	SENT_131	[p10l67t1001r184b1045],
2	—	CD	NUMBER	—	num	3	SENT_131	[p10l201t1026r266b1030],
3	no.	NN	O	no.	_	0	SENT_131	[p10l286t1013r362b1044],
4	(	CD	PERCENT	(	num	5	SENT_131	[p10l389t998r474b1059],
5	%	NN	PERCENT	%	dep	3	SENT_131	[p10l389t998r474b1059],
6	)	CD	NUMBER	)	dep	3	SENT_131	[p10l389t998r474b1059],

1	White	NNP	O	White	dep	3	SENT_132	[p10l157t1069r310b1117],
2	Black	JJ	O	black	dep	1	SENT_132	[p10l163t1141r297b1189],
3	Asian	JJ	O	asian	_	0	SENT_132	[p10l157t1216r300b1261],

1	Karnofsky	NNP	PERSON	Karnofsky	_	0	SENT_133	[p10l67t1309r319b1373],
2	performance-status	JJ	O	performance-status	amod	3	SENT_133	[p10l340t1309r851b1372],
3	score	NN	NUMBER	score	dep	1	SENT_133	[p10l873t1326r1010b1358],

1	—	JJ	O	—	amod	2	SENT_134	[p10l252t1411r317b1416],
2	no.	NN	O	no.	_	0	SENT_134	[p10l337t1398r413b1430],
3	(	CD	PERCENT	(	num	4	SENT_134	[p10l440t1384r525b1445],
4	%	NN	PERCENT	%	dep	2	SENT_134	[p10l440t1384r525b1445],
5	)	CD	NUMBER	)	dep	2	SENT_134	[p10l440t1384r525b1445],

1	Previous	JJ	O	previous	amod	3	SENT_135	[p10l67t1626r284b1670],
2	adjuvant	JJ	O	adjuvant	amod	3	SENT_135	[p10l305t1622r528b1686],
3	therapy	NN	O	therapy	dep	9	SENT_135	[p10l544t1622r738b1685],
4	—	CD	NUMBER	—	num	5	SENT_135	[p10l753t1652r818b1656],
5	no.	NN	O	no.	dep	3	SENT_135	[p10l837t1639r912b1670],
6	(	CD	PERCENT	(	num	7	SENT_135	[p10l939t1624r1024b1685],
7	%	NN	PERCENT	%	dep	9	SENT_135	[p10l939t1624r1024b1685],
8	)	CD	NUMBER	)	num	9	SENT_135	[p10l939t1624r1024b1685],
9	No.	NN	O	no.	_	0	SENT_135	[p10l67t1723r155b1766],
10	of	IN	O	of	_	0	SENT_135	[p10l176t1718r234b1766],
11	previous	JJ	O	previous	amod	13	SENT_135	[p10l246t1723r466b1781],
12	cancer	NN	O	cancer	nn	13	SENT_135	[p10l487t1735r659b1766],
13	treatments	NNS	O	treatment	prep_of	9	SENT_135	[p10l675t1728r961b1767],

1	—	JJ	O	—	amod	2	SENT_136	[p10l252t1821r317b1825],
2	no.	NN	O	no.	_	0	SENT_136	[p10l337t1808r413b1839],
3	(	CD	PERCENT	(	num	4	SENT_136	[p10l440t1793r525b1854],
4	%	NN	PERCENT	%	dep	2	SENT_136	[p10l440t1793r525b1854],
5	)	CD	NUMBER	)	dep	2	SENT_136	[p10l440t1793r525b1854],

1	One	CD	NUMBER	one	_	0	SENT_137	[p10l159t1867r268b1911],
2	Two	CD	NUMBER	two	dep	1	SENT_137	[p10l156t1939r260b1983],
3	More	JJR	O	more	mwe	4	SENT_137	[p10l163t2012r296b2055],
4	than	IN	O	than	quantmod	5	SENT_137	[p10l314t2007r428b2055],
5	two	CD	NUMBER	two	dep	2	SENT_137	[p10l449t2016r543b2055],

1	Prestudy	JJ	O	prestudy	amod	3	SENT_138	[p10l66t2104r290b2167],
2	irinotecan	NN	O	irinotecan	nn	3	SENT_138	[p10l311t2108r568b2152],
3	treatment	NN	O	treatment	_	0	SENT_138	[p10l588t2113r848b2152],

1	—	JJ	O	—	amod	2	SENT_139	[p10l252t2206r317b2210],
2	no.	NN	O	no.	_	0	SENT_139	[p10l337t2193r413b2224],
3	(	CD	PERCENT	(	num	4	SENT_139	[p10l440t2178r525b2239],
4	%	NN	PERCENT	%	dep	2	SENT_139	[p10l440t2178r525b2239],
5	)	CD	NUMBER	)	dep	2	SENT_139	[p10l440t2178r525b2239],

1	125	CD	NUMBER	125	num	2	SENT_140	[p10l163t2252r247b2296],
2	mg/m2/wk	NN	O	mg/m2/wk	_	0	SENT_140	[p10l273t2248r558b2312],
3	for	IN	O	for	dep	2	SENT_140	[p10l575t2247r647b2296],
4	4	CD	DURATION	4	num	5	SENT_140	[p10l664t2252r692b2296],
5	wk	NN	DURATION	wk	pobj	3	SENT_140	[p10l709t2248r781b2296],
6	followed	VBN	O	follow	partmod	5	SENT_140	[p10l798t2248r1016b2296],
7	by	IN	O	by	_	0	SENT_140	[p10l257t2320r312b2384],
8	2-wk	JJ	DURATION	2-wk	amod	9	SENT_140	[p10l330t2320r448b2369],
9	rest	NN	O	rest	agent	6	SENT_140	[p10l469t2329r564b2368],

1	180	CD	NUMBER	180	num	2	SENT_141	[p10l163t2396r251b2441],
2	mg/m2	NN	O	mg/m2	dep	10	SENT_141	[p10l273t2397r458b2456],
3	every	DT	SET	every	det	5	SENT_141	[p10l477t2409r611b2456],
4	2	CD	SET	2	num	5	SENT_141	[p10l629t2397r655b2440],
5	wk	NN	SET	wk	dep	2	SENT_141	[p10l674t2393r745b2441],
6	350	CD	NUMBER	350	num	7	SENT_141	[p10l160t2468r251b2513],
7	mg/m2	NN	O	mg/m2	dep	10	SENT_141	[p10l273t2469r458b2528],
8	every	DT	SET	every	det	10	SENT_141	[p10l478t2482r611b2528],
9	3	CD	SET	3	num	10	SENT_141	[p10l630t2469r653b2513],
10	wk	NN	SET	wk	_	0	SENT_141	[p10l674t2465r745b2513],
11	Other	JJ	O	other	amod	12	SENT_141	[p10l159t2537r311b2585],
12	regimens	NNS	O	regimen	dep	10	SENT_141	[p10l331t2541r571b2601],

1	Prior	RB	O	prior	advmod	3	SENT_142	[p10l66t2638r186b2681],
2	oxaliplatin	NN	O	oxaliplatin	nn	3	SENT_142	[p10l202t2633r462b2696],
3	treatment	NN	O	treatment	dep	10	SENT_142	[p10l481t2642r736b2681],
4	—	CD	NUMBER	—	num	5	SENT_142	[p10l750t2663r815b2668],
5	no.	NN	O	no.	dep	3	SENT_142	[p10l833t2650r908b2681],
6	(	CD	PERCENT	(	num	7	SENT_142	[p10l934t2636r1019b2697],
7	%	NN	PERCENT	%	dep	10	SENT_142	[p10l934t2636r1019b2697],
8	)	CD	NUMBER	)	num	10	SENT_142	[p10l934t2636r1019b2697],
9	Percentage	NN	O	percentage	nn	10	SENT_142	[p10l66t2734r352b2793],
10	ofcells	NNS	O	ofcell	dep	21	SENT_142	[p10l371t2729r551b2778],
11	positive	JJ	O	positive	amod	18	SENT_142	[p10l574t2734r775b2793],
12	for	IN	O	for	_	0	SENT_142	[p10l794t2729r866b2778],
13	epidermal	JJ	O	epidermal	amod	16	SENT_142	[p10l255t2802r515b2865],
14	growth	NN	O	growth	nn	16	SENT_142	[p10l538t2802r716b2865],
15	factor	NN	O	factor	nn	16	SENT_142	[p10l737t2801r888b2850],
16	receptor	NN	O	receptor	prep_for	11	SENT_142	[p10l258t2883r473b2937],
17	—	CD	NUMBER	—	tmod	11	SENT_142	[p10l488t2904r553b2908],
18	no.	NN	O	no.	dep	10	SENT_142	[p10l573t2891r649b2922],
19	(	CD	PERCENT	(	num	20	SENT_142	[p10l676t2876r761b2937],
20	%	NN	PERCENT	%	dep	18	SENT_142	[p10l676t2876r761b2937],
21	)	CD	NUMBER	)	_	0	SENT_142	[p10l676t2876r761b2937],

1	o	NN	O	o	_	0	SENT_143	[p10l158t2950r187b2995],
2	to	TO	O	to	dep	1	SENT_143	[p10l204t2955r255b2994],
3	<	JJR	O	<	dep	1	SENT_143	[p10l275t2950r370b2995],
4	10	CD	NUMBER	10	number	5	SENT_143	[p10l275t2950r370b2995],
5	10	CD	NUMBER	10	dep	1	SENT_143	[p10l163t3022r219b3067],
6	to	TO	O	to	_	0	SENT_143	[p10l236t3028r287b3067],
7	<	JJR	O	<	prep_to	5	SENT_143	[p10l306t3022r402b3067],
8	20	CD	NUMBER	20	number	9	SENT_143	[p10l306t3022r402b3067],
9	20	CD	NUMBER	20	amod	7	SENT_143	[p10l159t3094r219b3139],
10	to	TO	O	to	_	0	SENT_143	[p10l236t3100r287b3139],
11	<	JJR	O	<	prep_to	5	SENT_143	[p10l306t3094r402b3139],
12	40	CD	NUMBER	40	number	13	SENT_143	[p10l306t3094r402b3139],
13	240	CD	NUMBER	240	dep	11	SENT_143	[p10l158t3166r255b3211],

1	Cetuximab	NNP	O	Cetuximab	_	0	SENT_144	[p10l1099t180r1381b228],
2	plus	CC	O	plus	prep	1	SENT_144	[p10l1187t252r1294b314],
3	lrinotecan	JJ	O	lrinotecan	amod	4	SENT_144	[p10l1111t325r1370b372],
4	Monotherapy	NNP	O	Monotherapy	dep	2	SENT_144	[p10l1432t324r1783b387],
5	(	CD	NUMBER	(	num	6	SENT_144	[p10l1129t399r1351b460],
6	N	NN	O	n	dep	1	SENT_144	[p10l1129t399r1351b460],
7	=	JJ	O	=	amod	9	SENT_144	[p10l1129t399r1351b460],
8	218	CD	NUMBER	218	tmod	7	SENT_144	[p10l1129t399r1351b460],
9	)	NN	O	)	dep	6	SENT_144	[p10l1129t399r1351b460],

1	Cetuximab	NNP	O	Cetuximab	_	0	SENT_145	[p10l1464t252r1746b300],

1	(	NN	O	(	nn	2	SENT_146	[p10l1494t400r1716b460],
2	N	NN	O	n	_	0	SENT_146	[p10l1494t400r1716b460],
3	=	JJ	O	=	dep	2	SENT_146	[p10l1494t400r1716b460],
4	111	CD	NUMBER	111	num	5	SENT_146	[p10l1494t400r1716b460],
5	)	NN	O	)	dep	2	SENT_146	[p10l1494t400r1716b460],

1	Table	NNP	O	Table	_	0	SENT_147	[p10l60t51r196b99],
2	1	CD	NUMBER	1	dep	1	SENT_147	[p10l217t56r258b99],
3	.	.	O	.	_	0	SENT_147	[p10l217t56r258b99],

1	Baseline	NN	O	baseline	nn	2	SENT_148	[p10l280t51r498b99],
2	Characteristics	NNS	O	characteristic	_	0	SENT_148	[p10l515t51r906b99],
3	of	IN	O	of	_	0	SENT_148	[p10l924t50r984b99],
4	the	DT	O	the	det	5	SENT_148	[p10l989t51r1074b99],
5	Patients	NNS	O	patient	prep_of	2	SENT_148	[p10l1094t52r1318b99],
6	.	.	O	.	_	0	SENT_148	[p10l1094t52r1318b99],

1	Total	JJ	O	total	amod	3	SENT_149	[p10l1899t324r2022b372],
2	(	NN	O	(	nn	3	SENT_149	[p10l1851t400r1909b460],
3	N	NN	O	n	_	0	SENT_149	[p10l1851t400r1909b460],
4	=	JJ	O	=	dep	3	SENT_149	[p10l1922t400r2073b460],
5	329	CD	NUMBER	329	num	6	SENT_149	[p10l1922t400r2073b460],
6	)	NN	O	)	dep	3	SENT_149	[p10l1922t400r2073b460],

1	and	CC	O	and	cc	12	SENT_150	[p11l564t80r680b138],
2	analyzed	VBN	O	analyze	csubj	12	SENT_150	[p11l697t80r971b154],
3	by	IN	O	by	_	0	SENT_150	[p11l989t79r1062b154],
4	medical	JJ	O	medical	amod	7	SENT_150	[p11l1076t79r1324b138],
5	and	CC	O	and	_	0	SENT_150	[p11l1341t80r1457b138],
6	statistical	JJ	O	statistical	amod	7	SENT_150	[p11l1476t80r1774b138],
7	representatives	NNS	O	representative	prep_by	2	SENT_150	[p11l1792t92r2149b154, p11l564t175r702b233],
8	from	IN	O	from	_	0	SENT_150	[p11l721t174r876b233],
9	Merck	NNP	PERSON	Merck	prep_from	2	SENT_150	[p11l892t175r1109b246],
10	,	,	O	,	_	0	SENT_150	[p11l892t175r1109b246],
11	who	WP	O	who	dep	2	SENT_150	[p11l1129t175r1265b233],
12	worked	VBD	O	work	_	0	SENT_150	[p11l1282t175r1520b234],
13	in	IN	O	in	_	0	SENT_150	[p11l1538t175r1598b232],
14	conjunction	NN	O	conjunction	prep_in	12	SENT_150	[p11l1617t175r1994b249],
15	with	IN	O	with	_	0	SENT_150	[p11l2009t175r2150b234],
16	the	DT	O	the	det	17	SENT_150	[p11l564t270r661b328],
17	investigators	NNS	O	investigator	prep_with	12	SENT_150	[p11l688t270r1109b344],
18	.	.	O	.	_	0	SENT_150	[p11l688t270r1109b344],

1	All	PDT	O	all	predet	3	SENT_151	[p11l1138t270r1227b327],
2	the	DT	O	the	det	3	SENT_151	[p11l1254t270r1351b328],
3	investigators	NNS	O	investigator	nsubj	11	SENT_151	[p11l1378t270r1780b344],
4	had	VBD	O	have	_	0	SENT_151	[p11l1809t270r1925b328],
5	access	NN	O	access	dobj	4	SENT_151	[p11l1952t289r2148b328],
6	to	TO	O	to	_	0	SENT_151	[p11l564t377r624b423],
7	the	DT	O	the	det	9	SENT_151	[p11l646t365r743b423],
8	primary	JJ	O	primary	amod	9	SENT_151	[p11l764t365r1015b439],
9	data	NNS	O	datum	prep_to	5	SENT_151	[p11l1034t365r1168b423],
10	and	CC	O	and	_	0	SENT_151	[p11l1188t365r1304b423],
11	participated	VBD	O	participate	conj_and	4	SENT_151	[p11l1324t365r1701b439],
12	in	IN	O	in	_	0	SENT_151	[p11l1722t365r1783b422],
13	writing	VBG	O	write	prepc_in	11	SENT_151	[p11l1801t365r2034b439],
14	the	DT	O	the	det	15	SENT_151	[p11l2054t365r2150b423],
15	manuscript	NN	O	manuscript	dobj	13	SENT_151	[p11l564t460r949b534],
16	.	.	O	.	_	0	SENT_151	[p11l564t460r949b534],

1	All	PDT	O	all	predet	2	SENT_152	[p11l979t460r1069b517],
2	the	DT	O	the	nsubj	5	SENT_152	[p11l1097t459r1195b518],
3	participating	VBG	O	participate	partmod	2	SENT_152	[p11l1222t460r1640b534],
4	institutions	NNS	O	institution	dobj	3	SENT_152	[p11l1665t460r2034b518],
5	received	VBD	O	receive	_	0	SENT_152	[p11l2063t479r2148b518, p11l565t555r761b613],
6	grant	NN	O	grant	nn	7	SENT_152	[p11l791t567r961b629],
7	support	NN	O	support	dobj	5	SENT_152	[p11l988t567r1236b629],
8	from	IN	O	from	_	0	SENT_152	[p11l1262t554r1417b613],
9	Merck	NNP	PERSON	Merck	prep_from	5	SENT_152	[p11l1445t555r1647b614],
10	for	IN	O	for	_	0	SENT_152	[p11l1674t554r1766b613],
11	conducting	VBG	O	conduct	prepc_for	5	SENT_152	[p11l1794t554r2153b629],
12	the	DT	O	the	det	13	SENT_152	[p11l564t650r661b708],
13	study	NN	O	study	dobj	11	SENT_152	[p11l681t650r858b724],
14	.	.	O	.	_	0	SENT_152	[p11l681t650r858b724],

1	STATISTICAL	JJ	O	statistical	amod	2	SENT_153	[p11l564t861r948b898],
2	ANALYSIS	NN	O	analysis	nsubj	9	SENT_153	[p11l975t861r1274b898],
3	The	DT	O	the	det	6	SENT_153	[p11l562t936r682b994],
4	primary	JJ	O	primary	amod	6	SENT_153	[p11l708t936r960b1010],
5	end	NN	O	end	nn	6	SENT_153	[p11l984t935r1099b994],
6	point	NN	O	point	dep	2	SENT_153	[p11l1125t936r1296b1010],
7	was	VBD	O	be	cop	9	SENT_153	[p11l1316t955r1436b994],
8	the	DT	O	the	det	9	SENT_153	[p11l1465t936r1562b994],
9	rate	NN	O	rate	_	0	SENT_153	[p11l1589t948r1706b994],
10	of	IN	O	of	_	0	SENT_153	[p11l1734t935r1809b994],
11	conﬁrmed	JJ	O	conﬁrmed	amod	14	SENT_153	[p11l1823t935r2150b994],
12	radiologic	JJ	O	radiologic	amod	14	SENT_153	[p11l564t1030r890b1105],
13	tumor	NN	O	tumor	nn	14	SENT_153	[p11l915t1042r1112b1089],
14	response	NN	O	response	prep_of	9	SENT_153	[p11l1134t1049r1435b1105],
15	,	,	O	,	_	0	SENT_153	[p11l1134t1049r1435b1105],
16	as	IN	O	as	mark	17	SENT_153	[p11l1463t1050r1526b1089],
17	assessed	VBN	O	assess	advcl	9	SENT_153	[p11l1552t1030r1823b1089],
18	by	IN	O	by	_	0	SENT_153	[p11l1848t1031r1921b1105],
19	the	DT	O	the	det	22	SENT_153	[p11l1942t1031r2039b1089],
20	independent	JJ	O	independent	amod	22	SENT_153	[p11l2063t1031r2148b1088, p11l565t1125r901b1200],
21	review	NN	O	review	nn	22	SENT_153	[p11l924t1126r1126b1185],
22	committee	NN	O	committee	prep_by	17	SENT_153	[p11l1151t1126r1505b1197],
23	,	,	O	,	_	0	SENT_153	[p11l1151t1126r1505b1197],
24	in	IN	O	in	_	0	SENT_153	[p11l1535t1126r1596b1183],
25	the	DT	O	the	det	27	SENT_153	[p11l1623t1125r1719b1184],
26	intentiontotreat	NN	O	intentiontotreat	nn	27	SENT_153	[p11l1746t1126r2149b1184, p11l564t1233r708b1279],
27	population	NN	O	population	prep_in	17	SENT_153	[p11l724t1221r1088b1295],
28	.	.	O	.	_	0	SENT_153	[p11l724t1221r1088b1295],

1	Differences	NNS	O	difference	nsubjpass	10	SENT_154	[p11l1113t1220r1473b1279],
2	in	IN	O	in	_	0	SENT_154	[p11l1495t1221r1556b1278],
3	response	NN	O	response	nn	4	SENT_154	[p11l1577t1239r1860b1295],
4	rates	NNS	O	rate	prep_in	1	SENT_154	[p11l1882t1233r2030b1279],
5	between	IN	O	between	_	0	SENT_154	[p11l2053t1221r2149b1279, p11l564t1328r750b1375],
6	the	DT	O	the	det	8	SENT_154	[p11l768t1316r864b1374],
7	two	CD	NUMBER	two	num	8	SENT_154	[p11l882t1328r996b1374],
8	groups	NNS	O	group	prep_between	4	SENT_154	[p11l1014t1334r1233b1390],
9	were	VBD	O	be	auxpass	10	SENT_154	[p11l1249t1335r1400b1375],
10	evaluated	VBN	O	evaluate	_	0	SENT_154	[p11l1418t1315r1711b1374],
11	by	IN	O	by	_	0	SENT_154	[p11l1729t1316r1802b1390],
12	means	NNS	O	means	_	0	SENT_154	[p11l1816t1335r2020b1374],
13	of	IN	O	of	_	0	SENT_154	[p11l2040t1315r2115b1374],
14	a	DT	O	a	det	16	SENT_154	[p11l2118t1335r2151b1374],
15	two	CD	NUMBER	two	num	16	SENT_154	[p11l564t1411r875b1471],
16	—	CD	NUMBER	—	prep_by_means_of	10	SENT_154	[p11l564t1411r875b1471],
17	sided	VBD	O	side	partmod	16	SENT_154	[p11l564t1411r875b1471],
18	Fisher	NNP	PERSON	Fisher	poss	21	SENT_154	[p11l893t1411r1140b1470],
19	’s	POS	O	’s	_	0	SENT_154	[p11l893t1411r1140b1470],
20	exact	JJ	O	exact	amod	21	SENT_154	[p11l1162t1424r1323b1470],
21	test	NN	O	test	dobj	17	SENT_154	[p11l1340t1424r1466b1470],
22	.	.	O	.	_	0	SENT_154	[p11l1340t1424r1466b1470],

1	A	DT	O	a	det	3	SENT_155	[p11l1488t1417r1537b1469],
2	P	NN	O	p	nn	3	SENT_155	[p11l1554t1416r1592b1469],
3	value	NN	O	value	nsubjpass	9	SENT_155	[p11l1608t1412r1770b1471],
4	of	IN	O	of	_	0	SENT_155	[p11l1791t1411r1866b1470],
5	less	JJR	O	less	mwe	6	SENT_155	[p11l1871t1412r1987b1470],
6	than	IN	O	than	quantmod	7	SENT_155	[p11l2009t1411r2150b1470],
7	0.05	CD	NUMBER	0.05	prep_of	3	SENT_155	[p11l564t1511r697b1565],
8	was	VBD	O	be	auxpass	9	SENT_155	[p11l724t1526r843b1565],
9	considered	VBN	O	consider	_	0	SENT_155	[p11l873t1506r1215b1565],
10	to	TO	O	to	aux	11	SENT_155	[p11l1243t1519r1301b1565],
11	indicate	VB	O	indicate	xcomp	9	SENT_155	[p11l1329t1507r1575b1565],
12	statistical	JJ	O	statistical	amod	13	SENT_155	[p11l1604t1507r1899b1565],
13	significance	NN	O	significance	dobj	11	SENT_155	[p11l1927t1506r2148b1581, p11l11t1800r269b1853],
14	.	.	O	.	_	0	SENT_155	[p11l1927t1506r2148b1581, p11l11t1800r269b1853],

1	Secondary	JJ	O	secondary	amod	3	SENT_156	[p11l312t1774r747b1875],
2	end	NN	O	end	nn	3	SENT_156	[p11l779t1775r932b1853],
3	points	NNS	O	point	nsubj	4	SENT_156	[p11l966t1775r1230b1875],
4	included	VBD	O	include	_	0	SENT_156	[p11l1266t1774r1632b1854],
5	the	DT	O	the	det	6	SENT_156	[p11l1668t1774r1796b1853],
6	time	NN	O	time	dobj	4	SENT_156	[p11l1832t1775r2019b1853],
7	to	TO	O	to	_	0	SENT_156	[p11l2055t1791r2134b1853],
8	progression	NN	O	progression	prep_to	6	SENT_156	[p11l9t1903r541b2003],
9	,	,	O	,	_	0	SENT_156	[p11l9t1903r541b2003],
10	the	DT	O	the	det	11	SENT_156	[p11l574t1903r703b1981],
11	duration	NN	O	duration	dobj	4	SENT_156	[p11l731t1903r1091b1982],
12	of	IN	O	of	_	0	SENT_156	[p11l1119t1902r1220b1981],
13	response	NN	O	response	prep_of	11	SENT_156	[p11l1229t1928r1632b2003],
14	,	,	O	,	_	0	SENT_156	[p11l1229t1928r1632b2003],
15	overall	JJ	O	overall	amod	16	SENT_156	[p11l1665t1903r1943b1982],
16	sur	NN	O	sur	conj_and	6	SENT_156	[p11l1971t1929r2134b1982],
17	—	CD	NUMBER	—	num	19	SENT_156	[p11l1971t1929r2134b1982],
18	vival	JJ	O	vival	amod	19	SENT_156	[p11l6t2030r194b2108],
19	time	NN	O	time	dep	16	SENT_156	[p11l217t2030r427b2124],
20	,	,	O	,	_	0	SENT_156	[p11l217t2030r427b2124],
21	and	CC	O	and	_	0	SENT_156	[p11l455t2029r610b2108],
22	the	DT	O	the	det	23	SENT_156	[p11l633t2030r762b2107],
23	incidence	NN	O	incidence	dobj	4	SENT_156	[p11l785t2030r1188b2107],
24	of	IN	O	of	_	0	SENT_156	[p11l1212t2029r1312b2108],
25	adverse	JJ	O	adverse	amod	26	SENT_156	[p11l1316t2029r1629b2108],
26	effects	NNS	O	effect	prep_of	23	SENT_156	[p11l1653t2029r1948b2108],
27	.	.	O	.	_	0	SENT_156	[p11l1653t2029r1948b2108],

1	The	DT	O	the	det	2	SENT_157	[p11l1973t2029r2135b2107],
2	time	NN	O	time	nsubjpass	6	SENT_157	[p11l11t2158r197b2236],
3	to	TO	O	to	_	0	SENT_157	[p11l238t2174r317b2236],
4	progression	NN	O	progression	prep_to	2	SENT_157	[p11l357t2158r866b2258],
5	was	VBD	O	be	auxpass	6	SENT_157	[p11l901t2184r1063b2237],
6	calculated	VBN	O	calculate	_	0	SENT_157	[p11l1105t2158r1527b2237],
7	as	IN	O	as	_	0	SENT_157	[p11l1567t2184r1650b2236],
8	the	DT	O	the	det	9	SENT_157	[p11l1693t2157r1823b2236],
9	period	NN	O	period	prep_as	6	SENT_157	[p11l1861t2158r2135b2258],
10	from	IN	O	from	_	0	SENT_157	[p11l10t2285r218b2364],
11	the	DT	O	the	det	12	SENT_157	[p11l239t2285r368b2364],
12	date	NN	O	date	prep_from	9	SENT_157	[p11l390t2285r564b2364],
13	of	IN	O	of	_	0	SENT_157	[p11l586t2285r686b2364],
14	randomization	NN	O	randomization	prep_of	12	SENT_157	[p11l688t2285r1317b2364],
15	to	TO	O	to	_	0	SENT_157	[p11l1338t2302r1417b2364],
16	the	DT	O	the	det	18	SENT_157	[p11l1440t2286r1569b2364],
17	ﬁrst	JJ	O	ﬁrst	amod	18	SENT_157	[p11l1590t2285r1763b2364],
18	observation	NN	O	observation	prep_to	6	SENT_157	[p11l1780t2286r2134b2365, p11l11t2414r176b2492],
19	of	IN	O	of	_	0	SENT_157	[p11l216t2413r317b2492],
20	disease	NN	O	disease	nn	21	SENT_157	[p11l339t2413r642b2492],
21	progression	NN	O	progression	prep_of	18	SENT_157	[p11l680t2414r1188b2514],
22	or	CC	O	or	_	0	SENT_157	[p11l1229t2439r1318b2492],
23	to	TO	O	to	_	0	SENT_157	[p11l1355t2430r1433b2492],
24	death	NN	O	death	prep_to	6	SENT_157	[p11l1475t2413r1707b2492],
25	from	IN	O	from	_	0	SENT_157	[p11l1746t2413r1953b2492],
26	any	DT	O	any	det	27	SENT_157	[p11l1992t2439r2139b2514],
27	cause	NN	O	cause	prep_from	6	SENT_157	[p11l11t2568r241b2621],
28	within	IN	O	within	_	0	SENT_157	[p11l281t2542r556b2621],
29	60	CD	DURATION	60	num	30	SENT_157	[p11l599t2547r699b2620],
30	days	NNS	NUMBER	day	prep_within	27	SENT_157	[p11l744t2542r925b2642],
31	after	IN	O	after	_	0	SENT_157	[p11l970t2541r1163b2620],
32	randomization	NN	O	randomization	prep_after	30	SENT_157	[p11l1203t2542r1832b2620],
33	or	CC	O	or	_	0	SENT_157	[p11l1875t2567r1965b2620],
34	the	DT	O	the	det	38	SENT_157	[p11l2006t2541r2134b2620],
35	most	RBS	O	most	advmod	36	SENT_157	[p11l10t2686r227b2748],
36	recent	JJ	O	recent	amod	38	SENT_157	[p11l243t2686r506b2748],
37	tumor	NN	O	tumor	nn	38	SENT_157	[p11l522t2686r785b2749],
38	assessment	NN	O	assessment	prep_within	27	SENT_157	[p11l802t2686r1311b2748],
39	.	.	O	.	_	0	SENT_157	[p11l802t2686r1311b2748],

1	The	DT	O	the	det	4	SENT_158	[p11l1334t2670r1495b2748],
2	overall	JJ	O	overall	amod	4	SENT_158	[p11l1517t2670r1796b2749],
3	survival	NN	O	survival	nn	4	SENT_158	[p11l1817t2670r2135b2749],
4	time	NN	O	time	nsubjpass	6	SENT_158	[p11l11t2798r197b2876],
5	was	VBD	O	be	auxpass	6	SENT_158	[p11l224t2824r384b2877],
6	calculated	VBN	O	calculate	_	0	SENT_158	[p11l418t2798r840b2877],
7	as	IN	O	as	_	0	SENT_158	[p11l869t2824r953b2876],
8	the	DT	O	the	det	9	SENT_158	[p11l987t2798r1116b2876],
9	period	NN	O	period	prep_as	6	SENT_158	[p11l1145t2798r1419b2898],
10	from	IN	O	from	_	0	SENT_158	[p11l1449t2797r1656b2876],
11	the	DT	O	the	det	12	SENT_158	[p11l1687t2798r1816b2876],
12	date	NN	O	date	prep_from	6	SENT_158	[p11l1848t2798r2021b2876],
13	of	IN	O	of	_	0	SENT_158	[p11l2053t2797r2153b2876],
14	randomization	NN	O	randomization	prep_of	12	SENT_158	[p11l10t2926r638b3004],
15	until	IN	O	until	mark	27	SENT_158	[p11l668t2925r863b3005],
16	death	NN	O	death	nsubj	27	SENT_158	[p11l892t2925r1124b3004],
17	from	IN	O	from	_	0	SENT_158	[p11l1154t2925r1361b3004],
18	any	DT	O	any	det	19	SENT_158	[p11l1390t2951r1538b3026],
19	cause	NN	O	cause	prep_from	16	SENT_158	[p11l1563t2952r1793b3005],
20	or	CC	O	or	_	0	SENT_158	[p11l1825t2951r1913b3004],
21	until	IN	O	until	_	0	SENT_158	[p11l1940t2926r2135b3005],
22	the	DT	O	the	det	23	SENT_158	[p11l11t3054r139b3132],
23	date	NN	O	date	prep_until	16	SENT_158	[p11l174t3053r347b3132],
24	of	IN	O	of	_	0	SENT_158	[p11l380t3053r481b3132],
25	the	DT	O	the	det	26	SENT_158	[p11l495t3054r624b3132],
26	last	JJ	O	last	prep_of	23	SENT_158	[p11l656t3053r807b3132],
27	follow	VB	O	follow	advcl	6	SENT_158	[p11l834t3053r1269b3154],
28	—	RB	O	—	advmod	27	SENT_158	[p11l834t3053r1269b3154],
29	up	RB	O	up	advmod	27	SENT_158	[p11l834t3053r1269b3154],
30	,	,	O	,	_	0	SENT_158	[p11l834t3053r1269b3154],
31	at	IN	O	at	_	0	SENT_158	[p11l1307t3070r1386b3132],
32	which	WDT	O	which	dobj	36	SENT_158	[p11l1409t3053r1669b3133],
33	point	NN	O	point	nn	34	SENT_158	[p11l1700t3054r1929b3154],
34	data	NNS	O	datum	nsubjpass	36	SENT_158	[p11l1957t3054r2136b3132],
35	were	VBD	O	be	auxpass	36	SENT_158	[p11l6t3208r207b3261],
36	censored	VBN	O	censor	prepc_at	27	SENT_158	[p11l246t3182r648b3260],
37	.	.	O	.	_	0	SENT_158	[p11l246t3182r648b3260],

1	Both	CC	O	both	dep	3	SENT_159	[p11l690t3182r890b3260],
2	the	DT	O	the	det	3	SENT_159	[p11l927t3182r1057b3260],
3	time	NN	O	time	nsubjpass	20	SENT_159	[p11l1095t3182r1281b3260],
4	to	TO	O	to	dep	3	SENT_159	[p11l1318t3198r1397b3260],
5	progression	NN	O	progression	nn	9	SENT_159	[p11l1434t3182r1943b3282],
6	and	CC	O	and	_	0	SENT_159	[p11l1979t3182r2135b3260],
7	overall	JJ	O	overall	conj_and	5	SENT_159	[p11l11t3310r289b3389],
8	survival	NN	O	survival	nn	9	SENT_159	[p11l313t3310r631b3389],
9	time	NN	O	time	dep	3	SENT_159	[p11l653t3310r840b3388],
10	were	VBD	O	be	auxpass	11	SENT_159	[p11l859t3336r1060b3389],
11	estimated	VBN	O	estimate	_	0	SENT_159	[p11l1084t3310r1494b3388],
12	by	IN	O	by	_	0	SENT_159	[p11l1517t3309r1614b3410],
13	the	DT	O	the	det	14	SENT_159	[p11l1633t3310r1761b3388],
14	Ké1plan	NN	O	ké1plan	agent	11	SENT_159	[p11l1784t3309r2138b3410],
15	—	CD	NUMBER	—	num	18	SENT_159	[p11l1784t3309r2138b3410],
16	Meier	NN	O	meier	nn	18	SENT_159	[p11l7t3439r253b3516],
17	method	NN	O	method	nn	18	SENT_159	[p11l294t3432r702b3516],
18	”	NN	O	”	dep	14	SENT_159	[p11l294t3432r702b3516],
19	and	CC	O	and	_	0	SENT_159	[p11l745t3438r901b3516],
20	compared	VBN	O	compare	conj_and	11	SENT_159	[p11l946t3438r1369b3538],
21	between	IN	O	between	_	0	SENT_159	[p11l1413t3438r1762b3517],
22	the	DT	O	the	det	24	SENT_159	[p11l1807t3438r1936b3516],
23	two	CD	NUMBER	two	num	24	SENT_159	[p11l1981t3454r2134b3517],
24	groups	NNS	O	group	prep_between	20	SENT_159	[p11l10t3592r303b3667],
25	with	IN	O	with	_	0	SENT_159	[p11l343t3567r532b3646],
26	use	NN	O	use	prep_with	20	SENT_159	[p11l573t3593r712b3646],
27	of	IN	O	of	_	0	SENT_159	[p11l755t3566r855b3645],
28	the	DT	O	the	det	29	SENT_159	[p11l878t3567r1007b3645],
29	log	NN	O	log	prep_of	26	SENT_159	[p11l1048t3567r1415b3667],
30	—	CD	NUMBER	—	num	32	SENT_159	[p11l1048t3567r1415b3667],
31	rank	NN	O	rank	nn	32	SENT_159	[p11l1048t3567r1415b3667],
32	test	NN	O	test	dobj	11	SENT_159	[p11l1452t3562r1708b3645],
33	.	.	O	.	_	0	SENT_159	[p11l1452t3562r1708b3645],

1	”	NN	O	”	nn	4	SENT_160	[p11l1452t3562r1708b3645],
2	Stratiﬁed	JJ	O	stratiﬁed	amod	4	SENT_160	[p11l1753t3566r2135b3645],
3	permutation	NN	O	permutation	nn	4	SENT_160	[p11l9t3695r539b3795],
4	tests	NNS	O	test	nsubjpass	6	SENT_160	[p11l577t3711r765b3773],
5	were	VBD	O	be	auxpass	6	SENT_160	[p11l799t3721r1001b3774],
6	carried	VBN	O	carry	_	0	SENT_160	[p11l1039t3695r1330b3773],
7	out	RP	O	out	prt	6	SENT_160	[p11l1367t3711r1508b3774],
8	to	TO	O	to	aux	9	SENT_160	[p11l1540t3711r1619b3773],
9	explore	VB	O	explore	dep	6	SENT_160	[p11l1659t3695r1967b3795],
10	the	DT	O	the	det	11	SENT_160	[p11l2006t3694r2135b3773],
11	association	NN	O	association	dobj	9	SENT_160	[p12l10t21r485b98],
12	between	IN	O	between	_	0	SENT_160	[p12l514t21r863b99],
13	tumor	NN	O	tumor	nn	14	SENT_160	[p12l892t37r1155b99],
14	response	NN	O	response	prep_between	11	SENT_160	[p12l1180t45r1559b120],
15	and	CC	O	and	_	0	SENT_160	[p12l1587t21r1743b98],
16	rash	NN	O	rash	prep_between	11	SENT_160	[p12l1771t21r1952b98],
17	and	CC	O	and	_	0	SENT_160	[p12l1979t21r2135b98],
18	between	IN	O	between	dep	6	SENT_160	[p12l11t149r361b228],
19	tumor	NN	O	tumor	nn	20	SENT_160	[p12l386t165r649b228],
20	response	NN	O	response	pobj	18	SENT_160	[p12l670t174r1050b249],
21	and	CC	O	and	_	0	SENT_160	[p12l1074t149r1231b227],
22	EGFR	NN	ORGANIZATION	egfr	nn	23	SENT_160	[p12l1254t154r1513b232],
23	expression	NN	O	expression	pobj	18	SENT_160	[p12l1528t149r2005b249],
24	.	.	O	.	_	0	SENT_160	[p12l1528t149r2005b249],

1	The	DT	O	the	det	4	SENT_161	[p12l136t277r296b355],
2	planned	VBN	O	plan	amod	4	SENT_161	[p12l317t277r658b377],
3	sample	NN	O	sample	nn	4	SENT_161	[p12l681t277r979b377],
4	size	NN	O	size	nsubjpass	9	SENT_161	[p12l1003t277r1160b355],
5	for	IN	O	for	_	0	SENT_161	[p12l1182t276r1304b355],
6	the	DT	O	the	det	7	SENT_161	[p12l1323t277r1451b355],
7	study	NN	O	study	prep_for	4	SENT_161	[p12l1475t277r1698b377],
8	was	VBD	O	be	auxpass	9	SENT_161	[p12l1711t303r1871b356],
9	based	VBN	O	base	_	0	SENT_161	[p12l1896t276r2135b355],
10	on	IN	O	on	_	0	SENT_161	[p12l11t430r117b483],
11	power	NN	O	power	nn	12	SENT_161	[p12l148t430r414b505],
12	calculations	NNS	O	calculation	prep_on	9	SENT_161	[p12l444t405r945b484],
13	related	VBN	O	relate	partmod	12	SENT_161	[p12l979t404r1265b483],
14	to	TO	O	to	_	0	SENT_161	[p12l1297t421r1376b483],
15	the	DT	O	the	det	16	SENT_161	[p12l1410t405r1539b483],
16	estimation	NN	O	estimation	prep_to	13	SENT_161	[p12l1572t405r2020b483],
17	of	IN	O	of	_	0	SENT_161	[p12l2053t404r2153b483],
18	the	DT	O	the	det	20	SENT_161	[p12l11t533r139b611],
19	conﬁdence	NN	O	conﬁdence	nn	20	SENT_161	[p12l174t532r636b611],
20	interval	NN	O	interval	prep_of	16	SENT_161	[p12l668t533r982b612],
21	expected	VBN	O	expect	partmod	20	SENT_161	[p12l1015t532r1382b633],
22	for	IN	O	for	_	0	SENT_161	[p12l1415t532r1538b611],
23	the	DT	O	the	det	27	SENT_161	[p12l1568t532r1698b611],
24	combination	NN	O	combination	nn	27	SENT_161	[p12l1731t533r2133b611, p12l11t661r533b761],
25	—	NN	O	—	nn	27	SENT_161	[p12l1731t533r2133b611, p12l11t661r533b761],
26	therapy	NN	O	therapy	nn	27	SENT_161	[p12l1731t533r2133b611, p12l11t661r533b761],
27	group	NN	O	group	prep_for	21	SENT_161	[p12l552t686r828b761],
28	.	.	O	.	_	0	SENT_161	[p12l552t686r828b761],

1	Anticipating	VBG	O	anticipate	partmod	13	SENT_162	[p12l853t661r1383b761],
2	a	DT	O	a	det	4	SENT_162	[p12l1402t687r1446b739],
3	response	NN	O	response	nn	4	SENT_162	[p12l1469t686r1847b761],
4	rate	NN	O	rate	dobj	1	SENT_162	[p12l1872t677r2028b739],
5	of	IN	O	of	_	0	SENT_162	[p12l2052t660r2153b739],
6	19	CD	PERCENT	19	num	7	SENT_162	[p12l14t794r110b867],
7	percent	NN	PERCENT	percent	prep_of	4	SENT_162	[p12l140t805r468b889],
8	in	IN	O	in	_	0	SENT_162	[p12l492t789r574b866],
9	this	DT	O	this	det	10	SENT_162	[p12l606t789r761b867],
10	group	NN	O	group	prep_in	7	SENT_162	[p12l794t814r1075b889],
11	,	,	O	,	_	0	SENT_162	[p12l794t814r1075b889],
12	we	PRP	O	we	nsubj	13	SENT_162	[p12l1106t815r1226b868],
13	determined	VBD	O	determine	_	0	SENT_162	[p12l1257t788r1752b867],
14	that	IN	O	that	complm	19	SENT_162	[p12l1782t789r1952b867],
15	150	CD	NUMBER	150	num	16	SENT_162	[p12l1981t794r2133b867],
16	patients	NNS	O	patient	nsubj	19	SENT_162	[p12l9t917r351b1017],
17	would	MD	O	would	aux	19	SENT_162	[p12l380t916r650b996],
18	be	VB	O	be	cop	19	SENT_162	[p12l682t916r779b995],
19	sufficient	JJ	O	sufficient	ccomp	13	SENT_162	[p12l812t916r1220b996],
20	to	TO	O	to	aux	21	SENT_162	[p12l1248t933r1328b995],
21	exceed	VB	O	exceed	xcomp	19	SENT_162	[p12l1362t917r1647b995],
22	a	DT	O	a	det	27	SENT_162	[p12l1678t943r1722b995],
23	clinically	RB	O	clinically	advmod	24	SENT_162	[p12l1753t917r2139b1017],
24	relevant	JJ	O	relevant	amod	27	SENT_162	[p12l10t1045r353b1124],
25	nominal	JJ	O	nominal	amod	27	SENT_162	[p12l374t1045r729b1123],
26	response	NN	O	response	nn	27	SENT_162	[p12l755t1070r1134b1145],
27	rate	NN	O	rate	dobj	21	SENT_162	[p12l1161t1061r1317b1123],
28	of	IN	O	of	_	0	SENT_162	[p12l1345t1044r1445b1123],
29	10	CD	PERCENT	10	num	30	SENT_162	[p12l1456t1050r1553b1123],
30	percent	NN	PERCENT	percent	prep_of	27	SENT_162	[p12l1579t1061r1918b1145],
31	,	,	O	,	_	0	SENT_162	[p12l1579t1061r1918b1145],
32	with	IN	O	with	_	0	SENT_162	[p12l1945t1045r2135b1124],
33	85	CD	PERCENT	85	num	35	SENT_162	[p12l11t1178r108b1251],
34	percent	NN	PERCENT	percent	nn	35	SENT_162	[p12l144t1189r464b1273],
35	power	NN	O	power	prep_with	21	SENT_162	[p12l491t1198r774b1273],
36	.	.	O	.	_	0	SENT_162	[p12l491t1198r774b1273],

1	A	DT	O	a	det	3	SENT_163	[p12l809t1180r875b1250],
2	response	NN	O	response	nn	3	SENT_163	[p12l906t1198r1285b1273],
3	rate	NN	O	rate	nsubjpass	14	SENT_163	[p12l1318t1189r1475b1251],
4	of	IN	O	of	_	0	SENT_163	[p12l1509t1172r1610b1251],
5	5	CD	PERCENT	5	num	6	SENT_163	[p12l1628t1180r1669b1251],
6	percent	NN	PERCENT	percent	prep_of	3	SENT_163	[p12l1705t1189r2026b1273],
7	in	IN	O	in	_	0	SENT_163	[p12l2054t1173r2135b1250],
8	the	DT	O	the	det	12	SENT_163	[p12l11t1301r139b1379],
9	cetuximab	JJ	O	cetuximab	amod	12	SENT_163	[p12l177t1301r1223b1401],
10	—	NN	O	—	nn	12	SENT_163	[p12l177t1301r1223b1401],
11	monotherapy	NN	O	monotherapy	nn	12	SENT_163	[p12l177t1301r1223b1401],
12	group	NN	O	group	prep_in	6	SENT_163	[p12l1255t1326r1506b1401],
13	was	VBD	O	be	auxpass	14	SENT_163	[p12l1539t1327r1700b1380],
14	expected	VBN	O	expect	_	0	SENT_163	[p12l1739t1301r2129b1401],
15	.	.	O	.	_	0	SENT_163	[p12l1739t1301r2129b1401],

1	Given	VBN	O	give	prep	10	SENT_164	[p12l10t1429r255b1507],
2	this	DT	O	this	det	3	SENT_164	[p12l292t1429r444b1506],
3	expectation	NN	O	expectation	dep	1	SENT_164	[p12l483t1429r993b1528],
4	,	,	O	,	_	0	SENT_164	[p12l483t1429r993b1528],
5	a	DT	O	a	det	8	SENT_164	[p12l1034t1454r1078b1506],
6	2:1	CD	NUMBER	2:1	num	8	SENT_164	[p12l1112t1434r1242b1506],
7	randomization	NN	O	randomization	nn	8	SENT_164	[p12l1278t1429r1906b1506],
8	ratio	NN	O	ratio	nsubjpass	10	SENT_164	[p12l1942t1429r2134b1506],
9	was	VBD	O	be	auxpass	10	SENT_164	[p12l6t1583r166b1636],
10	considered	VBN	O	consider	_	0	SENT_164	[p12l198t1557r660b1635],
11	appropriate	JJ	O	appropriate	dep	10	SENT_164	[p12l687t1557r1179b1657],
12	and	CC	O	and	_	0	SENT_164	[p12l1207t1557r1363b1635],
13	ethically	RB	O	ethically	advmod	14	SENT_164	[p12l1392t1557r1743b1657],
14	justified	JJ	O	justified	dep	10	SENT_164	[p12l1753t1556r2129b1657],
15	.	.	O	.	_	0	SENT_164	[p12l1753t1556r2129b1657],

1	Therefore	RB	O	therefore	advmod	6	SENT_165	[p12l7t1684r423b1763],
2	the	DT	O	the	det	3	SENT_165	[p12l452t1685r581b1763],
3	study	NN	O	study	nsubjpass	6	SENT_165	[p12l611t1685r837b1785],
4	was	VBD	O	be	auxpass	6	SENT_165	[p12l857t1711r1018b1764],
5	originally	RB	O	originally	advmod	6	SENT_165	[p12l1050t1684r1454b1785],
6	set	VBN	O	set	_	0	SENT_165	[p12l1479t1701r1598b1763],
7	up	RP	O	up	prt	6	SENT_165	[p12l1622t1711r1726b1785],
8	to	TO	O	to	aux	9	SENT_165	[p12l1757t1701r1836b1763],
9	assign	VB	O	assign	xcomp	6	SENT_165	[p12l1865t1685r2135b1785],
10	225	CD	NUMBER	225	num	11	SENT_165	[p12l10t1818r161b1891],
11	patients	NNS	O	patient	dobj	9	SENT_165	[p12l190t1813r525b1913],
12	randomly	RB	O	randomly	advmod	9	SENT_165	[p12l555t1812r964b1913],
13	to	TO	O	to	_	0	SENT_165	[p12l988t1829r1066b1891],
14	one	CD	NUMBER	one	prep_to	9	SENT_165	[p12l1096t1838r1248b1891],
15	of	IN	O	of	_	0	SENT_165	[p12l1277t1812r1378b1891],
16	the	DT	O	the	det	19	SENT_165	[p12l1387t1813r1516b1891],
17	two	CD	NUMBER	two	num	19	SENT_165	[p12l1544t1829r1696b1892],
18	treatment	NN	O	treatment	nn	19	SENT_165	[p12l1726t1829r2140b1891],
19	groups	NNS	O	group	prep_of	14	SENT_165	[p12l10t1966r329b2041],
20	.	.	O	.	_	0	SENT_165	[p12l10t1966r329b2041],

1	This	DT	O	this	det	3	SENT_166	[p12l367t1940r552b2019],
2	sample	NN	O	sample	nn	3	SENT_166	[p12l590t1940r891b2041],
3	size	NN	O	size	nsubj	6	SENT_166	[p12l928t1941r1086b2019],
4	would	MD	O	would	aux	6	SENT_166	[p12l1118t1940r1383b2020],
5	also	RB	O	also	advmod	6	SENT_166	[p12l1417t1941r1584b2019],
6	allow	VB	O	allow	_	0	SENT_166	[p12l1621t1941r1850b2020],
7	detection	NN	O	detection	dobj	6	SENT_166	[p12l1883t1941r2134b2019, p12l11t2069r177b2147],
8	of	IN	O	of	_	0	SENT_166	[p12l202t2068r302b2147],
9	a	DT	O	a	det	12	SENT_166	[p12l308t2095r352b2147],
10	statistically	RB	O	statistically	advmod	11	SENT_166	[p12l376t2069r851b2169],
11	signiﬁcant	JJ	O	signiﬁcant	amod	12	SENT_166	[p12l872t2068r1323b2169],
12	difference	NN	O	difference	prep_of	7	SENT_166	[p12l1344t2068r1765b2147],
13	in	IN	O	in	_	0	SENT_166	[p12l1789t2069r1871b2146],
14	terms	NNS	O	term	prep_in	6	SENT_166	[p12l1895t2085r2133b2147],
15	of	IN	O	of	_	0	SENT_166	[p12l11t2196r112b2275],
16	response	NN	O	response	nn	17	SENT_166	[p12l127t2222r507b2297],
17	rates	NNS	O	rate	prep_of	14	SENT_166	[p12l541t2213r739b2275],
18	between	IN	O	between	_	0	SENT_166	[p12l777t2197r1126b2276],
19	the	DT	O	the	det	21	SENT_166	[p12l1162t2197r1291b2275],
20	two	CD	NUMBER	two	num	21	SENT_166	[p12l1326t2213r1478b2276],
21	groups	NNS	O	group	prep_between	17	SENT_166	[p12l1514t2222r1833b2297],
22	,	,	O	,	_	0	SENT_166	[p12l1514t2222r1833b2297],
23	with	IN	O	with	mark	42	SENT_166	[p12l1869t2197r2058b2276],
24	a	DT	O	a	det	25	SENT_166	[p12l2092t2223r2136b2275],
25	power	NN	O	power	nsubj	42	SENT_166	[p12l9t2350r276b2425],
26	of	IN	O	of	_	0	SENT_166	[p12l299t2324r400b2403],
27	about	IN	O	about	advmod	41	SENT_166	[p12l407t2324r650b2404],
28	80	CD	PERCENT	80	num	29	SENT_166	[p12l672t2330r772b2403],
29	percent	NN	PERCENT	percent	pobj	27	SENT_166	[p12l797t2341r1118b2425],
30	at	IN	O	at	_	0	SENT_166	[p12l1139t2341r1218b2403],
31	a	DT	O	a	det	33	SENT_166	[p12l1238t2351r1282b2403],
32	signiﬁcance	NN	O	signiﬁcance	nn	33	SENT_166	[p12l1308t2324r1814b2425],
33	level	NN	O	level	prep_at	27	SENT_166	[p12l1839t2324r2027b2404],
34	of	IN	O	of	_	0	SENT_166	[p12l2053t2324r2153b2403],
35	0.05	CD	NUMBER	0.05	prep_of	33	SENT_166	[p12l11t2458r190b2531],
36	by	IN	O	by	_	0	SENT_166	[p12l233t2452r330b2553],
37	means	NNS	O	means	_	0	SENT_166	[p12l364t2478r638b2531],
38	of	IN	O	of	_	0	SENT_166	[p12l681t2452r781b2531],
39	a	DT	O	a	det	40	SENT_166	[p12l801t2479r845b2531],
40	two	CD	NUMBER	two	prep_by_means_of	27	SENT_166	[p12l883t2453r1299b2532],
41	—	CD	NUMBER	—	prep_of	25	SENT_166	[p12l883t2453r1299b2532],
42	sided	VBD	O	side	advcl	6	SENT_166	[p12l883t2453r1299b2532],
43	Fisher	NNP	PERSON	Fisher	poss	46	SENT_166	[p12l1336t2452r1667b2531],
44	’s	POS	O	’s	_	0	SENT_166	[p12l1336t2452r1667b2531],
45	exact	JJ	O	exact	amod	46	SENT_166	[p12l1709t2469r1925b2531],
46	test	NN	O	test	dobj	42	SENT_166	[p12l1959t2469r2130b2531],
47	.	.	O	.	_	0	SENT_166	[p12l1959t2469r2130b2531],

1	However	RB	O	however	advmod	22	SENT_167	[p12l10t2588r402b2676],
2	,	,	O	,	_	0	SENT_167	[p12l10t2588r402b2676],
3	after	IN	O	after	mark	7	SENT_167	[p12l439t2580r632b2659],
4	the	DT	O	the	det	5	SENT_167	[p12l663t2580r791b2659],
5	study	NN	O	study	nsubj	7	SENT_167	[p12l825t2580r1051b2681],
6	had	VBD	O	have	aux	7	SENT_167	[p12l1079t2580r1234b2659],
7	commenced	VBN	O	commence	advcl	22	SENT_167	[p12l1268t2581r1785b2659],
8	and	CC	O	and	_	0	SENT_167	[p12l1817t2580r1973b2659],
9	the	DT	O	the	det	10	SENT_167	[p12l2006t2580r2134b2659],
10	majority	NN	O	majority	nsubjpass	15	SENT_167	[p12l10t2709r362b2809],
11	of	IN	O	of	_	0	SENT_167	[p12l392t2708r493b2787],
12	patients	NNS	O	patient	prep_of	10	SENT_167	[p12l506t2709r841b2809],
13	had	VBD	O	have	aux	15	SENT_167	[p12l877t2709r1032b2787],
14	been	VBN	O	be	auxpass	15	SENT_167	[p12l1066t2709r1265b2787],
15	enrolled	VBN	O	enrol	conj_and	7	SENT_167	[p12l1300t2709r1670b2804],
16	,	,	O	,	_	0	SENT_167	[p12l1300t2709r1670b2804],
17	the	DT	O	the	det	21	SENT_167	[p12l1710t2709r1839b2787],
18	Swedish	NNP	ORGANIZATION	Swedish	nn	21	SENT_167	[p12l1875t2708r2132b2788, p12l10t2837r136b2915],
19	Medical	NNP	ORGANIZATION	Medical	nn	21	SENT_167	[p12l157t2836r499b2915],
20	Products	NNP	ORGANIZATION	Products	nn	21	SENT_167	[p12l521t2836r898b2916],
21	Agency	NNP	ORGANIZATION	Agency	nsubj	22	SENT_167	[p12l921t2844r1238b2937],
22	advised	VBD	O	advise	_	0	SENT_167	[p12l1257t2837r1578b2916],
23	that	IN	O	that	complm	43	SENT_167	[p12l1602t2837r1772b2915],
24	patients	NNS	O	patient	nsubjpass	43	SENT_167	[p12l1789t2837r2131b2937],
25	whose	WP$	O	whose	poss	26	SENT_167	[p12l6t2964r284b3044],
26	disease	NN	O	disease	nsubj	28	SENT_167	[p12l312t2965r622b3043],
27	had	VBD	O	have	aux	28	SENT_167	[p12l650t2964r806b3043],
28	progressed	VBN	O	progress	rcmod	24	SENT_167	[p12l832t2965r1312b3065],
29	at	IN	O	at	_	0	SENT_167	[p12l1339t2981r1418b3043],
30	the	DT	O	the	det	31	SENT_167	[p12l1441t2965r1572b3043],
31	end	NN	O	end	prep_at	28	SENT_167	[p12l1601t2964r1756b3043],
32	of	IN	O	of	_	0	SENT_167	[p12l1784t2964r1885b3043],
33	irinotecan	NN	O	irinotecan	nn	34	SENT_167	[p12l1893t2965r2133b3043, p12l11t3109r236b3171],
34	treatment	NN	O	treatment	prep_of	31	SENT_167	[p12l276t3109r690b3171],
35	or	CC	O	or	_	0	SENT_167	[p12l723t3118r813b3171],
36	progressed	VBN	O	progress	rcmod	24	SENT_167	[p12l846t3093r1316b3193],
37	within	IN	O	within	_	0	SENT_167	[p12l1349t3093r1623b3172],
38	one	CD	DURATION	one	prep_within	36	SENT_167	[p12l1662t3118r1814b3171],
39	month	NN	NUMBER	month	tmod	36	SENT_167	[p12l1852t3093r2135b3171],
40	thereafter	RB	O	thereafter	advmod	43	SENT_167	[p12l11t3220r421b3299],
41	would	MD	O	would	aux	43	SENT_167	[p12l437t3220r702b3300],
42	be	VB	O	be	auxpass	43	SENT_167	[p12l726t3221r821b3299],
43	considered	VBN	O	consider	ccomp	22	SENT_167	[p12l845t3220r1308b3299],
44	to	TO	O	to	aux	45	SENT_167	[p12l1331t3237r1410b3299],
45	have	VB	O	have	xcomp	43	SENT_167	[p12l1434t3221r1622b3300],
46	disease	NN	O	disease	dobj	45	SENT_167	[p12l1646t3221r1949b3299],
47	that	WDT	O	that	nsubj	50	SENT_167	[p12l1973t3220r2140b3299],
48	was	VBD	O	be	cop	50	SENT_167	[p12l6t3375r166b3428],
49	strictly	RB	O	strictly	advmod	50	SENT_167	[p12l199t3349r483b3449],
50	refractory	JJ	O	refractory	rcmod	46	SENT_167	[p12l507t3348r918b3449],
51	to	TO	O	to	_	0	SENT_167	[p12l943t3365r1022b3427],
52	irinotecan	NN	O	irinotecan	prep_to	50	SENT_167	[p12l1051t3349r1501b3427],
53	.	.	O	.	_	0	SENT_167	[p12l1051t3349r1501b3427],

1	Therefore	RB	O	therefore	advmod	7	SENT_168	[p12l1532t3348r1971b3444],
2	,	,	O	,	_	0	SENT_168	[p12l1532t3348r1971b3444],
3	the	DT	O	the	det	5	SENT_168	[p12l2006t3348r2135b3427],
4	sample	NN	O	sample	nn	5	SENT_168	[p12l12t3477r312b3577],
5	size	NN	O	size	nsubjpass	7	SENT_168	[p12l339t3477r497b3555],
6	was	VBD	O	be	auxpass	7	SENT_168	[p12l517t3503r678b3556],
7	increased	VBN	O	increase	_	0	SENT_168	[p12l704t3477r1105b3555],
8	to	TO	O	to	_	0	SENT_168	[p12l1130t3493r1209b3555],
9	a	DT	O	a	det	10	SENT_168	[p12l1234t3503r1278b3555],
10	total	NN	O	total	prep_to	7	SENT_168	[p12l1301t3477r1491b3555],
11	of	IN	O	of	_	0	SENT_168	[p12l1515t3476r1615b3555],
12	300	CD	NUMBER	300	num	13	SENT_168	[p12l1622t3482r1775b3555],
13	patients	NNS	O	patient	prep_of	10	SENT_168	[p12l1798t3477r2133b3577],
14	to	TO	O	to	aux	15	SENT_168	[p12l11t3621r90b3683],
15	ensure	VB	O	ensure	xcomp	7	SENT_168	[p12l117t3630r397b3684],
16	that	IN	O	that	complm	22	SENT_168	[p12l423t3605r589b3683],
17	the	DT	O	the	det	19	SENT_168	[p12l610t3605r739b3683],
18	study	NN	O	study	nn	19	SENT_168	[p12l767t3605r992b3705],
19	objectives	NNS	O	objective	nsubjpass	22	SENT_168	[p12l1014t3605r1422b3705],
20	could	MD	O	could	aux	22	SENT_168	[p12l1451t3604r1682b3684],
21	be	VB	O	be	auxpass	22	SENT_168	[p12l1709t3605r1804b3683],
22	met	VBN	O	meet	ccomp	15	SENT_168	[p12l1830t3621r1994b3683],
23	for	IN	O	for	_	0	SENT_168	[p12l2015t3604r2138b3683],
24	this	DT	O	this	det	25	SENT_168	[p13l11t21r163b99],
25	subgroup	NN	O	subgroup	prep_for	22	SENT_168	[p13l192t21r595b121],
26	of	IN	O	of	_	0	SENT_168	[p13l622t20r722b99],
27	patients	NNS	O	patient	prep_of	25	SENT_168	[p13l727t21r1087b121],
28	.	.	O	.	_	0	SENT_168	[p13l727t21r1087b121],

1	Predeﬁned	JJ	O	predeﬁned	amod	3	SENT_169	[p13l138t148r601b227],
2	subgroup	NN	O	subgroup	nn	3	SENT_169	[p13l636t149r1046b249],
3	analyses	NNS	O	analysis	nsubj	4	SENT_169	[p13l1080t148r1436b249],
4	included	VBD	O	include	_	0	SENT_169	[p13l1470t149r1844b228],
5	analy	RB	O	analy	advmod	4	SENT_169	[p13l1876t148r2132b249],
6	—	CD	NUMBER	—	num	7	SENT_169	[p13l1876t148r2132b249],
7	ses	NNS	O	se	dobj	4	SENT_169	[p13l12t303r138b355],
8	of	IN	O	of	_	0	SENT_169	[p13l175t276r277b355],
9	the	DT	O	the	det	10	SENT_169	[p13l292t277r422b355],
10	patients	NNS	O	patient	prep_of	7	SENT_169	[p13l452t277r787b377],
11	whose	WP$	O	whose	poss	12	SENT_169	[p13l816t277r1090b356],
12	disease	NN	O	disease	nsubj	13	SENT_169	[p13l1122t277r1426b355],
13	progressed	VBN	O	progress	rcmod	10	SENT_169	[p13l1456t276r1926b377],
14	during	IN	O	during	_	0	SENT_169	[p13l1958t277r2134b356, p13l10t405r148b505],
15	or	CC	O	or	_	0	SENT_169	[p13l180t430r269b483],
16	within	IN	O	within	_	0	SENT_169	[p13l296t405r570b484],
17	one	CD	DURATION	one	num	18	SENT_169	[p13l605t430r757b483],
18	month	NN	NUMBER	month	prep_during	13	SENT_169	[p13l792t404r1075b483],
19	after	IN	O	after	_	0	SENT_169	[p13l1109t404r1302b483],
20	the	DT	O	the	det	21	SENT_169	[p13l1334t404r1463b483],
21	end	NN	O	end	prep_after	18	SENT_169	[p13l1498t405r1651b483],
22	of	IN	O	of	_	0	SENT_169	[p13l1686t404r1786b483],
23	the	DT	O	the	det	26	SENT_169	[p13l1802t405r1931b483],
24	prestudy	JJ	O	prestudy	amod	26	SENT_169	[p13l1965t431r2134b505, p13l12t533r236b633],
25	irinotecan	NN	O	irinotecan	nn	26	SENT_169	[p13l251t533r675b611],
26	treatment	NN	O	treatment	prep_of	21	SENT_169	[p13l696t549r1107b611],
27	(	RB	O	(	advmod	13	SENT_169	[p13l1128t540r1240b624],
28	as	IN	O	as	_	0	SENT_169	[p13l1128t540r1240b624],
29	described	VBN	O	describe	prepc_as	13	SENT_169	[p13l1264t533r1666b611],
30	above	IN	O	above	_	0	SENT_169	[p13l1687t533r1954b624],
31	)	NN	O	)	prep_above	29	SENT_169	[p13l1687t533r1954b624],
32	and	CC	O	and	_	0	SENT_169	[p13l1981t532r2135b611],
33	of	IN	O	of	_	0	SENT_169	[p13l11t660r111b739],
34	patients	NNS	O	patient	prep_of	13	SENT_169	[p13l122t661r464b761],
35	who	WP	O	who	nsubj	37	SENT_169	[p13l493t660r678b740],
36	had	VBD	O	have	aux	37	SENT_169	[p13l711t660r868b739],
37	received	VBN	O	receive	rcmod	34	SENT_169	[p13l900t661r1249b740],
38	previous	JJ	O	previous	amod	40	SENT_169	[p13l1278t661r1642b761],
39	oxaliplatin	NN	O	oxaliplatin	nn	40	SENT_169	[p13l1677t661r2134b761],
40	treatment	NN	O	treatment	dobj	37	SENT_169	[p13l11t805r444b867],
41	.	.	O	.	_	0	SENT_169	[p13l11t805r444b867],

1	340	CD	NUMBER	340	num	4	SENT_170	[p13l149t942r206b964],
2	N	NN	O	n	nn	4	SENT_170	[p13l917t944r930b959],
3	ENGLJ	NN	O	englj	nn	4	SENT_170	[p13l946t943r1030b965],
4	MED	NN	O	med	_	0	SENT_170	[p13l1045t944r1097b959],
5	351	CD	NUMBER	351	dep	4	SENT_170	[p13l1110t943r1174b965],
6	;	:	O	;	_	0	SENT_170	[p13l1110t943r1174b965],
7	4	CD	NUMBER	4	dep	4	SENT_170	[p13l1110t943r1174b965],
8	WWW	NNP	O	WWW	dep	7	SENT_170	[p13l1208t944r1320b959],
9	.	.	O	.	_	0	SENT_170	[p13l1208t944r1320b959],

1	NE	NN	O	ne	nn	3	SENT_171	[p13l1208t944r1320b959],
2	M.ORG	NN	O	m.org	nn	3	SENT_171	[p13l1336t943r1420b959],
3	JULY	NN	DATE	july	_	0	SENT_171	[p13l1453t944r1513b965],
4	22	CD	DATE	22	dep	3	SENT_171	[p13l1525t943r1562b963],
5	,	,	O	,	_	0	SENT_171	[p13l1525t943r1562b963],
6	2oo4	CD	NUMBER	2oo4	appos	4	SENT_171	[p13l1575t943r1643b965],

1	The	DT	O	the	det	5	SENT_172	[p13l936t976r987b1000],
2	New	NNP	O	New	nn	5	SENT_172	[p13l996t977r1058b1000],
3	England	NNP	O	England	nn	5	SENT_172	[p13l1067t976r1178b1007],
4	Journal	NNP	O	Journal	nn	5	SENT_172	[p13l1187t976r1284b1000],
5	o	NN	O	o	_	0	SENT_172	[p13l1294t984r1309b1000],
6	edicine	NN	O	edicine	dep	5	SENT_172	[p13l1360t976r1455b1000],

1	Downloaded	VBN	O	download	_	0	SENT_173	[p13l378t1017r548b1040],
2	from	IN	O	from	_	0	SENT_173	[p13l557t1017r621b1040],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_173	[p13l630t1017r748b1047],
4	at	IN	O	at	_	0	SENT_173	[p13l759t1021r782b1040],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_173	[p13l790t1017r973b1040],
6	on	IN	O	on	_	0	SENT_173	[p13l982t1024r1015b1040],
7	January	NNP	DATE	January	prep_on	1	SENT_173	[p13l1023t1017r1126b1047],
8	5	CD	DATE	5	num	7	SENT_173	[p13l1136t1017r1159b1044],
9	,	,	DATE	,	_	0	SENT_173	[p13l1136t1017r1159b1044],
10	2014	CD	DATE	2014	num	7	SENT_173	[p13l1170t1017r1242b1040],
11	.	.	O	.	_	0	SENT_173	[p13l1170t1017r1242b1040],

1	For	IN	O	for	_	0	SENT_174	[p13l1252t1017r1299b1040],
2	personal	JJ	O	personal	amod	3	SENT_174	[p13l1307t1017r1419b1047],
3	use	NN	O	use	pobj	1	SENT_174	[p13l1428t1024r1472b1040],
4	only	RB	O	only	advmod	3	SENT_174	[p13l1482t1017r1546b1047],
5	.	.	O	.	_	0	SENT_174	[p13l1482t1017r1546b1047],

1	No	DT	O	no	det	3	SENT_175	[p13l1557t1017r1597b1040],
2	other	JJ	O	other	amod	3	SENT_175	[p13l1607t1017r1675b1040],
3	uses	NNS	O	use	_	0	SENT_175	[p13l1683t1024r1739b1040],
4	without	IN	O	without	_	0	SENT_175	[p13l1749t1017r1850b1040],
5	permission	NN	O	permission	prep_without	3	SENT_175	[p13l1859t1017r2011b1047],
6	.	.	O	.	_	0	SENT_175	[p13l1859t1017r2011b1047],

1	Copyright	NN	O	copyright	_	0	SENT_176	[p13l728t1058r863b1089],
2	©	CD	NUMBER	©	num	6	SENT_176	[p13l872t1058r896b1082],
3	2004	CD	DATE	2004	num	6	SENT_176	[p13l906t1058r971b1082],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_176	[p13l980t1058r1171b1082],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_176	[p13l1181t1058r1289b1082],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_176	[p13l1300t1058r1405b1089],
7	.	.	O	.	_	0	SENT_176	[p13l1300t1058r1405b1089],

1	All	DT	O	all	det	2	SENT_177	[p13l1416t1058r1457b1082],
2	rights	NNS	O	rights	nsubj	3	SENT_177	[p13l1466t1058r1541b1089],
3	reserved	VBN	O	reserve	_	0	SENT_177	[p13l1551t1058r1670b1082],
4	.	.	O	.	_	0	SENT_177	[p13l1551t1058r1670b1082],

1	CETUXIMAB	NNP	O	CETUXIMAB	_	0	SENT_178	[p13l533t1164r727b1183],
2	IN	IN	O	in	dep	1	SENT_178	[p13l742t1164r780b1183],
3	IRINOTECAN-REFRACTORY	NNP	O	IRINOTECAN-REFRACTORY	nn	5	SENT_178	[p13l796t1164r1248b1183],
4	COLORECTAL	NNP	O	COLORECTAL	nn	5	SENT_178	[p13l1260t1164r1477b1183],
5	CANCER	NNP	O	CANCER	pobj	2	SENT_178	[p13l1490t1164r1626b1183],

1	The	DT	O	the	det	3	SENT_179	[p13l136t1378r298b1456],
2	cutoff	NN	O	cutoff	nn	3	SENT_179	[p13l334t1377r604b1457],
3	point	NN	O	point	nsubj	7	SENT_179	[p13l620t1378r853b1478],
4	for	IN	O	for	_	0	SENT_179	[p13l883t1377r1009b1456],
5	survival	NN	O	survival	nn	6	SENT_179	[p13l1042t1378r1367b1457],
6	data	NNS	O	datum	prep_for	3	SENT_179	[p13l1403t1377r1586b1456],
7	was	VBD	O	be	_	0	SENT_179	[p13l1615t1404r1778b1457],
8	January	NNP	DATE	January	tmod	7	SENT_179	[p13l1806t1385r2139b1478],
9	2003	CD	DATE	2003	num	8	SENT_179	[p13l11t1511r247b1601],
10	;	:	O	;	_	0	SENT_179	[p13l11t1511r247b1601],
11	for	IN	O	for	_	0	SENT_179	[p13l287t1505r412b1584],
12	safety	NN	O	safety	nn	13	SENT_179	[p13l446t1505r693b1606],
13	data	NNS	O	datum	prep_for	16	SENT_179	[p13l725t1505r930b1601],
14	,	,	O	,	_	0	SENT_179	[p13l725t1505r930b1601],
15	it	PRP	O	it	nsubj	16	SENT_179	[p13l971t1506r1031b1584],
16	was	VBD	O	be	parataxis	7	SENT_179	[p13l1057t1532r1220b1585],
17	November	NNP	DATE	November	tmod	16	SENT_179	[p13l1256t1506r1708b1585],
18	2002	CD	DATE	2002	num	17	SENT_179	[p13l1741t1511r1976b1584],
19	.	.	O	.	_	0	SENT_179	[p13l1741t1511r1976b1584],

1	All	DT	O	all	det	2	SENT_180	[p13l2013t1505r2135b1583],
2	analyses	NNS	O	analysis	nsubjpass	4	SENT_180	[p13l10t1634r366b1734],
3	were	VBD	O	be	auxpass	4	SENT_180	[p13l394t1660r596b1713],
4	performed	VBN	O	perform	_	0	SENT_180	[p13l623t1633r1072b1734],
5	using	VBG	O	use	xcomp	4	SENT_180	[p13l1101t1634r1338b1734],
6	SAS	NNP	O	SAS	nn	9	SENT_180	[p13l1365t1639r1524b1712],
7	software	NN	O	software	nn	9	SENT_180	[p13l1557t1633r1916b1713],
8	(	NN	O	(	nn	9	SENT_180	[p13l1950t1641r2134b1725, p13l12t1762r189b1839],
9	version	NN	O	version	dobj	5	SENT_180	[p13l1950t1641r2134b1725, p13l12t1762r189b1839],
10	8.2	CD	NUMBER	8.2	num	11	SENT_180	[p13l215t1767r402b1852],
11	)	NN	O	)	dep	9	SENT_180	[p13l215t1767r402b1852],
12	.	.	O	.	_	0	SENT_180	[p13l215t1767r402b1852],

1	RESULTS	NNS	O	result	_	0	SENT_181	[p13l828t2076r1306b2135],

1	Between	IN	O	between	_	0	SENT_182	[p13l9t2277r364b2350],
2	July	NNP	DATE	July	prep_between	11	SENT_182	[p13l376t2270r539b2371],
3	2001	CD	DATE	2001	num	2	SENT_182	[p13l557t2276r762b2349],
4	and	CC	O	and	_	0	SENT_182	[p13l784t2271r939b2349],
5	May	NNP	DATE	May	conj_and	2	SENT_182	[p13l958t2278r1137b2371],
6	2002	CD	DATE	2002	num	5	SENT_182	[p13l1154t2276r1383b2366],
7	,	,	O	,	_	0	SENT_182	[p13l1154t2276r1383b2366],
8	577	CD	NUMBER	577	num	5	SENT_182	[p13l1412t2278r1562b2349],
9	patients	NNS	O	patient	nsubjpass	11	SENT_182	[p13l1584t2271r1916b2371],
10	were	VBD	O	be	auxpass	11	SENT_182	[p13l1935t2297r2135b2350],
11	screened	VBN	O	screen	_	0	SENT_182	[p13l12t2399r407b2494],
12	;	:	O	;	_	0	SENT_182	[p13l12t2399r407b2494],
13	474	CD	NUMBER	474	nsubj	20	SENT_182	[p13l448t2404r605b2477],
14	of	IN	O	of	_	0	SENT_182	[p13l644t2398r744b2477],
15	them	PRP	O	they	nn	19	SENT_182	[p13l766t2398r982b2477],
16	(	RB	PERCENT	(	amod	19	SENT_182	[p13l1026t2404r1238b2490],
17	82.1	CD	PERCENT	82.1	tmod	16	SENT_182	[p13l1026t2404r1238b2490],
18	percent	NN	PERCENT	percent	nn	19	SENT_182	[p13l1277t2406r1620b2499],
19	)	NN	O	)	prep_of	13	SENT_182	[p13l1277t2406r1620b2499],
20	had	VBD	O	have	parataxis	11	SENT_182	[p13l1665t2399r1820b2477],
21	EGFR	NN	O	egfr	npadvmod	23	SENT_182	[p13l1858t2404r2134b2482],
22	—	CD	NUMBER	—	num	21	SENT_182	[p13l1858t2404r2134b2482],
23	positive	JJ	O	positive	amod	24	SENT_182	[p13l10t2527r335b2627],
24	tumors	NNS	O	tumor	dobj	20	SENT_182	[p13l375t2543r702b2606],
25	.	.	O	.	_	0	SENT_182	[p13l375t2543r702b2606],

1	Of	IN	O	of	_	0	SENT_183	[p13l747t2526r867b2605],
2	these	DT	O	these	det	4	SENT_183	[p13l889t2527r1107b2605],
3	474	CD	NUMBER	474	num	4	SENT_183	[p13l1145t2532r1301b2605],
4	patients	NNS	O	patient	prep_of	9	SENT_183	[p13l1339t2527r1699b2627],
5	,	,	O	,	_	0	SENT_183	[p13l1339t2527r1699b2627],
6	329	CD	NUMBER	329	nsubjpass	9	SENT_183	[p13l1745t2532r1897b2605],
7	were	VBD	O	be	auxpass	9	SENT_183	[p13l1933t2553r2135b2606],
8	randomly	RB	O	randomly	advmod	9	SENT_183	[p13l11t2654r414b2755],
9	assigned	VBN	O	assign	_	0	SENT_183	[p13l431t2655r796b2755],
10	either	CC	O	either	preconj	9	SENT_183	[p13l819t2654r1058b2733],
11	to	TO	O	to	_	0	SENT_183	[p13l1077t2671r1155b2733],
12	combination	NN	O	combination	nn	13	SENT_183	[p13l1180t2655r1711b2733],
13	treatment	NN	O	treatment	prep_to	9	SENT_183	[p13l1734t2671r2141b2733],
14	with	IN	O	with	_	0	SENT_183	[p13l6t2782r195b2862],
15	cetuximab	NN	O	cetuximab	nn	18	SENT_183	[p13l223t2782r658b2862],
16	and	CC	O	and	_	0	SENT_183	[p13l687t2783r842b2861],
17	irinotecan	NN	O	irinotecan	nn	18	SENT_183	[p13l869t2783r1297b2861],
18	(	NN	O	(	prep_with	13	SENT_183	[p13l1330t2788r1512b2874],
19	218	CD	NUMBER	218	num	20	SENT_183	[p13l1330t2788r1512b2874],
20	patients	NNS	O	patient	dep	18	SENT_183	[p13l1540t2783r1906b2883],
21	)	CD	NUMBER	)	dep	20	SENT_183	[p13l1540t2783r1906b2883],
22	or	CC	O	or	_	0	SENT_183	[p13l1940t2808r2029b2861],
23	to	TO	O	to	_	0	SENT_183	[p13l2055t2799r2134b2861],
24	cetuximab	JJ	O	cetuximab	amod	26	SENT_183	[p13l11t2911r446b2990],
25	monotherapy	NN	O	monotherapy	nn	26	SENT_183	[p13l491t2911r1062b3011],
26	(	NN	O	(	prep_to	9	SENT_183	[p13l1105t2916r1289b3002],
27	111	CD	NUMBER	111	num	28	SENT_183	[p13l1105t2916r1289b3002],
28	patients	NNS	O	patient	dep	26	SENT_183	[p13l1331t2911r1726b3011],
29	)	CD	NUMBER	)	dep	28	SENT_183	[p13l1331t2911r1726b3011],
30	.	.	O	.	_	0	SENT_183	[p13l1331t2911r1726b3011],

1	Figure	NNP	O	Figure	nsubj	3	SENT_184	[p13l1774t2911r2043b3011],
2	1	CD	NUMBER	1	num	1	SENT_184	[p13l2091t2916r2135b2988],
3	shows	VBZ	O	show	_	0	SENT_184	[p13l12t3039r280b3118],
4	the	DT	O	the	det	5	SENT_184	[p13l308t3039r438b3117],
5	design	NN	O	design	dobj	3	SENT_184	[p13l465t3038r749b3139],
6	of	IN	O	of	_	0	SENT_184	[p13l775t3038r876b3117],
7	the	DT	O	the	det	8	SENT_184	[p13l883t3038r1014b3117],
8	trial	NN	O	trial	prep_of	5	SENT_184	[p13l1040t3039r1235b3117],
9	.	.	O	.	_	0	SENT_184	[p13l1040t3039r1235b3117],

1	Major	JJ	O	major	amod	3	SENT_185	[p13l1263t3039r1518b3139],
2	protocol	NN	O	protocol	nn	3	SENT_185	[p13l1539t3038r1904b3139],
3	deviations	NNS	O	deviation	nsubjpass	5	SENT_185	[p13l1930t3038r2133b3118, p13l10t3167r271b3245],
4	were	VBD	O	be	auxpass	5	SENT_185	[p13l296t3193r498b3246],
5	reported	VBN	O	report	_	0	SENT_185	[p13l524t3167r883b3267],
6	in	IN	O	in	_	0	SENT_185	[p13l909t3167r989b3244],
7	three	CD	NUMBER	three	num	8	SENT_185	[p13l1016t3167r1228b3245],
8	patients	NNS	O	patient	prep_in	5	SENT_185	[p13l1253t3167r1613b3267],
9	.	.	O	.	_	0	SENT_185	[p13l1253t3167r1613b3267],

1	One	CD	NUMBER	one	num	2	SENT_186	[p13l1645t3172r1818b3245],
2	patient	NN	O	patient	nsubj	6	SENT_186	[p13l1842t3167r2140b3267],
3	in	IN	O	in	_	0	SENT_186	[p13l10t3295r91b3372],
4	each	DT	O	each	det	5	SENT_186	[p13l134t3295r327b3373],
5	group	NN	O	group	prep_in	2	SENT_186	[p13l369t3320r624b3395],
6	had	VBD	O	have	_	0	SENT_186	[p13l668t3295r826b3373],
7	a	DT	O	a	det	8	SENT_186	[p13l867t3321r911b3373],
8	tumor	NN	O	tumor	dobj	6	SENT_186	[p13l952t3311r1219b3374],
9	with	IN	O	with	_	0	SENT_186	[p13l1254t3295r1446b3374],
10	no	DT	O	no	det	11	SENT_186	[p13l1488t3320r1596b3373],
11	evidence	NN	O	evidence	prep_with	8	SENT_186	[p13l1640t3294r2008b3374],
12	of	IN	O	of	_	0	SENT_186	[p13l2051t3294r2153b3373],
13	EGFR	NN	ORGANIZATION	egfr	nn	14	SENT_186	[p13l9t3428r266b3505],
14	expression	NN	O	expression	prep_of	11	SENT_186	[p13l279t3423r747b3522],
15	,	,	O	,	_	0	SENT_186	[p13l279t3423r747b3522],
16	and	CC	O	and	_	0	SENT_186	[p13l775t3423r929b3500],
17	one	CD	NUMBER	one	num	18	SENT_186	[p13l952t3447r1103b3500],
18	patient	NN	O	patient	nsubj	23	SENT_186	[p13l1124t3423r1418b3522],
19	in	IN	O	in	_	0	SENT_186	[p13l1434t3423r1514b3499],
20	the	DT	O	the	det	22	SENT_186	[p13l1537t3423r1664b3500],
21	monotherapy	JJ	O	monotherapy	amod	22	SENT_186	[p13l1688t3423r2135b3500, p13l10t3577r154b3651],
22	group	NN	O	group	prep_in	18	SENT_186	[p13l175t3576r426b3651],
23	had	VBD	O	have	conj_and	6	SENT_186	[p13l452t3551r607b3629],
24	no	DT	O	no	det	25	SENT_186	[p13l632t3576r738b3629],
25	evidence	NN	O	evidence	dobj	23	SENT_186	[p13l765t3551r1125b3630],
26	of	IN	O	of	_	0	SENT_186	[p13l1152t3550r1252b3629],
27	metastatic	JJ	O	metastatic	amod	29	SENT_186	[p13l1259t3551r1697b3629],
28	colorectal	JJ	O	colorectal	amod	29	SENT_186	[p13l1722t3551r2136b3629],
29	cancer	NN	O	cancer	prep_of	25	SENT_186	[p13l11t3704r286b3757],
30	at	IN	O	at	_	0	SENT_186	[p13l325t3695r404b3757],
31	the	DT	O	the	det	32	SENT_186	[p13l441t3679r570b3757],
32	time	NN	O	time	prep_at	23	SENT_186	[p13l613t3679r800b3757],
33	of	IN	O	of	_	0	SENT_186	[p13l842t3678r943b3757],
34	enrollment	NN	O	enrollment	prep_of	32	SENT_186	[p13l967t3679r1458b3757],
35	.	.	O	.	_	0	SENT_186	[p13l967t3679r1458b3757],

1	There	EX	O	there	expl	2	SENT_187	[p13l1502t3679r1747b3757],
2	were	VBD	O	be	dep	15	SENT_187	[p13l1784t3705r1986b3758],
3	no	DT	O	no	det	5	SENT_187	[p13l2028t3704r2134b3757],
4	major	JJ	O	major	amod	5	SENT_187	[p14l11t32r259b132],
5	imbalances	NNS	O	imbalance	nsubj	2	SENT_187	[p14l277t31r755b110],
6	between	IN	O	between	_	0	SENT_187	[p14l779t31r1129b111],
7	the	DT	O	the	det	9	SENT_187	[p14l1150t31r1279b110],
8	two	CD	NUMBER	two	num	9	SENT_187	[p14l1301t48r1454b111],
9	groups	NNS	O	group	prep_between	5	SENT_187	[p14l1476t57r1770b132],
10	in	IN	O	in	_	0	SENT_187	[p14l1793t32r1873b109],
11	terms	NNS	O	term	prep_in	9	SENT_187	[p14l1896t48r2133b110],
12	of	IN	O	of	_	0	SENT_187	[p14l11t159r112b238],
13	baseline	NN	O	baseline	nn	14	SENT_187	[p14l119t160r464b238],
14	characteristics	NNS	O	characteristic	prep_of	11	SENT_187	[p14l491t160r1095b238],
15	(	VBP	O	(	_	0	SENT_187	[p14l1127t160r1381b251],
16	Table	NNP	O	Table	dobj	15	SENT_187	[p14l1127t160r1381b251],
17	1	CD	NUMBER	1	num	16	SENT_187	[p14l1410t165r1512b251],
18	)	CD	NUMBER	)	nsubj	15	SENT_187	[p14l1410t165r1512b251],
19	.	.	O	.	_	0	SENT_187	[p14l1410t165r1512b251],

1	Nearly	RB	O	nearly	quantmod	2	SENT_188	[p14l1541t160r1820b260],
2	80	CD	PERCENT	80	num	3	SENT_188	[p14l1841t165r1940b238],
3	percent	NN	PERCENT	percent	nsubj	11	SENT_188	[p14l1965t186r2134b260, p14l11t304r191b366],
4	of	IN	O	of	_	0	SENT_188	[p14l210t287r310b366],
5	the	DT	O	the	det	6	SENT_188	[p14l315t287r444b366],
6	patients	NNS	O	patient	prep_of	3	SENT_188	[p14l466t288r801b388],
7	who	WP	O	who	nsubj	8	SENT_188	[p14l822t288r1005b367],
8	underwent	VBD	O	undergo	rcmod	6	SENT_188	[p14l1030t288r1489b367],
9	randomization	NN	O	randomization	dobj	8	SENT_188	[p14l1508t288r2135b366],
10	had	VBD	O	have	aux	11	SENT_188	[p14l11t416r167b494],
11	received	VBN	O	receive	_	0	SENT_188	[p14l210t416r558b495],
12	two	CD	NUMBER	two	num	16	SENT_188	[p14l602t432r756b495],
13	or	CC	O	or	_	0	SENT_188	[p14l801t441r891b494],
14	more	JJR	O	more	num	16	SENT_188	[p14l931t441r1154b494],
15	previous	JJ	O	previous	amod	16	SENT_188	[p14l1196t416r1561b516],
16	regimens	NNS	O	regimen	dobj	11	SENT_188	[p14l1606t416r2005b516],
17	of	IN	O	of	_	0	SENT_188	[p14l2051t415r2153b494],
18	treatment	NN	O	treatment	prep_of	16	SENT_188	[p14l11t560r432b622],
19	for	IN	O	for	_	0	SENT_188	[p14l457t543r580b622],
20	cancer	NN	O	cancer	prep_for	11	SENT_188	[p14l609t569r900b622],
21	.	.	O	.	_	0	SENT_188	[p14l609t569r900b622],

1	All	PDT	O	all	predet	3	SENT_189	[p14l933t544r1052b621],
2	the	DT	O	the	det	3	SENT_189	[p14l1082t544r1211b622],
3	patients	NNS	O	patient	nsubj	5	SENT_189	[p14l1241t544r1575b644],
4	had	VBD	O	have	aux	5	SENT_189	[p14l1608t543r1764b622],
5	received	VBN	O	receive	dep	15	SENT_189	[p14l1794t543r2135b623],
6	irinotecan	NN	O	irinotecan	dobj	5	SENT_189	[p14l10t672r461b767],
7	,	,	O	,	_	0	SENT_189	[p14l10t672r461b767],
8	and	CC	O	and	_	0	SENT_189	[p14l489t672r645b750],
9	206	CD	PERCENT	206	number	10	SENT_189	[p14l668t677r821b750],
10	(	CD	PERCENT	(	dobj	5	SENT_189	[p14l850t677r1065b763],
11	62.6	CD	PERCENT	62.6	num	13	SENT_189	[p14l850t677r1065b763],
12	percent	NN	PERCENT	percent	nn	13	SENT_189	[p14l1088t679r1433b772],
13	)	NN	O	)	nsubj	15	SENT_189	[p14l1088t679r1433b772],
14	had	VBD	O	have	aux	15	SENT_189	[p14l1461t672r1617b750],
15	received	VBN	O	receive	_	0	SENT_189	[p14l1640t672r1981b751],
16	oxaliplatin	NN	O	oxaliplatin	dobj	15	SENT_189	[p14l2005t697r2134b750, p14l10t799r379b900],
17	.	.	O	.	_	0	SENT_189	[p14l2005t697r2134b750, p14l10t799r379b900],

1	The	DT	O	the	det	4	SENT_190	[p14l136t928r298b1006],
2	overall	JJ	O	overall	amod	4	SENT_190	[p14l331t927r610b1007],
3	response	NN	O	response	nn	4	SENT_190	[p14l642t953r1021b1028],
4	rate	NN	O	rate	nsubj	5	SENT_190	[p14l1055t944r1211b1006],
5	(	VBD	O	(	_	0	SENT_190	[p14l1249t927r1408b1019],
6	the	DT	O	the	det	7	SENT_190	[p14l1249t927r1408b1019],
7	rate	NN	O	rate	dobj	5	SENT_190	[p14l1441t944r1597b1006],
8	of	IN	O	of	_	0	SENT_190	[p14l1632t927r1732b1006],
9	complete	JJ	O	complete	amod	10	SENT_190	[p14l1748t928r2135b1028],
10	response	NN	O	response	prep_of	7	SENT_190	[p14l11t1081r389b1156],
11	plus	CC	O	plus	_	0	SENT_190	[p14l410t1056r587b1156],
12	the	DT	O	the	det	13	SENT_190	[p14l610t1056r739b1134],
13	rate	NN	O	rate	conj_plus	7	SENT_190	[p14l761t1072r917b1134],
14	of	IN	O	of	_	0	SENT_190	[p14l939t1055r1040b1134],
15	partial	JJ	O	partial	amod	17	SENT_190	[p14l1041t1056r1312b1156],
16	response	NN	O	response	nn	17	SENT_190	[p14l1333t1063r1742b1156],
17	)	NN	O	)	prep_of	13	SENT_190	[p14l1333t1063r1742b1156],
18	in	IN	O	in	_	0	SENT_190	[p14l1767t1056r1849b1133],
19	the	DT	O	the	det	20	SENT_190	[p14l1870t1056r1999b1134],
20	intention	NN	O	intention	prep_in	5	SENT_190	[p14l2020t1056r2134b1133, p14l11t1184r678b1261],
21	—	CD	NUMBER	—	number	23	SENT_190	[p14l2020t1056r2134b1133, p14l11t1184r678b1261],
22	to	TO	O	to	dep	23	SENT_190	[p14l2020t1056r2134b1133, p14l11t1184r678b1261],
23	—	CD	NUMBER	—	num	25	SENT_190	[p14l2020t1056r2134b1133, p14l11t1184r678b1261],
24	treat	NN	O	treat	nn	25	SENT_190	[p14l2020t1056r2134b1133, p14l11t1184r678b1261],
25	population	NN	O	population	nsubj	28	SENT_190	[p14l708t1184r1182b1283],
26	was	VBD	O	be	cop	28	SENT_190	[p14l1214t1210r1377b1262],
27	22.9	CD	PERCENT	22.9	num	28	SENT_190	[p14l1416t1189r1601b1261],
28	percent	NN	PERCENT	percent	rcmod	20	SENT_190	[p14l1638t1199r1965b1283],
29	(	CD	PERCENT	(	number	30	SENT_190	[p14l2002t1189r2131b1274],
30	95	CD	PERCENT	95	dep	28	SENT_190	[p14l2002t1189r2131b1274],
31	percent	NN	PERCENT	percent	nn	33	SENT_190	[p14l9t1328r326b1412],
32	conﬁdence	NN	O	conﬁdence	nn	33	SENT_190	[p14l344t1311r801b1390],
33	interval	NN	O	interval	dep	30	SENT_190	[p14l822t1312r1154b1407],
34	,	,	O	,	_	0	SENT_190	[p14l822t1312r1154b1407],
35	17.5	CD	NUMBER	17.5	number	37	SENT_190	[p14l1185t1317r1360b1390],
36	to	TO	O	to	dep	37	SENT_190	[p14l1385t1328r1463b1390],
37	29.1	CD	PERCENT	29.1	num	39	SENT_190	[p14l1486t1317r1667b1390],
38	percent	NN	PERCENT	percent	nn	39	SENT_190	[p14l1688t1319r2029b1412],
39	)	NN	O	)	conj_and	28	SENT_190	[p14l1688t1319r2029b1412],
40	in	IN	O	in	_	0	SENT_190	[p14l2055t1312r2136b1389],
41	the	DT	O	the	det	45	SENT_190	[p14l11t1440r140b1518],
42	combination	NN	O	combination	nn	45	SENT_190	[p14l180t1439r1076b1540],
43	—	NN	O	—	nn	45	SENT_190	[p14l180t1439r1076b1540],
44	therapy	NN	O	therapy	nn	45	SENT_190	[p14l180t1439r1076b1540],
45	group	NN	O	group	prep_in	39	SENT_190	[p14l1111t1465r1362b1540],
46	and	CC	O	and	_	0	SENT_190	[p14l1403t1440r1558b1518],
47	10.8	CD	PERCENT	10.8	num	48	SENT_190	[p14l1602t1445r1779b1518],
48	percent	NN	PERCENT	percent	conj_and	28	SENT_190	[p14l1820t1456r2140b1540],
49	(	CD	PERCENT	(	number	50	SENT_190	[p14l15t1573r142b1659],
50	95	CD	PERCENT	95	dep	48	SENT_190	[p14l15t1573r142b1659],
51	percent	NN	PERCENT	percent	nn	53	SENT_190	[p14l165t1584r482b1668],
52	conﬁdence	NN	O	conﬁdence	nn	53	SENT_190	[p14l499t1567r956b1646],
53	interval	NN	O	interval	dep	50	SENT_190	[p14l977t1568r1309b1663],
54	,	,	O	,	_	0	SENT_190	[p14l977t1568r1309b1663],
55	5.7	CD	NUMBER	5.7	number	57	SENT_190	[p14l1339t1575r1464b1646],
56	to	TO	O	to	dep	57	SENT_190	[p14l1487t1584r1566b1646],
57	18.1	CD	PERCENT	18.1	num	59	SENT_190	[p14l1592t1573r1769b1646],
58	percent	NN	PERCENT	percent	nn	59	SENT_190	[p14l1789t1575r2130b1668],
59	)	NN	O	)	dep	67	SENT_190	[p14l1789t1575r2130b1668],
60	in	IN	O	in	_	0	SENT_190	[p14l10t1696r90b1773],
61	the	DT	O	the	det	63	SENT_190	[p14l113t1696r241b1774],
62	monotherapy	NN	O	monotherapy	nn	63	SENT_190	[p14l263t1696r829b1796],
63	group	NN	O	group	prep_in	59	SENT_190	[p14l846t1721r1095b1796],
64	(	CD	NUMBER	(	num	65	SENT_190	[p14l1123t1701r1541b1787],
65	P	NN	O	p	dep	67	SENT_190	[p14l1123t1701r1541b1787],
66	=	JJ	O	=	amod	67	SENT_190	[p14l1123t1701r1541b1787],
67	0.007	CD	NUMBER	0.007	dep	72	SENT_190	[p14l1123t1701r1541b1787],
68	)	CD	NUMBER	)	number	69	SENT_190	[p14l1123t1701r1541b1787],
69	(	CD	NUMBER	(	dep	67	SENT_190	[p14l1573t1696r1824b1787],
70	Table	NNP	O	Table	dep	69	SENT_190	[p14l1573t1696r1824b1787],
71	2	CD	NUMBER	2	num	72	SENT_190	[p14l1847t1701r1952b1787],
72	)	CD	NUMBER	)	dep	5	SENT_190	[p14l1847t1701r1952b1787],
73	.	.	O	.	_	0	SENT_190	[p14l1847t1701r1952b1787],

1	The	DT	O	the	det	3	SENT_191	[p14l1976t1696r2136b1774],
2	median	JJ	O	median	amod	3	SENT_191	[p14l11t1824r326b1902],
3	duration	NN	O	duration	nsubj	8	SENT_191	[p14l368t1823r729b1903],
4	of	IN	O	of	_	0	SENT_191	[p14l771t1823r871b1902],
5	response	NN	O	response	prep_of	3	SENT_191	[p14l894t1849r1273b1924],
6	was	VBD	O	be	cop	8	SENT_191	[p14l1310t1850r1472b1903],
7	5.7	CD	DURATION	5.7	num	8	SENT_191	[p14l1517t1831r1645b1902],
8	months	NNS	NUMBER	month	_	0	SENT_191	[p14l1687t1824r2011b1902],
9	in	IN	O	in	_	0	SENT_191	[p14l2054t1824r2135b1901],
10	the	DT	O	the	det	14	SENT_191	[p14l11t1952r140b2030],
11	combination	NN	O	combination	nn	14	SENT_191	[p14l167t1952r1064b2052],
12	—	NN	O	—	nn	14	SENT_191	[p14l167t1952r1064b2052],
13	therapy	NN	O	therapy	nn	14	SENT_191	[p14l167t1952r1064b2052],
14	group	NN	O	group	prep_in	8	SENT_191	[p14l1086t1977r1336b2052],
15	and	CC	O	and	_	0	SENT_191	[p14l1363t1952r1520b2030],
16	4.2	CD	DURATION	4.2	num	17	SENT_191	[p14l1544t1957r1675b2030],
17	months	NNS	NUMBER	month	conj_and	8	SENT_191	[p14l1702t1952r2027b2030],
18	in	IN	O	in	_	0	SENT_191	[p14l2054t1952r2135b2029],
19	the	DT	O	the	det	21	SENT_191	[p14l11t2080r139b2158],
20	monotherapy	JJ	O	monotherapy	amod	21	SENT_191	[p14l163t2080r729b2180],
21	group	NN	O	group	prep_in	17	SENT_191	[p14l748t2105r1022b2180],
22	.	.	O	.	_	0	SENT_191	[p14l748t2105r1022b2180],

1	Disease	NN	O	disease	nn	2	SENT_192	[p14l1050t2080r1369b2158],
2	control	NN	O	control	nsubj	3	SENT_192	[p14l1394t2080r1694b2158],
3	(	VBD	O	(	_	0	SENT_192	[p14l1722t2079r2135b2180],
4	complete	JJ	O	complete	amod	5	SENT_192	[p14l1722t2079r2135b2180],
5	response	NN	O	response	dobj	3	SENT_192	[p14l11t2233r389b2308],
6	plus	CC	O	plus	_	0	SENT_192	[p14l415t2207r591b2308],
7	partial	JJ	O	partial	amod	8	SENT_192	[p14l617t2208r889b2308],
8	response	NN	O	response	nsubjpass	14	SENT_192	[p14l914t2233r1293b2308],
9	plus	CC	O	plus	_	0	SENT_192	[p14l1318t2208r1494b2308],
10	stable	JJ	O	stable	amod	12	SENT_192	[p14l1524t2207r1770b2286],
11	disease	NN	O	disease	nn	12	SENT_192	[p14l1797t2208r2130b2299],
12	)	NN	O	)	nsubjpass	14	SENT_192	[p14l1797t2208r2130b2299],
13	was	VBD	O	be	auxpass	14	SENT_192	[p14l6t2362r170b2415],
14	achieved	VBN	O	achieve	rcmod	5	SENT_192	[p14l198t2335r569b2415],
15	in	IN	O	in	_	0	SENT_192	[p14l595t2336r677b2413],
16	55.5	CD	PERCENT	55.5	num	17	SENT_192	[p14l706t2343r887b2414],
17	percent	NN	PERCENT	percent	prep_in	14	SENT_192	[p14l917t2352r1244b2436],
18	of	IN	O	of	_	0	SENT_192	[p14l1266t2335r1367b2414],
19	patients	NNS	O	patient	prep_of	17	SENT_192	[p14l1375t2336r1717b2436],
20	receiving	VBG	O	receive	partmod	19	SENT_192	[p14l1746t2336r2138b2436],
21	combination	NN	O	combination	nn	22	SENT_192	[p14l11t2463r562b2542],
22	treatment	NN	O	treatment	dobj	20	SENT_192	[p14l589t2480r1013b2542],
23	and	CC	O	and	_	0	SENT_192	[p14l1034t2464r1192b2542],
24	in	IN	O	in	_	0	SENT_192	[p14l1218t2464r1300b2541],
25	32.4	CD	PERCENT	32.4	num	26	SENT_192	[p14l1328t2469r1514b2542],
26	percent	NN	PERCENT	percent	prep_in	14	SENT_192	[p14l1540t2480r1867b2564],
27	of	IN	O	of	_	0	SENT_192	[p14l1890t2463r1991b2542],
28	pa	NN	O	pa	nn	30	SENT_192	[p14l1998t2490r2133b2564],
29	—	NN	O	—	nn	30	SENT_192	[p14l1998t2490r2133b2564],
30	tients	NNS	O	tient	prep_of	26	SENT_192	[p14l11t2593r246b2671],
31	treated	VBN	O	treat	partmod	30	SENT_192	[p14l303t2592r597b2671],
32	with	IN	O	with	_	0	SENT_192	[p14l647t2593r839b2672],
33	cetuximab	NN	O	cetuximab	prep_with	31	SENT_192	[p14l893t2593r1336b2672],
34	alone	RB	O	alone	advmod	33	SENT_192	[p14l1391t2593r1624b2671],
35	(	RB	O	(	advmod	36	SENT_192	[p14l1682t2598r2129b2684],
36	P	NN	O	p	rcmod	33	SENT_192	[p14l1682t2598r2129b2684],
37	<	JJR	O	<	dep	36	SENT_192	[p14l1682t2598r2129b2684],
38	0.001	CD	NUMBER	0.001	num	39	SENT_192	[p14l1682t2598r2129b2684],
39	)	NN	O	)	dep	37	SENT_192	[p14l1682t2598r2129b2684],
40	.	.	O	.	_	0	SENT_192	[p14l1682t2598r2129b2684],

1	When	WRB	O	when	advmod	21	SENT_193	[p14l7t2720r264b2799],
2	the	DT	O	the	det	5	SENT_193	[p14l295t2721r424b2799],
3	more	RBR	O	more	advmod	4	SENT_193	[p14l455t2746r674b2799],
4	stringent	JJ	O	stringent	amod	5	SENT_193	[p14l706t2721r1091b2821],
5	deﬁnition	NN	O	deﬁnition	nsubjpass	21	SENT_193	[p14l1116t2720r1529b2799],
6	for	IN	O	for	_	0	SENT_193	[p14l1558t2720r1682b2799],
7	irinotecan	JJ	O	irinotecan	amod	10	SENT_193	[p14l1708t2721r2135b2799],
8	resistance	NN	O	resistance	nn	10	SENT_193	[p14l11t2849r426b2927],
9	(	NN	O	(	nn	10	SENT_193	[p14l451t2849r978b2949],
10	progression	NN	O	progression	conj_or	10	SENT_193	[p14l451t2849r978b2949],
11	during	IN	O	during	_	0	SENT_193	[p14l998t2849r1278b2949],
12	or	CC	O	or	_	0	SENT_193	[p14l1295t2874r1384b2927],
13	within	IN	O	within	_	0	SENT_193	[p14l1395t2849r1666b2928],
14	one	CD	DURATION	one	num	15	SENT_193	[p14l1686t2874r1836b2927],
15	month	NN	NUMBER	month	prep_within	10	SENT_193	[p14l1856t2849r2135b2927],
16	after	IN	O	after	_	0	SENT_193	[p14l10t2976r204b3055],
17	irinotecan	NN	O	irinotecan	nn	19	SENT_193	[p14l225t2977r653b3055],
18	therapy	NN	O	therapy	nn	19	SENT_193	[p14l678t2977r1020b3077],
19	)	NN	O	)	prep_after	15	SENT_193	[p14l678t2977r1020b3077],
20	was	VBD	O	be	auxpass	21	SENT_193	[p14l1047t3003r1207b3056],
21	applied	VBN	O	apply	advcl	28	SENT_193	[p14l1234t2977r1570b3077],
22	,	,	O	,	_	0	SENT_193	[p14l1234t2977r1570b3077],
23	the	DT	O	the	det	25	SENT_193	[p14l1601t2977r1730b3055],
24	response	NN	O	response	nn	25	SENT_193	[p14l1756t3002r2135b3077],
25	rates	NNS	O	rate	nsubj	28	SENT_193	[p14l11t3121r209b3183],
26	were	VBD	O	be	cop	28	SENT_193	[p14l235t3131r437b3184],
27	25.2	CD	PERCENT	25.2	num	28	SENT_193	[p14l466t3110r649b3183],
28	percent	NN	PERCENT	percent	_	0	SENT_193	[p14l677t3121r997b3205],
29	(	CD	PERCENT	(	number	30	SENT_193	[p14l1026t3110r1153b3196],
30	95	CD	PERCENT	95	dep	28	SENT_193	[p14l1026t3110r1153b3196],
31	percent	NN	PERCENT	percent	nn	33	SENT_193	[p14l1184t3121r1505b3205],
32	conﬁdence	NN	O	conﬁdence	nn	33	SENT_193	[p14l1530t3104r1991b3183],
33	interval	NN	O	interval	dep	30	SENT_193	[p14l2020t3105r2134b3182, p14l11t3233r262b3328],
34	,	,	O	,	_	0	SENT_193	[p14l2020t3105r2134b3182, p14l11t3233r262b3328],
35	18.1	CD	NUMBER	18.1	number	37	SENT_193	[p14l306t3238r485b3311],
36	to	TO	O	to	dep	37	SENT_193	[p14l522t3249r601b3311],
37	33.4	CD	PERCENT	33.4	num	39	SENT_193	[p14l638t3238r821b3311],
38	percent	NN	PERCENT	percent	nn	39	SENT_193	[p14l855t3240r1200b3333],
39	)	NN	O	)	conj_and	28	SENT_193	[p14l855t3240r1200b3333],
40	and	CC	O	and	_	0	SENT_193	[p14l1240t3233r1396b3311],
41	14.1	CD	PERCENT	14.1	num	42	SENT_193	[p14l1434t3238r1614b3311],
42	percent	NN	PERCENT	percent	conj_and	39	SENT_193	[p14l1648t3249r1969b3333],
43	(	CD	PERCENT	(	number	44	SENT_193	[p14l2004t3238r2131b3324],
44	95	CD	PERCENT	95	dep	42	SENT_193	[p14l2004t3238r2131b3324],
45	percent	NN	PERCENT	percent	nn	47	SENT_193	[p14l9t3377r326b3461],
46	conﬁdence	NN	O	conﬁdence	nn	47	SENT_193	[p14l352t3360r806b3439],
47	interval	NN	O	interval	dep	44	SENT_193	[p14l836t3360r1166b3456],
48	,	,	O	,	_	0	SENT_193	[p14l836t3360r1166b3456],
49	7.0	CD	NUMBER	7.0	number	51	SENT_193	[p14l1203t3366r1330b3439],
50	to	TO	O	to	dep	51	SENT_193	[p14l1362t3377r1440b3439],
51	24.4	CD	PERCENT	24.4	num	53	SENT_193	[p14l1472t3366r1653b3439],
52	percent	NN	PERCENT	percent	nn	53	SENT_193	[p14l1682t3368r2020b3461],
53	)	NN	O	)	conj_and	28	SENT_193	[p14l1682t3368r2020b3461],
54	in	IN	O	in	_	0	SENT_193	[p14l2056t3361r2136b3438],
55	the	DT	O	the	det	58	SENT_193	[p14l11t3489r138b3567],
56	combination	NN	O	combination	nn	58	SENT_193	[p14l162t3489r1043b3589],
57	—	NN	O	—	nn	58	SENT_193	[p14l162t3489r1043b3589],
58	therapy	NN	O	therapy	prep_in	53	SENT_193	[p14l162t3489r1043b3589],
59	and	CC	O	and	_	0	SENT_193	[p14l1060t3488r1214b3567],
60	monotherapy	NN	O	monotherapy	nn	61	SENT_193	[p14l1237t3489r1799b3589],
61	groups	NNS	O	group	conj_and	28	SENT_193	[p14l1816t3514r2130b3589],
62	,	,	O	,	_	0	SENT_193	[p14l1816t3514r2130b3589],
63	respectively	RB	O	respectively	advmod	61	SENT_193	[p14l11t3617r503b3717],
64	(	CD	NUMBER	(	num	65	SENT_193	[p14l530t3622r933b3712],
65	P	NN	O	p	dep	61	SENT_193	[p14l530t3622r933b3712],
66	=	JJ	O	=	amod	68	SENT_193	[p14l530t3622r933b3712],
67	0.07	CD	NUMBER	0.07	tmod	66	SENT_193	[p14l530t3622r933b3712],
68	)	NN	O	)	dep	65	SENT_193	[p14l530t3622r933b3712],
69	,	,	O	,	_	0	SENT_193	[p14l530t3622r933b3712],
70	although	IN	O	although	_	0	SENT_193	[p14l966t3617r1347b3717],
71	the	DT	O	the	det	72	SENT_193	[p14l1375t3617r1504b3695],
72	number	NN	O	number	prep_although	28	SENT_193	[p14l1531t3617r1868b3696],
73	of	IN	O	of	_	0	SENT_193	[p14l1893t3616r1993b3695],
74	patients	NNS	O	patient	prep_of	72	SENT_193	[p14l2002t3643r2134b3717, p15l11t21r241b99],

1	in	IN	O	in	_	0	SENT_194	[p15l267t21r348b98],
2	this	DT	O	this	det	4	SENT_194	[p15l374t21r526b99],
3	comparison	NN	O	comparison	nn	4	SENT_194	[p15l554t21r1059b121],
4	(	NN	O	(	prep_in	8	SENT_194	[p15l1089t26r1302b112],
5	206	CD	NUMBER	206	num	6	SENT_194	[p15l1089t26r1302b112],
6	)	NN	O	)	nsubj	8	SENT_194	[p15l1089t26r1302b112],
7	was	VBD	O	be	cop	8	SENT_194	[p15l1328t47r1489b100],
8	small	JJ	O	small	_	0	SENT_194	[p15l1518t21r1768b99],
9	.	.	O	.	_	0	SENT_194	[p15l1518t21r1768b99],

1	Of	IN	O	of	_	0	SENT_195	[p15l140t148r260b227],
2	special	JJ	O	special	amod	3	SENT_195	[p15l265t149r552b249],
3	interest	NN	O	interest	prep_of	5	SENT_195	[p15l572t149r894b227],
4	is	VBZ	O	be	cop	5	SENT_195	[p15l910t149r975b227],
5	the	DT	O	the	_	0	SENT_195	[p15l999t149r1129b227],
6	ﬁnding	VBG	O	ﬁnding	amod	5	SENT_195	[p15l1150t148r1462b249],
7	that	IN	O	that	complm	14	SENT_195	[p15l1481t149r1647b227],
8	cetuXimab	NN	O	cetuximab	nn	9	SENT_195	[p15l1665t148r2134b228],
9	—	NN	O	—	nsubj	14	SENT_195	[p15l1665t148r2134b228],
10	based	VBN	O	base	partmod	9	SENT_195	[p15l11t276r250b355],
11	therapy	NN	O	therapy	dobj	10	SENT_195	[p15l269t277r582b377],
12	Was	VBD	O	be	cop	14	SENT_195	[p15l592t303r752b356],
13	similarly	RB	O	similarly	advmod	14	SENT_195	[p15l775t277r1135b377],
14	effective	JJ	O	effective	dep	5	SENT_195	[p15l1151t276r1489b356],
15	in	IN	O	in	_	0	SENT_195	[p15l1509t277r1589b354],
16	patients	NNS	O	patient	prep_in	14	SENT_195	[p15l1607t277r1936b377],
17	Who	WP	O	who	nsubj	20	SENT_195	[p15l1953t276r2135b356],
18	had	VBD	O	have	aux	20	SENT_195	[p15l11t405r165b483],
19	previously	RB	DATE	previously	advmod	20	SENT_195	[p15l203t405r638b505],
20	received	VBN	O	receive	rcmod	16	SENT_195	[p15l673t405r1015b484],
21	oxaliplatin	NN	O	oxaliplatin	dobj	20	SENT_195	[p15l1056t404r1502b505],
22	in	IN	O	in	_	0	SENT_195	[p15l1541t405r1623b482],
23	addition	NN	O	addition	prep_in	21	SENT_195	[p15l1662t404r2014b483],
24	to	TO	O	to	prep	20	SENT_195	[p15l2055t421r2134b483],

1	Table	NNP	O	Table	_	0	SENT_196	[p15l61t708r197b756],
2	2	CD	NUMBER	2	dep	1	SENT_196	[p15l214t712r258b756],
3	.	.	O	.	_	0	SENT_196	[p15l214t712r258b756],

1	Rates	NNS	O	rate	_	0	SENT_197	[p15l281t712r420b756],
2	of	IN	O	of	_	0	SENT_197	[p15l438t707r499b756],
3	Radiologic	NNP	O	Radiologic	nn	4	SENT_197	[p15l509t708r780b771],
4	Response	NNP	O	Response	prep_of	1	SENT_197	[p15l801t710r1100b770],
5	.	.	O	.	_	0	SENT_197	[p15l801t710r1100b770],

1	*	NN	O	*	_	0	SENT_198	[p15l801t710r1100b770],

1	Cetuximab	NNP	O	Cetuximab	_	0	SENT_199	[p15l1208t838r1489b886],
2	plus	CC	O	plus	advmod	1	SENT_199	[p15l1295t910r1403b973],

1	Subgroup	NN	O	subgroup	nn	4	SENT_200	[p15l62t982r318b1045],
2	and	CC	O	and	_	0	SENT_200	[p15l336t982r431b1031],
3	Variable	JJ	O	variable	nn	4	SENT_200	[p15l449t982r658b1031],
4	lrinotecan	NN	O	lrinotecan	_	0	SENT_200	[p15l1219t983r1479b1031],
5	Cetuximab	NNP	O	Cetuximab	dep	4	SENT_200	[p15l1561t982r1843b1031],
6	P	NN	O	p	nn	7	SENT_200	[p15l1906t987r1936b1030],
7	Value	NN	O	value	dep	4	SENT_200	[p15l1952t982r2095b1031],

1	Intention-to-treat	JJ	O	intention-to-treat	amod	3	SENT_201	[p15l66t1103r514b1151],
2	population	NN	O	population	nn	3	SENT_201	[p15l532t1102r811b1165],
3	No.	NN	O	no.	dep	9	SENT_201	[p15l67t1205r155b1248],
4	of	IN	O	of	_	0	SENT_201	[p15l177t1200r234b1248],
5	patients	NNS	O	patient	prep_of	3	SENT_201	[p15l247t1205r453b1263],
6	218	CD	NUMBER	218	num	7	SENT_201	[p15l1303t1203r1394b1249],
7	Response	NN	O	response	dep	9	SENT_201	[p15l67t1303r317b1361],
8	—	CD	NUMBER	—	num	9	SENT_201	[p15l334t1328r399b1332],
9	no.	NN	O	no.	dep	12	SENT_201	[p15l419t1315r495b1346],
10	(	CD	PERCENT	(	num	11	SENT_201	[p15l522t1301r607b1361],
11	%	NN	PERCENT	%	dep	9	SENT_201	[p15l522t1301r607b1361],
12	)	CD	NUMBER	)	_	0	SENT_201	[p15l522t1301r607b1361],

1	Complete	JJ	O	complete	amod	4	SENT_202	[p15l159t1396r411b1459],
2	response	NN	O	response	nn	4	SENT_202	[p15l433t1413r669b1459],
3	o	NN	O	o	nn	4	SENT_202	[p15l1263t1399r1292b1444],
4	o	NN	O	o	dep	18	SENT_202	[p15l1616t1399r1645b1444],
5	Partial	JJ	O	partial	amod	6	SENT_202	[p15l163t1494r321b1542],
6	response	NN	O	response	dep	4	SENT_202	[p15l346t1511r582b1557],
7	50	CD	NUMBER	50	num	14	SENT_202	[p15l1232t1497r1292b1542],
8	22.9	CD	NUMBER	22.9	number	9	SENT_202	[p15l1334t1498r1441b1542],
9	12	CD	NUMBER	12	num	10	SENT_202	[p15l1589t1498r1644b1542],
10	(	NN	O	(	npadvmod	13	SENT_202	[p15l1670t1497r1813b1557],
11	10.8	CD	NUMBER	10.8	number	12	SENT_202	[p15l1670t1497r1813b1557],
12	)	CD	NUMBER	)	num	10	SENT_202	[p15l1670t1497r1813b1557],
13	Stable	JJ	O	stable	amod	14	SENT_202	[p15l160t1592r318b1640],
14	disease	NN	O	disease	dep	6	SENT_202	[p15l338t1592r532b1640],
15	71	CD	NUMBER	71	number	16	SENT_202	[p15l1235t1596r1289b1640],
16	32.6	CD	NUMBER	32.6	num	14	SENT_202	[p15l1335t1596r1442b1640],
17	24	CD	NUMBER	24	dep	18	SENT_202	[p15l1585t1596r1644b1639],
18	(	NN	O	(	dep	26	SENT_202	[p15l1669t1596r1813b1655],
19	21.6	CD	NUMBER	21.6	number	20	SENT_202	[p15l1669t1596r1813b1655],
20	)	CD	NUMBER	)	num	22	SENT_202	[p15l1669t1596r1813b1655],
21	Progressive	JJ	O	progressive	amod	22	SENT_202	[p15l163t1694r463b1753],
22	disease	NN	O	disease	dep	18	SENT_202	[p15l482t1690r676b1738],
23	68	CD	NUMBER	68	number	24	SENT_202	[p15l1233t1693r1291b1738],
24	31.2	CD	NUMBER	31.2	amod	22	SENT_202	[p15l1335t1694r1441b1738],
25	59	CD	NUMBER	59	num	26	SENT_202	[p15l1586t1694r1644b1738],
26	(	NN	O	(	_	0	SENT_202	[p15l1670t1694r1813b1753],
27	53.2	CD	NUMBER	53.2	number	28	SENT_202	[p15l1670t1694r1813b1753],
28	)	CD	NUMBER	)	nsubjpass	32	SENT_202	[p15l1670t1694r1813b1753],
29	Could	MD	O	could	aux	32	SENT_202	[p15l159t1788r308b1836],
30	not	RB	O	not	neg	32	SENT_202	[p15l333t1797r416b1836],
31	be	VB	O	be	auxpass	32	SENT_202	[p15l436t1788r494b1836],
32	evaluated	VBN	O	evaluate	rcmod	26	SENT_202	[p15l513t1788r760b1836],
33	29	CD	NUMBER	29	number	34	SENT_202	[p15l1232t1792r1291b1836],
34	13.3	CD	NUMBER	13.3	dobj	32	SENT_202	[p15l1338t1792r1439b1836],
35	16	CD	NUMBER	16	num	36	SENT_202	[p15l1589t1792r1644b1836],
36	(	NN	O	(	dep	34	SENT_202	[p15l1669t1792r1813b1851],
37	14.4	CD	NUMBER	14.4	number	38	SENT_202	[p15l1669t1792r1813b1851],
38	)	CD	NUMBER	)	num	40	SENT_202	[p15l1669t1792r1813b1851],
39	Overall	JJ	O	overall	amod	40	SENT_202	[p15l159t1885r342b1934],
40	response'i	NNS	O	response'us	nsubj	41	SENT_202	[p15l367t1890r639b1949],
41	‘	VBP	O	‘	rcmod	34	SENT_202	[p15l367t1890r639b1949],
42	50	CD	NUMBER	50	number	43	SENT_202	[p15l1233t1889r1292b1934],
43	(	CD	NUMBER	(	num	45	SENT_202	[p15l1317t1890r1441b1949],
44	22.9	CD	NUMBER	22.9	number	45	SENT_202	[p15l1317t1890r1441b1949],
45	12	CD	NUMBER	12	dobj	41	SENT_202	[p15l1589t1890r1644b1933],
46	(	NN	O	(	dep	45	SENT_202	[p15l1669t1889r1794b1949],
47	10.8	CD	NUMBER	10.8	number	48	SENT_202	[p15l1669t1889r1794b1949],
48	0.007	CD	NUMBER	0.007	dep	46	SENT_202	[p15l1946t1889r2086b1934],

1	Disease	NN	O	disease	nn	2	SENT_203	[p15l67t2060r268b2104],
2	control	NN	O	control	_	0	SENT_203	[p15l287t2056r507b2119],
3	:	:	O	:	_	0	SENT_203	[p15l287t2056r507b2119],
4	i	FW	O	i	dep	2	SENT_203	[p15l287t2056r507b2119],
5	:	:	O	:	_	0	SENT_203	[p15l287t2056r507b2119],
6	121	CD	NUMBER	121	number	7	SENT_203	[p15l1203t2060r1288b2103],
7	(	CD	NUMBER	(	dep	4	SENT_203	[p15l1316t2060r1439b2119],
8	55.5	CD	NUMBER	55.5	dep	12	SENT_203	[p15l1316t2060r1439b2119],
9	36	CD	NUMBER	36	dep	8	SENT_203	[p15l1586t2060r1644b2104],
10	(	NN	O	(	dep	12	SENT_203	[p15l1669t2060r1795b2119],
11	32.4	CD	NUMBER	32.4	num	10	SENT_203	[p15l1669t2060r1795b2119],
12	<	JJR	O	<	dep	4	SENT_203	[p15l1911t2059r2084b2104],
13	0.001	CD	NUMBER	0.001	dep	12	SENT_203	[p15l1911t2059r2084b2104],

1	[	NN	O	[	_	0	SENT_204	[p15l1196t2131r1497b2191],
2	48.6	CD	NUMBER	48.6	num	1	SENT_204	[p15l1196t2131r1497b2191],
3	—	CD	NUMBER	—	number	4	SENT_204	[p15l1196t2131r1497b2191],
4	62.2	CD	NUMBER	62.2	dep	1	SENT_204	[p15l1196t2131r1497b2191],
5	]	NN	O	]	dep	4	SENT_204	[p15l1196t2131r1497b2191],
6	)	CD	NUMBER	)	num	5	SENT_204	[p15l1196t2131r1497b2191],
7	[	CD	NUMBER	[	number	8	SENT_204	[p15l1550t2131r1850b2191],
8	23.9	CD	NUMBER	23.9	dep	1	SENT_204	[p15l1550t2131r1850b2191],
9	—	NN	O	—	dep	8	SENT_204	[p15l1550t2131r1850b2191],
10	42	CD	NUMBER	42	num	9	SENT_204	[p15l1550t2131r1850b2191],
11	.	.	O	.	_	0	SENT_204	[p15l1550t2131r1850b2191],

1	o	NN	O	o	_	0	SENT_205	[p15l1550t2131r1850b2191],
2	]	CD	NUMBER	]	num	3	SENT_205	[p15l1550t2131r1850b2191],
3	)	NN	O	)	dep	1	SENT_205	[p15l1550t2131r1850b2191],

1	Subgroup	NN	O	subgroup	_	0	SENT_206	[p15l62t2242r313b2305],
2	with	IN	O	with	dep	1	SENT_206	[p15l329t2242r439b2290],
3	progression	NN	O	progression	pobj	2	SENT_206	[p15l460t2243r761b2305],
4	during	IN	O	during	prep	2	SENT_206	[p15l780t2242r949b2305],
5	or	CC	O	or	_	0	SENT_206	[p15l964t2258r1018b2290],
6	within	IN	O	within	prep	2	SENT_206	[p15l1031t2242r1190b2290],

1	4	CD	DURATION	4	num	2	SENT_207	[p15l253t2319r284b2361],
2	wk	NN	DURATION	wk	_	0	SENT_207	[p15l299t2314r373b2361],
3	after	IN	O	after	dep	2	SENT_207	[p15l389t2313r505b2362],
4	prestudy	JJ	O	prestudy	amod	5	SENT_207	[p15l522t2314r745b2377],
5	irinotecan	NN	O	irinotecan	pobj	3	SENT_207	[p15l763t2315r1015b2362],

1	No.	NN	O	no.	dep	10	SENT_208	[p15l67t2416r155b2460],
2	of	IN	O	of	_	0	SENT_208	[p15l177t2411r234b2460],
3	patients	NNS	O	patient	prep_of	1	SENT_208	[p15l247t2417r453b2475],
4	135	CD	NUMBER	135	number	5	SENT_208	[p15l1306t2416r1391b2460],
5	71	CD	NUMBER	71	dep	6	SENT_208	[p15l1691t2416r1745b2460],
6	Response	NN	O	response	dep	3	SENT_208	[p15l67t2514r317b2573],
7	—	CD	NUMBER	—	num	8	SENT_208	[p15l334t2540r399b2544],
8	no.	NN	O	no.	dep	10	SENT_208	[p15l419t2527r495b2558],
9	(	CD	PERCENT	(	num	10	SENT_208	[p15l522t2512r607b2573],
10	%	NN	PERCENT	%	dep	18	SENT_208	[p15l522t2512r607b2573],
11	)	CD	NUMBER	)	num	13	SENT_208	[p15l522t2512r607b2573],
12	34	CD	NUMBER	34	num	13	SENT_208	[p15l1233t2514r1291b2558],
13	(	NN	O	(	dep	10	SENT_208	[p15l1317t2514r1441b2573],
14	25.2	CD	NUMBER	25.2	number	15	SENT_208	[p15l1317t2514r1441b2573],
15	10	CD	NUMBER	10	num	16	SENT_208	[p15l1589t2513r1645b2558],
16	(	NN	O	(	dep	13	SENT_208	[p15l1669t2514r1792b2573],
17	14.1	CD	NUMBER	14.1	num	18	SENT_208	[p15l1669t2514r1792b2573],
18	0.07	CD	NUMBER	0.07	_	0	SENT_208	[p15l1944t2513r2053b2558],

1	Subgroup	NN	O	subgroup	dep	15	SENT_209	[p15l62t2696r313b2759],
2	with	IN	O	with	_	0	SENT_209	[p15l329t2696r439b2744],
3	prior	JJ	O	prior	amod	6	SENT_209	[p15l460t2697r581b2758],
4	oxaliplatin	NN	O	oxaliplatin	nn	6	SENT_209	[p15l595t2696r859b2758],
5	therapy	NN	O	therapy	nn	6	SENT_209	[p15l877t2696r1072b2759],
6	No.	NN	O	no.	prep_with	1	SENT_209	[p15l67t2798r155b2842],
7	of	IN	O	of	_	0	SENT_209	[p15l177t2793r234b2842],
8	patients	NNS	O	patient	prep_of	6	SENT_209	[p15l247t2798r453b2857],
9	135	CD	NUMBER	135	number	10	SENT_209	[p15l1306t2798r1391b2842],
10	71	CD	NUMBER	71	dep	11	SENT_209	[p15l1691t2798r1745b2842],
11	Response	NN	O	response	dep	8	SENT_209	[p15l67t2896r317b2955],
12	—	CD	NUMBER	—	num	13	SENT_209	[p15l334t2922r399b2926],
13	no.	NN	O	no.	dep	15	SENT_209	[p15l419t2909r495b2940],
14	(	CD	PERCENT	(	num	15	SENT_209	[p15l522t2894r607b2955],
15	%	NN	PERCENT	%	dep	23	SENT_209	[p15l522t2894r607b2955],
16	)	CD	NUMBER	)	num	18	SENT_209	[p15l522t2894r607b2955],
17	30	CD	NUMBER	30	num	18	SENT_209	[p15l1233t2895r1292b2940],
18	(	NN	O	(	dep	15	SENT_209	[p15l1317t2896r1441b2955],
19	22.2	CD	NUMBER	22.2	number	20	SENT_209	[p15l1317t2896r1441b2955],
20	6	CD	NUMBER	6	num	21	SENT_209	[p15l1646t2896r1672b2940],
21	(	NN	O	(	dep	18	SENT_209	[p15l1697t2895r1787b2955],
22	8.5	CD	NUMBER	8.5	num	23	SENT_209	[p15l1697t2895r1787b2955],
23	0.01	CD	NUMBER	0.01	_	0	SENT_209	[p15l1944t2895r2050b2940],

1	[	NN	O	[	nn	2	SENT_210	[p15l1196t2967r1497b3027],
2	l5	NN	O	l5	_	0	SENT_210	[p15l1196t2967r1497b3027],
3	.5	CD	NUMBER	.5	number	4	SENT_210	[p15l1196t2967r1497b3027],
4	—	CD	NUMBER	—	dep	2	SENT_210	[p15l1196t2967r1497b3027],
5	30.2	CD	NUMBER	30.2	number	6	SENT_210	[p15l1196t2967r1497b3027],
6	]	CD	NUMBER	]	num	7	SENT_210	[p15l1196t2967r1497b3027],
7	)	NN	O	)	dep	2	SENT_210	[p15l1196t2967r1497b3027],
8	[	CD	NUMBER	[	number	9	SENT_210	[p15l1582t2968r1850b3027],
9	3.2	CD	NUMBER	3.2	num	10	SENT_210	[p15l1582t2968r1850b3027],
10	—	NN	O	—	dep	7	SENT_210	[p15l1582t2968r1850b3027],
11	17.5	CD	NUMBER	17.5	number	12	SENT_210	[p15l1582t2968r1850b3027],
12	]	CD	NUMBER	]	num	13	SENT_210	[p15l1582t2968r1850b3027],
13	)	NN	O	)	dep	10	SENT_210	[p15l1582t2968r1850b3027],

1	7	CD	NUMBER	7	num	3	SENT_211	[p15l10t3142r38b3170],
2	"	``	O	"	punct	3	SENT_211	[p15l10t3142r38b3170],
3	Values	NNS	O	value	nsubj	10	SENT_211	[p15l57t3137r225b3186],
4	in	IN	O	in	_	0	SENT_211	[p15l248t3142r289b3185],
5	brackets	NNS	O	bracket	prep_in	3	SENT_211	[p15l314t3137r528b3186],
6	are	VBP	O	be	cop	10	SENT_211	[p15l550t3155r627b3186],
7	95	CD	PERCENT	95	num	10	SENT_211	[p15l647t3142r703b3186],
8	percent	NN	PERCENT	percent	nn	10	SENT_211	[p15l728t3147r922b3200],
9	confidence	NN	O	confidence	nn	10	SENT_211	[p15l940t3137r1226b3186],
10	intervals	NNS	O	interval	_	0	SENT_211	[p15l1247t3137r1481b3186],
11	.	.	O	.	_	0	SENT_211	[p15l1247t3137r1481b3186],

1	1	CD	NUMBER	1	num	2	SENT_212	[p15l12t3215r41b3274],
2	‘	CD	NUMBER	‘	nsubj	13	SENT_212	[p15l12t3215r41b3274],
3	The	DT	O	the	det	6	SENT_212	[p15l56t3210r153b3259],
4	overall	JJ	O	overall	amod	6	SENT_212	[p15l172t3210r340b3259],
5	response	NN	O	response	nn	6	SENT_212	[p15l364t3227r601b3273],
6	rate	NN	O	rate	dep	2	SENT_212	[p15l622t3219r717b3259],
7	is	VBZ	O	be	cop	13	SENT_212	[p15l738t3215r774b3259],
8	the	DT	O	the	det	13	SENT_212	[p15l793t3210r874b3259],
9	sum	NN	O	sum	nn	13	SENT_212	[p15l894t3227r1003b3259],
10	ofthe	NN	O	ofthe	nn	13	SENT_212	[p15l1025t3210r1171b3259],
11	rate	NN	O	rate	nn	13	SENT_212	[p15l1192t3219r1287b3259],
12	ofcomplete	NN	O	ofcomplete	nn	13	SENT_212	[p15l1306t3210r1615b3273],
13	response	NN	O	response	_	0	SENT_212	[p15l1636t3227r1873b3273],
14	and	CC	O	and	_	0	SENT_212	[p15l1892t3210r1984b3259],
15	the	DT	O	the	det	16	SENT_212	[p15l2003t3210r2085b3259],
16	rate	NN	O	rate	conj_and	13	SENT_212	[p15l61t3292r156b3332],
17	of	IN	O	of	_	0	SENT_212	[p15l176t3283r233b3332],
18	partial	JJ	O	partial	amod	19	SENT_212	[p15l246t3283r404b3346],
19	response	NN	O	response	prep_of	16	SENT_212	[p15l430t3300r679b3346],
20	.	.	O	.	_	0	SENT_212	[p15l430t3300r679b3346],

1	:	:	O	:	_	0	SENT_213	[p15l12t3361r41b3420],
2	i	FW	O	i	nsubj	12	SENT_213	[p15l12t3361r41b3420],
3	:	:	O	:	_	0	SENT_213	[p15l12t3361r41b3420],
4	The	DT	O	the	det	7	SENT_213	[p15l56t3356r153b3405],
5	rate	NN	O	rate	nn	7	SENT_213	[p15l175t3365r270b3405],
6	ofdisease	NN	O	ofdisease	nn	7	SENT_213	[p15l290t3356r551b3405],
7	control	NN	O	control	dep	2	SENT_213	[p15l571t3356r752b3405],
8	is	VBZ	O	be	cop	12	SENT_213	[p15l776t3361r813b3405],
9	the	DT	O	the	det	12	SENT_213	[p15l832t3356r914b3405],
10	sum	NN	O	sum	nn	12	SENT_213	[p15l934t3373r1044b3405],
11	ofthe	NN	O	ofthe	nn	12	SENT_213	[p15l1066t3356r1213b3405],
12	rates	NNS	O	rate	_	0	SENT_213	[p15l1235t3365r1357b3405],
13	ofcomplete	JJ	O	ofcomplete	amod	14	SENT_213	[p15l1378t3356r1689b3419],
14	response	NN	O	response	dep	12	SENT_213	[p15l1711t3373r1960b3419],
15	,	,	O	,	_	0	SENT_213	[p15l1711t3373r1960b3419],
16	partial	JJ	O	partial	amod	17	SENT_213	[p15l1985t3373r2082b3419, p15l57t3429r133b3478],
17	response	NN	O	response	appos	14	SENT_213	[p15l158t3446r408b3492],
18	,	,	O	,	_	0	SENT_213	[p15l158t3446r408b3492],
19	and	CC	O	and	_	0	SENT_213	[p15l430t3429r523b3478],
20	stable	JJ	O	stable	amod	21	SENT_213	[p15l546t3429r699b3478],
21	disease	NN	O	disease	conj_and	12	SENT_213	[p15l718t3429r926b3478],
22	.	.	O	.	_	0	SENT_213	[p15l718t3429r926b3478],

1	irinotecan	NN	O	irinotecan	_	0	SENT_214	[p16l10t80r329b138],
2	before	IN	O	before	_	0	SENT_214	[p16l351t79r550b138],
3	entering	VBG	O	enter	prepc_before	1	SENT_214	[p16l572t80r837b154],
4	the	DT	O	the	det	5	SENT_214	[p16l856t79r952b138],
5	study	NN	O	study	dobj	3	SENT_214	[p16l975t79r1152b154],
6	.	.	O	.	_	0	SENT_214	[p16l975t79r1152b154],

1	In	IN	O	in	mark	3	SENT_215	[p16l1176t85r1241b137],
2	these	DT	O	these	nsubj	3	SENT_215	[p16l1263t80r1426b138],
3	multiply	VBP	O	multiply	advcl	28	SENT_215	[p16l1448t80r1595b138, p16l11t175r148b249],
4	pretreated	JJ	O	pretreated	amod	5	SENT_215	[p16l162t175r477b249],
5	patients	NNS	O	patient	dobj	3	SENT_215	[p16l494t175r758b249],
6	,	,	O	,	_	0	SENT_215	[p16l494t175r758b249],
7	the	DT	O	the	det	9	SENT_215	[p16l781t175r877b233],
8	response	NN	O	response	nn	9	SENT_215	[p16l895t193r1174b249],
9	rate	NN	O	rate	nsubj	28	SENT_215	[p16l1193t186r1308b233],
10	was	VBD	O	be	cop	28	SENT_215	[p16l1323t194r1442b233],
11	22.2	CD	PERCENT	22.2	num	12	SENT_215	[p16l1462t179r1596b233],
12	percent	NN	PERCENT	percent	nn	28	SENT_215	[p16l9t282r249b344],
13	in	IN	O	in	_	0	SENT_215	[p16l266t270r326b327],
14	the	DT	O	the	det	16	SENT_215	[p16l348t270r444b328],
15	combination-therapy	JJ	O	combination-therapy	amod	16	SENT_215	[p16l466t270r1135b344],
16	group	NN	O	group	prep_in	12	SENT_215	[p16l1153t288r1340b344],
17	and	CC	O	and	_	0	SENT_215	[p16l1362t269r1478b328],
18	8.5	CD	PERCENT	8.5	num	19	SENT_215	[p16l1500t274r1594b328],
19	percent	NN	PERCENT	percent	conj_and	12	SENT_215	[p16l9t377r249b439],
20	in	IN	O	in	_	0	SENT_215	[p16l270t365r331b422],
21	the	DT	O	the	det	25	SENT_215	[p16l357t365r454b423],
22	monotherapy	NN	O	monotherapy	nn	25	SENT_215	[p16l480t365r907b439],
23	group	NN	O	group	nn	25	SENT_215	[p16l929t383r1116b439],
24	(	CD	NUMBER	(	num	25	SENT_215	[p16l1147t369r1445b432],
25	P	NN	O	p	prep_in	19	SENT_215	[p16l1147t369r1445b432],
26	=	JJ	O	=	amod	28	SENT_215	[p16l1147t369r1445b432],
27	0.01	CD	NUMBER	0.01	tmod	26	SENT_215	[p16l1147t369r1445b432],
28	)	NN	O	)	_	0	SENT_215	[p16l1147t369r1445b432],
29	.	.	O	.	_	0	SENT_215	[p16l1147t369r1445b432],

1	Statistical	JJ	O	statistical	amod	3	SENT_216	[p16l1477t369r1596b423, p16l11t460r217b518],
2	regression	NN	O	regression	nn	3	SENT_216	[p16l244t460r575b534],
3	modeling	NN	O	modeling	nsubj	4	SENT_216	[p16l602t459r907b534],
4	revealed	VBD	O	reveal	_	0	SENT_216	[p16l932t459r1188b519],
5	that	IN	O	that	complm	17	SENT_216	[p16l1216t460r1340b518],
6	the	DT	O	the	det	7	SENT_216	[p16l1364t460r1460b518],
7	differences	NNS	O	difference	nsubjpass	17	SENT_216	[p16l1488t459r1595b518, p16l11t554r270b613],
8	in	IN	O	in	_	0	SENT_216	[p16l299t555r359b612],
9	response	NN	O	response	nn	10	SENT_216	[p16l386t573r670b629],
10	rates	NNS	O	rate	prep_in	7	SENT_216	[p16l697t567r845b613],
11	between	IN	O	between	_	0	SENT_216	[p16l875t555r1136b614],
12	the	DT	O	the	det	15	SENT_216	[p16l1164t555r1260b613],
13	two	CD	NUMBER	two	num	15	SENT_216	[p16l1288t567r1402b614],
14	treatment	NN	O	treatment	nn	15	SENT_216	[p16l1431t567r1595b613, p16l11t662r176b708],
15	groups	NNS	O	group	prep_between	10	SENT_216	[p16l191t668r410b724],
16	were	VBD	O	be	auxpass	17	SENT_216	[p16l427t669r577b708],
17	maintained	VBN	O	maintain	ccomp	4	SENT_216	[p16l596t649r956b708],
18	after	IN	O	after	_	0	SENT_216	[p16l975t649r1119b708],
19	adjustment	NN	O	adjustment	prep_after	17	SENT_216	[p16l1135t650r1492b724],
20	for	IN	O	for	_	0	SENT_216	[p16l1507t649r1599b708],
21	age	NN	O	age	nn	26	SENT_216	[p16l10t764r134b819],
22	,	,	O	,	_	0	SENT_216	[p16l10t764r134b819],
23	sex	NN	O	sex	dep	26	SENT_216	[p16l160t764r275b816],
24	,	,	O	,	_	0	SENT_216	[p16l160t764r275b816],
25	performance	NN	O	performance	dep	26	SENT_216	[p16l299t744r704b819],
26	status	NN	O	status	prep_for	19	SENT_216	[p16l726t756r928b816],
27	,	,	O	,	_	0	SENT_216	[p16l726t756r928b816],
28	and	CC	O	and	_	0	SENT_216	[p16l953t745r1069b803],
29	number	NN	O	number	nsubj	34	SENT_216	[p16l1089t745r1340b803],
30	of	IN	O	of	_	0	SENT_216	[p16l1359t744r1435b803],
31	prior	JJ	O	prior	amod	33	SENT_216	[p16l1440t745r1599b819],
32	treatment	NN	O	treatment	nn	33	SENT_216	[p16l11t851r320b898],
33	regimens	NNS	O	regimen	prep_of	29	SENT_216	[p16l335t840r628b914],
34	(	VBP	O	(	conj_and	4	SENT_216	[p16l652t840r809b907],
35	data	NNS	O	datum	dobj	34	SENT_216	[p16l652t840r809b907],
36	not	RB	O	not	neg	37	SENT_216	[p16l826t852r933b898],
37	shown	VBN	O	show	rcmod	35	SENT_216	[p16l949t840r1201b907],
38	)	NN	O	)	dobj	37	SENT_216	[p16l949t840r1201b907],
39	.	.	O	.	_	0	SENT_216	[p16l949t840r1201b907],

1	The	DT	O	the	det	2	SENT_217	[p16l104t935r225b993],
2	degree	NN	O	degree	dep	26	SENT_217	[p16l256t934r464b1009],
3	of	IN	O	of	_	0	SENT_217	[p16l496t934r571b993],
4	EGFR	NN	ORGANIZATION	egfr	nn	5	SENT_217	[p16l587t939r780b997],
5	expression	NN	O	expression	prep_of	2	SENT_217	[p16l803t935r1159b1009],
6	,	,	O	,	_	0	SENT_217	[p16l803t935r1159b1009],
7	either	CC	O	either	dep	2	SENT_217	[p16l1195t935r1377b993],
8	as	IN	O	as	conj	2	SENT_217	[p16l1404t954r1467b993],
9	the	DT	O	the	det	10	SENT_217	[p16l1500t935r1596b993],
10	percentage	NN	O	percentage	pobj	8	SENT_217	[p16l9t1042r357b1104],
11	of	IN	O	of	_	0	SENT_217	[p16l381t1029r456b1088],
12	EGFR-positive	JJ	O	egfr-positive	amod	14	SENT_217	[p16l465t1030r918b1104],
13	tumor	NN	O	tumor	nn	14	SENT_217	[p16l943t1042r1139b1088],
14	cells	NNS	O	cell	prep_of	10	SENT_217	[p16l1162t1029r1298b1088],
15	or	CC	O	or	_	0	SENT_217	[p16l1324t1048r1390b1088],
16	as	IN	O	as	conj	2	SENT_217	[p16l1411t1049r1474b1088],
17	the	DT	O	the	det	20	SENT_217	[p16l1500t1030r1596b1088],
18	maximal	JJ	O	maximal	amod	20	SENT_217	[p16l11t1125r281b1183],
19	staining	NN	O	staining	nn	20	SENT_217	[p16l297t1125r551b1199],
20	intensity	NN	O	intensity	pobj	16	SENT_217	[p16l563t1125r831b1199],
21	per	IN	O	per	_	0	SENT_217	[p16l842t1144r944b1199],
22	cell	NN	O	cell	prep_per	20	SENT_217	[p16l958t1124r1078b1195],
23	,	,	O	,	_	0	SENT_217	[p16l958t1124r1078b1195],
24	did	VBD	O	do	aux	26	SENT_217	[p16l1098t1124r1196b1183],
25	not	RB	O	not	neg	26	SENT_217	[p16l1211t1137r1317b1183],
26	correlate	VB	O	correlate	_	0	SENT_217	[p16l1329t1125r1597b1183],
27	signiﬁcantly	RB	O	signiﬁcantly	advmod	26	SENT_217	[p16l12t1219r396b1294],
28	with	IN	O	with	_	0	SENT_217	[p16l406t1220r546b1278],
29	the	DT	O	the	det	32	SENT_217	[p16l562t1220r658b1278],
30	clinical	JJ	O	clinical	amod	32	SENT_217	[p16l675t1219r897b1278],
31	response	NN	O	response	nn	32	SENT_217	[p16l913t1238r1193b1294],
32	rate	NN	O	rate	prep_with	26	SENT_217	[p16l1209t1232r1325b1278],
33	(	CD	NUMBER	(	num	34	SENT_217	[p16l1345t1224r1596b1287],
34	P	NN	O	p	nsubj	26	SENT_217	[p16l1345t1224r1596b1287],
35	=	JJ	O	=	amod	34	SENT_217	[p16l1345t1224r1596b1287],
36	0.87	CD	NUMBER	0.87	tmod	35	SENT_217	[p16l1345t1224r1596b1287],
37	and	CC	O	and	_	0	SENT_217	[p16l10t1315r128b1373],
38	P	NN	O	p	nsubj	26	SENT_217	[p16l149t1319r407b1385],
39	=	JJ	O	=	amod	38	SENT_217	[p16l149t1319r407b1385],
40	0.64	CD	NUMBER	0.64	tmod	39	SENT_217	[p16l149t1319r407b1385],
41	,	,	O	,	_	0	SENT_217	[p16l149t1319r407b1385],
42	respectively	RB	O	respectively	advmod	38	SENT_217	[p16l433t1315r828b1389],
43	)	CD	NUMBER	)	number	44	SENT_217	[p16l433t1315r828b1389],
44	(	CD	NUMBER	(	num	47	SENT_217	[p16l857t1315r1051b1382],
45	Table	NNP	O	Table	nn	47	SENT_217	[p16l857t1315r1051b1382],
46	3	CD	NUMBER	3	num	47	SENT_217	[p16l1074t1319r1154b1382],
47	)	NN	O	)	dep	38	SENT_217	[p16l1074t1319r1154b1382],
48	.	.	O	.	_	0	SENT_217	[p16l1074t1319r1154b1382],

1	However	RB	O	however	advmod	15	SENT_218	[p16l1180t1320r1477b1386],
2	,	,	O	,	_	0	SENT_218	[p16l1180t1320r1477b1386],
3	the	DT	O	the	det	5	SENT_218	[p16l1501t1315r1597b1373],
4	response	NN	O	response	nn	5	SENT_218	[p16l11t1428r298b1484],
5	rates	NNS	O	rate	nsubj	15	SENT_218	[p16l323t1422r474b1468],
6	in	IN	O	in	_	0	SENT_218	[p16l500t1410r562b1467],
7	patients	NNS	O	patient	prep_in	5	SENT_218	[p16l586t1410r841b1484],
8	with	IN	O	with	_	0	SENT_218	[p16l865t1410r1008b1468],
9	skin	NN	O	skin	nn	10	SENT_218	[p16l1035t1409r1169b1469],
10	reactions	NNS	O	reaction	prep_with	7	SENT_218	[p16l1193t1410r1486b1468],
11	after	IN	O	after	_	0	SENT_218	[p16l1512t1409r1595b1468, p16l11t1517r96b1563],
12	cetuximab	NN	O	cetuximab	nn	13	SENT_218	[p16l112t1505r443b1563],
13	treatment	NN	O	treatment	prep_after	10	SENT_218	[p16l461t1517r777b1563],
14	were	VBD	O	be	cop	15	SENT_218	[p16l787t1524r940b1564],
15	higher	JJR	O	higher	_	0	SENT_218	[p16l957t1504r1169b1579],
16	than	IN	O	than	mark	23	SENT_218	[p16l1185t1505r1328b1563],
17	those	DT	O	those	nsubj	23	SENT_218	[p16l1345t1505r1517b1563],
18	in	IN	O	in	_	0	SENT_218	[p16l1534t1505r1596b1562],
19	patients	NNS	O	patient	prep_in	17	SENT_218	[p16l9t1600r265b1674],
20	without	IN	O	without	_	0	SENT_218	[p16l290t1600r546b1659],
21	skin	NN	O	skin	nn	22	SENT_218	[p16l570t1600r704b1659],
22	reactions	NNS	O	reaction	prep_without	19	SENT_218	[p16l731t1600r1023b1658],
23	(	VBP	O	(	ccomp	15	SENT_218	[p16l1056t1604r1216b1667],
24	25.8	CD	PERCENT	25.8	num	25	SENT_218	[p16l1056t1604r1216b1667],
25	percent	NN	PERCENT	percent	dobj	23	SENT_218	[p16l1244t1611r1489b1674],
26	vs.	IN	PERCENT	vs.	_	0	SENT_218	[p16l1508t1619r1592b1659],
27	6.3	CD	PERCENT	6.3	prep_vs.	25	SENT_218	[p16l11t1699r107b1753],
28	percent	NN	PERCENT	percent	dep	37	SENT_218	[p16l151t1707r395b1769],
29	in	IN	O	in	_	0	SENT_218	[p16l434t1695r496b1752],
30	the	DT	O	the	det	32	SENT_218	[p16l539t1695r637b1753],
31	combination-therapy	JJ	O	combination-therapy	amod	32	SENT_218	[p16l681t1694r1365b1769],
32	group	NN	O	group	prep_in	28	SENT_218	[p16l1404t1713r1595b1769],
33	[	CD	NUMBER	[	num	34	SENT_218	[p16l17t1794r339b1857],
34	P	NN	O	p	dep	37	SENT_218	[p16l17t1794r339b1857],
35	=	JJ	O	=	amod	37	SENT_218	[p16l17t1794r339b1857],
36	0.005	CD	NUMBER	0.005	tmod	35	SENT_218	[p16l17t1794r339b1857],
37	]	NN	O	]	dep	48	SENT_218	[p16l17t1794r339b1857],
38	and	CC	O	and	_	0	SENT_218	[p16l378t1790r495b1848],
39	13.0	CD	PERCENT	13.0	num	40	SENT_218	[p16l529t1794r662b1848],
40	percent	NN	PERCENT	percent	conj_and	37	SENT_218	[p16l693t1802r933b1864],
41	vs.	CC	O	vs.	prep	40	SENT_218	[p16l957t1809r1039b1849],
42	o	NN	O	o	nn	43	SENT_218	[p16l1074t1794r1109b1848],
43	percent	NN	O	percent	dep	41	SENT_218	[p16l1141t1802r1380b1864],
44	in	IN	O	in	_	0	SENT_218	[p16l1407t1790r1468b1847],
45	the	DT	O	the	det	47	SENT_218	[p16l1500t1790r1596b1848],
46	monotherapy	NN	O	monotherapy	nn	47	SENT_218	[p16l11t1885r437b1959],
47	group	NN	O	group	prep_in	37	SENT_218	[p16l452t1890r684b1959],
48	)	CD	NUMBER	)	dep	23	SENT_218	[p16l452t1890r684b1959],
49	.	.	O	.	_	0	SENT_218	[p16l452t1890r684b1959],

1	N	NN	O	n	nn	3	SENT_219	[p16l524t2036r537b2051],
2	ENGLJ	NN	O	englj	nn	3	SENT_219	[p16l553t2035r637b2057],
3	MED	NN	O	med	_	0	SENT_219	[p16l652t2036r704b2051],
4	351	CD	NUMBER	351	dep	3	SENT_219	[p16l716t2035r781b2057],
5	;	:	O	;	_	0	SENT_219	[p16l716t2035r781b2057],
6	4	CD	NUMBER	4	dep	3	SENT_219	[p16l716t2035r781b2057],
7	WWW.NEjM.ORG	NNP	O	WWW.NEjM.ORG	nn	8	SENT_219	[p16l815t2035r1026b2057],
8	JULY	NNP	DATE	JULY	dep	6	SENT_219	[p16l1060t2036r1120b2057],
9	22	CD	DATE	22	num	8	SENT_219	[p16l1132t2035r1169b2055],
10	,	,	DATE	,	_	0	SENT_219	[p16l1132t2035r1169b2055],
11	2004	CD	DATE	2004	num	8	SENT_219	[p16l1182t2035r1249b2057],
12	The	DT	O	the	det	15	SENT_219	[p16l701t2068r752b2092],
13	New	NNP	O	New	nn	15	SENT_219	[p16l761t2069r823b2092],
14	England	NNP	O	England	nn	15	SENT_219	[p16l833t2068r943b2099],
15	Journal	NNP	O	Journal	dep	3	SENT_219	[p16l952t2068r1049b2092],
16	of	IN	O	of	_	0	SENT_219	[p16l1059t2068r1088b2092],
17	Medicine	NNP	O	Medicine	prep_of	15	SENT_219	[p16l1095t2068r1220b2092],

1	Downloaded	VBN	O	download	_	0	SENT_220	[p16l144t2109r313b2132],
2	from	IN	O	from	_	0	SENT_220	[p16l322t2109r387b2132],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_220	[p16l395t2109r514b2139],
4	at	IN	O	at	_	0	SENT_220	[p16l524t2113r547b2132],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_220	[p16l556t2109r738b2132],
6	on	IN	O	on	_	0	SENT_220	[p16l748t2116r780b2132],
7	January	NNP	DATE	January	prep_on	1	SENT_220	[p16l789t2109r891b2139],
8	5	CD	DATE	5	num	7	SENT_220	[p16l901t2109r924b2136],
9	,	,	DATE	,	_	0	SENT_220	[p16l901t2109r924b2136],
10	2014	CD	DATE	2014	num	7	SENT_220	[p16l935t2109r1007b2132],
11	.	.	O	.	_	0	SENT_220	[p16l935t2109r1007b2132],

1	For	IN	O	for	_	0	SENT_221	[p16l1017t2109r1064b2132],
2	personal	JJ	O	personal	amod	3	SENT_221	[p16l1072t2109r1184b2139],
3	use	NN	O	use	pobj	1	SENT_221	[p16l1194t2116r1237b2132],
4	only	RB	O	only	advmod	3	SENT_221	[p16l1247t2109r1311b2139],
5	.	.	O	.	_	0	SENT_221	[p16l1247t2109r1311b2139],

1	No	DT	O	no	det	3	SENT_222	[p16l1322t2109r1362b2132],
2	other	JJ	O	other	amod	3	SENT_222	[p16l1372t2109r1440b2132],
3	uses	NNS	O	use	_	0	SENT_222	[p16l1448t2116r1504b2132],
4	without	IN	O	without	_	0	SENT_222	[p16l1514t2109r1615b2132],
5	permission	NN	O	permission	prep_without	3	SENT_222	[p16l1624t2109r1776b2139],
6	.	.	O	.	_	0	SENT_222	[p16l1624t2109r1776b2139],

1	Copyright	NN	O	copyright	_	0	SENT_223	[p16l494t2150r628b2181],
2	©	CD	NUMBER	©	num	6	SENT_223	[p16l638t2150r661b2174],
3	2004	CD	DATE	2004	num	6	SENT_223	[p16l671t2150r736b2174],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_223	[p16l746t2150r937b2174],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_223	[p16l947t2150r1055b2174],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_223	[p16l1065t2150r1170b2181],
7	.	.	O	.	_	0	SENT_223	[p16l1065t2150r1170b2181],

1	All	DT	O	all	det	2	SENT_224	[p16l1181t2150r1222b2174],
2	rights	NNS	O	rights	nsubj	3	SENT_224	[p16l1231t2150r1306b2181],
3	reserved	VBN	O	reserve	_	0	SENT_224	[p16l1316t2150r1435b2174],
4	.	.	O	.	_	0	SENT_224	[p16l1316t2150r1435b2174],

1	The	DT	O	the	det	4	SENT_225	[p16l715t2256r752b2277],
2	NEW	NNP	O	NEW	nn	4	SENT_225	[p16l764t2258r845b2277],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_225	[p16l859t2258r1034b2277],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_225	[p16l1048t2258r1214b2284],
5	ofMEDICINE	NN	O	ofmedicine	dep	4	SENT_225	[p16l1228t2256r1444b2283],

1	Table	NNP	O	Table	_	0	SENT_226	[p17l59t55r195b103],
2	3	CD	NUMBER	3	dep	1	SENT_226	[p17l213t59r256b103],
3	.	.	O	.	_	0	SENT_226	[p17l213t59r256b103],

1	Inﬂuence	NN	O	inﬂuence	_	0	SENT_227	[p17l279t54r520b103],
2	of	IN	O	of	_	0	SENT_227	[p17l537t54r597b103],
3	Epidermal	NNP	O	Epidermal	nn	4	SENT_227	[p17l607t55r868b117],
4	Growth	NNP	O	Growth	prep_of	1	SENT_227	[p17l888t55r1083b103],
5	Factor	NN	O	factor	nn	7	SENT_227	[p17l1107t59r1265b103],
6	Receptor	NN	O	receptor	nn	7	SENT_227	[p17l1284t59r1515b117],
7	Expression	NN	O	expression	dep	4	SENT_227	[p17l1534t56r1817b117],
8	and	CC	O	and	_	0	SENT_227	[p17l1837t55r1931b103],
9	Rash	NNP	O	Rash	prep_of	1	SENT_227	[p17l1955t55r2077b103],
10	on	IN	O	on	_	0	SENT_227	[p17l60t152r123b184],
11	Rates	NNP	O	Rates	prep_on	9	SENT_227	[p17l147t140r286b184],
12	of	IN	O	of	_	0	SENT_227	[p17l305t135r365b184],
13	Response	NN	O	response	prep_of	1	SENT_227	[p17l376t138r675b198],
14	.	.	O	.	_	0	SENT_227	[p17l376t138r675b198],

1	*	NN	O	*	_	0	SENT_228	[p17l376t138r675b198],

1	Cetuximab	NNP	O	Cetuximab	_	0	SENT_229	[p17l1142t272r1424b320],
2	plus	CC	O	plus	_	0	SENT_229	[p17l1230t344r1337b406],
3	Cetuximab	NNP	O	Cetuximab	conj_plus	1	SENT_229	[p17l1543t344r1825b392],
4	P	NN	O	p	nn	7	SENT_229	[p17l1905t348r1935b392],
5	Value	NN	O	value	nn	7	SENT_229	[p17l1951t344r2094b393],
6	lrinotecan	NN	O	lrinotecan	nn	7	SENT_229	[p17l1154t418r1413b464],
7	Monotherapy	NN	O	monotherapy	dep	1	SENT_229	[p17l1511t416r1862b480],
8	for	IN	O	for	_	0	SENT_229	[p17l1961t416r2035b464],
9	Variable	JJ	O	variable	amod	11	SENT_229	[p17l59t489r268b537],
10	(	NN	O	(	nn	11	SENT_229	[p17l1172t492r1394b552],
11	N	NN	O	n	nn	21	SENT_229	[p17l1172t492r1394b552],
12	=	JJ	O	=	dep	11	SENT_229	[p17l1172t492r1394b552],
13	218	CD	NUMBER	218	num	14	SENT_229	[p17l1172t492r1394b552],
14	)	CD	NUMBER	)	iobj	12	SENT_229	[p17l1172t492r1394b552],
15	(	NN	O	(	nn	16	SENT_229	[p17l1574t493r1795b552],
16	N	NN	O	n	dobj	12	SENT_229	[p17l1574t493r1795b552],
17	=	JJ	O	=	amod	16	SENT_229	[p17l1574t493r1795b552],
18	111	CD	NUMBER	111	tmod	17	SENT_229	[p17l1574t493r1795b552],
19	)	NN	O	)	nn	21	SENT_229	[p17l1574t493r1795b552],
20	Trend	NNP	O	Trend	nn	21	SENT_229	[p17l1923t489r2068b537],
21	no.	NNP	O	no.	prep_for	7	SENT_229	[p17l1269t632r1339b663],
22	/	:	O	/	punct	24	SENT_229	[p17l1345t615r1491b678],
23	total	JJ	O	total	dep	24	SENT_229	[p17l1345t615r1491b678],
24	no.	JJ	O	no.	dep	21	SENT_229	[p17l1508t632r1578b663],
25	(	CD	PERCENT	(	num	26	SENT_229	[p17l1607t617r1694b678],
26	%	NN	PERCENT	%	dep	24	SENT_229	[p17l1607t617r1694b678],
27	)	CD	NUMBER	)	dep	1	SENT_229	[p17l1607t617r1694b678],

1	Percentage	NN	O	percentage	dep	5	SENT_230	[p17l65t724r351b783],
2	of	IN	O	of	_	0	SENT_230	[p17l371t719r428b768],
3	EGFR-expressing	JJ	O	egfr-expressing	amod	4	SENT_230	[p17l442t723r887b783],
4	cells	NNS	O	cell	prep_of	1	SENT_230	[p17l905t719r1017b768],
5	s10	VBP	O	s10	_	0	SENT_230	[p17l157t827r253b872],
6	25/109	CD	NUMBER	25/109	number	7	SENT_230	[p17l1105t827r1286b887],
7	(	CD	NUMBER	(	num	9	SENT_230	[p17l1312t828r1456b887],
8	22.9	CD	NUMBER	22.9	number	9	SENT_230	[p17l1312t828r1456b887],
9	)	CD	NUMBER	)	dobj	5	SENT_230	[p17l1312t828r1456b887],
10	4/56	CD	NUMBER	4/56	num	11	SENT_230	[p17l1537t828r1656b887],
11	(	NN	O	(	dep	17	SENT_230	[p17l1682t828r1793b887],
12	7.1	CD	NUMBER	7.1	num	13	SENT_230	[p17l1682t828r1793b887],
13	)	NN	O	)	dep	11	SENT_230	[p17l1682t828r1793b887],
14	>	JJR	O	>	dep	13	SENT_230	[p17l157t899r321b944],
15	10to	CD	NUMBER	10to	dep	17	SENT_230	[p17l157t899r321b944],
16	520 4/20	CD	NUMBER	520 4/20	num	17	SENT_230	[p17l1136t899r1256b959],[p17l341t899r437b944],
17	(	NN	O	(	dep	27	SENT_230	[p17l1312t899r1456b959],
18	20.0	CD	NUMBER	20.0	number	19	SENT_230	[p17l1312t899r1456b959],
19	)	CD	NUMBER	)	dep	17	SENT_230	[p17l1312t899r1456b959],
20	5/16	CD	NUMBER	5/16	num	21	SENT_230	[p17l1539t900r1656b959],
21	(	NN	O	(	dep	19	SENT_230	[p17l1681t900r1825b959],
22	31.3	CD	NUMBER	31.3	number	23	SENT_230	[p17l1681t900r1825b959],
23	)	CD	NUMBER	)	num	24	SENT_230	[p17l1681t900r1825b959],
24	>	JJR	O	>	npadvmod	25	SENT_230	[p17l157t971r321b1017],
25	20to	JJ	O	20to	amod	19	SENT_230	[p17l157t971r321b1017],
26	535 6/27	CD	NUMBER	535 6/27	num	27	SENT_230	[p17l1138t972r1255b1031],[p17l341t972r433b1016],
27	(	CD	NUMBER	(	dep	34	SENT_230	[p17l1312t972r1456b1031],
28	22.2	CD	NUMBER	22.2	number	29	SENT_230	[p17l1312t972r1456b1031],
29	)	CD	NUMBER	)	dep	27	SENT_230	[p17l1312t972r1456b1031],
30	0/7	CD	NUMBER	0/7	num	32	SENT_230	[p17l1538t971r1624b1032],
31	(	NN	O	(	nn	32	SENT_230	[p17l1682t971r1745b1031],
32	o	NN	O	o	dep	29	SENT_230	[p17l1682t971r1745b1031],
33	)	CD	NUMBER	)	num	34	SENT_230	[p17l1682t971r1745b1031],
34	>	JJR	O	>	dep	9	SENT_230	[p17l157t1045r250b1089],
35	35 15/62	CD	NUMBER	35 15/62	num	36	SENT_230	[p17l1109t1045r1254b1104],[p17l157t1045r250b1089],
36	(	NN	O	(	dep	34	SENT_230	[p17l1312t1045r1456b1104],
37	24.2	CD	NUMBER	24.2	number	38	SENT_230	[p17l1312t1045r1456b1104],
38	)	CD	NUMBER	)	dep	36	SENT_230	[p17l1312t1045r1456b1104],
39	3/32	CD	NUMBER	3/32	num	42	SENT_230	[p17l1539t1045r1655b1104],
40	(	NN	O	(	nn	42	SENT_230	[p17l1681t1045r1793b1104],
41	9.4	CD	NUMBER	9.4	num	42	SENT_230	[p17l1681t1045r1793b1104],
42	)	NN	O	)	nsubj	5	SENT_230	[p17l1681t1045r1793b1104],

1	EG	NN	O	eg	nn	4	SENT_231	[p17l66t1165r133b1209],
2	FR	NN	O	fr	nn	4	SENT_231	[p17l146t1165r208b1208],
3	staining	NN	O	staining	nn	4	SENT_231	[p17l228t1165r438b1224],
4	intensity	NN	O	intensity	_	0	SENT_231	[p17l458t1165r679b1224],

1	Faint	JJ	O	faint	amod	2	SENT_232	[p17l162t1269r285b1313],
2	11/53	CD	NUMBER	11/53	dep	10	SENT_232	[p17l1109t1269r1252b1328],
3	(	CD	NUMBER	(	number	4	SENT_232	[p17l1312t1268r1456b1328],
4	20.8	CD	NUMBER	20.8	dep	2	SENT_232	[p17l1312t1268r1456b1328],
5	)	CD	NUMBER	)	dep	4	SENT_232	[p17l1312t1268r1456b1328],
6	1/21	CD	NUMBER	1/21	num	7	SENT_232	[p17l1542t1269r1653b1328],
7	(	NN	O	(	dep	10	SENT_232	[p17l1681t1268r1793b1328],
8	4.8	CD	NUMBER	4.8	number	9	SENT_232	[p17l1681t1268r1793b1328],
9	)	CD	NUMBER	)	num	10	SENT_232	[p17l1681t1268r1793b1328],
10	Weak	NN	O	weak	dep	18	SENT_232	[p17l156t1337r296b1386],
11	or	CC	O	or	_	0	SENT_232	[p17l314t1354r368b1386],
12	moderate	JJ	O	moderate	amod	14	SENT_232	[p17l387t1337r636b1386],
13	22/89	CD	NUMBER	22/89	number	14	SENT_232	[p17l1105t1340r1254b1400],
14	(	CD	NUMBER	(	dep	18	SENT_232	[p17l1312t1341r1456b1400],
15	24.7	CD	NUMBER	24.7	number	16	SENT_232	[p17l1312t1341r1456b1400],
16	)	CD	NUMBER	)	num	14	SENT_232	[p17l1312t1341r1456b1400],
17	7/55	CD	NUMBER	7/55	num	18	SENT_232	[p17l1541t1342r1653b1400],
18	(	NN	O	(	dep	27	SENT_232	[p17l1682t1341r1825b1400],
19	12.7	CD	NUMBER	12.7	number	20	SENT_232	[p17l1682t1341r1825b1400],
20	)	CD	NUMBER	)	num	21	SENT_232	[p17l1682t1341r1825b1400],
21	Strong	JJ	O	strong	dep	18	SENT_232	[p17l158t1413r332b1473],
22	17/75	CD	NUMBER	17/75	number	23	SENT_232	[p17l1109t1414r1252b1473],
23	(	CD	NUMBER	(	num	25	SENT_232	[p17l1312t1414r1456b1473],
24	22.7	CD	NUMBER	22.7	number	25	SENT_232	[p17l1312t1414r1456b1473],
25	)	CD	NUMBER	)	dep	21	SENT_232	[p17l1312t1414r1456b1473],
26	4/34	CD	NUMBER	4/34	num	27	SENT_232	[p17l1537t1414r1656b1473],
27	(	NN	O	(	dep	29	SENT_232	[p17l1682t1413r1825b1473],
28	11.8	CD	NUMBER	11.8	num	29	SENT_232	[p17l1682t1413r1825b1473],
29	)	NN	O	)	_	0	SENT_232	[p17l1682t1413r1825b1473],

1	Acne-like	JJ	O	acne-like	amod	2	SENT_233	[p17l59t1530r297b1578],
2	rash	NN	O	rash	_	0	SENT_233	[p17l319t1530r424b1578],

1	None	NN	O	none	_	0	SENT_234	[p17l162t1639r301b1683],
2	vs.	IN	O	vs.	_	0	SENT_234	[p17l319t1651r388b1683],
3	any	DT	O	any	prep_vs.	1	SENT_234	[p17l410t1651r498b1698],

1	None	NN	O	none	dep	9	SENT_235	[p17l258t1711r397b1755],
2	8/48	CD	NUMBER	8/48	num	1	SENT_235	[p17l1137t1710r1254b1770],
3	(	CD	NUMBER	(	number	4	SENT_235	[p17l1312t1711r1456b1770],
4	16.7	CD	NUMBER	16.7	dep	1	SENT_235	[p17l1312t1711r1456b1770],
5	)	CD	NUMBER	)	num	6	SENT_235	[p17l1312t1711r1456b1770],
6	2/28	CD	NUMBER	2/28	dep	4	SENT_235	[p17l1538t1710r1655b1770],
7	(	NN	O	(	dep	9	SENT_235	[p17l1682t1711r1793b1770],
8	7.1	CD	NUMBER	7.1	num	7	SENT_235	[p17l1682t1711r1793b1770],
9	)	CD	NUMBER	)	dep	18	SENT_235	[p17l1682t1711r1793b1770],
10	Any	DT	O	any	det	11	SENT_235	[p17l252t1782r350b1842],
11	42/170	CD	NUMBER	42/170	dep	9	SENT_235	[p17l1104t1782r1288b1842],
12	(	CD	NUMBER	(	number	13	SENT_235	[p17l1312t1783r1456b1842],
13	24.7	CD	NUMBER	24.7	num	14	SENT_235	[p17l1312t1783r1456b1842],
14	)	NN	O	)	dep	11	SENT_235	[p17l1312t1783r1456b1842],
15	10/83	CD	NUMBER	10/83	number	16	SENT_235	[p17l1510t1782r1653b1842],
16	(	CD	NUMBER	(	num	14	SENT_235	[p17l1681t1782r1825b1842],
17	12.0	CD	NUMBER	12.0	num	18	SENT_235	[p17l1681t1782r1825b1842],
18	)	NN	O	)	_	0	SENT_235	[p17l1681t1782r1825b1842],

1	None	NN	O	none	_	0	SENT_236	[p17l162t1888r299b1931],
2	vs.	CC	O	vs.	prep	1	SENT_236	[p17l315t1900r382b1931],
3	grade	NN	O	grade	dep	2	SENT_236	[p17l401t1883r543b1947],
4	1	CD	NUMBER	1	dep	1	SENT_236	[p17l564t1888r585b1931],
5	or	CC	O	or	_	0	SENT_236	[p17l605t1900r657b1931],
6	2	CD	NUMBER	2	dep	1	SENT_236	[p17l672t1888r699b1931],
7	vs.	CC	O	vs.	prep	4	SENT_236	[p17l715t1900r782b1931],
8	grade	NN	O	grade	nn	10	SENT_236	[p17l802t1883r943b1947],
9	3	CD	NUMBER	3	num	10	SENT_236	[p17l961t1887r985b1931],
10	or4	NN	O	or4	dep	7	SENT_236	[p17l1005t1888r1099b1931],

1	None	NN	O	none	dep	9	SENT_237	[p17l258t1960r397b2004],
2	8/48	CD	NUMBER	8/48	num	1	SENT_237	[p17l1137t1959r1254b2019],
3	(	CD	NUMBER	(	number	4	SENT_237	[p17l1312t1960r1456b2019],
4	16.7	CD	NUMBER	16.7	dep	1	SENT_237	[p17l1312t1960r1456b2019],
5	)	CD	NUMBER	)	dep	4	SENT_237	[p17l1312t1960r1456b2019],
6	2/28	CD	NUMBER	2/28	num	7	SENT_237	[p17l1538t1959r1655b2019],
7	(	NN	O	(	dep	9	SENT_237	[p17l1682t1960r1793b2019],
8	7.1	CD	NUMBER	7.1	number	9	SENT_237	[p17l1682t1960r1793b2019],
9	)	CD	NUMBER	)	dep	18	SENT_237	[p17l1682t1960r1793b2019],
10	Grade	NNP	O	Grade	dep	9	SENT_237	[p17l254t2028r412b2076],
11	1	CD	NUMBER	1	num	10	SENT_237	[p17l435t2032r456b2075],
12	or	CC	O	or	_	0	SENT_237	[p17l478t2045r531b2076],
13	2 29/143	CD	NUMBER	2 29/143	num	14	SENT_237	[p17l1105t2031r1286b2091],[p17l549t2032r575b2075],
14	(	NN	O	(	dep	18	SENT_237	[p17l1312t2032r1456b2091],
15	19.6	CD	NUMBER	19.6	number	16	SENT_237	[p17l1312t2032r1456b2091],
16	)	CD	NUMBER	)	dep	14	SENT_237	[p17l1312t2032r1456b2091],
17	9/79	CD	NUMBER	9/79	num	18	SENT_237	[p17l1539t2032r1656b2091],
18	(	NN	O	(	dep	20	SENT_237	[p17l1682t2032r1825b2091],
19	11.4	CD	NUMBER	11.4	number	20	SENT_237	[p17l1682t2032r1825b2091],
20	)	CD	NUMBER	)	dep	29	SENT_237	[p17l1682t2032r1825b2091],
21	Grade	NNP	O	Grade	dep	20	SENT_237	[p17l254t2100r412b2148],
22	3	CD	NUMBER	3	num	21	SENT_237	[p17l432t2104r455b2148],
23	or	CC	O	or	_	0	SENT_237	[p17l478t2117r532b2148],
24	4 13/22	CD	NUMBER	4 13/22	number	25	SENT_237	[p17l1109t2104r1254b2163],[p17l548t2104r576b2147],
25	(	CD	NUMBER	(	dep	29	SENT_237	[p17l1312t2104r1456b2163],
26	59.1	CD	NUMBER	59.1	num	27	SENT_237	[p17l1312t2104r1456b2163],
27	)	NN	O	)	dep	25	SENT_237	[p17l1312t2104r1456b2163],
28	1/4	CD	NUMBER	1/4	num	29	SENT_237	[p17l1542t2104r1624b2163],
29	(	CD	NUMBER	(	_	0	SENT_237	[p17l1681t2103r1825b2163],
30	25.0	CD	NUMBER	25.0	num	31	SENT_237	[p17l1681t2103r1825b2163],
31	)	NN	O	)	dep	29	SENT_237	[p17l1681t2103r1825b2163],

1	Skin	NN	O	skin	nn	2	SENT_238	[p17l62t2220r168b2268],
2	reaction	NN	O	reaction	_	0	SENT_238	[p17l193t2225r399b2268],

1	None	NN	O	none	_	0	SENT_239	[p17l162t2329r301b2373],
2	vs.	IN	O	vs.	_	0	SENT_239	[p17l319t2342r388b2373],
3	any	DT	O	any	prep_vs.	1	SENT_239	[p17l410t2342r497b2388],

1	None	NN	O	none	nn	3	SENT_240	[p17l258t2401r398b2445],
2	2/32	CD	NUMBER	2/32	num	3	SENT_240	[p17l1137t2401r1254b2460],
3	(	NN	O	(	dep	11	SENT_240	[p17l1312t2401r1424b2460],
4	6.3	CD	NUMBER	6.3	number	5	SENT_240	[p17l1312t2401r1424b2460],
5	)	CD	NUMBER	)	dep	3	SENT_240	[p17l1312t2401r1424b2460],
6	0/19	CD	NUMBER	0/19	num	7	SENT_240	[p17l1538t2400r1656b2460],
7	(	NN	O	(	dep	5	SENT_240	[p17l1681t2400r1745b2460],
8	o	NN	O	o	dep	11	SENT_240	[p17l1681t2400r1745b2460],
9	)	CD	NUMBER	)	num	8	SENT_240	[p17l1681t2400r1745b2460],
10	Any	DT	O	any	det	11	SENT_240	[p17l252t2472r350b2532],
11	48/186	CD	NUMBER	48/186	dep	18	SENT_240	[p17l1104t2472r1287b2532],
12	(	CD	NUMBER	(	number	13	SENT_240	[p17l1312t2472r1456b2532],
13	25.8	CD	NUMBER	25.8	num	14	SENT_240	[p17l1312t2472r1456b2532],
14	)	NN	O	)	dep	11	SENT_240	[p17l1312t2472r1456b2532],
15	12/92	CD	NUMBER	12/92	num	16	SENT_240	[p17l1510t2473r1655b2532],
16	(	CD	NUMBER	(	dep	14	SENT_240	[p17l1681t2472r1825b2532],
17	13.0	CD	NUMBER	13.0	num	18	SENT_240	[p17l1681t2472r1825b2532],
18	)	NN	O	)	_	0	SENT_240	[p17l1681t2472r1825b2532],

1	None	NN	O	none	_	0	SENT_241	[p17l162t2578r299b2622],
2	vs.	CC	O	vs.	prep	1	SENT_241	[p17l315t2591r382b2622],
3	grade	NN	O	grade	dep	2	SENT_241	[p17l401t2573r543b2637],
4	1	CD	NUMBER	1	dep	1	SENT_241	[p17l564t2578r585b2621],
5	or	CC	O	or	_	0	SENT_241	[p17l605t2591r657b2622],
6	2	CD	NUMBER	2	dep	1	SENT_241	[p17l672t2578r699b2621],
7	vs.	CC	O	vs.	prep	4	SENT_241	[p17l715t2591r782b2622],
8	grade	NN	O	grade	nn	10	SENT_241	[p17l802t2573r943b2637],
9	3	CD	NUMBER	3	num	10	SENT_241	[p17l961t2577r985b2622],
10	or4	NN	O	or4	dep	7	SENT_241	[p17l1005t2578r1099b2622],

1	None	NN	O	none	nn	3	SENT_242	[p17l258t2650r397b2694],
2	2/32	CD	NUMBER	2/32	num	3	SENT_242	[p17l1137t2650r1254b2709],
3	(	NN	O	(	dep	10	SENT_242	[p17l1312t2650r1424b2709],
4	6.3	CD	NUMBER	6.3	number	5	SENT_242	[p17l1312t2650r1424b2709],
5	)	CD	NUMBER	)	dep	3	SENT_242	[p17l1312t2650r1424b2709],
6	0/19	CD	NUMBER	0/19	num	7	SENT_242	[p17l1538t2649r1655b2709],
7	(	NN	O	(	dep	5	SENT_242	[p17l1681t2649r1745b2709],
8	o	NN	O	o	dep	10	SENT_242	[p17l1681t2649r1745b2709],
9	)	CD	NUMBER	)	num	8	SENT_242	[p17l1681t2649r1745b2709],
10	Grade	NNP	O	Grade	dep	24	SENT_242	[p17l254t2718r412b2766],
11	1	CD	NUMBER	1	number	15	SENT_242	[p17l435t2722r456b2765],
12	or	CC	O	or	_	0	SENT_242	[p17l478t2735r532b2766],
13	2 32/157	CD	NUMBER	2 32/157	num	16	SENT_242	[p17l1106t2722r1287b2781],[p17l549t2722r575b2765],
14	(	CD	NUMBER	(	number	15	SENT_242	[p17l1312t2721r1456b2781],
15	20.4	CD	NUMBER	20.4	num	16	SENT_242	[p17l1312t2721r1456b2781],
16	)	NN	O	)	dep	10	SENT_242	[p17l1312t2721r1456b2781],
17	10/86	CD	NUMBER	10/86	number	18	SENT_242	[p17l1510t2721r1656b2781],
18	(	CD	NUMBER	(	num	16	SENT_242	[p17l1682t2722r1825b2781],
19	11.6	CD	NUMBER	11.6	number	20	SENT_242	[p17l1682t2722r1825b2781],
20	)	CD	NUMBER	)	num	23	SENT_242	[p17l1682t2722r1825b2781],
21	Grade	NNP	O	Grade	nn	23	SENT_242	[p17l254t2790r412b2838],
22	3	CD	NUMBER	3	num	23	SENT_242	[p17l432t2794r455b2838],
23	or4	NN	O	or4	dep	16	SENT_242	[p17l478t2795r576b2838],
24	16/29	CD	NUMBER	16/29	dep	31	SENT_242	[p17l1109t2794r1254b2853],
25	(	CD	NUMBER	(	number	26	SENT_242	[p17l1312t2794r1456b2853],
26	55.2	CD	NUMBER	55.2	num	27	SENT_242	[p17l1312t2794r1456b2853],
27	)	NN	O	)	dep	24	SENT_242	[p17l1312t2794r1456b2853],
28	2/6	CD	NUMBER	2/6	num	29	SENT_242	[p17l1538t2794r1624b2853],
29	(	CD	NUMBER	(	dep	27	SENT_242	[p17l1682t2794r1825b2853],
30	33.3	CD	NUMBER	33.3	num	31	SENT_242	[p17l1682t2794r1825b2853],
31	)	NN	O	)	_	0	SENT_242	[p17l1682t2794r1825b2853],

1	*	NN	O	*	nn	3	SENT_243	[p17l8t2971r37b2999],
2	EG	NN	O	eg	nn	3	SENT_243	[p17l62t2971r129b3015],
3	FR	NN	O	fr	nsubj	4	SENT_243	[p17l142t2971r204b3014],
4	denotes	VBZ	O	denote	_	0	SENT_243	[p17l223t2967r430b3015],
5	epidermal	JJ	O	epidermal	amod	8	SENT_243	[p17l451t2967r711b3030],
6	growth	NN	O	growth	nn	8	SENT_243	[p17l734t2967r912b3030],
7	factor	NN	O	factor	nn	8	SENT_243	[p17l932t2966r1084b3015],
8	receptor	NN	O	receptor	dobj	4	SENT_243	[p17l1105t2976r1327b3030],
9	.	.	O	.	_	0	SENT_243	[p17l1105t2976r1327b3030],

1	In	IN	O	in	_	0	SENT_244	[p18l658t85r724b137],
2	the	DT	O	the	det	4	SENT_244	[p18l759t80r856b138],
3	intention-to-treat	NN	O	intention-to-treat	nn	4	SENT_244	[p18l891t80r1443b138],
4	analysis	NN	O	analysis	prep_in	15	SENT_244	[p18l1475t79r1741b154],
5	,	,	O	,	_	0	SENT_244	[p18l1475t79r1741b154],
6	the	DT	O	the	det	8	SENT_244	[p18l1781t80r1877b138],
7	median	JJ	O	median	amod	8	SENT_244	[p18l1913t79r2149b138],
8	time	NN	O	time	nsubj	15	SENT_244	[p18l563t175r703b233],
9	to	TO	O	to	_	0	SENT_244	[p18l728t187r787b233],
10	progression	NN	O	progression	prep_to	8	SENT_244	[p18l812t175r1192b249],
11	of	IN	O	of	_	0	SENT_244	[p18l1217t174r1292b233],
12	disease	NN	O	disease	prep_of	10	SENT_244	[p18l1303t175r1530b233],
13	was	VBD	O	be	cop	15	SENT_244	[p18l1552t194r1672b233],
14	4.1	CD	DURATION	4.1	num	15	SENT_244	[p18l1697t179r1795b233],
15	months	NNS	NUMBER	month	_	0	SENT_244	[p18l1820t175r2063b233],
16	in	IN	O	in	_	0	SENT_244	[p18l2089t175r2149b232],
17	the	DT	O	the	det	19	SENT_244	[p18l563t270r660b328],
18	combination-therapy	JJ	O	combination-therapy	amod	19	SENT_244	[p18l680t270r1350b344],
19	group	NN	O	group	prep_in	15	SENT_244	[p18l1365t288r1553b344],
20	and	CC	O	and	_	0	SENT_244	[p18l1573t269r1690b328],
21	1.5	CD	DURATION	1.5	num	22	SENT_244	[p18l1712t274r1803b328],
22	months	NNS	NUMBER	month	conj_and	15	SENT_244	[p18l1825t270r2068b328],
23	in	IN	O	in	_	0	SENT_244	[p18l2088t270r2149b327],
24	the	DT	O	the	det	26	SENT_244	[p18l563t365r660b423],
25	monotherapy	JJ	O	monotherapy	amod	26	SENT_244	[p18l684t365r1110b439],
26	group	NN	O	group	prep_in	22	SENT_244	[p18l1130t383r1336b439],
27	.	.	O	.	_	0	SENT_244	[p18l1130t383r1336b439],

1	The	DT	O	the	det	3	SENT_245	[p18l1362t364r1482b423],
2	hazard	NN	O	hazard	nn	3	SENT_245	[p18l1506t365r1721b423],
3	ratio	NN	O	ratio	nsubj	13	SENT_245	[p18l1744t365r1888b423],
4	for	IN	O	for	_	0	SENT_245	[p18l1912t364r2006b423],
5	disease	NN	O	disease	nn	6	SENT_245	[p18l2030t365r2147b423, p18l564t479r695b518],
6	progression	NN	O	progression	prep_for	3	SENT_245	[p18l712t460r1085b534],
7	in	IN	O	in	_	0	SENT_245	[p18l1102t460r1162b517],
8	the	DT	O	the	det	10	SENT_245	[p18l1179t460r1274b518],
9	combination-therapy	JJ	O	combination-therapy	amod	10	SENT_245	[p18l1293t460r1950b534],
10	group	NN	O	group	prep_in	6	SENT_245	[p18l1964t478r2149b534],
11	was	VBD	O	be	cop	13	SENT_245	[p18l560t574r680b613],
12	0.54	CD	PERCENT	0.54	num	13	SENT_245	[p18l710t559r847b613],
13	(	CD	PERCENT	(	_	0	SENT_245	[p18l878t559r973b622],
14	95	CD	PERCENT	95	num	17	SENT_245	[p18l878t559r973b622],
15	percent	NN	PERCENT	percent	nn	17	SENT_245	[p18l1003t567r1243b629],
16	conﬁdence	NN	O	conﬁdence	nn	17	SENT_245	[p18l1267t554r1612b613],
17	interval	NN	O	interval	dep	13	SENT_245	[p18l1640t555r1891b625],
18	,	,	O	,	_	0	SENT_245	[p18l1640t555r1891b625],
19	0.42	CD	NUMBER	0.42	appos	17	SENT_245	[p18l1924t559r2060b613],
20	to	TO	O	to	_	0	SENT_245	[p18l2089t567r2148b613],
21	0.71	CD	NUMBER	0.71	num	22	SENT_245	[p18l563t654r743b720],
22	)	CD	NUMBER	)	prep_to	19	SENT_245	[p18l563t654r743b720],
23	,	,	O	,	_	0	SENT_245	[p18l563t654r743b720],
24	indicating	VBG	O	indicate	partmod	13	SENT_245	[p18l767t649r1089b724],
25	a	DT	O	a	det	28	SENT_245	[p18l1106t669r1140b708],
26	46	CD	PERCENT	46	num	28	SENT_245	[p18l1158t654r1234b708],
27	percent	NN	PERCENT	percent	nn	28	SENT_245	[p18l1254t662r1494b724],
28	reduction	NN	O	reduction	dobj	24	SENT_245	[p18l1510t649r1813b708],
29	in	IN	O	in	_	0	SENT_245	[p18l1833t650r1893b707],
30	the	DT	O	the	det	31	SENT_245	[p18l1915t650r2011b708],
31	risk	NN	O	risk	prep_in	28	SENT_245	[p18l2032t649r2152b709],
32	of	IN	O	of	_	0	SENT_245	[p18l564t744r639b803],
33	progression	NN	O	progression	prep_of	31	SENT_245	[p18l648t745r1028b819],
34	with	IN	O	with	_	0	SENT_245	[p18l1048t745r1190b803],
35	combination	NN	O	combination	nn	36	SENT_245	[p18l1215t744r1618b803],
36	therapy	NN	O	therapy	prep_with	33	SENT_245	[p18l1642t745r1879b819],
37	as	IN	O	as	prep	24	SENT_245	[p18l1899t764r1962b803],
38	compared	VBN	O	compare	_	0	SENT_245	[p18l1988t763r2148b803, p18l562t840r740b914],
39	With	IN	O	with	prepc_compared_with	24	SENT_245	[p18l757t840r899b899],
40	monotherapy	NN	O	monotherapy	pobj	24	SENT_245	[p18l920t840r1346b914],
41	(	CD	NUMBER	(	num	42	SENT_245	[p18l1367t844r1650b907],
42	P	NN	O	p	npadvmod	43	SENT_245	[p18l1367t844r1650b907],
43	<	JJR	O	<	amod	40	SENT_245	[p18l1367t844r1650b907],
44	0.001	CD	NUMBER	0.001	dep	43	SENT_245	[p18l1367t844r1650b907],
45	by	IN	O	by	dep	44	SENT_245	[p18l1671t839r1744b914],
46	the	DT	O	the	det	51	SENT_245	[p18l1762t840r1858b898],
47	log-rank	JJ	O	log-rank	amod	51	SENT_245	[p18l1878t839r2152b914],
48	test	NN	O	test	nn	51	SENT_245	[p18l563t940r693b1002],
49	)	NN	O	)	nn	51	SENT_245	[p18l563t940r693b1002],
50	(	CD	NUMBER	(	num	51	SENT_245	[p18l716t935r851b1009],
51	Fig	NN	O	fig	pobj	45	SENT_245	[p18l716t935r851b1009],
52	.	.	O	.	_	0	SENT_245	[p18l716t935r851b1009],

1	2	CD	NUMBER	2	num	2	SENT_246	[p18l871t939r949b1002],
2	)	CD	NUMBER	)	_	0	SENT_246	[p18l871t939r949b1002],
3	.	.	O	.	_	0	SENT_246	[p18l871t939r949b1002],

1	In	IN	O	in	_	0	SENT_247	[p18l968t940r1032b992],
2	the	DT	O	the	det	4	SENT_247	[p18l1049t935r1144b993],
3	combination-therapy	JJ	O	combination-therapy	amod	4	SENT_247	[p18l1161t935r1819b1009],
4	group	NN	O	group	prep_in	21	SENT_247	[p18l1831t953r2034b1009],
5	,	,	O	,	_	0	SENT_247	[p18l1831t953r2034b1009],
6	the	DT	O	the	det	7	SENT_247	[p18l2055t935r2150b993],
7	percentages	NNS	O	percentage	nsubj	21	SENT_247	[p18l562t1042r934b1104],
8	of	IN	O	of	_	0	SENT_247	[p18l960t1029r1035b1088],
9	patients	NNS	O	patient	prep_of	7	SENT_247	[p18l1044t1030r1289b1104],
10	remaining	VBG	O	remain	partmod	9	SENT_247	[p18l1315t1030r1640b1104],
11	free	JJ	O	free	advmod	10	SENT_247	[p18l1661t1029r1777b1088],
12	of	IN	O	of	_	0	SENT_247	[p18l1802t1029r1876b1088],
13	progression	NN	O	progression	prep_of	11	SENT_247	[p18l1886t1048r2149b1104, p18l564t1125r694b1183],
14	at	IN	O	at	_	0	SENT_247	[p18l720t1137r780b1183],
15	three	CD	NUMBER	three	nn	18	SENT_247	[p18l803t1125r962b1183],
16	and	CC	O	and	_	0	SENT_247	[p18l987t1124r1103b1183],
17	six	CD	DURATION	six	nn	18	SENT_247	[p18l1131t1125r1217b1183],
18	months	NNS	NUMBER	month	prep_at	10	SENT_247	[p18l1241t1125r1483b1183],
19	were	VBD	O	be	cop	21	SENT_247	[p18l1507t1144r1658b1184],
20	54	CD	PERCENT	54	num	21	SENT_247	[p18l1686t1129r1760b1183],
21	percent	NN	PERCENT	percent	_	0	SENT_247	[p18l1785t1137r2024b1199],
22	(	CD	PERCENT	(	number	23	SENT_247	[p18l2050t1129r2145b1192],
23	95	CD	PERCENT	95	dep	21	SENT_247	[p18l2050t1129r2145b1192],
24	percent	NN	PERCENT	percent	nn	26	SENT_247	[p18l562t1232r806b1294],
25	conﬁdence	NN	O	conﬁdence	nn	26	SENT_247	[p18l822t1219r1174b1278],
26	interval	NN	O	interval	dep	23	SENT_247	[p18l1193t1220r1451b1291],
27	,	,	O	,	_	0	SENT_247	[p18l1193t1220r1451b1291],
28	47	CD	NUMBER	47	number	30	SENT_247	[p18l1473t1224r1550b1278],
29	to	TO	O	to	dep	30	SENT_247	[p18l1570t1232r1630b1278],
30	61	CD	PERCENT	61	conj_and	21	SENT_247	[p18l1651t1224r1726b1278],
31	percent	NN	PERCENT	percent	nn	32	SENT_247	[p18l1745t1225r2008b1294],
32	)	NN	O	)	dep	30	SENT_247	[p18l1745t1225r2008b1294],
33	and	CC	O	and	_	0	SENT_247	[p18l2030t1219r2148b1278],
34	30	CD	PERCENT	30	num	35	SENT_247	[p18l564t1319r639b1373],
35	percent	NN	PERCENT	percent	conj_and	21	SENT_247	[p18l656t1327r893b1389],
36	(	CD	PERCENT	(	number	37	SENT_247	[p18l910t1319r1004b1382],
37	95	CD	PERCENT	95	dep	35	SENT_247	[p18l910t1319r1004b1382],
38	percent	NN	PERCENT	percent	nn	40	SENT_247	[p18l1024t1327r1261b1389],
39	conﬁdence	NN	O	conﬁdence	nn	40	SENT_247	[p18l1275t1314r1617b1373],
40	interval	NN	O	interval	dep	37	SENT_247	[p18l1634t1315r1882b1385],
41	,	,	O	,	_	0	SENT_247	[p18l1634t1315r1882b1385],
42	23	CD	NUMBER	23	number	44	SENT_247	[p18l1904t1319r1977b1373],
43	to	TO	O	to	dep	44	SENT_247	[p18l1997t1327r2056b1373],
44	37	CD	PERCENT	37	num	46	SENT_247	[p18l2075t1319r2149b1373],
45	percent	NN	PERCENT	percent	nn	46	SENT_247	[p18l562t1415r845b1484],
46	)	NN	O	)	appos	37	SENT_247	[p18l562t1415r845b1484],
47	,	,	O	,	_	0	SENT_247	[p18l562t1415r845b1484],
48	respectively	RB	O	respectively	advmod	21	SENT_247	[p18l870t1410r1255b1484],
49	.	.	O	.	_	0	SENT_247	[p18l870t1410r1255b1484],

1	In	IN	O	in	_	0	SENT_248	[p18l1278t1415r1344b1467],
2	the	DT	O	the	det	4	SENT_248	[p18l1365t1410r1463b1468],
3	monotherapy	JJ	O	monotherapy	amod	4	SENT_248	[p18l1484t1410r1918b1484],
4	group	NN	O	group	prep_in	21	SENT_248	[p18l1935t1428r2145b1484],
5	,	,	O	,	_	0	SENT_248	[p18l1935t1428r2145b1484],
6	the	DT	O	the	det	7	SENT_248	[p18l563t1505r660b1563],
7	percentages	NNS	O	percentage	nsubj	21	SENT_248	[p18l682t1517r1060b1579],
8	of	IN	O	of	_	0	SENT_248	[p18l1085t1504r1160b1563],
9	patients	NNS	O	patient	prep_of	7	SENT_248	[p18l1168t1505r1418b1579],
10	remaining	VBG	O	remain	partmod	9	SENT_248	[p18l1442t1505r1772b1579],
11	free	JJ	O	free	advmod	10	SENT_248	[p18l1792t1504r1909b1563],
12	of	IN	O	of	_	0	SENT_248	[p18l1933t1504r2008b1563],
13	progression	NN	O	progression	prep_of	11	SENT_248	[p18l2016t1523r2148b1579, p18l563t1600r831b1674],
14	at	IN	O	at	_	0	SENT_248	[p18l856t1612r915b1658],
15	three	CD	NUMBER	three	nn	18	SENT_248	[p18l937t1599r1096b1658],
16	and	CC	O	and	_	0	SENT_248	[p18l1120t1600r1237b1658],
17	six	CD	DURATION	six	nn	18	SENT_248	[p18l1263t1600r1349b1658],
18	months	NNS	NUMBER	month	prep_at	10	SENT_248	[p18l1372t1600r1614b1658],
19	were	VBD	O	be	cop	21	SENT_248	[p18l1638t1619r1788b1658],
20	28	CD	PERCENT	28	num	21	SENT_248	[p18l1814t1604r1888b1658],
21	percent	NN	PERCENT	percent	_	0	SENT_248	[p18l1914t1612r2153b1674],
22	(	CD	PERCENT	(	number	23	SENT_248	[p18l567t1699r662b1762],
23	95	CD	PERCENT	95	dep	21	SENT_248	[p18l567t1699r662b1762],
24	percent	NN	PERCENT	percent	nn	26	SENT_248	[p18l689t1707r928b1769],
25	conﬁdence	NN	O	conﬁdence	nn	26	SENT_248	[p18l950t1694r1295b1753],
26	interval	NN	O	interval	dep	23	SENT_248	[p18l1320t1695r1571b1765],
27	,	,	O	,	_	0	SENT_248	[p18l1320t1695r1571b1765],
28	19	CD	NUMBER	19	number	30	SENT_248	[p18l1604t1699r1676b1753],
29	to	TO	O	to	dep	30	SENT_248	[p18l1703t1706r1761b1753],
30	37	CD	PERCENT	37	num	32	SENT_248	[p18l1789t1699r1862b1753],
31	percent	NN	PERCENT	percent	nn	32	SENT_248	[p18l1888t1700r2145b1769],
32	)	NN	O	)	appos	21	SENT_248	[p18l1888t1700r2145b1769],

1	and	CC	O	and	cc	2	SENT_249	[p18l10t1963r166b2041],
2	8	CD	PERCENT	8	num	3	SENT_249	[p18l194t1968r239b2041],
3	percent	NN	PERCENT	percent	_	0	SENT_249	[p18l268t1979r595b2063],
4	(	CD	PERCENT	(	number	5	SENT_249	[p18l623t1968r749b2054],
5	95	CD	PERCENT	95	num	7	SENT_249	[p18l623t1968r749b2054],
6	percent	NN	PERCENT	percent	nn	7	SENT_249	[p18l779t1979r1099b2063],
7	conﬁdence	NN	O	conﬁdence	nn	8	SENT_249	[p18l1122t1962r1583b2041],
8	interval	NN	O	interval	dep	3	SENT_249	[p18l1610t1963r1947b2058],
9	,	,	O	,	_	0	SENT_249	[p18l1610t1963r1947b2058],
10	1	CD	NUMBER	1	number	12	SENT_249	[p18l1982t1968r2027b2040],
11	to	TO	O	to	dep	12	SENT_249	[p18l2055t1979r2134b2041],
12	14	CD	PERCENT	14	num	14	SENT_249	[p18l14t2096r112b2168],
13	percent	NN	PERCENT	percent	nn	14	SENT_249	[p18l136t2097r510b2190],
14	)	NN	O	)	appos	8	SENT_249	[p18l136t2097r510b2190],
15	,	,	O	,	_	0	SENT_249	[p18l136t2097r510b2190],
16	respectively	RB	O	respectively	amod	8	SENT_249	[p18l543t2091r1045b2190],
17	.	.	O	.	_	0	SENT_249	[p18l543t2091r1045b2190],

1	The	DT	O	the	det	2	SENT_250	[p18l1074t2091r1236b2168],
2	times	NNS	O	time	nsubj	6	SENT_250	[p18l1263t2091r1491b2168],
3	to	TO	O	to	_	0	SENT_250	[p18l1521t2107r1600b2168],
4	progression	NN	O	progression	prep_to	2	SENT_250	[p18l1626t2091r2135b2190],
5	were	VBD	O	be	cop	6	SENT_250	[p18l6t2245r207b2298],
6	similar	JJ	O	similar	_	0	SENT_250	[p18l251t2219r547b2297],
7	among	IN	O	among	_	0	SENT_250	[p18l585t2244r884b2319],
8	patients	NNS	O	patient	prep_among	6	SENT_250	[p18l921t2219r1256b2319],
9	Whose	WP$	O	whose	poss	10	SENT_250	[p18l1295t2218r1569b2298],
10	disease	NN	O	disease	nsubj	11	SENT_250	[p18l1612t2218r1916b2297],
11	progressed	VBN	O	progress	conj_and	11	SENT_250	[p18l1956t2244r2134b2319, p18l10t2347r328b2447],
12	during	IN	O	during	_	0	SENT_250	[p18l357t2347r638b2447],
13	or	CC	O	or	prep_during	11	SENT_250	[p18l664t2372r752b2425],
14	Within	IN	O	within	dep	13	SENT_250	[p18l773t2347r1045b2426],
15	one	CD	DURATION	one	num	16	SENT_250	[p18l1073t2372r1224b2425],
16	month	NN	NUMBER	month	pobj	14	SENT_250	[p18l1252t2347r1534b2425],
17	after	IN	O	after	_	0	SENT_250	[p18l1561t2346r1752b2425],
18	prestudy	JJ	O	prestudy	amod	20	SENT_250	[p18l1776t2346r2140b2447],
19	irinotecan	NN	O	irinotecan	nn	20	SENT_250	[p18l10t2475r447b2553],
20	therapy	NN	O	therapy	prep_after	16	SENT_250	[p18l475t2475r799b2575],
21	and	CC	O	and	_	0	SENT_250	[p18l821t2475r976b2553],
22	among	IN	O	among	_	0	SENT_250	[p18l1002t2500r1302b2575],
23	those	DT	O	those	prep_among	11	SENT_250	[p18l1325t2475r1552b2553],
24	who	WP	O	who	nsubj	27	SENT_250	[p18l1574t2475r1757b2554],
25	had	VBD	O	have	aux	27	SENT_250	[p18l1785t2475r1940b2553],
26	previously	RB	DATE	previously	advmod	27	SENT_250	[p18l1964t2501r2134b2575, p18l6t2603r304b2703],
27	received	VBN	O	receive	rcmod	23	SENT_250	[p18l324t2603r666b2682],
28	oxaliplatin	NN	O	oxaliplatin	dobj	27	SENT_250	[p18l691t2602r1161b2703],
29	.	.	O	.	_	0	SENT_250	[p18l691t2602r1161b2703],

1	By	IN	O	by	_	0	SENT_251	[p18l138t2737r243b2831],
2	January	NNP	DATE	January	prep_by	23	SENT_251	[p18l260t2738r586b2831],
3	2003	CD	DATE	2003	num	2	SENT_251	[p18l612t2736r843b2826],
4	,	,	O	,	_	0	SENT_251	[p18l612t2736r843b2826],
5	215	CD	NUMBER	215	num	2	SENT_251	[p18l880t2736r1031b2809],
6	of	IN	O	of	_	0	SENT_251	[p18l1066t2730r1167b2809],
7	the	DT	O	the	det	9	SENT_251	[p18l1180t2731r1309b2809],
8	329	CD	NUMBER	329	num	9	SENT_251	[p18l1342t2736r1494b2809],
9	patients	NNS	O	patient	prep_of	2	SENT_251	[p18l1525t2731r1860b2831],
10	in	IN	O	in	_	0	SENT_251	[p18l1892t2731r1974b2808],
11	the	DT	O	the	det	12	SENT_251	[p18l2006t2730r2134b2809],
12	intention	NN	O	intention	prep_in	9	SENT_251	[p18l10t2859r749b2937],
13	—	CD	NUMBER	—	number	15	SENT_251	[p18l10t2859r749b2937],
14	to	TO	O	to	dep	15	SENT_251	[p18l10t2859r749b2937],
15	—	CD	NUMBER	—	num	20	SENT_251	[p18l10t2859r749b2937],
16	treat	NN	O	treat	nn	20	SENT_251	[p18l10t2859r749b2937],
17	analysis	NN	O	analysis	nn	20	SENT_251	[p18l775t2859r1105b2959],
18	(	CD	PERCENT	(	number	19	SENT_251	[p18l1144t2864r1353b2950],
19	65.3	CD	PERCENT	65.3	num	20	SENT_251	[p18l1144t2864r1353b2950],
20	percent	NN	PERCENT	percent	dep	12	SENT_251	[p18l1387t2866r1731b2959],
21	)	NN	O	)	nsubj	23	SENT_251	[p18l1387t2866r1731b2959],
22	had	VBD	O	have	aux	23	SENT_251	[p18l1768t2859r1924b2937],
23	died	VBN	O	die	_	0	SENT_251	[p18l1957t2859r2135b2937],
24	(	RB	O	(	advmod	23	SENT_251	[p18l15t2992r198b3078],
25	140	CD	NUMBER	140	dobj	23	SENT_251	[p18l15t2992r198b3078],
26	in	IN	O	in	_	0	SENT_251	[p18l233t2987r314b3064],
27	the	DT	O	the	det	29	SENT_251	[p18l349t2987r478b3065],
28	combination-therapy	JJ	O	combination-therapy	amod	29	SENT_251	[p18l514t2987r1411b3087],
29	group	NN	O	group	prep_in	25	SENT_251	[p18l1441t3012r1692b3087],
30	and	CC	O	and	_	0	SENT_251	[p18l1728t2987r1884b3065],
31	75	CD	NUMBER	75	prep_in	25	SENT_251	[p18l1919t2994r2016b3065],
32	in	IN	O	in	_	0	SENT_251	[p18l2054t2987r2135b3064],
33	the	DT	O	the	det	35	SENT_251	[p18l11t3115r139b3193],
34	monotherapy	NN	O	monotherapy	nn	35	SENT_251	[p18l172t3115r744b3215],
35	group	NN	O	group	prep_in	23	SENT_251	[p18l771t3122r1082b3215],
36	)	CD	NUMBER	)	dep	35	SENT_251	[p18l771t3122r1082b3215],
37	.	.	O	.	_	0	SENT_251	[p18l771t3122r1082b3215],

1	The	DT	O	the	det	5	SENT_252	[p18l1117t3115r1277b3193],
2	median	JJ	O	median	amod	5	SENT_252	[p18l1310t3114r1627b3193],
3	overall	JJ	O	overall	amod	5	SENT_252	[p18l1660t3115r1938b3193],
4	survival	NN	O	survival	nn	5	SENT_252	[p18l1971t3141r2134b3194, p18l6t3243r194b3322],
5	time	NN	O	time	nsubj	8	SENT_252	[p18l215t3243r402b3321],
6	was	VBD	O	be	cop	8	SENT_252	[p18l419t3269r579b3322],
7	8.6	CD	DURATION	8.6	num	8	SENT_252	[p18l603t3248r732b3321],
8	months	NNS	NUMBER	month	_	0	SENT_252	[p18l754t3243r1078b3321],
9	in	IN	O	in	_	0	SENT_252	[p18l1101t3243r1182b3320],
10	the	DT	O	the	det	11	SENT_252	[p18l1203t3243r1332b3321],
11	combinationtherapy	NN	O	combinationtherapy	prep_in	8	SENT_252	[p18l1354t3243r2134b3321, p18l10t3397r156b3471],

1	group	NN	O	group	nn	4	SENT_253	[p18l200t3396r451b3471],
2	and	CC	O	and	_	0	SENT_253	[p18l500t3371r656b3449],
3	6.9	CD	DURATION	6.9	nn	4	SENT_253	[p18l706t3376r834b3449],
4	months	NNS	NUMBER	month	_	0	SENT_253	[p18l884t3370r1209b3449],
5	in	IN	O	in	_	0	SENT_253	[p18l1259t3371r1340b3448],
6	the	DT	O	the	det	8	SENT_253	[p18l1390t3371r1519b3449],
7	monotherapy	JJ	O	monotherapy	amod	8	SENT_253	[p18l1568t3370r2139b3471],
8	group	NN	O	group	prep_in	4	SENT_253	[p18l10t3524r286b3599],
9	.	.	O	.	_	0	SENT_253	[p18l10t3524r286b3599],

1	The	DT	O	the	det	3	SENT_254	[p18l322t3499r484b3577],
2	hazard	NN	O	hazard	nn	3	SENT_254	[p18l518t3498r805b3577],
3	ratio	NN	O	ratio	nsubj	15	SENT_254	[p18l839t3499r1031b3577],
4	for	IN	O	for	_	0	SENT_254	[p18l1066t3498r1191b3577],
5	death	NN	O	death	prep_for	3	SENT_254	[p18l1225t3499r1461b3577],
6	with	IN	O	with	_	0	SENT_254	[p18l1493t3499r1686b3578],
7	combination	NN	O	combination	nn	8	SENT_254	[p18l1723t3499r2132b3577, p18l11t3627r179b3705],
8	therapy	NN	O	therapy	prep_with	5	SENT_254	[p18l205t3627r541b3727],
9	,	,	O	,	_	0	SENT_254	[p18l205t3627r541b3727],
10	as	IN	O	as	mark	3	SENT_254	[p18l571t3653r656b3705],
11	compared	VBN	O	compare	_	0	SENT_254	[p18l684t3627r1114b3727],
12	With	IN	O	with	_	0	SENT_254	[p18l1135t3627r1327b3706],
13	monotherapy	NN	O	monotherapy	prep_compared_with	3	SENT_254	[p18l1352t3627r1947b3727],
14	,	,	O	,	_	0	SENT_254	[p18l1352t3627r1947b3727],
15	was	VBD	O	be	_	0	SENT_254	[p18l1972t3653r2133b3706],

1	O.	NNP	O	O.	nsubj	16	SENT_255	[p19l11t26r193b99],
2	91	CD	PERCENT	91	num	1	SENT_255	[p19l11t26r193b99],
3	(	CD	PERCENT	(	number	4	SENT_255	[p19l224t26r351b112],
4	95	CD	PERCENT	95	dep	1	SENT_255	[p19l224t26r351b112],
5	percent	NN	PERCENT	percent	nn	7	SENT_255	[p19l379t37r699b121],
6	conﬁdence	NN	O	conﬁdence	nn	7	SENT_255	[p19l719t20r1182b99],
7	interval	NN	O	interval	dep	4	SENT_255	[p19l1206t21r1543b116],
8	,	,	O	,	_	0	SENT_255	[p19l1206t21r1543b116],
9	0.68	CD	NUMBER	0.68	number	11	SENT_255	[p19l1574t26r1755b99],
10	to	TO	O	to	dep	11	SENT_255	[p19l1783t37r1862b99],
11	1.21	CD	NUMBER	1.21	nsubj	16	SENT_255	[p19l1891t26r2130b116],
12	)	CD	NUMBER	)	dep	11	SENT_255	[p19l1891t26r2130b116],
13	,	,	O	,	_	0	SENT_255	[p19l1891t26r2130b116],
14	and	CC	O	and	_	0	SENT_255	[p19l10t149r167b227],
15	there	EX	O	there	nsubj	16	SENT_255	[p19l212t148r429b227],
16	was	VBD	O	be	_	0	SENT_255	[p19l470t175r633b228],
17	no	DT	O	no	det	20	SENT_255	[p19l680t174r787b227],
18	statistically	RB	O	statistically	advmod	19	SENT_255	[p19l834t149r1322b249],
19	signiﬁcant	JJ	O	signiﬁcant	amod	20	SENT_255	[p19l1363t148r1825b249],
20	difference	NN	O	difference	attr	16	SENT_255	[p19l1866t148r2133b227, p19l11t302r203b355],
21	between	IN	O	between	_	0	SENT_255	[p19l233t276r589b356],
22	the	DT	O	the	det	24	SENT_255	[p19l619t277r750b355],
23	two	CD	NUMBER	two	num	24	SENT_255	[p19l780t293r934b356],
24	groups	NNS	O	group	prep_between	20	SENT_255	[p19l965t302r1264b377],
25	(	CD	NUMBER	(	num	26	SENT_255	[p19l1300t282r1648b368],
26	P	NN	O	p	npadvmod	16	SENT_255	[p19l1300t282r1648b368],
27	=	JJ	O	=	amod	26	SENT_255	[p19l1300t282r1648b368],
28	0.48	CD	NUMBER	0.48	tmod	27	SENT_255	[p19l1300t282r1648b368],
29	by	IN	O	by	_	0	SENT_255	[p19l1681t277r1779b377],
30	the	DT	O	the	det	35	SENT_255	[p19l1804t277r1935b355],
31	logrank	JJ	O	logrank	amod	35	SENT_255	[p19l1963t276r2133b377, p19l10t405r209b484],
32	test	NN	O	test	nn	35	SENT_255	[p19l255t412r435b496],
33	)	NN	O	)	nn	35	SENT_255	[p19l255t412r435b496],
34	(	CD	NUMBER	(	num	35	SENT_255	[p19l495t405r682b505],
35	Fig	NN	O	fig	prep_by	16	SENT_255	[p19l495t405r682b505],
36	.	.	O	.	_	0	SENT_255	[p19l495t405r682b505],

1	3	CD	NUMBER	3	_	0	SENT_256	[p19l739t410r846b496],
2	)	NN	O	)	dep	1	SENT_256	[p19l739t410r846b496],
3	.	.	O	.	_	0	SENT_256	[p19l739t410r846b496],

1	In	IN	O	in	_	0	SENT_257	[p19l901t412r989b482],
2	the	DT	O	the	det	6	SENT_257	[p19l1040t405r1171b483],
3	combination	NN	O	combination	nn	6	SENT_257	[p19l1223t405r2139b505],
4	—	NN	O	—	nn	6	SENT_257	[p19l1223t405r2139b505],
5	therapy	NN	O	therapy	nn	6	SENT_257	[p19l1223t405r2139b505],
6	group	NN	O	group	prep_in	19	SENT_257	[p19l10t558r291b633],
7	,	,	O	,	_	0	SENT_257	[p19l10t558r291b633],
8	the	DT	O	the	det	11	SENT_257	[p19l325t533r453b611],
9	overall	JJ	O	overall	amod	11	SENT_257	[p19l478t533r753b612],
10	survival	NN	O	survival	nn	11	SENT_257	[p19l778t533r1092b612],
11	rates	NNS	O	rate	nsubj	19	SENT_257	[p19l1116t549r1312b611],
12	at	IN	O	at	_	0	SENT_257	[p19l1337t549r1416b611],
13	6	CD	NUMBER	6	nn	16	SENT_257	[p19l1435t538r1482b611],
14	and	CC	O	and	_	0	SENT_257	[p19l1507t533r1662b611],
15	12	CD	DURATION	12	nn	16	SENT_257	[p19l1689t538r1784b610],
16	months	NNS	NUMBER	month	prep_at	11	SENT_257	[p19l1810t533r2131b611],
17	were	VBD	O	be	cop	19	SENT_257	[p19l6t687r210b740],
18	66	CD	PERCENT	66	num	19	SENT_257	[p19l248t666r349b739],
19	percent	NN	PERCENT	percent	_	0	SENT_257	[p19l385t677r712b761],
20	(	CD	PERCENT	(	number	21	SENT_257	[p19l748t666r877b752],
21	95	CD	PERCENT	95	dep	19	SENT_257	[p19l748t666r877b752],
22	percent	NN	PERCENT	percent	nn	24	SENT_257	[p19l916t677r1243b761],
23	conﬁdence	NN	O	conﬁdence	nn	24	SENT_257	[p19l1275t660r1747b739],
24	interval	NN	O	interval	dep	21	SENT_257	[p19l1783t660r2128b756],
25	,	,	O	,	_	0	SENT_257	[p19l1783t660r2128b756],
26	60	CD	NUMBER	60	number	28	SENT_257	[p19l11t794r112b867],
27	to	TO	O	to	dep	28	SENT_257	[p19l141t805r221b867],
28	72	CD	PERCENT	72	conj_and	19	SENT_257	[p19l252t794r352b867],
29	percent	NN	PERCENT	percent	nn	30	SENT_257	[p19l380t796r731b889],
30	)	NN	O	)	dep	28	SENT_257	[p19l380t796r731b889],
31	and	CC	O	and	_	0	SENT_257	[p19l765t789r922b867],
32	29	CD	PERCENT	29	num	33	SENT_257	[p19l950t794r1051b867],
33	percent	NN	PERCENT	percent	conj_and	19	SENT_257	[p19l1079t805r1406b889],
34	(	CD	PERCENT	(	number	35	SENT_257	[p19l1434t794r1564b880],
35	95	CD	PERCENT	95	dep	33	SENT_257	[p19l1434t794r1564b880],
36	percent	NN	PERCENT	percent	nn	38	SENT_257	[p19l1594t805r1921b889],
37	conﬁdence	NN	O	conﬁdence	nn	38	SENT_257	[p19l1945t814r2133b867, p19l10t916r322b995],
38	interval	NN	O	interval	dep	35	SENT_257	[p19l348t917r693b1012],
39	,	,	O	,	_	0	SENT_257	[p19l348t917r693b1012],
40	22	CD	NUMBER	22	number	42	SENT_257	[p19l724t922r825b994],
41	to	TO	O	to	dep	42	SENT_257	[p19l853t933r933b995],
42	37	CD	PERCENT	37	num	44	SENT_257	[p19l961t922r1061b995],
43	percent	NN	PERCENT	percent	nn	44	SENT_257	[p19l1087t924r1468b1017],
44	)	NN	O	)	appos	35	SENT_257	[p19l1087t924r1468b1017],
45	,	,	O	,	_	0	SENT_257	[p19l1087t924r1468b1017],
46	respectively	RB	O	respectively	advmod	19	SENT_257	[p19l1500t917r2016b1017],
47	.	.	O	.	_	0	SENT_257	[p19l1500t917r2016b1017],

1	In	IN	O	in	_	0	SENT_258	[p19l2046t924r2134b994],
2	the	DT	O	the	det	4	SENT_258	[p19l11t1045r140b1123],
3	monotherapy	JJ	O	monotherapy	amod	4	SENT_258	[p19l164t1045r730b1145],
4	group	NN	O	group	prep_in	17	SENT_258	[p19l749t1070r1022b1145],
5	,	,	O	,	_	0	SENT_258	[p19l749t1070r1022b1145],
6	the	DT	O	the	det	9	SENT_258	[p19l1051t1045r1179b1123],
7	overall	JJ	O	overall	amod	9	SENT_258	[p19l1204t1045r1479b1124],
8	survival	NN	O	survival	nn	9	SENT_258	[p19l1504t1045r1818b1124],
9	rates	NNS	O	rate	nsubj	17	SENT_258	[p19l1841t1061r2037b1123],
10	at	IN	O	at	_	0	SENT_258	[p19l2062t1061r2140b1123],
11	6	CD	NUMBER	6	nn	14	SENT_258	[p19l11t1178r58b1251],
12	and	CC	O	and	_	0	SENT_258	[p19l79t1172r237b1251],
13	12	CD	DURATION	12	conj_and	11	SENT_258	[p19l265t1178r363b1250],
14	months	NNS	NUMBER	month	prep_at	9	SENT_258	[p19l389t1173r718b1251],
15	were	VBD	O	be	cop	17	SENT_258	[p19l740t1199r946b1252],
16	58	CD	PERCENT	58	num	17	SENT_258	[p19l972t1178r1071b1251],
17	percent	NN	PERCENT	percent	_	0	SENT_258	[p19l1096t1189r1423b1273],
18	(	CD	PERCENT	(	number	19	SENT_258	[p19l1447t1178r1576b1264],
19	95	CD	PERCENT	95	dep	17	SENT_258	[p19l1447t1178r1576b1264],
20	percent	NN	PERCENT	percent	nn	22	SENT_258	[p19l1603t1189r1930b1273],
21	conﬁdence	NN	O	conﬁdence	nn	22	SENT_258	[p19l1950t1198r2134b1251, p19l10t1300r311b1379],
22	interval	NN	O	interval	dep	19	SENT_258	[p19l348t1301r678b1396],
23	,	,	O	,	_	0	SENT_258	[p19l348t1301r678b1396],
24	49	CD	NUMBER	49	number	26	SENT_258	[p19l719t1306r820b1379],
25	to	TO	O	to	dep	26	SENT_258	[p19l860t1317r938b1379],
26	67	CD	PERCENT	67	conj_and	17	SENT_258	[p19l978t1306r1077b1379],
27	percent	NN	PERCENT	percent	nn	28	SENT_258	[p19l1114t1308r1452b1401],
28	)	NN	O	)	dep	26	SENT_258	[p19l1114t1308r1452b1401],
29	and	CC	O	and	_	0	SENT_258	[p19l1495t1300r1649b1379],
30	32	CD	PERCENT	32	num	31	SENT_258	[p19l1687t1306r1786b1379],
31	percent	NN	PERCENT	percent	conj_and	17	SENT_258	[p19l1824t1317r2139b1401],
32	(	CD	PERCENT	(	number	33	SENT_258	[p19l15t1434r144b1520],
33	95	CD	PERCENT	95	dep	31	SENT_258	[p19l15t1434r144b1520],
34	percent	NN	PERCENT	percent	nn	36	SENT_258	[p19l171t1445r498b1529],
35	conﬁdence	NN	O	conﬁdence	nn	36	SENT_258	[p19l518t1428r989b1507],
36	interval	NN	O	interval	dep	33	SENT_258	[p19l1013t1429r1358b1524],
37	,	,	O	,	_	0	SENT_258	[p19l1013t1429r1358b1524],
38	23	CD	NUMBER	23	number	40	SENT_258	[p19l1389t1434r1487b1507],
39	to	TO	O	to	dep	40	SENT_258	[p19l1515t1445r1596b1507],
40	41	CD	PERCENT	41	num	42	SENT_258	[p19l1620t1434r1723b1507],
41	percent	NN	PERCENT	percent	nn	42	SENT_258	[p19l1746t1436r2129b1529],
42	)	NN	O	)	appos	33	SENT_258	[p19l1746t1436r2129b1529],
43	,	,	O	,	_	0	SENT_258	[p19l1746t1436r2129b1529],
44	respectively	RB	O	respectively	advmod	17	SENT_258	[p19l10t1557r526b1657],
45	.	.	O	.	_	0	SENT_258	[p19l10t1557r526b1657],

1	The	DT	O	the	det	3	SENT_259	[p19l580t1556r744b1635],
2	median	JJ	O	median	amod	3	SENT_259	[p19l795t1557r1117b1635],
3	survival	NN	O	survival	nsubj	19	SENT_259	[p19l1170t1557r1496b1636],
4	times	NNS	O	time	advmod	19	SENT_259	[p19l1548t1557r1780b1635],
5	among	IN	O	among	_	0	SENT_259	[p19l1833t1582r2137b1657],
6	patients	NNS	O	patient	prep_among	4	SENT_259	[p19l9t1685r343b1785],
7	with	IN	O	with	_	0	SENT_259	[p19l363t1685r553b1764],
8	skin	NN	O	skin	nn	9	SENT_259	[p19l577t1685r752b1764],
9	reactions	NNS	O	reaction	prep_with	6	SENT_259	[p19l775t1685r1158b1763],
10	and	CC	O	and	_	0	SENT_259	[p19l1182t1685r1338b1763],
11	those	DT	O	those	conj_and	9	SENT_259	[p19l1360t1684r1587b1763],
12	without	IN	O	without	_	0	SENT_259	[p19l1606t1684r1940b1764],
13	skin	NN	O	skin	nn	14	SENT_259	[p19l1959t1684r2135b1764],
14	reactions	NNS	O	reaction	prep_without	4	SENT_259	[p19l10t1813r393b1891],
15	were	VBD	O	be	cop	19	SENT_259	[p19l416t1839r619b1892],
16	9.1	CD	NUMBER	9.1	number	19	SENT_259	[p19l645t1818r774b1891],
17	and	CC	O	and	_	0	SENT_259	[p19l801t1812r956b1891],
18	3.0	CD	DURATION	3.0	conj_and	19	SENT_259	[p19l983t1818r1112b1891],
19	months	NNS	NUMBER	month	_	0	SENT_259	[p19l1139t1813r1488b1908],
20	,	,	O	,	_	0	SENT_259	[p19l1139t1813r1488b1908],
21	respectively	RB	O	respectively	advmod	19	SENT_259	[p19l1520t1813r2023b1913],
22	,	,	O	,	_	0	SENT_259	[p19l1520t1813r2023b1913],
23	in	IN	O	in	_	0	SENT_259	[p19l2054t1813r2135b1890],
24	the	DT	O	the	det	28	SENT_259	[p19l11t1941r141b2019],
25	combination	NN	O	combination	nn	28	SENT_259	[p19l183t1941r1099b2041],
26	—	NN	O	—	nn	28	SENT_259	[p19l183t1941r1099b2041],
27	therapy	NN	O	therapy	nn	28	SENT_259	[p19l183t1941r1099b2041],
28	group	NN	O	group	prep_in	19	SENT_259	[p19l1135t1966r1390b2041],
29	and	CC	O	and	_	0	SENT_259	[p19l1432t1941r1589b2019],
30	8.1	CD	NUMBER	8.1	nn	33	SENT_259	[p19l1631t1946r1762b2019],
31	and	CC	O	and	_	0	SENT_259	[p19l1803t1941r1961b2019],
32	2.5	CD	DURATION	2.5	conj_and	30	SENT_259	[p19l2002t1946r2130b2019],
33	months	NNS	NUMBER	month	conj_and	28	SENT_259	[p19l10t2069r364b2164],
34	,	,	O	,	_	0	SENT_259	[p19l10t2069r364b2164],
35	respectively	RB	O	respectively	advmod	19	SENT_259	[p19l396t2069r899b2169],
36	,	,	O	,	_	0	SENT_259	[p19l396t2069r899b2169],
37	in	IN	O	in	_	0	SENT_259	[p19l929t2069r1010b2146],
38	the	DT	O	the	det	40	SENT_259	[p19l1036t2069r1165b2147],
39	monotherapy	JJ	O	monotherapy	amod	40	SENT_259	[p19l1190t2068r1761b2169],
40	group	NN	O	group	prep_in	19	SENT_259	[p19l1781t2094r2058b2169],
41	.	.	O	.	_	0	SENT_259	[p19l1781t2094r2058b2169],

1	Fifty	CD	NUMBER	fifty	num	4	SENT_260	[p19l138t2196r478b2297],
2	—	CD	NUMBER	—	num	4	SENT_260	[p19l138t2196r478b2297],
3	six	CD	NUMBER	six	num	4	SENT_260	[p19l138t2196r478b2297],
4	patients	NNS	O	patient	nsubj	9	SENT_260	[p19l504t2197r838b2297],
5	in	IN	O	in	_	0	SENT_260	[p19l870t2197r952b2274],
6	the	DT	O	the	det	8	SENT_260	[p19l983t2197r1112b2275],
7	monotherapy	NN	O	monotherapy	nn	8	SENT_260	[p19l1143t2197r1713b2297],
8	group	NN	O	group	prep_in	4	SENT_260	[p19l1739t2222r1990b2297],
9	received	VBD	O	receive	_	0	SENT_260	[p19l2022t2223r2134b2275, p19l11t2325r268b2404],
10	additional	JJ	O	additional	amod	11	SENT_260	[p19l300t2324r727b2403],
11	irinotecan	NN	O	irinotecan	dobj	9	SENT_260	[p19l758t2325r1186b2403],
12	after	IN	O	after	mark	16	SENT_260	[p19l1217t2324r1411b2403],
13	disease	NN	O	disease	nn	14	SENT_260	[p19l1441t2325r1744b2403],
14	progression	NN	O	progression	nsubjpass	16	SENT_260	[p19l1775t2350r2134b2425, p19l12t2453r188b2531],
15	was	VBD	O	be	auxpass	16	SENT_260	[p19l211t2479r372b2532],
16	recognized	VBN	O	recognize	advcl	9	SENT_260	[p19l401t2452r891b2553],
17	.	.	O	.	_	0	SENT_260	[p19l401t2452r891b2553],

1	Two	CD	NUMBER	two	nsubj	23	SENT_261	[p19l919t2458r1098b2532],
2	of	IN	O	of	_	0	SENT_261	[p19l1126t2452r1227b2531],
3	these	DT	O	these	det	5	SENT_261	[p19l1235t2452r1454b2531],
4	56	CD	NUMBER	56	num	5	SENT_261	[p19l1482t2458r1581b2531],
5	patients	NNS	O	patient	prep_of	1	SENT_261	[p19l1607t2453r1942b2553],
6	(	IN	PERCENT	(	mark	10	SENT_261	[p19l1975t2458r2134b2544],
7	3.6	CD	PERCENT	3.6	num	9	SENT_261	[p19l1975t2458r2134b2544],
8	percent	NN	PERCENT	percent	nn	9	SENT_261	[p19l9t2588r353b2681],
9	)	NN	O	)	nsubj	10	SENT_261	[p19l9t2588r353b2681],
10	had	VBD	O	have	dep	23	SENT_261	[p19l390t2581r546b2659],
11	a	DT	O	a	det	13	SENT_261	[p19l576t2607r620b2659],
12	partial	JJ	O	partial	amod	13	SENT_261	[p19l649t2581r920b2681],
13	response	NN	O	response	dobj	10	SENT_261	[p19l951t2606r1354b2681],
14	,	,	O	,	_	0	SENT_261	[p19l951t2606r1354b2681],
15	and	CC	O	and	_	0	SENT_261	[p19l1390t2581r1546b2659],
16	an	DT	O	a	det	18	SENT_261	[p19l1576t2606r1677b2659],
17	additional	JJ	O	additional	amod	18	SENT_261	[p19l1708t2581r2135b2659],
18	20	CD	PERCENT	20	dobj	10	SENT_261	[p19l10t2714r111b2787],
19	(	CD	PERCENT	(	number	20	SENT_261	[p19l145t2714r357b2800],
20	35.7	CD	PERCENT	35.7	num	22	SENT_261	[p19l145t2714r357b2800],
21	percent	NN	PERCENT	percent	nn	22	SENT_261	[p19l385t2716r730b2809],
22	)	NN	O	)	dep	18	SENT_261	[p19l385t2716r730b2809],
23	had	VBD	O	have	_	0	SENT_261	[p19l764t2708r919b2787],
24	stable	JJ	O	stable	amod	25	SENT_261	[p19l949t2709r1196b2787],
25	disease	NN	O	disease	dobj	23	SENT_261	[p19l1226t2709r1529b2787],
26	after	IN	O	after	_	0	SENT_261	[p19l1557t2708r1751b2787],
27	crossing	VBG	O	cross	prepc_after	23	SENT_261	[p19l1777t2709r2138b2809],
28	over	RP	O	over	prt	27	SENT_261	[p19l11t2862r205b2916],
29	.	.	O	.	_	0	SENT_261	[p19l11t2862r205b2916],

1	The	DT	O	the	det	3	SENT_262	[p19l243t2836r404b2915],
2	median	JJ	O	median	amod	3	SENT_262	[p19l440t2837r756b2915],
3	time	NN	O	time	nsubj	18	SENT_262	[p19l792t2837r979b2915],
4	to	TO	O	to	_	0	SENT_262	[p19l1015t2853r1094b2915],
5	progression	NN	O	progression	prep_to	3	SENT_262	[p19l1130t2837r1638b2937],
6	among	IN	O	among	_	0	SENT_262	[p19l1673t2862r1973b2937],
7	the	DT	O	the	det	8	SENT_262	[p19l2006t2836r2135b2915],
8	patients	NNS	O	patient	prep_among	5	SENT_262	[p19l9t2965r343b3065],
9	who	WP	O	who	nsubj	10	SENT_262	[p19l394t2965r578b3044],
10	crossed	VBD	O	cross	rcmod	8	SENT_262	[p19l633t2965r953b3043],
11	over	IN	O	over	prt	10	SENT_262	[p19l1007t2990r1184b3044],
12	to	TO	O	to	aux	13	SENT_262	[p19l1235t2981r1314b3043],
13	receive	VB	O	receive	xcomp	10	SENT_262	[p19l1369t2965r1655b3044],
14	additional	JJ	O	additional	amod	15	SENT_262	[p19l1708t2965r2135b3043],
15	irinotecan	NN	O	irinotecan	dobj	13	SENT_262	[p19l10t3093r437b3171],
16	was	VBD	O	be	cop	18	SENT_262	[p19l472t3119r633b3172],
17	1.4	CD	DURATION	1.4	num	18	SENT_262	[p19l677t3098r805b3171],
18	months	NNS	NUMBER	month	_	0	SENT_262	[p19l843t3093r1193b3171],
19	.	.	O	.	_	0	SENT_262	[p19l843t3093r1193b3171],

1	These	DT	O	these	det	2	SENT_263	[p19l1234t3093r1485b3171],
2	results	NNS	O	result	nsubj	6	SENT_263	[p19l1525t3092r1802b3172],
3	may	MD	O	may	aux	6	SENT_263	[p19l1843t3119r2020b3193],
4	in	IN	O	in	advmod	6	SENT_263	[p19l2054t3093r2135b3170],
5	part	NN	O	part	dep	4	SENT_263	[p19l9t3237r182b3321],
6	explain	VBP	O	explain	_	0	SENT_263	[p19l203t3221r507b3321],
7	the	DT	O	the	det	8	SENT_263	[p19l534t3221r663b3299],
8	absence	NN	O	absence	dobj	6	SENT_263	[p19l688t3221r1024b3299],
9	of	IN	O	of	_	0	SENT_263	[p19l1051t3220r1152b3299],
10	a	DT	O	a	det	12	SENT_263	[p19l1158t3247r1202b3299],
11	signiﬁcant	NN	O	signiﬁcant	nn	12	SENT_263	[p19l1229t3220r1691b3321],
12	difference	NN	O	difference	prep_of	8	SENT_263	[p19l1713t3220r2134b3299],
13	in	IN	O	in	_	0	SENT_263	[p19l10t3349r91b3426],
14	overall	JJ	O	overall	amod	15	SENT_263	[p19l117t3349r395b3428],
15	survival	NN	O	survival	prep_in	12	SENT_263	[p19l421t3348r739b3428],
16	between	IN	O	between	_	0	SENT_263	[p19l764t3349r1113b3428],
17	the	DT	O	the	det	19	SENT_263	[p19l1139t3349r1268b3427],
18	two	CD	NUMBER	two	num	19	SENT_263	[p19l1294t3365r1446b3428],
19	groups	NNS	O	group	prep_between	15	SENT_263	[p19l1472t3374r1791b3449],
20	.	.	O	.	_	0	SENT_263	[p19l1472t3374r1791b3449],

1	All	PDT	O	all	predet	3	SENT_264	[p19l136t3477r255b3554],
2	the	DT	O	the	det	3	SENT_264	[p19l282t3477r411b3555],
3	patients	NNS	O	patient	nsubj	4	SENT_264	[p19l438t3477r773b3577],
4	received	VBD	O	receive	_	0	SENT_264	[p19l803t3477r1144b3556],
5	at	IN	O	at	quantmod	7	SENT_264	[p19l1171t3493r1250b3555],
6	least	JJS	O	least	mwe	5	SENT_264	[p19l1272t3477r1469b3555],
7	one	CD	NUMBER	one	num	8	SENT_264	[p19l1492t3502r1645b3555],
8	infusion	NN	O	infusion	dobj	4	SENT_264	[p19l1672t3476r2024b3556],
9	of	IN	O	of	_	0	SENT_264	[p19l2053t3476r2153b3555],
10	cetuximab	NN	O	cetuximab	prep_of	8	SENT_264	[p19l11t3604r471b3684],
11	.	.	O	.	_	0	SENT_264	[p19l11t3604r471b3684],

1	The	DT	O	the	det	3	SENT_265	[p19l494t3605r655b3683],
2	median	JJ	O	median	amod	3	SENT_265	[p19l677t3605r993b3683],
3	number	NN	O	number	_	0	SENT_265	[p19l1015t3604r1351b3684],
4	of	IN	O	of	_	0	SENT_265	[p19l1370t3604r1471b3683],
5	cetuximab	JJ	O	cetuximab	amod	6	SENT_265	[p19l1474t3605r1909b3684],
6	infusions	NNS	O	infusion	prep_of	3	SENT_265	[p19l1931t3604r2133b3684, p20l12t32r230b110],

1	was	VBD	O	be	cop	2	SENT_266	[p20l275t58r437b111],
2	18	CD	NUMBER	18	_	0	SENT_266	[p20l490t37r586b110],
3	in	IN	O	in	_	0	SENT_266	[p20l635t32r716b109],
4	the	DT	O	the	det	8	SENT_266	[p20l765t32r894b110],
5	combination	NN	O	combination	nn	8	SENT_266	[p20l943t32r1840b132],
6	—	NN	O	—	nn	8	SENT_266	[p20l943t32r1840b132],
7	therapy	NN	O	therapy	nn	8	SENT_266	[p20l943t32r1840b132],
8	group	NN	O	group	prep_in	2	SENT_266	[p20l1882t57r2134b132],
9	and	CC	O	and	_	0	SENT_266	[p20l10t159r165b238],
10	7	CD	NUMBER	7	conj_and	2	SENT_266	[p20l197t167r242b238],
11	in	IN	O	in	_	0	SENT_266	[p20l273t160r354b237],
12	the	DT	O	the	det	14	SENT_266	[p20l385t160r514b238],
13	monotherapy	JJ	O	monotherapy	amod	14	SENT_266	[p20l544t160r1116b260],
14	group	NN	O	group	prep_in	10	SENT_266	[p20l1141t185r1416b260],
15	.	.	O	.	_	0	SENT_266	[p20l1141t185r1416b260],

1	Table	NNP	O	Table	nsubj	3	SENT_267	[p20l1449t159r1677b238],
2	4	CD	NUMBER	4	num	1	SENT_267	[p20l1705t166r1756b238],
3	summarizes	VBZ	O	summarize	_	0	SENT_267	[p20l1787t186r2134b239, p20l10t288r206b366],
4	the	DT	O	the	det	8	SENT_267	[p20l234t288r363b366],
5	most	RBS	O	most	advmod	6	SENT_267	[p20l389t304r606b366],
6	frequently	RB	O	frequently	advmod	7	SENT_267	[p20l627t287r1058b388],
7	observed	VBN	O	observe	amod	8	SENT_267	[p20l1081t288r1455b367],
8	grade	NN	O	grade	dobj	3	SENT_267	[p20l1481t288r1716b388],
9	3	CD	NUMBER	3	num	13	SENT_267	[p20l1743t293r1787b366],
10	or	CC	O	or	_	0	SENT_267	[p20l1817t313r1906b366],
11	4	CD	NUMBER	4	num	13	SENT_267	[p20l1927t293r1978b366],
12	adverse	JJ	O	adverse	amod	13	SENT_267	[p20l2002t288r2134b366, p20l6t442r218b495],
13	events	NNS	O	event	dobj	3	SENT_267	[p20l242t432r498b495],
14	related	JJ	O	related	amod	13	SENT_267	[p20l522t415r806b494],
15	to	TO	O	to	_	0	SENT_267	[p20l828t432r907b494],
16	treatment	NN	O	treatment	prep_to	14	SENT_267	[p20l931t432r1358b494],
17	.	.	O	.	_	0	SENT_267	[p20l931t432r1358b494],

1	Four	CD	NUMBER	four	num	2	SENT_268	[p20l1385t423r1583b495],
2	patients	NNS	O	patient	nsubj	45	SENT_268	[p20l1601t416r1931b516],
3	who	WP	O	who	nsubjpass	6	SENT_268	[p20l1952t416r2134b495],
4	were	VBD	O	be	auxpass	6	SENT_268	[p20l6t570r207b623],
5	randomly	RB	O	randomly	advmod	6	SENT_268	[p20l230t543r640b644],
6	assigned	VBN	O	assign	rcmod	2	SENT_268	[p20l657t544r1028b644],
7	to	TO	O	to	_	0	SENT_268	[p20l1051t560r1130b622],
8	the	DT	O	the	det	11	SENT_268	[p20l1155t544r1284b622],
9	combination	NN	O	combination	nn	11	SENT_268	[p20l1308t544r2134b622],
10	—	NN	O	—	nn	11	SENT_268	[p20l1308t544r2134b622],
11	thera	NN	O	thera	prep_to	6	SENT_268	[p20l1308t544r2134b622],
12	—	CD	NUMBER	—	num	14	SENT_268	[p20l1308t544r2134b622],
13	py	NN	O	py	nn	14	SENT_268	[p20l9t698r108b772],
14	group	NN	O	group	nsubjpass	22	SENT_268	[p20l140t697r391b772],
15	did	VBD	O	do	aux	17	SENT_268	[p20l429t672r562b750],
16	not	RB	O	not	neg	17	SENT_268	[p20l599t688r742b750],
17	receive	VB	O	receive	rcmod	11	SENT_268	[p20l774t672r1059b751],
18	irinotecan	NN	O	irinotecan	dobj	17	SENT_268	[p20l1095t672r1522b750],
19	and	CC	O	and	_	0	SENT_268	[p20l1558t672r1714b750],
20	therefore	RB	O	therefore	advmod	22	SENT_268	[p20l1751t671r2134b750],
21	were	VBD	O	be	auxpass	22	SENT_268	[p20l6t826r210b879],
22	evaluated	VBN	O	evaluate	conj_and	17	SENT_268	[p20l239t799r641b879],
23	for	IN	O	for	_	0	SENT_268	[p20l668t799r793b878],
24	safety	NN	O	safety	prep_for	22	SENT_268	[p20l819t799r1065b900],
25	as	IN	O	as	_	0	SENT_268	[p20l1087t826r1173b878],
26	part	NN	O	part	prep_as	22	SENT_268	[p20l1201t816r1378b900],
27	of	IN	O	of	_	0	SENT_268	[p20l1400t799r1502b878],
28	the	DT	O	the	det	30	SENT_268	[p20l1511t800r1642b878],
29	monotherapy	JJ	O	monotherapy	amod	30	SENT_268	[p20l1670t799r2132b878, p20l10t954r158b1028],
30	group	NN	O	group	prep_of	26	SENT_268	[p20l188t953r469b1028],
31	,	,	O	,	_	0	SENT_268	[p20l188t953r469b1028],
32	and	CC	O	and	_	0	SENT_268	[p20l509t928r667b1006],
33	two	CD	NUMBER	two	num	34	SENT_268	[p20l701t944r855b1007],
34	patients	NNS	O	patient	prep_to	6	SENT_268	[p20l890t928r1232b1028],
35	who	WP	O	who	nsubjpass	38	SENT_268	[p20l1265t928r1450b1007],
36	were	VBD	O	be	auxpass	38	SENT_268	[p20l1482t954r1686b1007],
37	randomly	RB	O	randomly	advmod	38	SENT_268	[p20l1722t927r2138b1028],
38	assigned	VBN	O	assign	rcmod	34	SENT_268	[p20l10t1056r387b1156],
39	to	TO	O	to	_	0	SENT_268	[p20l439t1072r518b1134],
40	the	DT	O	the	det	44	SENT_268	[p20l571t1056r700b1134],
41	combination	NN	O	combination	nn	44	SENT_268	[p20l753t1055r1650b1156],
42	—	NN	O	—	nn	44	SENT_268	[p20l753t1055r1650b1156],
43	therapy	NN	O	therapy	nn	44	SENT_268	[p20l753t1055r1650b1156],
44	group	NN	O	group	prep_to	38	SENT_268	[p20l1697t1081r1948b1156],
45	did	VBD	O	do	_	0	SENT_268	[p20l2002t1056r2135b1134],

1	342	CD	NUMBER	342	num	4	SENT_269	[p20l149t1231r206b1253],
2	N	NN	O	n	nn	4	SENT_269	[p20l917t1233r930b1248],
3	ENGLJ	NN	O	englj	nn	4	SENT_269	[p20l946t1232r1030b1254],
4	MED	NN	O	med	_	0	SENT_269	[p20l1045t1233r1097b1248],
5	351	CD	NUMBER	351	dep	4	SENT_269	[p20l1110t1232r1174b1254],
6	;	:	O	;	_	0	SENT_269	[p20l1110t1232r1174b1254],
7	4	CD	NUMBER	4	dep	4	SENT_269	[p20l1110t1232r1174b1254],
8	WWW	NNP	O	WWW	dep	7	SENT_269	[p20l1208t1233r1320b1248],
9	.	.	O	.	_	0	SENT_269	[p20l1208t1233r1320b1248],

1	NE	NN	O	ne	nn	3	SENT_270	[p20l1208t1233r1320b1248],
2	M.ORG	NN	O	m.org	nn	3	SENT_270	[p20l1336t1232r1420b1248],
3	JULY	NN	DATE	july	_	0	SENT_270	[p20l1453t1233r1513b1254],
4	22	CD	DATE	22	dep	3	SENT_270	[p20l1525t1232r1562b1252],
5	,	,	O	,	_	0	SENT_270	[p20l1525t1232r1562b1252],
6	2oo4	CD	NUMBER	2oo4	appos	4	SENT_270	[p20l1575t1232r1643b1254],

1	The	DT	O	the	det	5	SENT_271	[p20l936t1265r987b1289],
2	New	NNP	O	New	nn	5	SENT_271	[p20l996t1266r1058b1289],
3	England	NNP	O	England	nn	5	SENT_271	[p20l1067t1265r1178b1296],
4	Journal	NNP	O	Journal	nn	5	SENT_271	[p20l1187t1265r1284b1289],
5	o	NN	O	o	_	0	SENT_271	[p20l1294t1273r1309b1289],
6	edicine	NN	O	edicine	dep	5	SENT_271	[p20l1360t1265r1455b1289],

1	Downloaded	VBN	O	download	_	0	SENT_272	[p20l378t1306r548b1329],
2	from	IN	O	from	_	0	SENT_272	[p20l557t1306r621b1329],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_272	[p20l630t1306r748b1336],
4	at	IN	O	at	_	0	SENT_272	[p20l759t1310r782b1329],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_272	[p20l790t1306r973b1329],
6	on	IN	O	on	_	0	SENT_272	[p20l982t1313r1015b1329],
7	January	NNP	DATE	January	prep_on	1	SENT_272	[p20l1023t1306r1126b1336],
8	5	CD	DATE	5	num	7	SENT_272	[p20l1136t1306r1159b1333],
9	,	,	DATE	,	_	0	SENT_272	[p20l1136t1306r1159b1333],
10	2014	CD	DATE	2014	num	7	SENT_272	[p20l1170t1306r1242b1329],
11	.	.	O	.	_	0	SENT_272	[p20l1170t1306r1242b1329],

1	For	IN	O	for	_	0	SENT_273	[p20l1252t1306r1299b1329],
2	personal	JJ	O	personal	amod	3	SENT_273	[p20l1307t1306r1419b1336],
3	use	NN	O	use	pobj	1	SENT_273	[p20l1428t1313r1472b1329],
4	only	RB	O	only	advmod	3	SENT_273	[p20l1482t1306r1546b1336],
5	.	.	O	.	_	0	SENT_273	[p20l1482t1306r1546b1336],

1	No	DT	O	no	det	3	SENT_274	[p20l1557t1306r1597b1329],
2	other	JJ	O	other	amod	3	SENT_274	[p20l1607t1306r1675b1329],
3	uses	NNS	O	use	_	0	SENT_274	[p20l1683t1313r1739b1329],
4	without	IN	O	without	_	0	SENT_274	[p20l1749t1306r1850b1329],
5	permission	NN	O	permission	prep_without	3	SENT_274	[p20l1859t1306r2011b1336],
6	.	.	O	.	_	0	SENT_274	[p20l1859t1306r2011b1336],

1	Copyright	NN	O	copyright	_	0	SENT_275	[p20l728t1347r863b1378],
2	©	CD	NUMBER	©	num	6	SENT_275	[p20l872t1347r896b1371],
3	2004	CD	DATE	2004	num	6	SENT_275	[p20l906t1347r971b1371],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_275	[p20l980t1347r1171b1371],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_275	[p20l1181t1347r1289b1371],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_275	[p20l1300t1347r1405b1378],
7	.	.	O	.	_	0	SENT_275	[p20l1300t1347r1405b1378],

1	All	DT	O	all	det	2	SENT_276	[p20l1416t1347r1457b1371],
2	rights	NNS	O	rights	nsubj	3	SENT_276	[p20l1466t1347r1541b1378],
3	reserved	VBN	O	reserve	_	0	SENT_276	[p20l1551t1347r1670b1371],
4	.	.	O	.	_	0	SENT_276	[p20l1551t1347r1670b1371],

1	CETUXIMAB	NNP	O	CETUXIMAB	_	0	SENT_277	[p20l533t1453r727b1472],
2	IN	IN	O	in	dep	1	SENT_277	[p20l742t1453r780b1472],
3	IRINOTECAN-REFRACTORY	NNP	O	IRINOTECAN-REFRACTORY	nn	5	SENT_277	[p20l796t1453r1248b1472],
4	COLORECTAL	NNP	O	COLORECTAL	nn	5	SENT_277	[p20l1260t1453r1477b1472],
5	CANCER	NNP	O	CANCER	pobj	2	SENT_277	[p20l1490t1453r1626b1472],

1	not	RB	O	not	neg	2	SENT_278	[p20l11t1683r154b1745],
2	receive	VB	O	receive	_	0	SENT_278	[p20l184t1667r470b1746],
3	any	DT	O	any	det	5	SENT_278	[p20l505t1692r653b1767],
4	study	NN	O	study	nn	5	SENT_278	[p20l686t1667r911b1767],
5	medication	NN	O	medication	dobj	2	SENT_278	[p20l942t1667r1439b1745],
6	.	.	O	.	_	0	SENT_278	[p20l942t1667r1439b1745],

1	In	IN	O	in	_	0	SENT_279	[p20l1479t1674r1567b1744],
2	4	CD	NUMBER	4	prep_in	18	SENT_279	[p20l1601t1672r1651b1745],
3	of	IN	O	of	_	0	SENT_279	[p20l1687t1666r1788b1745],
4	the	DT	O	the	det	7	SENT_279	[p20l1808t1666r1939b1745],
5	329	CD	NUMBER	329	num	7	SENT_279	[p20l1978t1672r2132b1745],
6	enrolled	VBN	O	enrol	amod	7	SENT_279	[p20l11t1795r366b1873],
7	patients	NNS	O	patient	prep_of	2	SENT_279	[p20l386t1795r721b1895],
8	(	IN	O	(	_	0	SENT_279	[p20l750t1800r908b1886],
9	1.2	CD	PERCENT	1.2	num	11	SENT_279	[p20l750t1800r908b1886],
10	percent	NN	PERCENT	percent	nn	11	SENT_279	[p20l930t1802r1303b1895],
11	)	NN	O	)	prep_(	7	SENT_279	[p20l930t1802r1303b1895],
12	,	,	O	,	_	0	SENT_279	[p20l930t1802r1303b1895],
13	severe	JJ	O	severe	amod	15	SENT_279	[p20l1332t1821r1586b1874],
14	anaphylactic	JJ	O	anaphylactic	amod	15	SENT_279	[p20l1608t1795r2136b1895],
15	reactions	NNS	O	reaction	nsubj	18	SENT_279	[p20l11t1923r393b2001],
16	to	TO	O	to	_	0	SENT_279	[p20l439t1939r518b2001],
17	cetuximab	NN	O	cetuximab	prep_to	15	SENT_279	[p20l564t1923r998b2002],
18	developed	VBD	O	develop	_	0	SENT_279	[p20l1044t1922r1492b2023],
19	,	,	O	,	_	0	SENT_279	[p20l1044t1922r1492b2023],
20	and	CC	O	and	_	0	SENT_279	[p20l1540t1923r1696b2001],
21	the	DT	O	the	det	22	SENT_279	[p20l1740t1923r1869b2001],
22	treatment	NN	O	treatment	nsubjpass	24	SENT_279	[p20l1913t1939r2134b2001, p20l11t2067r233b2129],
23	Was	VBD	O	be	auxpass	24	SENT_279	[p20l253t2077r414b2130],
24	discontinued	VBN	O	discontinue	conj_and	18	SENT_279	[p20l446t2050r1020b2130],
25	.	.	O	.	_	0	SENT_279	[p20l446t2050r1020b2130],

1	There	EX	O	there	expl	2	SENT_280	[p20l1052t2051r1297b2129],
2	were	VBD	O	be	_	0	SENT_280	[p20l1323t2077r1524b2130],
3	no	DT	O	no	det	5	SENT_280	[p20l1554t2076r1660b2129],
4	treatmentrelated	JJ	O	treatmentrelated	amod	5	SENT_280	[p20l1691t2067r2134b2129, p20l11t2179r296b2257],
5	deaths	NNS	O	death	nsubj	2	SENT_280	[p20l321t2179r619b2257],
6	.	.	O	.	_	0	SENT_280	[p20l321t2179r619b2257],

1	Acne	NN	O	acne	nn	3	SENT_281	[p20l645t2179r1046b2258],
2	—	NN	O	—	nn	3	SENT_281	[p20l645t2179r1046b2258],
3	lil	NN	O	lil	_	0	SENT_281	[p20l645t2179r1046b2258],
4	<	JJR	O	<	amod	3	SENT_281	[p20l645t2179r1046b2258],
5	e	LS	O	e	dep	7	SENT_281	[p20l645t2179r1046b2258],
6	rash	NN	O	rash	nsubj	7	SENT_281	[p20l1069t2179r1250b2257],
7	occurred	VBD	O	occur	dep	4	SENT_281	[p20l1274t2179r1644b2258],
8	in	IN	O	in	dep	7	SENT_281	[p20l1667t2179r1748b2256],
9	about	IN	O	about	_	0	SENT_281	[p20l1772t2179r2015b2258],
10	80	CD	PERCENT	80	num	11	SENT_281	[p20l2035t2184r2134b2257],
11	percent	NN	PERCENT	percent	prep_about	7	SENT_281	[p20l10t2323r326b2407],
12	of	IN	O	of	_	0	SENT_281	[p20l344t2306r445b2385],
13	the	DT	O	the	det	14	SENT_281	[p20l448t2307r576b2385],
14	patients	NNS	O	patient	prep_of	11	SENT_281	[p20l598t2307r928b2407],
15	in	IN	O	in	_	0	SENT_281	[p20l952t2307r1033b2384],
16	each	DT	O	each	det	17	SENT_281	[p20l1056t2307r1244b2385],
17	group	NN	O	group	prep_in	7	SENT_281	[p20l1265t2332r1539b2407],
18	,	,	O	,	_	0	SENT_281	[p20l1265t2332r1539b2407],
19	but	CC	O	but	_	0	SENT_281	[p20l1567t2307r1707b2386],
20	grade	NN	O	grade	nsubjpass	30	SENT_281	[p20l1724t2307r1957b2407],
21	3	CD	NUMBER	3	num	20	SENT_281	[p20l1980t2312r2024b2385],
22	or	CC	O	or	_	0	SENT_281	[p20l2050t2332r2139b2385],
23	4	CD	NUMBER	4	num	25	SENT_281	[p20l9t2440r59b2513],
24	toxic	JJ	O	toxic	amod	25	SENT_281	[p20l92t2435r298b2513],
25	effects	NNS	O	effect	nsubjpass	30	SENT_281	[p20l334t2434r610b2513],
26	on	IN	O	on	_	0	SENT_281	[p20l650t2460r757b2513],
27	the	DT	O	the	det	28	SENT_281	[p20l794t2434r925b2513],
28	skin	NN	O	skin	prep_on	25	SENT_281	[p20l963t2435r1143b2514],
29	were	VBD	O	be	auxpass	30	SENT_281	[p20l1175t2461r1379b2514],
30	observed	VBN	O	observe	conj_but	7	SENT_281	[p20l1416t2435r1799b2514],
31	in	IN	O	in	_	0	SENT_281	[p20l1835t2435r1917b2512],
32	only	RB	O	only	quantmod	33	SENT_281	[p20l1954t2435r2139b2535],
33	9.4	CD	PERCENT	9.4	num	34	SENT_281	[p20l11t2568r143b2641],
34	percent	NN	PERCENT	percent	prep_in	30	SENT_281	[p20l185t2579r511b2663],
35	and	CC	O	and	_	0	SENT_281	[p20l545t2563r701b2641],
36	5.2	CD	PERCENT	5.2	num	37	SENT_281	[p20l744t2568r871b2641],
37	percent	NN	PERCENT	percent	conj_and	34	SENT_281	[p20l910t2579r1232b2663],
38	of	IN	O	of	_	0	SENT_281	[p20l1267t2562r1368b2641],
39	the	DT	O	the	det	43	SENT_281	[p20l1390t2563r1519b2641],
40	combinationtherapy	NN	O	combinationtherapy	nn	43	SENT_281	[p20l1561t2563r2134b2641, p20l11t2691r328b2791],
41	and	CC	O	and	_	0	SENT_281	[p20l357t2691r513b2769],
42	monotherapy	NN	O	monotherapy	nn	43	SENT_281	[p20l547t2691r1118b2791],
43	groups	NNS	O	group	prep_of	37	SENT_281	[p20l1148t2716r1467b2791],
44	,	,	O	,	_	0	SENT_281	[p20l1148t2716r1467b2791],
45	respectively	RB	O	respectively	dep	4	SENT_281	[p20l1506t2691r2010b2791],
46	.	.	O	.	_	0	SENT_281	[p20l1506t2691r2010b2791],

1	In	IN	O	in	_	0	SENT_282	[p20l2048t2698r2135b2768],
2	225	CD	NUMBER	225	prep_in	27	SENT_282	[p20l11t2824r161b2897],
3	of	IN	O	of	_	0	SENT_282	[p20l192t2818r292b2897],
4	the	DT	O	the	det	6	SENT_282	[p20l300t2819r429b2897],
5	253	CD	NUMBER	253	num	6	SENT_282	[p20l456t2824r607b2897],
6	patients	NNS	O	patient	prep_of	2	SENT_282	[p20l635t2819r970b2919],
7	in	IN	O	in	_	0	SENT_282	[p20l998t2819r1078b2896],
8	Whom	WP	O	whom	rel	14	SENT_282	[p20l1101t2818r1372b2898],
9	any	DT	O	any	det	10	SENT_282	[p20l1398t2844r1545b2919],
10	form	NN	O	form	nsubj	14	SENT_282	[p20l1567t2818r1775b2897],
11	of	IN	O	of	_	0	SENT_282	[p20l1802t2818r1902b2897],
12	acnelike	JJ	O	acnelike	amod	13	SENT_282	[p20l1910t2844r2134b2897, p20l10t2947r163b3026],
13	rash	NN	O	rash	prep_of	10	SENT_282	[p20l205t2947r389b3025],
14	developed	VBD	O	develop	rcmod	2	SENT_282	[p20l432t2946r864b3047],
15	(	CD	PERCENT	(	number	16	SENT_282	[p20l911t2952r1127b3038],
16	88.9	CD	PERCENT	88.9	num	18	SENT_282	[p20l911t2952r1127b3038],
17	percent	NN	PERCENT	percent	nn	18	SENT_282	[p20l1170t2954r1552b3047],
18	)	NN	O	)	dobj	14	SENT_282	[p20l1170t2954r1552b3047],
19	,	,	O	,	_	0	SENT_282	[p20l1170t2954r1552b3047],
20	the	DT	O	the	det	21	SENT_282	[p20l1599t2947r1731b3025],
21	rash	NN	O	rash	nsubj	27	SENT_282	[p20l1773t2947r1957b3025],
22	appeared	VBD	O	appear	cop	27	SENT_282	[p20l1999t2973r2132b3047, p20l10t3074r298b3175],
23	Within	IN	O	within	dep	27	SENT_282	[p20l318t3075r592b3154],
24	the	DT	O	the	det	25	SENT_282	[p20l616t3075r744b3153],
25	ﬁrst	NN	O	ﬁrst	pobj	23	SENT_282	[p20l768t3074r941b3153],
26	three	CD	DURATION	three	num	27	SENT_282	[p20l959t3075r1172b3153],
27	Weeks	NNS	DURATION	week	_	0	SENT_282	[p20l1191t3075r1450b3154],
28	after	IN	O	after	_	0	SENT_282	[p20l1475t3074r1668b3153],
29	the	DT	O	the	det	30	SENT_282	[p20l1689t3074r1818b3153],
30	start	NN	O	start	prep_after	27	SENT_282	[p20l1843t3091r2034b3153],
31	of	IN	O	of	_	0	SENT_282	[p20l2053t3074r2154b3153],
32	cetuximab	NN	O	cetuximab	nn	33	SENT_282	[p20l11t3203r455b3282],
33	treatment	NN	O	treatment	prep_of	30	SENT_282	[p20l500t3219r943b3281],
34	.	.	O	.	_	0	SENT_282	[p20l500t3219r943b3281],

1	Diarrhea	NNP	MISC	Diarrhea	nsubj	6	SENT_283	[p20l990t3203r1369b3281],
2	and	CC	O	and	_	0	SENT_283	[p20l1411t3203r1568b3281],
3	neutropenia	NN	O	neutropenia	conj_and	1	SENT_283	[p20l1612t3203r2136b3303],
4	Were	VBD	O	be	cop	6	SENT_283	[p20l6t3357r211b3410],
5	more	RBR	O	more	advmod	6	SENT_283	[p20l247t3356r467b3409],
6	frequent	JJ	O	frequent	_	0	SENT_283	[p20l501t3330r863b3431],
7	among	IN	O	among	_	0	SENT_283	[p20l891t3356r1191b3431],
8	the	DT	O	the	det	9	SENT_283	[p20l1222t3331r1352b3409],
9	patients	NNS	O	patient	prep_among	6	SENT_283	[p20l1385t3331r1719b3431],
10	receiving	VBG	O	receive	partmod	9	SENT_283	[p20l1755t3331r2138b3431],
11	irinotecan	NN	O	irinotecan	dobj	10	SENT_283	[p20l10t3459r446b3537],
12	in	IN	O	in	_	0	SENT_283	[p20l491t3459r574b3536],
13	combination	NN	O	combination	prep_in	6	SENT_283	[p20l620t3459r1171b3537],
14	with	IN	O	with	_	0	SENT_283	[p20l1212t3458r1405b3538],
15	cetuximab	NN	O	cetuximab	prep_with	6	SENT_283	[p20l1452t3459r1895b3538],
16	than	IN	O	than	mark	18	SENT_283	[p20l1943t3459r2134b3537],
17	they	PRP	O	they	nsubj	18	SENT_283	[p20l11t3587r191b3687],
18	were	VBD	O	be	ccomp	6	SENT_283	[p20l205t3613r406b3666],
19	among	IN	O	among	_	0	SENT_283	[p20l428t3612r727b3687],
20	those	DT	O	those	nsubj	21	SENT_283	[p20l745t3587r972b3665],
21	receiving	VBG	O	receive	prepc_among	18	SENT_283	[p20l993t3587r1376b3687],
22	cetuximab	NN	O	cetuximab	nn	23	SENT_283	[p20l1395t3587r1829b3666],
23	monotherapy	NN	O	monotherapy	dobj	21	SENT_283	[p20l1852t3612r2134b3665, p21l11t21r339b121],
24	,	,	O	,	_	0	SENT_283	[p20l1852t3612r2134b3665, p21l11t21r339b121],

1	but	CC	O	but	cc	6	SENT_284	[p21l371t21r512b100],
2	the	DT	O	the	det	3	SENT_284	[p21l533t20r663b99],
3	frequency	NN	O	frequency	nsubj	6	SENT_284	[p21l688t20r1106b121],
4	of	IN	O	of	_	0	SENT_284	[p21l1128t20r1228b99],
5	each	DT	O	each	prep_of	3	SENT_284	[p21l1236t21r1426b99],
6	Was	VBD	O	be	_	0	SENT_284	[p21l1447t47r1608b100],
7	in	IN	O	in	_	0	SENT_284	[p21l1635t21r1717b98],
8	the	DT	O	the	det	9	SENT_284	[p21l1742t21r1872b99],
9	range	NN	O	range	prep_in	6	SENT_284	[p21l1898t46r2135b121],
10	that	WDT	O	that	nsubjpass	13	SENT_284	[p21l11t149r178b227],
11	would	MD	O	would	aux	13	SENT_284	[p21l193t149r459b228],
12	be	VB	O	be	auxpass	13	SENT_284	[p21l484t149r579b227],
13	expected	VBN	O	expect	rcmod	9	SENT_284	[p21l606t149r972b249],
14	for	IN	O	for	_	0	SENT_284	[p21l998t148r1121b227],
15	irinotecan	NN	O	irinotecan	prep_for	13	SENT_284	[p21l1142t149r1570b227],
16	alone	RB	O	alone	advmod	13	SENT_284	[p21l1594t149r1846b227],
17	.	.	O	.	_	0	SENT_284	[p21l1594t149r1846b227],

1	DISCUSSION	NN	O	discussion	_	0	SENT_285	[p21l717t464r1415b523],

1	In	IN	O	in	_	0	SENT_286	[p21l9t666r96b735],
2	this	DT	O	this	det	4	SENT_286	[p21l118t659r267b736],
3	randomized	JJ	O	randomized	amod	4	SENT_286	[p21l291t658r791b737],
4	trial	NN	O	trial	prep_in	13	SENT_286	[p21l813t659r996b753],
5	,	,	O	,	_	0	SENT_286	[p21l813t659r996b753],
6	cetuximab	NN	O	cetuximab	prep_in	13	SENT_286	[p21l1024t659r1448b737],
7	alone	RB	O	alone	advmod	6	SENT_286	[p21l1470t659r1694b737],
8	or	CC	O	or	_	0	SENT_286	[p21l1717t684r1805b737],
9	in	IN	O	in	conj_or	4	SENT_286	[p21l1822t659r1903b735],
10	combination	NN	O	combination	pobj	9	SENT_286	[p21l1925t684r2135b737, p21l11t787r356b865],
11	with	IN	O	with	_	0	SENT_286	[p21l373t786r558b866],
12	irinotecan	NN	O	irinotecan	prep_with	4	SENT_286	[p21l579t787r996b865],
13	had	VBD	O	have	_	0	SENT_286	[p21l1017t787r1170b865],
14	clinical	JJ	O	clinical	amod	15	SENT_286	[p21l1191t787r1483b865],
15	activity	NN	O	activity	dobj	13	SENT_286	[p21l1504t787r1790b887],
16	in	IN	O	in	_	0	SENT_286	[p21l1807t787r1887b864],
17	irinotecan	NN	O	irinotecan	prep_in	15	SENT_286	[p21l1907t787r2135b865, p21l11t914r696b1015],
18	—	CD	NUMBER	—	num	21	SENT_286	[p21l1907t787r2135b865, p21l11t914r696b1015],
19	refractory	JJ	O	refractory	amod	21	SENT_286	[p21l1907t787r2135b865, p21l11t914r696b1015],
20	colorectal	JJ	O	colorectal	amod	21	SENT_286	[p21l717t915r1140b993],
21	cancer	NN	O	cancer	nsubj	13	SENT_286	[p21l1164t940r1462b1010],
22	,	,	O	,	_	0	SENT_286	[p21l1164t940r1462b1010],
23	conﬁrming	VBG	O	conﬁrming	partmod	13	SENT_286	[p21l1492t914r1981b1015],
24	the	DT	O	the	det	25	SENT_286	[p21l2003t915r2134b993],
25	results	NNS	O	result	dobj	23	SENT_286	[p21l11t1043r294b1122],
26	of	IN	O	of	_	0	SENT_286	[p21l333t1042r433b1121],
27	phase	NN	O	phase	nn	29	SENT_286	[p21l450t1043r696b1143],
28	2	CD	NUMBER	2	num	29	SENT_286	[p21l733t1048r780b1120],
29	studies	NNS	O	study	prep_of	25	SENT_286	[p21l819t1037r1327b1122],
30	.17	CD	NUMBER	.17	number	31	SENT_286	[p21l819t1037r1327b1122],
31	’18	CD	NUMBER	’18	tmod	23	SENT_286	[p21l819t1037r1327b1122],
32	The	DT	O	the	det	34	SENT_286	[p21l1362t1043r1523b1121],
33	combinationtherapy	JJ	O	combinationtherapy	amod	34	SENT_286	[p21l1560t1043r2133b1121, p21l11t1171r328b1271],
34	group	NN	O	group	nsubj	35	SENT_286	[p21l355t1196r606b1271],
35	had	VBD	O	have	rcmod	31	SENT_286	[p21l638t1171r794b1249],
36	a	DT	O	a	det	40	SENT_286	[p21l825t1197r869b1249],
37	signiﬁcantly	RB	O	signiﬁcantly	advmod	38	SENT_286	[p21l900t1170r1421b1271],
38	higher	JJR	O	higher	amod	40	SENT_286	[p21l1448t1171r1727b1271],
39	response	NN	O	response	nn	40	SENT_286	[p21l1755t1196r2135b1271],
40	rate	NN	O	rate	dobj	35	SENT_286	[p21l11t1315r167b1377],
41	and	CC	O	and	_	0	SENT_286	[p21l196t1299r352b1377],
42	a	DT	O	a	det	45	SENT_286	[p21l380t1325r424b1377],
43	signiﬁcantly	RB	O	signiﬁcantly	advmod	44	SENT_286	[p21l454t1298r975b1399],
44	longer	JJR	O	longer	amod	45	SENT_286	[p21l998t1299r1275b1399],
45	time	NN	O	time	dobj	35	SENT_286	[p21l1302t1299r1488b1377],
46	to	TO	O	to	_	0	SENT_286	[p21l1518t1315r1597b1377],
47	progression	NN	O	progression	prep_to	40	SENT_286	[p21l1626t1299r2135b1399],
48	than	IN	O	than	_	0	SENT_286	[p21l11t1427r199b1504],
49	the	DT	O	the	det	51	SENT_286	[p21l234t1427r362b1504],
50	monotherapy	JJ	O	monotherapy	amod	51	SENT_286	[p21l397t1427r969b1526],
51	group	NN	O	group	prep_than	47	SENT_286	[p21l998t1451r1273b1526],
52	,	,	O	,	_	0	SENT_286	[p21l998t1451r1273b1526],
53	suggesting	VBG	O	suggest	dobj	35	SENT_286	[p21l1315t1427r1779b1526],
54	that	IN	O	that	complm	63	SENT_286	[p21l1809t1427r1976b1504],
55	the	DT	O	the	det	56	SENT_286	[p21l2006t1427r2135b1504],
56	combination	NN	O	combination	nsubjpass	63	SENT_286	[p21l11t1555r551b1633],
57	of	IN	O	of	_	0	SENT_286	[p21l591t1554r691b1633],
58	irinotecan	NN	O	irinotecan	prep_of	56	SENT_286	[p21l711t1555r1139b1633],
59	and	CC	O	and	_	0	SENT_286	[p21l1176t1555r1332b1633],
60	cetuximab	NN	O	cetuximab	prep_of	56	SENT_286	[p21l1372t1555r1806b1634],
61	should	MD	O	should	aux	63	SENT_286	[p21l1848t1554r2135b1634],
62	be	VB	O	be	auxpass	63	SENT_286	[p21l11t1683r107b1761],
63	preferred	VBN	O	prefer	ccomp	53	SENT_286	[p21l131t1682r522b1783],
64	for	IN	O	for	_	0	SENT_286	[p21l546t1682r670b1761],
65	patients	NNS	O	patient	prep_for	63	SENT_286	[p21l691t1683r1025b1783],
66	with	IN	O	with	_	0	SENT_286	[p21l1048t1683r1237b1762],
67	irinotecan	NN	O	irinotecan	prep_with	65	SENT_286	[p21l1261t1682r2140b1783],
68	—	CD	NUMBER	—	num	70	SENT_286	[p21l1261t1682r2140b1783],
69	refractory	JJ	O	refractory	amod	70	SENT_286	[p21l1261t1682r2140b1783],
70	cancer	NN	O	cancer	dep	31	SENT_286	[p21l11t1836r295b1889],
71	.	.	O	.	_	0	SENT_286	[p21l11t1836r295b1889],

1	Moreover	RB	O	moreover	advmod	20	SENT_287	[p21l321t1818r733b1906],
2	,	,	O	,	_	0	SENT_287	[p21l321t1818r733b1906],
3	the	DT	O	the	det	4	SENT_287	[p21l762t1811r889b1889],
4	number	NN	O	number	nsubj	20	SENT_287	[p21l911t1811r1241b1890],
5	of	IN	O	of	_	0	SENT_287	[p21l1261t1810r1361b1889],
6	previous	JJ	O	previous	amod	8	SENT_287	[p21l1363t1811r1712b1911],
7	treatment	NN	O	treatment	nn	8	SENT_287	[p21l1737t1827r2141b1889],
8	regimens	NNS	O	regimen	prep_of	4	SENT_287	[p21l11t1939r410b2039],
9	and	CC	O	and	_	0	SENT_287	[p21l441t1939r598b2017],
10	previous	JJ	O	previous	amod	11	SENT_287	[p21l626t1939r991b2039],
11	use	NN	O	use	conj_and	4	SENT_287	[p21l1021t1965r1163b2018],
12	or	CC	O	or	_	0	SENT_287	[p21l1193t1964r1283b2017],
13	nonuse	NN	O	nonuse	conj_and	4	SENT_287	[p21l1309t1964r1623b2018],
14	of	IN	O	of	_	0	SENT_287	[p21l1652t1938r1754b2017],
15	oXalipla	NN	O	oxaliplum	nn	17	SENT_287	[p21l1765t1938r2135b2039],
16	—	CD	NUMBER	—	num	17	SENT_287	[p21l1765t1938r2135b2039],
17	tin	NN	O	tin	prep_of	11	SENT_287	[p21l11t2067r121b2145],
18	did	VBD	O	do	aux	20	SENT_287	[p21l149t2066r280b2145],
19	not	RB	O	not	neg	20	SENT_287	[p21l308t2083r449b2145],
20	affect	VB	O	affect	_	0	SENT_287	[p21l471t2066r703b2145],
21	the	DT	O	the	det	22	SENT_287	[p21l726t2067r853b2145],
22	efficacy	NN	O	efficacy	dobj	20	SENT_287	[p21l882t2066r1194b2167],
23	of	IN	O	of	_	0	SENT_287	[p21l1217t2066r1317b2145],
24	the	DT	O	the	det	26	SENT_287	[p21l1327t2067r1454b2145],
25	cetuXimab	NN	O	cetuximab	nn	26	SENT_287	[p21l1483t2067r2134b2146],
26	—	NN	O	—	prep_of	22	SENT_287	[p21l1483t2067r2134b2146],
27	and	CC	O	and	_	0	SENT_287	[p21l1483t2067r2134b2146],
28	—	NN	O	—	nn	30	SENT_287	[p21l1483t2067r2134b2146],
29	irinotecan	NN	O	irinotecan	nn	30	SENT_287	[p21l10t2195r437b2272],
30	combination	NN	O	combination	prep_of	22	SENT_287	[p21l473t2195r1036b2272],
31	.	.	O	.	_	0	SENT_287	[p21l473t2195r1036b2272],

1	Cetuximab	NNP	O	Cetuximab	nn	2	SENT_288	[p21l1077t2195r1532b2273],
2	monotherapy	NNP	O	monotherapy	nsubj	4	SENT_288	[p21l1568t2195r2140b2294],
3	also	RB	O	also	advmod	4	SENT_288	[p21l10t2323r175b2401],
4	had	VBD	O	have	_	0	SENT_288	[p21l198t2323r353b2401],
5	activity	NN	O	activity	dobj	4	SENT_288	[p21l373t2323r665b2423],
6	and	CC	O	and	cc	5	SENT_288	[p21l682t2323r837b2401],
7	only	RB	O	only	advmod	5	SENT_288	[p21l859t2323r1038b2423],
8	mild	JJ	O	mild	amod	10	SENT_288	[p21l1055t2323r1247b2401],
9	toxic	JJ	O	toxic	amod	10	SENT_288	[p21l1269t2323r1468b2401],
10	effects	NNS	O	effect	dep	5	SENT_288	[p21l1489t2322r1756b2401],
11	and	CC	O	and	_	0	SENT_288	[p21l1779t2323r1934b2401],
12	thus	RB	O	thus	advmod	16	SENT_288	[p21l1955t2323r2134b2402],
13	may	MD	O	may	aux	16	SENT_288	[p21l11t2477r187b2551],
14	be	VB	O	be	cop	16	SENT_288	[p21l213t2451r308b2529],
15	an	DT	O	a	det	16	SENT_288	[p21l338t2476r438b2529],
16	option	NN	O	option	conj_and	4	SENT_288	[p21l469t2451r744b2551],
17	for	IN	O	for	_	0	SENT_288	[p21l775t2450r897b2529],
18	patients	NNS	O	patient	prep_for	16	SENT_288	[p21l923t2451r1257b2551],
19	who	WP	O	who	nsubjpass	22	SENT_288	[p21l1284t2451r1468b2530],
20	are	VBP	O	be	auxpass	22	SENT_288	[p21l1498t2477r1624b2529],
21	not	RB	O	not	neg	22	SENT_288	[p21l1654t2467r1798b2529],
22	considered	VBN	O	consider	dep	16	SENT_288	[p21l1823t2451r2134b2529, p21l11t2579r191b2657],
23	candidates	NNS	O	candidate	dobj	22	SENT_288	[p21l220t2579r668b2657],
24	for	IN	O	for	_	0	SENT_288	[p21l700t2578r823b2657],
25	further	JJ	O	further	amod	26	SENT_288	[p21l848t2578r1144b2658],
26	treatment	NN	O	treatment	prep_for	23	SENT_288	[p21l1171t2595r1585b2657],
27	With	IN	O	with	_	0	SENT_288	[p21l1605t2579r1794b2658],
28	irinotecan	NN	O	irinotecan	nn	29	SENT_288	[p21l1822t2579r2134b2657, p21l11t2707r437b2784],
29	—	NN	O	—	prep_with	22	SENT_288	[p21l1822t2579r2134b2657, p21l11t2707r437b2784],
30	based	VBN	O	base	partmod	29	SENT_288	[p21l1822t2579r2134b2657, p21l11t2707r437b2784],
31	chemotherapy	NN	O	chemotherapy	dobj	30	SENT_288	[p21l466t2707r1073b2806],
32	or	CC	O	or	_	0	SENT_288	[p21l1098t2731r1187b2784],
33	who	WP	O	who	nsubj	34	SENT_288	[p21l1208t2707r1391b2785],
34	choose	VBP	O	choose	conj_or	22	SENT_288	[p21l1422t2707r1717b2784],
35	not	RB	O	not	neg	37	SENT_288	[p21l1746t2723r1890b2784],
36	to	TO	O	to	aux	37	SENT_288	[p21l1913t2722r1992b2784],
37	receive	VB	O	receive	xcomp	34	SENT_288	[p21l2022t2732r2134b2784, p21l11t2813r213b2892],
38	such	JJ	O	such	amod	39	SENT_288	[p21l240t2813r434b2892],
39	treatment	NN	O	treatment	dobj	37	SENT_288	[p21l460t2828r892b2891],
40	.	.	O	.	_	0	SENT_288	[p21l460t2828r892b2891],

1	The	DT	O	the	det	2	SENT_289	[p21l136t2941r300b3019],
2	effectiveness	NN	O	effectiveness	nsubj	15	SENT_289	[p21l333t2940r880b3020],
3	of	IN	O	of	_	0	SENT_289	[p21l915t2940r1016b3019],
4	the	DT	O	the	det	5	SENT_289	[p21l1030t2941r1162b3019],
5	combination	NN	O	combination	prep_of	2	SENT_289	[p21l1195t2941r1745b3019],
6	of	IN	O	of	_	0	SENT_289	[p21l1779t2940r1880b3019],
7	irinotecan	NN	O	irinotecan	prep_of	5	SENT_289	[p21l1893t2941r2132b3019, p21l11t3085r237b3147],
8	and	CC	O	and	_	0	SENT_289	[p21l272t3069r429b3147],
9	cetuximab	NN	O	cetuximab	prep_of	5	SENT_289	[p21l465t3069r908b3148],
10	in	IN	O	in	_	0	SENT_289	[p21l944t3069r1026b3146],
11	patients	NNS	O	patient	prep_in	7	SENT_289	[p21l1060t3069r1402b3169],
12	with	IN	O	with	_	0	SENT_289	[p21l1434t3068r1627b3148],
13	irinotecanrefractory	JJ	O	irinotecanrefractory	amod	14	SENT_289	[p21l1661t3069r2132b3147, p21l11t3196r432b3297],
14	tumors	NNS	O	tumor	prep_with	11	SENT_289	[p21l475t3213r782b3276],
15	suggests	VBZ	O	suggest	_	0	SENT_289	[p21l833t3213r1203b3297],
16	that	IN	O	that	complm	19	SENT_289	[p21l1253t3197r1424b3275],
17	cetuximab	NN	O	cetuximab	nsubj	19	SENT_289	[p21l1467t3197r1910b3276],
18	may	MD	O	may	aux	19	SENT_289	[p21l1959t3223r2139b3297],
19	circumvent	VB	O	circumvent	ccomp	15	SENT_289	[p21l11t3325r472b3403],
20	irinotecan	JJ	O	irinotecan	amod	21	SENT_289	[p21l485t3325r899b3402],
21	resistance	NN	O	resistance	dobj	19	SENT_289	[p21l918t3325r1349b3402],
22	.	.	O	.	_	0	SENT_289	[p21l918t3325r1349b3402],

1	Cells	NNS	O	cell	nsubj	2	SENT_290	[p21l1373t3325r1571b3402],
2	acquire	VBP	O	acquire	_	0	SENT_290	[p21l1590t3325r1891b3424],
3	irinotecan	JJ	O	irinotecan	amod	4	SENT_290	[p21l1909t3325r2135b3402, p21l11t3467r229b3529],
4	resistance	NN	O	resistance	dobj	2	SENT_290	[p21l264t3452r696b3529],
5	by	IN	O	by	_	0	SENT_290	[p21l732t3452r831b3551],
6	several	JJ	O	several	amod	7	SENT_290	[p21l863t3452r1153b3530],
7	mechanisms	NNS	O	mechanism	prep_by	2	SENT_290	[p21l1188t3447r1846b3529],
8	.	.	O	.	_	0	SENT_290	[p21l1188t3447r1846b3529],

1	”	JJ	O	”	amod	3	SENT_291	[p21l1188t3447r1846b3529],
2	EGFR	NN	ORGANIZATION	egfr	nn	3	SENT_291	[p21l1882t3457r2144b3534],
3	inhibition	NN	O	inhibition	nsubj	7	SENT_291	[p21l10t3580r438b3658],
4	by	IN	O	by	_	0	SENT_291	[p21l473t3580r570b3680],
5	cetuximab	NN	O	cetuximab	prep_by	3	SENT_291	[p21l600t3580r1034b3659],
6	may	MD	O	may	aux	7	SENT_291	[p21l1070t3606r1246b3680],
7	overcome	VB	O	overcome	_	0	SENT_291	[p21l1277t3605r1684b3659],
8	this	DT	O	this	det	9	SENT_291	[p21l1719t3580r1871b3658],
9	resistance	NN	O	resistance	dobj	7	SENT_291	[p21l1907t3580r2134b3658, p21l11t3722r235b3784],
10	by	IN	O	by	_	0	SENT_291	[p21l265t3707r362b3806],
11	abrogating	VBG	O	abrogate	prepc_by	7	SENT_291	[p21l386t3707r851b3806],
12	drug	NN	O	drug	nsubj	16	SENT_291	[p21l878t3707r1077b3806],
13	efﬂuX	NNP	O	efﬂuX	dep	12	SENT_291	[p21l1104t3702r1558b3801],
14	,2	CD	NUMBER	,2	num	13	SENT_291	[p21l1104t3702r1558b3801],
15	-3	CD	NUMBER	-3	num	16	SENT_291	[p21l1104t3702r1558b3801],
16	'28	CD	NUMBER	'28	xcomp	11	SENT_291	[p21l1104t3702r1558b3801],
17	restoring	VBG	O	restore	partmod	16	SENT_291	[p21l1589t3707r1976b3806],
18	apoptosis	NN	O	apoptosis	dobj	17	SENT_291	[p21l2002t3732r2133b3806, p22l11t19r427b124],
19	,29	CD	NUMBER	,29	num	18	SENT_291	[p21l2002t3732r2133b3806, p22l11t19r427b124],

1	or	CC	O	or	dep	2	SENT_292	[p22l453t49r542b102],
2	impairing	VBG	O	impair	_	0	SENT_292	[p22l563t24r985b124],
3	DNA	NN	MISC	dna	nn	7	SENT_292	[p22l1006t25r1501b124],
4	—	NN	O	—	nn	7	SENT_292	[p22l1006t25r1501b124],
5	repair	NN	O	repair	nn	7	SENT_292	[p22l1006t25r1501b124],
6	activity	NN	O	activity	nn	7	SENT_292	[p22l1523t18r2020b124],
7	.3	NN	NUMBER	.3	dobj	2	SENT_292	[p22l1523t18r2020b124],
8	°	CD	NUMBER	°	num	9	SENT_292	[p22l1523t18r2020b124],
9	’31	CD	NUMBER	’31	dep	7	SENT_292	[p22l1523t18r2020b124],

1	An	DT	O	a	det	3	SENT_293	[p22l136t159r256b229],
2	acne	NN	O	acne	nn	3	SENT_293	[p22l294t152r670b231],
3	—	NN	O	—	nsubj	18	SENT_293	[p22l294t152r670b231],
4	like	IN	O	like	prep	3	SENT_293	[p22l294t152r670b231],
5	or	CC	O	or	_	0	SENT_293	[p22l709t177r798b230],
6	maculopapular	JJ	O	maculopapular	amod	7	SENT_293	[p22l834t152r1468b252],
7	rash	NN	O	rash	conj_or	3	SENT_293	[p22l1504t152r1705b247],
8	,	,	O	,	_	0	SENT_293	[p22l1504t152r1705b247],
9	a	DT	O	a	det	12	SENT_293	[p22l1749t178r1793b230],
10	characteristic	JJ	O	characteristic	amod	12	SENT_293	[p22l1831t152r2134b230, p22l11t279r292b356],
11	side	NN	O	side	nn	12	SENT_293	[p22l326t278r490b357],
12	effect	NN	O	effect	appos	7	SENT_293	[p22l524t278r755b356],
13	of	IN	O	of	_	0	SENT_293	[p22l784t278r883b357],
14	EGFR	NN	ORGANIZATION	egfr	nn	15	SENT_293	[p22l896t284r1153b362],
15	blockade	NN	O	blockade	prep_of	12	SENT_293	[p22l1176t279r1575b373],
16	,	,	O	,	_	0	SENT_293	[p22l1176t279r1575b373],
17	is	VBZ	O	be	cop	18	SENT_293	[p22l1612t279r1677b356],
18	due	JJ	O	due	_	0	SENT_293	[p22l1712t279r1861b358],
19	to	TO	O	to	_	0	SENT_293	[p22l1895t295r1972b357],
20	the	DT	O	the	det	21	SENT_293	[p22l2007t279r2135b356],
21	role	NN	O	role	prep_to	18	SENT_293	[p22l11t407r171b485],
22	of	IN	O	of	_	0	SENT_293	[p22l214t406r314b485],
23	EGFR	NN	ORGANIZATION	egfr	prep_of	21	SENT_293	[p22l336t412r596b490],
24	in	IN	O	in	_	0	SENT_293	[p22l628t407r708b484],
25	maintaining	VBG	O	maintain	prepc_in	18	SENT_293	[p22l751t407r1274b507],
26	the	DT	O	the	det	27	SENT_293	[p22l1314t407r1443b485],
27	integrity	NN	O	integrity	dobj	25	SENT_293	[p22l1487t407r1842b507],
28	of	IN	O	of	_	0	SENT_293	[p22l1880t406r1981b485],
29	the	DT	O	the	det	30	SENT_293	[p22l2006t407r2135b485],
30	skin	NN	O	skin	prep_of	27	SENT_293	[p22l12t535r211b614],
31	.	.	O	.	_	0	SENT_293	[p22l12t535r211b614],

1	Response	NN	O	response	nsubjpass	6	SENT_294	[p22l239t541r648b635],
2	and	CC	O	and	_	0	SENT_294	[p22l671t534r827b613],
3	survival	NN	O	survival	conj_and	1	SENT_294	[p22l852t535r1170b614],
4	have	VBP	O	have	aux	6	SENT_294	[p22l1193t535r1381b614],
5	been	VBN	O	be	auxpass	6	SENT_294	[p22l1407t535r1606b613],
6	shown	VBN	O	show	_	0	SENT_294	[p22l1631t535r1910b614],
7	to	TO	O	to	aux	9	SENT_294	[p22l1935t551r2014b613],
8	be	VB	O	be	auxpass	9	SENT_294	[p22l2039t535r2135b613],
9	correlated	VBN	O	correlate	xcomp	6	SENT_294	[p22l11t663r433b741],
10	with	IN	O	with	_	0	SENT_294	[p22l463t663r652b742],
11	the	DT	O	the	det	12	SENT_294	[p22l687t663r816b741],
12	severity	NN	O	severity	prep_with	9	SENT_294	[p22l852t663r1167b763],
13	of	IN	O	of	_	0	SENT_294	[p22l1198t662r1299b741],
14	the	DT	O	the	det	15	SENT_294	[p22l1314t663r1443b741],
15	rash	NN	O	rash	prep_of	12	SENT_294	[p22l1478t663r1659b741],
16	in	IN	O	in	_	0	SENT_294	[p22l1692t663r1774b740],
17	phase	NN	O	phase	prep_in	15	SENT_294	[p22l1806t663r2052b763],
18	2	CD	NUMBER	2	num	17	SENT_294	[p22l2087t668r2134b740],

1	o	NN	O	o	nsubj	4	SENT_295	[p22l178t1058r223b1106],
2	\	SYM	O	\	dep	4	SENT_295	[p22l178t1058r223b1106],
3	°	CD	NUMBER	°	num	4	SENT_295	[p22l178t1058r223b1106],
4	8	CD	NUMBER	8	_	0	SENT_295	[p22l123t1108r235b1170],
5	?	.	O	?	_	0	SENT_295	[p22l123t1108r235b1170],

1	u	NN	O	u	_	0	SENT_296	[p22l112t1170r221b1245],
2	'	''	O	'	_	0	SENT_296	[p22l112t1170r221b1245],
3	:	:	O	:	_	0	SENT_296	[p22l112t1170r221b1245],
4	.	.	O	.	_	0	SENT_296	[p22l112t1170r221b1245],

1	%	NN	O	%	_	0	SENT_297	[p22l112t1170r221b1245],
2	~	CD	NUMBER	~	rcmod	1	SENT_297	[p22l115t1239r221b1300],
3	93	CD	NUMBER	93	number	4	SENT_297	[p22l115t1239r221b1300],
4	5	CD	NUMBER	5	dep	2	SENT_297	[p22l123t1286r220b1318],
5	;	:	O	;	_	0	SENT_297	[p22l123t1286r220b1318],
6	.	.	O	.	_	0	SENT_297	[p22l123t1286r220b1318],

1	.	.	O	.	_	0	SENT_298	[p22l109t1316r235b1355],

1	“	NN	O	“	_	0	SENT_299	[p22l109t1316r235b1355],
2	_	SYM	O	_	dep	1	SENT_299	[p22l109t1316r235b1355],
3	-	:	O	-	_	0	SENT_299	[p22l109t1316r235b1355],
4	’	NN	O	’	nn	5	SENT_299	[p22l109t1316r235b1355],
5	b1	NN	O	b1	dep	1	SENT_299	[p22l109t1316r235b1355],
6	)	CD	NUMBER	)	num	8	SENT_299	[p22l109t1316r235b1355],
7	4-o	NN	O	4-o	nn	8	SENT_299	[p22l115t1354r221b1382],
8	I5	NN	O	i5	dep	5	SENT_299	[p22l123t1379r153b1404],
9	n.E	NN	O	n.e	nn	11	SENT_299	[p22l112t1383r220b1434],
10	u.	NN	O	u.	nn	11	SENT_299	[p22l175t1443r220b1470],
11	o	NN	O	o	dep	5	SENT_299	[p22l191t1471r221b1499],

1	Time	NNP	O	Time	_	0	SENT_300	[p22l830t1650r955b1694],
2	to	TO	O	to	dep	1	SENT_300	[p22l970t1657r1019b1694],
3	Progression	NNP	O	Progression	nn	5	SENT_300	[p22l1040t1650r1328b1708],
4	(	CD	NUMBER	(	num	5	SENT_300	[p22l1351t1649r1572b1709],
5	months	NNS	NUMBER	month	pobj	2	SENT_300	[p22l1351t1649r1572b1709],
6	)	IN	O	)	dep	1	SENT_300	[p22l1351t1649r1572b1709],

1	Figure	NN	O	figure	_	0	SENT_301	[p22l66t1820r228b1882],
2	2	CD	NUMBER	2	dep	1	SENT_301	[p22l245t1823r289b1867],
3	.	.	O	.	_	0	SENT_301	[p22l245t1823r289b1867],

1	Time	NNP	O	Time	_	0	SENT_302	[p22l307t1820r440b1867],
2	to	TO	O	to	_	0	SENT_302	[p22l455t1827r507b1867],
3	Disease	NNP	O	Disease	nn	4	SENT_302	[p22l529t1820r732b1867],
4	Progression	NNP	O	Progression	prep_to	1	SENT_302	[p22l753t1820r1060b1882],
5	in	IN	O	in	_	0	SENT_302	[p22l1082t1820r1126b1866],
6	the	DT	O	the	det	9	SENT_302	[p22l1144t1819r1229b1867],
7	Two	CD	NUMBER	two	num	9	SENT_302	[p22l1245t1823r1351b1867],
8	Study	NNP	MISC	Study	nn	9	SENT_302	[p22l1368t1819r1518b1882],
9	Groups	NNS	MISC	group	prep_in	1	SENT_302	[p22l1535t1823r1745b1881],
10	.	.	O	.	_	0	SENT_302	[p22l1535t1823r1745b1881],

1	The	DT	O	the	det	3	SENT_303	[p22l60t1915r157b1964],
2	hazard	NN	O	hazard	nn	3	SENT_303	[p22l176t1915r348b1964],
3	ratio	NN	O	ratio	_	0	SENT_303	[p22l370t1920r485b1964],
4	for	IN	O	for	_	0	SENT_303	[p22l500t1914r573b1964],
5	disease	NN	O	disease	nn	6	SENT_303	[p22l588t1915r782b1964],
6	progression	NN	O	progression	prep_for	3	SENT_303	[p22l801t1920r1109b1979],
7	in	IN	O	in	_	0	SENT_303	[p22l1131t1920r1172b1963],
8	the	DT	O	the	det	10	SENT_303	[p22l1190t1915r1272b1964],
9	combination-therapy	JJ	O	combination-therapy	amod	10	SENT_303	[p22l1288t1915r1838b1979],
10	group	NN	O	group	prep_in	3	SENT_303	[p22l1853t1932r2006b1979],
11	as	IN	O	as	dep	19	SENT_303	[p22l2024t1932r2076b1964],
12	compared	VBN	O	compare	_	0	SENT_303	[p22l63t1995r324b2058],
13	with	IN	O	with	prepc_compared_with	19	SENT_303	[p22l344t1995r452b2044],
14	the	DT	O	the	det	16	SENT_303	[p22l472t1995r554b2044],
15	monotherapy	JJ	O	monotherapy	amod	16	SENT_303	[p22l576t1995r926b2059],
16	group	NN	O	group	pobj	19	SENT_303	[p22l944t2012r1097b2059],
17	was	VBD	O	be	cop	19	SENT_303	[p22l1114t2012r1213b2044],
18	0.54	CD	PERCENT	0.54	num	19	SENT_303	[p22l1233t1999r1341b2044],
19	(	CD	PERCENT	(	dep	3	SENT_303	[p22l1367t2000r1441b2059],
20	95	CD	PERCENT	95	num	23	SENT_303	[p22l1367t2000r1441b2059],
21	percent	NN	PERCENT	percent	nn	23	SENT_303	[p22l1466t2005r1660b2058],
22	confidence	NN	O	confidence	nn	23	SENT_303	[p22l1678t1995r1964b2044],
23	interval	NN	O	interval	nsubj	19	SENT_303	[p22l1986t2000r2047b2043, p22l61t2076r218b2132],
24	,	,	O	,	_	0	SENT_303	[p22l1986t2000r2047b2043, p22l61t2076r218b2132],
25	0.42	CD	NUMBER	0.42	num	27	SENT_303	[p22l239t2079r346b2124],
26	to	TO	O	to	dep	27	SENT_303	[p22l365t2085r416b2124],
27	0.71	CD	NUMBER	0.71	appos	23	SENT_303	[p22l435t2079r562b2139],
28	)	CD	NUMBER	)	number	29	SENT_303	[p22l435t2079r562b2139],
29	(	CD	NUMBER	(	num	30	SENT_303	[p22l592t2079r818b2139],
30	P	NN	O	p	npadvmod	31	SENT_303	[p22l592t2079r818b2139],
31	<	JJR	O	<	amod	27	SENT_303	[p22l592t2079r818b2139],
32	0.001	CD	NUMBER	0.001	dep	31	SENT_303	[p22l592t2079r818b2139],
33	by	IN	O	by	dep	32	SENT_303	[p22l843t2076r897b2139],
34	the	DT	O	the	det	37	SENT_303	[p22l913t2076r995b2124],
35	log-rank	JJ	O	log-rank	amod	37	SENT_303	[p22l1017t2076r1227b2139],
36	test	NN	O	test	nn	37	SENT_303	[p22l1244t2080r1377b2139],
37	)	NN	O	)	pobj	33	SENT_303	[p22l1244t2080r1377b2139],
38	.	.	O	.	_	0	SENT_303	[p22l1244t2080r1377b2139],

1	The	DT	O	the	det	2	SENT_304	[p22l1396t2076r1493b2124],
2	points	NNS	O	point	nsubj	6	SENT_304	[p22l1515t2080r1675b2139],
3	on	IN	O	on	_	0	SENT_304	[p22l1696t2092r1758b2124],
4	the	DT	O	the	det	5	SENT_304	[p22l1778t2076r1860b2124],
5	curves	NNS	O	curve	prep_on	2	SENT_304	[p22l1879t2092r2046b2124],
6	represent	VBP	O	represent	_	0	SENT_304	[p22l65t2165r311b2219],
7	the	DT	O	the	det	8	SENT_304	[p22l328t2156r409b2204],
8	dates	NNS	O	date	dobj	6	SENT_304	[p22l429t2156r567b2204],
9	on	IN	O	on	_	0	SENT_304	[p22l588t2173r649b2204],
10	which	WDT	O	which	rel	16	SENT_304	[p22l670t2156r820b2204],
11	a	DT	O	a	det	12	SENT_304	[p22l843t2173r867b2204],
12	patient	NN	O	patient	poss	14	SENT_304	[p22l891t2160r1113b2219],
13	’s	POS	O	’s	_	0	SENT_304	[p22l891t2160r1113b2219],
14	data	NNS	O	datum	nsubjpass	16	SENT_304	[p22l1134t2156r1244b2204],
15	were	VBD	O	be	auxpass	16	SENT_304	[p22l1263t2173r1385b2204],
16	censored	VBN	O	censor	rcmod	8	SENT_304	[p22l1404t2156r1656b2204],
17	.	.	O	.	_	0	SENT_304	[p22l1404t2156r1656b2204],

1	#	#	MONEY	#	number	3	SENT_305	[p23l689t228r739b266],
2	*	CD	MONEY	*	number	3	SENT_305	[p23l689t228r739b266],
3	5	CD	MONEY	5	_	0	SENT_305	[p23l766t233r768b235],
4	«	NN	O	«	dep	3	SENT_305	[p23l901t237r1196b298],
5	.	.	O	.	_	0	SENT_305	[p23l901t237r1196b298],

1	.	.	O	.	_	0	SENT_306	[p23l901t237r1196b298],

1	,	,	O	,	_	0	SENT_307	[p23l901t237r1196b298],
2	_	CD	NUMBER	_	num	3	SENT_307	[p23l901t237r1196b298],
3	HCetuximab	NN	O	hcetuximab	_	0	SENT_307	[p23l901t237r1196b298],
4	plus	CC	O	plus	prep	3	SENT_307	[p23l1217t237r1308b292],
5	irinotecan	NN	O	irinotecan	dep	4	SENT_307	[p23l1330t241r1554b279],
6	n.	SYM	O	n.	dep	5	SENT_307	[p23l747t270r758b278],
7	-	:	O	-	_	0	SENT_307	[p23l770t274r820b293],
8	u.	NN	O	u.	dep	3	SENT_307	[p23l770t274r820b293],
9	___	CD	NUMBER	___	number	10	SENT_307	[p23l770t274r820b293],
10	1	CD	NUMBER	1	dep	8	SENT_307	[p23l835t290r847b301],

1	Cetuximab	JJ	O	cetuximab	_	0	SENT_308	[p23l582t315r825b357],
2	"	``	O	"	punct	1	SENT_308	[p23l874t309r885b316],
3	om	FW	O	om	dep	1	SENT_308	[p23l943t305r1090b373],
4	$	$	MONEY	$	dep	1	SENT_308	[p23l943t305r1090b373],
5	*	CD	MONEY	*	num	4	SENT_308	[p23l943t305r1090b373],
6	$	$	MONEY	$	dep	4	SENT_308	[p23l1133t341r1194b373],
7	*	CD	MONEY	*	num	6	SENT_308	[p23l1133t341r1194b373],

1	Patients	NNS	O	patient	_	0	SENT_309	[p23l126t440r170b634],
2	Surviving	VBG	O	survive	partmod	1	SENT_309	[p23l126t188r184b421],
3	(	CD	PERCENT	(	num	4	SENT_309	[p23l127t89r184b168],
4	%	NN	PERCENT	%	dobj	2	SENT_309	[p23l127t89r184b168],
5	)	CD	NUMBER	)	tmod	2	SENT_309	[p23l127t89r184b168],

1	Overall	JJ	O	overall	amod	2	SENT_310	[p23l791t754r966b799],
2	Survival	NN	O	survival	_	0	SENT_310	[p23l986t754r1180b799],
3	Time	NNP	O	Time	nn	5	SENT_310	[p23l1198t755r1323b799],
4	(	CD	NUMBER	(	num	5	SENT_310	[p23l1344t754r1564b813],
5	months	NNS	NUMBER	month	dep	2	SENT_310	[p23l1344t754r1564b813],
6	)	IN	O	)	amod	5	SENT_310	[p23l1344t754r1564b813],

1	Figure	NNP	O	Figure	_	0	SENT_311	[p23l66t923r228b985],
2	3	CD	NUMBER	3	dep	1	SENT_311	[p23l246t926r289b970],
3	.	.	O	.	_	0	SENT_311	[p23l246t926r289b970],

1	Overall	JJ	O	overall	amod	2	SENT_312	[p23l308t922r495b970],
2	Survival	NN	O	survival	_	0	SENT_312	[p23l515t922r722b970],
3	in	IN	O	in	_	0	SENT_312	[p23l744t923r787b970],
4	the	DT	O	the	det	7	SENT_312	[p23l806t922r890b970],
5	Two	CD	NUMBER	two	num	7	SENT_312	[p23l906t927r1013b970],
6	Study	NNP	O	Study	nn	7	SENT_312	[p23l1030t922r1179b985],
7	Groups	NNS	O	group	prep_in	2	SENT_312	[p23l1196t926r1407b984],
8	.	.	O	.	_	0	SENT_312	[p23l1196t926r1407b984],

1	The	DT	O	the	det	3	SENT_313	[p23l60t1018r157b1067],
2	hazard	NN	O	hazard	nn	3	SENT_313	[p23l179t1018r350b1067],
3	ratio	NN	O	ratio	nsubj	18	SENT_313	[p23l376t1023r490b1067],
4	for	IN	O	for	_	0	SENT_313	[p23l509t1018r581b1067],
5	death	NN	O	death	prep_for	3	SENT_313	[p23l599t1018r741b1067],
6	in	IN	O	in	_	0	SENT_313	[p23l765t1023r807b1066],
7	the	DT	O	the	det	9	SENT_313	[p23l827t1018r909b1067],
8	combination-therapy	JJ	O	combination-therapy	amod	9	SENT_313	[p23l928t1018r1478b1081],
9	group	NN	O	group	prep_in	5	SENT_313	[p23l1496t1035r1649b1082],
10	as	IN	O	as	amod	9	SENT_313	[p23l1669t1035r1722b1067],
11	compared	VBN	O	compare	_	0	SENT_313	[p23l1743t1018r2004b1081],
12	with	IN	O	with	prepc_compared_with	5	SENT_313	[p23l61t1098r168b1147],
13	the	DT	O	the	det	15	SENT_313	[p23l189t1098r270b1147],
14	monotherapy	JJ	O	monotherapy	amod	15	SENT_313	[p23l292t1098r642b1162],
15	group	NN	O	group	pobj	5	SENT_313	[p23l660t1115r813b1162],
16	was	VBD	O	be	cop	18	SENT_313	[p23l831t1116r929b1147],
17	0.91	CD	PERCENT	0.91	number	18	SENT_313	[p23l949t1102r1055b1147],
18	(	CD	PERCENT	(	_	0	SENT_313	[p23l1083t1103r1157b1162],
19	95	CD	PERCENT	95	num	22	SENT_313	[p23l1083t1103r1157b1162],
20	percent	NN	PERCENT	percent	nn	22	SENT_313	[p23l1182t1108r1376b1161],
21	conﬁdence	NN	O	conﬁdence	nn	22	SENT_313	[p23l1395t1098r1680b1147],
22	interval	NN	O	interval	dep	18	SENT_313	[p23l1702t1098r1906b1155],
23	,	,	O	,	_	0	SENT_313	[p23l1702t1098r1906b1155],
24	0.68	CD	NUMBER	0.68	number	27	SENT_313	[p23l1927t1102r2035b1147],
25	to	TO	O	to	dep	27	SENT_313	[p23l61t1188r111b1227],
26	1.21	CD	NUMBER	1.21	number	27	SENT_313	[p23l135t1183r257b1242],
27	)	CD	NUMBER	)	num	36	SENT_313	[p23l135t1183r257b1242],
28	(	NN	O	(	nn	36	SENT_313	[p23l287t1182r483b1242],
29	P	NN	O	p	nn	36	SENT_313	[p23l287t1182r483b1242],
30	=	JJ	O	=	amod	36	SENT_313	[p23l287t1182r483b1242],
31	0.48	CD	NUMBER	0.48	tmod	30	SENT_313	[p23l287t1182r483b1242],
32	by	IN	O	by	_	0	SENT_313	[p23l506t1179r560b1242],
33	the	DT	O	the	det	35	SENT_313	[p23l576t1179r658b1227],
34	log-rank	JJ	O	log-rank	amod	35	SENT_313	[p23l680t1179r890b1242],
35	test	NN	O	test	prep_by	30	SENT_313	[p23l906t1183r1040b1242],
36	)	NN	O	)	appos	18	SENT_313	[p23l906t1183r1040b1242],
37	.	.	O	.	_	0	SENT_313	[p23l906t1183r1040b1242],

1	The	DT	O	the	det	2	SENT_314	[p23l1059t1179r1155b1227],
2	points	NNS	O	point	nsubj	6	SENT_314	[p23l1178t1183r1337b1242],
3	on	IN	O	on	_	0	SENT_314	[p23l1358t1196r1420b1227],
4	the	DT	O	the	det	5	SENT_314	[p23l1440t1179r1522b1227],
5	curves	NNS	O	curve	prep_on	2	SENT_314	[p23l1541t1196r1708b1227],
6	represent	VBP	O	represent	_	0	SENT_314	[p23l1732t1188r1977b1242],
7	the	DT	O	the	det	8	SENT_314	[p23l1994t1179r2075b1227],
8	dates	NNS	O	date	dobj	6	SENT_314	[p23l63t1259r200b1307],
9	on	IN	O	on	_	0	SENT_314	[p23l221t1276r283b1307],
10	which	WDT	O	which	rel	16	SENT_314	[p23l303t1259r454b1307],
11	a	DT	O	a	det	12	SENT_314	[p23l477t1276r501b1307],
12	patient	NN	O	patient	poss	14	SENT_314	[p23l525t1263r747b1322],
13	’s	POS	O	’s	_	0	SENT_314	[p23l525t1263r747b1322],
14	data	NNS	O	datum	nsubjpass	16	SENT_314	[p23l768t1259r878b1307],
15	were	VBD	O	be	auxpass	16	SENT_314	[p23l896t1276r1019b1307],
16	censored	VBN	O	censor	rcmod	8	SENT_314	[p23l1038t1259r1290b1307],
17	.	.	O	.	_	0	SENT_314	[p23l1038t1259r1290b1307],

1	studies	NNS	O	study	nsubjpass	8	SENT_315	[p23l12t1563r315b1637],
2	,	,	O	,	_	0	SENT_315	[p23l12t1563r315b1637],
3	”	NN	O	”	conj_and	1	SENT_315	[p23l12t1563r315b1637],
4	and	CC	O	and	_	0	SENT_315	[p23l339t1566r455b1625],
5	the	DT	O	the	det	6	SENT_315	[p23l480t1567r576b1625],
6	correlation	NN	O	correlation	conj_and	1	SENT_315	[p23l602t1567r945b1625],
7	is	VBZ	O	be	auxpass	8	SENT_315	[p23l970t1567r1018b1625],
8	conﬁrmed	VBN	O	conﬁrmed	_	0	SENT_315	[p23l1045t1566r1372b1625],
9	by	IN	O	by	_	0	SENT_315	[p23l1397t1566r1469b1641],
10	our	PRP$	O	we	poss	11	SENT_315	[p23l1491t1585r1599b1625],
11	study	NN	O	study	agent	8	SENT_315	[p23l12t1662r188b1736],
12	,	,	O	,	_	0	SENT_315	[p23l12t1662r188b1736],
13	although	IN	O	although	mark	16	SENT_315	[p23l219t1662r503b1736],
14	it	PRP	O	it	nsubjpass	16	SENT_315	[p23l528t1662r573b1720],
15	is	VBZ	O	be	auxpass	16	SENT_315	[p23l595t1662r643b1720],
16	based	VBN	O	base	advcl	8	SENT_315	[p23l672t1661r852b1720],
17	on	IN	O	on	_	0	SENT_315	[p23l879t1680r958b1720],
18	subgroup	NN	O	subgroup	nn	19	SENT_315	[p23l985t1662r1286b1736],
19	analyses	NNS	O	analysis	prep_on	16	SENT_315	[p23l1313t1662r1592b1736],
20	.	.	O	.	_	0	SENT_315	[p23l1313t1662r1592b1736],

1	Since	IN	O	since	mark	6	SENT_316	[p23l12t1757r181b1815],
2	no	DT	O	no	det	4	SENT_316	[p23l214t1775r294b1815],
3	dose-limiting	JJ	O	dose-limiting	amod	4	SENT_316	[p23l329t1757r766b1831],
4	toxicity	NN	O	toxicity	nsubjpass	6	SENT_316	[p23l798t1757r1032b1831],
5	was	VBD	O	be	auxpass	6	SENT_316	[p23l1059t1776r1180b1815],
6	observed	VBN	O	observe	csubj	35	SENT_316	[p23l1216t1756r1502b1815],
7	in	IN	O	in	_	0	SENT_316	[p23l1534t1757r1596b1814],
8	phase	NN	O	phase	prep_in	6	SENT_316	[p23l9t1852r197b1926],
9	1	CD	NUMBER	1	num	10	SENT_316	[p23l231t1856r264b1909],
10	studies	NNS	O	study	dobj	6	SENT_316	[p23l298t1851r517b1910],
11	of	IN	O	of	_	0	SENT_316	[p23l549t1851r625b1910],
12	cetuximab	NN	O	cetuximab	prep_of	10	SENT_316	[p23l641t1852r966b1910],
13	given	VBN	O	give	partmod	12	SENT_316	[p23l997t1852r1164b1926],
14	according	VBG	O	accord	_	0	SENT_316	[p23l1193t1851r1509b1926],
15	to	TO	O	to	prepc_according_to	13	SENT_316	[p23l1536t1864r1595b1910],
16	the	DT	O	the	det	20	SENT_316	[p23l11t1946r107b2005],
17	currently	RB	DATE	currently	advmod	20	SENT_316	[p23l128t1946r411b2021],
18	recommended	VBN	O	recommend	amod	20	SENT_316	[p23l428t1946r885b2005],
19	dosage	NN	O	dosage	nn	20	SENT_316	[p23l905t1946r1125b2021],
20	regimen	NN	O	regimen	pobj	13	SENT_316	[p23l1146t1943r1489b2021],
21	,	,	O	,	_	0	SENT_316	[p23l1146t1943r1489b2021],
22	”	CD	NUMBER	”	num	25	SENT_316	[p23l1146t1943r1489b2021],
23	individualized	JJ	O	individualized	amod	25	SENT_316	[p23l1510t1947r1595b2004, p23l11t2043r392b2102],
24	dose	NN	O	dose	nn	25	SENT_316	[p23l409t2043r554b2101],
25	titration	NN	O	titration	appos	20	SENT_316	[p23l571t2043r825b2101],
26	based	VBN	O	base	partmod	25	SENT_316	[p23l843t2043r1023b2101],
27	on	IN	O	on	_	0	SENT_316	[p23l1040t2061r1120b2101],
28	the	DT	O	the	det	29	SENT_316	[p23l1137t2043r1233b2101],
29	occurrence	NN	O	occurrence	prep_on	26	SENT_316	[p23l1251t2061r1596b2102],
30	and	CC	O	and	_	0	SENT_316	[p23l10t2138r127b2196],
31	severity	NN	O	severity	prep_on	26	SENT_316	[p23l150t2138r385b2212],
32	of	IN	O	of	_	0	SENT_316	[p23l405t2137r479b2196],
33	rash	NN	O	rash	prep_of	29	SENT_316	[p23l488t2138r623b2196],
34	may	MD	O	may	aux	35	SENT_316	[p23l645t2157r777b2212],
35	improve	VB	O	improve	_	0	SENT_316	[p23l795t2138r1054b2212],
36	the	DT	O	the	det	37	SENT_316	[p23l1077t2138r1174b2196],
37	effectiveness	NN	O	effectiveness	dobj	35	SENT_316	[p23l1197t2137r1595b2196],
38	of	IN	O	of	_	0	SENT_316	[p23l11t2233r87b2292],
39	cetuximab	NN	O	cetuximab	nn	40	SENT_316	[p23l95t2234r426b2293],
40	treatment	NN	O	treatment	prep_of	37	SENT_316	[p23l449t2246r779b2292],
41	.	.	O	.	_	0	SENT_316	[p23l449t2246r779b2292],

1	The	DT	O	the	det	2	SENT_317	[p23l802t2234r924b2292],
2	rates	NNS	O	rate	nsubj	17	SENT_317	[p23l946t2246r1097b2292],
3	of	IN	O	of	_	0	SENT_317	[p23l1121t2233r1197b2292],
4	incidence	NN	O	incidence	prep_of	2	SENT_317	[p23l1204t2234r1512b2292],
5	of	IN	O	of	_	0	SENT_317	[p23l1534t2233r1610b2292],
6	other	JJ	O	other	amod	11	SENT_317	[p23l11t2329r175b2387],
7	hematologic	JJ	O	hematologic	amod	11	SENT_317	[p23l187t2329r572b2403],
8	and	CC	O	and	_	0	SENT_317	[p23l586t2329r701b2387],
9	nonhematologic	JJ	O	nonhematologic	amod	11	SENT_317	[p23l715t2329r1225b2403],
10	toxic	JJ	O	toxic	amod	11	SENT_317	[p23l1239t2329r1385b2387],
11	effects	NNS	O	effect	prep_of	4	SENT_317	[p23l1400t2328r1596b2387],
12	in	IN	O	in	_	0	SENT_317	[p23l10t2424r71b2481],
13	the	DT	O	the	det	15	SENT_317	[p23l96t2424r192b2482],
14	combination-therapy	JJ	O	combination-therapy	amod	15	SENT_317	[p23l218t2424r887b2498],
15	group	NN	O	group	prep_in	11	SENT_317	[p23l908t2442r1095b2498],
16	were	VBD	O	be	cop	17	SENT_317	[p23l1117t2443r1268b2483],
17	similar	JJ	O	similar	_	0	SENT_317	[p23l1294t2424r1514b2482],
18	to	TO	O	to	_	0	SENT_317	[p23l1537t2436r1596b2482],
19	those	DT	O	those	det	20	SENT_317	[p23l11t2519r180b2577],
20	reported	VBN	O	report	prep_to	17	SENT_317	[p23l197t2519r465b2593],
21	in	IN	O	in	_	0	SENT_317	[p23l480t2519r541b2576],
22	randomized	JJ	O	randomized	amod	23	SENT_317	[p23l557t2519r938b2577],
23	studies	NNS	O	study	prep_in	20	SENT_317	[p23l955t2519r1174b2577],
24	of	IN	O	of	_	0	SENT_317	[p23l1193t2518r1268b2577],
25	irinotecan	NN	O	irinotecan	prep_of	23	SENT_317	[p23l1269t2519r1596b2577],
26	as	IN	O	as	_	0	SENT_317	[p23l10t2633r74b2672],
27	second	JJ	ORDINAL	second	amod	30	SENT_317	[p23l96t2613r469b2672],
28	—	NN	O	—	nn	30	SENT_317	[p23l96t2613r469b2672],
29	line	NN	O	line	nn	30	SENT_317	[p23l96t2613r469b2672],
30	therapy	NN	O	therapy	prep_as	25	SENT_317	[p23l490t2608r822b2688],
31	.67	CD	NUMBER	.67	num	20	SENT_317	[p23l490t2608r822b2688],

1	In	IN	O	in	_	0	SENT_318	[p23l106t2714r171b2766],
2	contrast	NN	O	contrast	prep_in	16	SENT_318	[p23l197t2721r456b2767],
3	to	TO	O	to	_	0	SENT_318	[p23l479t2721r538b2767],
4	the	DT	O	the	det	5	SENT_318	[p23l565t2709r661b2767],
5	blockade	NN	O	blockade	prep_to	2	SENT_318	[p23l688t2709r970b2768],
6	of	IN	O	of	_	0	SENT_318	[p23l997t2708r1072b2767],
7	HER2	NN	O	her2	prep_of	5	SENT_318	[p23l1084t2713r1269b2771],
8	by	IN	O	by	_	0	SENT_318	[p23l1297t2709r1369b2783],
9	trastuzumab	NN	O	trastuzumab	prep_by	2	SENT_318	[p23l1392t2721r1595b2767, p23l10t2803r223b2862],
10	in	IN	O	in	_	0	SENT_318	[p23l239t2804r300b2861],
11	breast	NN	O	breast	nn	12	SENT_318	[p23l316t2803r508b2862],
12	cancer	NN	O	cancer	prep_in	9	SENT_318	[p23l521t2822r736b2874],
13	,	,	O	,	_	0	SENT_318	[p23l521t2822r736b2874],
14	34	CD	NUMBER	34	appos	12	SENT_318	[p23l744t2800r801b2835],
15	there	EX	O	there	expl	16	SENT_318	[p23l818t2803r974b2862],
16	was	VBD	O	be	_	0	SENT_318	[p23l987t2823r1107b2862],
17	no	DT	O	no	det	19	SENT_318	[p23l1125t2822r1204b2862],
18	apparent	JJ	O	apparent	amod	19	SENT_318	[p23l1220t2816r1501b2878],
19	relationship	NN	O	relationship	nsubj	16	SENT_318	[p23l1513t2823r1596b2862, p23l10t2899r327b2973],
20	between	IN	O	between	_	0	SENT_318	[p23l357t2899r618b2957],
21	the	DT	O	the	det	22	SENT_318	[p23l647t2899r744b2957],
22	efficacy	NN	O	efficacy	prep_between	19	SENT_318	[p23l773t2898r1011b2973],
23	of	IN	O	of	_	0	SENT_318	[p23l1037t2898r1112b2957],
24	cetuximab	NN	O	cetuximab	prep_of	22	SENT_318	[p23l1127t2899r1451b2957],
25	and	CC	O	and	_	0	SENT_318	[p23l1481t2899r1597b2957],
26	the	DT	O	the	det	27	SENT_318	[p23l11t2995r107b3053],
27	level	NN	O	level	prep_between	19	SENT_318	[p23l129t2995r269b3054],
28	of	IN	O	of	_	0	SENT_318	[p23l292t2994r367b3053],
29	EGFR	NN	ORGANIZATION	egfr	prep_of	27	SENT_318	[p23l375t2999r569b3057],
30	in	IN	O	in	_	0	SENT_318	[p23l583t2995r644b3052],
31	the	DT	O	the	det	32	SENT_318	[p23l667t2995r763b3053],
32	tumor	NN	O	tumor	prep_in	29	SENT_318	[p23l787t3007r995b3054],
33	.	.	O	.	_	0	SENT_318	[p23l787t3007r995b3054],

1	A	DT	O	a	det	3	SENT_319	[p23l1019t3000r1068b3052],
2	similar	JJ	O	similar	amod	3	SENT_319	[p23l1090t2995r1310b3053],
3	observation	NN	O	observation	nsubjpass	6	SENT_319	[p23l1331t2995r1596b3054, p23l11t3090r134b3148],
4	has	VBZ	O	have	aux	6	SENT_319	[p23l160t3090r265b3148],
5	been	VBN	O	be	auxpass	6	SENT_319	[p23l293t3090r442b3148],
6	made	VBN	O	make	_	0	SENT_319	[p23l468t3090r640b3148],
7	with	IN	O	with	_	0	SENT_319	[p23l663t3090r804b3148],
8	geﬁtinib	NN	O	geﬁtinib	prep_with	6	SENT_319	[p23l829t3089r1113b3164],
9	,	,	O	,	_	0	SENT_319	[p23l829t3089r1113b3164],
10	another	DT	O	another	det	14	SENT_319	[p23l1142t3090r1388b3148],
11	EGFR	NN	ORGANIZATION	egfr	nn	14	SENT_319	[p23l1411t3094r1604b3152],
12	tyrosine	NN	O	tyrosine	nn	14	SENT_319	[p23l11t3185r261b3259],
13	kinase	NN	O	kinase	nn	14	SENT_319	[p23l283t3184r485b3244],
14	inhibitor	NN	O	inhibitor	appos	8	SENT_319	[p23l507t3181r862b3243],
15	.35	CD	NUMBER	.35	num	17	SENT_319	[p23l507t3181r862b3243],
16	Only	JJ	O	only	amod	17	SENT_319	[p23l886t3184r1037b3259],
17	patients	NNS	O	patient	dep	14	SENT_319	[p23l1055t3185r1304b3259],
18	with	IN	O	with	_	0	SENT_319	[p23l1325t3184r1466b3243],
19	imN	NN	O	imn	prep_with	6	SENT_319	[p23l1488t3185r1595b3242, p23l524t3336r537b3351],

1	ENGLJ	NNP	O	ENGLJ	nn	2	SENT_320	[p23l553t3335r637b3357],
2	MED	NNP	O	MED	_	0	SENT_320	[p23l652t3336r704b3351],
3	3S	NN	O	3	poss	5	SENT_320	[p23l716t3335r781b3357],
4	'	POS	O	'	_	0	SENT_320	[p23l716t3335r781b3357],
5	|	NN	O	|	dep	2	SENT_320	[p23l716t3335r781b3357],
6	;	:	O	;	_	0	SENT_320	[p23l716t3335r781b3357],
7	4	CD	NUMBER	4	num	9	SENT_320	[p23l716t3335r781b3357],
8	WWW.NEjM.ORG	NNP	O	WWW.NEjM.ORG	nn	9	SENT_320	[p23l815t3335r1026b3357],
9	JULY	NNP	DATE	JULY	dep	5	SENT_320	[p23l1060t3336r1120b3357],
10	22	CD	DATE	22	num	9	SENT_320	[p23l1132t3335r1169b3355],
11	,	,	DATE	,	_	0	SENT_320	[p23l1132t3335r1169b3355],
12	2004	CD	DATE	2004	num	13	SENT_320	[p23l1182t3335r1249b3357],
13	o	NN	O	o	appos	9	SENT_320	[p23l1959t3334r2015b3356],
14	$	$	MONEY	$	dep	2	SENT_320	[p23l1959t3334r2015b3356],
15	*	CD	MONEY	*	num	14	SENT_320	[p23l1959t3334r2015b3356],

1	The	DT	O	the	det	4	SENT_321	[p23l701t3368r752b3392],
2	New	NNP	O	New	nn	4	SENT_321	[p23l761t3369r823b3392],
3	England	NNP	O	England	nn	4	SENT_321	[p23l833t3368r943b3399],
4	Journal	NNP	O	Journal	_	0	SENT_321	[p23l952t3368r1049b3392],
5	of	IN	O	of	_	0	SENT_321	[p23l1059t3368r1088b3392],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_321	[p23l1095t3368r1220b3392],

1	Downloaded	VBN	O	download	_	0	SENT_322	[p23l144t3409r313b3432],
2	from	IN	O	from	_	0	SENT_322	[p23l322t3409r387b3432],
3	nejmorg	NN	O	nejmorg	prep_from	1	SENT_322	[p23l395t3409r514b3439],
4	at	IN	O	at	_	0	SENT_322	[p23l524t3413r547b3432],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_322	[p23l556t3409r738b3432],
6	on	IN	O	on	_	0	SENT_322	[p23l748t3416r780b3432],
7	January	NNP	DATE	January	prep_on	1	SENT_322	[p23l789t3409r891b3439],
8	5	CD	DATE	5	num	7	SENT_322	[p23l901t3409r924b3436],
9	,	,	DATE	,	_	0	SENT_322	[p23l901t3409r924b3436],
10	2014	CD	DATE	2014	num	7	SENT_322	[p23l935t3409r1007b3432],
11	.	.	O	.	_	0	SENT_322	[p23l935t3409r1007b3432],

1	For	IN	O	for	_	0	SENT_323	[p23l1017t3409r1064b3432],
2	personal	JJ	O	personal	amod	3	SENT_323	[p23l1072t3409r1184b3439],
3	use	NN	O	use	pobj	1	SENT_323	[p23l1194t3416r1237b3432],
4	only	RB	O	only	advmod	3	SENT_323	[p23l1247t3409r1311b3439],
5	.	.	O	.	_	0	SENT_323	[p23l1247t3409r1311b3439],

1	No	DT	O	no	det	3	SENT_324	[p23l1322t3409r1362b3432],
2	other	JJ	O	other	amod	3	SENT_324	[p23l1372t3409r1440b3432],
3	uses	NNS	O	use	_	0	SENT_324	[p23l1448t3416r1504b3432],
4	without	IN	O	without	_	0	SENT_324	[p23l1514t3409r1615b3432],
5	permission	NN	O	permission	prep_without	3	SENT_324	[p23l1624t3409r1776b3439],
6	.	.	O	.	_	0	SENT_324	[p23l1624t3409r1776b3439],

1	Copyright	NN	O	copyright	_	0	SENT_325	[p23l494t3450r628b3481],
2	©	CD	NUMBER	©	num	6	SENT_325	[p23l638t3450r661b3474],
3	2004	CD	DATE	2004	num	6	SENT_325	[p23l671t3450r736b3474],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_325	[p23l746t3450r937b3474],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_325	[p23l947t3450r1055b3474],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_325	[p23l1065t3450r1170b3481],
7	.	.	O	.	_	0	SENT_325	[p23l1065t3450r1170b3481],

1	All	DT	O	all	det	2	SENT_326	[p23l1181t3450r1222b3474],
2	rights	NNS	O	rights	nsubj	3	SENT_326	[p23l1231t3450r1306b3481],
3	reserved	VBN	O	reserve	_	0	SENT_326	[p23l1316t3450r1435b3474],
4	.	.	O	.	_	0	SENT_326	[p23l1316t3450r1435b3474],

1	The	DT	O	the	det	4	SENT_327	[p23l715t3556r752b3577],
2	NEW	NNP	O	NEW	nn	4	SENT_327	[p23l764t3558r845b3577],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_327	[p23l859t3558r1034b3577],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_327	[p23l1048t3558r1214b3584],
5	ofMEDICINE	NN	O	ofmedicine	dep	4	SENT_327	[p23l1228t3556r1444b3583],

1	Table	NNP	O	Table	_	0	SENT_328	[p24l59t141r195b189],
2	4	CD	NUMBER	4	dep	1	SENT_328	[p24l212t146r257b189],
3	.	.	O	.	_	0	SENT_328	[p24l212t146r257b189],

1	Grade	NNP	O	Grade	nsubj	7	SENT_329	[p24l276t141r436b189],
2	3	CD	NUMBER	3	num	1	SENT_329	[p24l453t145r479b189],
3	or	CC	O	or	_	0	SENT_329	[p24l499t157r554b189],
4	4	CD	NUMBER	4	num	6	SENT_329	[p24l568t145r600b189],
5	Adverse	JJ	O	adverse	amod	6	SENT_329	[p24l615t141r827b189],
6	Events	NNS	O	event	nsubj	7	SENT_329	[p24l848t145r1017b189],
7	Related	VBN	O	relate	_	0	SENT_329	[p24l1039t141r1228b189],
8	to	TO	O	to	_	0	SENT_329	[p24l1246t149r1298b189],
9	Treatment	NN	O	treatment	prep_to	7	SENT_329	[p24l1314t144r1630b189],
10	.	.	O	.	_	0	SENT_329	[p24l1314t144r1630b189],

1	*	NN	O	*	_	0	SENT_330	[p24l1314t144r1630b189],

1	Cetuximab	NNP	O	Cetuximab	nn	4	SENT_331	[p24l927t277r1209b326],
2	Cetuximab	NNP	O	Cetuximab	nn	4	SENT_331	[p24l1405t277r1687b326],
3	pluslrinotecan	NNP	O	pluslrinotecan	nn	4	SENT_331	[p24l873t350r1263b412],
4	Monotherapy	NNP	O	Monotherapy	_	0	SENT_331	[p24l1374t350r1725b413],

1	Adverse	JJ	O	adverse	amod	4	SENT_332	[p24l59t422r271b470],
2	Event	NN	O	event	nn	4	SENT_332	[p24l292t426r435b470],
3	(	NN	O	(	nn	4	SENT_332	[p24l958t426r1179b486],
4	N	NN	O	n	_	0	SENT_332	[p24l958t426r1179b486],
5	=	JJ	O	=	quantmod	7	SENT_332	[p24l958t426r1179b486],
6	212	CD	NUMBER	212	number	7	SENT_332	[p24l958t426r1179b486],
7	)	CD	NUMBER	)	num	15	SENT_332	[p24l958t426r1179b486],
8	(	NN	O	(	nn	15	SENT_332	[p24l1436t426r1657b486],
9	N	NN	O	n	nn	15	SENT_332	[p24l1436t426r1657b486],
10	=	JJ	O	=	amod	15	SENT_332	[p24l1436t426r1657b486],
11	115	CD	NUMBER	115	number	12	SENT_332	[p24l1436t426r1657b486],
12	)	CD	NUMBER	)	num	15	SENT_332	[p24l1436t426r1657b486],
13	P	NN	O	p	nn	15	SENT_332	[p24l1901t426r1931b469],
14	Value	NN	O	value	nn	15	SENT_332	[p24l1947t422r2090b471],
15	no.	NN	O	no.	dep	4	SENT_332	[p24l1067t565r1138b597],
16	of	IN	O	of	_	0	SENT_332	[p24l1162t548r1220b612],
17	patients	NNS	O	patient	prep_of	15	SENT_332	[p24l1221t551r1421b611],
18	(	CD	PERCENT	(	num	19	SENT_332	[p24l1445t551r1531b612],
19	%	NN	PERCENT	%	dep	15	SENT_332	[p24l1445t551r1531b612],
20	)	CD	NUMBER	)	dep	4	SENT_332	[p24l1445t551r1531b612],

1	Any	DT	O	any	dep	116	SENT_333	[p24l59t656r157b716],
2	138	CD	NUMBER	138	dep	116	SENT_333	[p24l939t656r1026b701],
3	(	NN	O	(	dep	116	SENT_333	[p24l1052t657r1196b716],
4	65.1	CD	NUMBER	65.1	dep	116	SENT_333	[p24l1052t657r1196b716],
5	)	CD	NUMBER	)	dep	116	SENT_333	[p24l1052t657r1196b716],
6	50	CD	NUMBER	50	dep	116	SENT_333	[p24l1431t656r1490b701],
7	(	CD	NUMBER	(	dep	116	SENT_333	[p24l1514t657r1658b716],
8	43.5	CD	NUMBER	43.5	dep	116	SENT_333	[p24l1514t657r1658b716],
9	)	NN	O	)	dep	116	SENT_333	[p24l1514t657r1658b716],
10	Anemia	NN	O	anemia	dep	116	SENT_333	[p24l59t760r260b805],
11	10	CD	NUMBER	10	dep	116	SENT_333	[p24l971t760r1028b805],
12	(	NN	O	(	dep	116	SENT_333	[p24l1052t761r1164b820],
13	4.7	CD	NUMBER	4.7	dep	116	SENT_333	[p24l1052t761r1164b820],
14	)	NN	O	)	dep	116	SENT_333	[p24l1052t761r1164b820],
15	3	CD	NUMBER	3	dep	116	SENT_333	[p24l1463t761r1486b805],
16	(	NN	O	(	dep	116	SENT_333	[p24l1514t761r1626b820],
17	2.6	CD	NUMBER	2.6	dep	116	SENT_333	[p24l1514t761r1626b820],
18	)	CD	NUMBER	)	dep	116	SENT_333	[p24l1514t761r1626b820],
19	Neutropenia	NNP	ORGANIZATION	Neutropenia	dep	116	SENT_333	[p24l66t866r391b924],
20	20	CD	NUMBER	20	dep	116	SENT_333	[p24l968t865r1028b910],
21	(	CD	NUMBER	(	dep	116	SENT_333	[p24l1052t866r1164b925],
22	9.4	CD	NUMBER	9.4	dep	116	SENT_333	[p24l1052t866r1164b925],
23	)	NN	O	)	dep	116	SENT_333	[p24l1052t866r1164b925],
24	o	NN	O	o	dep	116	SENT_333	[p24l1461t865r1490b910],
25	Thrombocytopenia	NN	ORGANIZATION	thrombocytopenia	dep	116	SENT_333	[p24l59t966r558b1029],
26	1	CD	NUMBER	1	dep	116	SENT_333	[p24l1004t970r1024b1013],
27	(	CD	NUMBER	(	dep	116	SENT_333	[p24l1052t969r1164b1029],
28	0.5	CD	NUMBER	0.5	dep	116	SENT_333	[p24l1052t969r1164b1029],
29	)	NN	O	)	dep	116	SENT_333	[p24l1052t969r1164b1029],
30	1	CD	NUMBER	1	dep	116	SENT_333	[p24l1466t970r1487b1013],
31	(	NN	O	(	dep	116	SENT_333	[p24l1514t969r1626b1029],
32	0.9	CD	NUMBER	0.9	dep	116	SENT_333	[p24l1514t969r1626b1029],
33	)	CD	NUMBER	)	dep	116	SENT_333	[p24l1514t969r1626b1029],
34	Diarrhea	NNP	O	Diarrhea	dep	116	SENT_333	[p24l65t1070r286b1118],
35	45	CD	NUMBER	45	dep	116	SENT_333	[p24l967t1075r1024b1118],
36	(	CD	NUMBER	(	dep	116	SENT_333	[p24l1052t1074r1196b1133],
37	21.2	CD	NUMBER	21.2	dep	116	SENT_333	[p24l1052t1074r1196b1133],
38	)	NN	O	)	dep	116	SENT_333	[p24l1052t1074r1196b1133],
39	2	CD	NUMBER	2	dep	116	SENT_333	[p24l1462t1075r1489b1118],
40	(	CD	NUMBER	(	dep	116	SENT_333	[p24l1514t1074r1626b1133],
41	1.7	CD	NUMBER	1.7	dep	116	SENT_333	[p24l1514t1074r1626b1133],
42	)	NN	O	)	dep	116	SENT_333	[p24l1514t1074r1626b1133],
43	Asthenia	NNP	ORGANIZATION	Asthenia	dep	116	SENT_333	[p24l59t1175r288b1223],
44	29	CD	NUMBER	29	dep	116	SENT_333	[p24l968t1179r1027b1223],
45	(	CD	NUMBER	(	dep	116	SENT_333	[p24l1053t1179r1196b1238],
46	13.7	CD	NUMBER	13.7	dep	116	SENT_333	[p24l1053t1179r1196b1238],
47	)	CD	NUMBER	)	dep	116	SENT_333	[p24l1053t1179r1196b1238],
48	12	CD	NUMBER	12	dep	116	SENT_333	[p24l1433t1179r1488b1222],
49	(	NN	O	(	dep	116	SENT_333	[p24l1514t1178r1658b1238],
50	10.4	CD	NUMBER	10.4	dep	116	SENT_333	[p24l1514t1178r1658b1238],
51	)	CD	NUMBER	)	dep	116	SENT_333	[p24l1514t1178r1658b1238],
52	Acne-like	JJ	O	acne-like	dep	116	SENT_333	[p24l59t1279r297b1327],
53	rash	NN	O	rash	dep	116	SENT_333	[p24l319t1279r424b1327],
54	20	CD	NUMBER	20	dep	116	SENT_333	[p24l968t1282r1028b1327],
55	(	NN	O	(	dep	116	SENT_333	[p24l1052t1283r1164b1342],
56	9.4	CD	NUMBER	9.4	dep	116	SENT_333	[p24l1052t1283r1164b1342],
57	)	NN	O	)	dep	116	SENT_333	[p24l1052t1283r1164b1342],
58	6	CD	NUMBER	6	dep	116	SENT_333	[p24l1463t1283r1489b1327],
59	(	NN	O	(	dep	116	SENT_333	[p24l1514t1283r1626b1342],
60	5.2	CD	NUMBER	5.2	dep	116	SENT_333	[p24l1514t1283r1626b1342],
61	)	CD	NUMBER	)	dep	116	SENT_333	[p24l1514t1283r1626b1342],
62	Nausea	NN	O	nausea	dep	116	SENT_333	[p24l65t1388r259b1431],
63	and	CC	O	and	dep	116	SENT_333	[p24l280t1383r372b1431],
64	vomiting	VBG	O	vomit	dep	116	SENT_333	[p24l393t1388r628b1447],
65	15	CD	NUMBER	15	dep	116	SENT_333	[p24l971t1388r1024b1431],
66	(	CD	NUMBER	(	dep	116	SENT_333	[p24l1053t1387r1164b1446],
67	7.1	CD	NUMBER	7.1	dep	116	SENT_333	[p24l1053t1387r1164b1446],
68	)	NN	O	)	dep	116	SENT_333	[p24l1053t1387r1164b1446],
69	5	CD	NUMBER	5	dep	116	SENT_333	[p24l1462t1388r1486b1431],
70	(	NN	O	(	dep	116	SENT_333	[p24l1514t1387r1626b1446],
71	4.3	CD	NUMBER	4.3	dep	116	SENT_333	[p24l1514t1387r1626b1446],
72	)	CD	NUMBER	)	dep	116	SENT_333	[p24l1514t1387r1626b1446],
73	Abdominal	JJ	O	abdominal	dep	116	SENT_333	[p24l59t1488r346b1536],
74	pain	NN	O	pain	dep	116	SENT_333	[p24l371t1492r477b1550],
75	7	CD	NUMBER	7	dep	116	SENT_333	[p24l1003t1492r1027b1535],
76	(	NN	O	(	dep	116	SENT_333	[p24l1052t1492r1164b1551],
77	3.3	CD	NUMBER	3.3	dep	116	SENT_333	[p24l1052t1492r1164b1551],
78	)	NN	O	)	dep	116	SENT_333	[p24l1052t1492r1164b1551],
79	6	CD	NUMBER	6	dep	116	SENT_333	[p24l1463t1492r1489b1536],
80	(	NN	O	(	dep	116	SENT_333	[p24l1514t1492r1626b1551],
81	5.2	CD	NUMBER	5.2	dep	116	SENT_333	[p24l1514t1492r1626b1551],
82	)	CD	NUMBER	)	dep	116	SENT_333	[p24l1514t1492r1626b1551],
83	Stomatitis	NNP	ORGANIZATION	Stomatitis	dep	116	SENT_333	[p24l62t1596r329b1640],
84	5	CD	NUMBER	5	dep	116	SENT_333	[p24l1001t1596r1024b1640],
85	(	CD	NUMBER	(	dep	116	SENT_333	[p24l1053t1596r1164b1655],
86	2.4	CD	NUMBER	2.4	dep	116	SENT_333	[p24l1053t1596r1164b1655],
87	)	NN	O	)	dep	116	SENT_333	[p24l1053t1596r1164b1655],
88	1	CD	NUMBER	1	dep	116	SENT_333	[p24l1466t1596r1487b1639],
89	(	CD	NUMBER	(	dep	116	SENT_333	[p24l1514t1595r1626b1655],
90	0.9	CD	NUMBER	0.9	dep	116	SENT_333	[p24l1514t1595r1626b1655],
91	)	NN	O	)	dep	116	SENT_333	[p24l1514t1595r1626b1655],
92	Dyspnea	NN	ORGANIZATION	dyspnea	dep	116	SENT_333	[p24l65t1701r286b1760],
93	3	CD	NUMBER	3	dep	116	SENT_333	[p24l1001t1700r1024b1744],
94	(	NN	O	(	dep	116	SENT_333	[p24l1052t1700r1164b1759],
95	1.4	CD	NUMBER	1.4	dep	116	SENT_333	[p24l1052t1700r1164b1759],
96	)	CD	NUMBER	)	dep	116	SENT_333	[p24l1052t1700r1164b1759],
97	15	CD	NUMBER	15	dep	116	SENT_333	[p24l1433t1701r1486b1744],
98	(	NN	O	(	dep	116	SENT_333	[p24l1514t1699r1658b1759],
99	13.0	CD	NUMBER	13.0	dep	116	SENT_333	[p24l1514t1699r1658b1759],
100	)	CD	NUMBER	)	dep	116	SENT_333	[p24l1514t1699r1658b1759],
101	Fever	NN	O	fever	dep	116	SENT_333	[p24l65t1805r200b1849],
102	5	CD	NUMBER	5	dep	116	SENT_333	[p24l1001t1805r1024b1849],
103	(	CD	NUMBER	(	dep	116	SENT_333	[p24l1053t1805r1164b1864],
104	2.4	CD	NUMBER	2.4	dep	116	SENT_333	[p24l1053t1805r1164b1864],
105	)	NN	O	)	dep	116	SENT_333	[p24l1053t1805r1164b1864],
106	o	NN	O	o	dep	116	SENT_333	[p24l1461t1804r1490b1849],
107	Hypersensitivity	NN	O	hypersensitivity	dep	116	SENT_333	[p24l65t1909r485b1968],
108	reaction	NN	O	reaction	dep	116	SENT_333	[p24l506t1909r711b1953],
109	o	NN	O	o	dep	116	SENT_333	[p24l999t1908r1028b1953],
110	4	CD	NUMBER	4	dep	116	SENT_333	[p24l1461t1909r1489b1952],
111	(	NN	O	(	dep	116	SENT_333	[p24l1514t1909r1626b1968],
112	3.5	CD	NUMBER	3.5	dep	116	SENT_333	[p24l1514t1909r1626b1968],
113	)	CD	NUMBER	)	dep	116	SENT_333	[p24l1514t1909r1626b1968],
114	Death	NN	O	death	dep	116	SENT_333	[p24l65t2009r215b2057],
115	o	NN	O	o	dep	116	SENT_333	[p24l999t2012r1028b2058],
116	o	NN	O	o	_	0	SENT_333	[p24l1461t2012r1490b2058],

1	*	NN	O	*	nsubj	14	SENT_334	[p24l8t2190r37b2218],
2	Four	CD	NUMBER	four	num	3	SENT_334	[p24l62t2190r177b2234],
3	patients	NNS	O	patient	dep	1	SENT_334	[p24l195t2190r401b2249],
4	who	WP	O	who	nsubjpass	7	SENT_334	[p24l419t2186r527b2234],
5	were	VBD	O	be	auxpass	7	SENT_334	[p24l544t2203r666b2234],
6	randomly	RB	O	randomly	advmod	7	SENT_334	[p24l687t2186r933b2249],
7	assigned	VBN	O	assign	rcmod	1	SENT_334	[p24l950t2186r1178b2249],
8	to	TO	O	to	_	0	SENT_334	[p24l1197t2195r1249b2234],
9	the	DT	O	the	det	11	SENT_334	[p24l1265t2186r1347b2234],
10	combination-therapy	JJ	O	combination-therapy	amod	11	SENT_334	[p24l1365t2186r1914b2249],
11	group	NN	O	group	prep_to	7	SENT_334	[p24l1931t2203r2084b2249],
12	did	VBD	O	do	aux	14	SENT_334	[p24l57t2259r135b2307],
13	not	RB	O	not	neg	14	SENT_334	[p24l160t2268r243b2307],
14	receive	VB	O	receive	_	0	SENT_334	[p24l264t2263r442b2307],
15	irinotecan	NN	O	irinotecan	dobj	14	SENT_334	[p24l463t2263r720b2307],
16	and	CC	O	and	_	0	SENT_334	[p24l743t2259r835b2307],
17	were	VBD	O	be	auxpass	19	SENT_334	[p24l855t2275r978b2307],
18	thus	RB	O	thus	advmod	19	SENT_334	[p24l995t2259r1109b2307],
19	evaluated	VBN	O	evaluate	conj_and	14	SENT_334	[p24l1130t2259r1377b2307],
20	for	IN	O	for	_	0	SENT_334	[p24l1398t2258r1471b2307],
21	safety	NN	O	safety	prep_for	19	SENT_334	[p24l1489t2258r1638b2322],
22	in	IN	O	in	_	0	SENT_334	[p24l1658t2263r1700b2306],
23	the	DT	O	the	det	25	SENT_334	[p24l1720t2259r1802b2307],
24	monotherapy	JJ	O	monotherapy	amod	25	SENT_334	[p24l1824t2259r2098b2307, p24l58t2348r146b2395],
25	group	NN	O	group	prep_in	21	SENT_334	[p24l164t2348r331b2395],
26	.	.	O	.	_	0	SENT_334	[p24l164t2348r331b2395],

1	Two	CD	NUMBER	two	num	2	SENT_335	[p24l351t2336r454b2380],
2	patients	NNS	O	patient	nsubj	13	SENT_335	[p24l477t2336r683b2395],
3	who	WP	O	who	nsubjpass	6	SENT_335	[p24l702t2332r810b2380],
4	were	VBD	O	be	auxpass	6	SENT_335	[p24l828t2348r951b2380],
5	randomly	RB	O	randomly	advmod	6	SENT_335	[p24l973t2332r1219b2395],
6	assigned	VBN	O	assign	rcmod	2	SENT_335	[p24l1238t2332r1466b2395],
7	to	TO	O	to	_	0	SENT_335	[p24l1486t2341r1537b2380],
8	the	DT	O	the	det	10	SENT_335	[p24l1555t2332r1637b2380],
9	combinationtherapy	JJ	O	combinationtherapy	amod	10	SENT_335	[p24l1656t2332r2007b2380, p24l56t2405r252b2468],
10	group	NN	O	group	prep_to	6	SENT_335	[p24l270t2421r423b2468],
11	did	VBD	O	do	aux	13	SENT_335	[p24l443t2405r521b2453],
12	not	RB	O	not	neg	13	SENT_335	[p24l545t2414r628b2453],
13	receive	VB	O	receive	_	0	SENT_335	[p24l649t2409r827b2453],
14	any	DT	O	any	det	16	SENT_335	[p24l848t2421r935b2468],
15	study	NN	O	study	nn	16	SENT_335	[p24l955t2405r1094b2468],
16	medication	NN	O	medication	dobj	13	SENT_335	[p24l1115t2405r1420b2453],
17	.	.	O	.	_	0	SENT_335	[p24l1115t2405r1420b2453],

1	munohistochemical	JJ	O	munohistochemical	amod	2	SENT_336	[p24l563t2673r1196b2732],
2	evidence	NN	O	evidence	nsubjpass	7	SENT_336	[p24l1220t2674r1490b2732],
3	of	IN	O	of	_	0	SENT_336	[p24l1515t2673r1590b2732],
4	EGFR	NN	ORGANIZATION	egfr	nn	5	SENT_336	[p24l1600t2678r1793b2736],
5	expression	NN	O	expression	prep_of	2	SENT_336	[p24l1810t2674r2149b2748],
6	were	VBD	O	be	auxpass	7	SENT_336	[p24l560t2788r710b2827],
7	included	VBN	O	include	_	0	SENT_336	[p24l733t2768r1006b2827],
8	in	IN	O	in	_	0	SENT_336	[p24l1028t2769r1088b2826],
9	our	PRP$	O	we	poss	10	SENT_336	[p24l1112t2787r1219b2827],
10	study	NN	O	study	prep_in	7	SENT_336	[p24l1241t2768r1417b2843],
11	,	,	O	,	_	0	SENT_336	[p24l1241t2768r1417b2843],
12	and	CC	O	and	_	0	SENT_336	[p24l1444t2768r1560b2827],
13	therefore	RB	O	therefore	advmod	20	SENT_336	[p24l1583t2768r1869b2827],
14	Whether	IN	O	whether	dep	20	SENT_336	[p24l1889t2769r2151b2828],
15	patients	NNS	O	patient	nsubj	20	SENT_336	[p24l562t2864r812b2938],
16	without	IN	O	without	_	0	SENT_336	[p24l841t2864r1092b2923],
17	EGFR	NN	ORGANIZATION	egfr	nn	18	SENT_336	[p24l1118t2868r1311b2926],
18	expression	NN	O	expression	prep_without	15	SENT_336	[p24l1335t2864r1674b2938],
19	would	MD	O	would	aux	20	SENT_336	[p24l1702t2863r1900b2923],
20	beneﬁt	VB	O	beneﬁt	csubj	24	SENT_336	[p24l1931t2863r2153b2922],
21	from	IN	O	from	_	0	SENT_336	[p24l563t2958r718b3017],
22	cetuximab	NN	O	cetuximab	prep_from	20	SENT_336	[p24l735t2959r1060b3017],
23	is	VBZ	O	be	cop	24	SENT_336	[p24l1077t2959r1126b3017],
24	unknown	JJ	O	unknown	conj_and	7	SENT_336	[p24l1144t2959r1463b3018],
25	.	.	O	.	_	0	SENT_336	[p24l1144t2959r1463b3018],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_337	[p24l1483t2963r1677b3021],
2	expression	NN	O	expression	_	0	SENT_337	[p24l1687t2959r2025b3033],
3	has	VBZ	O	have	aux	6	SENT_337	[p24l2042t2959r2147b3017],
4	not	RB	O	not	neg	6	SENT_337	[p24l563t3066r670b3112],
5	been	VBN	O	be	auxpass	6	SENT_337	[p24l683t3054r832b3112],
6	shown	VBN	O	show	rcmod	2	SENT_337	[p24l850t3053r1059b3113],
7	to	TO	O	to	aux	10	SENT_337	[p24l1075t3065r1134b3112],
8	be	VB	O	be	cop	10	SENT_337	[p24l1152t3054r1224b3112],
9	a	DT	O	a	det	10	SENT_337	[p24l1240t3073r1273b3112],
10	predictor	NN	O	predictor	xcomp	6	SENT_337	[p24l1287t3053r1578b3128],
11	of	IN	O	of	_	0	SENT_337	[p24l1593t3053r1669b3112],
12	responsiveness	NN	O	responsiveness	prep_of	10	SENT_337	[p24l1671t3054r2147b3128],
13	to	TO	O	to	dep	14	SENT_337	[p24l563t3161r623b3207],
14	geﬁtinib	NN	O	geﬁtinib	dep	22	SENT_337	[p24l642t3148r907b3223],
15	in	IN	O	in	_	0	SENT_337	[p24l927t3149r987b3206],
16	non	JJ	O	non	amod	21	SENT_337	[p24l1006t3148r1478b3207],
17	—	JJ	O	—	amod	21	SENT_337	[p24l1006t3148r1478b3207],
18	small	JJ	O	small	amod	21	SENT_337	[p24l1006t3148r1478b3207],
19	—	NN	O	—	nn	21	SENT_337	[p24l1006t3148r1478b3207],
20	cell	NN	O	cell	nn	21	SENT_337	[p24l1006t3148r1478b3207],
21	lung	NN	O	lung	prep_in	14	SENT_337	[p24l1496t3148r1641b3223],
22	cancer	NN	O	cancer	dep	2	SENT_337	[p24l1658t3143r2017b3207],
23	.3637	CD	NUMBER	.3637	num	22	SENT_337	[p24l1658t3143r2017b3207],
24	It	PRP	O	it	nsubj	26	SENT_337	[p24l2035t3154r2084b3207],
25	is	VBZ	O	be	cop	26	SENT_337	[p24l2099t3149r2147b3207],
26	possible	JJ	O	possible	rcmod	22	SENT_337	[p24l562t3244r824b3318],
27	that	IN	O	that	complm	37	SENT_337	[p24l844t3244r968b3302],
28	the	DT	O	the	det	29	SENT_337	[p24l984t3244r1080b3302],
29	level	NN	O	level	nsubj	37	SENT_337	[p24l1099t3243r1239b3302],
30	of	IN	O	of	_	0	SENT_337	[p24l1258t3243r1333b3302],
31	activated	VBN	O	activate	prep_of	29	SENT_337	[p24l1338t3243r1631b3314],
32	,	,	O	,	_	0	SENT_337	[p24l1338t3243r1631b3314],
33	phosphorylated	VBN	O	phosphorylate	partmod	31	SENT_337	[p24l1654t3243r2149b3318],
34	EGFR	NN	ORGANIZATION	egfr	dobj	33	SENT_337	[p24l562t3343r754b3401],
35	is	VBZ	O	be	cop	37	SENT_337	[p24l762t3339r809b3397],
36	more	RBR	O	more	advmod	37	SENT_337	[p24l827t3357r989b3397],
37	important	JJ	O	important	ccomp	26	SENT_337	[p24l1005t3339r1323b3413],
38	than	IN	O	than	_	0	SENT_337	[p24l1335t3338r1474b3397],
39	the	DT	O	the	det	41	SENT_337	[p24l1490t3338r1585b3397],
40	total	JJ	O	total	amod	41	SENT_337	[p24l1601t3338r1740b3397],
41	EGFRlevel35	NN	O	egfrlevel35	prep_than	37	SENT_337	[p24l1754t3335r2146b3401],

1	or	CC	O	or	dep	12	SENT_338	[p24l10t3632r115b3702],
2	,	,	O	,	_	0	SENT_338	[p24l10t3632r115b3702],
3	in	IN	O	in	dep	12	SENT_338	[p24l144t3607r226b3684],
4	lung	NN	O	lung	nn	5	SENT_338	[p24l249t3607r443b3707],
5	cancer	NN	O	cancer	pobj	3	SENT_338	[p24l464t3632r756b3702],
6	,	,	O	,	_	0	SENT_338	[p24l464t3632r756b3702],
7	the	DT	O	the	det	8	SENT_338	[p24l786t3607r916b3685],
8	presence	NN	O	presence	dep	12	SENT_338	[p24l939t3632r1312b3707],
9	of	IN	O	of	_	0	SENT_338	[p24l1338t3606r1439b3685],
10	mutations	NNS	O	mutation	prep_of	8	SENT_338	[p24l1444t3607r1875b3686],
11	in	IN	O	in	prep	8	SENT_338	[p24l1901t3607r1982b3684],
12	the	DT	O	the	_	0	SENT_338	[p24l2007t3607r2136b3685],

1	ATP	NN	O	atp	nn	2	SENT_339	[p25l6t20r560b121],
2	—	NN	O	—	_	0	SENT_339	[p25l6t20r560b121],
3	binding	VBG	O	bind	partmod	2	SENT_339	[p25l6t20r560b121],
4	site	NN	O	site	dobj	3	SENT_339	[p25l592t21r737b99],
5	of	IN	O	of	_	0	SENT_339	[p25l773t20r875b99],
6	EGFR,-38	NN	O	egfr,-38	prep_of	4	SENT_339	[p25l889t26r1254b116],
7	in	IN	O	in	_	0	SENT_339	[p25l1289t21r1371b98],
8	the	DT	O	the	det	9	SENT_339	[p25l1406t20r1537b99],
9	prediction	NN	O	prediction	prep_in	3	SENT_339	[p25l1571t20r2016b121],
10	of	IN	O	of	_	0	SENT_339	[p25l2052t20r2153b99],
11	efﬁcacy	NN	O	efﬁcacy	prep_of	9	SENT_339	[p25l10t148r349b249],
12	.	.	O	.	_	0	SENT_339	[p25l10t148r349b249],

1	Patients	NNS	O	patient	nsubj	21	SENT_340	[p25l136t277r475b355],
2	with	IN	O	with	_	0	SENT_340	[p25l510t277r702b356],
3	advanced	JJ	O	advanced	amod	5	SENT_340	[p25l739t276r1139b356],
4	colorectal	JJ	O	colorectal	amod	5	SENT_340	[p25l1176t276r1600b355],
5	cancer	NN	O	cancer	prep_with	1	SENT_340	[p25l1637t302r1918b355],
6	who	WP	O	who	nsubj	7	SENT_340	[p25l1948t277r2134b356],
7	receive	VBP	O	receive	rcmod	5	SENT_340	[p25l9t405r301b484],
8	ﬂuoropyrimidine	NN	O	ﬂuoropyrimidine	dobj	7	SENT_340	[p25l329t404r1077b505],
9	,	,	O	,	_	0	SENT_340	[p25l329t404r1077b505],
10	irinotecan	NN	O	irinotecan	dobj	7	SENT_340	[p25l1108t405r1559b500],
11	,	,	O	,	_	0	SENT_340	[p25l1108t405r1559b500],
12	and	CC	O	and	_	0	SENT_340	[p25l1590t404r1746b483],
13	oXalipla	NN	O	oxaliplum	dobj	7	SENT_340	[p25l1772t405r2135b505],
14	—	CD	NUMBER	—	num	15	SENT_340	[p25l1772t405r2135b505],
15	tin	NN	O	tin	advmod	7	SENT_340	[p25l10t533r121b611],
16	in	IN	O	in	_	0	SENT_340	[p25l154t533r236b610],
17	combination	NN	O	combination	prep_in	15	SENT_340	[p25l271t532r811b611],
18	or	CC	O	or	_	0	SENT_340	[p25l846t558r935b611],
19	sequentially	RB	O	sequentially	advmod	7	SENT_340	[p25l968t532r1474b633],
20	may	MD	O	may	aux	21	SENT_340	[p25l1504t559r1680b633],
21	survive	VB	O	survive	_	0	SENT_340	[p25l1712t533r2000b612],
22	18	CD	DURATION	18	number	24	SENT_340	[p25l2038t538r2134b611],
23	to	TO	DURATION	to	dep	24	SENT_340	[p25l10t677r89b739],
24	21	CD	DURATION	21	num	25	SENT_340	[p25l117t666r217b738],
25	months	NNS	NUMBER	month	tmod	21	SENT_340	[p25l245t661r595b739],
26	.	.	O	.	_	0	SENT_340	[p25l245t661r595b739],

1	However	RB	O	however	advmod	12	SENT_341	[p25l627t668r1019b756],
2	,	,	O	,	_	0	SENT_341	[p25l627t668r1019b756],
3	once	RB	DATE	once	advmod	9	SENT_341	[p25l1052t686r1250b739],
4	these	DT	O	these	det	7	SENT_341	[p25l1277t661r1496b739],
5	three	CD	NUMBER	three	num	7	SENT_341	[p25l1524t661r1736b739],
6	standard	JJ	O	standard	amod	7	SENT_341	[p25l1765t661r2136b739],
7	drugs	NNS	O	drug	nsubj	9	SENT_341	[p25l10t789r252b890],
8	have	VBP	O	have	aux	9	SENT_341	[p25l278t790r470b869],
9	failed	VBN	O	fail	dep	12	SENT_341	[p25l495t789r758b885],
10	,	,	O	,	_	0	SENT_341	[p25l495t789r758b885],
11	there	EX	O	there	expl	12	SENT_341	[p25l789t790r1006b868],
12	are	VBP	O	be	_	0	SENT_341	[p25l1030t816r1158b868],
13	no	DT	O	no	det	16	SENT_341	[p25l1184t815r1290b868],
14	accepted	VBN	O	accept	amod	16	SENT_341	[p25l1316t789r1692b890],
15	treatment	NN	O	treatment	nn	16	SENT_341	[p25l1716t806r2140b868],
16	options	NNS	O	option	nsubj	12	SENT_341	[p25l10t918r357b1018],
17	.	.	O	.	_	0	SENT_341	[p25l10t918r357b1018],

1	Therefore	RB	O	therefore	advmod	22	SENT_342	[p25l396t917r836b1013],
2	,	,	O	,	_	0	SENT_342	[p25l396t917r836b1013],
3	the	DT	O	the	det	8	SENT_342	[p25l878t918r1007b996],
4	observed	VBN	O	observe	amod	8	SENT_342	[p25l1045t917r1420b997],
5	tumor	NN	O	tumor	nn	8	SENT_342	[p25l1457t934r2136b1018],
6	—	NN	O	—	nn	8	SENT_342	[p25l1457t934r2136b1018],
7	response	NN	O	response	nn	8	SENT_342	[p25l1457t934r2136b1018],
8	rate	NN	O	rate	nsubj	22	SENT_342	[p25l9t1062r164b1124],
9	of	IN	O	of	_	0	SENT_342	[p25l185t1045r285b1124],
10	22.9	CD	PERCENT	22.9	number	11	SENT_342	[p25l287t1051r466b1124],
11	percent	NN	PERCENT	percent	amod	19	SENT_342	[p25l487t1062r803b1146],
12	among	IN	O	among	_	0	SENT_342	[p25l817t1071r1114b1146],
13	patients	NNS	O	patient	prep_among	11	SENT_342	[p25l1130t1046r1458b1146],
14	with	IN	O	with	_	0	SENT_342	[p25l1476t1046r1664b1125],
15	irinotecan	NN	O	irinotecan	prep_with	13	SENT_342	[p25l1683t1046r2135b1124],
16	—	CD	NUMBER	—	num	15	SENT_342	[p25l1683t1046r2135b1124],
17	refractory	JJ	O	refractory	amod	19	SENT_342	[p25l9t1173r418b1274],
18	colorectal	JJ	O	colorectal	amod	19	SENT_342	[p25l442t1174r856b1252],
19	cancer	NN	O	cancer	prep_of	8	SENT_342	[p25l884t1199r1160b1252],
20	is	VBZ	O	be	cop	22	SENT_342	[p25l1184t1174r1249b1252],
21	clinically	RB	O	clinically	advmod	22	SENT_342	[p25l1280t1174r1656b1274],
22	important	JJ	O	important	_	0	SENT_342	[p25l1678t1174r2131b1274],
23	.	.	O	.	_	0	SENT_342	[p25l1678t1174r2131b1274],

1	Cetuximab	NNP	O	Cetuximab	nsubj	2	SENT_343	[p25l9t1302r465b1381],
2	compares	VBZ	O	compare	_	0	SENT_343	[p25l518t1327r927b1402],
3	favorably	RB	O	favorably	advmod	2	SENT_343	[p25l980t1301r1368b1402],
4	with	IN	O	with	_	0	SENT_343	[p25l1410t1302r1600b1381],
5	oXaliplatin	NN	O	oxaliplatin	prep_with	2	SENT_343	[p25l1652t1302r2134b1402],
6	—	CD	NUMBER	—	num	5	SENT_343	[p25l1652t1302r2134b1402],
7	based	VBN	O	base	partmod	5	SENT_343	[p25l10t1429r256b1508],
8	therapy	NN	O	therapy	dobj	7	SENT_343	[p25l294t1430r617b1530],
9	in	IN	O	in	_	0	SENT_343	[p25l649t1430r731b1507],
10	patients	NNS	O	patient	prep_in	8	SENT_343	[p25l767t1430r1109b1530],
11	with	IN	O	with	_	0	SENT_343	[p25l1144t1430r1337b1509],
12	irinotecan	JJ	O	irinotecan	amod	14	SENT_343	[p25l1374t1429r2134b1508],
13	—	NN	O	—	nn	14	SENT_343	[p25l1374t1429r2134b1508],
14	refrac	NN	O	refrac	prep_with	7	SENT_343	[p25l1374t1429r2134b1508],
15	—	CD	NUMBER	—	num	17	SENT_343	[p25l1374t1429r2134b1508],
16	tory	JJ	O	tory	amod	17	SENT_343	[p25l10t1574r177b1658],
17	disease	NN	O	disease	dep	14	SENT_343	[p25l207t1558r534b1636],
18	.	.	O	.	_	0	SENT_343	[p25l207t1558r534b1636],

1	The	DT	O	the	det	4	SENT_344	[p25l570t1558r732b1636],
2	22.9	CD	PERCENT	22.9	amod	4	SENT_344	[p25l767t1563r949b1636],
3	percent	NN	PERCENT	percent	nn	4	SENT_344	[p25l983t1574r1304b1658],
4	rate	NN	O	rate	nsubj	14	SENT_344	[p25l1333t1574r1489b1636],
5	of	IN	O	of	_	0	SENT_344	[p25l1525t1557r1626b1636],
6	response	NN	O	response	prep_of	4	SENT_344	[p25l1641t1583r2020b1658],
7	to	TO	O	to	aux	8	SENT_344	[p25l2056t1574r2135b1636],
8	cetuximab	VB	O	cetuximab	infmod	6	SENT_344	[p25l10t1686r436b1765],
9	in	IN	O	in	_	0	SENT_344	[p25l456t1686r536b1763],
10	combination	NN	O	combination	prep_in	8	SENT_344	[p25l556t1686r1085b1764],
11	with	IN	O	with	_	0	SENT_344	[p25l1099t1686r1285b1765],
12	irinotecan	NN	O	irinotecan	prep_with	8	SENT_344	[p25l1303t1686r1720b1764],
13	was	VBD	O	be	cop	14	SENT_344	[p25l1736t1712r1894b1765],
14	higher	JJR	O	higher	_	0	SENT_344	[p25l1915t1686r2136b1786, p25l10t1840r91b1892],
15	than	IN	O	than	_	0	SENT_344	[p25l122t1814r313b1892],
16	the	DT	O	the	det	18	SENT_344	[p25l346t1814r477b1892],
17	response	NN	O	response	nn	18	SENT_344	[p25l510t1839r897b1914],
18	rate	NN	O	rate	prep_than	14	SENT_344	[p25l930t1830r1090b1892],
19	reported	VBN	O	report	partmod	18	SENT_344	[p25l1123t1814r1489b1914],
20	for	IN	O	for	_	0	SENT_344	[p25l1522t1813r1647b1892],
21	oxaliplatin	NN	O	oxaliplatin	prep_for	19	SENT_344	[p25l1677t1814r2135b1914],
22	in	IN	O	in	_	0	SENT_344	[p25l8t1942r90b2019],
23	combination	NN	O	combination	prep_in	21	SENT_344	[p25l125t1942r669b2020],
24	with	IN	O	with	_	0	SENT_344	[p25l695t1942r884b2021],
25	infused	VBN	O	infuse	amod	26	SENT_344	[p25l914t1941r1228b2021],
26	ﬂuorouracil	NN	O	ﬂuorouracil	prep_with	19	SENT_344	[p25l1259t1941r1758b2021],
27	and	CC	O	and	_	0	SENT_344	[p25l1787t1941r1945b2020],
28	leucovorin	NN	O	leucovorin	conj_and	26	SENT_344	[p25l1975t1942r2135b2021, p25l10t2071r324b2150],

1	(	NN	O	(	nsubj	17	SENT_345	[p25l353t2076r513b2162],
2	9.6	CD	PERCENT	9.6	num	3	SENT_345	[p25l353t2076r513b2162],
3	percent	NN	PERCENT	percent	dep	1	SENT_345	[p25l537t2066r956b2171],
4	)	CD	NUMBER	)	number	5	SENT_345	[p25l537t2066r956b2171],
5	,8	CD	NUMBER	,8	dep	1	SENT_345	[p25l537t2066r956b2171],
6	but	CC	O	but	prep	5	SENT_345	[p25l983t2071r1124b2150],
7	the	DT	O	the	det	9	SENT_345	[p25l1144t2071r1273b2149],
8	median	JJ	O	median	amod	9	SENT_345	[p25l1299t2071r1615b2149],
9	time	NN	O	time	dep	6	SENT_345	[p25l1640t2071r1827b2149],
10	to	TO	O	to	_	0	SENT_345	[p25l1853t2087r1932b2149],
11	progression	NN	O	progression	prep_to	9	SENT_345	[p25l1957t2096r2135b2171, p25l9t2199r365b2299],
12	and	CC	O	and	_	0	SENT_345	[p25l388t2199r542b2277],
13	the	DT	O	the	det	15	SENT_345	[p25l567t2198r695b2277],
14	survival	NN	O	survival	nn	15	SENT_345	[p25l720t2199r1034b2278],
15	time	NN	O	time	conj_and	11	SENT_345	[p25l1058t2199r1244b2277],
16	were	VBD	O	be	cop	17	SENT_345	[p25l1263t2225r1463b2278],
17	similar	JJ	O	similar	_	0	SENT_345	[p25l1488t2199r1780b2277],
18	with	IN	O	with	_	0	SENT_345	[p25l1796t2199r1984b2278],
19	the	DT	O	the	det	21	SENT_345	[p25l2008t2199r2136b2277],
20	two	CD	NUMBER	two	num	21	SENT_345	[p25l10t2343r162b2406],
21	regimens	NNS	O	regimen	prep_with	17	SENT_345	[p25l197t2327r625b2427],
22	.	.	O	.	_	0	SENT_345	[p25l197t2327r625b2427],

1	Furthermore	RB	O	furthermore	advmod	8	SENT_346	[p25l663t2326r1237b2422],
2	,	,	O	,	_	0	SENT_346	[p25l663t2326r1237b2422],
3	previous	JJ	O	previous	amod	5	SENT_346	[p25l1276t2327r1641b2427],
4	oxaliplatin	NN	O	oxaliplatin	nn	5	SENT_346	[p25l1677t2327r2135b2427],
5	treatment	NN	O	treatment	nsubj	8	SENT_346	[p25l10t2471r430b2533],
6	did	VBD	O	do	aux	8	SENT_346	[p25l451t2454r584b2533],
7	not	RB	O	not	neg	8	SENT_346	[p25l609t2471r753b2533],
8	negate	VB	O	negate	_	0	SENT_346	[p25l773t2471r1050b2555],
9	any	DT	O	any	det	10	SENT_346	[p25l1075t2480r1223b2555],
10	beneﬁt	NN	O	beneﬁt	dobj	8	SENT_346	[p25l1245t2454r1541b2533],
11	of	IN	O	of	_	0	SENT_346	[p25l1562t2454r1662b2533],
12	cetuximab	NN	O	cetuximab	prep_of	10	SENT_346	[p25l1671t2455r2130b2534],
13	.	.	O	.	_	0	SENT_346	[p25l1671t2455r2130b2534],

1	The	DT	O	the	det	6	SENT_347	[p25l6t2583r167b2661],
2	one	CD	NUMBER	one	number	3	SENT_347	[p25l197t2608r560b2683],
3	—	CD	NUMBER	—	dep	4	SENT_347	[p25l197t2608r560b2683],
4	year	NN	NUMBER	year	dep	6	SENT_347	[p25l197t2608r560b2683],
5	survival	NN	O	survival	nn	6	SENT_347	[p25l587t2583r905b2662],
6	rates	NNS	O	rate	nsubj	34	SENT_347	[p25l934t2599r1132b2661],
7	in	IN	O	in	_	0	SENT_347	[p25l1162t2583r1244b2660],
8	this	DT	O	this	det	9	SENT_347	[p25l1273t2583r1426b2661],
9	group	NN	O	group	prep_in	6	SENT_347	[p25l1456t2608r1707b2683],
10	of	IN	O	of	_	0	SENT_347	[p25l1738t2582r1839b2661],
11	heavily	RB	O	heavily	advmod	32	SENT_347	[p25l1849t2583r2141b2683],
12	pretreated	JJ	O	pretreated	amod	13	SENT_347	[p25l7t2710r438b2811],
13	patients	NNS	O	patient	pobj	11	SENT_347	[p25l470t2711r805b2811],
14	—	IN	O	—	_	0	SENT_347	[p25l836t2755r944b2763],
15	29	CD	PERCENT	29	num	16	SENT_347	[p25l973t2716r1073b2789],
16	percent	NN	PERCENT	percent	prep_—	11	SENT_347	[p25l1106t2727r1427b2811],
17	in	IN	O	in	_	0	SENT_347	[p25l1454t2711r1536b2788],
18	the	DT	O	the	det	22	SENT_347	[p25l1569t2711r1698b2789],
19	combination	NN	O	combination	nn	22	SENT_347	[p25l1733t2711r2135b2789, p25l10t2838r524b2939],
20	—	NN	O	—	nn	22	SENT_347	[p25l1733t2711r2135b2789, p25l10t2838r524b2939],
21	therapy	NN	O	therapy	nn	22	SENT_347	[p25l1733t2711r2135b2789, p25l10t2838r524b2939],
22	group	NN	O	group	prep_in	16	SENT_347	[p25l540t2864r788b2939],
23	and	CC	O	and	_	0	SENT_347	[p25l810t2839r965b2917],
24	32	CD	PERCENT	32	num	25	SENT_347	[p25l986t2844r1085b2917],
25	percent	NN	PERCENT	percent	prep_—	11	SENT_347	[p25l1105t2855r1421b2939],
26	in	IN	O	in	_	0	SENT_347	[p25l1437t2839r1518b2916],
27	the	DT	O	the	det	31	SENT_347	[p25l1539t2839r1666b2917],
28	monother	JJ	O	monother	amod	31	SENT_347	[p25l1688t2838r2135b2917],
29	—	NN	O	—	nn	31	SENT_347	[p25l1688t2838r2135b2917],
30	apy	NN	O	apy	nn	31	SENT_347	[p25l8t2992r153b3066],
31	group	NN	O	group	prep_in	25	SENT_347	[p25l173t2991r424b3066],
32	—	CD	NUMBER	—	prep_of	9	SENT_347	[p25l447t3011r555b3019],
33	are	VBP	O	be	cop	34	SENT_347	[p25l574t2992r701b3044],
34	encouraging	VBG	O	encourage	_	0	SENT_347	[p25l727t2967r1281b3066],
35	.	.	O	.	_	0	SENT_347	[p25l727t2967r1281b3066],

1	Moreover	RB	O	moreover	_	0	SENT_348	[p25l1309t2973r1732b3061],
2	,	,	O	,	_	0	SENT_348	[p25l1309t2973r1732b3061],
3	about	IN	O	about	dep	1	SENT_348	[p25l1762t2967r2011b3045],
4	48	CD	PERCENT	48	num	5	SENT_348	[p25l2031t2972r2133b3044],
5	percent	NN	PERCENT	percent	pobj	3	SENT_348	[p25l7t3111r335b3195],
6	of	IN	O	of	_	0	SENT_348	[p25l373t3094r473b3173],
7	the	DT	O	the	det	8	SENT_348	[p25l495t3095r625b3173],
8	patients	NNS	O	patient	prep_of	5	SENT_348	[p25l665t3095r999b3195],
9	obtained	VBN	O	obtain	partmod	8	SENT_348	[p25l1043t3095r1415b3173],
10	clinically	RB	O	clinically	advmod	11	SENT_348	[p25l1457t3094r1833b3195],
11	meaningﬁil	JJ	O	meaningﬁil	amod	13	SENT_348	[p25l1869t3120r2135b3173, p25l8t3222r261b3323],
12	disease	NN	O	disease	nn	13	SENT_348	[p25l286t3223r589b3301],
13	control	NN	O	control	dobj	9	SENT_348	[p25l616t3223r941b3301],
14	.	.	O	.	_	0	SENT_348	[p25l616t3223r941b3301],

1	Supported	VBN	O	support	_	0	SENT_349	[p26l96t22r424b97],
2	by	IN	O	by	_	0	SENT_349	[p26l460t22r533b97],
3	grants	NNS	O	grant	prep_by	1	SENT_349	[p26l565t35r763b98],
4	to	TO	O	to	_	0	SENT_349	[p26l802t35r861b81],
5	all	PDT	O	all	predet	8	SENT_349	[p26l897t22r971b81],
6	the	DT	O	the	det	8	SENT_349	[p26l1007t22r1104b81],
7	participating	VBG	O	participate	amod	8	SENT_349	[p26l1139t23r1550b98],
8	institutions	NNS	O	institution	prep_to	3	SENT_349	[p26l1582t23r1945b81],
9	from	IN	O	from	prep	1	SENT_349	[p26l1982t22r2138b81],

1	Merck	NNP	PERSON	Merck	nn	3	SENT_350	[p26l6t106r210b165],
2	(	NNP	O	(	nn	3	SENT_350	[p26l229t105r607b177],
3	Darmstadt	NNP	LOCATION	Darmstadt	_	0	SENT_350	[p26l229t105r607b177],
4	,	,	O	,	_	0	SENT_350	[p26l229t105r607b177],
5	Germany	NNP	LOCATION	Germany	appos	3	SENT_350	[p26l630t110r965b181],
6	)	CD	NUMBER	)	num	5	SENT_350	[p26l630t110r965b181],
7	.	.	O	.	_	0	SENT_350	[p26l630t110r965b181],

1	Dr.	NNP	O	Dr.	nn	2	SENT_351	[p26l93t195r189b249],
2	Cunningham	NNP	PERSON	Cunningham	nsubj	3	SENT_351	[p26l217t191r639b266],
3	reports	VBZ	O	report	_	0	SENT_351	[p26l661t203r886b266],
4	having	VBG	O	have	aux	5	SENT_351	[p26l910t190r1125b266],
5	received	VBN	O	receive	xcomp	3	SENT_351	[p26l1145t190r1402b250],
6	consulting	NN	O	consulting	nn	9	SENT_351	[p26l1425t190r1764b266],
7	and	CC	O	and	_	0	SENT_351	[p26l1785t190r1901b249],
8	lecture	NN	O	lecture	nn	9	SENT_351	[p26l1923t190r2137b250],
9	fees	NNS	O	fee	dobj	5	SENT_351	[p26l8t275r129b334],
10	from	IN	O	from	_	0	SENT_351	[p26l154t275r310b334],
11	Merck	NNP	PERSON	Merck	prep_from	5	SENT_351	[p26l331t276r549b347],
12	,	,	O	,	_	0	SENT_351	[p26l331t276r549b347],
13	Aventis	NNP	ORGANIZATION	Aventis	prep_from	5	SENT_351	[p26l574t276r823b347],
14	,	,	O	,	_	0	SENT_351	[p26l574t276r823b347],
15	and	CC	O	and	_	0	SENT_351	[p26l849t276r966b334],
16	Sanoﬁ	NNP	PERSON	Sanoﬁ	prep_from	5	SENT_351	[p26l989t275r1581b351],
17	.	.	O	.	_	0	SENT_351	[p26l989t275r1581b351],

1	—	NN	O	—	_	0	SENT_352	[p26l989t275r1581b351],
2	.	.	O	.	_	0	SENT_352	[p26l989t275r1581b351],

1	Synthelabo	NNP	ORGANIZATION	Synthelabo	_	0	SENT_353	[p26l989t275r1581b351],
2	;	:	O	;	_	0	SENT_353	[p26l989t275r1581b351],
3	Dr.	NNP	O	Dr.	nn	6	SENT_353	[p26l1605t280r1698b334],
4	Humblet	NNP	PERSON	Humblet	nn	6	SENT_353	[p26l1724t275r2008b335],
5	lecture	NN	O	lecture	nn	6	SENT_353	[p26l2025t275r2136b334, p26l8t372r130b419],
6	fees	NNS	O	fee	dep	1	SENT_353	[p26l148t359r267b418],
7	from	IN	O	from	_	0	SENT_353	[p26l286t359r440b418],
8	Aventis	NNP	ORGANIZATION	Aventis	prep_from	6	SENT_353	[p26l455t360r703b431],
9	,	,	O	,	_	0	SENT_353	[p26l455t360r703b431],
10	N	NNP	O	N	nn	11	SENT_353	[p26l723t365r780b419],
11	ovartis	NN	O	ovarti	prep_from	6	SENT_353	[p26l782t360r1005b431],
12	,	,	O	,	_	0	SENT_353	[p26l782t360r1005b431],
13	Janssen	NNP	PERSON	Janssen	prep_from	6	SENT_353	[p26l1019t365r1281b431],
14	,	,	O	,	_	0	SENT_353	[p26l1019t365r1281b431],
15	and	CC	O	and	_	0	SENT_353	[p26l1302t359r1418b418],
16	Amgen	NNP	ORGANIZATION	Amgen	prep_from	6	SENT_353	[p26l1432t365r1680b435],
17	;	:	O	;	_	0	SENT_353	[p26l1432t365r1680b435],
18	Dr.	NNP	O	Dr.	nn	19	SENT_353	[p26l1699t364r1791b418],
19	Siena	NNP	PERSON	Siena	conj_and	6	SENT_353	[p26l1815t360r1982b418],
20	consulting	VBG	O	consult	partmod	19	SENT_353	[p26l1999t378r2136b418, p26l10t444r227b520],
21	fees	NNS	O	fee	dobj	20	SENT_353	[p26l250t444r369b503],
22	from	IN	O	from	_	0	SENT_353	[p26l397t444r551b503],
23	Amgen	NNP	ORGANIZATION	Amgen	prep_from	20	SENT_353	[p26l574t450r803b520],
24	and	CC	O	and	_	0	SENT_353	[p26l829t445r944b503],
25	Roche	NNP	PERSON	Roche	conj_and	23	SENT_353	[p26l971t444r1170b507],
26	and	CC	O	and	_	0	SENT_353	[p26l1197t444r1314b503],
27	lecture	NN	O	lecture	nn	28	SENT_353	[p26l1341t445r1555b504],
28	fees	NNS	O	fee	conj_and	6	SENT_353	[p26l1582t444r1704b503],
29	from	IN	O	from	_	0	SENT_353	[p26l1733t444r1889b503],
30	Merck	NNP	LOCATION	Merck	prep_from	28	SENT_353	[p26l1914t445r2133b516],
31	,	,	O	,	_	0	SENT_353	[p26l1914t445r2133b516],
32	Amgen	NNP	ORGANIZATION	Amgen	prep_from	28	SENT_353	[p26l6t535r254b605],
33	,	,	O	,	_	0	SENT_353	[p26l6t535r254b605],
34	and	CC	O	and	_	0	SENT_353	[p26l276t529r394b588],
35	Roche	NNP	LOCATION	Roche	prep_from	28	SENT_353	[p26l410t530r629b601],
36	;	:	O	;	_	0	SENT_353	[p26l410t530r629b601],
37	Dr.	NNP	O	Dr.	nn	38	SENT_353	[p26l649t534r743b588],
38	Khayat	NNP	PERSON	Khayat	dep	1	SENT_353	[p26l765t530r985b605],
39	consulting	VBG	O	consult	partmod	38	SENT_353	[p26l1001t530r1340b605],
40	fees	NNS	O	fee	dobj	39	SENT_353	[p26l1356t529r1478b588],
41	from	IN	O	from	_	0	SENT_353	[p26l1497t529r1653b588],
42	Merck	NNP	PERSON	Merck	prep_from	40	SENT_353	[p26l1669t530r1887b601],
43	,	,	O	,	_	0	SENT_353	[p26l1669t530r1887b601],
44	SanoﬁSynthelabo	NNP	O	SanoﬁSynthelabo	prep_from	40	SENT_353	[p26l1912t529r2136b588, p26l10t614r377b690],
45	,	,	O	,	_	0	SENT_353	[p26l1912t529r2136b588, p26l10t614r377b690],
46	and	CC	O	and	_	0	SENT_353	[p26l409t614r526b673],
47	Aventis	NNP	ORGANIZATION	Aventis	prep_from	40	SENT_353	[p26l551t615r781b674],
48	and	CC	O	and	_	0	SENT_353	[p26l809t614r925b673],
49	lecture	NN	O	lecture	nn	50	SENT_353	[p26l951t614r1162b674],
50	fees	NNS	O	fee	dobj	39	SENT_353	[p26l1190t614r1310b673],
51	from	IN	O	from	_	0	SENT_353	[p26l1339t614r1493b673],
52	Merck	NNP	ORGANIZATION	Merck	prep_from	50	SENT_353	[p26l1518t615r1721b674],
53	and	CC	O	and	_	0	SENT_353	[p26l1744t614r1860b673],
54	Aventis	NNP	ORGANIZATION	Aventis	conj_and	52	SENT_353	[p26l1884t615r2135b686],
55	;	:	O	;	_	0	SENT_353	[p26l1884t615r2135b686],
56	and	CC	O	and	_	0	SENT_353	[p26l7t700r124b760],
57	Dr.	NNP	O	Dr.	nn	61	SENT_353	[p26l140t705r234b760],
58	Van	NNP	PERSON	Van	nn	61	SENT_353	[p26l254t706r372b760],
59	Cutsem	NNP	PERSON	Cutsem	nn	61	SENT_353	[p26l389t705r631b760],
60	lecture	NN	O	lecture	nn	61	SENT_353	[p26l648t700r860b760],
61	fees	NNS	O	fee	conj_and	40	SENT_353	[p26l879t700r1001b760],
62	from	IN	O	from	_	0	SENT_353	[p26l1021t700r1177b760],
63	Merck	NNP	PERSON	Merck	prep_from	61	SENT_353	[p26l1193t700r1412b760],
64	.	.	O	.	_	0	SENT_353	[p26l1193t700r1412b760],

1	We	PRP	O	we	nsubj	3	SENT_354	[p26l91t791r192b844],
2	are	VBP	O	be	cop	3	SENT_354	[p26l220t805r316b844],
3	indebted	JJ	O	indebted	_	0	SENT_354	[p26l343t785r627b844],
4	to	TO	O	to	_	0	SENT_354	[p26l655t798r715b844],
5	all	DT	O	all	predet	7	SENT_354	[p26l743t786r820b844],
6	the	DT	O	the	det	7	SENT_354	[p26l847t785r946b844],
7	patients	NNS	O	patient	prep_to	3	SENT_354	[p26l972t786r1230b861],
8	who	WP	O	who	nsubj	9	SENT_354	[p26l1255t786r1395b845],
9	took	VBD	O	take	conj_and	9	SENT_354	[p26l1424t786r1572b845],
10	part	NN	O	part	dobj	9	SENT_354	[p26l1594t798r1727b861],
11	in	IN	O	in	_	0	SENT_354	[p26l1750t786r1812b843],
12	the	DT	O	the	det	13	SENT_354	[p26l1840t786r1939b844],
13	study	NN	O	study	prep_in	9	SENT_354	[p26l1967t785r2140b861],
14	and	CC	O	and	_	0	SENT_354	[p26l7t871r126b930],
15	to	TO	O	to	_	0	SENT_354	[p26l147t884r207b930],
16	their	PRP$	O	they	poss	17	SENT_354	[p26l228t872r381b930],
17	families	NNS	O	family	prep_to	9	SENT_354	[p26l399t871r669b930],
18	.	.	O	.	_	0	SENT_354	[p26l399t871r669b930],

1	APPENDIX	NN	O	appendix	_	0	SENT_355	[p26l1144t1005r1292b1021],

1	The	DT	O	the	det	3	SENT_356	[p26l376t1048r423b1071],
2	following	VBG	O	follow	amod	3	SENT_356	[p26l429t1048r548b1078],
3	investigators	NNS	O	investigator	nsubj	4	SENT_356	[p26l553t1048r710b1078],
4	participated	VBD	O	participate	_	0	SENT_356	[p26l717t1048r863b1078],
5	in	IN	O	in	_	0	SENT_356	[p26l869t1048r893b1071],
6	the	DT	O	the	det	7	SENT_356	[p26l900t1048r937b1071],
7	study	NN	O	study	prep_in	4	SENT_356	[p26l944t1048r1016b1078],
8	:	:	O	:	_	0	SENT_356	[p26l944t1048r1016b1078],
9	the	DT	O	the	det	10	SENT_356	[p26l1023t1048r1061b1071],
10	Netherlands	NNP	LOCATION	Netherlands	dep	7	SENT_356	[p26l1067t1048r1218b1071],
11	.	.	O	.	_	0	SENT_356	[p26l1224t1050r1312b1071],

1	—	NN	O	—	_	0	SENT_357	[p26l1224t1050r1312b1071],
2	.	.	O	.	_	0	SENT_357	[p26l1224t1050r1312b1071],

1	G.S.	NNP	PERSON	G.S.	nn	2	SENT_358	[p26l1224t1050r1312b1071],
2	Liem	NNP	PERSON	Liem	_	0	SENT_358	[p26l1319t1048r1387b1076],
3	,	,	O	,	_	0	SENT_358	[p26l1319t1048r1387b1076],
4	H.	NNP	PERSON	H.	nn	5	SENT_358	[p26l1395t1050r1423b1071],
5	Goey	NNP	PERSON	Goey	appos	2	SENT_358	[p26l1431t1050r1498b1078],
6	,	,	O	,	_	0	SENT_358	[p26l1431t1050r1498b1078],
7	CJ	NNP	O	CJ	appos	5	SENT_358	[p26l1505t1050r1547b1075],
8	.	.	O	.	_	0	SENT_358	[p26l1505t1050r1547b1075],

1	van	NN	PERSON	van	nn	2	SENT_359	[p26l1554t1056r1596b1072],
2	Groeningen	NN	PERSON	groeningen	_	0	SENT_359	[p26l1603t1048r1758b1078],
3	,	,	O	,	_	0	SENT_359	[p26l1603t1048r1758b1078],
4	and	CC	O	and	_	0	SENT_359	[p26l1766t1048r1811b1071],
5	R.J.M.	NNP	PERSON	R.J.M.	nn	7	SENT_359	[p26l1817t1050r1893b1075],
6	van	NNP	PERSON	van	nn	7	SENT_359	[p26l1899t1056r1942b1072],
7	Leendert	NNP	PERSON	Leendert	conj_and	2	SENT_359	[p26l1948t1048r2063b1076],
8	;	:	O	;	_	0	SENT_359	[p26l1948t1048r2063b1076],
9	United	NNP	LOCATION	United	nn	13	SENT_359	[p26l377t1085r460b1108],
10	Kingdom	NNP	LOCATION	Kingdom	nn	13	SENT_359	[p26l466t1085r583b1115],
11	—	NNP	O	—	nn	13	SENT_359	[p26l588t1098r619b1101],
12	D.	NNP	PERSON	D.	nn	13	SENT_359	[p26l624t1087r650b1108],
13	Cunningham	NNP	PERSON	Cunningham	dep	2	SENT_359	[p26l658t1085r828b1115],
14	,	,	O	,	_	0	SENT_359	[p26l658t1085r828b1115],
15	L.	NNP	PERSON	L.	nn	16	SENT_359	[p26l836t1087r857b1108],
16	Samuel	NNP	PERSON	Samuel	dep	2	SENT_359	[p26l866t1085r963b1113],
17	,	,	O	,	_	0	SENT_359	[p26l866t1085r963b1113],
18	T.	NNP	PERSON	T.	nn	19	SENT_359	[p26l970t1087r991b1108],
19	Hickish	NNP	PERSON	Hickish	conj_and	13	SENT_359	[p26l999t1085r1102b1113],
20	,	,	O	,	_	0	SENT_359	[p26l999t1085r1102b1113],
21	M.	NNP	PERSON	M.	nn	22	SENT_359	[p26l1109t1087r1141b1108],
22	Hill	NNP	PERSON	Hill	conj_and	13	SENT_359	[p26l1149t1085r1201b1113],
23	,	,	O	,	_	0	SENT_359	[p26l1149t1085r1201b1113],
24	T.	NNP	PERSON	T.	nn	25	SENT_359	[p26l1208t1087r1230b1108],
25	Iveson	NNP	PERSON	Iveson	conj_and	13	SENT_359	[p26l1238t1087r1324b1113],
26	,	,	O	,	_	0	SENT_359	[p26l1238t1087r1324b1113],
27	J.	NNP	PERSON	J.	nn	28	SENT_359	[p26l1329t1087r1347b1112],
28	Ledermann	NNP	PERSON	Ledermann	conj_and	13	SENT_359	[p26l1354t1085r1502b1113],
29	,	,	O	,	_	0	SENT_359	[p26l1354t1085r1502b1113],
30	P.	NNP	PERSON	P.	nn	31	SENT_359	[p26l1510t1087r1528b1108],
31	Mainwaring	NNP	PERSON	Mainwaring	conj_and	13	SENT_359	[p26l1535t1085r1692b1115],
32	,	,	O	,	_	0	SENT_359	[p26l1535t1085r1692b1115],
33	and	CC	O	and	_	0	SENT_359	[p26l1700t1085r1745b1108],
34	J.	NNP	PERSON	J.	nn	35	SENT_359	[p26l1749t1087r1766b1112],
35	Cassidy	NNP	PERSON	Cassidy	conj_and	13	SENT_359	[p26l1774t1085r1875b1115],
36	;	:	O	;	_	0	SENT_359	[p26l1774t1085r1875b1115],
37	Germany	NNP	LOCATION	Germany	nn	40	SENT_359	[p26l1883t1087r1997b1115],
38	—	NNP	O	—	nn	40	SENT_359	[p26l2001t1098r2033b1101],
39	C.	NNP	PERSON	C.	nn	40	SENT_359	[p26l2038t1087r2062b1108],
40	Bokemeyer	NNP	PERSON	Bokemeyer	dep	2	SENT_359	[p26l377t1122r519b1151],
41	,	,	O	,	_	0	SENT_359	[p26l377t1122r519b1151],
42	M.	NNP	PERSON	M.	nn	43	SENT_359	[p26l528t1124r559b1145],
43	Miihler	NNP	PERSON	Miihler	appos	40	SENT_359	[p26l568t1122r663b1150],
44	,	,	O	,	_	0	SENT_359	[p26l568t1122r663b1150],
45	N.	NNP	PERSON	N.	nn	46	SENT_359	[p26l672t1124r699b1145],
46	Niederle	NNP	PERSON	Niederle	appos	40	SENT_359	[p26l708t1122r819b1150],
47	,	,	O	,	_	0	SENT_359	[p26l708t1122r819b1150],
48	H.-J	NN	O	h.-j	appos	40	SENT_359	[p26l828t1124r884b1149],
49	.	.	O	.	_	0	SENT_359	[p26l828t1124r884b1149],

1	Schmoll	NNP	PERSON	Schmoll	_	0	SENT_360	[p26l894t1122r1001b1150],
2	,	,	O	,	_	0	SENT_360	[p26l894t1122r1001b1150],
3	C.	NNP	PERSON	C.	nn	4	SENT_360	[p26l1010t1124r1035b1145],
4	Peschel	NNP	PERSON	Peschel	conj_and	1	SENT_360	[p26l1044t1122r1142b1150],
5	,	,	O	,	_	0	SENT_360	[p26l1044t1122r1142b1150],
6	and	CC	O	and	_	0	SENT_360	[p26l1151t1122r1197b1145],
7	E.	NNP	PERSON	E.	nn	8	SENT_360	[p26l1204t1124r1227b1145],
8	Kettner	NNP	PERSON	Kettner	conj_and	1	SENT_360	[p26l1236t1124r1334b1150],
9	;	:	O	;	_	0	SENT_360	[p26l1236t1124r1334b1150],
10	France	NNP	LOCATION	France	nn	13	SENT_360	[p26l1343t1124r1425b1145],
11	—	NNP	O	—	nn	13	SENT_360	[p26l1431t1135r1463b1138],
12	M.	NNP	PERSON	M.	nn	13	SENT_360	[p26l1469t1124r1500b1145],
13	Ychou	NNP	PERSON	Ychou	dep	1	SENT_360	[p26l1508t1122r1590b1150],
14	,	,	O	,	_	0	SENT_360	[p26l1508t1122r1590b1150],
15	A.	NNP	PERSON	A.	nn	17	SENT_360	[p26l1598t1124r1623b1145],
16	de	NNP	PERSON	de	nn	17	SENT_360	[p26l1633t1122r1661b1145],
17	Gramont	NNP	PERSON	Gramont	appos	13	SENT_360	[p26l1668t1124r1788b1150],
18	,	,	O	,	_	0	SENT_360	[p26l1668t1124r1788b1150],
19	M.	NNP	PERSON	M.	nn	20	SENT_360	[p26l1796t1124r1828b1145],
20	Ducreux	NNP	PERSON	Ducreux	appos	13	SENT_360	[p26l1837t1124r1946b1150],
21	,	,	O	,	_	0	SENT_360	[p26l1837t1124r1946b1150],
22	M.C.	NNP	PERSON	M.C.	nn	23	SENT_360	[p26l1955t1124r2012b1145],
23	Kaminsky	NNP	PERSON	Kaminsky	appos	13	SENT_360	[p26l2021t1124r2063b1146, p26l377t1159r471b1189],
24	,	,	O	,	_	0	SENT_360	[p26l2021t1124r2063b1146, p26l377t1159r471b1189],
25	]	CD	NUMBER	]	appos	13	SENT_360	[p26l476t1161r524b1186],
26	.	.	O	.	_	0	SENT_360	[p26l476t1161r524b1186],

1	.	.	O	.	_	0	SENT_361	[p26l476t1161r524b1186],

1	—	NN	O	—	_	0	SENT_362	[p26l476t1161r524b1186],
2	.	.	O	.	_	0	SENT_362	[p26l476t1161r524b1186],

1	F.	NNP	PERSON	F.	nn	2	SENT_363	[p26l476t1161r524b1186],
2	Seitz	NNP	PERSON	Seitz	_	0	SENT_363	[p26l533t1159r598b1187],
3	,	,	O	,	_	0	SENT_363	[p26l533t1159r598b1187],
4	D.	NNP	PERSON	D.	nn	5	SENT_363	[p26l605t1161r631b1182],
5	Khayat	NNP	PERSON	Khayat	conj_and	2	SENT_363	[p26l639t1159r730b1189],
6	,	,	O	,	_	0	SENT_363	[p26l639t1159r730b1189],
7	and	CC	O	and	_	0	SENT_363	[p26l738t1159r784b1182],
8	Y.	NNP	PERSON	Y.	nn	9	SENT_363	[p26l789t1161r809b1182],
9	Becouarn	NNP	PERSON	Becouarn	conj_and	2	SENT_363	[p26l817t1161r941b1187],
10	;	:	O	;	_	0	SENT_363	[p26l817t1161r941b1187],
11	Austria	NNP	LOCATION	Austria	nn	14	SENT_363	[p26l947t1159r1037b1183],
12	—	NNP	O	—	nn	14	SENT_363	[p26l1042t1172r1073b1175],
13	W.	NNP	PERSON	W.	nn	14	SENT_363	[p26l1078t1161r1108b1182],
14	Scheidiauer	NNP	PERSON	Scheidiauer	dep	2	SENT_363	[p26l1117t1159r1266b1187],
15	,	,	O	,	_	0	SENT_363	[p26l1117t1159r1266b1187],
16	H.	NNP	PERSON	H.	nn	17	SENT_363	[p26l1274t1161r1303b1182],
17	Ludwig	NNP	PERSON	Ludwig	dep	2	SENT_363	[p26l1310t1159r1409b1189],
18	,	,	O	,	_	0	SENT_363	[p26l1310t1159r1409b1189],
19	J.	NNP	PERSON	J.	nn	20	SENT_363	[p26l1414t1161r1431b1186],
20	Schiiller	NNP	PERSON	Schiiller	conj_and	14	SENT_363	[p26l1440t1159r1545b1187],
21	,	,	O	,	_	0	SENT_363	[p26l1440t1159r1545b1187],
22	H.	NNP	PERSON	H.	nn	23	SENT_363	[p26l1553t1161r1581b1182],
23	Zwierzina	NNP	PERSON	Zwierzina	conj_and	14	SENT_363	[p26l1589t1159r1718b1187],
24	,	,	O	,	_	0	SENT_363	[p26l1589t1159r1718b1187],
25	H.	NNP	PERSON	H.	nn	26	SENT_363	[p26l1726t1161r1754b1182],
26	Samonigg	NNP	PERSON	Samonigg	conj_and	14	SENT_363	[p26l1763t1159r1894b1189],
27	,	,	O	,	_	0	SENT_363	[p26l1763t1159r1894b1189],
28	and	CC	O	and	_	0	SENT_363	[p26l1902t1159r1947b1182],
29	H.	NNP	PERSON	H.	nn	30	SENT_363	[p26l1954t1161r1982b1182],
30	Hausmaninger	NNP	PERSON	Hausmaninger	conj_and	14	SENT_363	[p26l1990t1161r2063b1183, p26l377t1196r503b1226],
31	;	:	O	;	_	0	SENT_363	[p26l1990t1161r2063b1183, p26l377t1196r503b1226],
32	Belgium	NNP	LOCATION	Belgium	nn	36	SENT_363	[p26l511t1196r614b1226],
33	—	NNP	O	—	nn	36	SENT_363	[p26l620t1209r651b1212],
34	E.	NNP	LOCATION	E.	nn	36	SENT_363	[p26l656t1198r679b1219],
35	Van	NNP	LOCATION	Van	nn	36	SENT_363	[p26l686t1198r732b1219],
36	Cutsem	NNP	LOCATION	Cutsem	dep	2	SENT_363	[p26l738t1198r839b1224],
37	,	,	O	,	_	0	SENT_363	[p26l738t1198r839b1224],
38	J.	NNP	PERSON	J.	nn	40	SENT_363	[p26l845t1198r862b1223],
39	van	NNP	PERSON	van	nn	40	SENT_363	[p26l869t1204r912b1220],
40	Laediem	NNP	PERSON	Laediem	conj_and	36	SENT_363	[p26l918t1196r1031b1224],
41	,	,	O	,	_	0	SENT_363	[p26l918t1196r1031b1224],
42	H.	NNP	PERSON	H.	nn	43	SENT_363	[p26l1039t1198r1067b1219],
43	Bleiberg	NNP	PERSON	Bleiberg	conj_and	36	SENT_363	[p26l1075t1196r1184b1226],
44	,	,	O	,	_	0	SENT_363	[p26l1075t1196r1184b1226],
45	and	CC	O	and	_	0	SENT_363	[p26l1192t1196r1237b1219],
46	Y.	NNP	PERSON	Y.	nn	47	SENT_363	[p26l1243t1198r1263b1219],
47	Humblet	NNP	PERSON	Humblet	conj_and	36	SENT_363	[p26l1271t1196r1387b1224],
48	;	:	O	;	_	0	SENT_363	[p26l1271t1196r1387b1224],
49	Sweden	NNP	LOCATION	Sweden	nn	52	SENT_363	[p26l1396t1196r1490b1220],
50	—	NNP	O	—	nn	52	SENT_363	[p26l1495t1209r1527b1212],
51	H.	NNP	PERSON	H.	nn	52	SENT_363	[p26l1532t1198r1560b1219],
52	Mellstedt	NNP	PERSON	Mellstedt	dep	2	SENT_363	[p26l1567t1196r1684b1219],
53	and	CC	O	and	_	0	SENT_363	[p26l1689t1196r1734b1219],
54	M.	NNP	PERSON	M.	nn	55	SENT_363	[p26l1740t1198r1771b1219],
55	Albertsson	NNP	PERSON	Albertsson	dep	2	SENT_363	[p26l1779t1196r1920b1224],
56	;	:	O	;	_	0	SENT_363	[p26l1779t1196r1920b1224],
57	Spain	NNP	LOCATION	Spain	dep	2	SENT_363	[p26l1928t1196r1996b1226],
58	.	.	O	.	_	0	SENT_363	[p26l2001t1198r2062b1219],

1	—	NN	O	—	_	0	SENT_364	[p26l2001t1198r2062b1219],
2	.	.	O	.	_	0	SENT_364	[p26l2001t1198r2062b1219],

1	A.	NN	PERSON	a.	nn	3	SENT_365	[p26l2001t1198r2062b1219],
2	Cervantes	NNP	PERSON	Cervantes	nn	3	SENT_365	[p26l377t1235r496b1257],
3	Ruipérez	NNP	PERSON	Ruipérez	_	0	SENT_365	[p26l504t1233r621b1263],
4	,	,	O	,	_	0	SENT_365	[p26l504t1233r621b1263],
5	J.	NNP	PERSON	J.	nn	7	SENT_365	[p26l627t1236r644b1261],
6	Tabernero	NNP	PERSON	Tabernero	nn	7	SENT_365	[p26l653t1234r778b1257],
7	Caturla	NNP	PERSON	Caturla	appos	3	SENT_365	[p26l786t1234r882b1262],
8	,	,	O	,	_	0	SENT_365	[p26l786t1234r882b1262],
9	E.	NNP	PERSON	E.	nn	10	SENT_365	[p26l891t1236r914b1257],
10	Diaz	NNP	PERSON	Diaz	appos	7	SENT_365	[p26l923t1234r1070b1262],
11	.	.	O	.	_	0	SENT_365	[p26l923t1234r1070b1262],

1	—	NN	O	—	_	0	SENT_366	[p26l923t1234r1070b1262],
2	.	.	O	.	_	0	SENT_366	[p26l923t1234r1070b1262],

1	Rubio	NNP	PERSON	Rubio	_	0	SENT_367	[p26l923t1234r1070b1262],
2	,	,	O	,	_	0	SENT_367	[p26l923t1234r1070b1262],
3	P.	NNP	PERSON	P.	nn	5	SENT_367	[p26l1079t1235r1098b1257],
4	Gascén	NNP	PERSON	Gascén	nn	5	SENT_367	[p26l1107t1233r1200b1257],
5	Vilaplana	NNP	PERSON	Vilaplana	conj_and	1	SENT_367	[p26l1206t1234r1329b1263],
6	,	,	O	,	_	0	SENT_367	[p26l1206t1234r1329b1263],
7	M.	NNP	PERSON	M.	nn	9	SENT_367	[p26l1337t1236r1369b1257],
8	Navarro	NNP	PERSON	Navarro	nn	9	SENT_367	[p26l1378t1236r1476b1257],
9	Garcia	NNP	PERSON	Garcia	conj_and	1	SENT_367	[p26l1484t1234r1571b1262],
10	,	,	O	,	_	0	SENT_367	[p26l1484t1234r1571b1262],
11	and	CC	O	and	_	0	SENT_367	[p26l1580t1234r1626b1257],
12	A.	NN	PERSON	a.	nn	14	SENT_367	[p26l1632t1236r1658b1257],
13	Anton	NNP	PERSON	Anton	nn	14	SENT_367	[p26l1666t1233r1743b1257],
14	Torres	NNP	PERSON	Torres	conj_and	1	SENT_367	[p26l1749t1235r1835b1262],
15	;	:	O	;	_	0	SENT_367	[p26l1749t1235r1835b1262],
16	Italy	NNP	LOCATION	Italy	nn	19	SENT_367	[p26l1843t1234r1897b1263],
17	—	NNP	O	—	nn	19	SENT_367	[p26l1903t1247r1934b1249],
18	E.	NNP	PERSON	E.	nn	19	SENT_367	[p26l1940t1236r1963b1257],
19	Bajetta	NNP	PERSON	Bajetta	dep	1	SENT_367	[p26l1972t1234r2062b1263],
20	,	,	O	,	_	0	SENT_367	[p26l1972t1234r2062b1263],
21	P.	NNP	PERSON	P.	nn	22	SENT_367	[p26l377t1273r395b1294],
22	Conte	NNP	PERSON	Conte	dep	1	SENT_367	[p26l404t1273r483b1299],
23	,	,	O	,	_	0	SENT_367	[p26l404t1273r483b1299],
24	F.	NNP	PERSON	F.	nn	26	SENT_367	[p26l492t1273r510b1294],
25	de	NNP	PERSON	de	nn	26	SENT_367	[p26l519t1271r547b1294],
26	Brand	NNP	PERSON	Brand	dep	1	SENT_367	[p26l553t1271r634b1299],
27	,	,	O	,	_	0	SENT_367	[p26l553t1271r634b1299],
28	A.	NNP	PERSON	A.	nn	29	SENT_367	[p26l641t1273r666b1294],
29	Santoro	NNP	PERSON	Santoro	dep	1	SENT_367	[p26l676t1273r778b1299],
30	,	,	O	,	_	0	SENT_367	[p26l676t1273r778b1299],
31	S.	NNP	PERSON	S.	nn	32	SENT_367	[p26l787t1273r807b1294],
32	Siena	NNP	PERSON	Siena	dep	1	SENT_367	[p26l816t1271r889b1299],
33	,	,	O	,	_	0	SENT_367	[p26l816t1271r889b1299],
34	S.	NNP	PERSON	S.	nn	35	SENT_367	[p26l898t1273r918b1294],
35	Artale	NNP	PERSON	Artale	dep	1	SENT_367	[p26l926t1271r1006b1299],
36	,	,	O	,	_	0	SENT_367	[p26l926t1271r1006b1299],
37	F.	NNP	PERSON	F.	nn	38	SENT_367	[p26l1015t1273r1033b1294],
38	Grossi	NNP	PERSON	Grossi	dep	1	SENT_367	[p26l1041t1271r1129b1299],
39	,	,	O	,	_	0	SENT_367	[p26l1041t1271r1129b1299],
40	A.R.	NNP	PERSON	A.R.	nn	41	SENT_367	[p26l1137t1273r1189b1295],
41	Bianco	NNP	PERSON	Bianco	dep	1	SENT_367	[p26l1198t1271r1289b1299],
42	,	,	O	,	_	0	SENT_367	[p26l1198t1271r1289b1299],
43	and	CC	O	and	_	0	SENT_367	[p26l1297t1271r1343b1294],
44	A.	NN	PERSON	a.	nn	45	SENT_367	[p26l1349t1273r1374b1294],
45	Sobrero	NNP	PERSON	Sobrero	dep	1	SENT_367	[p26l1383t1271r1487b1299],
46	;	:	O	;	_	0	SENT_367	[p26l1383t1271r1487b1299],
47	Switzerland	NNP	LOCATION	Switzerland	nn	50	SENT_367	[p26l1495t1271r1640b1294],
48	—	NNP	O	—	nn	50	SENT_367	[p26l1646t1284r1677b1287],
49	R.	NNP	PERSON	R.	nn	50	SENT_367	[p26l1683t1273r1708b1295],
50	Herrmann	NNP	PERSON	Herrmann	dep	1	SENT_367	[p26l1716t1273r1845b1294],
51	and	CC	O	and	_	0	SENT_367	[p26l1852t1271r1897b1294],
52	C.	NNP	PERSON	C.	nn	53	SENT_367	[p26l1904t1273r1929b1294],
53	Sessa	NNP	PERSON	Sessa	conj_and	50	SENT_367	[p26l1938t1273r2011b1299],
54	;	:	O	;	_	0	SENT_367	[p26l1938t1273r2011b1299],
55	and	CC	O	and	_	0	SENT_367	[p26l2019t1271r2064b1294],
56	Norway	NNP	LOCATION	Norway	nn	59	SENT_367	[p26l376t1310r473b1337],
57	—	NNP	O	—	nn	59	SENT_367	[p26l478t1321r509b1324],
58	S.	NNP	PERSON	S.	nn	59	SENT_367	[p26l516t1310r536b1331],
59	Dueland	NNP	PERSON	Dueland	dep	1	SENT_367	[p26l545t1308r655b1331],
60	.	.	O	.	_	0	SENT_367	[p26l545t1308r655b1331],

1	REFERENCES	NNS	O	reference	_	0	SENT_368	[p26l379t1412r561b1428],
2	1	CD	NUMBER	1	num	1	SENT_368	[p26l378t1458r397b1478],
3	.	.	O	.	_	0	SENT_368	[p26l378t1458r397b1478],

1	de	IN	O	de	amod	3	SENT_369	[p26l427t1455r455b1478],
2	Gramont	NNP	O	Gramont	nn	3	SENT_369	[p26l465t1457r579b1478],
3	A	NNP	O	A	_	0	SENT_369	[p26l586t1458r612b1483],
4	,	,	O	,	_	0	SENT_369	[p26l586t1458r612b1483],
5	Figer	NNP	PERSON	Figer	nn	6	SENT_369	[p26l623t1456r687b1485],
6	A	NNP	O	A	appos	3	SENT_369	[p26l695t1458r720b1483],
7	,	,	O	,	_	0	SENT_369	[p26l695t1458r720b1483],
8	Seymour	NNP	PERSON	Seymour	nn	9	SENT_369	[p26l732t1457r841b1485],
9	M	NNP	PERSON	M	appos	6	SENT_369	[p26l849t1458r881b1483],
10	,	,	O	,	_	0	SENT_369	[p26l849t1458r881b1483],
11	et	FW	O	et	dep	6	SENT_369	[p26l893t1460r915b1478],
12	compared	VBN	O	compare	prep	6	SENT_369	[p26l952t1455r1075b1485],
13	wiﬂi	NN	O	wiﬂi	nn	14	SENT_369	[p26l1087t1455r1142b1479],
14	ﬂuorouracil	NN	O	ﬂuorouracil	npadvmod	16	SENT_369	[p26l1155t1455r1300b1479],
15	alone	RB	O	alone	advmod	14	SENT_369	[p26l1312t1455r1379b1478],
16	as	IN	O	as	pcomp	12	SENT_369	[p26l1392t1463r1416b1478],
17	firstline	NN	O	firstline	nn	18	SENT_369	[p26l1430t1455r1488b1478, p26l952t1492r997b1516],
18	treatment	NN	O	treatment	pobj	16	SENT_369	[p26l1005t1497r1125b1516],
19	for	IN	O	for	_	0	SENT_369	[p26l1131t1492r1167b1516],
20	metastatic	JJ	O	metastatic	amod	22	SENT_369	[p26l1174t1493r1301b1516],
21	colorectal	JJ	O	colorectal	amod	22	SENT_369	[p26l1309t1492r1429b1516],
22	cancer	NN	O	cancer	prep_for	18	SENT_369	[p26l1436t1500r1488b1516, p26l952t1537r995b1553],
23	:	:	O	:	_	0	SENT_369	[p26l1436t1500r1488b1516, p26l952t1537r995b1553],
24	a	DT	O	a	det	27	SENT_369	[p26l1007t1537r1020b1553],
25	multicentre	JJ	O	multicentre	amod	26	SENT_369	[p26l1030t1529r1172b1553],
26	randomised	JJ	O	randomised	amod	27	SENT_369	[p26l1183t1529r1330b1553],
27	trial	NN	O	trial	dep	6	SENT_369	[p26l1341t1530r1396b1553],
28	.	.	O	.	_	0	SENT_369	[p26l1341t1530r1396b1553],

1	Lancet	NNP	O	Lancet	_	0	SENT_370	[p26l1408t1532r1490b1553],
2	2000	CD	DATE	2000	num	1	SENT_370	[p26l952t1569r1174b1595],
3	;	:	O	;	_	0	SENT_370	[p26l952t1569r1174b1595],
4	355:1041	CD	NUMBER	355:1041	number	5	SENT_370	[p26l952t1569r1174b1595],
5	-7	CD	NUMBER	-7	dep	1	SENT_370	[p26l952t1569r1174b1595],
6	.	.	O	.	_	0	SENT_370	[p26l952t1569r1174b1595],

1	[	NN	O	[	_	0	SENT_371	[p26l1191t1569r1310b1595],
2	Erratum	NN	O	erratum	dep	1	SENT_371	[p26l1191t1569r1310b1595],
3	,	,	O	,	_	0	SENT_371	[p26l1191t1569r1310b1595],
4	Lancet	NNP	O	Lancet	appos	2	SENT_371	[p26l1324t1569r1407b1590],
5	2000	CD	DATE	2000	rcmod	4	SENT_371	[p26l1418t1569r1487b1595],
6	;	:	O	;	_	0	SENT_371	[p26l1418t1569r1487b1595],
7	355:1372	CD	NUMBER	355:1372	dep	5	SENT_371	[p26l952t1606r1085b1631],
8	.	.	O	.	_	0	SENT_371	[p26l952t1606r1085b1631],
9	]	SYM	O	]	dep	5	SENT_371	[p26l952t1606r1085b1631],

1	2	LS	NUMBER	2	_	0	SENT_372	[p26l376t1644r397b1664],
2	.	.	O	.	_	0	SENT_372	[p26l376t1644r397b1664],

1	Douillard	NNP	PERSON	Douillard	nn	2	SENT_373	[p26l426t1641r543b1665],
2	IY	NNP	O	IY	_	0	SENT_373	[p26l549t1643r580b1669],
3	,	,	O	,	_	0	SENT_373	[p26l549t1643r580b1669],
4	Cunningham	NNP	ORGANIZATION	Cunningham	nn	5	SENT_373	[p26l590t1641r754b1671],
5	D	NNP	ORGANIZATION	D	appos	2	SENT_373	[p26l762t1643r788b1669],
6	,	,	O	,	_	0	SENT_373	[p26l762t1643r788b1669],
7	Roth	NNP	PERSON	Roth	nn	8	SENT_373	[p26l798t1641r858b1666],
8	AD	NN	O	ad	appos	2	SENT_373	[p26l866t1643r912b1669],
9	,	,	O	,	_	0	SENT_373	[p26l866t1643r912b1669],
10	3	CD	NUMBER	3	appos	2	SENT_373	[p26l952t1644r972b1664],
11	.	.	O	.	_	0	SENT_373	[p26l952t1644r972b1664],

1	Giacchetti	NNP	PERSON	Giacchetti	nn	2	SENT_374	[p26l1002t1641r1127b1664],
2	S	NNP	O	S	_	0	SENT_374	[p26l1136t1643r1156b1669],
3	,	,	O	,	_	0	SENT_374	[p26l1136t1643r1156b1669],
4	Perpoint	NNP	O	Perpoint	nn	5	SENT_374	[p26l1165t1642r1271b1671],
5	B	NNP	O	B	appos	2	SENT_374	[p26l1277t1643r1301b1669],
6	,	,	O	,	_	0	SENT_374	[p26l1277t1643r1301b1669],
7	Zidani	NNP	PERSON	Zidani	nn	8	SENT_374	[p26l1310t1641r1389b1664],
8	R	NNP	PERSON	R	appos	2	SENT_374	[p26l1396t1643r1421b1669],
9	,	,	O	,	_	0	SENT_374	[p26l1396t1643r1421b1669],
10	et	FW	O	et	nn	13	SENT_374	[p26l1431t1646r1453b1664],
11	al.	FW	O	al.	nn	13	SENT_374	[p26l1460t1641r1487b1664],
12	et	FW	O	et	nn	13	SENT_374	[p26l377t1683r400b1702],
13	al.	FW	O	al.	appos	2	SENT_374	[p26l406t1678r433b1702],
14	.	.	O	.	_	0	SENT_374	[p26l406t1678r433b1702],

1	Irinotecan	NNP	O	Irinotecan	nsubj	2	SENT_375	[p26l442t1679r568b1702],
2	combined	VBN	O	combine	_	0	SENT_375	[p26l576t1678r700b1702],
3	with	IN	O	with	_	0	SENT_375	[p26l706t1679r761b1702],
4	ﬂuorouracil	NN	O	ﬂuorouracil	nn	5	SENT_375	[p26l769t1678r914b1702],
5	Phase	NN	O	phase	prep_with	2	SENT_375	[p26l952t1679r1023b1702],
6	III	CD	NUMBER	iii	num	9	SENT_375	[p26l1029t1681r1057b1701],
7	multicenter	JJ	O	multicenter	amod	9	SENT_375	[p26l1063t1678r1205b1702],
8	randomized	JJ	O	randomized	amod	9	SENT_375	[p26l1211t1678r1359b1702],
9	trial	NN	O	trial	dobj	2	SENT_375	[p26l1366t1678r1414b1702],
10	of	IN	O	of	_	0	SENT_375	[p26l1420t1678r1450b1702],
11	oxal	NN	O	oxal	prep_of	9	SENT_375	[p26l1451t1686r1488b1702, p26l377t1492r404b1516],
12	.	.	O	.	_	0	SENT_375	[p26l1451t1686r1488b1702, p26l377t1492r404b1516],

1	Leucovorin	NNP	O	Leucovorin	_	0	SENT_376	[p26l412t1493r548b1516],
2	and	CC	O	and	_	0	SENT_376	[p26l555t1492r600b1516],
3	ﬂuorouracil	NN	O	ﬂuorouracil	conj_and	1	SENT_376	[p26l607t1492r751b1516],
4	with	IN	O	with	dep	1	SENT_376	[p26l756t1492r811b1516],
5	or	CC	O	or	_	0	SENT_376	[p26l818t1500r844b1516],
6	without	IN	O	without	dep	1	SENT_376	[p26l848t1492r913b1516, p26l377t1534r418b1553],
7	oxaliplatin	NN	O	oxaliplatin	pobj	4	SENT_376	[p26l426t1529r556b1559],
8	as	IN	O	as	_	0	SENT_376	[p26l565t1537r589b1553],
9	ﬁrst	NN	O	ﬁrst	nn	12	SENT_376	[p26l599t1529r705b1553],
10	—	CD	NUMBER	—	num	12	SENT_376	[p26l599t1529r705b1553],
11	line	NN	O	line	nn	12	SENT_376	[p26l599t1529r705b1553],
12	treatment	NN	O	treatment	prep_as	7	SENT_376	[p26l714t1534r835b1553],
13	in	IN	O	in	dep	1	SENT_376	[p26l842t1530r866b1552],
14	advanced	JJ	O	advanced	amod	16	SENT_376	[p26l875t1529r913b1553, p26l375t1567r461b1590],
15	colorectal	JJ	O	colorectal	amod	16	SENT_376	[p26l469t1567r589b1590],
16	cancer	NN	O	cancer	pobj	13	SENT_376	[p26l596t1574r681b1590],
17	.	.	O	.	_	0	SENT_376	[p26l596t1574r681b1590],

1	J	NNP	O	J	nn	3	SENT_377	[p26l688t1569r699b1593],
2	Clin	NNP	O	Clin	nn	3	SENT_377	[p26l705t1567r756b1590],
3	Oncol	NNP	O	Oncol	_	0	SENT_377	[p26l763t1567r837b1590],
4	2000	CD	DATE	2000	num	3	SENT_377	[p26l845t1569r912b1595],
5	;	:	O	;	_	0	SENT_377	[p26l845t1569r912b1595],
6	182293847	CD	NUMBER	182293847	dep	3	SENT_377	[p26l378t1606r524b1627],
7	.	.	O	.	_	0	SENT_377	[p26l378t1606r524b1627],

1	aliplatin	NN	O	aliplatin	nsubj	2	SENT_378	[p26l1527t1455r1628b1485],
2	added	VBD	O	add	_	0	SENT_378	[p26l1636t1455r1710b1478],
3	to	TO	O	to	aux	4	SENT_378	[p26l1718t1460r1741b1478],
4	chronomodulated	VBN	O	chronomodulate	xcomp	2	SENT_378	[p26l1750t1455r1971b1479],
5	ﬂuorouraci1	NN	O	ﬂuorouraci1	nn	7	SENT_378	[p26l1979t1455r2063b1479, p26l1527t1492r1736b1516],
6	—	CD	NUMBER	—	num	7	SENT_378	[p26l1979t1455r2063b1479, p26l1527t1492r1736b1516],
7	1eucovorin	NN	O	1eucovorin	dobj	4	SENT_378	[p26l1979t1455r2063b1479, p26l1527t1492r1736b1516],
8	as	IN	O	as	_	0	SENT_378	[p26l1749t1500r1774b1516],
9	ﬁrst	NN	O	ﬁrst	nn	12	SENT_378	[p26l1788t1492r1893b1516],
10	—	CD	NUMBER	—	num	12	SENT_378	[p26l1788t1492r1893b1516],
11	line	NN	O	line	nn	12	SENT_378	[p26l1788t1492r1893b1516],
12	treatment	NN	O	treatment	prep_as	4	SENT_378	[p26l1907t1497r2028b1516],
13	of	IN	O	of	_	0	SENT_378	[p26l2040t1492r2069b1516],
14	metastatic	JJ	O	metastatic	amod	16	SENT_378	[p26l1527t1530r1655b1553],
15	colorectal	JJ	O	colorectal	amod	16	SENT_378	[p26l1669t1529r1789b1553],
16	cancer	NN	O	cancer	prep_of	12	SENT_378	[p26l1803t1537r1888b1553],
17	.	.	O	.	_	0	SENT_378	[p26l1803t1537r1888b1553],

1	J	NNP	O	J	nn	3	SENT_379	[p26l1901t1532r1912b1557],
2	Clin	NNP	O	Clin	nn	3	SENT_379	[p26l1925t1529r1976b1553],
3	Oncol	NNP	O	Oncol	_	0	SENT_379	[p26l1990t1529r2064b1553],
4	2000	CD	DATE	2000	num	3	SENT_379	[p26l1527t1569r1729b1595],
5	;	:	O	;	_	0	SENT_379	[p26l1527t1569r1729b1595],
6	18:136	CD	NUMBER	18:136	number	7	SENT_379	[p26l1527t1569r1729b1595],
7	-47	CD	NUMBER	-47	dep	3	SENT_379	[p26l1527t1569r1729b1595],
8	.	.	O	.	_	0	SENT_379	[p26l1527t1569r1729b1595],

1	4	LS	NUMBER	4	_	0	SENT_380	[p26l1526t1607r1547b1627],
2	.	.	O	.	_	0	SENT_380	[p26l1526t1607r1547b1627],

1	Goldberg	NNP	PERSON	Goldberg	nn	2	SENT_381	[p26l1577t1604r1695b1634],
2	RM	NN	O	rm	_	0	SENT_381	[p26l1705t1606r1755b1632],
3	,	,	O	,	_	0	SENT_381	[p26l1705t1606r1755b1632],
4	Sargent	NNP	PERSON	Sargent	nn	6	SENT_381	[p26l1769t1606r1863b1634],
5	D	NNP	O	D	nn	6	SENT_381	[p26l1873t1606r1908b1632],
6	]	NN	O	]	appos	2	SENT_381	[p26l1873t1606r1908b1632],
7	,	,	O	,	_	0	SENT_381	[p26l1873t1606r1908b1632],
8	Morton	NNP	PERSON	Morton	nn	9	SENT_381	[p26l1920t1606r2014b1627],
9	RF	NNP	O	RF	appos	2	SENT_381	[p26l2025t1606r2062b1632],
10	,	,	O	,	_	0	SENT_381	[p26l2025t1606r2062b1632],
11	et	FW	O	et	nn	12	SENT_381	[p26l1527t1646r1550b1664],
12	al.	FW	O	al.	appos	2	SENT_381	[p26l1554t1641r1581b1664],
13	.	.	O	.	_	0	SENT_381	[p26l1554t1641r1581b1664],

1	A	DT	O	a	det	4	SENT_382	[p26l1588t1644r1607b1664],
2	randomized	VBN	O	randomize	amod	4	SENT_382	[p26l1612t1641r1760b1664],
3	controlled	JJ	O	controlled	amod	4	SENT_382	[p26l1766t1641r1890b1664],
4	trial	NN	O	trial	_	0	SENT_382	[p26l1896t1641r1944b1664],
5	of	IN	O	of	_	0	SENT_382	[p26l1950t1641r1979b1664],
6	ﬂuorouracil	NN	O	ﬂuorouracil	prep_of	4	SENT_382	[p26l1980t1641r2064b1665, p26l1527t1679r1596b1702],
7	plus	CC	O	plus	_	0	SENT_382	[p26l1602t1678r1653b1708],
8	leucovorin	NN	O	leucovorin	prep_of	4	SENT_382	[p26l1660t1678r1796b1707],
9	,	,	O	,	_	0	SENT_382	[p26l1660t1678r1796b1707],
10	irinotecan	NN	O	irinotecan	conj_plus	6	SENT_382	[p26l1804t1679r1936b1707],
11	,	,	O	,	_	0	SENT_382	[p26l1804t1679r1936b1707],
12	and	CC	O	and	_	0	SENT_382	[p26l1944t1678r1989b1702],
13	oxali344	NN	O	oxali344	conj_and	8	SENT_382	[p26l1996t1678r2064b1702, p26l90t1783r147b1805],

1	N	NN	O	n	_	0	SENT_383	[p26l858t1785r871b1800],
2	ENGLJ	NN	O	englj	prep	1	SENT_383	[p26l887t1784r971b1806],
3	MED	NN	O	med	nn	6	SENT_383	[p26l986t1785r1038b1800],
4	35	CD	NUMBER	35	num	6	SENT_383	[p26l1051t1784r1115b1806],
5	'	''	O	'	_	0	SENT_383	[p26l1051t1784r1115b1806],
6	|	NN	O	|	dep	2	SENT_383	[p26l1051t1784r1115b1806],
7	;	:	O	;	_	0	SENT_383	[p26l1051t1784r1115b1806],
8	4	CD	NUMBER	4	dep	1	SENT_383	[p26l1051t1784r1115b1806],
9	WWW.NEJM.ORG	NNP	O	WWW.NEJM.ORG	nn	10	SENT_383	[p26l1149t1784r1361b1806],
10	JULY	NNP	DATE	JULY	dep	8	SENT_383	[p26l1394t1785r1454b1806],
11	22	CD	DATE	22	num	10	SENT_383	[p26l1466t1784r1503b1804],
12	,	,	DATE	,	_	0	SENT_383	[p26l1466t1784r1503b1804],
13	2004	CD	DATE	2004	num	10	SENT_383	[p26l1516t1784r1584b1806],
14	.	.	O	.	_	0	SENT_383	[p26l1516t1784r1584b1806],

1	The	DT	O	the	det	4	SENT_384	[p26l877t1881r928b1905],
2	New	NNP	O	New	nn	4	SENT_384	[p26l937t1882r999b1905],
3	England	NNP	O	England	nn	4	SENT_384	[p26l1008t1881r1119b1912],
4	Journal	NNP	O	Journal	_	0	SENT_384	[p26l1128t1881r1225b1905],
5	of	IN	O	of	_	0	SENT_384	[p26l1235t1881r1264b1905],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_384	[p26l1271t1881r1396b1905],

1	Downloaded	VBN	O	download	_	0	SENT_385	[p26l319t1922r489b1945],
2	from	IN	O	from	_	0	SENT_385	[p26l498t1922r562b1945],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_385	[p26l571t1922r689b1952],
4	at	IN	O	at	_	0	SENT_385	[p26l700t1926r723b1945],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_385	[p26l731t1922r914b1945],
6	on	IN	O	on	_	0	SENT_385	[p26l923t1929r956b1945],
7	January	NNP	DATE	January	prep_on	1	SENT_385	[p26l964t1922r1067b1952],
8	5	CD	DATE	5	num	7	SENT_385	[p26l1077t1922r1100b1949],
9	,	,	DATE	,	_	0	SENT_385	[p26l1077t1922r1100b1949],
10	2014	CD	DATE	2014	num	7	SENT_385	[p26l1111t1922r1182b1945],
11	.	.	O	.	_	0	SENT_385	[p26l1111t1922r1182b1945],

1	For	IN	O	for	_	0	SENT_386	[p26l1193t1922r1240b1945],
2	personal	JJ	O	personal	amod	3	SENT_386	[p26l1248t1922r1360b1952],
3	use	NN	O	use	pobj	1	SENT_386	[p26l1369t1929r1413b1945],
4	only	RB	O	only	advmod	3	SENT_386	[p26l1423t1922r1487b1952],
5	.	.	O	.	_	0	SENT_386	[p26l1423t1922r1487b1952],

1	No	DT	O	no	det	3	SENT_387	[p26l1498t1922r1538b1945],
2	other	JJ	O	other	amod	3	SENT_387	[p26l1548t1922r1616b1945],
3	uses	NNS	O	use	_	0	SENT_387	[p26l1624t1929r1680b1945],
4	without	IN	O	without	_	0	SENT_387	[p26l1690t1922r1791b1945],
5	permission	NN	O	permission	prep_without	3	SENT_387	[p26l1800t1922r1952b1952],
6	.	.	O	.	_	0	SENT_387	[p26l1800t1922r1952b1952],

1	Copyright	NN	O	copyright	_	0	SENT_388	[p26l669t1963r804b1994],
2	©	CD	NUMBER	©	num	6	SENT_388	[p26l813t1963r837b1987],
3	2004	CD	DATE	2004	num	6	SENT_388	[p26l847t1963r912b1987],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_388	[p26l921t1963r1112b1987],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_388	[p26l1122t1963r1230b1987],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_388	[p26l1241t1963r1346b1994],
7	.	.	O	.	_	0	SENT_388	[p26l1241t1963r1346b1994],

1	All	DT	O	all	det	2	SENT_389	[p26l1357t1963r1398b1987],
2	rights	NNS	O	rights	nsubj	3	SENT_389	[p26l1407t1963r1482b1994],
3	reserved	VBN	O	reserve	_	0	SENT_389	[p26l1492t1963r1611b1987],
4	.	.	O	.	_	0	SENT_389	[p26l1492t1963r1611b1987],

1	CETUXIMAB	NNP	O	CETUXIMAB	_	0	SENT_390	[p26l533t2069r727b2088],
2	IN	IN	O	in	dep	1	SENT_390	[p26l742t2069r780b2088],
3	IRINOTECAN-REFRACTORY	NNP	O	IRINOTECAN-REFRACTORY	nn	5	SENT_390	[p26l796t2069r1248b2088],
4	COLORECTAL	NNP	O	COLORECTAL	nn	5	SENT_390	[p26l1260t2069r1477b2088],
5	CANCER	NNP	O	CANCER	pobj	2	SENT_390	[p26l1490t2069r1626b2088],

1	platin	NN	O	platin	nn	2	SENT_391	[p26l11t2232r147b2288],
2	combinations	NNS	O	combination	_	0	SENT_391	[p26l167t2232r491b2276],
3	in	IN	O	in	_	0	SENT_391	[p26l512t2233r557b2276],
4	patients	NNS	O	patient	prep_in	2	SENT_391	[p26l576t2233r763b2288],
5	with	IN	O	with	_	0	SENT_391	[p26l781t2232r887b2277],
6	previously	RB	DATE	previously	advmod	7	SENT_391	[p26l906t2233r1039b2288, p26l12t2303r135b2359],
7	untreated	JJ	O	untreated	amod	10	SENT_391	[p26l147t2302r367b2347],
8	metastatic	JJ	O	metastatic	amod	10	SENT_391	[p26l381t2303r621b2346],
9	colorectal	JJ	O	colorectal	amod	10	SENT_391	[p26l635t2302r861b2347],
10	cancer	NN	O	cancer	prep_with	2	SENT_391	[p26l875t2317r1036b2347],
11	.	.	O	.	_	0	SENT_391	[p26l875t2317r1036b2347],

1	JClin	NN	O	jclin	nn	2	SENT_392	[p26l6t2374r136b2424],
2	Oncol	NN	O	oncol	_	0	SENT_392	[p26l150t2373r292b2418],
3	2004	CD	DATE	2004	dep	2	SENT_392	[p26l306t2377r663b2427],
4	;	:	O	;	_	0	SENT_392	[p26l306t2377r663b2427],
5	22:23	CD	TIME	22:23	number	6	SENT_392	[p26l306t2377r663b2427],
6	—	CD	NUMBER	—	dep	2	SENT_392	[p26l306t2377r663b2427],
7	30	CD	NUMBER	30	dep	6	SENT_392	[p26l306t2377r663b2427],
8	.	.	O	.	_	0	SENT_392	[p26l306t2377r663b2427],

1	5	CD	NUMBER	5	_	0	SENT_393	[p26l12t2451r49b2489],
2	.	.	O	.	_	0	SENT_393	[p26l12t2451r49b2489],

1	Saltz	NNP	PERSON	Saltz	nn	7	SENT_394	[p26l109t2445r220b2489],
2	LB	NNP	O	LB	nn	7	SENT_394	[p26l233t2449r308b2499],
3	,	,	O	,	_	0	SENT_394	[p26l233t2449r308b2499],
4	CoXJV	NNP	O	CoXJV	appos	7	SENT_394	[p26l325t2449r483b2499],
5	,	,	O	,	_	0	SENT_394	[p26l325t2449r483b2499],
6	Blanke	NNP	PERSON	Blanke	appos	7	SENT_394	[p26l500t2445r661b2490],
7	C	NNP	O	C	_	0	SENT_394	[p26l676t2449r722b2499],
8	,	,	O	,	_	0	SENT_394	[p26l676t2449r722b2499],
9	et	FW	O	et	nn	10	SENT_394	[p26l740t2454r783b2489],
10	al.	FW	O	al.	appos	7	SENT_394	[p26l793t2445r846b2489],
11	.	.	O	.	_	0	SENT_394	[p26l793t2445r846b2489],

1	Irinotecan	NN	O	irinotecan	_	0	SENT_395	[p26l862t2446r1039b2489, p26l12t2530r92b2559],
2	plus	CC	O	plus	prep	1	SENT_395	[p26l105t2515r202b2572],
3	ﬂuorouracil	NN	O	ﬂuorouracil	dep	2	SENT_395	[p26l216t2515r488b2560],
4	and	CC	O	and	_	0	SENT_395	[p26l500t2515r586b2560],
5	leucovorin	NN	O	leucovorin	dep	2	SENT_395	[p26l598t2515r842b2560],
6	for	IN	O	for	_	0	SENT_395	[p26l855t2515r923b2560],
7	metastatic	JJ	O	metastatic	amod	9	SENT_395	[p26l934t2525r1040b2559, p26l11t2587r161b2630],
8	colorectal	JJ	O	colorectal	amod	9	SENT_395	[p26l173t2586r404b2631],
9	cancer	NN	O	cancer	prep_for	1	SENT_395	[p26l417t2601r579b2631],
10	.	.	O	.	_	0	SENT_395	[p26l417t2601r579b2631],

1	N	NN	O	n	nn	3	SENT_396	[p26l593t2591r635b2631],
2	Engll	NNP	O	Engll	nn	3	SENT_396	[p26l646t2586r782b2643],
3	Med	NNP	O	Med	_	0	SENT_396	[p26l792t2586r896b2631],
4	2000	CD	DATE	2000	num	3	SENT_396	[p26l908t2590r1038b2640],
5	;	:	O	;	_	0	SENT_396	[p26l908t2590r1038b2640],
6	343:905	CD	NUMBER	343:905	number	7	SENT_396	[p26l12t2662r294b2703],
7	—	CD	NUMBER	—	dep	3	SENT_396	[p26l12t2662r294b2703],
8	14	CD	NUMBER	14	dep	7	SENT_396	[p26l12t2662r294b2703],
9	.	.	O	.	_	0	SENT_396	[p26l12t2662r294b2703],

1	6	CD	NUMBER	6	_	0	SENT_397	[p26l12t2734r49b2773],
2	.	.	O	.	_	0	SENT_397	[p26l12t2734r49b2773],

1	Cunningham	NNP	PERSON	Cunningham	nn	2	SENT_398	[p26l107t2728r421b2785],
2	D	NNP	PERSON	D	_	0	SENT_398	[p26l434t2732r484b2782],
3	,	,	O	,	_	0	SENT_398	[p26l434t2732r484b2782],
4	Pyrhonen	NNP	O	Pyrhonen	nn	5	SENT_398	[p26l501t2728r726b2784],
5	S	NNP	O	S	appos	2	SENT_398	[p26l742t2732r780b2782],
6	,	,	O	,	_	0	SENT_398	[p26l742t2732r780b2782],
7	James	NNP	PERSON	James	nn	8	SENT_398	[p26l793t2732r936b2779],
8	RD	NNP	PERSON	RD	appos	2	SENT_398	[p26l951t2732r1037b2782],
9	,	,	O	,	_	0	SENT_398	[p26l951t2732r1037b2782],
10	et	FW	O	et	nn	11	SENT_398	[p26l12t2809r55b2844],
11	al.	FW	O	al.	appos	2	SENT_398	[p26l78t2800r131b2844],
12	.	.	O	.	_	0	SENT_398	[p26l78t2800r131b2844],

1	Randomised	JJ	O	randomised	amod	2	SENT_399	[p26l160t2799r459b2846],
2	trial	NN	O	trial	_	0	SENT_399	[p26l485t2800r578b2843],
3	of	IN	O	of	_	0	SENT_399	[p26l605t2799r661b2844],
4	irinotecan	NN	O	irinotecan	prep_of	2	SENT_399	[p26l677t2800r915b2844],
5	plus	CC	O	plus	prep	4	SENT_399	[p26l940t2799r1039b2856],
6	supportive	JJ	O	supportive	amod	7	SENT_399	[p26l12t2872r260b2928],
7	care	NN	O	care	dep	5	SENT_399	[p26l274t2886r369b2915],
8	versus	CC	O	versus	prep	7	SENT_399	[p26l380t2886r528b2916],
9	supportive	JJ	O	supportive	amod	10	SENT_399	[p26l543t2872r791b2928],
10	care	NN	O	care	dep	8	SENT_399	[p26l805t2886r899b2916],
11	alone	RB	O	alone	advmod	2	SENT_399	[p26l913t2871r1040b2916],
12	after	IN	O	after	_	0	SENT_399	[p26l11t2942r121b2986],
13	ﬂuorouracil	NN	O	ﬂuorouracil	nn	14	SENT_399	[p26l143t2942r427b2987],
14	failure	NN	O	failure	prep_after	11	SENT_399	[p26l451t2942r604b2987],
15	for	IN	O	for	_	0	SENT_399	[p26l628t2942r698b2987],
16	patients	NNS	O	patient	prep_for	14	SENT_399	[p26l719t2943r910b2999],
17	with	IN	O	with	_	0	SENT_399	[p26l932t2942r1040b2987],
18	metastatic	JJ	O	metastatic	amod	20	SENT_399	[p26l12t3015r260b3058],
19	colorectal	JJ	O	colorectal	amod	20	SENT_399	[p26l285t3014r515b3059],
20	cancer	NN	O	cancer	prep_with	16	SENT_399	[p26l540t3029r702b3059],
21	.	.	O	.	_	0	SENT_399	[p26l540t3029r702b3059],

1	Lancet	NNP	O	Lancet	_	0	SENT_400	[p26l729t3019r886b3058],
2	1998	CD	DATE	1998	num	1	SENT_400	[p26l910t3018r1037b3068],
3	;	:	O	;	_	0	SENT_400	[p26l910t3018r1037b3068],
4	352:1413	CD	NUMBER	352:1413	number	5	SENT_400	[p26l12t3089r294b3130],
5	—	CD	NUMBER	—	dep	1	SENT_400	[p26l12t3089r294b3130],
6	8	CD	NUMBER	8	dep	5	SENT_400	[p26l12t3089r294b3130],
7	.	.	O	.	_	0	SENT_400	[p26l12t3089r294b3130],

1	7	CD	NUMBER	7	_	0	SENT_401	[p26l13t3161r49b3200],
2	.	.	O	.	_	0	SENT_401	[p26l13t3161r49b3200],

1	Rougier	NNP	PERSON	Rougier	nn	2	SENT_402	[p26l107t3156r296b3212],
2	P	NN	O	p	_	0	SENT_402	[p26l306t3159r342b3209],
3	,	,	O	,	_	0	SENT_402	[p26l306t3159r342b3209],
4	Van	NNP	PERSON	Van	nn	6	SENT_402	[p26l354t3159r442b3199],
5	Cutsem	NNP	PERSON	Cutsem	nn	6	SENT_402	[p26l454t3159r635b3200],
6	E	NNP	O	E	appos	2	SENT_402	[p26l645t3159r689b3209],
7	,	,	O	,	_	0	SENT_402	[p26l645t3159r689b3209],
8	Baj	NNP	PERSON	Baj	nn	10	SENT_402	[p26l703t3156r772b3211],
9	etta	FW	O	etta	nn	10	SENT_402	[p26l778t3164r863b3199],
10	E	NNP	O	E	appos	2	SENT_402	[p26l874t3159r917b3209],
11	,	,	O	,	_	0	SENT_402	[p26l874t3159r917b3209],
12	et	FW	O	et	nn	13	SENT_402	[p26l932t3165r975b3199],
13	al.	FW	O	al.	appos	2	SENT_402	[p26l984t3155r1037b3199],
14	.	.	O	.	_	0	SENT_402	[p26l984t3155r1037b3199],

1	Randomised	JJ	O	randomised	amod	2	SENT_403	[p26l11t3226r310b3273],
2	trial	NN	O	trial	_	0	SENT_403	[p26l329t3226r422b3270],
3	of	IN	O	of	_	0	SENT_403	[p26l441t3226r497b3271],
4	irinotecan	NN	O	irinotecan	prep_of	2	SENT_403	[p26l506t3227r744b3271],
5	versus	CC	O	versus	prep	2	SENT_403	[p26l761t3241r908b3271],
6	ﬂuorouracil	NN	O	ﬂuorouracil	dep	5	SENT_403	[p26l929t3226r1039b3271, p26l12t3297r199b3342],
7	by	IN	O	by	_	0	SENT_403	[p26l218t3298r272b3354],
8	continuous	JJ	O	continuous	amod	9	SENT_403	[p26l289t3298r559b3342],
9	infusion	NN	O	infusion	prep_by	6	SENT_403	[p26l578t3297r780b3342],
10	after	IN	O	after	_	0	SENT_403	[p26l798t3297r908b3341],
11	ﬂuorouracil	NN	O	ﬂuorouracil	nn	12	SENT_403	[p26l926t3297r1039b3342, p26l12t3368r199b3413],
12	failure	NN	O	failure	prep_after	9	SENT_403	[p26l218t3368r371b3413],
13	in	IN	O	in	_	0	SENT_403	[p26l390t3369r436b3412],
14	patients	NNS	O	patient	prep_in	2	SENT_403	[p26l454t3369r646b3425],
15	with	IN	O	with	_	0	SENT_403	[p26l663t3369r771b3413],
16	metastatic	JJ	O	metastatic	amod	18	SENT_403	[p26l790t3369r1039b3413],
17	colorectal	JJ	O	colorectal	amod	18	SENT_403	[p26l12t3440r248b3485],
18	cancer	NN	O	cancer	prep_with	14	SENT_403	[p26l276t3455r442b3485],
19	.	.	O	.	_	0	SENT_403	[p26l276t3455r442b3485],

1	Lancet	NNP	O	Lancet	_	0	SENT_404	[p26l473t3445r632b3484],
2	1998	CD	DATE	1998	num	1	SENT_404	[p26l660t3444r1039b3494, p26l13t3515r82b3556],
3	;	:	O	;	_	0	SENT_404	[p26l660t3444r1039b3494, p26l13t3515r82b3556],
4	352:140712	CD	NUMBER	352:140712	dep	1	SENT_404	[p26l660t3444r1039b3494, p26l13t3515r82b3556],
5	.	.	O	.	_	0	SENT_404	[p26l660t3444r1039b3494, p26l13t3515r82b3556],

1	[	NN	O	[	_	0	SENT_405	[p26l106t3515r333b3565],
2	Erratum	NN	O	erratum	dep	1	SENT_405	[p26l106t3515r333b3565],
3	,	,	O	,	_	0	SENT_405	[p26l106t3515r333b3565],
4	Lancet	NNP	O	Lancet	appos	2	SENT_405	[p26l351t3516r510b3555],
5	1998	CD	DATE	1998	rcmod	4	SENT_405	[p26l524t3515r918b3565],
6	;	:	O	;	_	0	SENT_405	[p26l524t3515r918b3565],
7	352:1634	CD	NUMBER	352:1634	dep	5	SENT_405	[p26l524t3515r918b3565],
8	.	.	O	.	_	0	SENT_405	[p26l524t3515r918b3565],
9	]	SYM	O	]	dep	5	SENT_405	[p26l524t3515r918b3565],

1	8	CD	NUMBER	8	_	0	SENT_406	[p26l11t3586r49b3626],
2	.	.	O	.	_	0	SENT_406	[p26l11t3586r49b3626],

1	Rothenberg	NNP	PERSON	Rothenberg	nn	2	SENT_407	[p26l107t3581r389b3638],
2	ML	NNP	O	ML	_	0	SENT_407	[p26l403t3585r493b3635],
3	,	,	O	,	_	0	SENT_407	[p26l403t3585r493b3635],
4	Oza	NNP	PERSON	Oza	nn	5	SENT_407	[p26l514t3585r606b3625],
5	AM	NNP	O	AM	appos	2	SENT_407	[p26l621t3585r718b3635],
6	,	,	O	,	_	0	SENT_407	[p26l621t3585r718b3635],
7	Bigelow	NNP	PERSON	Bigelow	nn	8	SENT_407	[p26l738t3581r931b3638],
8	RH	NNP	O	RH	appos	2	SENT_407	[p26l946t3585r1037b3635],
9	,	,	O	,	_	0	SENT_407	[p26l946t3585r1037b3635],
10	et	FW	O	et	nn	11	SENT_407	[p26l12t3662r55b3697],
11	al.	FW	O	al.	appos	2	SENT_407	[p26l70t3652r123b3697],
12	.	.	O	.	_	0	SENT_407	[p26l70t3652r123b3697],

1	Superiority	NN	O	superiority	_	0	SENT_408	[p26l146t3653r412b3709],
2	of	IN	O	of	_	0	SENT_408	[p26l428t3652r485b3697],
3	oxaliplatin	NN	O	oxaliplatin	prep_of	1	SENT_408	[p26l494t3652r749b3709],
4	and	CC	O	and	_	0	SENT_408	[p26l767t3652r855b3697],
5	ﬂuorouracil	NN	O	ﬂuorouracil	nn	7	SENT_408	[p26l873t3652r1039b3697, p26l12t3723r421b3768],
6	—	CD	NUMBER	—	num	7	SENT_408	[p26l873t3652r1039b3697, p26l12t3723r421b3768],
7	leucovorin	NN	O	leucovorin	prep_of	1	SENT_408	[p26l873t3652r1039b3697, p26l12t3723r421b3768],
8	compared	VBN	O	compare	_	0	SENT_408	[p26l467t3723r707b3780],
9	with	IN	O	with	prepc_compared_with	7	SENT_408	[p26l750t3723r857b3768],
10	either	CC	O	either	dep	7	SENT_408	[p26l903t3724r1041b3768],
11	LM	NNP	O	LM	conj	7	SENT_408	[p26l1113t2236r1202b2286],
12	,	,	O	,	_	0	SENT_408	[p26l1113t2236r1202b2286],
13	Waksal	NNP	PERSON	Waksal	nn	14	SENT_408	[p26l1217t2232r1388b2277],
14	HVV	NNP	O	HVV	appos	7	SENT_408	[p26l1400t2236r1500b2286],
15	,	,	O	,	_	0	SENT_408	[p26l1400t2236r1500b2286],
16	Hicklin	NNP	PERSON	Hicklin	nn	17	SENT_408	[p26l1516t2232r1691b2277],
17	DJ	NNP	O	DJ	appos	14	SENT_408	[p26l1703t2236r1772b2283],
18	.	.	O	.	_	0	SENT_408	[p26l1703t2236r1772b2283],

1	Enhanced	VBN	O	enhance	_	0	SENT_409	[p26l1787t2232r2021b2276],
2	antitumor	NN	O	antitumor	nn	3	SENT_409	[p26l2034t2233r2142b2276, p26l1114t2312r1261b2347],
3	activity	NN	O	activity	nsubj	12	SENT_409	[p26l1273t2303r1438b2359],
4	of	IN	O	of	_	0	SENT_409	[p26l1450t2302r1507b2347],
5	anti	JJ	O	anti	amod	6	SENT_409	[p26l1511t2302r1859b2359],
6	—	NN	O	—	prep_of	3	SENT_409	[p26l1511t2302r1859b2359],
7	epidermal	JJ	O	epidermal	amod	12	SENT_409	[p26l1511t2302r1859b2359],
8	growth	NN	O	growth	nn	12	SENT_409	[p26l1873t2302r2042b2359],
9	fac	NN	O	fac	nn	12	SENT_409	[p26l2057t2302r2142b2346],
10	—	CD	NUMBER	—	num	12	SENT_409	[p26l2057t2302r2142b2346],
11	tor	NN	O	tor	nn	12	SENT_409	[p26l1114t2383r1181b2418],
12	receptor	NN	O	receptor	xcomp	1	SENT_409	[p26l1192t2383r1384b2430],
13	monoclonal	JJ	O	monoclonal	amod	15	SENT_409	[p26l1396t2373r1675b2418],
14	antibody	NN	O	antibody	nn	15	SENT_409	[p26l1687t2373r1891b2430],
15	IMC	NN	O	imc	dep	12	SENT_409	[p26l1901t2377r2141b2418],
16	.	.	O	.	_	0	SENT_409	[p26l1901t2377r2141b2418],

1	—	NN	O	—	_	0	SENT_410	[p26l1901t2377r2141b2418],
2	.	.	O	.	_	0	SENT_410	[p26l1901t2377r2141b2418],

1	C225	NN	O	c225	_	0	SENT_411	[p26l1901t2377r2141b2418],
2	in	IN	O	in	_	0	SENT_411	[p26l1114t2446r1159b2489],
3	combination	NN	O	combination	prep_in	1	SENT_411	[p26l1195t2446r1492b2490],
4	with	IN	O	with	_	0	SENT_411	[p26l1525t2445r1630b2490],
5	irinotecan	NN	O	irinotecan	nn	7	SENT_411	[p26l1665t2446r1900b2490],
6	(	CD	NUMBER	(	num	7	SENT_411	[p26l1938t2449r2139b2496],
7	CPT	NNP	O	CPT	prep_with	1	SENT_411	[p26l1938t2449r2139b2496],
8	—	CD	NUMBER	—	number	9	SENT_411	[p26l1938t2449r2139b2496],
9	11	CD	NUMBER	11	num	10	SENT_411	[p26l1938t2449r2139b2496],
10	)	NN	O	)	dep	7	SENT_411	[p26l1938t2449r2139b2496],
11	against	IN	O	against	_	0	SENT_411	[p26l1114t2516r1283b2572],
12	human	JJ	O	human	amod	15	SENT_411	[p26l1293t2516r1460b2560],
13	colorectal	JJ	O	colorectal	amod	15	SENT_411	[p26l1474t2516r1704b2560],
14	tumor	NN	O	tumor	nn	15	SENT_411	[p26l1718t2525r1865b2560],
15	Xenografts	NNS	O	xenograft	prep_against	10	SENT_411	[p26l1875t2515r2139b2572],
16	.	.	O	.	_	0	SENT_411	[p26l1875t2515r2139b2572],

1	Clin	NNP	O	Clin	nn	3	SENT_412	[p26l1114t2586r1211b2631],
2	Cancer	NNP	O	Cancer	nn	3	SENT_412	[p26l1224t2590r1389b2631],
3	Res	NNP	O	Res	_	0	SENT_412	[p26l1401t2590r1484b2633],
4	2002	CD	DATE	2002	num	3	SENT_412	[p26l1499t2590r1916b2640],
5	;	:	O	;	_	0	SENT_412	[p26l1499t2590r1916b2640],
6	8:994	CD	NUMBER	8:994	number	7	SENT_412	[p26l1499t2590r1916b2640],
7	—	CD	NUMBER	—	dep	3	SENT_412	[p26l1499t2590r1916b2640],
8	1003	CD	DATE	1003	dep	7	SENT_412	[p26l1499t2590r1916b2640],
9	.	.	O	.	_	0	SENT_412	[p26l1499t2590r1916b2640],

1	17	CD	NUMBER	17	_	0	SENT_413	[p26l1116t2664r1180b2702],
2	.	.	O	.	_	0	SENT_413	[p26l1116t2664r1180b2702],

1	Saltz	NNP	PERSON	Saltz	nn	2	SENT_414	[p26l1211t2658r1324b2702],
2	L	NNP	O	L	_	0	SENT_414	[p26l1343t2662r1384b2712],
3	,	,	O	,	_	0	SENT_414	[p26l1343t2662r1384b2712],
4	Rubin	NNP	PERSON	Rubin	nn	5	SENT_414	[p26l1405t2658r1551b2705],
5	MS	NN	O	m	appos	2	SENT_414	[p26l1568t2662r1659b2712],
6	,	,	O	,	_	0	SENT_414	[p26l1568t2662r1659b2712],
7	Hochster	NNP	PERSON	Hochster	nn	8	SENT_414	[p26l1680t2658r1903b2702],
8	HS	NN	O	h	appos	2	SENT_414	[p26l1919t2662r2004b2712],
9	,	,	O	,	_	0	SENT_414	[p26l1919t2662r2004b2712],
10	et	FW	O	et	nn	11	SENT_414	[p26l2026t2667r2069b2702],
11	al.	FW	O	al.	appos	2	SENT_414	[p26l2085t2658r2139b2702],
12	.	.	O	.	_	0	SENT_414	[p26l2085t2658r2139b2702],

1	Cetuximab	NNP	O	Cetuximab	_	0	SENT_415	[p26l1114t2729r1373b2773],
2	(	CD	NUMBER	(	num	1	SENT_415	[p26l1421t2732r1704b2779],
3	IMC	NNP	O	IMC	dep	1	SENT_415	[p26l1421t2732r1704b2779],
4	.	.	O	.	_	0	SENT_415	[p26l1421t2732r1704b2779],

1	—	NN	O	—	_	0	SENT_416	[p26l1421t2732r1704b2779],
2	.	.	O	.	_	0	SENT_416	[p26l1421t2732r1704b2779],

1	C225	CD	NUMBER	c225	num	2	SENT_417	[p26l1421t2732r1704b2779],
2	)	NN	O	)	nsubj	11	SENT_417	[p26l1421t2732r1704b2779],
3	plus	CC	O	plus	prep	2	SENT_417	[p26l1751t2729r1852b2785],
4	irinotecan	NN	O	irinotecan	nn	6	SENT_417	[p26l1898t2729r2142b2773],
5	(	CD	NUMBER	(	num	6	SENT_417	[p26l1117t2803r1319b2850],
6	CPT	NNP	O	CPT	dep	3	SENT_417	[p26l1117t2803r1319b2850],
7	—	CD	NUMBER	—	number	8	SENT_417	[p26l1117t2803r1319b2850],
8	11	CD	NUMBER	11	num	9	SENT_417	[p26l1117t2803r1319b2850],
9	)	NN	O	)	dep	6	SENT_417	[p26l1117t2803r1319b2850],
10	is	VBZ	O	be	cop	11	SENT_417	[p26l1342t2800r1379b2843],
11	active	JJ	O	active	_	0	SENT_417	[p26l1400t2800r1534b2844],
12	in	IN	O	in	_	0	SENT_417	[p26l1554t2800r1600b2843],
13	CPT	NNP	O	CPT	prep_in	11	SENT_417	[p26l1621t2803r1795b2844],
14	—	CD	NUMBER	—	num	13	SENT_417	[p26l1621t2803r1795b2844],
15	11	CD	NUMBER	11	num	18	SENT_417	[p26l1621t2803r1795b2844],
16	refractory	JJ	O	refractory	amod	18	SENT_417	[p26l1816t2799r2050b2856],
17	colorectal	JJ	O	colorectal	amod	18	SENT_417	[p26l2069t2814r2141b2844, p26l1113t2872r1294b2916],
18	cancer	NN	O	cancer	attr	11	SENT_417	[p26l1326t2886r1482b2915],
19	that	WDT	O	that	nsubj	20	SENT_417	[p26l1513t2872r1608b2915],
20	expresses	VBZ	O	express	rcmod	18	SENT_417	[p26l1638t2886r1866b2928],
21	epidermal	JJ	O	epidermal	amod	24	SENT_417	[p26l1900t2871r2142b2928],
22	growth	NN	O	growth	nn	24	SENT_417	[p26l1114t2943r1286b2999],
23	factor	NN	O	factor	nn	24	SENT_417	[p26l1306t2942r1447b2987],
24	receptor	NN	O	receptor	dobj	20	SENT_417	[p26l1466t2952r1675b2999],
25	.	.	O	.	_	0	SENT_417	[p26l1466t2952r1675b2999],

1	Prog	NN	O	prog	dep	6	SENT_418	[p26l1698t2946r1811b2999],
2	Proc	NNP	O	Proc	nn	6	SENT_418	[p26l1829t2946r1935b2987],
3	Am	NNP	O	Am	nn	6	SENT_418	[p26l1953t2947r2038b2986],
4	Soc	NNP	O	Soc	nn	6	SENT_418	[p26l2060t2946r2142b2987],
5	Clin	NNP	O	Clin	nn	6	SENT_418	[p26l1114t3014r1213b3059],
6	Oncol	NNP	O	Oncol	_	0	SENT_418	[p26l1227t3014r1372b3059],
7	2001	CD	DATE	2001	num	6	SENT_418	[p26l1387t3018r1668b3067],
8	;	:	O	;	_	0	SENT_418	[p26l1387t3018r1668b3067],
9	20:3	CD	NUMBER	20:3	num	10	SENT_418	[p26l1387t3018r1668b3067],
10	a.	NN	O	a.	dep	11	SENT_418	[p26l1387t3018r1668b3067],
11	abstract	JJ	O	abstract	parataxis	6	SENT_418	[p26l1684t3015r1883b3059],
12	.	.	O	.	_	0	SENT_418	[p26l1684t3015r1883b3059],

1	18	CD	NUMBER	18	_	0	SENT_419	[p26l1116t3090r1180b3130],
2	.	.	O	.	_	0	SENT_419	[p26l1116t3090r1180b3130],

1	Saltz	NNP	PERSON	Saltz	nn	2	SENT_420	[p26l1211t3085r1321b3129],
2	LB	NNP	O	LB	_	0	SENT_420	[p26l1333t3089r1406b3139],
3	,	,	O	,	_	0	SENT_420	[p26l1333t3089r1406b3139],
4	Meropol	NNP	PERSON	Meropol	nn	6	SENT_420	[p26l1420t3085r1619b3141],
5	N	NNP	O	N	nn	6	SENT_420	[p26l1630t3089r1699b3139],
6	]	NNP	O	]	appos	2	SENT_420	[p26l1630t3089r1699b3139],
7	,	,	O	,	_	0	SENT_420	[p26l1630t3089r1699b3139],
8	Loehrer	NNP	O	Loehrer	appos	2	SENT_420	[p26l1714t3085r1896b3129],
9	P	NN	O	p	nn	11	SENT_420	[p26l1905t3089r1951b3136],
10	]	CD	NUMBER	]	num	11	SENT_420	[p26l1905t3089r1951b3136],
11	Sr	NNP	O	Sr	dep	8	SENT_420	[p26l1963t3089r2018b3139],
12	,	,	O	,	_	0	SENT_420	[p26l1963t3089r2018b3139],
13	N	NNP	O	N	nsubj	14	SENT_420	[p26l2032t3089r2074b3130],
14	eedle	VBD	O	eedle	dep	2	SENT_420	[p26l2076t3100r2142b3129, p26l1114t3155r1182b3200],
15	MN	NN	O	mn	dobj	14	SENT_420	[p26l1200t3160r1300b3209],
16	,	,	O	,	_	0	SENT_420	[p26l1200t3160r1300b3209],
17	Kopit	NNP	PERSON	Kopit	nn	18	SENT_420	[p26l1323t3156r1455b3212],
18	J	NNP	O	J	appos	2	SENT_420	[p26l1467t3160r1500b3209],
19	,	,	O	,	_	0	SENT_420	[p26l1467t3160r1500b3209],
20	Mayer	NNP	PERSON	Mayer	nn	21	SENT_420	[p26l1521t3160r1667b3212],
21	RI	NN	O	rus	appos	2	SENT_420	[p26l1685t3159r1738b3206],
22	.	.	O	.	_	0	SENT_420	[p26l1741t3191r1750b3200],

1	Phase	NN	O	phase	nn	3	SENT_421	[p26l1772t3155r1908b3200],
2	II	CD	NUMBER	ii	num	3	SENT_421	[p26l1928t3160r1963b3199],
3	trial	NN	O	trial	_	0	SENT_421	[p26l1983t3156r2076b3199],
4	of	IN	O	of	_	0	SENT_421	[p26l2096t3155r2153b3200],
5	cetuximab	NN	O	cetuximab	prep_of	3	SENT_421	[p26l1114t3227r1357b3271],
6	in	IN	O	in	_	0	SENT_421	[p26l1378t3227r1424b3270],
7	patients	NNS	O	patient	prep_in	5	SENT_421	[p26l1444t3227r1630b3283],
8	with	IN	O	with	_	0	SENT_421	[p26l1650t3227r1756b3271],
9	refractory	JJ	O	refractory	amod	11	SENT_421	[p26l1777t3226r2006b3283],
10	colorectal	JJ	O	colorectal	amod	11	SENT_421	[p26l2025t3226r2142b3271, p26l1114t3297r1244b3342],
11	cancer	NN	O	cancer	prep_with	7	SENT_421	[p26l1268t3312r1422b3342],
12	that	WDT	O	that	nsubj	13	SENT_421	[p26l1445t3298r1538b3341],
13	expresses	VBZ	O	express	rcmod	11	SENT_421	[p26l1559t3312r1783b3354],
14	the	DT	O	the	det	18	SENT_421	[p26l1809t3297r1881b3341],
15	epidermal	JJ	O	epidermal	amod	18	SENT_421	[p26l1905t3297r2143b3354],
16	growth	NN	O	growth	nn	18	SENT_421	[p26l1114t3369r1283b3425],
17	factor	NN	O	factor	nn	18	SENT_421	[p26l1305t3368r1442b3413],
18	receptor	NN	O	receptor	dobj	13	SENT_421	[p26l1463t3378r1667b3425],
19	.	.	O	.	_	0	SENT_421	[p26l1463t3378r1667b3425],

1	J	NNP	O	J	nn	3	SENT_422	[p26l1687t3373r1708b3419],
2	Clin	NNP	O	Clin	nn	3	SENT_422	[p26l1728t3369r1825b3413],
3	Oncol	NNP	O	Oncol	_	0	SENT_422	[p26l1847t3368r1989b3413],
4	2004	CD	DATE	2004	num	3	SENT_422	[p26l2011t3372r2140b3422],
5	;	:	O	;	_	0	SENT_422	[p26l2011t3372r2140b3422],
6	22:1201	CD	NUMBER	22:1201	number	7	SENT_422	[p26l1114t3444r1366b3485],
7	—	CD	NUMBER	—	dep	3	SENT_422	[p26l1114t3444r1366b3485],
8	8	CD	NUMBER	8	dep	7	SENT_422	[p26l1114t3444r1366b3485],
9	.	.	O	.	_	0	SENT_422	[p26l1114t3444r1366b3485],

1	19	CD	NUMBER	19	_	0	SENT_423	[p26l1116t3516r1180b3555],
2	.	.	O	.	_	0	SENT_423	[p26l1116t3516r1180b3555],

1	Therasse	NN	O	therasse	nn	2	SENT_424	[p26l1208t3511r1419b3555],
2	P	NN	O	p	_	0	SENT_424	[p26l1436t3515r1471b3565],
3	,	,	O	,	_	0	SENT_424	[p26l1436t3515r1471b3565],
4	Arbuck	NNP	O	Arbuck	nn	5	SENT_424	[p26l1490t3511r1664b3556],
5	SG	NNP	O	SG	appos	2	SENT_424	[p26l1680t3515r1761b3565],
6	,	,	O	,	_	0	SENT_424	[p26l1680t3515r1761b3565],
7	Eisenhauer	NNP	PERSON	Eisenhauer	nn	8	SENT_424	[p26l1781t3511r2045b3556],
8	EA	NN	PERSON	ea	appos	2	SENT_424	[p26l2060t3515r2139b3565],
9	,	,	O	,	_	0	SENT_424	[p26l2060t3515r2139b3565],
10	et	FW	O	et	nn	11	SENT_424	[p26l1114t3591r1157b3625],
11	al.	FW	O	al.	appos	2	SENT_424	[p26l1179t3582r1231b3626],
12	.	.	O	.	_	0	SENT_424	[p26l1179t3582r1231b3626],

1	New	NNP	O	New	nn	2	SENT_425	[p26l1262t3586r1373b3626],
2	guidelines	NNS	O	guideline	nsubj	18	SENT_425	[p26l1400t3581r1647b3638],
3	to	TO	O	to	aux	4	SENT_425	[p26l1678t3591r1723b3626],
4	evaluate	VB	O	evaluate	_	0	SENT_425	[p26l1753t3582r1945b3626],
5	the	DT	O	the	det	6	SENT_425	[p26l1975t3582r2048b3626],
6	response	NN	O	response	dobj	4	SENT_425	[p26l2077t3596r2141b3626, p26l1115t3667r1282b3709],
7	to	TO	O	to	_	0	SENT_425	[p26l1301t3662r1346b3697],
8	treatment	NN	O	treatment	prep_to	4	SENT_425	[p26l1366t3662r1600b3697],
9	in	IN	O	in	_	0	SENT_425	[p26l1614t3653r1660b3696],
10	solid	JJ	O	solid	amod	11	SENT_425	[p26l1678t3652r1791b3697],
11	tumors	NNS	O	tumor	prep_in	8	SENT_425	[p26l1809t3662r1992b3697],
12	:	:	O	:	_	0	SENT_425	[p26l1809t3662r1992b3697],
13	European	JJ	ORGANIZATION	european	amod	8	SENT_425	[p26l2011t3657r2142b3697, p26l1113t3738r1226b3780],
14	Organization	NNP	ORGANIZATION	Organization	dep	8	SENT_425	[p26l1246t3724r1558b3780],
15	for	IN	ORGANIZATION	for	_	0	SENT_425	[p26l1578t3723r1647b3768],
16	Research	NNP	ORGANIZATION	Research	prep_for	4	SENT_425	[p26l1664t3723r1878b3770],
17	and	CC	O	and	_	0	SENT_425	[p26l1898t3723r1985b3768],
18	Treat	VB	O	treat	conj_and	4	SENT_425	[p26l2003t3727r2141b3767],
19	—	NN	O	—	dobj	18	SENT_425	[p26l2003t3727r2141b3767],

1	therapy	NN	O	therapy	_	0	SENT_426	[p27l12t15r192b71],
2	alone	RB	O	alone	advmod	1	SENT_426	[p27l210t14r340b59],
3	in	IN	O	in	_	0	SENT_426	[p27l360t15r406b58],
4	patients	NNS	O	patient	prep_in	1	SENT_426	[p27l426t15r617b71],
5	with	IN	O	with	_	0	SENT_426	[p27l636t14r743b59],
6	progressive	JJ	O	progressive	amod	8	SENT_426	[p27l763t15r1039b71],
7	colorectal	JJ	O	colorectal	amod	8	SENT_426	[p27l12t86r248b131],
8	cancer	NN	O	cancer	prep_with	4	SENT_426	[p27l265t101r421b130],
9	after	IN	O	after	_	0	SENT_426	[p27l436t86r546b130],
10	irinotecan	NN	O	irinotecan	prep_after	8	SENT_426	[p27l561t87r805b131],
11	and	CC	O	and	_	0	SENT_426	[p27l821t86r909b131],
12	ﬂuorouracil-leucovorin	NN	O	ﬂuorouracil-leucovorin	prep_after	8	SENT_426	[p27l926t86r1039b131, p27l12t157r481b202],
13	:	:	O	:	_	0	SENT_426	[p27l926t86r1039b131, p27l12t157r481b202],
14	interim	JJ	O	interim	amod	15	SENT_426	[p27l522t158r695b201],
15	results	NNS	O	result	dep	1	SENT_426	[p27l735t158r890b202],
16	of	IN	O	of	_	0	SENT_426	[p27l931t157r987b202],
17	a	DT	O	a	det	20	SENT_426	[p27l1016t172r1041b201],
18	phase	NN	O	phase	nn	20	SENT_426	[p27l11t227r147b284],
19	III	CD	NUMBER	iii	num	20	SENT_426	[p27l159t232r211b271],
20	trial	NN	O	trial	prep_of	15	SENT_426	[p27l223t227r327b272],
21	.	.	O	.	_	0	SENT_426	[p27l223t227r327b272],

1	J	NNP	O	J	nn	3	SENT_427	[p27l337t232r358b278],
2	Clin	NNP	O	Clin	nn	3	SENT_427	[p27l369t227r464b272],
3	Oncol	NNP	O	Oncol	_	0	SENT_427	[p27l476t227r616b272],
4	2003	CD	DATE	2003	num	3	SENT_427	[p27l629t231r740b272],
5	;	:	O	;	_	0	SENT_427	[p27l748t231r1038b281],
6	21:2059	CD	NUMBER	21:2059	number	7	SENT_427	[p27l748t231r1038b281],
7	—	CD	NUMBER	—	dep	3	SENT_427	[p27l748t231r1038b281],
8	69	CD	NUMBER	69	dep	7	SENT_427	[p27l748t231r1038b281],
9	.	.	O	.	_	0	SENT_427	[p27l748t231r1038b281],

1	9	CD	NUMBER	9	_	0	SENT_428	[p27l11t303r49b342],
2	.	.	O	.	_	0	SENT_428	[p27l11t303r49b342],

1	Messa	FW	O	messa	_	0	SENT_429	[p27l106t302r255b342],
2	C	NN	O	c	dep	1	SENT_429	[p27l266t302r313b352],
3	,	,	O	,	_	0	SENT_429	[p27l266t302r313b352],
4	Russo	NNP	PERSON	Russo	nn	5	SENT_429	[p27l328t302r471b345],
5	F	NN	O	f	dep	1	SENT_429	[p27l483t302r519b352],
6	,	,	O	,	_	0	SENT_429	[p27l483t302r519b352],
7	Caruso	NNP	PERSON	Caruso	nn	8	SENT_429	[p27l534t302r699b343],
8	MG	NN	O	mg	conj_and	2	SENT_429	[p27l711t302r814b352],
9	,	,	O	,	_	0	SENT_429	[p27l711t302r814b352],
10	Di	NNP	PERSON	Di	nn	13	SENT_429	[p27l829t299r883b342],
11	Leo	NNP	PERSON	Leo	nn	13	SENT_429	[p27l894t302r977b342],
12	A.	NNP	PERSON	A.	nn	13	SENT_429	[p27l989t302r1037b342],
13	EGF	NN	PERSON	egf	conj_and	2	SENT_429	[p27l11t373r120b423],
14	,	,	O	,	_	0	SENT_429	[p27l11t373r120b423],
15	TGF	NN	O	tgf	nn	17	SENT_429	[p27l134t370r402b426],
16	—	NN	O	—	nn	17	SENT_429	[p27l134t370r402b426],
17	alpha	NN	O	alpha	conj_and	2	SENT_429	[p27l134t370r402b426],
18	,	,	O	,	_	0	SENT_429	[p27l134t370r402b426],
19	and	CC	O	and	_	0	SENT_429	[p27l417t369r504b414],
20	EGF	NN	O	egf	dep	1	SENT_429	[p27l516t370r731b416],
21	.	.	O	.	_	0	SENT_429	[p27l516t370r731b416],

1	—	NN	O	—	_	0	SENT_430	[p27l516t370r731b416],
2	.	.	O	.	_	0	SENT_430	[p27l516t370r731b416],

1	Rin	NN	O	rin	_	0	SENT_431	[p27l516t370r731b416],
2	human	JJ	O	human	amod	4	SENT_431	[p27l743t370r910b414],
3	colorectal	JJ	O	colorectal	amod	4	SENT_431	[p27l922t370r1039b414, p27l12t441r141b485],
4	adenocarcinoma	NN	O	adenocarcinoma	dep	1	SENT_431	[p27l169t441r575b486],
5	.	.	O	.	_	0	SENT_431	[p27l169t441r575b486],

1	Acta	NNP	O	Acta	nn	2	SENT_432	[p27l605t446r711b485],
2	Oncol	NNP	O	Oncol	_	0	SENT_432	[p27l738t442r880b486],
3	1998	CD	DATE	1998	num	2	SENT_432	[p27l910t445r1038b495],
4	;	:	O	;	_	0	SENT_432	[p27l910t445r1038b495],
5	37:285	CD	NUMBER	37:285	number	6	SENT_432	[p27l12t515r235b556],
6	—	CD	NUMBER	—	dep	2	SENT_432	[p27l12t515r235b556],
7	9	CD	NUMBER	9	dep	6	SENT_432	[p27l12t515r235b556],
8	.	.	O	.	_	0	SENT_432	[p27l12t515r235b556],

1	10	CD	NUMBER	10	_	0	SENT_433	[p27l13t588r77b627],
2	.	.	O	.	_	0	SENT_433	[p27l13t588r77b627],

1	Porebska	FW	MISC	porebska	tmod	18	SENT_434	[p27l107t583r324b628],
2	I	PRP	O	I	dep	1	SENT_434	[p27l343t587r373b637],
3	,	,	O	,	_	0	SENT_434	[p27l343t587r373b637],
4	Harlozinska	NNP	LOCATION	Harlozinska	nn	5	SENT_434	[p27l397t583r686b628],
5	A	NNP	O	A	nsubj	18	SENT_434	[p27l705t587r753b637],
6	,	,	O	,	_	0	SENT_434	[p27l705t587r753b637],
7	Bojarowski	NNP	PERSON	Bojarowski	nn	9	SENT_434	[p27l776t583r1040b639],
8	T.	NNP	O	T.	nn	9	SENT_434	[p27l10t657r51b698],
9	Expression	NN	O	expression	appos	5	SENT_434	[p27l71t654r332b710],
10	of	IN	O	of	_	0	SENT_434	[p27l350t653r406b698],
11	the	DT	O	the	det	17	SENT_434	[p27l414t654r486b698],
12	tyrosine	NN	O	tyrosine	nn	17	SENT_434	[p27l505t654r691b710],
13	kinase	NN	O	kinase	nn	17	SENT_434	[p27l709t653r860b698],
14	activity	NN	O	activity	nn	17	SENT_434	[p27l878t654r1043b710],
15	growth	NN	O	growth	nn	17	SENT_434	[p27l12t724r181b781],
16	factor	NN	O	factor	nn	17	SENT_434	[p27l212t724r349b769],
17	receptors	NNS	O	receptor	prep_of	9	SENT_434	[p27l378t734r596b781],
18	(	VBP	O	(	_	0	SENT_434	[p27l630t728r798b778],
19	EGFR	NN	ORGANIZATION	egfr	dobj	18	SENT_434	[p27l630t728r798b778],
20	,	,	O	,	_	0	SENT_434	[p27l630t728r798b778],
21	ERB	NN	O	erb	nn	22	SENT_434	[p27l831t728r931b771],
22	B2	NN	O	b2	appos	19	SENT_434	[p27l962t728r1037b778],
23	,	,	O	,	_	0	SENT_434	[p27l962t728r1037b778],
24	ERB	NNP	O	ERB	nn	26	SENT_434	[p27l11t800r111b843],
25	B3	NN	O	b3	nn	26	SENT_434	[p27l125t800r203b847],
26	)	NN	O	)	appos	19	SENT_434	[p27l125t800r203b847],
27	in	IN	O	in	_	0	SENT_434	[p27l219t797r265b840],
28	colorectal	JJ	O	colorectal	amod	29	SENT_434	[p27l279t797r509b841],
29	adenocarcinomas	NNS	O	adenocarcinoma	prep_in	26	SENT_434	[p27l522t796r938b841],
30	and	CC	O	and	_	0	SENT_434	[p27l953t796r1040b841],
31	adenomas	NNS	O	adenoma	prep_in	26	SENT_434	[p27l11t867r266b912],
32	.	.	O	.	_	0	SENT_434	[p27l11t867r266b912],

1	Tumour	NN	O	tumour	_	0	SENT_435	[p27l281t871r475b912],
2	Biol	NNP	O	Biol	dep	1	SENT_435	[p27l486t867r580b912],
3	2000	CD	DATE	2000	num	2	SENT_435	[p27l593t871r980b921],
4	;	:	O	;	_	0	SENT_435	[p27l593t871r980b921],
5	21:105	CD	NUMBER	21:105	number	6	SENT_435	[p27l593t871r980b921],
6	—	CD	NUMBER	—	dep	1	SENT_435	[p27l593t871r980b921],
7	15	CD	NUMBER	15	dep	6	SENT_435	[p27l593t871r980b921],
8	.	.	O	.	_	0	SENT_435	[p27l593t871r980b921],

1	11	CD	NUMBER	11	_	0	SENT_436	[p27l13t944r77b982],
2	.	.	O	.	_	0	SENT_436	[p27l13t944r77b982],

1	Salomon	NNP	O	Salomon	nn	2	SENT_437	[p27l109t938r317b982],
2	DS	NN	O	d	nsubj	18	SENT_437	[p27l349t942r430b992],
3	,	,	O	,	_	0	SENT_437	[p27l349t942r430b992],
4	Brandt	NNP	PERSON	Brandt	nn	5	SENT_437	[p27l465t938r627b982],
5	R	NNP	PERSON	R	appos	2	SENT_437	[p27l657t942r704b992],
6	,	,	O	,	_	0	SENT_437	[p27l657t942r704b992],
7	Ciardiello	NNP	PERSON	Ciardiello	nn	8	SENT_437	[p27l740t938r969b982],
8	F	NN	O	f	appos	2	SENT_437	[p27l1002t942r1036b992],
9	,	,	O	,	_	0	SENT_437	[p27l1002t942r1036b992],
10	Normanno	NNP	O	Normanno	nn	17	SENT_437	[p27l11t1012r268b1053],
11	N.	NNP	O	N.	nn	17	SENT_437	[p27l282t1013r333b1053],
12	Epidermal	NNP	O	Epidermal	nn	17	SENT_437	[p27l349t1008r590b1065],
13	growth	NN	O	growth	nn	17	SENT_437	[p27l603t1009r770b1065],
14	factor	NN	O	factor	nn	17	SENT_437	[p27l783t1008r1040b1053],
15	—	CD	NUMBER	—	num	17	SENT_437	[p27l783t1008r1040b1053],
16	rela	NN	O	relum	nn	17	SENT_437	[p27l783t1008r1040b1053],
17	—	NN	O	—	appos	2	SENT_437	[p27l783t1008r1040b1053],
18	ted	VBD	O	ted	_	0	SENT_437	[p27l12t1079r82b1124],
19	peptides	NNS	O	peptide	dobj	18	SENT_437	[p27l102t1079r300b1136],
20	and	CC	O	and	_	0	SENT_437	[p27l324t1079r411b1124],
21	their	PRP$	O	they	poss	22	SENT_437	[p27l433t1080r544b1124],
22	receptors	NNS	O	receptor	conj_and	19	SENT_437	[p27l565t1089r782b1136],
23	in	IN	O	in	_	0	SENT_437	[p27l805t1080r851b1123],
24	human	JJ	O	human	amod	25	SENT_437	[p27l873t1079r1040b1124],
25	malignancies	NNS	O	malignancy	prep_in	18	SENT_437	[p27l12t1150r334b1207],
26	.	.	O	.	_	0	SENT_437	[p27l12t1150r334b1207],

1	Crit	NNP	O	Crit	nn	4	SENT_438	[p27l350t1151r438b1195],
2	Rev	NN	O	rev	nn	4	SENT_438	[p27l448t1154r533b1197],
3	Oncol	NNP	O	Oncol	nn	4	SENT_438	[p27l544t1150r684b1195],
4	Hematol	NNP	O	Hematol	_	0	SENT_438	[p27l696t1151r898b1195],
5	1995	CD	DATE	1995	num	4	SENT_438	[p27l913t1154r1038b1204],
6	;	:	O	;	_	0	SENT_438	[p27l913t1154r1038b1204],
7	19:183	CD	NUMBER	19:183	number	8	SENT_438	[p27l13t1225r294b1266],
8	-232	CD	NUMBER	-232	dep	4	SENT_438	[p27l13t1225r294b1266],
9	.	.	O	.	_	0	SENT_438	[p27l13t1225r294b1266],

1	12	CD	NUMBER	12	_	0	SENT_439	[p27l14t1298r77b1336],
2	.	.	O	.	_	0	SENT_439	[p27l14t1298r77b1336],

1	Goldstein	NNP	PERSON	Goldstein	nn	2	SENT_440	[p27l107t1292r341b1337],
2	NS	NNP	O	NS	_	0	SENT_440	[p27l377t1296r461b1346],
3	,	,	O	,	_	0	SENT_440	[p27l377t1296r461b1346],
4	Armin	NNP	PERSON	Armin	nn	13	SENT_440	[p27l499t1293r654b1336],
5	M.	NNP	PERSON	M.	nn	13	SENT_440	[p27l689t1296r751b1336],
6	Epidermal	NNP	PERSON	Epidermal	nn	13	SENT_440	[p27l790t1292r1040b1348],
7	growth	NN	O	growth	nn	13	SENT_440	[p27l12t1363r184b1420],
8	factor	NN	O	factor	nn	13	SENT_440	[p27l200t1363r341b1408],
9	receptor	NN	O	receptor	nn	13	SENT_440	[p27l356t1373r552b1420],
10	immunohistochem	NN	O	immunohistochem	nn	13	SENT_440	[p27l566t1363r1039b1408],
11	—	CD	NUMBER	—	num	13	SENT_440	[p27l566t1363r1039b1408],
12	ical	JJ	O	ical	amod	13	SENT_440	[p27l11t1434r91b1478],
13	reactivity	NN	O	reactivity	appos	2	SENT_440	[p27l105t1435r311b1491],
14	in	IN	O	in	_	0	SENT_440	[p27l322t1435r368b1478],
15	patients	NNS	O	patient	prep_in	13	SENT_440	[p27l381t1435r564b1491],
16	with	IN	O	with	_	0	SENT_440	[p27l577t1435r681b1479],
17	American	JJ	ORGANIZATION	american	amod	19	SENT_440	[p27l693t1435r919b1479],
18	Joint	NNP	ORGANIZATION	Joint	nn	19	SENT_440	[p27l928t1435r1044b1486],
19	Committee	NNP	ORGANIZATION	Committee	prep_with	15	SENT_440	[p27l12t1506r274b1550],
20	on	IN	O	on	_	0	SENT_440	[p27l287t1520r346b1550],
21	Cancer	NNP	O	Cancer	nn	25	SENT_440	[p27l359t1509r524b1550],
22	Stage	NNP	O	Stage	nn	25	SENT_440	[p27l536t1509r661b1562],
23	IV	CD	NUMBER	iv	num	25	SENT_440	[p27l673t1510r725b1549],
24	colon	NN	O	colon	nn	25	SENT_440	[p27l735t1506r866b1550],
25	adenocarcinoma	NN	O	adenocarcinoma	prep_on	19	SENT_440	[p27l878t1505r1039b1550, p27l12t1577r273b1621],
26	:	:	O	:	_	0	SENT_440	[p27l878t1505r1039b1550, p27l12t1577r273b1621],
27	implications	NNS	O	implication	dep	2	SENT_440	[p27l293t1576r587b1633],
28	for	IN	O	for	_	0	SENT_440	[p27l607t1576r675b1621],
29	a	DT	O	a	det	32	SENT_440	[p27l692t1591r717b1620],
30	standardized	JJ	O	standardized	amod	32	SENT_440	[p27l735t1576r1040b1621],
31	scoring	VBG	O	score	amod	32	SENT_440	[p27l12t1648r189b1704],
32	system	NN	O	system	prep_for	27	SENT_440	[p27l202t1657r375b1704],
33	.	.	O	.	_	0	SENT_440	[p27l202t1657r375b1704],

1	Cancer	NN	O	cancer	_	0	SENT_441	[p27l392t1651r557b1692],
2	2001	CD	DATE	2001	num	1	SENT_441	[p27l570t1651r986b1701],
3	;	:	O	;	_	0	SENT_441	[p27l570t1651r986b1701],
4	92:1331	CD	NUMBER	92:1331	number	5	SENT_441	[p27l570t1651r986b1701],
5	—	CD	NUMBER	—	dep	1	SENT_441	[p27l570t1651r986b1701],
6	46	CD	NUMBER	46	dep	5	SENT_441	[p27l570t1651r986b1701],
7	.	.	O	.	_	0	SENT_441	[p27l570t1651r986b1701],

1	13	CD	NUMBER	13	_	0	SENT_442	[p27l14t1724r77b1762],
2	.	.	O	.	_	0	SENT_442	[p27l14t1724r77b1762],

1	Mayer	NNP	PERSON	Mayer	nn	2	SENT_443	[p27l106t1722r250b1774],
2	A	NNP	O	A	_	0	SENT_443	[p27l258t1722r306b1772],
3	,	,	O	,	_	0	SENT_443	[p27l258t1722r306b1772],
4	Takimoto	NNP	PERSON	Takimoto	nn	5	SENT_443	[p27l318t1718r540b1763],
5	M	NNP	O	M	appos	2	SENT_443	[p27l551t1722r611b1772],
6	,	,	O	,	_	0	SENT_443	[p27l551t1722r611b1772],
7	Fritz	NNP	PERSON	Fritz	nn	8	SENT_443	[p27l625t1719r730b1762],
8	E	NNP	PERSON	E	appos	2	SENT_443	[p27l741t1722r783b1772],
9	,	,	O	,	_	0	SENT_443	[p27l741t1722r783b1772],
10	Schelland	NNP	O	Schelland	appos	2	SENT_443	[p27l799t1718r1040b1763],
11	—	CD	NUMBER	—	num	13	SENT_443	[p27l799t1718r1040b1763],
12	er	NN	O	er	nn	13	SENT_443	[p27l12t1804r56b1834],
13	G	NN	O	g	dep	10	SENT_443	[p27l76t1793r129b1843],
14	,	,	O	,	_	0	SENT_443	[p27l76t1793r129b1843],
15	Koﬂer	NN	O	koﬂer	nn	16	SENT_443	[p27l153t1789r298b1835],
16	K	NN	O	k	appos	2	SENT_443	[p27l319t1794r368b1843],
17	,	,	O	,	_	0	SENT_443	[p27l319t1794r368b1843],
18	Ludwig	NNP	PERSON	Ludwig	nn	22	SENT_443	[p27l394t1789r571b1846],
19	H.	NNP	O	H.	nn	22	SENT_443	[p27l593t1794r647b1834],
20	The	NNP	O	The	nn	22	SENT_443	[p27l672t1790r761b1834],
21	prognostic	JJ	O	prognostic	amod	22	SENT_443	[p27l785t1790r1040b1846],
22	signiﬁcance	NN	O	signiﬁcance	appos	2	SENT_443	[p27l12t1860r295b1917],
23	of	IN	O	of	_	0	SENT_443	[p27l310t1860r366b1905],
24	proliferating	VBG	O	proliferate	prepc_of	22	SENT_443	[p27l370t1860r670b1917],
25	cell	NN	O	cell	nn	27	SENT_443	[p27l683t1860r762b1905],
26	nuclear	JJ	O	nuclear	amod	27	SENT_443	[p27l777t1861r952b1905],
27	antigen	NN	O	antigen	dobj	24	SENT_443	[p27l965t1875r1039b1904, p27l12t1932r143b1988],
28	,	,	O	,	_	0	SENT_443	[p27l965t1875r1039b1904, p27l12t1932r143b1988],
29	epidermal	JJ	O	epidermal	amod	32	SENT_443	[p27l158t1931r395b1988],
30	growth	NN	O	growth	nn	32	SENT_443	[p27l406t1931r576b1988],
31	factor	NN	O	factor	nn	32	SENT_443	[p27l587t1931r724b1976],
32	receptor	NN	O	receptor	conj_and	27	SENT_443	[p27l734t1941r938b1988],
33	,	,	O	,	_	0	SENT_443	[p27l734t1941r938b1988],
34	and	CC	O	and	_	0	SENT_443	[p27l953t1931r1039b1976],
35	mdr	NN	O	mdr	nn	37	SENT_443	[p27l12t2002r111b2047],
36	gene	NN	O	gene	nn	37	SENT_443	[p27l134t2017r245b2059],
37	expression	NN	O	expression	conj_and	27	SENT_443	[p27l271t2003r524b2059],
38	in	IN	O	in	_	0	SENT_443	[p27l548t2003r594b2046],
39	colorectal	JJ	O	colorectal	amod	40	SENT_443	[p27l619t2003r849b2047],
40	cancer	NN	O	cancer	prep_in	37	SENT_443	[p27l874t2017r1036b2047],
41	.	.	O	.	_	0	SENT_443	[p27l874t2017r1036b2047],

1	Cancer	NN	O	cancer	_	0	SENT_444	[p27l12t2078r177b2119],
2	1993	CD	DATE	1993	num	1	SENT_444	[p27l191t2078r605b2128],
3	;	:	O	;	_	0	SENT_444	[p27l191t2078r605b2128],
4	71:2454	CD	NUMBER	71:2454	number	5	SENT_444	[p27l191t2078r605b2128],
5	—	CD	NUMBER	—	dep	1	SENT_444	[p27l191t2078r605b2128],
6	60	CD	NUMBER	60	dep	5	SENT_444	[p27l191t2078r605b2128],
7	.	.	O	.	_	0	SENT_444	[p27l191t2078r605b2128],

1	14	CD	NUMBER	14	_	0	SENT_445	[p27l14t2151r77b2189],
2	.	.	O	.	_	0	SENT_445	[p27l14t2151r77b2189],

1	Klapper	NNP	PERSON	Klapper	nn	2	SENT_446	[p27l107t2145r295b2201],
2	LN	NN	O	ln	_	0	SENT_446	[p27l315t2149r396b2199],
3	,	,	O	,	_	0	SENT_446	[p27l315t2149r396b2199],
4	Kirschbaum	NNP	PERSON	Kirschbaum	nn	5	SENT_446	[p27l422t2145r711b2191],
5	MH	NNP	O	MH	appos	2	SENT_446	[p27l732t2149r836b2199],
6	,	,	O	,	_	0	SENT_446	[p27l732t2149r836b2199],
7	Sela	NNP	PERSON	Sela	nn	8	SENT_446	[p27l863t2145r956b2189],
8	M	NNP	PERSON	M	appos	2	SENT_446	[p27l976t2149r1037b2199],
9	,	,	O	,	_	0	SENT_446	[p27l976t2149r1037b2199],
10	Yarden	NNP	PERSON	Yarden	nn	11	SENT_446	[p27l10t2215r172b2260],
11	Y.	NNP	PERSON	Y.	appos	8	SENT_446	[p27l188t2220r226b2260],
12	Biochemical	JJ	PERSON	biochemical	amod	15	SENT_446	[p27l246t2215r538b2260],
13	and	CC	O	and	_	0	SENT_446	[p27l555t2215r642b2260],
14	clinical	JJ	O	clinical	amod	15	SENT_446	[p27l660t2215r828b2259],
15	implications	NNS	O	implication	dep	2	SENT_446	[p27l845t2215r1039b2272, p27l12t2287r128b2331],
16	of	IN	O	of	_	0	SENT_446	[p27l144t2286r200b2331],
17	the	DT	O	the	det	20	SENT_446	[p27l205t2286r277b2331],
18	ErbB/HER	NN	O	erbb/her	nn	20	SENT_446	[p27l291t2287r542b2337],
19	signaling	NN	O	signaling	nn	20	SENT_446	[p27l552t2286r772b2343],
20	network	NN	O	network	prep_of	15	SENT_446	[p27l785t2287r982b2331],
21	of	IN	O	of	_	0	SENT_446	[p27l994t2286r1051b2331],
22	growth	NN	O	growth	nn	24	SENT_446	[p27l12t2357r183b2414],
23	factor	NN	O	factor	nn	24	SENT_446	[p27l211t2357r351b2402],
24	receptors	NNS	O	receptor	prep_of	20	SENT_446	[p27l377t2367r614b2414],
25	.	.	O	.	_	0	SENT_446	[p27l377t2367r614b2414],

1	Adv	NNP	O	Adv	nn	3	SENT_447	[p27l642t2357r735b2402],
2	Cancer	NNP	O	Cancer	nn	3	SENT_447	[p27l761t2361r929b2402],
3	Res	NNP	O	Res	_	0	SENT_447	[p27l954t2361r1038b2404],
4	2000	CD	DATE	2000	num	3	SENT_447	[p27l12t2432r373b2482],
5	;	:	O	;	_	0	SENT_447	[p27l12t2432r373b2482],
6	77:25	CD	NUMBER	77:25	number	7	SENT_447	[p27l12t2432r373b2482],
7	—	CD	NUMBER	—	dep	3	SENT_447	[p27l12t2432r373b2482],
8	79	CD	NUMBER	79	dep	7	SENT_447	[p27l12t2432r373b2482],
9	.	.	O	.	_	0	SENT_447	[p27l12t2432r373b2482],

1	15	CD	NUMBER	15	_	0	SENT_448	[p27l13t2506r77b2545],
2	.	.	O	.	_	0	SENT_448	[p27l13t2506r77b2545],

1	Ciardiello	NNP	PERSON	Ciardiello	nn	2	SENT_449	[p27l107t2500r333b2544],
2	F	NN	PERSON	f	_	0	SENT_449	[p27l345t2504r380b2554],
3	,	,	O	,	_	0	SENT_449	[p27l345t2504r380b2554],
4	Tortora	NNP	PERSON	Tortora	nn	8	SENT_449	[p27l393t2504r566b2544],
5	G.	NNP	O	G.	nn	8	SENT_449	[p27l576t2504r629b2544],
6	A	NNP	O	A	nn	8	SENT_449	[p27l641t2504r678b2544],
7	novel	JJ	O	novel	amod	8	SENT_449	[p27l688t2500r812b2545],
8	approach	NN	O	approach	appos	2	SENT_449	[p27l823t2500r1040b2556],
9	in	IN	O	in	_	0	SENT_449	[p27l11t2571r56b2614],
10	the	DT	O	the	det	11	SENT_449	[p27l69t2571r140b2614],
11	treatment	NN	O	treatment	prep_in	8	SENT_449	[p27l154t2579r385b2615],
12	of	IN	O	of	_	0	SENT_449	[p27l396t2570r452b2615],
13	cancer	NN	O	cancer	prep_of	11	SENT_449	[p27l456t2585r622b2615],
14	:	:	O	:	_	0	SENT_449	[p27l456t2585r622b2615],
15	targeting	VBG	O	target	dep	11	SENT_449	[p27l638t2571r853b2627],
16	the	DT	O	the	det	20	SENT_449	[p27l865t2571r937b2615],
17	epidermal	JJ	O	epidermal	amod	20	SENT_449	[p27l951t2571r1039b2627, p27l12t2641r177b2686],
18	growth	NN	O	growth	nn	20	SENT_449	[p27l195t2641r364b2698],
19	factor	NN	O	factor	nn	20	SENT_449	[p27l382t2641r519b2686],
20	receptor	NN	O	receptor	dobj	15	SENT_449	[p27l536t2651r740b2698],
21	.	.	O	.	_	0	SENT_449	[p27l536t2651r740b2698],

1	Clin	NNP	O	Clin	nn	3	SENT_450	[p27l761t2642r858b2686],
2	Cancer	NNP	O	Cancer	nn	3	SENT_450	[p27l876t2645r1041b2686],
3	Res	NNP	O	Res	_	0	SENT_450	[p27l11t2716r94b2759],
4	2001	CD	DATE	2001	num	3	SENT_450	[p27l109t2716r496b2766],
5	;	:	O	;	_	0	SENT_450	[p27l109t2716r496b2766],
6	7:2958	CD	NUMBER	7:2958	number	7	SENT_450	[p27l109t2716r496b2766],
7	—	CD	NUMBER	—	dep	3	SENT_450	[p27l109t2716r496b2766],
8	70	CD	NUMBER	70	dep	7	SENT_450	[p27l109t2716r496b2766],
9	.	.	O	.	_	0	SENT_450	[p27l109t2716r496b2766],

1	16	CD	NUMBER	16	_	0	SENT_451	[p27l14t2790r77b2828],
2	.	.	O	.	_	0	SENT_451	[p27l14t2790r77b2828],

1	Prewett	NNP	PERSON	Prewett	nn	2	SENT_452	[p27l107t2788r285b2829],
2	MC	NNP	O	MC	_	0	SENT_452	[p27l303t2788r400b2838],
3	,	,	O	,	_	0	SENT_452	[p27l303t2788r400b2838],
4	Hooper	NNP	PERSON	Hooper	nn	5	SENT_452	[p27l425t2788r605b2840],
5	AT	NNP	O	AT	appos	2	SENT_452	[p27l624t2788r698b2838],
6	,	,	O	,	_	0	SENT_452	[p27l624t2788r698b2838],
7	Bassi	NNP	PERSON	Bassi	nn	8	SENT_452	[p27l723t2785r846b2828],
8	R	NNP	PERSON	R	appos	2	SENT_452	[p27l867t2788r914b2838],
9	,	,	O	,	_	0	SENT_452	[p27l867t2788r914b2838],
10	Ellis	NNP	PERSON	Ellis	nn	11	SENT_452	[p27l939t2784r1039b2828],
11	ment	NN	O	ment	appos	2	SENT_452	[p27l1114t24r1238b59],
12	of	IN	O	of	_	0	SENT_452	[p27l1248t14r1304b59],
13	Cancer	NN	O	cancer	prep_of	11	SENT_452	[p27l1306t18r1480b68],
14	,	,	O	,	_	0	SENT_452	[p27l1306t18r1480b68],
15	National	NNP	ORGANIZATION	National	nn	17	SENT_452	[p27l1495t14r1699b59],
16	Cancer	NNP	ORGANIZATION	Cancer	nn	17	SENT_452	[p27l1712t18r1876b59],
17	Institute	NNP	ORGANIZATION	Institute	appos	2	SENT_452	[p27l1887t15r2083b59],
18	of	IN	O	of	_	0	SENT_452	[p27l2096t14r2152b59],
19	the	DT	O	the	det	21	SENT_452	[p27l1114t86r1185b130],
20	United	NNP	LOCATION	United	nn	21	SENT_452	[p27l1195t86r1350b131],
21	States	NNPS	LOCATION	States	prep_of	17	SENT_452	[p27l1361t90r1507b140],
22	,	,	O	,	_	0	SENT_452	[p27l1361t90r1507b140],
23	National	NNP	ORGANIZATION	National	nn	25	SENT_452	[p27l1519t86r1718b131],
24	Cancer	NNP	ORGANIZATION	Cancer	nn	25	SENT_452	[p27l1728t90r1889b131],
25	Institute	NNP	ORGANIZATION	Institute	appos	2	SENT_452	[p27l1897t87r2087b131],
26	of	IN	ORGANIZATION	of	_	0	SENT_452	[p27l2098t86r2153b131],
27	Canada	NNP	ORGANIZATION	Canada	prep_of	25	SENT_452	[p27l1114t157r1298b202],
28	.	.	O	.	_	0	SENT_452	[p27l1114t157r1298b202],

1	J	NNP	O	J	nn	4	SENT_453	[p27l1308t162r1329b208],
2	Natl	NNP	O	Natl	nn	4	SENT_453	[p27l1339t157r1437b202],
3	Cancer	NNP	O	Cancer	nn	4	SENT_453	[p27l1449t161r1611b202],
4	Inst	NNP	O	Inst	_	0	SENT_453	[p27l1621t161r1712b201],
5	2000	CD	DATE	2000	num	4	SENT_453	[p27l1722t161r2099b211],
6	;	:	O	;	_	0	SENT_453	[p27l1722t161r2099b211],
7	92:205	CD	NUMBER	92:205	number	8	SENT_453	[p27l1722t161r2099b211],
8	—	CD	NUMBER	—	dep	4	SENT_453	[p27l1722t161r2099b211],
9	16	CD	NUMBER	16	dep	8	SENT_453	[p27l1722t161r2099b211],
10	.	.	O	.	_	0	SENT_453	[p27l1722t161r2099b211],

1	20	CD	NUMBER	20	_	0	SENT_454	[p27l1113t232r1180b271],
2	.	.	O	.	_	0	SENT_454	[p27l1113t232r1180b271],

1	Miller	NNP	ORGANIZATION	Miller	nn	2	SENT_455	[p27l1208t227r1351b271],
2	AB	NNP	ORGANIZATION	AB	nsubj	13	SENT_455	[p27l1373t231r1455b281],
3	,	,	O	,	_	0	SENT_455	[p27l1373t231r1455b281],
4	Hoogstraten	NNP	PERSON	Hoogstraten	nn	5	SENT_455	[p27l1484t231r1779b284],
5	B	NNP	PERSON	B	appos	2	SENT_455	[p27l1804t231r1849b281],
6	,	,	O	,	_	0	SENT_455	[p27l1804t231r1849b281],
7	Staquet	NNP	O	Staquet	nn	8	SENT_455	[p27l1880t231r2057b283],
8	M	NNP	O	M	appos	2	SENT_455	[p27l2078t231r2139b281],
9	,	,	O	,	_	0	SENT_455	[p27l2078t231r2139b281],
10	Winkler	NNP	PERSON	Winkler	nn	12	SENT_455	[p27l1112t298r1305b343],
11	A.	NNP	O	A.	nn	12	SENT_455	[p27l1314t303r1362b343],
12	Reporting	NNP	O	Reporting	appos	2	SENT_455	[p27l1377t299r1616b355],
13	results	VBZ	O	result	_	0	SENT_455	[p27l1627t298r1782b343],
14	of	IN	O	of	_	0	SENT_455	[p27l1795t298r1852b343],
15	cancer	NN	O	cancer	nn	16	SENT_455	[p27l1854t313r2008b343],
16	treatment	NN	O	treatment	prep_of	13	SENT_455	[p27l2019t308r2142b343, p27l1114t379r1248b414],
17	.	.	O	.	_	0	SENT_455	[p27l2019t308r2142b343, p27l1114t379r1248b414],

1	Cancer	NN	O	cancer	_	0	SENT_456	[p27l1265t373r1430b414],
2	1981	CD	DATE	1981	num	1	SENT_456	[p27l1444t373r1829b423],
3	;	:	O	;	_	0	SENT_456	[p27l1444t373r1829b423],
4	47:207	CD	NUMBER	47:207	number	5	SENT_456	[p27l1444t373r1829b423],
5	—	CD	NUMBER	—	dep	1	SENT_456	[p27l1444t373r1829b423],
6	14	CD	NUMBER	14	dep	5	SENT_456	[p27l1444t373r1829b423],
7	.	.	O	.	_	0	SENT_456	[p27l1444t373r1829b423],

1	21	CD	NUMBER	21	_	0	SENT_457	[p27l1113t447r1180b485],
2	.	.	O	.	_	0	SENT_457	[p27l1113t447r1180b485],

1	Kaplan	NNP	PERSON	Kaplan	nn	2	SENT_458	[p27l1209t441r1376b497],
2	EL	NNP	O	EL	_	0	SENT_458	[p27l1387t445r1460b495],
3	,	,	O	,	_	0	SENT_458	[p27l1387t445r1460b495],
4	Meier	NNP	PERSON	Meier	nn	7	SENT_458	[p27l1474t442r1611b485],
5	P.	NNP	PERSON	P.	nn	7	SENT_458	[p27l1620t445r1656b485],
6	Nonparametric	NNP	PERSON	Nonparametric	nn	7	SENT_458	[p27l1670t442r2031b497],
7	estimation	NN	O	estimation	appos	2	SENT_458	[p27l2043t442r2142b485, p27l1114t512r1282b556],
8	from	IN	O	from	_	0	SENT_458	[p27l1296t511r1411b556],
9	incomplete	JJ	O	incomplete	amod	10	SENT_458	[p27l1425t511r1689b568],
10	observations	NNS	O	observation	prep_from	7	SENT_458	[p27l1704t512r2015b556],
11	.	.	O	.	_	0	SENT_458	[p27l1704t512r2015b556],

1	J	NNP	O	J	nn	3	SENT_459	[p27l2027t516r2048b562],
2	Am	NNP	O	Am	nn	3	SENT_459	[p27l2059t516r2143b555],
3	Stat	NN	O	stat	_	0	SENT_459	[p27l1115t587r1206b628],
4	Assoc	NNP	O	Assoc	dep	3	SENT_459	[p27l1215t588r1354b628],
5	1958	CD	DATE	1958	num	4	SENT_459	[p27l1370t587r1754b637],
6	;	:	O	;	_	0	SENT_459	[p27l1370t587r1754b637],
7	53:457	CD	NUMBER	53:457	number	8	SENT_459	[p27l1370t587r1754b637],
8	—	CD	NUMBER	—	dep	3	SENT_459	[p27l1370t587r1754b637],
9	81	CD	NUMBER	81	dep	8	SENT_459	[p27l1370t587r1754b637],
10	.	.	O	.	_	0	SENT_459	[p27l1370t587r1754b637],

1	22	CD	NUMBER	22	_	0	SENT_460	[p27l1113t659r1180b697],
2	.	.	O	.	_	0	SENT_460	[p27l1113t659r1180b697],

1	Peto	JJ	PERSON	peto	amod	2	SENT_461	[p27l1209t657r1310b697],
2	R	NN	PERSON	r	_	0	SENT_461	[p27l1329t657r1378b707],
3	,	,	O	,	_	0	SENT_461	[p27l1329t657r1378b707],
4	Peto	NNP	PERSON	Peto	nn	6	SENT_461	[p27l1399t657r1502b698],
5	I.	NNP	PERSON	I.	nn	6	SENT_461	[p27l1516t657r1549b704],
6	Asymptotically	NNP	PERSON	Asymptotically	appos	2	SENT_461	[p27l1569t653r1929b709],
7	efﬁcient	JJ	O	efﬁcient	amod	10	SENT_461	[p27l1946t653r2145b697],
8	invariant	JJ	O	invariant	amod	10	SENT_461	[p27l1114t725r1329b769],
9	test	NN	O	test	nn	10	SENT_461	[p27l1347t734r1434b768],
10	procedures	NNS	O	procedure	dep	6	SENT_461	[p27l1451t724r1734b781],
11	.	.	O	.	_	0	SENT_461	[p27l1451t724r1734b781],

1	I	PRP	O	I	dep	6	SENT_462	[p27l1752t729r1774b775],
2	R	NN	O	r	nn	6	SENT_462	[p27l1793t728r1833b771],
3	Stat	NN	O	stat	nn	6	SENT_462	[p27l1850t728r1942b769],
4	Soc	NN	O	soc	nn	6	SENT_462	[p27l1962t728r2044b769],
5	[	NN	O	[	nn	6	SENT_462	[p27l2070t728r2136b775],
6	A	NN	O	a	_	0	SENT_462	[p27l2070t728r2136b775],
7	]	CD	NUMBER	]	num	8	SENT_462	[p27l2070t728r2136b775],
8	1972	CD	DATE	1972	dep	6	SENT_462	[p27l1116t800r1563b850],
9	;	:	O	;	_	0	SENT_462	[p27l1116t800r1563b850],
10	135:185	CD	NUMBER	135:185	num	11	SENT_462	[p27l1116t800r1563b850],
11	—	NN	O	—	dep	12	SENT_462	[p27l1116t800r1563b850],
12	206	CD	NUMBER	206	parataxis	6	SENT_462	[p27l1116t800r1563b850],
13	.	.	O	.	_	0	SENT_462	[p27l1116t800r1563b850],

1	23	CD	NUMBER	23	_	0	SENT_463	[p27l1113t873r1180b911],
2	.	.	O	.	_	0	SENT_463	[p27l1113t873r1180b911],

1	Xu	FW	O	xu	_	0	SENT_464	[p27l1208t871r1271b912],
2	Y	NN	O	y	dep	1	SENT_464	[p27l1293t871r1331b921],
3	,	,	O	,	_	0	SENT_464	[p27l1293t871r1331b921],
4	Villalona	NNP	PERSON	Villalona	appos	2	SENT_464	[p27l1356t867r1739b911],
5	.	.	O	.	_	0	SENT_464	[p27l1356t867r1739b911],

1	—	NN	O	—	_	0	SENT_465	[p27l1356t867r1739b911],
2	.	.	O	.	_	0	SENT_465	[p27l1356t867r1739b911],

1	Calero	NNP	PERSON	Calero	nn	2	SENT_466	[p27l1356t867r1739b911],
2	MA	NNP	O	MA	_	0	SENT_466	[p27l1762t871r1858b911],
3	.	.	O	.	_	0	SENT_466	[p27l1762t871r1858b911],

1	Irinotecan	NNP	O	Irinotecan	_	0	SENT_467	[p27l1884t868r2140b911],
2	:	:	O	:	_	0	SENT_467	[p27l1884t868r2140b911],
3	mechanisms	NNS	O	mechanism	dep	1	SENT_467	[p27l1114t938r1412b982],
4	of	IN	O	of	_	0	SENT_467	[p27l1432t938r1488b983],
5	tumor	NN	O	tumor	nn	6	SENT_467	[p27l1496t948r1643b983],
6	resistance	NN	O	resistance	prep_of	3	SENT_467	[p27l1659t939r1894b982],
7	and	CC	O	and	_	0	SENT_467	[p27l1912t938r1999b983],
8	novel	JJ	O	novel	amod	9	SENT_467	[p27l2017t938r2142b983],
9	strategies	NNS	O	strategy	conj_and	3	SENT_467	[p27l1115t1009r1337b1065],
10	for	IN	O	for	_	0	SENT_467	[p27l1366t1008r1434b1053],
11	modulating	VBG	O	modulate	prepc_for	9	SENT_467	[p27l1460t1008r1737b1065],
12	its	PRP$	O	its	poss	13	SENT_467	[p27l1762t1009r1816b1052],
13	activity	NN	O	activity	dobj	11	SENT_467	[p27l1843t1009r2014b1065],
14	.	.	O	.	_	0	SENT_467	[p27l1843t1009r2014b1065],

1	Ann	NNP	PERSON	Ann	nn	2	SENT_468	[p27l2043t1013r2142b1052],
2	Oncol	NNP	O	Oncol	_	0	SENT_468	[p27l1114t1080r1256b1124],
3	2002	CD	DATE	2002	num	2	SENT_468	[p27l1269t1083r1641b1133],
4	;	:	O	;	_	0	SENT_468	[p27l1269t1083r1641b1133],
5	13:1841	CD	NUMBER	13:1841	number	6	SENT_468	[p27l1269t1083r1641b1133],
6	—	CD	NUMBER	—	num	8	SENT_468	[p27l1269t1083r1641b1133],
7	5	CD	NUMBER	5	number	8	SENT_468	[p27l1269t1083r1641b1133],
8	1	CD	NUMBER	1	dep	2	SENT_468	[p27l1648t1083r1686b1124],
9	.	.	O	.	_	0	SENT_468	[p27l1648t1083r1686b1124],

1	24	CD	NUMBER	24	_	0	SENT_469	[p27l1113t1156r1180b1194],
2	.	.	O	.	_	0	SENT_469	[p27l1113t1156r1180b1194],

1	Chen	NNP	PERSON	Chen	nn	2	SENT_470	[p27l1210t1150r1333b1195],
2	ZS	NNP	O	ZS	_	0	SENT_470	[p27l1344t1154r1416b1204],
3	,	,	O	,	_	0	SENT_470	[p27l1344t1154r1416b1204],
4	Furukawa	NNP	ORGANIZATION	Furukawa	nn	5	SENT_470	[p27l1430t1150r1663b1195],
5	T	NN	ORGANIZATION	t	appos	2	SENT_470	[p27l1672t1154r1713b1204],
6	,	,	O	,	_	0	SENT_470	[p27l1672t1154r1713b1204],
7	Sumizawa	NN	ORGANIZATION	sumizawa	nn	8	SENT_470	[p27l1729t1151r1970b1195],
8	T	NN	ORGANIZATION	t	appos	2	SENT_470	[p27l1979t1154r2020b1204],
9	,	,	O	,	_	0	SENT_470	[p27l1979t1154r2020b1204],
10	et	FW	O	et	nn	11	SENT_470	[p27l2035t1159r2078b1194],
11	al.	FW	O	al.	appos	2	SENT_470	[p27l2086t1150r2139b1194],
12	.	.	O	.	_	0	SENT_470	[p27l2086t1150r2139b1194],

1	ATP	NN	O	atp	nn	2	SENT_471	[p27l1112t1221r1481b1278],
2	—	NN	O	—	_	0	SENT_471	[p27l1112t1221r1481b1278],
3	dependent	JJ	O	dependent	amod	4	SENT_471	[p27l1112t1221r1481b1278],
4	efﬂux	NN	O	efﬂux	dep	2	SENT_471	[p27l1495t1221r1628b1266],
5	of	IN	O	of	_	0	SENT_471	[p27l1643t1221r1699b1266],
6	CPT	NNP	O	CPT	prep_of	4	SENT_471	[p27l1705t1225r1876b1266],
7	—	CD	NUMBER	—	num	6	SENT_471	[p27l1705t1225r1876b1266],
8	11	CD	NUMBER	11	dep	2	SENT_471	[p27l1705t1225r1876b1266],
9	and	CC	O	and	_	0	SENT_471	[p27l1892t1221r1979b1266],
10	SN	NNP	O	SN	dep	2	SENT_471	[p27l1996t1225r2141b1266],
11	—	CD	NUMBER	—	number	12	SENT_471	[p27l1996t1225r2141b1266],
12	38	CD	NUMBER	38	dep	2	SENT_471	[p27l1996t1225r2141b1266],
13	by	IN	O	by	_	0	SENT_471	[p27l1114t1293r1168b1349],
14	the	DT	O	the	det	17	SENT_471	[p27l1188t1293r1260b1336],
15	multidrug	JJ	O	multidrug	amod	17	SENT_471	[p27l1282t1292r1522b1349],
16	resistance	NN	O	resistance	nn	17	SENT_471	[p27l1541t1293r1777b1337],
17	protein	NN	O	protein	prep_by	12	SENT_471	[p27l1798t1293r1969b1349],
18	(	CD	NUMBER	(	num	20	SENT_471	[p27l1994t1296r2139b1343],
19	MRP	NN	ORGANIZATION	mrp	nn	20	SENT_471	[p27l1994t1296r2139b1343],
20	)	NN	O	)	dep	2	SENT_471	[p27l1994t1296r2139b1343],
21	and	CC	O	and	_	0	SENT_471	[p27l1114t1363r1200b1408],
22	its	PRP$	O	its	poss	23	SENT_471	[p27l1223t1364r1277b1407],
23	inhibition	NN	O	inhibition	dep	2	SENT_471	[p27l1302t1364r1536b1408],
24	by	IN	O	by	_	0	SENT_471	[p27l1560t1363r1614b1420],
25	PAK	NN	O	pak	nn	27	SENT_471	[p27l1634t1367r1874b1409],
26	—	CD	NUMBER	—	num	27	SENT_471	[p27l1634t1367r1874b1409],
27	104P	NN	O	104p	prep_by	23	SENT_471	[p27l1634t1367r1874b1409],
28	.	.	O	.	_	0	SENT_471	[p27l1634t1367r1874b1409],

1	Mol	NNP	O	Mol	nn	4	SENT_472	[p27l1899t1363r1993b1408],
2	Phar	NNP	O	Phar	nn	4	SENT_472	[p27l2016t1363r2141b1407],
3	—	NN	O	—	nn	4	SENT_472	[p27l2016t1363r2141b1407],
4	macol	NN	O	macol	_	0	SENT_472	[p27l1114t1434r1257b1479],
5	1999	CD	DATE	1999	dep	4	SENT_472	[p27l1273t1438r1628b1488],
6	;	:	O	;	_	0	SENT_472	[p27l1273t1438r1628b1488],
7	55:921	CD	NUMBER	55:921	number	8	SENT_472	[p27l1273t1438r1628b1488],
8	—	CD	NUMBER	—	dep	4	SENT_472	[p27l1273t1438r1628b1488],
9	8	CD	NUMBER	8	dep	8	SENT_472	[p27l1273t1438r1628b1488],
10	.	.	O	.	_	0	SENT_472	[p27l1273t1438r1628b1488],

1	25	CD	NUMBER	25	_	0	SENT_473	[p27l1113t1511r1180b1550],
2	.	.	O	.	_	0	SENT_473	[p27l1113t1511r1180b1550],

1	Chu	NNP	O	Chu	nn	2	SENT_474	[p27l1210t1505r1306b1550],
2	XY	NN	O	xy	_	0	SENT_474	[p27l1322t1509r1394b1559],
3	,	,	O	,	_	0	SENT_474	[p27l1322t1509r1394b1559],
4	Suzuki	NNP	PERSON	Suzuki	nn	5	SENT_474	[p27l1417t1505r1576b1550],
5	H	NNP	PERSON	H	conj_and	2	SENT_474	[p27l1593t1509r1647b1559],
6	,	,	O	,	_	0	SENT_474	[p27l1593t1509r1647b1559],
7	Ueda	NNP	PERSON	Ueda	nn	8	SENT_474	[p27l1668t1505r1789b1550],
8	K	NNP	PERSON	K	conj_and	2	SENT_474	[p27l1807t1509r1855b1559],
9	,	,	O	,	_	0	SENT_474	[p27l1807t1509r1855b1559],
10	Kato	NNP	PERSON	Kato	nn	11	SENT_474	[p27l1876t1509r1985b1551],
11	Y	NN	PERSON	y	conj_and	2	SENT_474	[p27l2001t1509r2039b1559],
12	,	,	O	,	_	0	SENT_474	[p27l2001t1509r2039b1559],
13	Akiyama	NNP	PERSON	Akiyama	nn	14	SENT_474	[p27l2059t1505r2141b1550, p27l1114t1577r1252b1633],
14	S	NNP	O	S	conj_and	2	SENT_474	[p27l1266t1580r1304b1630],
15	,	,	O	,	_	0	SENT_474	[p27l1266t1580r1304b1630],
16	Sugiyama	NNP	PERSON	Sugiyama	nn	19	SENT_474	[p27l1321t1577r1549b1633],
17	Y.	NNP	O	Y.	nn	19	SENT_474	[p27l1559t1581r1596b1621],
18	Active	JJ	O	active	amod	19	SENT_474	[p27l1610t1577r1753b1621],
19	efflux	NN	O	efflux	conj_and	2	SENT_474	[p27l1766t1576r1900b1621],
20	of	IN	O	of	_	0	SENT_474	[p27l1911t1576r1967b1621],
21	CPT	NNP	O	CPT	prep_of	19	SENT_474	[p27l1970t1580r2142b1621],
22	—	CD	NUMBER	—	num	21	SENT_474	[p27l1970t1580r2142b1621],
23	11	CD	NUMBER	11	dep	19	SENT_474	[p27l1970t1580r2142b1621],
24	and	CC	O	and	_	0	SENT_474	[p27l1114t1647r1200b1692],
25	its	PRP$	O	its	poss	26	SENT_474	[p27l1212t1648r1264b1691],
26	metabolites	NNS	O	metabolite	conj_and	2	SENT_474	[p27l1278t1647r1548b1692],
27	in	IN	O	in	_	0	SENT_474	[p27l1561t1648r1606b1691],
28	human	JJ	O	human	amod	30	SENT_474	[p27l1618t1648r1783b1692],
29	KB	NN	O	kb	nn	30	SENT_474	[p27l1795t1647r2053b1693],
30	—	NN	O	—	prep_in	26	SENT_474	[p27l1795t1647r2053b1693],
31	derived	VBN	O	derive	partmod	2	SENT_474	[p27l1795t1647r2053b1693],
32	cell	NN	O	cell	nn	33	SENT_474	[p27l2066t1648r2143b1692],
33	lines	NNS	O	line	dobj	31	SENT_474	[p27l1113t1719r1237b1763],
34	.	.	O	.	_	0	SENT_474	[p27l1113t1719r1237b1763],

1	J	NNP	O	J	nn	4	SENT_475	[p27l1254t1723r1275b1770],
2	Pharmacol	NNP	O	Pharmacol	nn	4	SENT_475	[p27l1291t1719r1545b1763],
3	Exp	NNP	O	Exp	nn	4	SENT_475	[p27l1563t1723r1650b1775],
4	Ther	NNP	O	Ther	_	0	SENT_475	[p27l1668t1718r1781b1762],
5	1999	CD	DATE	1999	num	4	SENT_475	[p27l1800t1722r2142b1772, p27l1113t1793r1183b1834],
6	;	:	O	;	_	0	SENT_475	[p27l1800t1722r2142b1772, p27l1113t1793r1183b1834],
7	288:73541	CD	NUMBER	288:73541	dep	4	SENT_475	[p27l1800t1722r2142b1772, p27l1113t1793r1183b1834],
8	.	.	O	.	_	0	SENT_475	[p27l1800t1722r2142b1772, p27l1113t1793r1183b1834],

1	26	CD	NUMBER	26	_	0	SENT_476	[p27l1113t1866r1180b1905],
2	.	.	O	.	_	0	SENT_476	[p27l1113t1866r1180b1905],

1	Meyers	NNP	ORGANIZATION	Meyers	nn	2	SENT_477	[p27l1208t1864r1375b1916],
2	MB	NNP	ORGANIZATION	MB	_	0	SENT_477	[p27l1396t1864r1491b1914],
3	,	,	O	,	_	0	SENT_477	[p27l1396t1864r1491b1914],
4	Merluzzi	NNP	O	Merluzzi	nn	5	SENT_477	[p27l1514t1860r1723b1905],
5	VJ	NNP	O	VJ	appos	2	SENT_477	[p27l1742t1864r1805b1914],
6	,	,	O	,	_	0	SENT_477	[p27l1742t1864r1805b1914],
7	Spengler	NNP	ORGANIZATION	Spengler	nn	8	SENT_477	[p27l1831t1860r2039b1917],
8	BA	NN	ORGANIZATION	ba	appos	2	SENT_477	[p27l2058t1864r2139b1914],
9	,	,	O	,	_	0	SENT_477	[p27l2058t1864r2139b1914],
10	BiedlerJL	NN	O	biedlerjl	appos	2	SENT_477	[p27l1113t1931r1348b1982],
11	.	.	O	.	_	0	SENT_477	[p27l1113t1931r1348b1982],

1	Epidermal	JJ	O	epidermal	amod	4	SENT_478	[p27l1363t1931r1608b1988],
2	growth	NN	O	growth	nn	4	SENT_478	[p27l1619t1932r1788b1988],
3	factor	NN	O	factor	nn	4	SENT_478	[p27l1800t1931r1938b1976],
4	receptor	NN	O	receptor	nsubjpass	6	SENT_478	[p27l1948t1940r2144b1988],
5	is	VBZ	O	be	auxpass	6	SENT_478	[p27l1114t2003r1150b2046],
6	increased	VBN	O	increase	_	0	SENT_478	[p27l1169t2002r1393b2047],
7	in	IN	O	in	_	0	SENT_478	[p27l1410t2003r1456b2046],
8	multidrug	JJ	O	multidrug	amod	9	SENT_478	[p27l1474t2002r1938b2059],
9	—	NN	O	—	prep_in	6	SENT_478	[p27l1474t2002r1938b2059],
10	resistant	JJ	O	resistant	amod	12	SENT_478	[p27l1474t2002r1938b2059],
11	Chinese	JJ	MISC	chinese	amod	12	SENT_478	[p27l1953t2003r2142b2047],
12	hamster	NN	O	hamster	nsubjpass	6	SENT_478	[p27l1114t2075r1308b2118],
13	and	CC	O	and	_	0	SENT_478	[p27l1327t2074r1414b2119],
14	mouse	NN	O	mouse	nn	16	SENT_478	[p27l1435t2089r1591b2119],
15	tumor	NN	O	tumor	nn	16	SENT_478	[p27l1613t2084r1759b2119],
16	cells	NNS	O	cell	conj_and	12	SENT_478	[p27l1779t2074r1895b2118],
17	.	.	O	.	_	0	SENT_478	[p27l1779t2074r1895b2118],

1	Proc	NNP	ORGANIZATION	Proc	nn	7	SENT_479	[p27l1918t2078r2023b2119],
2	Natl	NNP	ORGANIZATION	Natl	nn	7	SENT_479	[p27l2042t2075r2143b2119],
3	Acad	NNP	ORGANIZATION	Acad	nn	7	SENT_479	[p27l1112t2145r1229b2190],
4	Sci	NNP	ORGANIZATION	Sci	nn	7	SENT_479	[p27l1244t2146r1311b2190],
5	U	NNP	ORGANIZATION	U	nn	7	SENT_479	[p27l1324t2150r1362b2190],
6	S	NNP	ORGANIZATION	S	nn	7	SENT_479	[p27l1376t2149r1400b2190],
7	A	NNP	O	A	_	0	SENT_479	[p27l1414t2150r1451b2189],
8	1986	CD	DATE	1986	num	7	SENT_479	[p27l1465t2149r1849b2199],
9	;	:	O	;	_	0	SENT_479	[p27l1465t2149r1849b2199],
10	83:5521	CD	NUMBER	83:5521	number	11	SENT_479	[p27l1465t2149r1849b2199],
11	—	CD	NUMBER	—	dep	7	SENT_479	[p27l1465t2149r1849b2199],
12	5	CD	NUMBER	5	dep	11	SENT_479	[p27l1465t2149r1849b2199],
13	.	.	O	.	_	0	SENT_479	[p27l1465t2149r1849b2199],

1	27	CD	NUMBER	27	_	0	SENT_480	[p27l1113t2221r1180b2259],
2	.	.	O	.	_	0	SENT_480	[p27l1113t2221r1180b2259],

1	Meyers	NNP	ORGANIZATION	Meyers	nn	2	SENT_481	[p27l1208t2219r1378b2271],
2	MB	NNP	ORGANIZATION	MB	_	0	SENT_481	[p27l1391t2219r1487b2269],
3	,	,	O	,	_	0	SENT_481	[p27l1391t2219r1487b2269],
4	Yu	NNP	PERSON	Yu	nn	5	SENT_481	[p27l1502t2219r1561b2260],
5	P	NN	PERSON	p	appos	2	SENT_481	[p27l1574t2219r1611b2269],
6	,	,	O	,	_	0	SENT_481	[p27l1574t2219r1611b2269],
7	Mendelsohn	NNP	PERSON	Mendelsohn	nn	9	SENT_481	[p27l1626t2215r1927b2260],
8	J.	NNP	O	J.	nn	9	SENT_481	[p27l1936t2219r1969b2266],
9	Crosstalk	NNP	O	Crosstalk	appos	2	SENT_481	[p27l1986t2219r2141b2260, p27l1114t2286r1206b2331],
10	between	IN	O	between	_	0	SENT_481	[p27l1233t2287r1429b2331],
11	epidermal	JJ	O	epidermal	amod	14	SENT_481	[p27l1456t2286r1694b2343],
12	growth	NN	O	growth	nn	14	SENT_481	[p27l1720t2286r1890b2343],
13	factor	NN	O	factor	nn	14	SENT_481	[p27l1916t2286r2054b2331],
14	receptor	NN	O	receptor	prep_between	9	SENT_481	[p27l2079t2301r2142b2331, p27l1114t2367r1267b2414],
15	and	CC	O	and	_	0	SENT_481	[p27l1288t2357r1377b2402],
16	P	NN	O	p	prep_between	9	SENT_481	[p27l1400t2357r1753b2414],
17	—	CD	NUMBER	—	num	18	SENT_481	[p27l1400t2357r1753b2414],
18	glycoprotein	NN	O	glycoprotein	dep	2	SENT_481	[p27l1400t2357r1753b2414],
19	in	IN	O	in	_	0	SENT_481	[p27l1777t2358r1823b2401],
20	actinomycin	NN	O	actinomycin	nn	21	SENT_481	[p27l1846t2358r2142b2414],
21	D	NN	O	d	prep_in	18	SENT_481	[p27l1113t2429r1383b2473],
22	—	CD	NUMBER	—	num	25	SENT_481	[p27l1113t2429r1383b2473],
23	resistant	JJ	O	resistant	amod	25	SENT_481	[p27l1113t2429r1383b2473],
24	Chinese	JJ	MISC	chinese	amod	25	SENT_481	[p27l1392t2428r1580b2473],
25	hamster	NN	O	hamster	dep	2	SENT_481	[p27l1592t2429r1786b2472],
26	lung	NN	O	lung	nn	27	SENT_481	[p27l1796t2428r1904b2485],
27	cells	NNS	O	cell	dep	25	SENT_481	[p27l1915t2428r2031b2473],
28	.	.	O	.	_	0	SENT_481	[p27l1915t2428r2031b2473],

1	Biochem	NNP	O	Biochem	nn	2	SENT_482	[p27l2045t2429r2142b2473, p27l1114t2500r1243b2544],
2	Pharmacol	NNP	O	Pharmacol	_	0	SENT_482	[p27l1256t2500r1509b2545],
3	1993	CD	DATE	1993	num	2	SENT_482	[p27l1524t2504r1910b2554],
4	;	:	O	;	_	0	SENT_482	[p27l1524t2504r1910b2554],
5	46:1841	CD	NUMBER	46:1841	number	6	SENT_482	[p27l1524t2504r1910b2554],
6	—	CD	NUMBER	—	dep	2	SENT_482	[p27l1524t2504r1910b2554],
7	8	CD	NUMBER	8	dep	6	SENT_482	[p27l1524t2504r1910b2554],
8	.	.	O	.	_	0	SENT_482	[p27l1524t2504r1910b2554],

1	28	CD	NUMBER	28	_	0	SENT_483	[p27l1113t2575r1180b2615],
2	.	.	O	.	_	0	SENT_483	[p27l1113t2575r1180b2615],

1	Naruse	NNP	PERSON	Naruse	nn	2	SENT_484	[p27l1209t2574r1380b2615],
2	I	NNP	O	I	_	0	SENT_484	[p27l1395t2574r1426b2624],
3	,	,	O	,	_	0	SENT_484	[p27l1395t2574r1426b2624],
4	Ohmori	NNP	PERSON	Ohmori	nn	5	SENT_484	[p27l1444t2570r1634b2615],
5	T	NN	O	t	appos	2	SENT_484	[p27l1647t2574r1689b2624],
6	,	,	O	,	_	0	SENT_484	[p27l1647t2574r1689b2624],
7	Ao	NNP	O	Ao	nn	8	SENT_484	[p27l1706t2574r1772b2614],
8	Y	NN	O	y	appos	2	SENT_484	[p27l1786t2574r1824b2624],
9	,	,	O	,	_	0	SENT_484	[p27l1786t2574r1824b2624],
10	et	FW	O	et	nn	11	SENT_484	[p27l1844t2579r1887b2614],
11	al.	FW	O	al.	appos	2	SENT_484	[p27l1900t2570r1954b2614],
12	.	.	O	.	_	0	SENT_484	[p27l1900t2570r1954b2614],

1	Antitu	FW	O	antitu	nn	4	SENT_485	[p27l1971t2571r2141b2615],
2	—	FW	O	—	nn	4	SENT_485	[p27l1971t2571r2141b2615],
3	mor	NN	O	mor	nn	4	SENT_485	[p27l1114t2656r1212b2686],
4	activity	NN	O	activity	dep	19	SENT_485	[p27l1220t2642r1382b2698],
5	of	IN	O	of	_	0	SENT_485	[p27l1391t2641r1447b2686],
6	the	DT	O	the	det	16	SENT_485	[p27l1447t2642r1519b2686],
7	selective	JJ	O	selective	amod	16	SENT_485	[p27l1530t2642r1721b2686],
8	epidermal	JJ	O	epidermal	amod	16	SENT_485	[p27l1732t2641r1966b2698],
9	growth	NN	O	growth	nn	16	SENT_485	[p27l1976t2642r2143b2698],
10	factor	NN	O	factor	nn	16	SENT_485	[p27l1114t2712r1254b2757],
11	receptor	NN	O	receptor	nn	16	SENT_485	[p27l1289t2713r1702b2769],
12	—	NN	O	—	nn	16	SENT_485	[p27l1289t2713r1702b2769],
13	tyrosine	NN	O	tyrosine	nn	16	SENT_485	[p27l1289t2713r1702b2769],
14	kinase	NN	O	kinase	nn	16	SENT_485	[p27l1739t2713r1893b2757],
15	inhibitor	NN	O	inhibitor	nn	16	SENT_485	[p27l1929t2712r2144b2757],
16	(	NN	O	(	prep_of	4	SENT_485	[p27l1117t2788r1395b2835],
17	EGFR-TKI	NN	O	egfr-tkus	dep	19	SENT_485	[p27l1117t2788r1395b2835],
18	)	CD	NUMBER	)	num	17	SENT_485	[p27l1117t2788r1395b2835],
19	Iressa	NNP	O	Iressa	_	0	SENT_485	[p27l1420t2789r1562b2828],
20	(	CD	NUMBER	(	num	22	SENT_485	[p27l1587t2788r1811b2835],
21	ZD1839	NN	O	zd1839	nn	22	SENT_485	[p27l1587t2788r1811b2835],
22	)	NN	O	)	dep	19	SENT_485	[p27l1587t2788r1811b2835],
23	in	IN	O	in	_	0	SENT_485	[p27l1837t2785r1883b2828],
24	an	DT	O	a	det	25	SENT_485	[p27l1906t2799r1962b2828],
25	EGFRexpressing	NN	O	egfrexpressing	prep_in	22	SENT_485	[p27l1984t2788r2140b2831, p27l18t3137r553b3251],

1	multidrug	JJ	O	multidrug	amod	2	SENT_486	[p27l591t3135r1566b3251],
2	—	NN	O	—	nsubj	3	SENT_486	[p27l591t3135r1566b3251],
3	resistant	JJ	O	resistant	_	0	SENT_486	[p27l591t3135r1566b3251],
4	cell	NN	O	cell	nn	5	SENT_486	[p27l1605t3135r1771b3226],
5	line	NN	O	line	dobj	3	SENT_486	[p27l1810t3137r1993b3226],
6	in	FW	O	in	nn	7	SENT_486	[p27l2035t3137r2130b3224],
7	vitro	FW	O	vitro	dep	5	SENT_486	[p27l12t3284r240b3373],
8	and	CC	O	and	_	0	SENT_486	[p27l303t3284r485b3373],
9	in	IN	O	in	dep	5	SENT_486	[p27l546t3284r642b3371],
10	Vivo	NNP	LOCATION	Vivo	pobj	9	SENT_486	[p27l699t3284r924b3373],
11	.	.	O	.	_	0	SENT_486	[p27l699t3284r924b3373],

1	Int	NN	O	int	nn	3	SENT_487	[p27l991t3292r1225b3386],
2	]	CD	NUMBER	]	num	3	SENT_487	[p27l991t3292r1225b3386],
3	Cancer	NN	O	cancer	_	0	SENT_487	[p27l1284t3290r1633b3373],
4	2002	CD	DATE	2002	num	6	SENT_487	[p27l1692t3290r2125b3392],
5	;	:	O	;	_	0	SENT_487	[p27l1692t3290r2125b3392],
6	98	CD	NUMBER	98	dep	3	SENT_487	[p27l1692t3290r2125b3392],
7	:	:	O	:	_	0	SENT_487	[p27l1692t3290r2125b3392],

1	29	CD	NUMBER	29	_	0	SENT_488	[p27l16t3588r152b3667],
2	.	.	O	.	_	0	SENT_488	[p27l16t3588r152b3667],

1	Sclabas	NNP	ORGANIZATION	Sclabas	nn	2	SENT_489	[p27l217t3577r571b3667],
2	GM	NNP	ORGANIZATION	GM	_	0	SENT_489	[p27l610t3585r818b3687],
3	,	,	O	,	_	0	SENT_489	[p27l610t3585r818b3687],
4	Fujioka	NNP	PERSON	Fujioka	nn	5	SENT_489	[p27l861t3577r1218b3691],
5	S	NNP	O	S	appos	2	SENT_489	[p27l1256t3585r1336b3687],
6	,	,	O	,	_	0	SENT_489	[p27l1256t3585r1336b3687],
7	Schmidt	NNP	PERSON	Schmidt	nn	8	SENT_489	[p27l1381t3577r1787b3667],
8	C	NNP	O	C	appos	2	SENT_489	[p27l1818t3585r1913b3687],
9	,	,	O	,	_	0	SENT_489	[p27l1818t3585r1913b3687],
10	Pan	NNP	O	Pan	appos	2	SENT_489	[p27l1954t3585r2131b3667],

1	Z	NN	O	z	_	0	SENT_490	[p28l16t33r104b133],
2	,	,	O	,	_	0	SENT_490	[p28l16t33r104b133],
3	Evans	NNP	PERSON	Evans	nn	4	SENT_490	[p28l144t33r422b114],
4	DB	NNP	O	DB	appos	1	SENT_490	[p28l459t31r634b133],
5	,	,	O	,	_	0	SENT_490	[p28l459t31r634b133],
6	Chiao	NNP	PERSON	Chiao	nn	8	SENT_490	[p28l677t23r958b114],
7	P	NN	O	p	nn	8	SENT_490	[p28l993t31r1113b127],
8	]	NN	O	]	appos	4	SENT_490	[p28l993t31r1113b127],
9	.	.	O	.	_	0	SENT_490	[p28l993t31r1113b127],

1	Restoring	VBG	O	restore	amod	2	SENT_491	[p28l1152t25r1631b139],
2	apoptosis	NN	O	apoptosis	_	0	SENT_491	[p28l1662t25r2129b139],
3	in	IN	O	in	_	0	SENT_491	[p28l16t172r110b259],
4	pancreatic	JJ	O	pancreatic	amod	6	SENT_491	[p28l158t172r660b286],
5	cancer	NN	O	cancer	nn	6	SENT_491	[p28l709t200r1025b261],
6	cells	NNS	O	cell	prep_in	2	SENT_491	[p28l1073t170r1282b261],
7	by	IN	O	by	_	0	SENT_491	[p28l1335t172r1446b286],
8	targeting	VBG	O	target	prepc_by	2	SENT_491	[p28l1493t172r1935b286],
9	the	DT	O	the	det	12	SENT_491	[p28l1982t172r2130b261],
10	nuclear	JJ	O	nuclear	amod	12	SENT_491	[p28l18t317r377b408],
11	factor	NN	O	factor	nn	12	SENT_491	[p28l447t317r1131b433],
12	—	NN	O	—	dobj	8	SENT_491	[p28l447t317r1131b433],
13	l	NN	O	l	tmod	8	SENT_491	[p28l447t317r1131b433],
14	<	JJR	O	<	amod	17	SENT_491	[p28l447t317r1131b433],
15	appaB	NN	O	appab	nn	17	SENT_491	[p28l447t317r1131b433],
16	signaling	NN	O	signaling	nn	17	SENT_491	[p28l1209t319r1661b433],
17	pathway	NN	O	pathway	npadvmod	8	SENT_491	[p28l1729t317r2137b433],
18	with	IN	O	with	_	0	SENT_491	[p28l12t466r230b556],
19	the	DT	O	the	det	21	SENT_491	[p28l268t464r416b555],
20	anti	JJ	O	anti	amod	21	SENT_491	[p28l455t464r1170b580],
21	—	NN	O	—	prep_with	8	SENT_491	[p28l455t464r1170b580],
22	epidermal	JJ	O	epidermal	amod	26	SENT_491	[p28l455t464r1170b580],
23	growth	NN	O	growth	nn	26	SENT_491	[p28l1207t466r1555b580],
24	factor	NN	O	factor	nn	26	SENT_491	[p28l1593t464r1875b555],
25	antibody	NN	O	antibody	nn	26	SENT_491	[p28l1909t466r2130b555, p28l18t613r256b725],
26	IMC	NN	O	imc	dep	21	SENT_491	[p28l274t619r775b702],
27	.	.	O	.	_	0	SENT_491	[p28l274t619r775b702],

1	—	NN	O	—	_	0	SENT_492	[p28l274t619r775b702],
2	.	.	O	.	_	0	SENT_492	[p28l274t619r775b702],

1	C225	NN	O	c225	_	0	SENT_493	[p28l274t619r775b702],
2	.	.	O	.	_	0	SENT_493	[p28l790t685r806b702],

1	J	NNP	O	J	nn	3	SENT_494	[p28l827t621r871b715],
2	Gastrointest	NNP	O	Gastrointest	nn	3	SENT_494	[p28l894t613r1497b702],
3	Surg	NNP	O	Surg	_	0	SENT_494	[p28l1521t619r1745b727],
4	2003	CD	DATE	2003	num	3	SENT_494	[p28l1767t619r2127b721],
5	;	:	O	;	_	0	SENT_494	[p28l1767t619r2127b721],
6	7	CD	NUMBER	7	num	8	SENT_494	[p28l1767t619r2127b721],
7	:	:	O	:	_	0	SENT_494	[p28l1767t619r2127b721],
8	37-43	CD	NUMBER	37-43	dep	3	SENT_494	[p28l18t767r321b850],
9	.	.	O	.	_	0	SENT_494	[p28l18t767r321b850],

1	30	CD	NUMBER	30	_	0	SENT_495	[p28l18t917r152b997],
2	.	.	O	.	_	0	SENT_495	[p28l18t917r152b997],

1	Bandyopadhyay	NNP	PERSON	Bandyopadhyay	nn	2	SENT_496	[p28l213t907r977b1021],
2	D	NNP	O	D	_	0	SENT_496	[p28l1009t915r1109b1017],
3	,	,	O	,	_	0	SENT_496	[p28l1009t915r1109b1017],
4	Mandal	NNP	PERSON	Mandal	nn	5	SENT_496	[p28l1150t907r1517b997],
5	M	NNP	PERSON	M	appos	2	SENT_496	[p28l1552t915r1676b1017],
6	,	,	O	,	_	0	SENT_496	[p28l1552t915r1676b1017],
7	Adam	NNP	PERSON	Adam	nn	8	SENT_496	[p28l1716t907r2005b997],
8	L	NNP	PERSON	L	appos	2	SENT_496	[p28l2041t915r2124b1017],
9	,	,	O	,	_	0	SENT_496	[p28l2041t915r2124b1017],
10	Mendelsohn	NNP	PERSON	Mendelsohn	nn	11	SENT_496	[p28l14t1053r623b1144],
11	J	NNP	PERSON	J	appos	2	SENT_496	[p28l662t1063r729b1163],
12	,	,	O	,	_	0	SENT_496	[p28l662t1063r729b1163],
13	Kumar	NNP	PERSON	Kumar	nn	15	SENT_496	[p28l786t1063r1121b1146],
14	R.	NNP	O	R.	nn	15	SENT_496	[p28l1166t1061r1265b1149],
15	Physical	NNP	O	Physical	appos	11	SENT_496	[p28l1320t1053r1714b1167],
16	interaction	NN	O	interaction	dep	2	SENT_496	[p28l1763t1055r2130b1144, p28l18t1202r207b1291],
17	between	IN	O	between	_	0	SENT_496	[p28l233t1202r631b1291],
18	epidermal	JJ	O	epidermal	amod	21	SENT_496	[p28l658t1200r1140b1316],
19	growth	NN	O	growth	nn	21	SENT_496	[p28l1164t1200r1509b1316],
20	factor	NN	O	factor	nn	21	SENT_496	[p28l1535t1200r1814b1291],
21	receptor	NN	O	receptor	prep_between	16	SENT_496	[p28l1838t1231r2130b1316, p28l18t1367r156b1438],
22	and	CC	O	and	_	0	SENT_496	[p28l203t1347r382b1438],
23	DNA	NN	O	dna	nn	24	SENT_496	[p28l431t1347r1229b1463],
24	—	NN	O	—	prep_between	16	SENT_496	[p28l431t1347r1229b1463],
25	dependent	JJ	O	dependent	amod	27	SENT_496	[p28l431t1347r1229b1463],
26	protein	NN	O	protein	nn	27	SENT_496	[p28l1274t1349r1625b1463],
27	kinase	NN	O	kinase	dep	2	SENT_496	[p28l1676t1347r1986b1438],
28	in	IN	O	in	_	0	SENT_496	[p28l2037t1349r2131b1436],
29	mammalian	JJ	O	mammalian	amod	30	SENT_496	[p28l18t1497r603b1585],
30	cells	NNS	O	cell	prep_in	27	SENT_496	[p28l662t1495r900b1586],
31	.	.	O	.	_	0	SENT_496	[p28l662t1495r900b1586],

1	J	NNP	O	J	nn	3	SENT_497	[p28l953t1505r997b1599],
2	Biol	NNP	O	Biol	nn	3	SENT_497	[p28l1050t1497r1243b1586],
3	Chem	NNP	O	Chem	_	0	SENT_497	[p28l1300t1495r1588b1586],
4	1998	CD	DATE	1998	num	3	SENT_497	[p28l1649t1503r2127b1605],
5	;	:	O	;	_	0	SENT_497	[p28l1649t1503r2127b1605],
6	273	CD	NUMBER	273	num	8	SENT_497	[p28l1649t1503r2127b1605],
7	:	:	O	:	_	0	SENT_497	[p28l1649t1503r2127b1605],
8	1568-73	CD	NUMBER	1568-73	dep	3	SENT_497	[p28l22t1650r443b1733],
9	.	.	O	.	_	0	SENT_497	[p28l22t1650r443b1733],

1	31	CD	NUMBER	31	_	0	SENT_498	[p28l18t1801r152b1879],
2	.	.	O	.	_	0	SENT_498	[p28l18t1801r152b1879],

1	Huang	NNP	PERSON	Huang	nn	2	SENT_499	[p28l214t1797r548b1905],
2	SM	NNP	O	SM	_	0	SENT_499	[p28l595t1797r772b1899],
3	,	,	O	,	_	0	SENT_499	[p28l595t1797r772b1899],
4	Harari	NNP	PERSON	Harari	nn	5	SENT_499	[p28l827t1791r1137b1879],
5	PM	NNP	O	PM	appos	2	SENT_499	[p28l1184t1797r1367b1879],
6	.	.	O	.	_	0	SENT_499	[p28l1184t1797r1367b1879],

1	Modulation	NN	O	modulation	_	0	SENT_500	[p28l1420t1789r1988b1880],
2	of	IN	O	of	_	0	SENT_500	[p28l2037t1789r2153b1880],
3	radiation	NN	O	radiation	nn	4	SENT_500	[p28l18t1936r455b2027],
4	response	NN	O	response	prep_of	1	SENT_500	[p28l502t1966r936b2052],
5	after	IN	O	after	_	0	SENT_500	[p28l983t1936r1204b2027],
6	epidermal	JJ	O	epidermal	amod	10	SENT_500	[p28l1251t1936r1738b2052],
7	growth	NN	O	growth	nn	10	SENT_500	[p28l1784t1938r2131b2052],
8	factor	NN	O	factor	nn	10	SENT_500	[p28l18t2083r300b2174],
9	receptor	NN	O	receptor	nn	10	SENT_500	[p28l345t2103r749b2199],
10	blockade	NN	O	blockade	prep_after	4	SENT_500	[p28l796t2083r1229b2175],
11	in	IN	O	in	_	0	SENT_500	[p28l1278t2085r1371b2172],
12	squamous	JJ	O	squamous	amod	14	SENT_500	[p28l1422t2112r1917b2199],
13	cell	NN	O	cell	nn	14	SENT_500	[p28l1970t2083r2132b2174],
14	carcinomas	NNS	O	carcinoma	prep_in	10	SENT_500	[p28l18t2232r599b2321],
15	:	:	O	:	_	0	SENT_500	[p28l18t2232r599b2321],
16	inhibition	NN	O	inhibition	dep	1	SENT_500	[p28l624t2232r1101b2321],
17	of	IN	O	of	_	0	SENT_500	[p28l1125t2230r1239b2321],
18	damage	NN	O	damage	nn	19	SENT_500	[p28l1243t2232r1618b2346],
19	repair	NN	O	repair	prep_of	16	SENT_500	[p28l1641t2232r1940b2346],
20	,	,	O	,	_	0	SENT_500	[p28l1641t2232r1940b2346],
21	cell	NN	O	cell	nn	23	SENT_500	[p28l1970t2232r2131b2321],
22	cycle	NN	O	cycle	nn	23	SENT_500	[p28l18t2379r248b2491],
23	kinetics	NNS	O	kinetics	conj_and	19	SENT_500	[p28l274t2379r676b2487],
24	,	,	O	,	_	0	SENT_500	[p28l274t2379r676b2487],
25	and	CC	O	and	_	0	SENT_500	[p28l709t2377r887b2468],
26	tumor	NN	O	tumor	nn	27	SENT_500	[p28l914t2397r1215b2468],
27	angiogenesis	NN	O	angiogenesis	conj_and	19	SENT_500	[p28l1237t2379r1899b2493],
28	.	.	O	.	_	0	SENT_500	[p28l1237t2379r1899b2493],

1	Clin	NNP	O	Clin	nn	3	SENT_501	[p28l1932t2379r2132b2468],
2	Cancer	NNP	O	Cancer	nn	3	SENT_501	[p28l18t2533r357b2616],
3	Res	NNP	O	Res	_	0	SENT_501	[p28l380t2533r552b2621],
4	2000	CD	DATE	2000	num	3	SENT_501	[p28l583t2533r1377b2635],
5	;	:	O	;	_	0	SENT_501	[p28l583t2533r1377b2635],
6	6:2166	CD	NUMBER	6:2166	number	7	SENT_501	[p28l583t2533r1377b2635],
7	—	CD	NUMBER	—	dep	3	SENT_501	[p28l583t2533r1377b2635],
8	74	CD	NUMBER	74	dep	7	SENT_501	[p28l583t2533r1377b2635],
9	.	.	O	.	_	0	SENT_501	[p28l583t2533r1377b2635],

1	32	CD	NUMBER	32	_	0	SENT_502	[p28l18t2684r152b2762],
2	.	.	O	.	_	0	SENT_502	[p28l18t2684r152b2762],

1	Saltz	NNP	PERSON	Saltz	nn	2	SENT_503	[p28l217t2672r451b2762],
2	L	NNP	PERSON	L	_	0	SENT_503	[p28l477t2680r562b2782],
3	,	,	O	,	_	0	SENT_503	[p28l477t2680r562b2782],
4	Kies	NNP	PERSON	Kies	nn	5	SENT_503	[p28l597t2674r804b2764],
5	MS	NN	O	m	appos	2	SENT_503	[p28l833t2680r1019b2782],
6	,	,	O	,	_	0	SENT_503	[p28l833t2680r1019b2782],
7	AbbruzzeseJ	NN	O	abbruzzesej	appos	2	SENT_503	[p28l1050t2672r1716b2782],
8	,	,	O	,	_	0	SENT_503	[p28l1050t2672r1716b2782],
9	Azarnia	NNP	ORGANIZATION	Azarnia	nn	10	SENT_503	[p28l1747t2674r2132b2762],
10	N	NNP	ORGANIZATION	N	appos	2	SENT_503	[p28l16t2828r124b2928],
11	,	,	O	,	_	0	SENT_503	[p28l16t2828r124b2928],
12	Needle	NNP	O	Needle	nn	13	SENT_503	[p28l165t2818r508b2909],
13	MN	NN	O	mn	appos	2	SENT_503	[p28l542t2828r752b2909],
14	.	.	O	.	_	0	SENT_503	[p28l542t2828r752b2909],

1	The	DT	O	the	det	2	SENT_504	[p28l792t2818r979b2909],
2	presence	NN	O	presence	nsubj	9	SENT_504	[p28l1015t2848r1452b2934],
3	and	CC	O	and	_	0	SENT_504	[p28l1489t2818r1670b2909],
4	intensity	NN	O	intensity	nsubj	9	SENT_504	[p28l1706t2820r2135b2932],
5	of	IN	O	of	_	0	SENT_504	[p28l18t2966r134b3057],
6	the	DT	O	the	det	8	SENT_504	[p28l179t2966r329b3057],
7	cetuximab	NN	O	cetuximab	nn	8	SENT_504	[p28l396t2966r1346b3057],
8	—	NN	O	—	prep_of	2	SENT_504	[p28l396t2966r1346b3057],
9	induced	VBD	O	induce	_	0	SENT_504	[p28l396t2966r1346b3057],
10	acne-like	JJ	O	acne-like	amod	11	SENT_504	[p28l1408t2966r1854b3059],
11	rash	NN	O	rash	nsubj	12	SENT_504	[p28l1919t2968r2130b3057],
12	predicts	VBZ	O	predict	ccomp	9	SENT_504	[p28l16t3115r398b3229],
13	increased	VBN	O	increase	amod	14	SENT_504	[p28l437t3113r892b3204],
14	survival	NN	O	survival	dobj	12	SENT_504	[p28l930t3113r1290b3204],
15	in	IN	O	in	_	0	SENT_504	[p28l1326t3115r1418b3202],
16	studies	NNS	O	study	prep_in	14	SENT_504	[p28l1458t3113r1791b3204],
17	across	IN	O	across	_	0	SENT_504	[p28l1830t3143r2130b3204],
18	multiple	JJ	O	multiple	amod	19	SENT_504	[p28l18t3260r432b3376],
19	malignancies	NNS	O	malignancy	prep_across	16	SENT_504	[p28l476t3262r1164b3376],
20	.	.	O	.	_	0	SENT_504	[p28l476t3262r1164b3376],

1	Prog	NN	O	prog	_	0	SENT_505	[p28l1212t3268r1444b3376],
2	Proc	NNP	O	Proc	nn	6	SENT_505	[p28l1483t3268r1702b3351],
3	Am	NNP	O	Am	nn	6	SENT_505	[p28l1741t3270r1915b3349],
4	Soc	NNP	O	Soc	nn	6	SENT_505	[p28l1962t3268r2131b3351],
5	Clin	NNP	O	Clin	nn	6	SENT_505	[p28l18t3408r221b3499],
6	Oncol	NNP	O	Oncol	dep	1	SENT_505	[p28l250t3410r548b3499],
7	2003	CD	DATE	2003	num	9	SENT_505	[p28l577t3416r1225b3516],
8	;	:	O	;	_	0	SENT_505	[p28l577t3416r1225b3516],
9	22:204	CD	NUMBER	22:204	dep	6	SENT_505	[p28l577t3416r1225b3516],
10	.	.	O	.	_	0	SENT_505	[p28l577t3416r1225b3516],

1	abstract	JJ	O	abstract	_	0	SENT_506	[p28l1262t3410r1680b3499],
2	.	.	O	.	_	0	SENT_506	[p28l1262t3410r1680b3499],

1	33	CD	NUMBER	33	_	0	SENT_507	[p28l18t3566r152b3645],
2	.	.	O	.	_	0	SENT_507	[p28l18t3566r152b3645],

1	Baselga	NNP	PERSON	Baselga	nn	2	SENT_508	[p28l213t3554r585b3670],
2	J	NNP	PERSON	J	_	0	SENT_508	[p28l618t3562r685b3664],
3	,	,	O	,	_	0	SENT_508	[p28l618t3562r685b3664],
4	Pﬁster	NNP	O	Pﬁster	nn	5	SENT_508	[p28l735t3554r1048b3644],
5	D	NNP	O	D	appos	2	SENT_508	[p28l1087t3562r1190b3664],
6	,	,	O	,	_	0	SENT_508	[p28l1087t3562r1190b3664],
7	Cooper	NNP	PERSON	Cooper	nn	8	SENT_508	[p28l1241t3562r1598b3668],
8	MR	NN	PERSON	mr	appos	2	SENT_508	[p28l1637t3562r1836b3664],
9	,	,	O	,	_	0	SENT_508	[p28l1637t3562r1836b3664],
10	et	FW	O	et	nn	11	SENT_508	[p28l1889t3573r1978b3644],
11	al.	FW	O	al.	appos	2	SENT_508	[p28l2017t3554r2124b3644],
12	.	.	O	.	_	0	SENT_508	[p28l2017t3554r2124b3644],

1	Phase	NN	O	phase	_	0	SENT_509	[p29l16t24r294b113],
2	1	CD	NUMBER	1	num	3	SENT_509	[p29l317t32r353b111],
3	studies	NNS	O	study	dep	1	SENT_509	[p29l376t22r709b113],
4	of	IN	O	of	_	0	SENT_509	[p29l738t22r853b113],
5	anti	JJ	O	anti	amod	6	SENT_509	[p29l855t24r1564b138],
6	—	NN	O	—	prep_of	3	SENT_509	[p29l855t24r1564b138],
7	epidermal	JJ	O	epidermal	amod	10	SENT_509	[p29l855t24r1564b138],
8	growth	NN	O	growth	nn	10	SENT_509	[p29l1587t24r1932b138],
9	factor	NN	O	factor	nn	10	SENT_509	[p29l1956t22r2130b113, p29l18t189r156b260],
10	receptor	NN	O	receptor	dep	1	SENT_509	[p29l197t189r599b285],
11	chimeric	JJ	O	chimeric	amod	13	SENT_509	[p29l642t171r1064b260],
12	antibody	NN	O	antibody	nn	13	SENT_509	[p29l1109t169r1533b285],
13	C225	NN	O	c225	npadvmod	10	SENT_509	[p29l1574t177r1820b260],
14	alone	RB	O	alone	dep	13	SENT_509	[p29l1869t169r2131b260],
15	and	CC	O	and	_	0	SENT_509	[p29l17t316r195b407],
16	in	IN	O	in	dep	13	SENT_509	[p29l256t318r351b405],
17	combination	NN	O	combination	pobj	16	SENT_509	[p29l413t318r1032b407],
18	with	IN	O	with	_	0	SENT_509	[p29l1089t316r1306b407],
19	cisplatin	NN	O	cisplatin	prep_with	10	SENT_509	[p29l1369t318r1805b432],
20	.	.	O	.	_	0	SENT_509	[p29l1369t318r1805b432],

1	JClin	NN	O	jclin	nn	2	SENT_510	[p29l1863t318r2130b420],
2	Oncol	NN	O	oncol	_	0	SENT_510	[p29l18t466r309b555],
3	2000	CD	DATE	2000	dep	2	SENT_510	[p29l337t472r1133b574],
4	;	:	O	;	_	0	SENT_510	[p29l337t472r1133b574],
5	18:904	CD	NUMBER	18:904	number	6	SENT_510	[p29l337t472r1133b574],
6	—	CD	NUMBER	—	dep	2	SENT_510	[p29l337t472r1133b574],
7	14	CD	NUMBER	14	dep	6	SENT_510	[p29l337t472r1133b574],
8	.	.	O	.	_	0	SENT_510	[p29l337t472r1133b574],

1	34	CD	NUMBER	34	_	0	SENT_511	[p29l18t623r152b701],
2	.	.	O	.	_	0	SENT_511	[p29l18t623r152b701],

1	Slamon	NN	PERSON	slamon	nn	2	SENT_512	[p29l217t611r583b701],
2	D	NN	O	d	_	0	SENT_512	[p29l619t619r759b721],
3	]	CD	NUMBER	]	dep	2	SENT_512	[p29l619t619r759b721],
4	,	,	O	,	_	0	SENT_512	[p29l619t619r759b721],
5	Leyland	NNP	PERSON	Leyland	appos	3	SENT_512	[p29l800t611r1477b725],
6	.	.	O	.	_	0	SENT_512	[p29l800t611r1477b725],

1	—	NN	O	—	_	0	SENT_513	[p29l800t611r1477b725],
2	.	.	O	.	_	0	SENT_513	[p29l800t611r1477b725],

1	Jones	NNP	PERSON	Jones	nn	2	SENT_514	[p29l800t611r1477b725],
2	B	NNP	O	B	_	0	SENT_514	[p29l1515t619r1608b721],
3	,	,	O	,	_	0	SENT_514	[p29l1515t619r1608b721],
4	Shal	NNP	PERSON	Shal	appos	2	SENT_514	[p29l1653t611r1891b702],
5	<	JJR	O	<	amod	6	SENT_514	[p29l1653t611r1891b702],
6	S	NN	O	s	dep	4	SENT_514	[p29l1926t619r2005b721],
7	,	,	O	,	_	0	SENT_514	[p29l1926t619r2005b721],
8	et	FW	O	et	nn	9	SENT_514	[p29l2049t630r2137b701],
9	al.	FW	O	al.	appos	2	SENT_514	[p29l17t757r124b848],
10	.	.	O	.	_	0	SENT_514	[p29l17t757r124b848],

1	Use	NN	O	use	_	0	SENT_515	[p29l164t767r343b848],
2	of	IN	O	of	_	0	SENT_515	[p29l378t757r493b848],
3	chemotherapy	NN	O	chemotherapy	prep_of	1	SENT_515	[p29l506t757r1202b873],
4	plus	CC	O	plus	prep	1	SENT_515	[p29l1229t759r1430b873],
5	a	DT	O	a	det	7	SENT_515	[p29l1466t788r1517b848],
6	monoclonal	JJ	O	monoclonal	amod	7	SENT_515	[p29l1548t757r2132b848],
7	antibody	NN	O	antibody	dep	4	SENT_515	[p29l17t904r443b1020],
8	against	IN	O	against	_	0	SENT_515	[p29l463t906r818b1020],
9	HER2	NN	O	her2	prep_against	1	SENT_515	[p29l837t912r1121b1000],
10	for	IN	O	for	_	0	SENT_515	[p29l1148t904r1289b995],
11	metastatic	JJ	O	metastatic	amod	13	SENT_515	[p29l1312t906r1812b995],
12	breast	NN	O	breast	nn	13	SENT_515	[p29l1838t906r2136b995],
13	cancer	NN	O	cancer	prep_for	1	SENT_515	[p29l18t1081r339b1142],
14	that	WDT	O	that	nsubj	15	SENT_515	[p29l380t1053r575b1142],
15	overexpresses	VBZ	O	overexpress	rcmod	13	SENT_515	[p29l614t1080r1295b1167],
16	HER2	NN	O	her2	dobj	15	SENT_515	[p29l1341t1059r1659b1147],
17	.	.	O	.	_	0	SENT_515	[p29l1341t1059r1659b1147],

1	N	NN	O	n	nn	2	SENT_516	[p29l1706t1061r1792b1142],
2	EnglJ	NN	O	englj	nsubj	3	SENT_516	[p29l1832t1053r2133b1167],
3	Med	VBD	O	med	_	0	SENT_516	[p29l14t1199r231b1290],
4	2001	CD	DATE	2001	dobj	3	SENT_516	[p29l260t1207r1117b1309],
5	;	:	O	;	_	0	SENT_516	[p29l260t1207r1117b1309],
6	344:783	CD	NUMBER	344:783	number	7	SENT_516	[p29l260t1207r1117b1309],
7	—	CD	NUMBER	—	dep	4	SENT_516	[p29l260t1207r1117b1309],
8	92	CD	NUMBER	92	dep	7	SENT_516	[p29l260t1207r1117b1309],
9	.	.	O	.	_	0	SENT_516	[p29l260t1207r1117b1309],

1	35	CD	NUMBER	35	_	0	SENT_517	[p29l18t1358r152b1436],
2	.	.	O	.	_	0	SENT_517	[p29l18t1358r152b1436],

1	Ciardiello	NNP	O	Ciardiello	nn	2	SENT_518	[p29l215t1346r696b1437],
2	F	NN	O	f	nsubj	20	SENT_518	[p29l788t1354r861b1456],
3	,	,	O	,	_	0	SENT_518	[p29l788t1354r861b1456],
4	Tortora	NNP	PERSON	Tortora	nn	9	SENT_518	[p29l953t1354r1322b1437],
5	G.	NNP	O	G.	nn	9	SENT_518	[p29l1412t1354r1521b1437],
6	Epidermal	NNP	O	Epidermal	nn	9	SENT_518	[p29l1617t1346r2130b1460],
7	growth	NN	O	growth	nn	9	SENT_518	[p29l18t1492r371b1608],
8	factor	NN	O	factor	nn	9	SENT_518	[p29l402t1492r686b1583],
9	receptor	NN	O	receptor	appos	2	SENT_518	[p29l711t1512r1113b1608],
10	(	CD	NUMBER	(	num	11	SENT_518	[p29l1144t1500r1495b1596],
11	EGFR	NN	ORGANIZATION	egfr	tmod	9	SENT_518	[p29l1144t1500r1495b1596],
12	)	RB	O	)	advmod	11	SENT_518	[p29l1144t1500r1495b1596],
13	as	IN	O	as	_	0	SENT_518	[p29l1528t1523r1624b1583],
14	a	DT	O	a	det	15	SENT_518	[p29l1653t1523r1704b1583],
15	target	NN	O	target	prep_as	2	SENT_518	[p29l1731t1512r2015b1608],
16	in	IN	O	in	_	0	SENT_518	[p29l2037t1494r2130b1581],
17	cancer	NN	O	cancer	nn	18	SENT_518	[p29l18t1669r333b1730],
18	therapy	NN	O	therapy	prep_in	15	SENT_518	[p29l384t1641r771b1755],
19	:	:	O	:	_	0	SENT_518	[p29l384t1641r771b1755],
20	understanding	VBG	O	understand	_	0	SENT_518	[p29l829t1641r1546b1755],
21	the	DT	O	the	det	22	SENT_518	[p29l1596t1641r1744b1730],
22	role	NN	O	role	dobj	20	SENT_518	[p29l1798t1641r1982b1730],
23	of	IN	O	of	_	0	SENT_518	[p29l2037t1639r2151b1730],
24	receptor	NN	O	receptor	nn	25	SENT_518	[p29l18t1806r428b1902],
25	expression	NN	O	expression	prep_of	22	SENT_518	[p29l485t1788r1017b1902],
26	and	CC	O	and	_	0	SENT_518	[p29l1075t1786r1257b1877],
27	other	JJ	O	other	amod	29	SENT_518	[p29l1318t1786r1578b1877],
28	molecular	JJ	O	molecular	amod	29	SENT_518	[p29l1635t1786r2133b1877],
29	determinants	NNS	O	determinant	conj_and	22	SENT_518	[p29l18t1934r674b2025],
30	that	WDT	O	that	nsubj	32	SENT_518	[p29l727t1934r922b2025],
31	could	MD	O	could	aux	32	SENT_518	[p29l967t1934r1239b2025],
32	inﬂuence	VB	O	inﬂuence	rcmod	29	SENT_518	[p29l1288t1934r1745b2025],
33	the	DT	O	the	det	34	SENT_518	[p29l1797t1936r1948b2025],
34	response	NN	O	response	dobj	32	SENT_518	[p29l1998t1965r2128b2025, p29l20t2111r363b2197],

1	to	TO	O	to	_	0	SENT_519	[p29l420t2101r512b2172],
2	anti	JJ	O	anti	pobj	1	SENT_519	[p29l569t2083r1094b2177],
3	.	.	O	.	_	0	SENT_519	[p29l569t2083r1094b2177],

1	—	NN	O	—	_	0	SENT_520	[p29l569t2083r1094b2177],
2	.	.	O	.	_	0	SENT_520	[p29l569t2083r1094b2177],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_521	[p29l569t2083r1094b2177],
2	drugs	NNS	O	drug	_	0	SENT_521	[p29l1135t2081r1436b2197],
3	.	.	O	.	_	0	SENT_521	[p29l1135t2081r1436b2197],

1	Eur	NNP	MISC	Eur	nn	3	SENT_522	[p29l1493t2091r1745b2185],
2	]	NNP	O	]	nn	3	SENT_522	[p29l1493t2091r1745b2185],
3	Cancer	NNP	O	Cancer	_	0	SENT_522	[p29l1795t2089r2134b2172],
4	2003	CD	DATE	2003	num	3	SENT_522	[p29l18t2237r873b2339],
5	;	:	O	;	_	0	SENT_522	[p29l18t2237r873b2339],
6	39:1348	CD	NUMBER	39:1348	number	7	SENT_522	[p29l18t2237r873b2339],
7	—	CD	NUMBER	—	dep	3	SENT_522	[p29l18t2237r873b2339],
8	54	CD	NUMBER	54	dep	7	SENT_522	[p29l18t2237r873b2339],
9	.	.	O	.	_	0	SENT_522	[p29l18t2237r873b2339],

1	36	CD	NUMBER	36	_	0	SENT_523	[p29l18t2388r152b2466],
2	.	.	O	.	_	0	SENT_523	[p29l18t2388r152b2466],

1	Kris	NNP	PERSON	Kris	nn	2	SENT_524	[p29l214t2378r408b2468],
2	MG	NN	PERSON	mg	_	0	SENT_524	[p29l431t2384r644b2486],
3	,	,	O	,	_	0	SENT_524	[p29l431t2384r644b2486],
4	Natale	NNP	PERSON	Natale	nn	5	SENT_524	[p29l672t2376r987b2467],
5	RB	NN	O	rb	appos	2	SENT_524	[p29l1010t2384r1178b2486],
6	,	,	O	,	_	0	SENT_524	[p29l1010t2384r1178b2486],
7	Herbst	NNP	ORGANIZATION	Herbst	nn	8	SENT_524	[p29l1207t2376r1542b2466],
8	RS	NN	ORGANIZATION	r	appos	2	SENT_524	[p29l1560t2384r1718b2486],
9	,	,	O	,	_	0	SENT_524	[p29l1560t2384r1718b2486],
10	et	FW	O	et	nn	11	SENT_524	[p29l1749t2395r1836b2466],
11	al.	FW	O	al.	appos	2	SENT_524	[p29l1855t2376r1962b2466],
12	.	.	O	.	_	0	SENT_524	[p29l1855t2376r1962b2466],

1	Efﬁcacy	NN	O	efﬁcacy	_	0	SENT_525	[p29l1991t2376r2129b2465, p29l18t2522r294b2638],
2	of	IN	O	of	_	0	SENT_525	[p29l315t2522r430b2613],
3	gefitinib	NN	O	gefitinib	prep_of	1	SENT_525	[p29l435t2522r869b2638],
4	,	,	O	,	_	0	SENT_525	[p29l435t2522r869b2638],
5	an	DT	O	a	det	6	SENT_525	[p29l902t2551r1017b2613],
6	inhibitor	NN	O	inhibitor	appos	3	SENT_525	[p29l1042t2522r1472b2613],
7	of	IN	O	of	_	0	SENT_525	[p29l1495t2522r1610b2613],
8	the	DT	O	the	det	14	SENT_525	[p29l1615t2524r1763b2613],
9	epidermal	JJ	O	epidermal	amod	14	SENT_525	[p29l1791t2524r2130b2638, p29l18t2671r199b2759],
10	growth	NN	O	growth	nn	14	SENT_525	[p29l234t2671r581b2785],
11	factor	NN	O	factor	nn	14	SENT_525	[p29l617t2669r899b2760],
12	receptor	NN	O	receptor	nn	14	SENT_525	[p29l932t2689r1335b2785],
13	tyrosine	NN	O	tyrosine	nn	14	SENT_525	[p29l1369t2671r1751b2783],
14	kinase	NN	O	kinase	prep_of	6	SENT_525	[p29l1788t2671r2125b2779],
15	,	,	O	,	_	0	SENT_525	[p29l1788t2671r2125b2779],
16	in	IN	O	in	_	0	SENT_525	[p29l16t2818r110b2905],
17	symptomatic	JJ	O	symptomatic	amod	18	SENT_525	[p29l140t2818r767b2932],
18	patients	NNS	O	patient	prep_in	3	SENT_525	[p29l792t2818r1176b2932],
19	with	IN	O	with	_	0	SENT_525	[p29l1201t2816r1418b2907],
20	non	JJ	O	non	amod	25	SENT_525	[p29l1446t2818r1942b2907],
21	—	JJ	O	—	amod	25	SENT_525	[p29l1446t2818r1942b2907],
22	small	JJ	O	small	amod	25	SENT_525	[p29l1446t2818r1942b2907],
23	cell	NN	O	cell	nn	25	SENT_525	[p29l1970t2816r2132b2907],
24	lung	NN	O	lung	nn	25	SENT_525	[p29l16t2965r239b3079],
25	cancer	NN	O	cancer	prep_with	18	SENT_525	[p29l260t2992r601b3054],
26	:	:	O	:	_	0	SENT_525	[p29l260t2992r601b3054],
27	a	DT	O	a	det	29	SENT_525	[p29l629t2994r680b3053],
28	randomized	JJ	O	randomized	amod	29	SENT_525	[p29l703t2963r1288b3054],
29	trial	NN	O	trial	dep	1	SENT_525	[p29l1312t2965r1529b3054],
30	.	.	O	.	_	0	SENT_525	[p29l1312t2965r1529b3054],

1	JAMA	NNP	O	JAMA	_	0	SENT_526	[p29l1548t2973r1840b3067],
2	2003	CD	DATE	2003	num	1	SENT_526	[p29l1861t2971r2127b3073],
3	;	:	O	;	_	0	SENT_526	[p29l1861t2971r2127b3073],
4	290:2149	CD	NUMBER	290:2149	number	5	SENT_526	[p29l18t3119r658b3202],
5	-58	CD	NUMBER	-58	dep	1	SENT_526	[p29l18t3119r658b3202],
6	.	.	O	.	_	0	SENT_526	[p29l18t3119r658b3202],

1	37	CD	NUMBER	37	_	0	SENT_527	[p29l18t3271r152b3349],
2	.	.	O	.	_	0	SENT_527	[p29l18t3271r152b3349],

1	Fukuoka	NNP	LOCATION	Fukuoka	nn	2	SENT_528	[p29l213t3259r636b3350],
2	M	NNP	O	M	_	0	SENT_528	[p29l672t3267r796b3369],
3	,	,	O	,	_	0	SENT_528	[p29l672t3267r796b3369],
4	Yano	NNP	PERSON	Yano	nn	5	SENT_528	[p29l839t3267r1076b3349],
5	S	NNP	O	S	appos	2	SENT_528	[p29l1121t3267r1198b3369],
6	,	,	O	,	_	0	SENT_528	[p29l1121t3267r1198b3369],
7	Giaccone	NNP	PERSON	Giaccone	nn	8	SENT_528	[p29l1247t3261r1696b3349],
8	G	NNP	O	G	appos	2	SENT_528	[p29l1737t3267r1846b3369],
9	,	,	O	,	_	0	SENT_528	[p29l1737t3267r1846b3369],
10	et	FW	O	et	nn	11	SENT_528	[p29l1895t3278r1982b3349],
11	al.	FW	O	al.	appos	2	SENT_528	[p29l2017t3259r2124b3349],
12	.	.	O	.	_	0	SENT_528	[p29l2017t3259r2124b3349],

1	Multi	JJ	O	multi	amod	2	SENT_529	[p29l14t3405r910b3496],
2	—	NN	O	—	nsubj	12	SENT_529	[p29l14t3405r910b3496],
3	institutional	JJ	O	institutional	amod	5	SENT_529	[p29l14t3405r910b3496],
4	randomized	JJ	O	randomized	amod	5	SENT_529	[p29l945t3405r1531b3496],
5	phase	NN	O	phase	dep	2	SENT_529	[p29l1564t3407r1846b3521],
6	II	CD	NUMBER	ii	num	7	SENT_529	[p29l1881t3415r1952b3494],
7	trial	NN	O	trial	dep	2	SENT_529	[p29l1988t3407r2130b3495, p29l17t3552r99b3642],
8	of	IN	O	of	_	0	SENT_529	[p29l130t3552r245b3643],
9	geﬁtinib	NN	O	geﬁtinib	prep_of	7	SENT_529	[p29l254t3552r662b3668],
10	for	IN	O	for	prep	9	SENT_529	[p29l693t3552r835b3643],
11	previously	RB	DATE	previously	pcomp	10	SENT_529	[p29l861t3552r1359b3668],
12	treated	VBN	O	treat	_	0	SENT_529	[p29l1385t3552r1716b3643],
13	patients	NNS	O	patient	dobj	12	SENT_529	[p29l1745t3554r2129b3668],
14	with	IN	O	with	_	0	SENT_529	[p30l12t24r230b114],
15	advanced	JJ	O	advanced	amod	17	SENT_529	[p30l277t22r725b113],
16	non	JJ	O	non	amod	17	SENT_529	[p30l774t22r1478b113],
17	—	NN	O	—	prep_with	12	SENT_529	[p30l774t22r1478b113],
18	small	JJ	O	small	amod	22	SENT_529	[p30l774t22r1478b113],
19	—	NN	O	—	nn	22	SENT_529	[p30l774t22r1478b113],
20	cell	NN	O	cell	nn	22	SENT_529	[p30l774t22r1478b113],
21	lung	NN	O	lung	nn	22	SENT_529	[p30l1523t24r1746b138],
22	cancer	NN	O	cancer	dep	17	SENT_529	[p30l1791t52r2124b113],
23	.	.	O	.	_	0	SENT_529	[p30l1791t52r2124b113],

1	J	NNP	O	J	nn	3	SENT_530	[p30l6t180r50b274],
2	Clin	NNP	O	Clin	nn	3	SENT_530	[p30l77t172r276b261],
3	Oncol	NNP	O	Oncol	_	0	SENT_530	[p30l303t170r595b261],
4	2003	CD	DATE	2003	num	3	SENT_530	[p30l622t178r1479b280],
5	;	:	O	;	_	0	SENT_530	[p30l622t178r1479b280],
6	21:2237	CD	NUMBER	21:2237	number	7	SENT_530	[p30l622t178r1479b280],
7	—	CD	NUMBER	—	dep	3	SENT_530	[p30l622t178r1479b280],
8	46	CD	NUMBER	46	dep	7	SENT_530	[p30l622t178r1479b280],
9	.	.	O	.	_	0	SENT_530	[p30l622t178r1479b280],

1	38	CD	NUMBER	38	_	0	SENT_531	[p30l18t327r152b408],
2	.	.	O	.	_	0	SENT_531	[p30l18t327r152b408],

1	Lynch	NNP	PERSON	Lynch	nn	3	SENT_532	[p30l213t317r502b431],
2	T	NN	O	t	nn	3	SENT_532	[p30l522t325r650b427],
3	]	NN	O	]	_	0	SENT_532	[p30l522t325r650b427],
4	,	,	O	,	_	0	SENT_532	[p30l522t325r650b427],
5	Bell	NNP	ORGANIZATION	Bell	nn	6	SENT_532	[p30l680t317r863b407],
6	DW	NNP	ORGANIZATION	DW	appos	3	SENT_532	[p30l886t325r1083b427],
7	,	,	O	,	_	0	SENT_532	[p30l886t325r1083b427],
8	Sordella	NNP	PERSON	Sordella	nn	9	SENT_532	[p30l1117t317r1509b407],
9	R	NNP	PERSON	R	appos	3	SENT_532	[p30l1530t325r1627b427],
10	,	,	O	,	_	0	SENT_532	[p30l1530t325r1627b427],
11	et	FW	O	et	nn	12	SENT_532	[p30l1660t336r1747b407],
12	al.	FW	O	al.	appos	3	SENT_532	[p30l1765t317r1873b407],
13	.	.	O	.	_	0	SENT_532	[p30l1765t317r1873b407],

1	Activating	VBG	O	activate	amod	2	SENT_533	[p30l1901t319r2129b407, p30l12t465r315b579],
2	mutations	NNS	O	mutation	_	0	SENT_533	[p30l360t465r853b554],
3	in	IN	O	in	_	0	SENT_533	[p30l904t465r999b552],
4	the	DT	O	the	det	7	SENT_533	[p30l1048t465r1196b554],
5	epidermal	JJ	O	epidermal	amod	7	SENT_533	[p30l1247t465r1735b579],
6	growth	NN	O	growth	nn	7	SENT_533	[p30l1784t465r2131b579],
7	factor	NN	O	factor	prep_in	2	SENT_533	[p30l18t610r300b701],
8	receptor	NN	O	receptor	nn	10	SENT_533	[p30l356t630r759b726],
9	underlying	VBG	O	underlie	amod	10	SENT_533	[p30l815t612r1342b726],
10	responsiveness	NN	O	responsiveness	dep	2	SENT_533	[p30l1397t612r2129b726],
11	of	IN	O	of	_	0	SENT_533	[p30l18t757r134b848],
12	non	JJ	O	non	amod	18	SENT_533	[p30l159t757r883b848],
13	—	JJ	O	—	amod	18	SENT_533	[p30l159t757r883b848],
14	small	JJ	O	small	amod	18	SENT_533	[p30l159t757r883b848],
15	—	NN	O	—	nn	18	SENT_533	[p30l159t757r883b848],
16	cell	NN	O	cell	nn	18	SENT_533	[p30l159t757r883b848],
17	lung	NN	O	lung	nn	18	SENT_533	[p30l928t759r1150b873],
18	cancer	NN	O	cancer	prep_of	10	SENT_533	[p30l1194t787r1509b848],
19	to	TO	O	to	_	0	SENT_533	[p30l1552t777r1643b848],
20	geﬁtinib	NN	O	geﬁtinib	prep_to	10	SENT_533	[p30l1690t757r2125b873],
21	.	.	O	.	_	0	SENT_533	[p30l1690t757r2125b873],

1	N	NN	O	n	nn	3	SENT_534	[p30l16t914r101b995],
2	Engl	NNP	O	Engl	nn	3	SENT_534	[p30l136t906r418b1020],
3	]	NNP	O	]	nsubj	4	SENT_534	[p30l136t906r418b1020],
4	Med	VBD	O	med	_	0	SENT_534	[p30l441t906r654b995],
5	2004	CD	DATE	2004	dobj	4	SENT_534	[p30l683t912r1600b1014],
6	;	:	O	;	_	0	SENT_534	[p30l683t912r1600b1014],
7	350:2129	CD	NUMBER	350:2129	number	8	SENT_534	[p30l683t912r1600b1014],
8	—	CD	NUMBER	—	dep	5	SENT_534	[p30l683t912r1600b1014],
9	39	CD	NUMBER	39	dep	8	SENT_534	[p30l683t912r1600b1014],
10	.	.	O	.	_	0	SENT_534	[p30l683t912r1600b1014],

1	Copyright	NN	O	copyright	_	0	SENT_535	[p30l20t1038r386b1136],
2	©	CD	NUMBER	©	num	6	SENT_535	[p30l418t1046r500b1127],
3	2004	CD	DATE	2004	num	6	SENT_535	[p30l536t1044r729b1113],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_535	[p30l760t1038r1312b1112],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_535	[p30l1343t1038r1647b1112],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_535	[p30l1672t1042r1952b1134],
7	.	.	O	.	_	0	SENT_535	[p30l1672t1042r1952b1134],

1	N	NN	O	n	nn	3	SENT_536	[p30l524t1213r538b1228],
2	ENGLJ	NN	O	englj	nn	3	SENT_536	[p30l553t1212r637b1234],
3	MED	NN	O	med	_	0	SENT_536	[p30l652t1213r705b1228],
4	351	CD	NUMBER	351	dep	3	SENT_536	[p30l717t1212r782b1234],
5	;	:	O	;	_	0	SENT_536	[p30l717t1212r782b1234],
6	4	CD	NUMBER	4	num	8	SENT_536	[p30l717t1212r782b1234],
7	WWW.NEJM.ORG	NN	O	www.nejm.org	nn	8	SENT_536	[p30l815t1212r1027b1234],
8	ULY	NN	O	uly	dep	4	SENT_536	[p30l1075t1213r1120b1228],
9	22,2004	CD	NUMBER	22,2004	number	10	SENT_536	[p30l1132t1212r1250b1234],
10	345	CD	NUMBER	345	dep	8	SENT_536	[p30l1959t1211r2015b1233],

1	The	DT	O	the	det	5	SENT_537	[p30l702t1245r753b1269],
2	New	NNP	O	New	nn	5	SENT_537	[p30l762t1246r824b1269],
3	England	NNP	O	England	nn	5	SENT_537	[p30l833t1245r944b1276],
4	Journa	NNP	O	Journa	nn	5	SENT_537	[p30l953t1246r1041b1269],
5	o	NN	O	o	_	0	SENT_537	[p30l1060t1253r1075b1269],
6	Medicine	NN	O	medicine	dep	5	SENT_537	[p30l1095t1245r1220b1269],

1	Downloaded	VBN	O	download	_	0	SENT_538	[p30l144t1286r314b1309],
2	from	IN	O	from	_	0	SENT_538	[p30l323t1286r387b1309],
3	nejmorg	NN	O	nejmorg	prep_from	1	SENT_538	[p30l396t1286r514b1316],
4	at	IN	O	at	_	0	SENT_538	[p30l524t1290r548b1309],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_538	[p30l556t1286r739b1309],
6	on	IN	O	on	_	0	SENT_538	[p30l748t1293r780b1309],
7	January	NNP	DATE	January	prep_on	1	SENT_538	[p30l789t1286r892b1316],
8	5	CD	DATE	5	num	7	SENT_538	[p30l902t1286r924b1314],
9	,	,	DATE	,	_	0	SENT_538	[p30l902t1286r924b1314],
10	2014	CD	DATE	2014	num	7	SENT_538	[p30l935t1286r1007b1309],
11	.	.	O	.	_	0	SENT_538	[p30l935t1286r1007b1309],

1	or	CC	O	or	dep	4	SENT_539	[p30l1037t1293r1064b1309],
2	ersonal	JJ	O	ersonal	amod	3	SENT_539	[p30l1090t1286r1185b1309],
3	use	NN	O	use	npadvmod	4	SENT_539	[p30l1194t1293r1237b1309],
4	only	RB	O	only	_	0	SENT_539	[p30l1247t1286r1312b1316],
5	.	.	O	.	_	0	SENT_539	[p30l1247t1286r1312b1316],

1	No	DT	O	no	det	3	SENT_540	[p30l1322t1286r1362b1309],
2	other	JJ	O	other	amod	3	SENT_540	[p30l1372t1286r1440b1309],
3	uses	NNS	O	use	_	0	SENT_540	[p30l1449t1293r1504b1309],
4	without	IN	O	without	_	0	SENT_540	[p30l1515t1286r1616b1309],
5	permission	NN	O	permission	prep_without	3	SENT_540	[p30l1624t1286r1777b1316],
6	.	.	O	.	_	0	SENT_540	[p30l1624t1286r1777b1316],

1	Copyright	NN	O	copyright	nn	5	SENT_541	[p30l494t1327r629b1358],
2	©	CD	NUMBER	©	num	5	SENT_541	[p30l638t1327r661b1351],
3	2004	CD	DATE	2004	num	5	SENT_541	[p30l672t1327r737b1351],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	5	SENT_541	[p30l746t1327r937b1351],
5	Medica	NNP	ORGANIZATION	Medica	_	0	SENT_541	[p30l947t1327r1047b1351],
6	ociety	NN	O	ociety	dep	5	SENT_541	[p30l1084t1327r1170b1358],
7	.	.	O	.	_	0	SENT_541	[p30l1084t1327r1170b1358],

1	All	DT	O	all	det	2	SENT_542	[p30l1181t1327r1223b1351],
2	rights	NNS	O	rights	nsubj	3	SENT_542	[p30l1232t1327r1307b1358],
3	reserved	VBN	O	reserve	_	0	SENT_542	[p30l1316t1327r1435b1351],
4	.	.	O	.	_	0	SENT_542	[p30l1316t1327r1435b1351],

